0	They developed ENT1 nephrotic syndrome ENT1END and finally renal failure. The time-course curve of creatinine clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, AMNS alone, ENT2 PS ENT2END alone or saline injected
1	They developed ENT1 nephrotic syndrome ENT1END  and finally renal failure. The time-course curve of creatinine clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, ENT2 AMNS ENT2END alone, PS alone or saline injected
0	They developed ENT1 nephrotic syndrome ENT1END  and finally renal failure. The time-course curve of ENT2 creatinine ENT2END clearance dropped and showed significant difference (P less than 0
0	They developed ENT1 nephrotic syndrome ENT1END  and finally renal failure. The time-course curve of creatinine clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, AMNS alone, PS alone or saline injected. Their glomeruli showed changes of progressive FSGS. The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ENT2 ruthenium ENT2END red on the lamina rara externa and marked changes in epithelial cell cytoplasm
0	The enhancement of aminonucleoside ENT1 nephrosis ENT1END  by the co-administration of protamine.An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and ENT2 protamine sulfate ENT2END (PS)
0	The enhancement of ENT1 aminonucleoside ENT1END ENT2 nephrosis ENT2END by the co-administration of protamine
0	The enhancement of aminonucleoside ENT1 nephrosis  ENT1END  by the co-administration of protamine.An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (PS). Male Sprague-Dawley rats, uninephrectomized three weeks before, received daily injections of subcutaneous AMNS (1 mg/100 g body wt) and intravenous PS (2 separated doses of 2.5 mg/100 g body wt) for four days. The series of injections were repeated another three times at 10 day intervals. The animals were sacrificed on days 24, 52, and 80. They developed nephrotic syndrome and finally renal failure. The time-course curve of ENT2 creatinine ENT2END clearance dropped and showed significant difference (P less than 0
0	Therefore, it is suggested that the administration of ENT1 PS ENT1END enhances the ENT2 toxicity ENT2END of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease
0	Therefore, it is suggested that the administration of PS enhances the ENT1 toxicity ENT1END  of ENT2 AMNS ENT2END on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease
0	The time-course curve of ENT1 creatinine  ENT1END  clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, AMNS alone, PS alone or saline injected. Their glomeruli showed changes of progressive FSGS. The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ruthenium red on the lamina rara externa and marked changes in epithelial cell cytoplasm. Therefore, it is suggested that the administration of PS enhances the ENT2 toxicity ENT2END of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease
0	The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ENT1 ruthenium  ENT1END  red on the lamina rara externa and marked changes in epithelial cell cytoplasm. Therefore, it is suggested that the administration of PS enhances the ENT2 toxicity ENT2END of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease
0	They developed nephrotic syndrome and finally ENT1 renal failure  ENT1END  The time-course curve of creatinine clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, AMNS alone, ENT2 PS ENT2END alone or saline injected
0	They developed nephrotic syndrome and finally ENT1 renal failure  ENT1END . The time-course curve of creatinine clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, ENT2 AMNS ENT2END alone, PS alone or saline injected
0	They developed nephrotic syndrome and finally ENT1 renal failure  ENT1END . The time-course curve of ENT2 creatinine ENT2END clearance dropped and showed significant difference (P less than 0
0	They developed nephrotic syndrome and finally ENT1 renal failure  ENT1END . The time-course curve of creatinine clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, AMNS alone, PS alone or saline injected. Their glomeruli showed changes of progressive FSGS. The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ENT2 ruthenium ENT2END red on the lamina rara externa and marked changes in epithelial cell cytoplasm
0	Therefore, it is suggested that the administration of ENT1 PS ENT1END  enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the ENT2 end-stage renal disease ENT2END
1	Therefore, it is suggested that the administration of PS enhances the toxicity of ENT1 AMNS  ENT1END  on the glomerulus and readily produces progressive FSGS in rats resulting in the ENT2 end-stage renal disease ENT2END
0	The time-course curve of ENT1 creatinine  ENT1END  clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, AMNS alone, PS alone or saline injected. Their glomeruli showed changes of progressive FSGS. The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ruthenium red on the lamina rara externa and marked changes in epithelial cell cytoplasm. Therefore, it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the ENT2 end-stage renal disease ENT2END
0	The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ENT1 ruthenium  ENT1END  red on the lamina rara externa and marked changes in epithelial cell cytoplasm. Therefore, it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the ENT2 end-stage renal disease ENT2END
0	01) from that of each control group, such as, AMNS alone, ENT1 PS ENT1END  alone or saline injected. Their glomeruli showed changes of progressive ENT2 FSGS ENT2END
1	Therefore, it is suggested that the administration of PS enhances the toxicity of ENT1 AMNS ENT1END  on the glomerulus and readily produces progressive ENT2 FSGS ENT2END in rats resulting in the end-stage renal disease
0	The time-course curve of ENT1 creatinine  ENT1END  clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, AMNS alone, PS alone or saline injected. Their glomeruli showed changes of progressive ENT2 FSGS ENT2END
0	Their glomeruli showed changes of progressive ENT1 FSGS  ENT1END . The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ENT2 ruthenium ENT2END red on the lamina rara externa and marked changes in epithelial cell cytoplasm
0	Conversion to ENT1 SRL ENT1END prevented CsA-induced ENT2 renal damage ENT2END evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL
1	Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent ENT1 CsA ENT1END induced ENT2 nephropathy ENT2END , but the molecular mechanisms underlying these protocols remain nuclear
0	ENT1 Renal lesions ENT1END were analyzed in ENT2 hematoxylin ENT2END and eosin, periodic acid-Schiff, and Masson's trichrome stains
0	ENT1 Renal lesions ENT1END  were analyzed in hematoxylin and ENT2 eosin ENT2END , periodic acid-Schiff, and Masson's trichrome stains
1	ENT1 SRL ENT1END treated rats presented ENT2 proteinuria ENT2END and NGAL (serum and urinary) as the best markers of renal impairment
0	SRL-treated rats presented ENT1 proteinuria ENT1END  and NGAL (serum and urinary) as the best markers of renal impairment. Short ENT2 CsA ENT2END treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes
0	Renal lesions were analyzed in ENT1 hematoxylin  ENT1END  and eosin, periodic acid-Schiff, and Masson's trichrome stains. SRL-treated rats presented ENT2 proteinuria ENT2END and NGAL (serum and urinary) as the best markers of renal impairment
0	Renal lesions were analyzed in hematoxylin and ENT1 eosin  ENT1END , periodic acid-Schiff, and Masson's trichrome stains. SRL-treated rats presented ENT2 proteinuria ENT2END and NGAL (serum and urinary) as the best markers of renal impairment
1	ENT1 LV hypertrophy ENT1END induced by ENT2 Iso ENT2END treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0
0	The greater ENT1 LV hypertrophy ENT1END in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats. The decrease in the heart rate (HR) induced by the beta-AR antagonist ENT2 metoprolol ENT2END in conscious rats was significantly attenuated in TGR compared with SD rats (-9
0	The greater ENT1 LV hypertrophy ENT1END  in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats. The decrease in the heart rate (HR) induced by the beta-AR antagonist metoprolol in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs. -18.1 +/- 1.5%), whereas the effect of parasympathetic blockade by ENT2 atropine ENT2END on HR was similar in both strains
0	Enhanced isoproterenol-induced ENT1 cardiac hypertrophy  ENT1END  in transgenic rats with low brain angiotensinogen.We have previously shown that a permanent deficiency in the brain renin- ENT2 angiotensin ENT2END system (RAS) may increase the sensitivity of the baroreflex control of heart rate
0	LV hypertrophy induced by ENT1 Iso ENT1END  treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/- 0.004 vs. 0.24 +/- 0.004, respectively). The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats. The decrease in the heart rate (HR) induced by the beta-AR antagonist metoprolol in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs. -18.1 +/- 1.5%), whereas the effect of parasympathetic blockade by atropine on HR was similar in both strains. These results indicate that TGR are more sensitive to beta-AR agonist-induced ENT2 cardiac inotropic ENT2END response and hypertrophy, possibly due to chronically low sympathetic outflow directed to the heart
0	The decrease in the heart rate (HR) induced by the beta-AR antagonist ENT1 metoprolol  ENT1END  in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs. -18.1 +/- 1.5%), whereas the effect of parasympathetic blockade by atropine on HR was similar in both strains. These results indicate that TGR are more sensitive to beta-AR agonist-induced ENT2 cardiac inotropic ENT2END response and hypertrophy, possibly due to chronically low sympathetic outflow directed to the heart
0	5%), whereas the effect of parasympathetic blockade by ENT1 atropine  ENT1END  on HR was similar in both strains. These results indicate that TGR are more sensitive to beta-AR agonist-induced ENT2 cardiac inotropic ENT2END response and hypertrophy, possibly due to chronically low sympathetic outflow directed to the heart
0	LV hypertrophy induced by ENT1 Iso ENT1END  treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/- 0.004 vs. 0.24 +/- 0.004, respectively). The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats. The decrease in the heart rate (HR) induced by the beta-AR antagonist metoprolol in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs. -18.1 +/- 1.5%), whereas the effect of parasympathetic blockade by atropine on HR was similar in both strains. These results indicate that TGR are more sensitive to beta-AR agonist-induced cardiac inotropic response and ENT2 hypertrophy ENT2END , possibly due to chronically low sympathetic outflow directed to the heart
0	The decrease in the heart rate (HR) induced by the beta-AR antagonist ENT1 metoprolol  ENT1END  in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs. -18.1 +/- 1.5%), whereas the effect of parasympathetic blockade by atropine on HR was similar in both strains. These results indicate that TGR are more sensitive to beta-AR agonist-induced cardiac inotropic response and ENT2 hypertrophy ENT2END , possibly due to chronically low sympathetic outflow directed to the heart
0	5%), whereas the effect of parasympathetic blockade by ENT1 atropine  ENT1END  on HR was similar in both strains. These results indicate that TGR are more sensitive to beta-AR agonist-induced cardiac inotropic response and ENT2 hypertrophy ENT2END , possibly due to chronically low sympathetic outflow directed to the heart
0	Histopathological examination of the kidney showed ENT1 tubular necrosis ENT1END in D-AmB-treated rats but no change in NS-718-treated rats. ENT2 Amphotericin B ENT2END concentrations in the kidney in NS-718-treated rats were higher than those in D-AmB-treated rats
0	Serum blood urea and ENT1 creatinine  ENT1END concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718. Histopathological examination of the kidney showed ENT2 tubular necrosis ENT2END in D-AmB-treated rats but no change in NS-718-treated rats
0	Serum blood ENT1 urea  ENT1END and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718. Histopathological examination of the kidney showed ENT2 tubular necrosis ENT2END in D-AmB-treated rats but no change in NS-718-treated rats
1	Histopathological examination of the kidney showed ENT1 tubular necrosis ENT1END  in ENT2 D-AmB ENT2END -treated rats but no change in NS-718-treated rats
0	We compared the ENT1 toxicity ENT1END of NS-718 with that of ENT2 Fungizone ENT2END (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats
0	We compared the ENT1 toxicity  ENT1END  of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats. Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and ENT2 creatinine ENT2END concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718
0	We compared the ENT1 toxicity  ENT1END  of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats. Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood ENT2 urea ENT2END and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718
0	We compared the ENT1 toxicity  ENT1END  of NS-718 with that of Fungizone ( ENT2 amphotericin B-sodium deoxycholate ENT2END ; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats
0	Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the ENT1 nephrotoxicity ENT1END of ENT2 amphotericin B ENT2END
0	Serum blood urea and ENT1 creatinine  ENT1END  concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718. Histopathological examination of the kidney showed tubular necrosis in D-AmB-treated rats but no change in NS-718-treated rats. Amphotericin B concentrations in the kidney in NS-718-treated rats were higher than those in D-AmB-treated rats. Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the ENT2 nephrotoxicity ENT2END of amphotericin B
0	Serum blood ENT1 urea  ENT1END  and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718. Histopathological examination of the kidney showed tubular necrosis in D-AmB-treated rats but no change in NS-718-treated rats. Amphotericin B concentrations in the kidney in NS-718-treated rats were higher than those in D-AmB-treated rats. Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the ENT2 nephrotoxicity ENT2END of amphotericin B
0	Amphotericin B concentrations in the kidney in NS-718-treated rats were higher than those in ENT1 D-AmB  ENT1END treated rats. Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the ENT2 nephrotoxicity ENT2END of amphotericin B
0	Anesthesia was performed by injecting 20 to 40 mL of a mixture of long-acting ( ENT1 ropivacaine ENT1END  and short-acting (prilocaine) anesthetic. RESULTS: All patients had normal vocal cord function preoperatively. Twelve patients (43%) were found to have intraoperative ipsilateral ENT2 vocal cord paralysis ENT2END
1	Anesthesia was performed by injecting 20 to 40 mL of a mixture of long-acting (ropivacaine) and short-acting ( ENT1 prilocaine  ENT1END  anesthetic. RESULTS: All patients had normal vocal cord function preoperatively. Twelve patients (43%) were found to have intraoperative ipsilateral ENT2 vocal cord paralysis ENT2END
0	Such complications are most important in situations where there is a pre-existing contralateral ENT1 paralysis ENT1END  We therefore examined the effect of local anesthesia on vocal cord function to better understand its possible consequences. METHODS: This prospective study included 28 patients undergoing carotid endarterectomy under local anesthesia. Vocal cord function was evaluated before, during, and after surgery (postoperative day 1) using flexible laryngoscopy. Anesthesia was performed by injecting 20 to 40 mL of a mixture of long-acting ENT2 ropivacaine ENT2END ) and short-acting (prilocaine) anesthetic
0	Such complications are most important in situations where there is a pre-existing contralateral ENT1 paralysis ENT1END . We therefore examined the effect of local anesthesia on vocal cord function to better understand its possible consequences. METHODS: This prospective study included 28 patients undergoing carotid endarterectomy under local anesthesia. Vocal cord function was evaluated before, during, and after surgery (postoperative day 1) using flexible laryngoscopy. Anesthesia was performed by injecting 20 to 40 mL of a mixture of long-acting (ropivacaine) and short-acting ENT2 prilocaine ENT2END ) anesthetic
0	Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and ENT1 tiapride  ENT1END  in a Japanese patient with ENT2 Huntington's disease ENT2END at the terminal stage of recurrent breast cancer
0	5 mg/day) for ENT1 Huntington's disease ENT1END  The patient had been treated with tiapride or tetrabenazine alone without any adverse effects before the administration of the combination therapy. She also had advanced breast cancer when the combination therapy was initiated. To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported. Tetrabenazine should be administered very carefully in combination with other ENT2 neuroleptic drugs ENT2END , particularly in patients with a worsening general condition
0	We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and ENT1 tetrabenazine  ENT1END (12.5 mg/day) for ENT2 Huntington's disease ENT2END
1	To the best of our knowledge, the occurrence of ENT1 neuroleptic malignant syndrome ENT1END due to combination therapy with tetrabenazine and ENT2 tiapride ENT2END has not been previously reported
0	To the best of our knowledge, the occurrence of ENT1 neuroleptic malignant syndrome  ENT1END  due to combination therapy with tetrabenazine and tiapride has not been previously reported. Tetrabenazine should be administered very carefully in combination with other ENT2 neuroleptic drugs ENT2END , particularly in patients with a worsening general condition
1	To the best of our knowledge, the occurrence of ENT1 neuroleptic malignant syndrome ENT1END  due to combination therapy with ENT2 tetrabenazine ENT2END and tiapride has not been previously reported
0	Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and ENT1 tiapride  ENT1END  in a Japanese patient with Huntington's disease at the terminal stage of recurrent ENT2 breast cancer ENT2END
0	She also had advanced ENT1 breast cancer  ENT1END when the combination therapy was initiated. To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported. Tetrabenazine should be administered very carefully in combination with other ENT2 neuroleptic drugs ENT2END , particularly in patients with a worsening general condition
0	Neuroleptic malignant syndrome induced by combination therapy with ENT1 tetrabenazine  ENT1END  and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent ENT2 breast cancer ENT2END
1	CONCLUSION: Among non-users of aspirin, ENT1 naproxen ENT1END seemed to carry the highest risk for ENT2 AMI ENT2END /GI bleeding
1	OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) ENT1 non-steroidal anti-inflammatory drugs ENT1END (NSAIDs). We aimed to compare the risks of hospitalization for ENT2 AMI ENT2END and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen
0	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for ENT1 AMI ENT1END GI vs the acetaminophen (with no ENT2 aspirin ENT2END ) group were: rofecoxib 1
0	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for ENT1 AMI ENT1END /GI vs the ENT2 acetaminophen ENT2END (with no aspirin) group were: rofecoxib 1
0	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for ENT1 AMI ENT1END /GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ENT2 ibuprofen ENT2END 1
1	OBJECTIVES: The risk of acute myocardial infarction ( ENT1 AMI ENT1END  with ENT2 COX-2 inhibitors ENT2END may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs)
0	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for ENT1 AMI ENT1END /GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), ENT2 diclofenac ENT2END 1
0	The ENT1 AMI ENT1END GI toxicity of ENT2 celecoxib ENT2END was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs
1	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for ENT1 AMI ENT1END /GI vs the acetaminophen (with no aspirin) group were: ENT2 rofecoxib ENT2END 1
0	CONCLUSION: Among non-users of aspirin, ENT1 naproxen ENT1END  seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI ENT2 toxicity ENT2END of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs
0	CONCLUSION: Among non-users of ENT1 aspirin  ENT1END  naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI ENT2 toxicity ENT2END of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs
0	The AMI/GI ENT1 toxicity ENT1END  of celecoxib was similar to that of ENT2 acetaminophen ENT2END and seemed to be better than those of rofecoxib and NS-NSAIDs
0	52), ENT1 ibuprofen  ENT1END 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI ENT2 toxicity ENT2END of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs
0	41), ENT1 diclofenac  ENT1END 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI ENT2 toxicity ENT2END of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs
0	The AMI/GI ENT1 toxicity  ENT1END  of ENT2 celecoxib ENT2END was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs
0	The AMI/GI ENT1 toxicity ENT1END  of celecoxib was similar to that of acetaminophen and seemed to be better than those of ENT2 rofecoxib ENT2END and NS-NSAIDs
1	CONCLUSION: Among non-users of aspirin, ENT1 naproxen  ENT1END  seemed to carry the highest risk for AMI/ ENT2 GI bleeding ENT2END
1	OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) ENT1 non-steroidal anti-inflammatory drugs ENT1END  (NSAIDs). We aimed to compare the risks of hospitalization for AMI and ENT2 GI bleeding ENT2END among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen
0	CONCLUSION: Among non-users of ENT1 aspirin  ENT1END , naproxen seemed to carry the highest risk for AMI ENT2 GI bleeding ENT2END
0	CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/ ENT1 GI bleeding  ENT1END . The AMI/GI toxicity of celecoxib was similar to that of ENT2 acetaminophen ENT2END and seemed to be better than those of rofecoxib and NS-NSAIDs
0	52), ENT1 ibuprofen  ENT1END  1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI ENT2 GI bleeding ENT2END
0	We aimed to compare the risks of hospitalization for AMI and ENT1 GI bleeding ENT1END  among elderly patients using ENT2 COX-2 inhibitors ENT2END , NS-NSAIDs and acetaminophen
0	41), ENT1 diclofenac  ENT1END  1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI ENT2 GI bleeding ENT2END
0	CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/ ENT1 GI bleeding  ENT1END . The AMI/GI toxicity of ENT2 celecoxib ENT2END was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs
1	CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/ ENT1 GI bleeding  ENT1END . The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of ENT2 rofecoxib ENT2END and NS-NSAIDs
1	Abnormalities of the pupil and visual-evoked potential in ENT1 quinine ENT1END  amblyopia.Total blindness with a transient ENT2 tonic pupillary ENT2END response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps
1	Abnormalities of the pupil and visual-evoked potential in ENT1 quinine ENT1END  amblyopia.Total ENT2 blindness ENT2END with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps
0	A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in ENT1 quinine ENT1END ENT2 toxicity ENT2END , to our knowledge, have not been previously reported
1	Abnormalities of the pupil and visual-evoked potential in ENT1 quinine ENT1END ENT2 amblyopia ENT2END
0	Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of ENT1 quinine sulfate ENT1END for ENT2 leg cramps ENT2END
1	ENT1 Doxorubicin  ENT1END -induced ENT2 cardiotoxicity ENT2END monitored by ECG in freely moving mice
0	These findings result in a model that allows the testing of protectors against doxorubicin-induced ENT1 cardiotoxicity ENT1END as demonstrated by the protection provided by ENT2 ICRF-187 ENT2END
0	As this schedule exerted more toxicity than needed to investigate protective agents, the protection of ICRF-187 was determined using a dose schedule with lower general ENT1 toxicity ENT1END (6 weekly doses of 4 mg/kg ENT2 doxorubicin ENT2END given i
0	As this schedule exerted more toxicity than needed to investigate protective agents, the protection of ENT1 ICRF-187  ENT1END was determined using a dose schedule with lower general ENT2 toxicity ENT2END (6 weekly doses of 4 mg/kg doxorubicin given i
0	After sacrifice the hearts of ENT1 doxorubicin ENT1END treated animals were enlarged and the atria were ENT2 hypertrophic ENT2END
0	After sacrifice the hearts of doxorubicin-treated animals were enlarged and the atria were ENT1 hypertrophic  ENT1END . As this schedule exerted more toxicity than needed to investigate protective agents, the protection of ENT2 ICRF-187 ENT2END was determined using a dose schedule with lower general toxicity (6 weekly doses of 4 mg/kg doxorubicin given i
0	ENT1 Nifedipine ENT1END  induced bradycardia in a patient with autonomic neuropathy.An 80 year old diabetic male with evidence of ENT2 peripheral and autonomic neuropathy ENT2END was admitted with chest pain
0	ENT1 Nifedipine  ENT1END  induced bradycardia in a patient with ENT2 autonomic neuropathy ENT2END
0	ENT1 Nifedipine ENT1END  induced bradycardia in a patient with autonomic neuropathy.An 80 year old ENT2 diabetic ENT2END male with evidence of peripheral and autonomic neuropathy was admitted with chest pain
1	ENT1 Nifedipine  ENT1END  induced ENT2 bradycardia ENT2END in a patient with autonomic neuropathy
0	He was found to have ENT1 atrial flutter ENT1END at a ventricular rate of 70/min which slowed down to 30-40/min when ENT2 nifedipine ENT2END (60 mg) in 3 divided doses, during which he was paced at a rate of 70/min
1	This is inconsistent with the well-established finding that ENT1 nifedipine ENT1END induces ENT2 tachycardia ENT2END in normally innervated hearts
0	An 80 year old diabetic male with evidence of peripheral and autonomic neuropathy was admitted with ENT1 chest pain  ENT1END  He was found to have atrial flutter at a ventricular rate of 70/min which slowed down to 30-40/min when ENT2 nifedipine ENT2END (60 mg) in 3 divided doses, during which he was paced at a rate of 70/min
1	ENT1 Penicillin ENT1END ENT2 anaphylaxis ENT2END
0	Switching the immunosuppressive regimen from tacrolimus to ENT1 cyclosporine ENT1END did not improve the clinical situation. The termination of treatment with any calcineurin inhibitor resulted in a complete resolution of that complication. CONCLUSIONS: ENT2 Posterior reversible encephalopathy syndrome ENT2END after liver transplant is rare
1	Switching the immunosuppressive regimen from ENT1 tacrolimus  ENT1END to cyclosporine did not improve the clinical situation. The termination of treatment with any calcineurin inhibitor resulted in a complete resolution of that complication. CONCLUSIONS: ENT2 Posterior reversible encephalopathy syndrome ENT2END after liver transplant is rare
0	OBJECTIVES: Posterior leukoencephalopathy due to calcineurin-inhibitor-related ENT1 neurotoxicity  ENT1END is a rare but severe complication that results from treatment with immunosuppressive agents (primarily those administered after a liver or kidney transplant). The pathophysiologic mechanisms of that disorder remain unknown. CASE: We report the case of a 46-year-old woman who received a liver transplant in our center as treatment for alcoholic cirrhosis and in whom either a fulminant course of posterior leukoencephalopathy or posterior reversible encephalopathy syndrome developed 110 days after transplant. After an initially uneventful course after the transplant, the patient rapidly fell into deep coma. RESULTS: Cerebral MRI scan showed typical signs of enhancement in the pontine and posterior regions. Switching the immunosuppressive regimen from tacrolimus to ENT2 cyclosporine ENT2END did not improve the clinical situation
0	OBJECTIVES: Posterior leukoencephalopathy due to calcineurin-inhibitor-related ENT1 neurotoxicity  ENT1END  is a rare but severe complication that results from treatment with immunosuppressive agents (primarily those administered after a liver or kidney transplant). The pathophysiologic mechanisms of that disorder remain unknown. CASE: We report the case of a 46-year-old woman who received a liver transplant in our center as treatment for alcoholic cirrhosis and in whom either a fulminant course of posterior leukoencephalopathy or posterior reversible encephalopathy syndrome developed 110 days after transplant. After an initially uneventful course after the transplant, the patient rapidly fell into deep coma. RESULTS: Cerebral MRI scan showed typical signs of enhancement in the pontine and posterior regions. Switching the immunosuppressive regimen from ENT2 tacrolimus ENT2END to cyclosporine did not improve the clinical situation
0	CASE: We report the case of a 46-year-old woman who received a liver transplant in our center as treatment for ENT1 alcoholic cirrhosis  ENT1END and in whom either a fulminant course of posterior leukoencephalopathy or posterior reversible encephalopathy syndrome developed 110 days after transplant. After an initially uneventful course after the transplant, the patient rapidly fell into deep coma. RESULTS: Cerebral MRI scan showed typical signs of enhancement in the pontine and posterior regions. Switching the immunosuppressive regimen from tacrolimus to ENT2 cyclosporine ENT2END did not improve the clinical situation
0	CASE: We report the case of a 46-year-old woman who received a liver transplant in our center as treatment for ENT1 alcoholic cirrhosis  ENT1END  and in whom either a fulminant course of posterior leukoencephalopathy or posterior reversible encephalopathy syndrome developed 110 days after transplant. After an initially uneventful course after the transplant, the patient rapidly fell into deep coma. RESULTS: Cerebral MRI scan showed typical signs of enhancement in the pontine and posterior regions. Switching the immunosuppressive regimen from ENT2 tacrolimus ENT2END to cyclosporine did not improve the clinical situation
1	ENT1 Hypertensive  ENT1END  response during ENT2 dobutamine ENT2END stress echocardiography
0	CONCLUSIONS: Initiating treatment of ENT1 type 2 diabetes ENT1END with ENT2 glibenclamide ENT2END or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride
0	CONCLUSIONS: Initiating treatment of ENT1 type 2 diabetes ENT1END  with glibenclamide or ENT2 glipizide ENT2END is associated with increased risk of CAD in comparison to gliclazide or glimepiride
0	000) with either, and was unchanged with ENT1 metformin  ENT1END  The hazard decreased 0.3-fold (0.7-1.7, P=0.385) with glimepiride, 0.4-fold (0.7-1.3, P=0.192) with gliclazide, and 0.4-fold (0.7-1.1, P=0.09) with either. CONCLUSIONS: Initiating treatment of ENT2 type 2 diabetes ENT2END with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride
0	CONCLUSIONS: Initiating treatment of ENT1 type 2 diabetes ENT1END  with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or ENT2 glimepiride ENT2END
0	192) with ENT1 gliclazide  ENT1END  and 0.4-fold (0.7-1.1, P=0.09) with either. CONCLUSIONS: Initiating treatment of ENT2 type 2 diabetes ENT2END with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride
1	CONCLUSIONS: Initiating treatment of type 2 diabetes with ENT1 glibenclamide ENT1END  or glipizide is associated with increased risk of ENT2 CAD ENT2END in comparison to gliclazide or glimepiride
0	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or ENT1 glipizide  ENT1END  is associated with increased risk of ENT2 CAD ENT2END in comparison to gliclazide or glimepiride
0	The hazard of developing ENT1 CAD  ENT1END (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with ENT2 metformin ENT2END
0	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of ENT1 CAD  ENT1END  in comparison to gliclazide or ENT2 glimepiride ENT2END
0	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of ENT1 CAD ENT1END  in comparison to ENT2 gliclazide ENT2END or glimepiride
0	The 20-year risk of CAD at diagnosis of ENT1 diabetes ENT1END  using the UKPDS risk engine, was used to match cases with controls. RESULTS: The 76 cases of CAD were compared with 152 controls. The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with ENT2 glibenclamide ENT2END ; 2-fold (0
0	The 20-year risk of CAD at diagnosis of ENT1 diabetes ENT1END , using the UKPDS risk engine, was used to match cases with controls. RESULTS: The 76 cases of CAD were compared with 152 controls. The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with ENT2 glipizide ENT2END ; 2
0	The 20-year risk of CAD at diagnosis of ENT1 diabetes  ENT1END , using the UKPDS risk engine, was used to match cases with controls. RESULTS: The 76 cases of CAD were compared with 152 controls. The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with ENT2 metformin ENT2END
0	The 20-year risk of CAD at diagnosis of ENT1 diabetes ENT1END , using the UKPDS risk engine, was used to match cases with controls. RESULTS: The 76 cases of CAD were compared with 152 controls. The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin. The hazard decreased 0.3-fold (0.7-1.7, P=0.385) with ENT2 glimepiride ENT2END , 0
0	The 20-year risk of CAD at diagnosis of ENT1 diabetes  ENT1END , using the UKPDS risk engine, was used to match cases with controls. RESULTS: The 76 cases of CAD were compared with 152 controls. The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin. The hazard decreased 0.3-fold (0.7-1.7, P=0.385) with glimepiride, 0.4-fold (0.7-1.3, P=0.192) with ENT2 gliclazide ENT2END , and 0
1	Posttransplant ENT1 anemia  ENT1END : the role of ENT2 sirolimus ENT2END
1	Losartan reduced ENT1 uraemia ENT1END and increased urea clearance in advanced ENT2 ADR ENT2END nephropathy in SHR
0	Losartan reduced ENT1 uraemia ENT1END  and increased ENT2 urea ENT2END clearance in advanced ADR nephropathy in SHR
0	ENT1 Losartan  ENT1END reduced ENT2 uraemia ENT2END and increased urea clearance in advanced ADR nephropathy in SHR
0	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously ENT1 hypertensive ENT1END rats (SHR) with ENT2 adriamycin ENT2END (ADR) nephropathy
0	Reduced progression of adriamycin nephropathy in spontaneously ENT1 hypertensive  ENT1END  rats treated by ENT2 losartan ENT2END
0	Reduced progression of adriamycin nephropathy in spontaneously ENT1 hypertensive ENT1END  rats treated by losartan.BACKGROUND: The aim of the study was to investigate the antihypertensive effects of ENT2 angiotensin II ENT2END type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy
0	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and ENT1 fibrosis ENT1END in ENT2 ADR ENT2END nephropathy
0	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and ENT1 interstitial fibrosis  ENT1END  thus preventing heavy proteinuria and chronic renal failure. Losartan reduced uraemia and increased ENT2 urea ENT2END clearance in advanced ADR nephropathy in SHR
0	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and ENT1 fibrosis ENT1END  in ADR nephropathy. CONCLUSION: ENT2 Losartan ENT2END reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR
1	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy ENT1 proteinuria  ENT1END and chronic renal failure. Losartan reduced uraemia and increased urea clearance in advanced ENT2 ADR ENT2END nephropathy in SHR
0	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy ENT1 proteinuria  ENT1END  and chronic renal failure. Losartan reduced uraemia and increased ENT2 urea ENT2END clearance in advanced ADR nephropathy in SHR
0	RESULTS: Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased ENT1 proteinuria ENT1END  Prolonged treatment with ENT2 losartan ENT2END showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure
0	Losartan reduced uraemia and increased urea clearance in advanced ENT1 ADR ENT1END  ENT2 nephropathy ENT2END in SHR
0	Losartan reduced uraemia and increased ENT1 urea  ENT1END  clearance in advanced ADR ENT2 nephropathy ENT2END in SHR
0	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR ENT1 nephropathy  ENT1END  CONCLUSION: ENT2 Losartan ENT2END reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR
0	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of ENT1 angiotensin II ENT1END  type-1 receptor blocker, losartan, and its potential in slowing down ENT2 renal disease ENT2END progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy
0	Histological examination showed that losartan could prevent tubular ENT1 atrophy  ENT1END  interstitial infiltration and fibrosis in ENT2 ADR ENT2END nephropathy
0	Losartan reduced uraemia and increased ENT1 urea  ENT1END  clearance in advanced ADR nephropathy in SHR. Histological examination showed that losartan could prevent tubular ENT2 atrophy ENT2END , interstitial infiltration and fibrosis in ADR nephropathy
0	Histological examination showed that ENT1 losartan  ENT1END could prevent tubular ENT2 atrophy ENT2END , interstitial infiltration and fibrosis in ADR nephropathy
0	CONCLUSION: Losartan reduces the rate of progression of ENT1 ADR ENT1END induced focal segmental glomerulosclerosis to ENT2 end-stage renal disease ENT2END in SHR
0	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and ENT1 chronic renal failure  ENT1END  Losartan reduced uraemia and increased ENT2 urea ENT2END clearance in advanced ADR nephropathy in SHR
0	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and ENT1 chronic renal failure  ENT1END . ENT2 Losartan ENT2END reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR
1	CONCLUSION: Losartan reduces the rate of progression of ENT1 ADR ENT1END -induced ENT2 focal segmental glomerulosclerosis ENT2END to end-stage renal disease in SHR
0	Losartan reduced uraemia and increased ENT1 urea  ENT1END  clearance in advanced ADR nephropathy in SHR. Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy. CONCLUSION: Losartan reduces the rate of progression of ADR-induced ENT2 focal segmental glomerulosclerosis ENT2END to end-stage renal disease in SHR
0	CONCLUSION: ENT1 Losartan  ENT1END  reduces the rate of progression of ADR-induced ENT2 focal segmental glomerulosclerosis ENT2END to end-stage renal disease in SHR
0	Prolonged treatment with losartan showed further reduction of ENT1 glomerulosclerosis  ENT1END associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure. Losartan reduced uraemia and increased urea clearance in advanced ENT2 ADR ENT2END nephropathy in SHR
0	Prolonged treatment with losartan showed further reduction of ENT1 glomerulosclerosis  ENT1END  associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure. Losartan reduced uraemia and increased ENT2 urea ENT2END clearance in advanced ADR nephropathy in SHR
0	Prolonged treatment with ENT1 losartan  ENT1END  showed further reduction of ENT2 glomerulosclerosis ENT2END associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure
0	Neuroleptic drugs such as haloperidol, which block ENT1 dopamine ENT1END receptors, also cause ENT2 catalepsy ENT2END in rodents
0	RESULTS: L-NOARG sub-chronic administration produced tolerance of ENT1 L-NOARG ENT1END and of haloperidol-induced ENT2 catalepsy ENT2END
1	Sub-chronic inhibition of nitric-oxide synthesis modifies ENT1 haloperidol  ENT1END -induced ENT2 catalepsy ENT2END and the number of NADPH-diaphorase neurons in mice
0	RATIONALE: NG-nitro-L-arginine (L-NOARG), an inhibitor of ENT1 nitric-oxide ENT1END synthase (NOS), induces ENT2 catalepsy ENT2END in mice
0	Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced ENT1 catalepsy  ENT1END  and the number of ENT2 NADPH ENT2END -diaphorase neurons in mice
1	Chemical ENT1 cystitis ENT1END was induced by ENT2 cyclophosphamide ENT2END (CYP) which is metabolized to acrolein, an irritant eliminated in the urine
0	Chemical ENT1 cystitis ENT1END  was induced by cyclophosphamide (CYP) which is metabolized to ENT2 acrolein ENT2END , an irritant eliminated in the urine
0	Immunocytochemical techniques were used to examine alterations in the expression of neuronal ENT1 nitric oxide  ENT1END synthase (NOS) in bladder pathways following acute and chronic irritation of the urinary tract of the rat. Chemical ENT2 cystitis ENT2END was induced by cyclophosphamide (CYP) which is metabolized to acrolein, an irritant eliminated in the urine
0	Immunocytochemical techniques were used to examine alterations in the expression of neuronal nitric oxide synthase (NOS) in bladder pathways following acute and chronic ENT1 irritation of the urinary tract  ENT1END of the rat. Chemical cystitis was induced by ENT2 cyclophosphamide ENT2END (CYP) which is metabolized to acrolein, an irritant eliminated in the urine
0	Immunocytochemical techniques were used to examine alterations in the expression of neuronal nitric oxide synthase (NOS) in bladder pathways following acute and chronic ENT1 irritation of the urinary tract  ENT1END  of the rat. Chemical cystitis was induced by cyclophosphamide (CYP) which is metabolized to ENT2 acrolein ENT2END , an irritant eliminated in the urine
0	Immunocytochemical techniques were used to examine alterations in the expression of neuronal ENT1 nitric oxide  ENT1END  synthase (NOS) in bladder pathways following acute and chronic ENT2 irritation of the urinary tract ENT2END of the rat
0	Increased expression of neuronal nitric oxide synthase in bladder afferent pathways following chronic ENT1 bladder irritation  ENT1END .Immunocytochemical techniques were used to examine alterations in the expression of neuronal nitric oxide synthase (NOS) in bladder pathways following acute and chronic irritation of the urinary tract of the rat. Chemical cystitis was induced by ENT2 cyclophosphamide ENT2END (CYP) which is metabolized to acrolein, an irritant eliminated in the urine
0	Increased expression of neuronal nitric oxide synthase in bladder afferent pathways following chronic ENT1 bladder irritation  ENT1END .Immunocytochemical techniques were used to examine alterations in the expression of neuronal nitric oxide synthase (NOS) in bladder pathways following acute and chronic irritation of the urinary tract of the rat. Chemical cystitis was induced by cyclophosphamide (CYP) which is metabolized to ENT2 acrolein ENT2END , an irritant eliminated in the urine
0	Increased expression of neuronal ENT1 nitric oxide  ENT1END  synthase in bladder afferent pathways following chronic ENT2 bladder irritation ENT2END
0	The plasticity of primary motor cortex (M1) in patients with Parkinson's disease ( ENT1 PD ENT1END  and ENT2 levodopa ENT2END -induced dyskinesias (LIDs) is severely impaired
1	The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and ENT1 levodopa ENT1END -induced ENT2 dyskinesias ENT2END (LIDs) is severely impaired
0	Safety of ENT1 celecoxib  ENT1END  in patients with adverse ENT2 skin reactions ENT2END to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs
1	OBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse ENT1 cutaneous reactions ENT1END to ENT2 P ENT2END and N associated or not to classic NSAIDs
1	The diagnosis of P and ENT1 N ENT1END induced ENT2 skin reactions ENT2END was based in vivo challenge
0	The challenge was considered positive if one or more of the following appeared: ENT1 erythema ENT1END  rush or urticaria-angioedema. RESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated ENT2 CE ENT2END
0	The challenge was considered positive if one or more of the following appeared: ENT1 erythema ENT1END , rush or urticaria-angioedema. RESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips. CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 ENT2 P ENT2END and N-highly NSAIDs intolerant patients
0	The challenge was considered positive if one or more of the following appeared: ENT1 erythema ENT1END , rush or urticaria-angioedema. RESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips. CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and ENT2 N ENT2END -highly NSAIDs intolerant patients
0	CONCLUSION: Only one ENT1 hypersensitivity ENT1END reaction to ENT2 CE ENT2END was documented among 9 P and N-highly NSAIDs intolerant patients
0	METHODS: We studied 9 patients with ENT1 hypersensitivity ENT1END to ENT2 P ENT2END and N with or without associated reactions to classic NSAIDs
0	METHODS: We studied 9 patients with ENT1 hypersensitivity ENT1END  to P and ENT2 N ENT2END with or without associated reactions to classic NSAIDs
1	8%) tolerated ENT1 CE ENT1END . Only one patient developed a moderate ENT2 angioedema ENT2END of the lips
0	Only one patient developed a moderate ENT1 angioedema  ENT1END  of the lips. CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 ENT2 P ENT2END and N-highly NSAIDs intolerant patients
0	Only one patient developed a moderate ENT1 angioedema  ENT1END  of the lips. CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and ENT2 N ENT2END -highly NSAIDs intolerant patients
0	The challenge was considered positive if one or more of the following appeared: erythema, rush or ENT1 urticaria  ENT1END angioedema. RESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated ENT2 CE ENT2END
0	The challenge was considered positive if one or more of the following appeared: erythema, rush or ENT1 urticaria  ENT1END -angioedema. RESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips. CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 ENT2 P ENT2END and N-highly NSAIDs intolerant patients
0	The challenge was considered positive if one or more of the following appeared: erythema, rush or ENT1 urticaria  ENT1END -angioedema. RESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips. CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and ENT2 N ENT2END -highly NSAIDs intolerant patients
1	ENT1 Fluconazole  ENT1END  associated ENT2 agranulocytosis ENT2END and thrombocytopenia
1	ENT1 Fluconazole  ENT1END  associated agranulocytosis and ENT2 thrombocytopenia ENT2END
0	In particular the temporal relationship of ENT1 bone marrow suppression ENT1END to the initiation of ENT2 fluconazole ENT2END and the abatement of symptoms that rapidly reversed immediately following discontinuation
0	The patient began to have changes in white blood cells and platelets within 48 h of administration of ENT1 fluconazole ENT1END and began to recover with 48 h of discontinuation. This case highlights that drug-induced ENT2 blood dyscrasias ENT2END can occur unexpectedly as a result of treatment with a commonly used drug thought to be "safe"
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, ENT1 heparin ENT1END associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, ENT2 hyperkalemia ENT2END , hypoaldosteronism, and priapism
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, ENT1 hypoaldosteronism ENT1END  and priapism. These side effects are relatively rare in a given individual, but given the extremely widespread use of ENT2 heparin ENT2END , some are quite common, particularly HITT and osteoporosis
1	However, additional important untoward effects of heparin therapy include heparin-induced ENT1 thrombocytopenia ENT1END ENT2 heparin ENT2END -associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, ENT1 heparin ENT1END -associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, ENT2 alopecia ENT2END , transaminasemia, hyperkalemia, hypoaldosteronism, and priapism
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, ENT1 heparin ENT1END -associated ENT2 osteoporosis ENT2END , eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and ENT1 priapism  ENT1END  These side effects are relatively rare in a given individual, but given the extremely widespread use of ENT2 heparin ENT2END , some are quite common, particularly HITT and osteoporosis
0	Clinical aspects of heparin-induced thrombocytopenia and ENT1 thrombosis  ENT1END  and other side effects of ENT2 heparin ENT2END therapy
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, ENT1 heparin ENT1END -associated osteoporosis, ENT2 eosinophilia ENT2END , skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, ENT1 heparin ENT1END -associated osteoporosis, eosinophilia, ENT2 skin reactions ENT2END , allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, ENT1 heparin ENT1END -associated osteoporosis, eosinophilia, skin reactions, ENT2 allergic reactions ENT2END other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism
0	Bleeding is the primary untoward effect of ENT1 heparin ENT1END  Major ENT2 bleeding ENT2END is of primary concern in patients receiving heparin therapy
1	Spontaneous ENT1 pain ENT1END behaviors following the administration of ENT2 CYP ENT2END were observed
0	injected with CYP with subsequently perfusion of bladder with P2X3 and NK1 receptors' antagonists, ENT1 Suramin  ENT1END and GR 82334. Spontaneous ENT2 pain ENT2END behaviors following the administration of CYP were observed
0	injected with CYP with subsequently perfusion of bladder with P2X3 and NK1 receptors' antagonists, Suramin and ENT1 GR 82334  ENT1END  Spontaneous ENT2 pain ENT2END behaviors following the administration of CYP were observed
1	Histological changes evident in model and intervention groups rats' bladder included ENT1 edema ENT1END  vasodilation, and infiltration of inflammatory cells. In model group, the expression of P2X3 receptor increased in urothelium and suburothelium, and NK1 receptor increased in suburothelium, while the expression of them in intervention group was lower. CONCLUSIONS: In ENT2 CYP ENT2END -induced cystitis, the expression of P2X3 and NK1 receptors increased in urothelium and/or suburothelium
1	CONCLUSIONS: In ENT1 CYP ENT1END -induced ENT2 cystitis ENT2END , the expression of P2X3 and NK1 receptors increased in urothelium and/or suburothelium
0	PURPOSE: The purpose of the study is to explore the function of P2X3 and NK1 receptors antagonists on cyclophosphamide (CYP)-induced ENT1 cystitis  ENT1END in rats. METHODS: Sixty female Sprague-Dawley (SD) rats were randomly divided into three groups. The rats in the control group were intraperitoneally (i.p.) injected with 0.9% saline (4 ml/kg); the rats in the model group were i.p. injected with CYP (150 mg/kg); and the rats in the intervention group were i.p. injected with CYP with subsequently perfusion of bladder with P2X3 and NK1 receptors' antagonists, ENT2 Suramin ENT2END and GR 82334
0	PURPOSE: The purpose of the study is to explore the function of P2X3 and NK1 receptors antagonists on cyclophosphamide (CYP)-induced ENT1 cystitis  ENT1END  in rats. METHODS: Sixty female Sprague-Dawley (SD) rats were randomly divided into three groups. The rats in the control group were intraperitoneally (i.p.) injected with 0.9% saline (4 ml/kg); the rats in the model group were i.p. injected with CYP (150 mg/kg); and the rats in the intervention group were i.p. injected with CYP with subsequently perfusion of bladder with P2X3 and NK1 receptors' antagonists, Suramin and ENT2 GR 82334 ENT2END
0	On the other hand, induction of metallothionein (MT) by ENT1 ZnSO(4) ENT1END and its role in neuroprotection has been documented. The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal ENT2 cognitive dysfunction ENT2END in rats
1	The present study aimed to explore the effect of MT induction on carmustine ( ENT1 BCNU  ENT1END -induced hippocampal ENT2 cognitive dysfunction ENT2END in rats
0	The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal ENT1 cognitive dysfunction ENT1END  in rats. A total of 60 male Wistar albino rats were randomly divided into four groups (15/group): The control group injected with single doses of normal saline (i.c.v) followed 24 h later by BCNU solvent (i.v). The second group administered ZnSO(4) (0.1 micromol/10 microl normal saline, i.c.v, once) then BCNU solvent (i.v) after 24 h. Third group received BCNU (20 mg/kg, i.v, once) 24 h after injection with normal saline (i.c.v). Fourth group received a single dose of ZnSO(4) (0.1 micromol/10 microl normal saline, i.c.v) then BCNU (20 mg/kg, i.v, once) after 24 h. The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal ENT2 glutathione ENT2END reductase (GR) activity and reduced glutathione (GSH) content
0	The present study aimed to explore the effect of ENT1 MT  ENT1END induction on carmustine (BCNU)-induced hippocampal ENT2 cognitive dysfunction ENT2END in rats
0	Also, BCNU administration increased serum ENT1 tumor ENT1END necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations. ENT2 ZnSO(4) ENT2END pretreatment counteracted BCNU-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3
0	Also, ENT1 BCNU  ENT1END administration increased serum ENT2 tumor ENT2END necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione ( ENT1 GSH  ENT1END  content. Also, BCNU administration increased serum ENT2 tumor ENT2END necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	Also, BCNU administration increased serum ENT1 tumor ENT1END  necrosis factor-alpha (TNFalpha), hippocampal MT and ENT2 malondialdehyde ENT2END (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	Also, BCNU administration increased serum ENT1 tumor ENT1END  necrosis factor-alpha (TNFalpha), hippocampal ENT2 MT ENT2END and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	The histological features were improved in hippocampus of rats treated with ENT1 ZnSO(4) ENT1END + BCNU compared to only BCNU-treated animals. In conclusion, MT induction halts BCNU-induced hippocampal ENT2 toxicity ENT2END as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition
0	In conclusion, MT induction halts ENT1 BCNU  ENT1END induced hippocampal ENT2 toxicity ENT2END as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition
0	In conclusion, MT induction halts BCNU-induced hippocampal ENT1 toxicity ENT1END  as it prevented GR inhibition and ENT2 GSH ENT2END depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition
0	In conclusion, MT induction halts BCNU-induced hippocampal ENT1 toxicity ENT1END  as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, ENT2 MDA ENT2END and caspase-3 activity with subsequent preservation of cognition
0	In conclusion, ENT1 MT  ENT1END induction halts BCNU-induced hippocampal ENT2 toxicity ENT2END as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition
0	Fourth group received a single dose of ENT1 ZnSO(4) ENT1END (0.1 micromol/10 microl normal saline, i.c.v) then BCNU (20 mg/kg, i.v, once) after 24 h. The obtained data revealed that BCNU administration resulted in ENT2 deterioration of learning and short-term memory ENT2END (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content
1	The obtained data revealed that ENT1 BCNU  ENT1END administration resulted in ENT2 deterioration of learning and short-term memory ENT2END (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content
0	The obtained data revealed that BCNU administration resulted in ENT1 deterioration of learning and short-term memory  ENT1END  (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal ENT2 glutathione ENT2END reductase (GR) activity and reduced glutathione (GSH) content
0	The obtained data revealed that BCNU administration resulted in ENT1 deterioration of learning and short-term memory  ENT1END  (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content. Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and ENT2 malondialdehyde ENT2END (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	The obtained data revealed that BCNU administration resulted in ENT1 deterioration of learning and short-term memory  ENT1END  (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content. Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal ENT2 MT ENT2END and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	Also, BCNU administration increased serum tumor ENT1 necrosis  ENT1END factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations. ENT2 ZnSO(4) ENT2END pretreatment counteracted BCNU-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3
0	Also, ENT1 BCNU  ENT1END  administration increased serum tumor ENT2 necrosis ENT2END factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione ( ENT1 GSH  ENT1END ) content. Also, BCNU administration increased serum tumor ENT2 necrosis ENT2END factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	Also, BCNU administration increased serum tumor ENT1 necrosis  ENT1END  factor-alpha (TNFalpha), hippocampal MT and ENT2 malondialdehyde ENT2END (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	Also, BCNU administration increased serum tumor ENT1 necrosis  ENT1END  factor-alpha (TNFalpha), hippocampal ENT2 MT ENT2END and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	Fourth group received a single dose of ENT1 ZnSO(4) ENT1END  (0.1 micromol/10 microl normal saline, i.c.v) then BCNU (20 mg/kg, i.v, once) after 24 h. The obtained data revealed that BCNU administration resulted in ENT2 deterioration of learning and short-term memory ENT2END (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content
1	The obtained data revealed that ENT1 BCNU  ENT1END  administration resulted in ENT2 deterioration of learning and short-term memory ENT2END (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content
0	The obtained data revealed that BCNU administration resulted in ENT1 deterioration of learning and short-term memory  ENT1END  (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal ENT2 glutathione ENT2END reductase (GR) activity and reduced glutathione (GSH) content
0	The obtained data revealed that BCNU administration resulted in ENT1 deterioration of learning and short-term memory  ENT1END  (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content. Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and ENT2 malondialdehyde ENT2END (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	The obtained data revealed that BCNU administration resulted in ENT1 deterioration of learning and short-term memory  ENT1END  (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content. Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal ENT2 MT ENT2END and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) cisplatin every 3 weeks and those with ENT1 hypertension ENT1END are at the greatest risk of nephrotoxicity and would benefit from the addition of ENT2 mannitol ENT2END
0	Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) ENT1 cisplatin  ENT1END every 3 weeks and those with ENT2 hypertension ENT2END are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol
0	2% of patients had head and neck cancer as their primary ENT1 malignancy ENT1END  Patients who did not receive ENT2 mannitol ENT2END were more likely to develop nephrotoxicity: odds ratio [OR] = 2
0	Rates of Renal Toxicity in ENT1 Cancer  ENT1END  Patients Receiving ENT2 Cisplatin ENT2END With and Without Mannitol
0	There are many strategies to prevent this ENT1 toxicity ENT1END  including the use of ENT2 mannitol ENT2END as a nephroprotectant in combination with hydration
0	One of the major complications of ENT1 cisplatin  ENT1END use is dose-limiting nephrotoxicity. There are many strategies to prevent this ENT2 toxicity ENT2END , including the use of mannitol as a nephroprotectant in combination with hydration
0	Patients who did not receive ENT1 mannitol ENT1END  were more likely to develop ENT2 nephrotoxicity ENT2END : odds ratio [OR] = 2
0	OBJECTIVE: We aimed to evaluate the rates of ENT1 cisplatin ENT1END induced ENT2 nephrotoxicity ENT2END in cancer patients receiving single-agent cisplatin with and without mannitol
0	METHODS: This single-center retrospective analysis was a quasi experiment created by the national ENT1 mannitol ENT1END shortage. Data were collected on adult cancer patients receiving single-agent cisplatin as an outpatient from January 2011 to September 2012. The primary outcome was ENT2 acute kidney injury ENT2END (AKI)
1	The primary outcome was acute kidney injury ( ENT1 AKI ENT1END . RESULTS: We evaluated 143 patients who received single-agent ENT2 cisplatin ENT2END ; 97
0	2% of patients had ENT1 head and neck cancer  ENT1END as their primary malignancy. Patients who did not receive ENT2 mannitol ENT2END were more likely to develop nephrotoxicity: odds ratio [OR] = 2
0	RESULTS: We evaluated 143 patients who received single-agent ENT1 cisplatin  ENT1END ; 97.2% of patients had ENT2 head and neck cancer ENT2END as their primary malignancy
0	Peak ENT1 CE ENT1END levels were associated with a 45% (SD +/- 22%, 95% CI = 22% to 69%) decrease in cardiac output (p < 0.05), a 56% (SD +/- 23%, 95% CI = 32% to 80%) decrease in dP/dt(max) (p <.006), and a 23% (SD +/- 15%, 95% CI = 7% to 49%) decrease in SVO(2) (p < 0.025). ENT2 Ventricular arrhythmias ENT2END were primarily observed in the C+E group, in which four of eight dogs experienced ventricular tachycardia
0	ENT1 Ventricular arrhythmias ENT1END  were primarily observed in the C+E group, in which four of eight dogs experienced ventricular tachycardia. CONCLUSIONS: ENT2 Cocaine ENT2END and ethanol in combination were more toxic than either substance alone
0	ENT1 Ventricular arrhythmias ENT1END  were primarily observed in the C+E group, in which four of eight dogs experienced ventricular tachycardia. CONCLUSIONS: Cocaine and ENT2 ethanol ENT2END in combination were more toxic than either substance alone
0	Cocaine, ethanol, and ENT1 cocaethylene ENT1END ENT2 cardiotoxity ENT2END in an animal model of cocaine and ethanol abuse
0	The purpose of this study was to delineate the role of CE in the combined ENT1 cardiotoxicity ENT1END of ENT2 cocaine ENT2END and ethanol in a model simulating their abuse
0	The purpose of this study was to delineate the role of CE in the combined ENT1 cardiotoxicity ENT1END  of cocaine and ENT2 ethanol ENT2END in a model simulating their abuse
0	Cocaine, ethanol, and ENT1 cocaethylene  ENT1END  cardiotoxity in an animal model of ENT2 cocaine and ethanol abuse ENT2END
0	ENT1 Cocaine  ENT1END , ethanol, and cocaethylene cardiotoxity in an animal model of ENT2 cocaine and ethanol abuse ENT2END
0	Cocaine, ENT1 ethanol  ENT1END , and cocaethylene cardiotoxity in an animal model of ENT2 cocaine and ethanol abuse ENT2END
0	Cocaine, ethanol, and ENT1 cocaethylene  ENT1END  cardiotoxity in an animal model of ENT2 cocaine and ethanol abuse ENT2END
0	ENT1 Cocaine  ENT1END , ethanol, and cocaethylene cardiotoxity in an animal model of ENT2 cocaine and ethanol abuse ENT2END
0	Cocaine, ENT1 ethanol  ENT1END , and cocaethylene cardiotoxity in an animal model of ENT2 cocaine and ethanol abuse ENT2END
0	Ventricular arrhythmias were primarily observed in the C+E group, in which four of eight dogs experienced ENT1 ventricular tachycardia ENT1END  CONCLUSIONS: Cocaine and ethanol in combination were more toxic than either substance alone. Co-administration resulted in prolonged cardiac toxicity and was dysrhythmogenic. Peak serum ENT2 cocaethylene ENT2END concentrations were associated with prolonged myocardial depression
1	Ventricular arrhythmias were primarily observed in the C+E group, in which four of eight dogs experienced ENT1 ventricular tachycardia  ENT1END . CONCLUSIONS: ENT2 Cocaine ENT2END and ethanol in combination were more toxic than either substance alone
1	Ventricular arrhythmias were primarily observed in the C+E group, in which four of eight dogs experienced ENT1 ventricular tachycardia  ENT1END . CONCLUSIONS: Cocaine and ENT2 ethanol ENT2END in combination were more toxic than either substance alone
0	Peak serum ENT1 cocaethylene ENT1END  concentrations were associated with prolonged ENT2 myocardial depression ENT2END
0	CONCLUSIONS: ENT1 Cocaine  ENT1END  and ethanol in combination were more toxic than either substance alone. Co-administration resulted in prolonged cardiac toxicity and was dysrhythmogenic. Peak serum cocaethylene concentrations were associated with prolonged ENT2 myocardial depression ENT2END
0	CONCLUSIONS: Cocaine and ENT1 ethanol  ENT1END  in combination were more toxic than either substance alone. Co-administration resulted in prolonged cardiac toxicity and was dysrhythmogenic. Peak serum cocaethylene concentrations were associated with prolonged ENT2 myocardial depression ENT2END
1	Peak ENT1 CE ENT1END  levels were associated with a 45% (SD +/- 22%, 95% CI = 22% to 69%) ENT2 decrease in cardiac output ENT2END (p < 0
0	The most dramatic hemodynamic changes occurred after each ENT1 cocaine  ENT1END bolus in the C+E and C only groups; however, persistent hemodynamic changes occurred in the C+E group. Peak CE levels were associated with a 45% (SD +/- 22%, 95% CI = 22% to 69%) ENT2 decrease in cardiac output ENT2END (p < 0
0	Peak CE levels were associated with a 45% (SD +/- 22%, 95% CI = 22% to 69%) ENT1 decrease in cardiac output  ENT1END  (p < 0.05), a 56% (SD +/- 23%, 95% CI = 32% to 80%) decrease in dP/dt(max) (p <.006), and a 23% (SD +/- 15%, 95% CI = 7% to 49%) decrease in SVO(2) (p < 0.025). Ventricular arrhythmias were primarily observed in the C+E group, in which four of eight dogs experienced ventricular tachycardia. CONCLUSIONS: Cocaine and ENT2 ethanol ENT2END in combination were more toxic than either substance alone
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENT1 potassium aspartate  ENT1END tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti- ENT2 arrhythmic ENT2END property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC
0	ENT1 Quinine  ENT1END -induced ENT2 arrhythmia ENT2END in a patient with severe malaria
0	He was treated with ENT1 lidocaine  ENT1END 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti ENT2 arrhythmic ENT2END property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC
0	It was reported that there was a case of severe malaria patient with jaundice who presented with ENT1 arrhythmia ENT1END (premature ventricular contraction) while getting quinine infusion was reported. A man, 25 years old, was admitted to hospital with high fever, chill, vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total ENT2 bilirubin ENT2END 8
0	Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, ENT1 potassium  ENT1END level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti ENT2 arrhythmic ENT2END property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in ENT1 dextrose  ENT1END 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti ENT2 arrhythmic ENT2END property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC
0	Quinine, like ENT1 quinidine  ENT1END  is a chincona alkaloid that has anti ENT2 arrhythmic ENT2END property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC
0	A man, 25 years old, was admitted to hospital with high ENT1 fever  ENT1END  chill, vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENT2 potassium aspartate ENT2END tablet
0	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting ENT1 quinine  ENT1END infusion was reported. A man, 25 years old, was admitted to hospital with high ENT2 fever ENT2END , chill, vomiting, jaundice
0	A man, 25 years old, was admitted to hospital with high ENT1 fever  ENT1END , chill, vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENT2 lidocaine ENT2END 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	A man, 25 years old, was admitted to hospital with high ENT1 fever  ENT1END , chill, vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total ENT2 bilirubin ENT2END 8
0	A man, 25 years old, was admitted to hospital with high ENT1 fever ENT1END , chill, vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, ENT2 potassium ENT2END 3
0	A man, 25 years old, was admitted to hospital with high ENT1 fever ENT1END , chill, vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in ENT2 dextrose ENT2END 5% 500 mg/8 hour
0	On the second day the patient had vomitus, diarrhea, ENT1 tinnitus  ENT1END  loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENT2 potassium aspartate ENT2END tablet
0	On the second day the patient had vomitus, diarrhea, ENT1 tinnitus ENT1END , loss of hearing. After 30 hours of ENT2 quinine ENT2END infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave
0	On the second day the patient had vomitus, diarrhea, ENT1 tinnitus  ENT1END , loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENT2 lidocaine ENT2END 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	36 mg/dL, unconjugated ENT1 bilirubin  ENT1END 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, ENT2 tinnitus ENT2END , loss of hearing
0	89 mg/dL, ENT1 potassium  ENT1END  3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, ENT2 tinnitus ENT2END , loss of hearing
0	52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in ENT1 dextrose  ENT1END  5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, ENT2 tinnitus ENT2END , loss of hearing
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENT1 potassium aspartate  ENT1END  tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder ( ENT2 hypokalemia ENT2END ) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Administration of parenteral ENT1 quinine ENT1END must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder ENT2 hypokalemia ENT2END ) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	He was treated with ENT1 lidocaine ENT1END  50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder ENT2 hypokalemia ENT2END ) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, ENT1 potassium ENT1END  level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder ENT2 hypokalemia ENT2END ) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in ENT1 dextrose ENT1END  5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder ENT2 hypokalemia ENT2END ) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Quinine, like ENT1 quinidine ENT1END , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder ENT2 hypokalemia ENT2END ) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	On the second day the patient had ENT1 vomitus  ENT1END  diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENT2 potassium aspartate ENT2END tablet
0	On the second day the patient had ENT1 vomitus  ENT1END , diarrhea, tinnitus, loss of hearing. After 30 hours of ENT2 quinine ENT2END infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave
0	On the second day the patient had ENT1 vomitus  ENT1END , diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENT2 lidocaine ENT2END 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	36 mg/dL, unconjugated ENT1 bilirubin  ENT1END  3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had ENT2 vomitus ENT2END , diarrhea, tinnitus, loss of hearing
0	89 mg/dL, ENT1 potassium  ENT1END  3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had ENT2 vomitus ENT2END , diarrhea, tinnitus, loss of hearing
0	52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in ENT1 dextrose  ENT1END  5% 500 mg/8 hour. On the second day the patient had ENT2 vomitus ENT2END , diarrhea, tinnitus, loss of hearing
0	Quinine, like ENT1 quinidine ENT1END , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to ENT2 vomiting ENT2END and or diarrhea in malaria cases
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENT1 potassium aspartate ENT1END  tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in ENT2 malaria ENT2END cases
0	Administration of parenteral ENT1 quinine  ENT1END  must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in ENT2 malaria ENT2END cases
0	He was treated with ENT1 lidocaine  ENT1END  50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in ENT2 malaria ENT2END cases
0	Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, ENT1 potassium  ENT1END  level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in ENT2 malaria ENT2END cases
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in ENT1 dextrose  ENT1END  5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in ENT2 malaria ENT2END cases
0	Quinine, like ENT1 quinidine  ENT1END , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in ENT2 malaria ENT2END cases
0	On the second day the patient had vomitus, diarrhea, tinnitus, ENT1 loss of hearing  ENT1END  After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENT2 potassium aspartate ENT2END tablet
0	On the second day the patient had vomitus, diarrhea, tinnitus, ENT1 loss of hearing  ENT1END . After 30 hours of ENT2 quinine ENT2END infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave
0	On the second day the patient had vomitus, diarrhea, tinnitus, ENT1 loss of hearing  ENT1END . After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENT2 lidocaine ENT2END 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	36 mg/dL, unconjugated ENT1 bilirubin  ENT1END  3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, ENT2 loss of hearing ENT2END
0	89 mg/dL, ENT1 potassium  ENT1END  3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, ENT2 loss of hearing ENT2END
0	52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in ENT1 dextrose  ENT1END  5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, ENT2 loss of hearing ENT2END
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENT1 potassium aspartate ENT1END  tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with ENT2 electrolyte disorder ENT2END (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Administration of parenteral ENT1 quinine  ENT1END  must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with ENT2 electrolyte disorder ENT2END (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	He was treated with ENT1 lidocaine  ENT1END  50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with ENT2 electrolyte disorder ENT2END (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, ENT1 potassium  ENT1END  level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with ENT2 electrolyte disorder ENT2END (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in ENT1 dextrose  ENT1END  5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with ENT2 electrolyte disorder ENT2END (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Quinine, like ENT1 quinidine  ENT1END , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with ENT2 electrolyte disorder ENT2END (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type-- ENT1 sinoatrial block  ENT1END  positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENT2 potassium aspartate ENT2END tablet
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type-- ENT1 sinoatrial block ENT1END , positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. ENT2 Quinine ENT2END infusion was discontinued and changed with sulfate quinine tablets
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type-- ENT1 sinoatrial block  ENT1END , positive U wave. He was treated with ENT2 lidocaine ENT2END 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	36 mg/dL, unconjugated ENT1 bilirubin  ENT1END  3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type- ENT2 sinoatrial block ENT2END , positive U wave
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type-- ENT1 sinoatrial block  ENT1END , positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, ENT2 potassium ENT2END level was 3
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type-- ENT1 sinoatrial block  ENT1END , positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in ENT2 dextrose ENT2END 5%/24 hour and potassium aspartate tablet
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type-- ENT1 sinoatrial block  ENT1END , positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like ENT2 quinidine ENT2END , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC
0	On the second day the patient had vomitus, ENT1 diarrhea  ENT1END  tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENT2 potassium aspartate ENT2END tablet
0	On the second day the patient had vomitus, ENT1 diarrhea  ENT1END , tinnitus, loss of hearing. After 30 hours of ENT2 quinine ENT2END infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave
0	On the second day the patient had vomitus, ENT1 diarrhea  ENT1END , tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENT2 lidocaine ENT2END 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	36 mg/dL, unconjugated ENT1 bilirubin  ENT1END  3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, ENT2 diarrhea ENT2END , tinnitus, loss of hearing
0	89 mg/dL, ENT1 potassium  ENT1END  3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, ENT2 diarrhea ENT2END , tinnitus, loss of hearing
0	52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in ENT1 dextrose  ENT1END  5% 500 mg/8 hour. On the second day the patient had vomitus, ENT2 diarrhea ENT2END , tinnitus, loss of hearing
0	Quinine, like ENT1 quinidine ENT1END , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or ENT2 diarrhea ENT2END in malaria cases
0	52 meq/L Patient was diagnosed as ENT1 severe malaria  ENT1END with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENT2 potassium aspartate ENT2END tablet
0	52 meq/L Patient was diagnosed as ENT1 severe malaria ENT1END  with jaundice and got ENT2 quinine ENT2END infusion in dextrose 5% 500 mg/8 hour
0	52 meq/L Patient was diagnosed as ENT1 severe malaria  ENT1END  with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENT2 lidocaine ENT2END 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	36 mg/dL, unconjugated ENT1 bilirubin  ENT1END  3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as ENT2 severe malaria ENT2END with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour
0	89 mg/dL, ENT1 potassium  ENT1END  3.52 meq/L Patient was diagnosed as ENT2 severe malaria ENT2END with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour
0	52 meq/L Patient was diagnosed as ENT1 severe malaria  ENT1END  with jaundice and got quinine infusion in ENT2 dextrose ENT2END 5% 500 mg/8 hour
0	A man, 25 years old, was admitted to hospital with high fever, ENT1 chill  ENT1END  vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENT2 potassium aspartate ENT2END tablet
0	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting ENT1 quinine  ENT1END  infusion was reported. A man, 25 years old, was admitted to hospital with high fever, ENT2 chill ENT2END , vomiting, jaundice
0	A man, 25 years old, was admitted to hospital with high fever, ENT1 chill  ENT1END , vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENT2 lidocaine ENT2END 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	A man, 25 years old, was admitted to hospital with high fever, ENT1 chill  ENT1END , vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total ENT2 bilirubin ENT2END 8
0	A man, 25 years old, was admitted to hospital with high fever, ENT1 chill  ENT1END , vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, ENT2 potassium ENT2END 3
0	A man, 25 years old, was admitted to hospital with high fever, ENT1 chill  ENT1END , vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in ENT2 dextrose ENT2END 5% 500 mg/8 hour
0	52 meq/L Patient was diagnosed as severe malaria with ENT1 jaundice  ENT1END and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENT2 potassium aspartate ENT2END tablet
0	52 meq/L Patient was diagnosed as severe malaria with ENT1 jaundice  ENT1END  and got ENT2 quinine ENT2END infusion in dextrose 5% 500 mg/8 hour
0	52 meq/L Patient was diagnosed as severe malaria with ENT1 jaundice  ENT1END  and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENT2 lidocaine ENT2END 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	36 mg/dL, unconjugated ENT1 bilirubin  ENT1END  3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with ENT2 jaundice ENT2END and got quinine infusion in dextrose 5% 500 mg/8 hour
0	89 mg/dL, ENT1 potassium  ENT1END  3.52 meq/L Patient was diagnosed as severe malaria with ENT2 jaundice ENT2END and got quinine infusion in dextrose 5% 500 mg/8 hour
0	52 meq/L Patient was diagnosed as severe malaria with ENT1 jaundice  ENT1END  and got quinine infusion in ENT2 dextrose ENT2END 5% 500 mg/8 hour
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENT1 potassium aspartate ENT1END  tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have ENT2 heart diseases ENT2END or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Administration of parenteral ENT1 quinine  ENT1END  must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have ENT2 heart diseases ENT2END or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	He was treated with ENT1 lidocaine  ENT1END  50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have ENT2 heart diseases ENT2END or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, ENT1 potassium  ENT1END  level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have ENT2 heart diseases ENT2END or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in ENT1 dextrose  ENT1END  5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have ENT2 heart diseases ENT2END or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Quinine, like ENT1 quinidine  ENT1END , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have ENT2 heart diseases ENT2END or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENT1 potassium aspartate ENT1END  tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of ENT2 PVC ENT2END reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3
1	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia ( ENT1 premature ventricular contraction  ENT1END  while getting ENT2 quinine ENT2END infusion was reported
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction ( ENT1 PVC  ENT1END  > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENT2 lidocaine ENT2END 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia ( ENT1 premature ventricular contraction  ENT1END ) while getting quinine infusion was reported. A man, 25 years old, was admitted to hospital with high fever, chill, vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total ENT2 bilirubin ENT2END 8
0	Three hours later the patient felt better, the frequency of ENT1 PVC  ENT1END  reduced to 4 - 5 x/minute and on the third day ECG was normal, ENT2 potassium ENT2END level was 3
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction ( ENT1 PVC  ENT1END ) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in ENT2 dextrose ENT2END 5%/24 hour and potassium aspartate tablet
0	Three hours later the patient felt better, the frequency of ENT1 PVC  ENT1END  reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like ENT2 quinidine ENT2END , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC
0	The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the ENT1 neurotoxic ENT1END action of ENT2 DSP4 ENT2END
0	The hyperactivity induced by ENT1 D-amphetamine  ENT1END (10 mumol/kg) was significantly reduced by DSP4 pretreatment. However, the increased rearings and the amphetamine-induced stereotypies were not blocked by pretreatment with DSP4. The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the ENT2 neurotoxic ENT2END action of DSP4
0	The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, ENT1 desipramine  ENT1END  which prevents the ENT2 neurotoxic ENT2END action of DSP4
0	The reduction of ENT1 amphetamine  ENT1END hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the ENT2 neurotoxic ENT2END action of DSP4
0	The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the ENT1 noradrenaline  ENT1END uptake blocking agent, desipramine, which prevents the ENT2 neurotoxic ENT2END action of DSP4
0	The reduction of amphetamine ENT1 hyperactivity ENT1END induced by ENT2 DSP4 ENT2END was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4
1	The ENT1 hyperactivity  ENT1END induced by ENT2 D-amphetamine ENT2END (10 mumol/kg) was significantly reduced by DSP4 pretreatment
0	The reduction of amphetamine ENT1 hyperactivity  ENT1END  induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, ENT2 desipramine ENT2END , which prevents the neurotoxic action of DSP4
0	The reduction of ENT1 amphetamine ENT1END ENT2 hyperactivity ENT2END induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4
0	The reduction of amphetamine ENT1 hyperactivity  ENT1END  induced by DSP4 was blocked by pretreatment with the ENT2 noradrenaline ENT2END -uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4
0	However, the increased rearings and the amphetamine-induced ENT1 stereotypies ENT1END were not blocked by pretreatment with ENT2 DSP4 ENT2END
0	The hyperactivity induced by ENT1 D-amphetamine  ENT1END  (10 mumol/kg) was significantly reduced by DSP4 pretreatment. However, the increased rearings and the amphetamine-induced ENT2 stereotypies ENT2END were not blocked by pretreatment with DSP4
0	However, the increased rearings and the amphetamine-induced ENT1 stereotypies  ENT1END  were not blocked by pretreatment with DSP4. The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, ENT2 desipramine ENT2END , which prevents the neurotoxic action of DSP4
0	However, the increased rearings and the ENT1 amphetamine  ENT1END induced ENT2 stereotypies ENT2END were not blocked by pretreatment with DSP4
0	However, the increased rearings and the amphetamine-induced ENT1 stereotypies  ENT1END  were not blocked by pretreatment with DSP4. The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the ENT2 noradrenaline ENT2END -uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4
1	OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and ENT1 verapamil ENT1END resulting in ENT2 atrioventricular (AV) block ENT2END in both patients and severe hypotension in one patient
1	After the addition of ENT1 clonidine ENT1END 0.15 mg bid she developed complete ENT2 AV block ENT2END , which resolved after all therapy was stopped
0	CASE SUMMARIES: A 54-year-old woman with hyperaldosteronism was treated with verapamil 480 mg/d and ENT1 spironolactone ENT1END 100 mg/d. After the addition of a minimal dose of clonidine (0.15 mg bid), she developed complete ENT2 AV block ENT2END and severe hypotension, which resolved upon cessation of all medications
0	CASE SUMMARIES: A 54-year-old woman with ENT1 hyperaldosteronism ENT1END was treated with ENT2 verapamil ENT2END 480 mg/d and spironolactone 100 mg/d
0	CASE SUMMARIES: A 54-year-old woman with ENT1 hyperaldosteronism ENT1END  was treated with verapamil 480 mg/d and spironolactone 100 mg/d. After the addition of a minimal dose of ENT2 clonidine ENT2END (0
0	CASE SUMMARIES: A 54-year-old woman with ENT1 hyperaldosteronism  ENT1END  was treated with verapamil 480 mg/d and ENT2 spironolactone ENT2END 100 mg/d
1	OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and ENT1 verapamil ENT1END  resulting in atrioventricular (AV) block in both patients and severe ENT2 hypotension ENT2END in one patient
1	After the addition of a minimal dose of ENT1 clonidine ENT1END  (0.15 mg bid), she developed complete AV block and severe ENT2 hypotension ENT2END , which resolved upon cessation of all medications
0	OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and verapamil resulting in atrioventricular (AV) block in both patients and severe ENT1 hypotension  ENT1END  in one patient. CASE SUMMARIES: A 54-year-old woman with hyperaldosteronism was treated with verapamil 480 mg/d and ENT2 spironolactone ENT2END 100 mg/d
0	The ENT1 infections ENT1END responded to antibiotic treatment. Two patients needed a lateral tarsorrhaphy for persistent epithelial defects. CONCLUSIONS: Aerosolized ENT2 crack cocaine ENT2END use can be associated with the development of corneal ulcers
0	Corneal ulcers associated with aerosolized ENT1 crack cocaine ENT1END  use.PURPOSE: We report 4 cases of corneal ulcers associated with drug abuse. The pathogenesis of these ENT2 ulcers ENT2END and management of these patients are also reviewed
0	CONCLUSIONS: Aerosolized ENT1 crack cocaine ENT1END  use can be associated with the development of corneal ulcers. ENT2 Drug abuse ENT2END provides additional challenges for management
1	RESULTS: Four patients with ENT1 corneal ulcers ENT1END associated with ENT2 crack cocaine ENT2END use were reviewed
1	Effects of exercise on the severity of ENT1 isoproterenol  ENT1END -induced ENT2 myocardial infarction ENT2END
0	The results indicated that exercise reduced the mortality associated with the effects of large dosages of ENT1 isoproterenol ENT1END but had little on the severity of the ENT2 infarction ENT2END
0	Randomized clinical trials comparing VNR with other drugs in the treatment of ENT1 cancer ENT1END were searched in Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library from 1987 to 2002. Outcomes of interest were severe cardiac events, toxic deaths and cardiac event-related deaths reported in each publication. We found 19 trials, involving 2441 patients treated by VNR and 2050 control patients. The incidence of cardiac events with VNR was 1.19% [95% confidence interval (CI) (0.75; 1.67)]. There was no difference in the risk of cardiac events between VNR and other drugs [odds ratio: 0.92, 95% CI (0.54; 1.55)]. The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, ENT2 anthracyclines ENT2END , gemcitabine (GEM) em leader ]
0	Randomized clinical trials comparing ENT1 VNR  ENT1END with other drugs in the treatment of ENT2 cancer ENT2END were searched in Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library from 1987 to 2002
0	Randomized clinical trials comparing VNR with other drugs in the treatment of ENT1 cancer ENT1END  were searched in Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library from 1987 to 2002. Outcomes of interest were severe cardiac events, toxic deaths and cardiac event-related deaths reported in each publication. We found 19 trials, involving 2441 patients treated by VNR and 2050 control patients. The incidence of cardiac events with VNR was 1.19% [95% confidence interval (CI) (0.75; 1.67)]. There was no difference in the risk of cardiac events between VNR and other drugs [odds ratio: 0.92, 95% CI (0.54; 1.55)]. The risk of VNR cardiac events was similar to ENT2 vindesine ENT2END (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ]
0	Randomized clinical trials comparing VNR with other drugs in the treatment of ENT1 cancer  ENT1END  were searched in Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library from 1987 to 2002. Outcomes of interest were severe cardiac events, toxic deaths and cardiac event-related deaths reported in each publication. We found 19 trials, involving 2441 patients treated by VNR and 2050 control patients. The incidence of cardiac events with VNR was 1.19% [95% confidence interval (CI) (0.75; 1.67)]. There was no difference in the risk of cardiac events between VNR and other drugs [odds ratio: 0.92, 95% CI (0.54; 1.55)]. The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [ ENT2 fluorouracil ENT2END , anthracyclines, gemcitabine (GEM) em leader ]
0	Randomized clinical trials comparing VNR with other drugs in the treatment of ENT1 cancer ENT1END  were searched in Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library from 1987 to 2002. Outcomes of interest were severe cardiac events, toxic deaths and cardiac event-related deaths reported in each publication. We found 19 trials, involving 2441 patients treated by VNR and 2050 control patients. The incidence of cardiac events with VNR was 1.19% [95% confidence interval (CI) (0.75; 1.67)]. There was no difference in the risk of cardiac events between VNR and other drugs [odds ratio: 0.92, 95% CI (0.54; 1.55)]. The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, ENT2 gemcitabine ENT2END (GEM) em leader ]
0	The risk of VNR cardiac events was similar to vindesine (VDS) and other ENT1 cardiotoxic  ENT1END drugs [fluorouracil, ENT2 anthracyclines ENT2END , gemcitabine (GEM) em leader ]
1	The risk of ENT1 VNR  ENT1END cardiac events was similar to vindesine (VDS) and other ENT2 cardiotoxic ENT2END drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ]
0	The risk of VNR cardiac events was similar to vindesine ( ENT1 VDS  ENT1END  and other ENT2 cardiotoxic ENT2END drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ]
0	The risk of VNR cardiac events was similar to vindesine (VDS) and other ENT1 cardiotoxic ENT1END  drugs ENT2 fluorouracil ENT2END , anthracyclines, gemcitabine (GEM) em leader ]
0	The risk of VNR cardiac events was similar to vindesine (VDS) and other ENT1 cardiotoxic  ENT1END  drugs [fluorouracil, anthracyclines, ENT2 gemcitabine ENT2END (GEM) em leader ]
0	The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, ENT1 anthracyclines ENT1END , gemcitabine (GEM) em leader ]. Even if it did not reach statistical significance because of a few number of cases, the risk was lower in trials excluding patients with cardiac history, and seemed to be higher in trials including patients with pre-existing ENT2 cardiac diseases ENT2END
0	Even if it did not reach statistical significance because of a few number of cases, the risk was lower in trials excluding patients with cardiac history, and seemed to be higher in trials including patients with pre-existing ENT1 cardiac diseases ENT1END . ENT2 Vinorelbine ENT2END -related cardiac events concern about 1% of treated patients in clinical trials
0	The risk of VNR cardiac events was similar to vindesine ( ENT1 VDS  ENT1END ) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ]. Even if it did not reach statistical significance because of a few number of cases, the risk was lower in trials excluding patients with cardiac history, and seemed to be higher in trials including patients with pre-existing ENT2 cardiac diseases ENT2END
0	The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [ ENT1 fluorouracil  ENT1END , anthracyclines, gemcitabine (GEM) em leader ]. Even if it did not reach statistical significance because of a few number of cases, the risk was lower in trials excluding patients with cardiac history, and seemed to be higher in trials including patients with pre-existing ENT2 cardiac diseases ENT2END
0	The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine ( ENT1 GEM  ENT1END  em leader ]. Even if it did not reach statistical significance because of a few number of cases, the risk was lower in trials excluding patients with cardiac history, and seemed to be higher in trials including patients with pre-existing ENT2 cardiac diseases ENT2END
1	ENT1 Morphine  ENT1END -induced ENT2 seizures ENT2END in newborn infants
0	BACKGROUND: Most patients presenting to emergency departments (EDs) with ENT1 cocaine ENT1END associated chest pain are admitted for at least 12 hours and receive a "rule out ENT2 acute coronary syndrome ENT2END " protocol, often with noninvasive testing prior to discharge
0	Six patients had ENT1 coronary stenosis ENT1END >or=50%. During the 30-day follow-up period, no patients died of a cardiovascular event (0%; 95% CI, 0-6.1%) and no patient sustained a nonfatal myocardial infarction (0%; 95% CI, 0-6.1%). CONCLUSIONS: Although ENT2 cocaine ENT2END -associated myocardial ischemia can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events
0	CONCLUSIONS: Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with ENT1 cocaine  ENT1END associated chest pain, a non- ENT2 ischemic ENT2END ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events
1	CONCLUSIONS: Although ENT1 cocaine ENT1END -associated ENT2 myocardial ischemia ENT2END can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events
0	The main outcome was 30-day cardiovascular death or ENT1 myocardial infarction ENT1END  RESULTS: A total of 59 patients with ENT2 cocaine ENT2END -associated chest pain were evaluated
1	Coronary computerized tomography angiography for rapid discharge of low-risk patients with ENT1 cocaine  ENT1END -associated ENT2 chest pain ENT2END
0	It is unclear whether a coronary CTA strategy would be efficacious in ENT1 cocaine ENT1END associated chest pain, as ENT2 coronary vasospasm ENT2END may account for some of the ischemia
0	Patients with negative coronary CTA (maximal ENT1 stenosis  ENT1END less than 50%) were discharged. The main outcome was 30-day cardiovascular death or myocardial infarction. RESULTS: A total of 59 patients with ENT2 cocaine ENT2END -associated chest pain were evaluated
0	An unexpected diagnosis in a renal-transplant patient with proteinuria treated with everolimus: AL ENT1 amyloidosis ENT1END .Proteinuria is an expected complication in transplant patients treated with mammalian target of ENT2 rapamycin ENT2END inhibitors (mTOR-i)
0	In this case we report the unexpected diagnosis of ENT1 amyloidosis ENT1END in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from ENT2 tacrolimus ENT2END to everolimus
1	An unexpected diagnosis in a renal-transplant patient with proteinuria treated with ENT1 everolimus  ENT1END : ENT2 AL ENT2END amyloidosis
0	Proteinuria is an expected complication in transplant patients treated with mammalian target of ENT1 rapamycin ENT1END  inhibitors (mTOR-i). However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial fibrosis and tubular atrophy, or recurrent or de novo ENT2 glomerulopathy ENT2END
0	However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial fibrosis and tubular atrophy, or recurrent or de novo ENT1 glomerulopathy  ENT1END . In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from ENT2 tacrolimus ENT2END to everolimus
0	However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial fibrosis and tubular atrophy, or recurrent or de novo ENT1 glomerulopathy ENT1END . In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to ENT2 everolimus ENT2END
0	Proteinuria is an expected complication in transplant patients treated with mammalian target of ENT1 rapamycin ENT1END  inhibitors (mTOR-i). However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial ENT2 fibrosis ENT2END and tubular atrophy, or recurrent or de novo glomerulopathy
0	However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial ENT1 fibrosis  ENT1END  and tubular atrophy, or recurrent or de novo glomerulopathy. In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from ENT2 tacrolimus ENT2END to everolimus
0	However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial ENT1 fibrosis  ENT1END  and tubular atrophy, or recurrent or de novo glomerulopathy. In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to ENT2 everolimus ENT2END
0	Proteinuria is an expected complication in transplant patients treated with mammalian target of ENT1 rapamycin ENT1END  inhibitors (mTOR-i). However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial fibrosis and tubular ENT2 atrophy ENT2END , or recurrent or de novo glomerulopathy
0	However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial fibrosis and tubular ENT1 atrophy  ENT1END , or recurrent or de novo glomerulopathy. In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from ENT2 tacrolimus ENT2END to everolimus
0	However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial fibrosis and tubular ENT1 atrophy  ENT1END , or recurrent or de novo glomerulopathy. In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to ENT2 everolimus ENT2END
0	ENT1 Proteinuria  ENT1END is an expected complication in transplant patients treated with mammalian target of ENT2 rapamycin ENT2END inhibitors (mTOR-i)
0	In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed ENT1 proteinuria  ENT1END after conversion from ENT2 tacrolimus ENT2END to everolimus
1	An unexpected diagnosis in a renal-transplant patient with ENT1 proteinuria  ENT1END  treated with ENT2 everolimus ENT2END : AL amyloidosis
0	Dehydrated rats regularly develop ENT1 acute renal failure ENT1END following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe ENT2 TCA ENT2END cycle and other acidic compounds
0	Dehydrated rats regularly develop ENT1 acute renal failure ENT1END  following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, ENT2 sugar alcohols ENT2END , substances inthe TCA cycle and other acidic compounds
0	Dehydrated rats regularly develop ENT1 acute renal failure ENT1END  following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of ENT2 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone ENT2END protected rats against renal failure induced by kanamycin-dextran
1	Dehydrated rats regularly develop ENT1 acute renal failure ENT1END  following single injection of ENT2 aminoglycoside ENT2END antibiotics combined with dextran or of antibiotics only
1	Dehydrated rats regularly develop ENT1 acute renal failure ENT1END  following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by ENT2 kanamycin ENT2END -dextran
0	Dehydrated rats regularly develop ENT1 acute renal failure ENT1END  following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, ENT2 hexauronic acids ENT2END and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe TCA cycle and other acidic compounds
0	Effect of ENT1 D-Glucarates  ENT1END  on basic antibiotic-induced renal damage in rats.Dehydrated rats regularly develop ENT2 acute renal failure ENT2END following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only
0	Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against ENT1 renal failure  ENT1END induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe ENT2 TCA ENT2END cycle and other acidic compounds
0	Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against ENT1 renal failure  ENT1END  induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, ENT2 sugar alcohols ENT2END , substances inthe TCA cycle and other acidic compounds
0	Oral administration of ENT1 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone  ENT1END  protected rats against ENT2 renal failure ENT2END induced by kanamycin-dextran
0	Dehydrated rats regularly develop acute renal failure following single injection of ENT1 aminoglycoside  ENT1END  antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against ENT2 renal failure ENT2END induced by kanamycin-dextran
0	Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against ENT1 renal failure  ENT1END  induced by ENT2 kanamycin ENT2END -dextran
0	Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against ENT1 renal failure  ENT1END  induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, ENT2 hexauronic acids ENT2END and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe TCA cycle and other acidic compounds
0	Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against ENT1 renal failure ENT1END  induced by kanamycin-dextran. The protective effect was prevalent among ENT2 D-glucarates ENT2END , and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe TCA cycle and other acidic compounds
0	The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe ENT1 TCA ENT1END  cycle and other acidic compounds. D-Glucarates were effective against ENT2 renal damage ENT2END induced by peptide antibiotics as well as various aminoglycoside antibitocis
0	The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, ENT1 sugar alcohols  ENT1END , substances inthe TCA cycle and other acidic compounds. D-Glucarates were effective against ENT2 renal damage ENT2END induced by peptide antibiotics as well as various aminoglycoside antibitocis
0	Effect of D-Glucarates on basic antibiotic-induced ENT1 renal damage  ENT1END  in rats.Dehydrated rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of ENT2 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone ENT2END protected rats against renal failure induced by kanamycin-dextran
0	Rats excreted acidic urine when they were spared from ENT1 renal lesions ENT1END by ENT2 monosaccharides ENT2END
0	D-Glucarates were effective against ENT1 renal damage ENT1END  induced by peptide antibiotics as well as various ENT2 aminoglycoside ENT2END antibitocis
0	Effect of D-Glucarates on basic antibiotic-induced ENT1 renal damage  ENT1END  in rats.Dehydrated rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by ENT2 kanamycin ENT2END -dextran
0	The protective effect was prevalent among D-glucarates, and also to other saccharic acid, ENT1 hexauronic acids  ENT1END  and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe TCA cycle and other acidic compounds. D-Glucarates were effective against ENT2 renal damage ENT2END induced by peptide antibiotics as well as various aminoglycoside antibitocis
0	The reduction effect of ENT1 D-glucarates ENT1END against ENT2 nephrotoxicity ENT2END of basic antibiotics was discussed
0	ENT1 Dehydrated  ENT1END rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe ENT2 TCA ENT2END cycle and other acidic compounds
0	ENT1 Dehydrated  ENT1END  rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, ENT2 sugar alcohols ENT2END , substances inthe TCA cycle and other acidic compounds
0	ENT1 Dehydrated  ENT1END  rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of ENT2 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone ENT2END protected rats against renal failure induced by kanamycin-dextran
0	ENT1 Dehydrated  ENT1END  rats regularly develop acute renal failure following single injection of ENT2 aminoglycoside ENT2END antibiotics combined with dextran or of antibiotics only
0	ENT1 Dehydrated  ENT1END  rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by ENT2 kanamycin ENT2END -dextran
0	ENT1 Dehydrated  ENT1END  rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, ENT2 hexauronic acids ENT2END and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe TCA cycle and other acidic compounds
0	Effect of ENT1 D-Glucarates  ENT1END  on basic antibiotic-induced renal damage in rats ENT2 Dehydrated ENT2END rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only
0	Codeine ENT1 catalepsy ENT1END was increased by clonidine and decreased by naphazoline and xylometazoline. The brain concentration of NA was not changed by morphine and fentanyl, but one of the doses of codeine (45 mg/kg) slightly enhanced it. Pentazocine dose-dependently decreased the brain level of NA. The rate of NA turnover was not altered by analgesics except for the higher dose of fentanyl (0.2 mg/kg) following which the disappearance of NA from the brain was diminished. The results are discussed in the light of various and non-uniform data from the literature. It is suggested that in rats the brain NA plays a less important function than the other ENT2 monoamines ENT2END in the behavioural activity of potent analgesics
1	ENT1 Codeine ENT1END ENT2 catalepsy ENT2END was increased by clonidine and decreased by naphazoline and xylometazoline
0	It was found that three drugs stimulating central ENT1 NA ENT1END receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced ENT2 catalepsy ENT2END induced by morphine and fentanyl
1	The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on ENT1 cataleptic ENT1END effect of ENT2 morphine ENT2END , codine and fentanyl was studied in rats
1	Codeine ENT1 catalepsy ENT1END  was increased by clonidine and decreased by naphazoline and ENT2 xylometazoline ENT2END
1	It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced catalepsy induced by morphine and ENT1 fentanyl  ENT1END  Codeine ENT2 catalepsy ENT2END was increased by clonidine and decreased by naphazoline and xylometazoline
1	Codeine ENT1 catalepsy ENT1END  was increased by clonidine and decreased by ENT2 naphazoline ENT2END and xylometazoline
1	Codeine ENT1 catalepsy ENT1END  was increased by ENT2 clonidine ENT2END and decreased by naphazoline and xylometazoline
0	The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and ENT1 pentazocine  ENT1END  and on ENT2 cataleptic ENT2END effect of morphine, codine and fentanyl was studied in rats
1	After the end of fenoterol-hydrobromide infusion, ENT1 tremor ENT1END amplitudes decreased significantly faster than those following ENT2 ritodrin-HCl ENT2END infusion
1	After the end of ENT1 fenoterol-hydrobromide  ENT1END infusion, ENT2 tremor ENT2END amplitudes decreased significantly faster than those following ritodrin-HCl infusion
0	Changes in serum ENT1 creatinine ENT1END after intervention (after-before) were significantly different between the PTRA and PCI groups (-0.12+/-0.5 vs. 0.13+/-0.3, P=0.014). This difference was not related to either a different clinical risk profile or to the volume of CM administered. CONCLUSION: In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients. The effectiveness of PTRA on renal function seems to be barely influenced by CM ENT2 toxicity ENT2END
0	The effectiveness of PTRA on renal function seems to be barely influenced by ENT1 CM ENT1END ENT2 toxicity ENT2END
0	PURPOSE: To compare the susceptibility to ENT1 nephrotoxic ENT1END effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention (PCI). MATERIAL AND METHODS: A total of 33 patients successfully treated with PTRA (PTRA group, mean age 70+/-12 years, 23 female, basal ENT2 creatinine ENT2END 1
1	ENT1 Contrast medium ENT1END ENT2 nephrotoxicity ENT2END after renal artery and coronary angioplasty
0	CB1 KO mice exhibited higher ENT1 MDA ENT1END levels and iNOS protein expression in the CPu and Cg compared to WT mice. Treatment with L-DOPA+benserazide (12 weeks) resulted in less severe ENT2 dyskinesias ENT2END in CB1 KO than in WT mice
0	Increased vulnerability to 6-hydroxydopamine lesion and reduced development of ENT1 dyskinesias ENT1END  in mice lacking CB1 cannabinoid receptors.Motor impairment, dopamine (DA) neuronal activity and ENT2 proenkephalin ENT2END (PENK) gene expression in the caudate-putamen (CPu) were measured in 6-OHDA-lesioned and treated (L-DOPA+benserazide) CB1 KO and WT mice
0	Treatment with ENT1 L-DOPA+benserazide  ENT1END (12 weeks) resulted in less severe ENT2 dyskinesias ENT2END in CB1 KO than in WT mice
1	The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and DA lesion, and reduced ENT1 L-DOPA ENT1END induced ENT2 dyskinesias ENT2END
0	The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and ENT1 DA  ENT1END lesion, and reduced L-DOPA-induced ENT2 dyskinesias ENT2END
0	Increased vulnerability to ENT1 6-hydroxydopamine  ENT1END  lesion and reduced development of ENT2 dyskinesias ENT2END in mice lacking CB1 cannabinoid receptors
1	Central cardiovascular effects of ENT1 AVP  ENT1END  and ANP in normotensive and spontaneously ENT2 hypertensive ENT2END rats
0	Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced ENT1 hypertension ENT1END and ENT2 sodium nitroprusside ENT2END (SN)-induced hypotension
1	Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine ( ENT1 Phe  ENT1END -induced ENT2 hypertension ENT2END and sodium nitroprusside (SN)-induced hypotension
0	CCB was reduced in WKY and SHR after LV administration of ENT1 AVP ENT1END during SN-induced ENT2 hypotension ENT2END
1	CCB was reduced in WKY and SHR after LV administration of AVP during ENT1 SN  ENT1END induced ENT2 hypotension ENT2END
0	Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine ( ENT1 Phe ENT1END )-induced hypertension and sodium nitroprusside (SN)-induced ENT2 hypotension ENT2END
0	We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial ENT1 fibrosis ENT1END independently of microalbuminuria in mice with ENT2 streptozotocin ENT2END (STZ)-induced diabetes
0	OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin- ENT1 angiotensin  ENT1END system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy). We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial ENT2 fibrosis ENT2END independently of microalbuminuria in mice with streptozotocin (STZ)-induced diabetes
0	We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin ( ENT1 STZ ENT1END -induced ENT2 diabetes ENT2END
0	OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin- ENT1 angiotensin  ENT1END  system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy). We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin (STZ)-induced ENT2 diabetes ENT2END
0	Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of ENT1 streptozotocin ENT1END -induced diabetic nephropathy.OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-angiotensin system in patients with ENT2 type 1 diabetes ENT2END and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy)
0	OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin- ENT1 angiotensin  ENT1END  system in patients with ENT2 type 1 diabetes ENT2END and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy)
0	Immunoprecipitation/Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in ENT1 STZ ENT1END induced diabetic nephropathy. Confocal microscopy and real-time PCR further demonstrated that SIS3 abrogated EndoMT, reduced renal fibrosis, and retarded progression of ENT2 nephropathy ENT2END
0	OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin- ENT1 angiotensin ENT1END  system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of ENT2 nephropathy ENT2END , suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy)
0	Immunoprecipitation/Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in ENT1 STZ ENT1END -induced diabetic nephropathy. Confocal microscopy and real-time PCR further demonstrated that SIS3 abrogated EndoMT, reduced renal fibrosis, and retarded progression of nephropathy. CONCLUSIONS: EndoMT is a novel pathway leading to early development of diabetic nephropathy. Blockade of EndoMT by SIS3 may provide a new strategy to retard the progression of diabetic nephropathy and other ENT2 diabetes complications ENT2END
1	Blocking studies using receptor for AGE siRNA and a specific inhibitor of Smad3 (SIS3) were performed in MMECs and in ENT1 STZ ENT1END induced ENT2 diabetic nephropathy ENT2END in Tie2-Cre;Loxp-EGFP mice
0	Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced ENT1 diabetic nephropathy  ENT1END .OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin ENT2 angiotensin ENT2END system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy)
0	The aim of this study is to show that FPD from MEA (Multielectrode array) of hiPS-CMs can detect ENT1 QT prolongation ENT1END induced by multichannel blockers. hiPS-CMs were seeded onto MEA and FPD was measured for 2min every 10min for 30min after drug exposure for the vehicle and each drug concentration. IKr and IKs blockers concentration-dependently prolonged corrected FPD (FPDc), whereas Ca(2+) channel blockers concentration-dependently shortened FPDc. Also, the multichannel blockers ENT2 Amiodarone ENT2END , Paroxetine, Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner
0	The aim of this study is to show that FPD from MEA (Multielectrode array) of hiPS-CMs can detect ENT1 QT prolongation ENT1END  induced by multichannel blockers. hiPS-CMs were seeded onto MEA and FPD was measured for 2min every 10min for 30min after drug exposure for the vehicle and each drug concentration. IKr and IKs blockers concentration-dependently prolonged corrected FPD (FPDc), whereas Ca(2+) channel blockers concentration-dependently shortened FPDc. Also, the multichannel blockers Amiodarone, ENT2 Paroxetine ENT2END , Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner
0	Field potential duration (FPD) in human-induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs), which can express QT interval in an electrocardiogram, is reported to be a useful tool to predict K(+) channel and ENT1 Ca ENT1END 2+) channel blocker effects on QT interval. However, there is no report showing that this technique can be used to predict multichannel blocker potential for ENT2 QT prolongation ENT2END
0	The aim of this study is to show that FPD from MEA (Multielectrode array) of hiPS-CMs can detect ENT1 QT prolongation ENT1END  induced by multichannel blockers. hiPS-CMs were seeded onto MEA and FPD was measured for 2min every 10min for 30min after drug exposure for the vehicle and each drug concentration. IKr and IKs blockers concentration-dependently prolonged corrected FPD (FPDc), whereas Ca(2+) channel blockers concentration-dependently shortened FPDc. Also, the multichannel blockers Amiodarone, Paroxetine, Terfenadine and ENT2 Citalopram ENT2END prolonged FPDc in a concentration dependent manner
0	Field potential duration (FPD) in human-induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs), which can express QT interval in an electrocardiogram, is reported to be a useful tool to predict ENT1 K  ENT1END +) channel and Ca(2+) channel blocker effects on QT interval. However, there is no report showing that this technique can be used to predict multichannel blocker potential for ENT2 QT prolongation ENT2END
0	The aim of this study is to show that FPD from MEA (Multielectrode array) of hiPS-CMs can detect ENT1 QT prolongation ENT1END  induced by multichannel blockers. hiPS-CMs were seeded onto MEA and FPD was measured for 2min every 10min for 30min after drug exposure for the vehicle and each drug concentration. IKr and IKs blockers concentration-dependently prolonged corrected FPD (FPDc), whereas Ca(2+) channel blockers concentration-dependently shortened FPDc. Also, the multichannel blockers Amiodarone, Paroxetine, ENT2 Terfenadine ENT2END and Citalopram prolonged FPDc in a concentration dependent manner
0	Also, the multichannel blockers ENT1 Amiodarone ENT1END , Paroxetine, Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner. Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause ENT2 Torsade de Pointes ENT2END (TdP) in clinical practice, produced early afterdepolarization (EAD)
0	Also, the multichannel blockers Amiodarone, ENT1 Paroxetine  ENT1END , Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner. Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause ENT2 Torsade de Pointes ENT2END (TdP) in clinical practice, produced early afterdepolarization (EAD)
0	IKr and IKs blockers concentration-dependently prolonged corrected FPD (FPDc), whereas ENT1 Ca  ENT1END 2+) channel blockers concentration-dependently shortened FPDc. Also, the multichannel blockers Amiodarone, Paroxetine, Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner. Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause ENT2 Torsade de Pointes ENT2END (TdP) in clinical practice, produced early afterdepolarization (EAD)
1	Finally, the IKr blockers, Terfenadine and ENT1 Citalopram  ENT1END  which are reported to cause ENT2 Torsade de Pointes ENT2END (TdP) in clinical practice, produced early afterdepolarization (EAD)
1	Finally, the IKr blockers, ENT1 Terfenadine  ENT1END and Citalopram, which are reported to cause ENT2 Torsade de Pointes ENT2END (TdP) in clinical practice, produced early afterdepolarization (EAD)
0	In a random fashion, they received cimetidine 200 mg iv on one day, and on the other, a pretreatment of ENT1 diphenhydramine ENT1END 40 mg iv with cimetidine 200 mg iv. In the non-pretreatment group, mean arterial pressure (MAP) decreased from 107.4 +/- 8.4 mmHg to 86.7 +/- 11.4 mmHg (P less than 0.01) two minutes after cimetidine. Also, systemic vascular resistance (SVR) decreased during the eight-minute observation period (P less than 0.01). In contrast, in the pretreatment group, little haemodynamic change was seen. We conclude that an H1 antagonist may be useful in preventing ENT2 hypotension ENT2END caused by iv cimetidine, since the vasodilating activity of cimetidine is mediated, in part, through the H1 receptor
1	We conclude that an H1 antagonist may be useful in preventing ENT1 hypotension ENT1END  caused by iv ENT2 cimetidine ENT2END , since the vasodilating activity of cimetidine is mediated, in part, through the H1 receptor
1	In the control group implants contained no ENT1 PDN ENT1END  ENT2 Anxiety ENT2END was assessed using an open field and elevated plus-maze devices
0	ENT1 Misoprostol ENT1END has been associated with adverse reactions, including gastrointestinal symptoms, gynecologic problems, and ENT2 headache ENT2END
1	Her ENT1 delirium ENT1END significantly improved after ENT2 misoprostol ENT2END was discontinued and her mental status returned to normal within a week
0	We report a case of acute renal failure after HD- ENT1 MTX ENT1END therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for congenital ENT2 biliary atresia ENT2END
0	High-dose methotrexate (HD- ENT1 MTX ENT1END  is an important treatment for Burkitt lymphoma, but can cause ENT2 hepatic and renal toxicity ENT2END when its clearance is delayed
0	High-dose methotrexate (HD- ENT1 MTX ENT1END ) is an important treatment for ENT2 Burkitt lymphoma ENT2END , but can cause hepatic and renal toxicity when its clearance is delayed
0	Subsequent HD- ENT1 MTX ENT1END therapy caused acute renal failure that required continuous hemodialysis. We supposed that intravascular ENT2 hypovolemia ENT2END due to substantial drainage from the ileostoma caused acute prerenal failure
1	We report a case of ENT1 acute renal failure  ENT1END after HD ENT2 MTX ENT2END therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for congenital biliary atresia
0	High-dose methotrexate (HD- ENT1 MTX ENT1END ) is an important treatment for Burkitt lymphoma, but can cause ENT2 hepatic and renal toxicity ENT2END when its clearance is delayed
0	At day 833 after the transplantation, he was diagnosed with PTLD ( ENT1 post-transplantation lymphoproliferative disorder  ENT1END  Burkitt-type malignant lymphoma). During induction therapy, he suffered ileal perforation and ileostomy was performed. Subsequent HD ENT2 MTX ENT2END therapy caused acute renal failure that required continuous hemodialysis
1	ENT1 Downbeat nystagmus  ENT1END  associated with intravenous patient-controlled administration of ENT2 morphine ENT2END
1	Downbeat nystagmus associated with intravenous patient-controlled administration of ENT1 morphine ENT1END .IMPLICATIONS: This case documents a patient who developed ENT2 dizziness ENT2END with downbeating nystagmus while receiving a relatively large dose of IV patient-controlled analgesia morphine
0	Anticholinesterases were administered in an attempt to antagonize prolonged ENT1 neuromuscular blockade ENT1END following the administration of succinylcholine in a patient later found to be homozygous for atypical plasma cholinesterase. ENT2 Edrophonium ENT2END 10 mg, given 74 min after succinylcholine, when train-of-four stimulation was characteristic of phase II block, produced partial antagonism which was not sustained
0	Anticholinesterases were administered in an attempt to antagonize prolonged ENT1 neuromuscular blockade ENT1END  following the administration of ENT2 succinylcholine ENT2END in a patient later found to be homozygous for atypical plasma cholinesterase
0	Anticholinesterases were administered in an attempt to antagonize prolonged ENT1 neuromuscular blockade ENT1END  following the administration of succinylcholine in a patient later found to be homozygous for atypical plasma cholinesterase. Edrophonium 10 mg, given 74 min after succinylcholine, when train-of-four stimulation was characteristic of phase II block, produced partial antagonism which was not sustained. Repeated doses of edrophonium to 70 mg and ENT2 neostigmine ENT2END to 2
0	Succinylcholine ENT1 apnoea  ENT1END : attempted reversal with anticholinesterases.Anticholinesterases were administered in an attempt to antagonize prolonged neuromuscular blockade following the administration of succinylcholine in a patient later found to be homozygous for atypical plasma cholinesterase. ENT2 Edrophonium ENT2END 10 mg, given 74 min after succinylcholine, when train-of-four stimulation was characteristic of phase II block, produced partial antagonism which was not sustained
1	ENT1 Succinylcholine ENT1END ENT2 apnoea ENT2END : attempted reversal with anticholinesterases
0	Repeated doses of edrophonium to 70 mg and ENT1 neostigmine ENT1END  to 2.5 mg did not antagonize or augment the block. Spontaneous respiration recommenced 200 min after succinylcholine administration. It is concluded that anticholinesterases are only partially effective in restoring neuromuscular function in succinylcholine ENT2 apnoea ENT2END despite muscle twitch activity typical of phase II block
0	ENT1 Cancer  ENT1END  incidence and ENT2 metolachlor ENT2END use in the Agricultural Health Study: An update
0	An earlier suggestion of increased ENT1 lung cancer ENT1END risk at high levels of ENT2 metolachlor ENT2END use in this cohort was not confirmed in this update
1	A similar pattern was observed for ENT1 follicular cell lymphoma  ENT1END  but no other lymphoma subtypes. An earlier suggestion of increased lung cancer risk at high levels of ENT2 metolachlor ENT2END use in this cohort was not confirmed in this update
0	However, our findings for both liver cancer and follicular cell ENT1 lymphoma ENT1END warrant follow-up to better differentiate effects of ENT2 metolachlor ENT2END use from other factors
1	This suggestion of an association between ENT1 metolachlor ENT1END and ENT2 liver cancer ENT2END among pesticide applicators is a novel finding and echoes observation of increased liver neoplasms in some animal studies
0	ENT1 Topotecan ENT1END is an attractive option as it exhibits growth inhibition of human ENT2 glioma ENT2END as well as brain penetration
0	The present study assessed the combination of radiotherapy (60 Gy/30 fractions/40 days) and ENT1 topotecan ENT1END (0.9 mg/m(2)/day on days 1-5 on weeks 1, 3 and 5) in 50 adults with histologically proven and untreated GBM. The incidence of non-hematological ENT2 toxicities ENT2END was low and grade 3-4 hematological toxicities were reported in 20 patients (mainly lymphopenia and neutropenia)
0	ENT1 Topotecan  ENT1END  in combination with radiotherapy in unresectable ENT2 glioblastoma ENT2END : a phase 2 study
1	The incidence of non-hematological toxicities was low and grade 3-4 hematological toxicities were reported in 20 patients (mainly ENT1 lymphopenia ENT1END and neutropenia). Partial response and stabilization rates were 2% and 32%, respectively, with an overall time to progression of 12 weeks. One-year overall survival (OS) rate was 42%, with a median OS of 40 weeks. ENT2 Topotecan ENT2END in combination with radiotherapy was well tolerated
1	The incidence of non-hematological toxicities was low and grade 3-4 hematological toxicities were reported in 20 patients (mainly lymphopenia and ENT1 neutropenia  ENT1END . Partial response and stabilization rates were 2% and 32%, respectively, with an overall time to progression of 12 weeks. One-year overall survival (OS) rate was 42%, with a median OS of 40 weeks. ENT2 Topotecan ENT2END in combination with radiotherapy was well tolerated
0	CONCLUSIONS: The increases in ENT1 anxiety ENT1END and depression are in line with previous observations in recreational ENT2 ecstasy ENT2END -polydrug users
0	Significant between group differences were also observed in afternoon cortisol levels and in overall ENT1 cortisol  ENT1END secretion across the day. CONCLUSIONS: The increases in ENT2 anxiety ENT2END and depression are in line with previous observations in recreational ecstasy-polydrug users
1	CONCLUSIONS: The increases in anxiety and ENT1 depression  ENT1END are in line with previous observations in recreational ENT2 ecstasy ENT2END -polydrug users
0	RESULTS: Both user groups exhibited significantly greater levels of anxiety and ENT1 depression ENT1END than nonusers. On day 1, all participants exhibited a typical ENT2 cortisol ENT2END profile, though light users had significantly elevated levels pre-bed
0	RATIONALE: Ecstasy ( ENT1 MDMA ENT1END  is a psychostimulant drug which is increasingly associated with ENT2 psychobiological dysfunction ENT2END
0	RATIONALE: Ecstasy (MDMA) is a psychostimulant drug which is increasingly associated with ENT1 psychobiological dysfunction ENT1END . While some recent studies suggest acute changes in neuroendocrine function, less is known about long-term changes in HPA functionality in recreational users. OBJECTIVES: The current study is the first to explore the effects of ecstasy-polydrug use on psychological distress and basal functioning of the HPA axis through assessing the secretion of ENT2 cortisol ENT2END across the diurnal period
0	Hypokalemia, sometimes severe, was observed in some L-dopa-treated ENT1 parkinsonian ENT1END patients. The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and ENT2 aldosterone ENT2END
0	Hypokalemia, sometimes severe, was observed in some L-dopa-treated ENT1 parkinsonian ENT1END  patients. The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and ENT2 sodium ENT2END as well as urinary excretion of potassium, sodium and aldosterone
0	Hypokalemia, sometimes severe, was observed in some L-dopa-treated ENT1 parkinsonian ENT1END  patients. The influence of L-dopa on the renal excretion of ENT2 potassium ENT2END was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone
0	Hypokalemia, sometimes severe, was observed in some ENT1 L-dopa  ENT1END treated ENT2 parkinsonian ENT2END patients
0	The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with ENT1 hypokalemia  ENT1END and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and ENT2 aldosterone ENT2END
0	The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with ENT1 hypokalemia  ENT1END  and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and ENT2 sodium ENT2END as well as urinary excretion of potassium, sodium and aldosterone
0	The influence of L-dopa on the renal excretion of ENT1 potassium  ENT1END  was studied in 3 patients with ENT2 hypokalemia ENT2END and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone
1	Kaliuretic effect of ENT1 L-dopa  ENT1END  treatment in parkinsonian patients. ENT2 Hypokalemia ENT2END , sometimes severe, was observed in some L-dopa-treated parkinsonian patients
0	METHODS: This is a cross-sectional study involving 95 patients with ENT1 PD ENT1END on uninterrupted ENT2 levodopa ENT2END therapy for at least 6 months
1	Risk factors and predictors of ENT1 levodopa  ENT1END -induced ENT2 dyskinesia ENT2END among multiethnic Malaysians with Parkinson's disease
1	Peri-operative ENT1 atrioventricular block  ENT1END  as a result of chemotherapy with epirubicin and ENT2 paclitaxel ENT2END
1	Peri-operative ENT1 atrioventricular block  ENT1END  as a result of chemotherapy with ENT2 epirubicin ENT2END and paclitaxel
1	In the preceding months she had received neo-adjuvant chemotherapy with epirubicin, paclitaxel (Taxol) and ENT1 cyclophosphamide ENT1END  This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity. She was found to be bradycardic at pre-operative assessment but had no cardiac symptoms. Second degree Mobitz type II ENT2 atrioventricular block ENT2END was diagnosed on electrocardiogram, and temporary transvenous ventricular pacing instituted in the peri-operative period
0	In the preceding months she had received neo-adjuvant chemotherapy with epirubicin, paclitaxel ( ENT1 Taxol ENT1END  and cyclophosphamide. This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity. She was found to be bradycardic at pre-operative assessment but had no cardiac symptoms. Second degree Mobitz type II atrioventricular block was diagnosed on electrocardiogram, and temporary transvenous ventricular pacing instituted in the peri-operative period. We discuss how evidence-based guidelines would not have been helpful in this case, and how chemotherapy can exhibit substantial ENT2 cardiotoxicity ENT2END that may develop over many years
0	In the preceding months she had received neo-adjuvant chemotherapy with ENT1 epirubicin  ENT1END  paclitaxel (Taxol) and cyclophosphamide. This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity. She was found to be bradycardic at pre-operative assessment but had no cardiac symptoms. Second degree Mobitz type II atrioventricular block was diagnosed on electrocardiogram, and temporary transvenous ventricular pacing instituted in the peri-operative period. We discuss how evidence-based guidelines would not have been helpful in this case, and how chemotherapy can exhibit substantial ENT2 cardiotoxicity ENT2END that may develop over many years
0	In the preceding months she had received neo-adjuvant chemotherapy with epirubicin, paclitaxel (Taxol) and ENT1 cyclophosphamide  ENT1END . This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity. She was found to be bradycardic at pre-operative assessment but had no cardiac symptoms. Second degree Mobitz type II atrioventricular block was diagnosed on electrocardiogram, and temporary transvenous ventricular pacing instituted in the peri-operative period. We discuss how evidence-based guidelines would not have been helpful in this case, and how chemotherapy can exhibit substantial ENT2 cardiotoxicity ENT2END that may develop over many years
0	A 47-year-old woman presented for mastectomy and immediate latissimus dorsi flap reconstruction having been diagnosed with ENT1 carcinoma of the breast ENT1END 6 months previously. In the preceding months she had received neo-adjuvant chemotherapy with epirubicin, ENT2 paclitaxel ENT2END (Taxol) and cyclophosphamide
0	A 47-year-old woman presented for mastectomy and immediate latissimus dorsi flap reconstruction having been diagnosed with ENT1 carcinoma of the breast  ENT1END  6 months previously. In the preceding months she had received neo-adjuvant chemotherapy with ENT2 epirubicin ENT2END , paclitaxel (Taxol) and cyclophosphamide
0	A 47-year-old woman presented for mastectomy and immediate latissimus dorsi flap reconstruction having been diagnosed with ENT1 carcinoma of the breast  ENT1END  6 months previously. In the preceding months she had received neo-adjuvant chemotherapy with epirubicin, paclitaxel (Taxol) and ENT2 cyclophosphamide ENT2END
0	In the preceding months she had received neo-adjuvant chemotherapy with epirubicin, paclitaxel ( ENT1 Taxol ENT1END ) and cyclophosphamide. This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity. She was found to be ENT2 bradycardic ENT2END at pre-operative assessment but had no cardiac symptoms
0	In the preceding months she had received neo-adjuvant chemotherapy with ENT1 epirubicin  ENT1END , paclitaxel (Taxol) and cyclophosphamide. This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity. She was found to be ENT2 bradycardic ENT2END at pre-operative assessment but had no cardiac symptoms
0	In the preceding months she had received neo-adjuvant chemotherapy with epirubicin, paclitaxel (Taxol) and ENT1 cyclophosphamide  ENT1END . This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity. She was found to be ENT2 bradycardic ENT2END at pre-operative assessment but had no cardiac symptoms
0	AIMS: Doxorubicin ( ENT1 DOX  ENT1END  is an effective anti- ENT2 cancer ENT2END therapeutic, but is associated with both acute and late-stage cardiotoxicity
0	P53 inhibition exacerbates late-stage ENT1 anthracycline  ENT1END  cardiotoxicity.AIMS: Doxorubicin (DOX) is an effective anti ENT2 cancer ENT2END therapeutic, but is associated with both acute and late-stage cardiotoxicity
1	Children are particularly sensitive to ENT1 DOX ENT1END induced ENT2 heart failure ENT2END
0	P53 inhibition exacerbates late-stage ENT1 anthracycline  ENT1END  cardiotoxicity.AIMS: Doxorubicin (DOX) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage cardiotoxicity. Children are particularly sensitive to DOX-induced ENT2 heart failure ENT2END
0	late-stage ENT1 DOX ENT1END ENT2 cardiotoxicity ENT2END was examined in a juvenile model
0	P53 inhibition exacerbates late-stage ENT1 anthracycline ENT1END ENT2 cardiotoxicity ENT2END
0	People aged over 75 in ENT1 atrial fibrillation  ENT1END  on ENT2 warfarin ENT2END : the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up
1	People aged over 75 in atrial fibrillation on ENT1 warfarin  ENT1END : the rate of major ENT2 hemorrhage ENT2END and stroke in more than 500 patient-years of follow-up
0	MEASUREMENTS: Information regarding major bleeding episodes, ENT1 strokes ENT1END  and ENT2 warfarin ENT2END use was obtained from patients, relatives, primary physicians, and medical records
0	On the contrary, among primary coronary artery bypass surgery patients, there were more acute ENT1 myocardial infarctions ENT1END and renal dysfunction in Group A (5.8% vs 2.0%, P = 0.027; 22.5% vs 15.2%, P = 0.036, respectively). The 1-yr mortality was significantly higher after aprotinin treatment in the high risk surgery group (17.7% vs 9.8%, P = 0.034). CONCLUSION: Both antifibrinolytic drugs bear the risk of adverse outcome depending on the type of cardiac surgery. Administration of aprotinin should be avoided in coronary artery bypass graft and high risk patients, whereas administration of ENT2 tranexamic acid ENT2END is not recommended in valve surgery
1	During the first 5 mo, 596 patients received aprotinin (Group A); in the next 5 mo, 592 patients were treated with ENT1 tranexamic acid ENT1END (Group T). Except for antifibrinolytic therapy, the anesthetic and surgical protocols remained unchanged. RESULTS: The pre- and intraoperative variables were comparable between the treatment groups. Postoperatively, a significantly higher incidence of ENT2 seizures ENT2END was found in Group T (4
0	On the contrary, among primary coronary artery bypass surgery patients, there were more acute myocardial infarctions and ENT1 renal dysfunction  ENT1END in Group A (5.8% vs 2.0%, P = 0.027; 22.5% vs 15.2%, P = 0.036, respectively). The 1-yr mortality was significantly higher after aprotinin treatment in the high risk surgery group (17.7% vs 9.8%, P = 0.034). CONCLUSION: Both antifibrinolytic drugs bear the risk of adverse outcome depending on the type of cardiac surgery. Administration of aprotinin should be avoided in coronary artery bypass graft and high risk patients, whereas administration of ENT2 tranexamic acid ENT2END is not recommended in valve surgery
1	During the first 5 mo, 596 patients received aprotinin (Group A); in the next 5 mo, 592 patients were treated with ENT1 tranexamic acid ENT1END  (Group T). Except for antifibrinolytic therapy, the anesthetic and surgical protocols remained unchanged. RESULTS: The pre- and intraoperative variables were comparable between the treatment groups. Postoperatively, a significantly higher incidence of seizures was found in Group T (4.6% vs 1.2%, P < 0.001). This difference was also significant in the primary valve surgery and the high risk surgery subgroups (7.9% vs 1.2%, P = 0.003; 7.3% vs 2.4%, P = 0.035, respectively). Persistent atrial fibrillation (7.9% vs 2.3%, P = 0.020) and ENT2 renal failure ENT2END (9
1	During ENT1 hypotension ENT1END produced by ENT2 SNP ENT2END similar decreases were observed in mean pulmonary arterial pressure (p less than 0
0	001), total body ENT1 oxygen  ENT1END consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after ATP was stopped. Cardiac output did not change. During ENT2 hypotension ENT2END produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0
1	ENT1 Hypotension ENT1END induced by ENT2 ATP ENT2END was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0
1	A total of 675 patients were included; 163 of these had therapy with vancomycin, ENT1 gentamicin ENT1END  or tobramycin; were >18 years; and treated in the ICU for >24 hours. Patients with an adherence to SOP >70% were classified into the high adherence group (HAG) and patients with an adherence of <70% into the low adherence group (LAG). ENT2 AKI ENT2END was defined according to RIFLE criteria
1	A total of 675 patients were included; 163 of these had therapy with ENT1 vancomycin  ENT1END  gentamicin, or tobramycin; were >18 years; and treated in the ICU for >24 hours. Patients with an adherence to SOP >70% were classified into the high adherence group (HAG) and patients with an adherence of <70% into the low adherence group (LAG). ENT2 AKI ENT2END was defined according to RIFLE criteria
1	A total of 675 patients were included; 163 of these had therapy with vancomycin, gentamicin, or ENT1 tobramycin  ENT1END  were >18 years; and treated in the ICU for >24 hours. Patients with an adherence to SOP >70% were classified into the high adherence group (HAG) and patients with an adherence of <70% into the low adherence group (LAG). ENT2 AKI ENT2END was defined according to RIFLE criteria
0	The aim of this study was to investigate, whether there is an association between adherence to guidelines (standard operating procedures (SOP)) for potentially ENT1 nephrotoxic  ENT1END antibiotics and the occurrence of AKI. METHODS: This study was carried out as a prospective, clinical, non-interventional, observational study. Data collection was performed over a total of 170 days in three ICUs at Charite - Universitaetsmedizin Berlin. A total of 675 patients were included; 163 of these had therapy with vancomycin, ENT2 gentamicin ENT2END , or tobramycin; were >18 years; and treated in the ICU for >24 hours
0	The aim of this study was to investigate, whether there is an association between adherence to guidelines (standard operating procedures (SOP)) for potentially ENT1 nephrotoxic  ENT1END  antibiotics and the occurrence of AKI. METHODS: This study was carried out as a prospective, clinical, non-interventional, observational study. Data collection was performed over a total of 170 days in three ICUs at Charite - Universitaetsmedizin Berlin. A total of 675 patients were included; 163 of these had therapy with ENT2 vancomycin ENT2END , gentamicin, or tobramycin; were >18 years; and treated in the ICU for >24 hours
0	The aim of this study was to investigate, whether there is an association between adherence to guidelines (standard operating procedures (SOP)) for potentially ENT1 nephrotoxic  ENT1END  antibiotics and the occurrence of AKI. METHODS: This study was carried out as a prospective, clinical, non-interventional, observational study. Data collection was performed over a total of 170 days in three ICUs at Charite - Universitaetsmedizin Berlin. A total of 675 patients were included; 163 of these had therapy with vancomycin, gentamicin, or ENT2 tobramycin ENT2END ; were >18 years; and treated in the ICU for >24 hours
0	We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated ENT1 AKI ENT1END who underwent intraoperative dialytic support during liver transplantation anticoagulated with ENT2 citrate ENT2END dialysate during the entire procedure
1	We report a case of a 40-year-old female with ENT1 acetaminophen  ENT1END induced fulminant liver failure with associated ENT2 AKI ENT2END who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure
0	Citrate dialysate, a new dialysate with citric acid can be used for anticoagulation in patients who cannot tolerate ENT1 heparin  ENT1END or regional citrate. We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated ENT2 AKI ENT2END who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure
0	Systemic anticoagulation is unsafe and regional citrate anticoagulation in the absence of a functional liver carries the risk of ENT1 citrate ENT1END ENT2 toxicity ENT2END
0	Systemic anticoagulation is unsafe and regional citrate anticoagulation in the absence of a functional liver carries the risk of citrate ENT1 toxicity  ENT1END . Citrate dialysate, a new dialysate with citric acid can be used for anticoagulation in patients who cannot tolerate heparin or regional citrate. We report a case of a 40-year-old female with ENT2 acetaminophen ENT2END -induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure
0	Systemic anticoagulation is unsafe and regional citrate anticoagulation in the absence of a functional liver carries the risk of citrate ENT1 toxicity  ENT1END . Citrate dialysate, a new dialysate with citric acid can be used for anticoagulation in patients who cannot tolerate ENT2 heparin ENT2END or regional citrate
0	Intraoperative dialysis during liver transplantation with ENT1 citrate ENT1END  dialysate.Liver transplantation for acutely ill patients with ENT2 fulminant liver failure ENT2END carries high intraoperative and immediate postoperative risks
1	We report a case of a 40-year-old female with ENT1 acetaminophen ENT1END -induced ENT2 fulminant liver failure ENT2END with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure
0	Citrate dialysate, a new dialysate with citric acid can be used for anticoagulation in patients who cannot tolerate ENT1 heparin  ENT1END  or regional citrate. We report a case of a 40-year-old female with acetaminophen-induced ENT2 fulminant liver failure ENT2END with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure
0	METHODS: A retrospective chart analysis and a review of the organ transplant database identified 51 patients (43 men and 8 women) transplanted for benign HBV-related ENT1 cirrhotic diseases ENT1END between June 2002 and December 2004 who had survived more than 3 months. HBIg was administered intravenously during the first week and intramuscularly thereafter. RESULTS: At a median follow-up of 14.1 months, the overall recurrence rate in the 51 patients was 3.9% (2/51). The overall patient survival was 88.3%, and 82.4% after 1 and 2 years, respectively. A daily oral dose of 100 mg ENT2 lamivudine ENT2END for 2 weeks before transplantation for 10 patients enabled 57
0	BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of ENT1 HBsAg  ENT1END positive patients. This study was undertaken to evaluate the outcomes of liver transplantation for patients with hepatitis B virus (HBV). METHODS: A retrospective chart analysis and a review of the organ transplant database identified 51 patients (43 men and 8 women) transplanted for benign HBV-related ENT2 cirrhotic diseases ENT2END between June 2002 and December 2004 who had survived more than 3 months
0	METHODS: A retrospective chart analysis and a review of the organ transplant database identified 51 patients (43 men and 8 women) transplanted for benign HBV-related ENT1 cirrhotic diseases ENT1END  between June 2002 and December 2004 who had survived more than 3 months. HBIg was administered intravenously during the first week and intramuscularly thereafter. RESULTS: At a median follow-up of 14.1 months, the overall recurrence rate in the 51 patients was 3.9% (2/51). The overall patient survival was 88.3%, and 82.4% after 1 and 2 years, respectively. A daily oral dose of 100 mg lamivudine for 2 weeks before transplantation for 10 patients enabled 57.1% (4/7) and 62.5% (5/8) of HBV-DNA and ENT2 HBeAg ENT2END positive patients respectively to convert to be negative
0	Intramuscular hepatitis B immune globulin combined with ENT1 lamivudine  ENT1END  in prevention of ENT2 hepatitis B ENT2END recurrence after liver transplantation
0	BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of ENT1 hepatitis B  ENT1END after liver transplantation has significantly improved the survival of ENT2 HBsAg ENT2END positive patients
1	This study was undertaken to evaluate the outcomes of liver transplantation for patients with ENT1 hepatitis B  ENT1END virus (HBV). METHODS: A retrospective chart analysis and a review of the organ transplant database identified 51 patients (43 men and 8 women) transplanted for benign HBV-related cirrhotic diseases between June 2002 and December 2004 who had survived more than 3 months. HBIg was administered intravenously during the first week and intramuscularly thereafter. RESULTS: At a median follow-up of 14.1 months, the overall recurrence rate in the 51 patients was 3.9% (2/51). The overall patient survival was 88.3%, and 82.4% after 1 and 2 years, respectively. A daily oral dose of 100 mg lamivudine for 2 weeks before transplantation for 10 patients enabled 57.1% (4/7) and 62.5% (5/8) of HBV-DNA and ENT2 HBeAg ENT2END positive patients respectively to convert to be negative
0	An F1 hybrid of F344 and BN exhibited significant pituitary growth after 10 weeks of ENT1 DES ENT1END treatment with an average mass of 26.3 +/- 0.7 mg compared with 8.6 +/- 0.9 mg for untreated rats. Surprisingly, the F1 hybrid ENT2 tumors ENT2END were not hemorrhagic and had hemoglobin content and outward appearance identical to that of BN
0	Genetic separation of tumor growth and hemorrhagic phenotypes in an ENT1 estrogen  ENT1END -induced ENT2 tumor ENT2END
1	Chronic administration of estrogen to the Fischer 344 (F344) rat induces growth of large, hemorrhagic ENT1 pituitary tumors ENT1END  Ten weeks of ENT2 diethylstilbestrol ENT2END (DES) treatment caused female F344 rat pituitaries to grow to an average of 109
0	Chronic administration of ENT1 estrogen  ENT1END to the Fischer 344 (F344) rat induces growth of large, hemorrhagic ENT2 pituitary tumors ENT2END
0	4 mg for untreated rats, and to become highly ENT1 hemorrhagic ENT1END  The same ENT2 DES ENT2END treatment produced no significant growth (8
0	Genetic separation of tumor growth and ENT1 hemorrhagic  ENT1END  phenotypes in an ENT2 estrogen ENT2END -induced tumor
0	Hodgkin lymphoma (HL) is a relatively chemosensitive ENT1 malignancy ENT1END  However, for those who relapse, high-dose chemotherapy with autologous stem cell transplant is the treatment of choice which relies on adequate disease control with salvage chemotherapy. Regimens commonly used often require inpatient administration and can be difficult to deliver due to toxicity. Gemcitabine and cisplatin have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting. In this retrospective single-centre analysis, patients with relapsed or refractory HL treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; ENT2 methylprednisolone ENT2END 1,000 mg D1-5; and cisplatin 100 mg/m(2) D15, every 28 days (GEM-P) were included
0	ENT1 GEM  ENT1END -P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.Hodgkin lymphoma (HL) is a relatively chemosensitive ENT2 malignancy ENT2END
0	Hodgkin lymphoma (HL) is a relatively chemosensitive ENT1 malignancy ENT1END . However, for those who relapse, high-dose chemotherapy with autologous stem cell transplant is the treatment of choice which relies on adequate disease control with salvage chemotherapy. Regimens commonly used often require inpatient administration and can be difficult to deliver due to toxicity. Gemcitabine and ENT2 cisplatin ENT2END have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting
1	The most common grade 3/4 toxicities were haematological: neutropenia 54 % and ENT1 thrombocytopenia ENT1END 51 %. Median follow-up from the start of ENT2 GEM ENT2END -P was 4
0	In this retrospective single-centre analysis, patients with relapsed or refractory HL treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; ENT1 methylprednisolone ENT1END  1,000 mg D1-5; and cisplatin 100 mg/m(2) D15, every 28 days (GEM-P) were included. Demographic, survival, response and ENT2 toxicity ENT2END data were recorded
0	Regimens commonly used often require inpatient administration and can be difficult to deliver due to ENT1 toxicity ENT1END  ENT2 Gemcitabine ENT2END and cisplatin have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting
0	Regimens commonly used often require inpatient administration and can be difficult to deliver due to ENT1 toxicity  ENT1END . Gemcitabine and ENT2 cisplatin ENT2END have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting
1	The most common grade 3/4 toxicities were haematological: ENT1 neutropenia  ENT1END 54 % and thrombocytopenia 51 %. Median follow-up from the start of ENT2 GEM ENT2END -P was 4
0	In this retrospective single-centre analysis, patients with relapsed or refractory ENT1 HL  ENT1END treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; ENT2 methylprednisolone ENT2END 1,000 mg D1-5; and cisplatin 100 mg/m(2) D15, every 28 days (GEM-P) were included
0	In this retrospective single-centre analysis, patients with relapsed or refractory ENT1 HL ENT1END  treated with ENT2 gemcitabine ENT2END 1,000 mg/m(2) day (D)1, D8 and D15; methylprednisolone 1,000 mg D1-5; and cisplatin 100 mg/m(2) D15, every 28 days (GEM-P) were included
0	Gemcitabine and ENT1 cisplatin ENT1END  have activity in ENT2 HL ENT2END , non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting
1	BACKGROUND: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension ( ENT1 PPH ENT1END . Recently, ENT2 fenfluramine ENT2END appetite suppressants became widely used in the United States but were withdrawn in September 1997 because of concerns over adverse effects
0	A history of drug exposure also was taken with special attention on the use of antidepressants, anorexigens, and ENT1 amphetamines ENT1END  RESULTS: Five hundred seventy-nine patients were studied, 205 with ENT2 PPH ENT2END and 374 with pulmonary hypertension from other causes (secondary pulmonary hypertension [SPH])
0	The muscarinic cholinergic agonist pilocarpine induces in rats seizures and ENT1 status epilepticus ENT1END followed by widespread damage to the forebrain. The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, ENT2 sodium salicylate ENT2END , phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine
0	The muscarinic cholinergic agonist pilocarpine induces in rats seizures and ENT1 status epilepticus ENT1END  followed by widespread damage to the forebrain. The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and ENT2 mefenamic acid ENT2END , on seizures produced by pilocarpine
0	The muscarinic cholinergic agonist pilocarpine induces in rats seizures and ENT1 status epilepticus ENT1END  followed by widespread damage to the forebrain. The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, ENT2 phenylbutazone ENT2END , indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine
0	The muscarinic cholinergic agonist pilocarpine induces in rats seizures and ENT1 status epilepticus ENT1END  followed by widespread damage to the forebrain. The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ENT2 ibuprofen ENT2END and mefenamic acid, on seizures produced by pilocarpine
0	The muscarinic cholinergic agonist pilocarpine induces in rats seizures and ENT1 status epilepticus ENT1END  followed by widespread damage to the forebrain. The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, ENT2 indomethacin ENT2END , ibuprofen and mefenamic acid, on seizures produced by pilocarpine
1	The muscarinic cholinergic agonist ENT1 pilocarpine  ENT1END induces in rats seizures and ENT2 status epilepticus ENT2END followed by widespread damage to the forebrain
1	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on ENT1 seizures ENT1END produced by pilocarpine. Pretreatment of rats with ENT2 sodium salicylate ENT2END , ED50 103 mg/kg (60-174), and phenylbutazone, 59 mg/kg (50-70) converted the non-convulsant dose of pilocarpine, 200 mg/kg, to a convulsant one
0	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and ENT1 mefenamic acid  ENT1END , on ENT2 seizures ENT2END produced by pilocarpine
1	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, ENT1 phenylbutazone  ENT1END , indomethacin, ibuprofen and mefenamic acid, on ENT2 seizures ENT2END produced by pilocarpine
0	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ENT1 ibuprofen  ENT1END  and mefenamic acid, on ENT2 seizures ENT2END produced by pilocarpine
0	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, ENT1 indomethacin  ENT1END , ibuprofen and mefenamic acid, on ENT2 seizures ENT2END produced by pilocarpine
1	These results indicate that non-steroidal anti-inflammatory drugs differentially modulate the threshold for ENT1 pilocarpine ENT1END induced ENT2 seizures ENT2END
0	Pretreatment of rats with ENT1 sodium salicylate ENT1END , ED50 103 mg/kg (60-174), and phenylbutazone, 59 mg/kg (50-70) converted the non-convulsant dose of pilocarpine, 200 mg/kg, to a convulsant one. Indomethacin, 1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate seizures produced by pilocarpine. Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related ENT2 brain damage ENT2END induced by pilocarpine, 380 mg/kg
0	ENT1 Mefenamic acid  ENT1END  26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related ENT2 brain damage ENT2END induced by pilocarpine, 380 mg/kg
0	Pretreatment of rats with sodium salicylate, ED50 103 mg/kg (60-174), and ENT1 phenylbutazone  ENT1END  59 mg/kg (50-70) converted the non-convulsant dose of pilocarpine, 200 mg/kg, to a convulsant one. Indomethacin, 1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate seizures produced by pilocarpine. Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related ENT2 brain damage ENT2END induced by pilocarpine, 380 mg/kg
0	Indomethacin, 1-10 mg/kg, and ENT1 ibuprofen  ENT1END  10-100 mg/kg, failed to modulate seizures produced by pilocarpine. Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related ENT2 brain damage ENT2END induced by pilocarpine, 380 mg/kg
0	ENT1 Indomethacin  ENT1END  1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate seizures produced by pilocarpine. Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related ENT2 brain damage ENT2END induced by pilocarpine, 380 mg/kg
0	Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related ENT1 brain damage ENT1END  induced by ENT2 pilocarpine ENT2END , 380 mg/kg
0	Despite popular use of piperacillin, the dire ENT1 neurotoxicity ENT1END associated with piperacillin still goes unrecognized, leading to a delay in appropriate management. We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ENT2 ammonia ENT2END levels but leukocytosis
0	ENT1 Piperacillin/tazobactam  ENT1END -induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.Despite popular use of piperacillin, the dire ENT2 neurotoxicity ENT2END associated with piperacillin still goes unrecognized, leading to a delay in appropriate management
0	Despite popular use of ENT1 piperacillin  ENT1END  the dire ENT2 neurotoxicity ENT2END associated with piperacillin still goes unrecognized, leading to a delay in appropriate management
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for ENT1 bronchiectasis  ENT1END with secondary infection. The laboratory data revealed normal plasma electrolyte and ENT2 ammonia ENT2END levels but leukocytosis
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of ENT1 piperacillin/tazobactam  ENT1END (2 g/250 mg) were given for ENT2 bronchiectasis ENT2END with secondary infection
0	Despite popular use of piperacillin, the dire neurotoxicity associated with ENT1 piperacillin  ENT1END still goes unrecognized, leading to a delay in appropriate management. We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for ENT2 bronchiectasis ENT2END with secondary infection
0	Despite the use of antiepileptic agents, another GTCS episode recurred after the sixth dose of ENT1 piperacillin/tazobactam ENT1END  Brain magnetic resonance imaging did not demonstrate acute infarction and organic brain lesions. Initiation of high-flux hemodialysis rapidly reversed the neurologic symptoms within 4 hours. Piperacillin-induced ENT2 encephalopathy ENT2END should be considered in any uremic patients with unexplained neurological manifestations
0	ENT1 Piperacillin  ENT1END induced ENT2 encephalopathy ENT2END should be considered in any uremic patients with unexplained neurological manifestations
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental ENT1 confusion  ENT1END  and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ENT2 ammonia ENT2END levels but leukocytosis
1	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental ENT1 confusion  ENT1END , and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of ENT2 piperacillin/tazobactam ENT2END (2 g/250 mg) were given for bronchiectasis with secondary infection
0	Despite popular use of piperacillin, the dire neurotoxicity associated with ENT1 piperacillin  ENT1END  still goes unrecognized, leading to a delay in appropriate management. We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental ENT2 confusion ENT2END , and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection
0	The laboratory data revealed normal plasma electrolyte and ENT1 ammonia ENT1END  levels but leukocytosis. Neurologic examinations showed dysarthria and bilateral Babinski sign. Computed tomography of brain and electroencephalogram were unremarkable. Despite the use of antiepileptic agents, another GTCS episode recurred after the sixth dose of piperacillin/tazobactam. Brain magnetic resonance imaging did not demonstrate acute ENT2 infarction ENT2END and organic brain lesions
0	Despite the use of antiepileptic agents, another GTCS episode recurred after the sixth dose of ENT1 piperacillin/tazobactam  ENT1END . Brain magnetic resonance imaging did not demonstrate acute ENT2 infarction ENT2END and organic brain lesions
0	Brain magnetic resonance imaging did not demonstrate acute ENT1 infarction  ENT1END  and organic brain lesions. Initiation of high-flux hemodialysis rapidly reversed the neurologic symptoms within 4 hours. ENT2 Piperacillin ENT2END -induced encephalopathy should be considered in any uremic patients with unexplained neurological manifestations
0	Piperacillin/tazobactam-induced ENT1 seizure  ENT1END  rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.Despite popular use of piperacillin, the dire neurotoxicity associated with piperacillin still goes unrecognized, leading to a delay in appropriate management. We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ENT2 ammonia ENT2END levels but leukocytosis
0	ENT1 Piperacillin/tazobactam  ENT1END -induced ENT2 seizure ENT2END rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis
0	Piperacillin/tazobactam-induced ENT1 seizure  ENT1END  rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.Despite popular use of ENT2 piperacillin ENT2END , the dire neurotoxicity associated with piperacillin still goes unrecognized, leading to a delay in appropriate management
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, ENT1 tremor  ENT1END  bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ENT2 ammonia ENT2END levels but leukocytosis
1	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, ENT1 tremor  ENT1END , bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of ENT2 piperacillin/tazobactam ENT2END (2 g/250 mg) were given for bronchiectasis with secondary infection
0	Despite popular use of piperacillin, the dire neurotoxicity associated with ENT1 piperacillin  ENT1END  still goes unrecognized, leading to a delay in appropriate management. We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, ENT2 tremor ENT2END , bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection
0	We report a 57-year-old woman with ENT1 end-stage renal disease  ENT1END receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ENT2 ammonia ENT2END levels but leukocytosis
0	We report a 57-year-old woman with ENT1 end-stage renal disease  ENT1END  receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of ENT2 piperacillin/tazobactam ENT2END (2 g/250 mg) were given for bronchiectasis with secondary infection
0	Despite popular use of piperacillin, the dire neurotoxicity associated with ENT1 piperacillin  ENT1END  still goes unrecognized, leading to a delay in appropriate management. We report a 57-year-old woman with ENT2 end-stage renal disease ENT2END receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with ENT1 secondary infection  ENT1END  The laboratory data revealed normal plasma electrolyte and ENT2 ammonia ENT2END levels but leukocytosis
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of ENT1 piperacillin/tazobactam  ENT1END  (2 g/250 mg) were given for bronchiectasis with ENT2 secondary infection ENT2END
0	Despite popular use of piperacillin, the dire neurotoxicity associated with ENT1 piperacillin  ENT1END  still goes unrecognized, leading to a delay in appropriate management. We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with ENT2 secondary infection ENT2END
0	The laboratory data revealed normal plasma electrolyte and ENT1 ammonia ENT1END  levels but ENT2 leukocytosis ENT2END
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of ENT1 piperacillin/tazobactam  ENT1END  (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ammonia levels but ENT2 leukocytosis ENT2END
0	The laboratory data revealed normal plasma electrolyte and ENT1 ammonia ENT1END  levels but leukocytosis. Neurologic examinations showed ENT2 dysarthria ENT2END and bilateral Babinski sign
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of ENT1 piperacillin/tazobactam  ENT1END  (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ammonia levels but leukocytosis. Neurologic examinations showed ENT2 dysarthria ENT2END and bilateral Babinski sign
0	Neurologic examinations showed ENT1 dysarthria  ENT1END  and bilateral Babinski sign. Computed tomography of brain and electroencephalogram were unremarkable. Despite the use of antiepileptic agents, another GTCS episode recurred after the sixth dose of piperacillin/tazobactam. Brain magnetic resonance imaging did not demonstrate acute infarction and organic brain lesions. Initiation of high-flux hemodialysis rapidly reversed the neurologic symptoms within 4 hours. ENT2 Piperacillin ENT2END -induced encephalopathy should be considered in any uremic patients with unexplained neurological manifestations
0	Despite the use of antiepileptic agents, another GTCS episode recurred after the sixth dose of ENT1 piperacillin/tazobactam ENT1END . Brain magnetic resonance imaging did not demonstrate acute infarction and organic brain lesions. Initiation of high-flux hemodialysis rapidly reversed the neurologic symptoms within 4 hours. Piperacillin-induced encephalopathy should be considered in any ENT2 uremic ENT2END patients with unexplained neurological manifestations
0	ENT1 Piperacillin  ENT1END -induced encephalopathy should be considered in any ENT2 uremic ENT2END patients with unexplained neurological manifestations
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure ( ENT1 GTCS  ENT1END  after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ENT2 ammonia ENT2END levels but leukocytosis
1	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure ( ENT1 GTCS  ENT1END ) after 5 doses of ENT2 piperacillin/tazobactam ENT2END (2 g/250 mg) were given for bronchiectasis with secondary infection
0	Despite the use of antiepileptic agents, another ENT1 GTCS  ENT1END episode recurred after the sixth dose of piperacillin/tazobactam. Brain magnetic resonance imaging did not demonstrate acute infarction and organic brain lesions. Initiation of high-flux hemodialysis rapidly reversed the neurologic symptoms within 4 hours. ENT2 Piperacillin ENT2END -induced encephalopathy should be considered in any uremic patients with unexplained neurological manifestations
1	Acute ENT1 heart failure ENT1END was induced by ENT2 propranolol ENT2END and volume loading after weaning from cardiopulmonary bypass; an absence of MR was confirmed by echocardiography
0	Acute heart failure was induced by ENT1 propranolol ENT1END  and volume loading after weaning from cardiopulmonary bypass; an absence of ENT2 MR ENT2END was confirmed by echocardiography
0	Sumatriptan succinate, a serotonin-1 ( ENT1 5-hydroxytryptamine ENT1END 1) receptor agonist, is an antimigraine drug that is reported to act by selectively constricting intracranial arteries. Recently, vasopressor responses that are distinct from the cranial circulation have been demonstrated to occur in the systemic, pulmonary, and coronary circulations. Cases have been published of coronary vasospasm, myocardial ischemia, and ENT2 myocardial infarction ENT2END occurring after sumatriptan use
0	Cases have been published of coronary vasospasm, myocardial ischemia, and ENT1 myocardial infarction ENT1END  occurring after ENT2 sumatriptan ENT2END use
0	Sumatriptan succinate, a serotonin-1 ( ENT1 5-hydroxytryptamine ENT1END -1) receptor agonist, is an antimigraine drug that is reported to act by selectively constricting intracranial arteries. Recently, vasopressor responses that are distinct from the cranial circulation have been demonstrated to occur in the systemic, pulmonary, and coronary circulations. Cases have been published of coronary vasospasm, myocardial ischemia, and myocardial infarction occurring after sumatriptan use. We report on the development of 8 serious cases of ischemic colitis in patients with ENT2 migraine ENT2END treated with sumatriptan
0	We report on the development of 8 serious cases of ischemic colitis in patients with ENT1 migraine ENT1END  treated with ENT2 sumatriptan ENT2END
0	ENT1 Ischemic colitis ENT1END  and sumatriptan use.Sumatriptan succinate, a ENT2 serotonin ENT2END -1 (5-hydroxytryptamine-1) receptor agonist, is an antimigraine drug that is reported to act by selectively constricting intracranial arteries
1	ENT1 Ischemic colitis  ENT1END  and ENT2 sumatriptan ENT2END use
0	Sumatriptan succinate, a serotonin-1 ( ENT1 5-hydroxytryptamine ENT1END -1) receptor agonist, is an antimigraine drug that is reported to act by selectively constricting intracranial arteries. Recently, vasopressor responses that are distinct from the cranial circulation have been demonstrated to occur in the systemic, pulmonary, and coronary circulations. Cases have been published of ENT2 coronary vasospasm ENT2END , myocardial ischemia, and myocardial infarction occurring after sumatriptan use
0	Cases have been published of ENT1 coronary vasospasm  ENT1END , myocardial ischemia, and myocardial infarction occurring after ENT2 sumatriptan ENT2END use
0	Sumatriptan succinate, a serotonin-1 ( ENT1 5-hydroxytryptamine ENT1END -1) receptor agonist, is an antimigraine drug that is reported to act by selectively constricting intracranial arteries. Recently, vasopressor responses that are distinct from the cranial circulation have been demonstrated to occur in the systemic, pulmonary, and coronary circulations. Cases have been published of coronary vasospasm, ENT2 myocardial ischemia ENT2END , and myocardial infarction occurring after sumatriptan use
0	Cases have been published of coronary vasospasm, ENT1 myocardial ischemia  ENT1END , and myocardial infarction occurring after ENT2 sumatriptan ENT2END use
0	An adverse drug interaction with ENT1 piroxicam ENT1END  which she took occasionally, may have exacerbated the ENT2 coagulopathy ENT2END
0	A case of intercerebral hematoma due to ENT1 warfarin ENT1END induced ENT2 coagulopathy ENT2END is presented
0	A case of intercerebral ENT1 hematoma  ENT1END due to warfarin-induced coagulopathy is presented. The 39-year-old woman had spread a warfarin-type rat poison around her house weekly using her bare hands, with no washing post application. Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used. An adverse drug interaction with ENT2 piroxicam ENT2END , which she took occasionally, may have exacerbated the coagulopathy
0	A case of intercerebral ENT1 hematoma  ENT1END  due to ENT2 warfarin ENT2END -induced coagulopathy is presented
0	Cutaneous exposure to warfarin-like anticoagulant causing an ENT1 intracerebral hemorrhage  ENT1END : a case report.A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented. The 39-year-old woman had spread a warfarin-type rat poison around her house weekly using her bare hands, with no washing post application. Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used. An adverse drug interaction with ENT2 piroxicam ENT2END , which she took occasionally, may have exacerbated the coagulopathy
1	Cutaneous exposure to ENT1 warfarin  ENT1END -like anticoagulant causing an ENT2 intracerebral hemorrhage ENT2END : a case report
1	Fatal ENT1 myeloencephalopathy  ENT1END  due to intrathecal ENT2 vincristine ENT2END administration
1	Vincristine was accidentally given intrathecally to a child with leukaemia, producing ENT1 sensory and motor dysfunction ENT1END followed by encephalopathy and death. Separate times for administering ENT2 vincristine ENT2END and intrathecal therapy is recommended
0	ENT1 Vincristine ENT1END was accidentally given intrathecally to a child with ENT2 leukaemia ENT2END , producing sensory and motor dysfunction followed by encephalopathy and death
1	We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with ENT1 danazol ENT1END for a continuous period of 6 months or longer. The mean age of the patients was 35.2 years and the mean duration of therapy was 59.7 months. Virtually all patients experienced one or more adverse reactions. ENT2 Menstrual abnormalities ENT2END (79%), weight gain (60%), muscle cramps/myalgias (40%), and transaminase elevations (40%) were the most common adverse reactions
1	We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with ENT1 danazol ENT1END  for a continuous period of 6 months or longer. The mean age of the patients was 35.2 years and the mean duration of therapy was 59.7 months. Virtually all patients experienced one or more adverse reactions. Menstrual abnormalities (79%), ENT2 weight gain ENT2END (60%), muscle cramps/myalgias (40%), and transaminase elevations (40%) were the most common adverse reactions
1	We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with ENT1 danazol ENT1END  for a continuous period of 6 months or longer. The mean age of the patients was 35.2 years and the mean duration of therapy was 59.7 months. Virtually all patients experienced one or more adverse reactions. Menstrual abnormalities (79%), weight gain (60%), ENT2 muscle cramps ENT2END /myalgias (40%), and transaminase elevations (40%) were the most common adverse reactions
0	We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with ENT1 danazol  ENT1END  for a continuous period of 6 months or longer. The mean age of the patients was 35.2 years and the mean duration of therapy was 59.7 months. Virtually all patients experienced one or more adverse reactions. Menstrual abnormalities (79%), weight gain (60%), muscle cramps/ ENT2 myalgias ENT2END (40%), and transaminase elevations (40%) were the most common adverse reactions
0	We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with ENT1 hereditary angioedema  ENT1END treated with ENT2 danazol ENT2END for a continuous period of 6 months or longer
0	Glomeruli of ENT1 PAN ENT1END rats contained significantly more CC than glomeruli of controls. Glomeruli with ENT2 sclerosis ENT2END contained significantly more CC than non-sclerotic glomeruli in the same kidneys
0	After 4 weeks the PAN rats were severely proteinuric (190 +/- 80 mg/24 hr), and all rats were given colloidal ENT1 carbon  ENT1END (CC) intravenously. At 5 months glomerular sclerosis was found in 7.6 +/- 3.4% of the glomeruli of PAN rats; glomeruli of the controls were normal. Glomeruli of PAN rats contained significantly more CC than glomeruli of controls. Glomeruli with ENT2 sclerosis ENT2END contained significantly more CC than non-sclerotic glomeruli in the same kidneys
1	After 4 weeks the ENT1 PAN ENT1END rats were severely ENT2 proteinuric ENT2END (190 +/- 80 mg/24 hr), and all rats were given colloidal carbon (CC) intravenously
0	After 4 weeks the PAN rats were severely ENT1 proteinuric  ENT1END  (190 +/- 80 mg/24 hr), and all rats were given colloidal ENT2 carbon ENT2END (CC) intravenously
0	Mesangial function and ENT1 glomerular sclerosis  ENT1END  in rats with ENT2 aminonucleoside ENT2END nephrosis
0	After 4 weeks the PAN rats were severely proteinuric (190 +/- 80 mg/24 hr), and all rats were given colloidal ENT1 carbon ENT1END  (CC) intravenously. At 5 months ENT2 glomerular sclerosis ENT2END was found in 7
0	Similar to the remnant kidney model in ENT1 PAN ENT1END ENT2 nephrosis ENT2END the development of glomerular sclerosis may be related to "mesangial overloading
0	Mesangial function and glomerular sclerosis in rats with aminonucleoside ENT1 nephrosis  ENT1END .The possible relationship between mesangial dysfunction and development of glomerular sclerosis was studied in the puromycin aminonucleoside (PAN) model. Five male Wistar rats received repeated subcutaneous PAN injections; five controls received saline only. After 4 weeks the PAN rats were severely proteinuric (190 +/- 80 mg/24 hr), and all rats were given colloidal ENT2 carbon ENT2END (CC) intravenously
0	Early ENT1 CY ENT1END ENT2 toxicity ENT2END caused a typical haemorrhagic cystitis in both strains that was completely repaired in about 7-10 days
1	Early ENT1 CY ENT1END  toxicity caused a typical ENT2 haemorrhagic ENT2END cystitis in both strains that was completely repaired in about 7-10 days
1	Early ENT1 CY ENT1END  toxicity caused a typical haemorrhagic ENT2 cystitis ENT2END in both strains that was completely repaired in about 7-10 days
0	These results indicate that delayed toxicity of ENT1 CY ENT1END in female DBA/2 mice causes a bladder pathology that is not observed in C57BL/6 mice. This pathology resembles ENT2 interstitial cystitis ENT2END in humans and could perhaps be used as an animal model for studies on the disease
1	Cardiac work was significantly reduced during ENT1 SNP ENT1END ENT2 hypotension ENT2END
1	Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, ENT1 trimetaphan ENT1END ENT2 hypotension ENT2END to 20% mean blood pressure decrease
0	Cardiac work was significantly reduced during SNP ENT1 hypotension ENT1END . Myocardial ENT2 O2 ENT2END consumption and O2 availability were directly dependent on the coronary perfusion
1	Relationship between ENT1 nicotine  ENT1END -induced ENT2 seizures ENT2END and hippocampal nicotinic receptors
0	The binding sites from seizure sensitive and resistant mice were equally affected by treatment with ENT1 dithiothreitol ENT1END  trypsin or heat. Thus it appears that the difference between ENT2 seizure ENT2END sensitive and insensitive animals may be due to a difference in hippocampal nicotinic receptor concentration as measured with alpha-bungarotoxin binding
0	Levodopa (15 mg/kg and ENT1 benserazide ENT1END  3.75 mg/kg) p.o. b.i.d, was administered for 30 days. Animals were evaluated for parkinsonian disability, dyskinesia and on-time (motor fluctuations) and ENT2 neuropsychiatric-like behaviors ENT2END on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day
0	These symptoms may be due to 'sensitisation' following repeated levodopa treatment or a direct effect of ENT1 dopamine ENT1END on the disease state. The levodopa-treated MPTP-lesioned marmoset was used as a model of ENT2 neuropsychiatric symptoms ENT2END in PD patients
0	The levodopa-treated ENT1 MPTP  ENT1END lesioned marmoset was used as a model of ENT2 neuropsychiatric symptoms ENT2END in PD patients
0	In contrast, ENT1 levodopa ENT1END induced ENT2 neuropsychiatric-like behaviors ENT2END were present on Day 1 of levodopa treatment and their severity did not correlate with duration of treatment
0	Levodopa (15 mg/kg and ENT1 benserazide ENT1END , 3.75 mg/kg) p.o. b.i.d, was administered for 30 days. Animals were evaluated for parkinsonian disability, ENT2 dyskinesia ENT2END and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day
0	METHODS: Marmosets were administered ENT1 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  ENT1END (2.0 mg/kg s.c.) for five days, resulting in stable parkinsonism. Levodopa (15 mg/kg and benserazide, 3.75 mg/kg) p.o. b.i.d, was administered for 30 days. Animals were evaluated for parkinsonian disability, ENT2 dyskinesia ENT2END and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day
1	As anticipated, animals exhibited a progressive increase in ENT1 levodopa ENT1END induced motor fluctuations, ENT2 dyskinesia ENT2END and wearing-off, that correlated with the duration of levodopa therapy
0	) for five days, resulting in stable ENT1 parkinsonism  ENT1END  Levodopa (15 mg/kg and ENT2 benserazide ENT2END , 3
0	OBJECTIVES: Neuropsychiatric symptoms are increasingly recognised as a significant problem in patients with Parkinson's disease ( ENT1 PD  ENT1END . These symptoms may be due to 'sensitisation' following repeated levodopa treatment or a direct effect of ENT2 dopamine ENT2END on the disease state
0	Neuropsychiatric behaviors in the ENT1 MPTP  ENT1END  marmoset model of ENT2 Parkinson's disease ENT2END
0	) for five days, resulting in stable ENT1 parkinsonism ENT1END . ENT2 Levodopa ENT2END (15 mg/kg and benserazide, 3
0	Levodopa (15 mg/kg and ENT1 benserazide ENT1END , 3.75 mg/kg) p.o. b.i.d, was administered for 30 days. Animals were evaluated for ENT2 parkinsonian disability ENT2END , dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day
1	METHODS: Marmosets were administered ENT1 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  ENT1END  (2.0 mg/kg s.c.) for five days, resulting in stable parkinsonism. Levodopa (15 mg/kg and benserazide, 3.75 mg/kg) p.o. b.i.d, was administered for 30 days. Animals were evaluated for ENT2 parkinsonian disability ENT2END , dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day
0	Animals were evaluated for ENT1 parkinsonian disability ENT1END , dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to ENT2 levodopa ENT2END ) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day
0	We conclude that previously reported hypoglycemia, hyperbilirubinemia, ENT1 polycythemia ENT1END  neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic ENT2 propranolol ENT2END therapy
0	We conclude that previously reported ENT1 hypoglycemia  ENT1END  hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic ENT2 propranolol ENT2END therapy
0	We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and ENT1 bradycardia  ENT1END are not invariable and cannot be statistically correlated with chronic ENT2 propranolol ENT2END therapy
0	We conclude that previously reported hypoglycemia, ENT1 hyperbilirubinemia  ENT1END  polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic ENT2 propranolol ENT2END therapy
1	We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic ENT1 propranolol ENT1END  therapy. ENT2 Growth retardation ENT2END , however, appears to be significant in both of our series
0	We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, ENT1 neonatal apnea  ENT1END  and bradycardia are not invariable and cannot be statistically correlated with chronic ENT2 propranolol ENT2END therapy
0	Thus, dronedarone and ENT1 amiodarone ENT1END displayed a similar level of antiadrenergic effect and did not impair the resting left ventricular function. Consequently, dronedarone might be particularly suitable for the treatment and prevention of various clinical ENT2 arrhythmias ENT2END , without compromising the left ventricular function
0	Consequently, ENT1 dronedarone  ENT1END might be particularly suitable for the treatment and prevention of various clinical ENT2 arrhythmias ENT2END , without compromising the left ventricular function
0	Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the ENT1 isoproterenol  ENT1END induced tachycardia. Thus, dronedarone and amiodarone displayed a similar level of antiadrenergic effect and did not impair the resting left ventricular function. Consequently, dronedarone might be particularly suitable for the treatment and prevention of various clinical ENT2 arrhythmias ENT2END , without compromising the left ventricular function
0	Hemodynamic and antiadrenergic effects of dronedarone and ENT1 amiodarone  ENT1END  in animals with a healed ENT2 myocardial infarction ENT2END
0	Hemodynamic and antiadrenergic effects of ENT1 dronedarone  ENT1END  and amiodarone in animals with a healed ENT2 myocardial infarction ENT2END
0	The hemodynamic and antiadrenergic effects of dronedarone, a noniodinated compound structurally related to amiodarone, were compared with those of amiodarone after prolonged oral administration, both at rest and during sympathetic stimulation in conscious dogs with a healed ENT1 myocardial infarction ENT1END  All dogs (n = 6) randomly received orally dronedarone (10 and 30 mg/kg), amiodarone (10 and 30 mg/kg), and placebo twice daily for 7 days, with a 3-week washout between consecutive treatments. Heart rate (HR), mean arterial pressure (MBP), positive rate of increase of left ventricular pressure (+LVdP/dt), echocardiographically assessed left ventricular ejection fraction (LVEF), and fractional shortening (FS), as well as chronotropic response to ENT2 isoproterenol ENT2END and exercise-induced sympathetic stimulation were evaluated under baseline and posttreatment conditions
0	Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced ENT1 tachycardia  ENT1END  Thus, dronedarone and ENT2 amiodarone ENT2END displayed a similar level of antiadrenergic effect and did not impair the resting left ventricular function
0	Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced ENT1 tachycardia ENT1END . Thus, ENT2 dronedarone ENT2END and amiodarone displayed a similar level of antiadrenergic effect and did not impair the resting left ventricular function
1	Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the ENT1 isoproterenol  ENT1END -induced ENT2 tachycardia ENT2END
0	The ENT1 QT prolongation ENT1END appeared to respond to administration of i.v. ENT2 calcium gluconate ENT2END
1	Two cases of ENT1 amisulpride  ENT1END  overdose: a cause for ENT2 prolonged QT syndrome ENT2END
0	Two cases of deliberate self- ENT1 poisoning  ENT1END with 5 g and 3.6 g of amisulpride, respectively, are reported. In both cases, QT prolongation and hypocalcaemia were noted. The QT prolongation appeared to respond to administration of i.v. ENT2 calcium gluconate ENT2END
0	Two cases of deliberate self- ENT1 poisoning ENT1END  with 5 g and 3.6 g of ENT2 amisulpride ENT2END , respectively, are reported
0	Two cases of amisulpride ENT1 overdose  ENT1END : a cause for prolonged QT syndrome.Two cases of deliberate self-poisoning with 5 g and 3.6 g of amisulpride, respectively, are reported. In both cases, QT prolongation and hypocalcaemia were noted. The QT prolongation appeared to respond to administration of i.v. ENT2 calcium gluconate ENT2END
0	Two cases of ENT1 amisulpride ENT1END ENT2 overdose ENT2END : a cause for prolonged QT syndrome
0	In both cases, QT prolongation and ENT1 hypocalcaemia  ENT1END were noted. The QT prolongation appeared to respond to administration of i.v. ENT2 calcium gluconate ENT2END
1	6 g of ENT1 amisulpride  ENT1END , respectively, are reported. In both cases, QT prolongation and ENT2 hypocalcaemia ENT2END were noted
1	Several cytopathic mechanisms have been suggested to mediate the dose-limiting cumulative and irreversible ENT1 cardiomyopathy ENT1END caused by ENT2 doxorubicin ENT2END
0	ENT1 Carvedilol  ENT1END  protects against doxorubicin-induced mitochondrial ENT2 cardiomyopathy ENT2END
0	Carvedilol also prevented the decrease in mitochondrial ENT1 Ca ENT1END 2+) loading capacity and the inhibition of the respiratory complexes of heart mitochondria caused by doxorubicin. Carvedilol by itself did not affect any of the parameters measured for heart or liver mitochondria. It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and ENT2 cardiomyopathy ENT2END that accompanies long-term doxorubicin therapy in cancer patients
0	It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term ENT1 doxorubicin ENT1END therapy in ENT2 cancer ENT2END patients
0	It is concluded that this protection by ENT1 carvedilol  ENT1END against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in ENT2 cancer ENT2END patients
0	Carvedilol also prevented the decrease in mitochondrial ENT1 Ca  ENT1END (2+) loading capacity and the inhibition of the respiratory complexes of heart mitochondria caused by doxorubicin. Carvedilol by itself did not affect any of the parameters measured for heart or liver mitochondria. It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in ENT2 cancer ENT2END patients
0	The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic ENT1 doxorubicin ENT1END ENT2 toxicity ENT2END
0	The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin ENT1 toxicity ENT1END . Heart and liver mitochondria were isolated from rats treated for 7 weeks with doxorubicin (2 mg/kg sc/week), ENT2 carvedilol ENT2END (1 mg/kg ip/week), or the combination of the two drugs
0	The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin ENT1 toxicity ENT1END . Heart and liver mitochondria were isolated from rats treated for 7 weeks with doxorubicin (2 mg/kg sc/week), carvedilol (1 mg/kg ip/week), or the combination of the two drugs. Heart mitochondria isolated from doxorubicin-treated rats exhibited depressed rates for state 3 respiration (336 +/- 26 versus 425 +/- 53 natom O/min/mg protein) and a lower respiratory control ratio (RCR) (4.3 +/- 0.6 versus 5.8 +/- 0.4) compared with cardiac mitochondria isolated from saline-treated rats. Mitochondrial ENT2 calcium ENT2END -loading capacity and the activity of NADH-dehydrogenase were also suppressed in cardiac mitochondria from doxorubicin-treated rats
0	It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting ENT1 mitochondrial dysfunction  ENT1END and cardiomyopathy that accompanies long-term ENT2 doxorubicin ENT2END therapy in cancer patients
0	Recent evidence indicates that oxidative stress and ENT1 mitochondrial dysfunction ENT1END are key factors in the pathogenic process. The objective of this investigation was to test the hypothesis that ENT2 carvedilol ENT2END , a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin toxicity
0	Carvedilol also prevented the decrease in mitochondrial ENT1 Ca  ENT1END (2+) loading capacity and the inhibition of the respiratory complexes of heart mitochondria caused by doxorubicin. Carvedilol by itself did not affect any of the parameters measured for heart or liver mitochondria. It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting ENT2 mitochondrial dysfunction ENT2END and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients
0	ENT1 Bortezomib ENT1END and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell ENT2 malignancies ENT2END
0	Bortezomib and high-dose ENT1 dexamethasone  ENT1END containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell ENT2 malignancies ENT2END
0	Physicians should recognise the possibility of fatal ENT1 bacterial infections ENT1END related to ENT2 bortezomib ENT2END plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation
0	Physicians should recognise the possibility of fatal ENT1 bacterial infections ENT1END  related to bortezomib plus high-dose ENT2 dexamethasone ENT2END in elderly patients, and we believe this case warrants further investigation
1	ENT1 Necrotising fasciitis  ENT1END  after ENT2 bortezomib ENT2END and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia
1	ENT1 Necrotising fasciitis  ENT1END  after bortezomib and ENT2 dexamethasone ENT2END -containing regimen in an elderly patient of Waldenstrom macroglobulinaemia
0	Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of ENT1 Waldenstrom macroglobulinaemia ENT1END ENT2 Bortezomib ENT2END and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies
0	Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of ENT1 Waldenstrom macroglobulinaemia  ENT1END .Bortezomib and high-dose ENT2 dexamethasone ENT2END -containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies
0	We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without ENT1 neutropenia ENT1END after the combination treatment with ENT2 bortezomib ENT2END , high-dose dexamethasone and rituximab
0	We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without ENT1 neutropenia ENT1END  after the combination treatment with bortezomib, high-dose ENT2 dexamethasone ENT2END and rituximab
1	Pure red cell aplasia, ENT1 toxic dermatitis  ENT1END  and lymphadenopathy in a patient taking ENT2 diphenylhydantoin ENT2END
1	ENT1 Pure red cell aplasia ENT1END associated with ENT2 diphenylhydantoin ENT2END medication has been reported in 3 patients
0	In this patient the time relation between the ingestion of ENT1 diphenylhydantoin ENT1END and the occurrence of the ENT2 skin rash ENT2END , lymphadenopathy and pure red cell aplasia is very suggestive of a direct connection
1	Pure red cell aplasia, toxic dermatitis and ENT1 lymphadenopathy  ENT1END  in a patient taking ENT2 diphenylhydantoin ENT2END
0	PURPOSE: Apnea is known to occur during ENT1 seizures ENT1END  but systematic studies of ictal respiratory changes in adults are few. Data regarding respiratory pattern defects during interictal periods also are scarce. Here we sought to generate information with regard to the interictal period in animals with ENT2 pilocarpine ENT2END -induced epilepsy
0	PURPOSE: ENT1 Apnea  ENT1END is known to occur during seizures, but systematic studies of ictal respiratory changes in adults are few. Data regarding respiratory pattern defects during interictal periods also are scarce. Here we sought to generate information with regard to the interictal period in animals with ENT2 pilocarpine ENT2END -induced epilepsy
1	Here we sought to generate information with regard to the interictal period in animals with ENT1 pilocarpine ENT1END -induced ENT2 epilepsy ENT2END
0	RESULTS: The ENT1 hyperventilation ENT1END maneuver caused a decrease in spontaneous ventilation in ENT2 pilocarpine ENT2END -treated and control rats
1	Furthermore, ENT1 dexamethasone ENT1END induced ENT2 ocular hypertension ENT2END was associated with chronic ER stress of the trabecular meshwork (TM)
0	Furthermore, reduction of ER stress in the TM with ENT1 sodium 4-phenylbutyrate ENT1END prevented dexamethasone-induced ENT2 ocular hypertension ENT2END in WT mice
0	1% ENT1 dexamethasone ENT1END led to elevation of intraocular pressure (IOP), functional and structural loss of ENT2 retinal ganglion ENT2END cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients
0	1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of ENT1 retinal ganglion  ENT1END  cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients. Furthermore, dexamethasone-induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork (TM). Similar to patients, withdrawal of dexamethasone treatment reduced elevated IOP and ER stress in this animal model. Dexamethasone induced the transcriptional factor CHOP, a marker for chronic ER stress, in the anterior segment tissues, and Chop deletion reduced ER stress in these tissues and prevented dexamethasone-induced ocular hypertension. Furthermore, reduction of ER stress in the TM with ENT2 sodium 4-phenylbutyrate ENT2END prevented dexamethasone-induced ocular hypertension in WT mice
0	If untreated, these patients can develop a secondary glaucoma that resembles primary open-angle glaucoma ( ENT1 POAG  ENT1END . The underlying pathology of glucocorticoid-induced glaucoma is not fully understood, due in part to lack of an appropriate animal model. Here, we developed a murine model of glucocorticoid-induced glaucoma that exhibits glaucoma features that are observed in patients. Treatment of WT mice with topical ocular 0.1% ENT2 dexamethasone ENT2END led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients
1	1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration, resembling glucocorticoid-induced ENT1 glaucoma  ENT1END in human patients. Furthermore, ENT2 dexamethasone ENT2END -induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork (TM)
0	Furthermore, reduction of ER stress in the TM with ENT1 sodium 4-phenylbutyrate ENT1END  prevented dexamethasone-induced ocular hypertension in WT mice. Our data indicate that ER stress contributes to glucocorticoid-induced ocular hypertension and suggest that reducing ER stress has potential as a therapeutic strategy for treating glucocorticoid-induced ENT2 glaucoma ENT2END
1	1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and ENT1 axonal degeneration  ENT1END  resembling glucocorticoid-induced glaucoma in human patients. Furthermore, ENT2 dexamethasone ENT2END -induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork (TM)
0	1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and ENT1 axonal degeneration  ENT1END , resembling glucocorticoid-induced glaucoma in human patients. Furthermore, dexamethasone-induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork (TM). Similar to patients, withdrawal of dexamethasone treatment reduced elevated IOP and ER stress in this animal model. Dexamethasone induced the transcriptional factor CHOP, a marker for chronic ER stress, in the anterior segment tissues, and Chop deletion reduced ER stress in these tissues and prevented dexamethasone-induced ocular hypertension. Furthermore, reduction of ER stress in the TM with ENT2 sodium 4-phenylbutyrate ENT2END prevented dexamethasone-induced ocular hypertension in WT mice
0	Anti-thyroid drugs, like carbimazole and propylthiouracil (PTU) are commonly prescribed for the treatment of ENT1 hyperthyroidism ENT1END  One should be aware of the side effects of ENT2 antithyroid medications ENT2END
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENT1 PTU  ENT1END  are commonly prescribed for the treatment of ENT2 hyperthyroidism ENT2END
0	Anti-thyroid drugs, like ENT1 carbimazole  ENT1END and propylthiouracil (PTU) are commonly prescribed for the treatment of ENT2 hyperthyroidism ENT2END
0	The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and ENT1 parotiditis ENT1END but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have myositis. Carbimazole and ENT2 methimazole ENT2END have a lower incidence of reported ANCA positive side effects than PUT
1	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of ENT1 antithyroidmedications  ENT1END  We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and ENT2 parotiditis ENT2END but no renal or pulmonary involvement
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENT1 PTU  ENT1END ) are commonly prescribed for the treatment of hyperthyroidism. One should be aware of the side effects of antithyroid medications. Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and ENT2 parotiditis ENT2END but no renal or pulmonary involvement
1	We report a patient with Graves' disease who developed ANCA positive ENT1 carbimazole  ENT1END induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and ENT2 parotiditis ENT2END but no renal or pulmonary involvement
0	The episode was characterized by a vasculitic skin rash associated with large joint arthritis, ENT1 pyrexia  ENT1END and parotiditis but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have myositis. Carbimazole and ENT2 methimazole ENT2END have a lower incidence of reported ANCA positive side effects than PUT
1	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of ENT1 antithyroidmedications  ENT1END . We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, ENT2 pyrexia ENT2END and parotiditis but no renal or pulmonary involvement
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENT1 PTU  ENT1END ) are commonly prescribed for the treatment of hyperthyroidism. One should be aware of the side effects of antithyroid medications. Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, ENT2 pyrexia ENT2END and parotiditis but no renal or pulmonary involvement
1	We report a patient with Graves' disease who developed ANCA positive ENT1 carbimazole  ENT1END  induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, ENT2 pyrexia ENT2END and parotiditis but no renal or pulmonary involvement
0	The episode was characterized by a vasculitic ENT1 skin rash  ENT1END associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have myositis. Carbimazole and ENT2 methimazole ENT2END have a lower incidence of reported ANCA positive side effects than PUT
0	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of ENT1 antithyroidmedications  ENT1END . We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic ENT2 skin rash ENT2END associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENT1 PTU  ENT1END ) are commonly prescribed for the treatment of hyperthyroidism. One should be aware of the side effects of antithyroid medications. Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic ENT2 skin rash ENT2END associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement
0	We report a patient with Graves' disease who developed ANCA positive ENT1 carbimazole  ENT1END  induced vasculitis. The episode was characterized by a vasculitic ENT2 skin rash ENT2END associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement
0	He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have ENT1 myositis  ENT1END  Carbimazole and ENT2 methimazole ENT2END have a lower incidence of reported ANCA positive side effects than PUT
0	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of ENT1 antithyroidmedications  ENT1END . We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have ENT2 myositis ENT2END
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENT1 PTU  ENT1END ) are commonly prescribed for the treatment of hyperthyroidism. One should be aware of the side effects of antithyroid medications. Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have ENT2 myositis ENT2END
0	He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have ENT1 myositis ENT1END . ENT2 Carbimazole ENT2END and methimazole have a lower incidence of reported ANCA positive side effects than PUT
0	We report a patient with ENT1 Graves' disease  ENT1END who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have myositis. Carbimazole and ENT2 methimazole ENT2END have a lower incidence of reported ANCA positive side effects than PUT
0	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of ENT1 antithyroidmedications  ENT1END . We report a patient with ENT2 Graves' disease ENT2END who developed ANCA positive carbimazole induced vasculitis
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENT1 PTU  ENT1END ) are commonly prescribed for the treatment of hyperthyroidism. One should be aware of the side effects of antithyroid medications. Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with ENT2 Graves' disease ENT2END who developed ANCA positive carbimazole induced vasculitis
0	We report a patient with ENT1 Graves' disease  ENT1END  who developed ANCA positive ENT2 carbimazole ENT2END induced vasculitis
0	Carbimazole and ENT1 methimazole ENT1END  have a lower incidence of reported ANCA positive side effects than PUT. To the best of our knowledge this is the first ANCA positive carbimazole induced ENT2 vasculitis ENT2END case reported from India
0	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of ENT1 antithyroidmedications ENT1END . We report a patient with Graves' disease who developed ANCA positive carbimazole induced ENT2 vasculitis ENT2END
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENT1 PTU  ENT1END ) are commonly prescribed for the treatment of hyperthyroidism. One should be aware of the side effects of antithyroid medications. Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with Graves' disease who developed ANCA positive carbimazole induced ENT2 vasculitis ENT2END
0	We report a patient with Graves' disease who developed ANCA positive ENT1 carbimazole  ENT1END  induced ENT2 vasculitis ENT2END
0	ENT1 Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis  ENT1END is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have myositis. Carbimazole and ENT2 methimazole ENT2END have a lower incidence of reported ANCA positive side effects than PUT
1	Carbimazole induced ENT1 ANCA positive vasculitis  ENT1END . ENT2 Anti-thyroid drugs ENT2END , like carbimazole and propylthiouracil (PTU) are commonly prescribed for the treatment of hyperthyroidism
0	Carbimazole induced ENT1 ANCA positive vasculitis ENT1END .Anti-thyroid drugs, like carbimazole and ENT2 propylthiouracil ENT2END (PTU) are commonly prescribed for the treatment of hyperthyroidism
1	ENT1 Carbimazole  ENT1END  induced ENT2 ANCA positive vasculitis ENT2END
0	The episode was characterized by a vasculitic skin rash associated with large joint ENT1 arthritis  ENT1END  pyrexia and parotiditis but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have myositis. Carbimazole and ENT2 methimazole ENT2END have a lower incidence of reported ANCA positive side effects than PUT
1	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of ENT1 antithyroidmedications  ENT1END . We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint ENT2 arthritis ENT2END , pyrexia and parotiditis but no renal or pulmonary involvement
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENT1 PTU  ENT1END ) are commonly prescribed for the treatment of hyperthyroidism. One should be aware of the side effects of antithyroid medications. Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint ENT2 arthritis ENT2END , pyrexia and parotiditis but no renal or pulmonary involvement
1	We report a patient with Graves' disease who developed ANCA positive ENT1 carbimazole  ENT1END  induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint ENT2 arthritis ENT2END , pyrexia and parotiditis but no renal or pulmonary involvement
1	A case of phenytoin ( ENT1 DPH ENT1END  ENT2 encephalopathy ENT2END with increasing seizures and EEG and mental changes is described
0	A case of phenytoin ( ENT1 DPH ENT1END ) encephalopathy with increasing ENT2 seizures ENT2END and EEG and mental changes is described
0	In fact the concentration of free DPH was normal, the patient presented a retarded morbilliform ENT1 rash ENT1END during ENT2 DPH ENT2END treatment, the protidogram was normal, and an intradermic DPH injection had no local effect
0	DESIGN: A randomised crossover study of recovery time of systolic and diastolic left ventricular function after exercise and ENT1 dobutamine ENT1END induced ENT2 ischaemia ENT2END
0	Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both ENT1 dobutamine  ENT1END  and exercise induced ENT2 myocardial ischaemia ENT2END
1	CONCLUSIONS: In patients with coronary artery disease, ENT1 dobutamine ENT1END induced ischaemia results in prolonged reversible ENT2 left ventricular dysfunction ENT2END , presumed to be myocardial stunning, similar to that seen after exercise
1	CONCLUSIONS: In patients with coronary artery disease, dobutamine induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be ENT1 myocardial stunning ENT1END  similar to that seen after exercise. ENT2 Dobutamine ENT2END induced ischaemia could therefore be used to study the pathophysiology of this phenomenon further in patients with coronary artery disease
0	53) or ST ENT1 depression ENT1END (p = 0.63) with either form of stress. After exercise, ejection fraction was reduced at 15 and 30 minutes compared with baseline (mean (SEM), -5.6 (1.5)%, p < 0.05; and -6.1 (2.2)%, p < 0. 01), and at 30 and 45 minutes after ENT2 dobutamine ENT2END (-10
0	CONCLUSIONS: In patients with ENT1 coronary artery disease ENT1END ENT2 dobutamine ENT2END induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be myocardial stunning, similar to that seen after exercise
0	DESIGN: A randomised crossover study of recovery time of systolic and diastolic left ventricular function after exercise and ENT1 dobutamine ENT1END  induced ischaemia. SUBJECTS: 10 patients with ENT2 stable angina ENT2END , angiographically proven coronary artery disease, and normal left ventricular function
0	The ENT1 dopamine ENT1END agonist significantly ENT2 impaired novel word learning ENT2END compared to placebo
1	Subjects received the tonically stimulating dopamine-receptor agonist ENT1 pergolide  ENT1END (0.1 mg) vs placebo 120 min before training on each training day. The dopamine agonist significantly ENT2 impaired novel word learning ENT2END compared to placebo
0	Tonic dopaminergic stimulation ENT1 impairs associative learning ENT1END  in healthy subjects.Endogenous dopamine plays a central role in salience coding during associative learning. Administration of the dopamine precursor ENT2 levodopa ENT2END enhances learning in healthy subjects and stroke patients
0	Thus, phasic signaling seems to be the critical mechanism by which ENT1 dopamine ENT1END enhances associative learning in healthy subjects and ENT2 stroke ENT2END patients
0	The extent of 'flattened' affect with ENT1 pergolide  ENT1END was related to the degree of learning inhibition. These findings suggest that tonic occupation of dopamine receptors impairs learning by competition with phasic dopamine signals. Thus, phasic signaling seems to be the critical mechanism by which dopamine enhances associative learning in healthy subjects and ENT2 stroke ENT2END patients
0	Administration of the dopamine precursor levodopa enhances learning in healthy subjects and ENT1 stroke ENT1END patients. Because ENT2 levodopa ENT2END increases both phasic and tonic dopaminergic neurotransmission, the critical mechanism mediating the enhancement of learning is unresolved
0	1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or ENT1 schizoaffective disorder ENT1END (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or ENT2 risperidone ENT2END (1-6 mg/day)
0	1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or ENT1 schizoaffective disorder ENT1END  (8%) were randomly assigned to treatment with ENT2 olanzapine ENT2END (2
1	Significantly more ENT1 weight gain ENT1END occurred with olanzapine than with ENT2 risperidone ENT2END : the increase in weight at 4 months relative to baseline weight was 17
1	Significantly more ENT1 weight gain ENT1END  occurred with ENT2 olanzapine ENT2END than with risperidone: the increase in weight at 4 months relative to baseline weight was 17
1	ENT1 Extrapyramidal symptom ENT1END severity scores were 1.4 (95% CI=1.2-1.6) with ENT2 risperidone ENT2END and 1
1	ENT1 Extrapyramidal symptom ENT1END  severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with ENT2 olanzapine ENT2END
0	OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus ENT1 risperidone ENT1END in patients with first-episode ENT2 schizophrenia ENT2END spectrum disorders
0	OBJECTIVE: The authors compared 4-month treatment outcomes for ENT1 olanzapine  ENT1END versus risperidone in patients with first-episode ENT2 schizophrenia ENT2END spectrum disorders
0	Negative symptom outcomes and measures of parkinsonism and ENT1 akathisia  ENT1END did not differ between medications. Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with ENT2 risperidone ENT2END and 1
0	Negative symptom outcomes and measures of parkinsonism and ENT1 akathisia  ENT1END  did not differ between medications. Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with ENT2 olanzapine ENT2END
0	Negative symptom outcomes and measures of ENT1 parkinsonism  ENT1END and akathisia did not differ between medications. Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with ENT2 risperidone ENT2END and 1
0	Negative symptom outcomes and measures of ENT1 parkinsonism  ENT1END  and akathisia did not differ between medications. Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with ENT2 olanzapine ENT2END
0	Of 6 patients with irreversible visual impairment, 4 patients had diabetes mellitus, ENT1 glaucoma ENT1END and a history of heavy smoking. CONCLUSION: Early recognition of optic neuropathy should be considered in patients with ENT2 ethambutol ENT2END therapy
0	METHOD: Thirteen patients who developed optic neuropathy after being treated with ENT1 ethambutol ENT1END for ENT2 tuberculosis of the lung or lymph node ENT2END at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed
0	CONCLUSION: Early recognition of optic neuropathy should be considered in patients with ENT1 ethambutol ENT1END  therapy. A low dose and prompt discontinuation of the drug is recommended particularly in individuals with ENT2 diabetes mellitus ENT2END , glaucoma or who are heavy smokers
0	Of 6 patients with irreversible ENT1 visual impairment  ENT1END  4 patients had diabetes mellitus, glaucoma and a history of heavy smoking. CONCLUSION: Early recognition of optic neuropathy should be considered in patients with ENT2 ethambutol ENT2END therapy
1	ENT1 Ethambutol  ENT1END  and ENT2 optic neuropathy ENT2END
0	METHOD: Thirteen patients who developed optic neuropathy after being treated with ENT1 ethambutol ENT1END  for ENT2 tuberculosis of the lung or lymph node ENT2END at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed
0	0 mg/dL), patients in the ENT1 hypercalcemic ENT1END group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch, compared with the mean value obtained during the 7 months of observation after the switch (2.4 +/- 0.03 to 2.5 +/- 0.03 mmol/L [9.7 +/- 0.2 to 10.2 +/- 0.1 mg/dL], P = 0.006). In contrast, eucalcemic patients exhibited no change in mean calcium values over the same time period (2.3 +/- 0.05 to 2.3 +/- 0.05 mmol/L [9.2 +/- 0.2 to 9.2 +/- 0.2 mg/dL]). CaCO3 dosage, calculated dietary calcium intake, and circulating levels of ENT2 vitamin D ENT2END metabolites were similar in both groups
0	Fourteen of 39 dialysis patients (36%) became ENT1 hypercalcemic ENT1END after switching to calcium carbonate as their principal ENT2 phosphate ENT2END binder
0	0 mg/dL), patients in the ENT1 hypercalcemic ENT1END  group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch, compared with the mean value obtained during the 7 months of observation after the switch (2.4 +/- 0.03 to 2.5 +/- 0.03 mmol/L [9.7 +/- 0.2 to 10.2 +/- 0.1 mg/dL], P = 0.006). In contrast, eucalcemic patients exhibited no change in mean calcium values over the same time period (2.3 +/- 0.05 to 2.3 +/- 0.05 mmol/L [9.2 +/- 0.2 to 9.2 +/- 0.2 mg/dL]). CaCO3 dosage, calculated dietary calcium intake, and circulating levels of vitamin D metabolites were similar in both groups. Physical activity index and predialysis serum ENT2 bicarbonate ENT2END levels also were similar in both groups
1	Fourteen of 39 dialysis patients (36%) became ENT1 hypercalcemic ENT1END  after switching to ENT2 calcium carbonate ENT2END as their principal phosphate binder
0	In addition to experiencing ENT1 hypercalcemic ENT1END episodes with peak ENT2 calcium ENT2END values of 2
0	In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of ENT1 renal disease  ENT1END  In addition to experiencing hypercalcemic episodes with peak calcium values of 2.7 to 3.8 mmol/L (10.7 to 15.0 mg/dL), patients in the hypercalcemic group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch, compared with the mean value obtained during the 7 months of observation after the switch (2.4 +/- 0.03 to 2.5 +/- 0.03 mmol/L [9.7 +/- 0.2 to 10.2 +/- 0.1 mg/dL], P = 0.006). In contrast, eucalcemic patients exhibited no change in mean calcium values over the same time period (2.3 +/- 0.05 to 2.3 +/- 0.05 mmol/L [9.2 +/- 0.2 to 9.2 +/- 0.2 mg/dL]). CaCO3 dosage, calculated dietary calcium intake, and circulating levels of ENT2 vitamin D ENT2END metabolites were similar in both groups
0	Fourteen of 39 dialysis patients (36%) became hypercalcemic after switching to calcium carbonate as their principal ENT1 phosphate  ENT1END  binder. In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of ENT2 renal disease ENT2END
0	In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of ENT1 renal disease  ENT1END . In addition to experiencing hypercalcemic episodes with peak calcium values of 2.7 to 3.8 mmol/L (10.7 to 15.0 mg/dL), patients in the hypercalcemic group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch, compared with the mean value obtained during the 7 months of observation after the switch (2.4 +/- 0.03 to 2.5 +/- 0.03 mmol/L [9.7 +/- 0.2 to 10.2 +/- 0.1 mg/dL], P = 0.006). In contrast, eucalcemic patients exhibited no change in mean calcium values over the same time period (2.3 +/- 0.05 to 2.3 +/- 0.05 mmol/L [9.2 +/- 0.2 to 9.2 +/- 0.2 mg/dL]). CaCO3 dosage, calculated dietary calcium intake, and circulating levels of vitamin D metabolites were similar in both groups. Physical activity index and predialysis serum ENT2 bicarbonate ENT2END levels also were similar in both groups
0	Fourteen of 39 dialysis patients (36%) became hypercalcemic after switching to ENT1 calcium carbonate  ENT1END  as their principal phosphate binder. In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of ENT2 renal disease ENT2END
0	In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of ENT1 renal disease  ENT1END . In addition to experiencing hypercalcemic episodes with peak ENT2 calcium ENT2END values of 2
0	Thalidomide neuropathy in patients treated for metastatic ENT1 prostate cancer ENT1END .We prospectively evaluated ENT2 thalidomide ENT2END -induced neuropathy using electrodiagnostic studies
0	Sixty-seven men with metastatic ENT1 androgen ENT1END independent ENT2 prostate cancer ENT2END in an open-label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies (NCS) prior to and at 3-month intervals during treatment
1	Neuropathy may thus be a common complication of ENT1 thalidomide ENT1END in older patients. The SNAP index can be used to monitor ENT2 peripheral neuropathy ENT2END , but not for early detection
0	ENT1 Thalidomide ENT1END ENT2 neuropathy ENT2END in patients treated for metastatic prostate cancer
0	We prospectively evaluated thalidomide-induced ENT1 neuropathy  ENT1END using electrodiagnostic studies. Sixty-seven men with metastatic ENT2 androgen ENT2END -independent prostate cancer in an open-label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies (NCS) prior to and at 3-month intervals during treatment
0	However, livers from female, and especially pregnant female rats, were strikingly resistant to the effects of ENT1 tetracycline ENT1END on ENT2 depression ENT2END of output of triglyceride under these experimental conditions
0	With provision of adequate oleic acid as a substrate for the isolated perfused liver, a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and ENT1 depression ENT1END of output of ENT2 triglyceride ENT2END by livers from male and female rats
0	With provision of adequate ENT1 oleic acid  ENT1END as a substrate for the isolated perfused liver, a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and ENT2 depression ENT2END of output of triglyceride by livers from male and female rats
1	ENT1 Fatty liver  ENT1END  induced by ENT2 tetracycline ENT2END in the rat
0	Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the ENT1 triglyceride ENT1END rich ENT2 fatty liver ENT2END in response to tetracycline
0	These differences between the sexes could not be related to altered disposition of tetracycline or altered uptake of ENT1 oleic acid  ENT1END  Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich ENT2 fatty liver ENT2END in response to tetracycline
1	The main side-effects were ENT1 headache ENT1END  dizziness, palpitation and flushing and these were not more frequent than reported in other studies with ENT2 isradipine ENT2END or with placebo
0	The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with ENT1 isradipine ENT1END  or with placebo. Supine blood pressure was reduced (P less than 0.01) from 170 +/- 20/102 +/- 6 mmHg to 153 +/- 19/92 +/- 8, 147 +/- 18/88 +/- 7 and 144 +/- 14/87 +/- 6 mmHg at 2, 4 and 6 weeks respectively in evaluable patients. Similar reductions occurred in standing blood pressure and there was no evidence of ENT2 postural hypotension ENT2END
0	ENT1 Isradipine  ENT1END  treatment for ENT2 hypertension ENT2END in general practice in Hong Kong
1	The main side-effects were headache, dizziness, palpitation and ENT1 flushing  ENT1END and these were not more frequent than reported in other studies with ENT2 isradipine ENT2END or with placebo
1	The main side-effects were headache, ENT1 dizziness  ENT1END  palpitation and flushing and these were not more frequent than reported in other studies with ENT2 isradipine ENT2END or with placebo
0	Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) ENT1 acute lymphoblastic leukemia  ENT1END  protocols (ACCL0131): a ENT2 methotrexate ENT2END consequence? A report from the Children's Oncology Group
1	Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic ENT1 MTX ENT1END administration in children with acute lymphoblastic leukemia. In this study, neurocognitive outcomes and neuroradiologic evidence of ENT2 leukoencephalopathy ENT2END were compared in children treated with intense central nervous system (CNS)-directed therapy (P9605) versus those receiving fewer CNS-directed treatment days during intensive consolidation (P9201)
0	Concerns about long-term methotrexate ( ENT1 MTX ENT1END  ENT2 neurotoxicity ENT2END in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia
1	Children on both studies had significant ENT1 attention problems ENT1END  but P9605 children scored below average on more neurocognitive measures than those treated on P9201 (82%, 14/17 measures vs. 24%, 4/17 measures). This supports ongoing concerns about intensive ENT2 MTX ENT2END exposure as a major contributor to CNS late effects
0	Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic ENT1 MTX ENT1END  administration in children with acute lymphoblastic leukemia. In this study, neurocognitive outcomes and neuroradiologic evidence of leukoencephalopathy were compared in children treated with intense central nervous system (CNS)-directed therapy (P9605) versus those receiving fewer CNS-directed treatment days during intensive consolidation (P9201). A total of 66 children from 16 Pediatric Oncology Group institutions with "standard-risk" acute lymphoblastic leukemia, 1.00 to 9.99 years at diagnosis, without evidence of CNS ENT2 leukemia ENT2END at diagnosis were enrolled on ACCL0131: 28 from P9201 and 38 from P9605
1	A significant reduction in urinary guanosine 3',5'-cyclic monophosphate (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in ENT1 GM ENT1END mediated ENT2 nephropathy ENT2END
0	Administration of GM at 40 mg/kg sc for 13 days to rats induced a significant reduction in renal blood flow (RBF) and inulin clearance (CIn) as well as marked ENT1 tubular damage ENT1END  A significant reduction in urinary ENT2 guanosine 3',5'-cyclic monophosphate ENT2END (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in GM-mediated nephropathy
0	A significant reduction in urinary guanosine 3',5'-cyclic monophosphate (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in GM-mediated ENT1 nephropathy ENT1END . ENT2 Superoxide ENT2END dismutase (SOD) or dimethylthiourea (DMTU) significantly lessened the GM-induced decrement in CIn
0	SOD did not attenuate the ENT1 tubular damage ENT1END  In contrast, ENT2 DMTU ENT2END significantly reduced the tubular damage and lipid peroxidation, but it did not affect renal hemodynamics and vasoactive substances
0	The total doses of ACC-9653 or ENT1 phenytoin sodium ENT1END necessary to convert the ENT2 arrhythmia ENT2END to a normal sinus rhythm were 24 +/- 6 and 14 +/- 3 mg/kg, respectively
0	ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ENT1 ouabain  ENT1END induced ventricular tachycardia in anesthetized dogs. The total doses of ACC-9653 or phenytoin sodium necessary to convert the ENT2 arrhythmia ENT2END to a normal sinus rhythm were 24 +/- 6 and 14 +/- 3 mg/kg, respectively
1	Only phenytoin sodium displayed in vitro antiarrhythmic activity against ENT1 strophanthidin ENT1END induced ENT2 arrhythmias ENT2END in guinea pig right atria
0	ACC-9653, the disodium phosphate ester of ENT1 3-hydroxymethyl-5,5-diphenylhydantoin ENT1END  is a prodrug of phenytoin with advantageous physicochemical properties. ACC-9653 is rapidly converted enzymatically to phenytoin in vivo. ACC-9653 and phenytoin sodium have equivalent anticonvulsant activity against ENT2 seizures ENT2END induced by maximal electroshock (MES) in mice following i
0	ACC-9653 and ENT1 phenytoin sodium  ENT1END have equivalent anticonvulsant activity against ENT2 seizures ENT2END induced by maximal electroshock (MES) in mice following i
0	ACC-9653 and phenytoin sodium have equivalent anticonvulsant activity against ENT1 seizures  ENT1END  induced by maximal electroshock (MES) in mice following i.p., oral, or i.v. administration. The ED50 doses were 16 mg/kg for i.v. ACC-9653 and 8 mg/kg for i.v. phenytoin sodium. ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ENT2 ouabain ENT2END -induced ventricular tachycardia in anesthetized dogs
0	ACC-9653 is rapidly converted enzymatically to ENT1 phenytoin  ENT1END in vivo. ACC-9653 and phenytoin sodium have equivalent anticonvulsant activity against ENT2 seizures ENT2END induced by maximal electroshock (MES) in mice following i
0	Acute ENT1 toxicity ENT1END studies of ENT2 ACC-9653 ENT2END and phenytoin sodium were carried out in mice, rats, rabbits, and dogs by i
0	Only phenytoin sodium displayed in vitro antiarrhythmic activity against ENT1 strophanthidin  ENT1END -induced arrhythmias in guinea pig right atria. In anesthetized dogs, a high dose of ACC-9653 (31 mg/kg) was infused over 15, 20, and 30 min and the responses were compared to an equimolar dose of phenytoin sodium (21 mg/kg). The ACC-9653 and phenytoin sodium treatments produced similar marked reductions in diastolic blood pressure and contractile force (LVdP/dt). The maximum effects of each treatment occurred at the time of maximum phenytoin sodium levels. Acute ENT2 toxicity ENT2END studies of ACC-9653 and phenytoin sodium were carried out in mice, rats, rabbits, and dogs by i
0	ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ouabain-induced ENT1 ventricular tachycardia ENT1END in anesthetized dogs. The total doses of ENT2 ACC-9653 ENT2END or phenytoin sodium necessary to convert the arrhythmia to a normal sinus rhythm were 24 +/- 6 and 14 +/- 3 mg/kg, respectively
1	ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ENT1 ouabain  ENT1END -induced ENT2 ventricular tachycardia ENT2END in anesthetized dogs
0	ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ouabain-induced ENT1 ventricular tachycardia  ENT1END  in anesthetized dogs. The total doses of ACC-9653 or phenytoin sodium necessary to convert the arrhythmia to a normal sinus rhythm were 24 +/- 6 and 14 +/- 3 mg/kg, respectively. Only phenytoin sodium displayed in vitro antiarrhythmic activity against ENT2 strophanthidin ENT2END -induced arrhythmias in guinea pig right atria
0	Furthermore, Rg1 showed a tendency to aggravate ENT1 OIH ENT1END in the ENT2 acetic acid ENT2END -induced writhing test
0	Effects of ENT1 ginsenosides  ENT1END  on opioid-induced ENT2 hyperalgesia ENT2END in mice
1	ENT1 OIH ENT1END was achieved in mice after subcutaneous administration of ENT2 morphine ENT2END for 7 consecutive days three times per day
0	However, the ENT1 Rg1 and Rb1 ginsenosides ENT1END failed to prevent ENT2 OIH ENT2END in either test
0	ENT1 Re ENT1END (300 mg/kg) inhibited ENT2 OIH ENT2END in both the thermal sensitivity test and the acetic acid-induced writhing test
0	However, the ENT1 Rg1 and Rb1 ginsenosides  ENT1END failed to prevent ENT2 OIH ENT2END in either test
0	OIH can limit the clinical use of opioid analgesics and complicate withdrawal from ENT1 opioid addiction ENT1END  In this study, we investigated the effects of Re, Rg1, and Rb1 ginsenosides, the bioactive components of ginseng, on OIH. OIH was achieved in mice after subcutaneous administration of morphine for 7 consecutive days three times per day. During withdrawal (days 8 and 9), these mice were administered Re, Rg1, or Rb1 intragastrically two times per day. On the test day (day 10), mice were subjected to the thermal sensitivity test and the ENT2 acetic acid ENT2END -induced writhing test
0	Effects of ENT1 ginsenosides  ENT1END  on opioid-induced hyperalgesia in mice.Opioid-induced hyperalgesia (OIH) is characterized by nociceptive sensitization caused by the cessation of chronic opioid use. OIH can limit the clinical use of opioid analgesics and complicate withdrawal from ENT2 opioid addiction ENT2END
0	OIH can limit the clinical use of opioid analgesics and complicate withdrawal from ENT1 opioid addiction  ENT1END . In this study, we investigated the effects of Re, Rg1, and Rb1 ginsenosides, the bioactive components of ginseng, on OIH. OIH was achieved in mice after subcutaneous administration of ENT2 morphine ENT2END for 7 consecutive days three times per day
0	OIH can limit the clinical use of opioid analgesics and complicate withdrawal from ENT1 opioid addiction ENT1END . In this study, we investigated the effects of ENT2 Re, Rg1, and Rb1 ginsenosides ENT2END , the bioactive components of ginseng, on OIH
0	OIH can limit the clinical use of opioid analgesics and complicate withdrawal from ENT1 opioid addiction ENT1END . In this study, we investigated the effects of ENT2 Re, Rg1, and Rb1 ginsenosides ENT2END , the bioactive components of ginseng, on OIH
0	OIH can limit the clinical use of opioid analgesics and complicate withdrawal from ENT1 opioid addiction ENT1END . In this study, we investigated the effects of ENT2 Re, Rg1, and Rb1 ginsenosides ENT2END , the bioactive components of ginseng, on OIH
0	Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle ENT1 necroses ENT1END  The initial response to the primary attack by the ENT2 cyclophosphamide ENT2END metabolites seems to be fragmentation of the luminal membrane
0	Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle ENT1 necroses ENT1END . The initial response to the primary attack by the cyclophosphamide metabolites seems to be fragmentation of the ENT2 luminal ENT2END membrane
0	Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by ENT1 mesna  ENT1END .Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle ENT2 necroses ENT2END
0	Fully developed ENT1 cyclophosphamide ENT1END induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal ENT2 edema ENT2END owing to damage to the microvascular bed and focal muscle necroses
0	Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal ENT1 edema  ENT1END  owing to damage to the microvascular bed and focal muscle necroses. The initial response to the primary attack by the cyclophosphamide metabolites seems to be fragmentation of the ENT2 luminal ENT2END membrane
0	Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by ENT1 mesna  ENT1END .Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal ENT2 edema ENT2END owing to damage to the microvascular bed and focal muscle necroses
0	Fully developed ENT1 cyclophosphamide ENT1END -induced ENT2 cystitis ENT2END is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses
0	Fully developed cyclophosphamide-induced ENT1 cystitis  ENT1END  is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses. The initial response to the primary attack by the cyclophosphamide metabolites seems to be fragmentation of the ENT2 luminal ENT2END membrane
0	Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by ENT1 mesna  ENT1END .Fully developed cyclophosphamide-induced ENT2 cystitis ENT2END is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses
1	Electron microscopic investigations of the ENT1 cyclophosphamide  ENT1END -induced ENT2 lesions of the urinary bladder ENT2END of the rat and their prevention by mesna
0	Electron microscopic investigations of the cyclophosphamide-induced ENT1 lesions of the urinary bladder  ENT1END  of the rat and their prevention by mesna.Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses. The initial response to the primary attack by the cyclophosphamide metabolites seems to be fragmentation of the ENT2 luminal ENT2END membrane
0	Electron microscopic investigations of the cyclophosphamide-induced ENT1 lesions of the urinary bladder  ENT1END  of the rat and their prevention by ENT2 mesna ENT2END
0	RESULTS: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of ENT1 triglyceride ENT1END levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by ENT2 coronary heart disease ENT2END
0	5 years on ENT1 CPA  ENT1END treatment, four patients out of twenty-four were found to be affected by ENT2 coronary heart disease ENT2END
0	5 years on CPA treatment, four patients out of twenty-four were found to be affected by ENT1 coronary heart disease ENT1END . CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL ENT2 cholesterol ENT2END , Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen
0	5 years on CPA treatment, four patients out of twenty-four were found to be affected by ENT1 coronary heart disease ENT1END . CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by ENT2 estrogen ENT2END
0	AIM: To study the change of lipid metabolism by antiandrogen therapy in patients with ENT1 prostate cancer ENT1END  MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), ENT2 triglycerides ENT2END (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy
0	5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk ENT1 prostate cancer ENT1END (stage: T1cN0M0, Gleason score: 2-5) during treatment with ENT2 cyproterone acetate ENT2END (CPA) without surgical management or radiation therapy
0	AIM: To study the change of lipid metabolism by antiandrogen therapy in patients with ENT1 prostate cancer ENT1END . MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma ENT2 cholesterols ENT2END (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy
0	5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk ENT1 prostate cancer  ENT1END  (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy. RESULTS: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by ENT2 estrogen ENT2END
0	RESULTS: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of ENT1 triglyceride ENT1END  levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known ENT2 hyperglyceridemic effect ENT2END caused by estrogen
1	6% as caused by prolonged ENT1 CPA  ENT1END therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known ENT2 hyperglyceridemic effect ENT2END caused by estrogen
0	6% as caused by prolonged CPA therapy is mediated through changes in HDL ENT1 cholesterol  ENT1END , Apo A-I and Apo A-II pro fi les, other than the well-known ENT2 hyperglyceridemic effect ENT2END caused by estrogen
0	6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known ENT1 hyperglyceridemic effect  ENT1END  caused by ENT2 estrogen ENT2END
0	RESULTS: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of ENT1 triglyceride ENT1END  levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. CONCLUSIONS: Ischaemic ENT2 coronary arteriosclerosis ENT2END with an incidence rate of 16
1	CONCLUSIONS: Ischaemic ENT1 coronary arteriosclerosis  ENT1END  with an incidence rate of 16.6% as caused by prolonged ENT2 CPA ENT2END therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen
0	CONCLUSIONS: Ischaemic ENT1 coronary arteriosclerosis  ENT1END  with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL ENT2 cholesterol ENT2END , Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen
0	CONCLUSIONS: Ischaemic ENT1 coronary arteriosclerosis  ENT1END  with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by ENT2 estrogen ENT2END
1	The effect of ENT1 pupil dilation  ENT1END  with ENT2 tropicamide ENT2END on vision and driving simulator performance
0	ENT1 Metformin  ENT1END  protects against seizures, ENT2 learning and memory impairments ENT2END and oxidative damage induced by pentylenetetrazole-induced kindling in mice
1	Metformin protects against seizures, ENT1 learning and memory impairments  ENT1END  and oxidative damage induced by ENT2 pentylenetetrazole ENT2END -induced kindling in mice
0	This study was designed to evaluate the ameliorative effects of ENT1 metformin ENT1END on ENT2 seizures ENT2END , cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals
1	Metformin protects against ENT1 seizures  ENT1END , learning and memory impairments and oxidative damage induced by ENT2 pentylenetetrazole ENT2END -induced kindling in mice
0	ENT1 Metformin  ENT1END  protects against seizures, ENT2 learning and memory impairments ENT2END and oxidative damage induced by pentylenetetrazole-induced kindling in mice
1	Metformin protects against seizures, ENT1 learning and memory impairments  ENT1END  and oxidative damage induced by ENT2 pentylenetetrazole ENT2END -induced kindling in mice
0	This study was designed to evaluate the ameliorative effects of ENT1 metformin ENT1END  on seizures, ENT2 cognitive impairment ENT2END and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals
1	Metformin protects against seizures, learning and memory impairments and oxidative damage induced by ENT1 pentylenetetrazole  ENT1END -induced kindling in mice. ENT2 Cognitive impairment ENT2END , the most common and severe comorbidity of epilepsy, greatly diminishes the quality of life
0	Thus the present study concluded that ENT1 metformin ENT1END may be a potential agent for the treatment of ENT2 epilepsy ENT2END as well as a protective medicine against cognitive impairment induced by seizures
0	Metformin protects against seizures, learning and memory impairments and oxidative damage induced by ENT1 pentylenetetrazole ENT1END -induced kindling in mice.Cognitive impairment, the most common and severe comorbidity of ENT2 epilepsy ENT2END , greatly diminishes the quality of life
1	A 30-year-old cocaine-dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion ( ENT1 DEP ENT1END  became ENT2 manic ENT2END during his second week on the study drug
0	Pupillary changes associated with the development of stimulant-induced ENT1 mania ENT1END : a case report.A 30-year-old ENT2 cocaine ENT2END -dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion (DEP) became manic during his second week on the study drug
0	Pupillometric changes while on ENT1 DEP ENT1END  especially changes in the total power of ENT2 pupillary oscillation ENT2END , were dramatically different than those observed in the eight other study subjects who did not become manic
0	A 30-year-old ENT1 cocaine  ENT1END -dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion (DEP) became manic during his second week on the study drug. Pupillometric changes while on DEP, especially changes in the total power of ENT2 pupillary oscillation ENT2END , were dramatically different than those observed in the eight other study subjects who did not become manic
1	A Case of ENT1 Sudden Cardiac Death  ENT1END  due to ENT2 Pilsicainide ENT2END -Induced Torsades de Pointes
0	A Case of ENT1 Sudden Cardiac Death ENT1END  due to Pilsicainide-Induced Torsades de Pointes.An 84-year-old male received oral pilsicainide, a pure ENT2 sodium ENT2END channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed sudden cardiac death two days later
0	Although the oral administration of class IC drugs, including ENT1 pilsicainide ENT1END  is effective to terminate ENT2 atrial fibrillation ENT2END , careful consideration must be taken before giving these drugs to octogenarians
0	An 84-year-old male received oral pilsicainide, a pure ENT1 sodium ENT1END  channel blocker with slow recovery kinetics, to convert his paroxysmal ENT2 atrial fibrillation ENT2END to a sinus rhythm; the patient developed sudden cardiac death two days later
1	A Case of Sudden Cardiac Death due to ENT1 Pilsicainide  ENT1END -Induced ENT2 Torsades de Pointes ENT2END
0	A Case of Sudden Cardiac Death due to Pilsicainide-Induced ENT1 Torsades de Pointes  ENT1END .An 84-year-old male received oral pilsicainide, a pure ENT2 sodium ENT2END channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed sudden cardiac death two days later
1	The cardioprotective effect of the ethanol extract of Picrorrhiza kurroa rhizomes and roots (PK) on ENT1 isoproterenol ENT1END induced ENT2 myocardial infarction ENT2END in rats with respect to lipid metabolism in serum and heart tissue has been investigated
0	The cardioprotective effect of the ENT1 ethanol  ENT1END extract of Picrorrhiza kurroa rhizomes and roots (PK) on isoproterenol-induced ENT2 myocardial infarction ENT2END in rats with respect to lipid metabolism in serum and heart tissue has been investigated
1	Severe ENT1 polyneuropathy  ENT1END  and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases.Two cases of severe delayed neurologic toxicity related to the administration of intrathecal (IT) combination chemotherapy including thiotepa (TSPA) are presented. Both cases developed axonal neuropathy with motor predominance in the lower extremities 1 and 6 months after IT chemotherapy was administered. Neurologic toxicities have been described with IT- ENT2 methotrexate ENT2END , IT-cytosine arabinoside and IT-TSPA
1	Severe ENT1 polyneuropathy  ENT1END  and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases.Two cases of severe delayed neurologic toxicity related to the administration of intrathecal (IT) combination chemotherapy including thiotepa (TSPA) are presented. Both cases developed axonal neuropathy with motor predominance in the lower extremities 1 and 6 months after IT chemotherapy was administered. Neurologic toxicities have been described with IT-methotrexate, IT- ENT2 cytosine arabinoside ENT2END and IT-TSPA
1	Severe ENT1 polyneuropathy  ENT1END  and motor loss after intrathecal ENT2 thiotepa ENT2END combination chemotherapy: description of two cases
1	ENT1 Neurologic toxicities  ENT1END have been described with IT ENT2 methotrexate ENT2END , IT-cytosine arabinoside and IT-TSPA
1	In spite of the fact that TSPA is a useful IT agent, its combination with MTX, ENT1 ara-C ENT1END and radiotherapy could cause severe ENT2 neurotoxicity ENT2END
1	ENT1 Neurologic toxicities  ENT1END  have been described with IT-methotrexate, IT-cytosine arabinoside and IT- ENT2 TSPA ENT2END
0	Neurologic toxicities have been described with IT- ENT1 methotrexate ENT1END , IT-cytosine arabinoside and IT-TSPA. To our knowledge, however, ENT2 axonal neuropathy ENT2END following administration of these three agents has not been previously described
0	Neurologic toxicities have been described with IT-methotrexate, IT- ENT1 cytosine arabinoside  ENT1END  and IT-TSPA. To our knowledge, however, ENT2 axonal neuropathy ENT2END following administration of these three agents has not been previously described
0	Neurologic toxicities have been described with IT-methotrexate, IT-cytosine arabinoside and IT- ENT1 TSPA  ENT1END . To our knowledge, however, ENT2 axonal neuropathy ENT2END following administration of these three agents has not been previously described
1	Worsening of ENT1 Parkinsonism  ENT1END  after the use of ENT2 veralipride ENT2END for treatment of menopause: case report
0	Segmental necrotising glomerulonephritis has been reported as complication of ENT1 rifampicin ENT1END therapy in patients receiving treatment for ENT2 tuberculosis ENT2END
0	Changing epidemiology of ENT1 infections ENT1END such as infective endocarditis (IE) has led to an increase in the use of ENT2 rifampicin ENT2END for Staphylococcal infections
0	Changing epidemiology of infections such as infective endocarditis (IE) has led to an increase in the use of ENT1 rifampicin ENT1END  for ENT2 Staphylococcal infections ENT2END
0	Changing epidemiology of infections such as infective endocarditis ( ENT1 IE  ENT1END  has led to an increase in the use of ENT2 rifampicin ENT2END for Staphylococcal infections
1	We describe a case of a patient with Staphylococcal IE who developed ENT1 acute renal failure ENT1END secondary to a segmental necrotising glomerulonephritis while being treated with ENT2 rifampicin ENT2END , and review the literature regarding this complication of rifampicin therapy
1	We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising ENT1 glomerulonephritis  ENT1END while being treated with ENT2 rifampicin ENT2END , and review the literature regarding this complication of rifampicin therapy
0	The intracerebroventricular (ICV) administration of ouabain (a Na(+)/ ENT1 K ENT1END +)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human ENT2 bipolar mania ENT2END
0	Clinical studies have shown that ENT1 bipolar disorder ENT1END may be related to mitochondrial dysfunction. Herein, we investigated the behavioral and biochemical effects induced by the ICV administration of ouabain in rats. To achieve this aim, the effects of ouabain injection immediately after and 7 days following a single ICV administration (at concentrations of 10(-2) and 10(-3)M) on locomotion was measured using the open-field test. Additionally, ENT2 thiobarbituric acid ENT2END reactive substances (TBARSs) and superoxide production were measured in submitochondrial particles of the prefrontal cortex, hippocampus, striatum and amygdala
1	In conclusion, ENT1 ouabain ENT1END induced ENT2 mania ENT2END -like behavior may provide a useful animal model to test the hypothesis of the involvement of oxidative stress in bipolar disorder
0	In addition, we observed that the persistent increase in the rat spontaneous locomotion is associated with increased TBARS levels and ENT1 superoxide  ENT1END generation in submitochondrial particles in the prefrontal cortex, striatum and amygdala. In conclusion, ouabain-induced ENT2 mania ENT2END -like behavior may provide a useful animal model to test the hypothesis of the involvement of oxidative stress in bipolar disorder
0	The intracerebroventricular (ICV) administration of ouabain (a ENT1 Na  ENT1END +)/K(+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human ENT2 bipolar mania ENT2END
0	The intracerebroventricular (ICV) administration of ouabain (a Na(+)/ ENT1 K ENT1END (+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human bipolar mania. Clinical studies have shown that bipolar disorder may be related to ENT2 mitochondrial dysfunction ENT2END
0	Clinical studies have shown that bipolar disorder may be related to ENT1 mitochondrial dysfunction  ENT1END . Herein, we investigated the behavioral and biochemical effects induced by the ICV administration of ouabain in rats. To achieve this aim, the effects of ouabain injection immediately after and 7 days following a single ICV administration (at concentrations of 10(-2) and 10(-3)M) on locomotion was measured using the open-field test. Additionally, ENT2 thiobarbituric acid ENT2END reactive substances (TBARSs) and superoxide production were measured in submitochondrial particles of the prefrontal cortex, hippocampus, striatum and amygdala
0	Clinical studies have shown that bipolar disorder may be related to ENT1 mitochondrial dysfunction ENT1END . Herein, we investigated the behavioral and biochemical effects induced by the ICV administration of ENT2 ouabain ENT2END in rats
0	Clinical studies have shown that bipolar disorder may be related to ENT1 mitochondrial dysfunction ENT1END . Herein, we investigated the behavioral and biochemical effects induced by the ICV administration of ouabain in rats. To achieve this aim, the effects of ouabain injection immediately after and 7 days following a single ICV administration (at concentrations of 10(-2) and 10(-3)M) on locomotion was measured using the open-field test. Additionally, thiobarbituric acid reactive substances (TBARSs) and ENT2 superoxide ENT2END production were measured in submitochondrial particles of the prefrontal cortex, hippocampus, striatum and amygdala
0	The intracerebroventricular (ICV) administration of ouabain (a ENT1 Na  ENT1END (+)/K(+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human bipolar mania. Clinical studies have shown that bipolar disorder may be related to ENT2 mitochondrial dysfunction ENT2END
0	The intracerebroventricular (ICV) administration of ouabain (a Na(+)/ ENT1 K ENT1END (+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human bipolar mania. Clinical studies have shown that bipolar disorder may be related to mitochondrial dysfunction. Herein, we investigated the behavioral and biochemical effects induced by the ICV administration of ouabain in rats. To achieve this aim, the effects of ouabain injection immediately after and 7 days following a single ICV administration (at concentrations of 10(-2) and 10(-3)M) on locomotion was measured using the open-field test. Additionally, thiobarbituric acid reactive substances (TBARSs) and superoxide production were measured in submitochondrial particles of the prefrontal cortex, hippocampus, striatum and amygdala. Our findings demonstrated that ouabain at 10(-2) and 10(-3)M induced ENT2 hyperlocomotion ENT2END in rats, and this response remained up to 7 days following a single ICV injection
0	Additionally, ENT1 thiobarbituric acid  ENT1END  reactive substances (TBARSs) and superoxide production were measured in submitochondrial particles of the prefrontal cortex, hippocampus, striatum and amygdala. Our findings demonstrated that ouabain at 10(-2) and 10(-3)M induced ENT2 hyperlocomotion ENT2END in rats, and this response remained up to 7 days following a single ICV injection
0	Our findings demonstrated that ENT1 ouabain  ENT1END at 10(-2) and 10(-3)M induced ENT2 hyperlocomotion ENT2END in rats, and this response remained up to 7 days following a single ICV injection
0	Additionally, thiobarbituric acid reactive substances (TBARSs) and ENT1 superoxide  ENT1END  production were measured in submitochondrial particles of the prefrontal cortex, hippocampus, striatum and amygdala. Our findings demonstrated that ouabain at 10(-2) and 10(-3)M induced ENT2 hyperlocomotion ENT2END in rats, and this response remained up to 7 days following a single ICV injection
0	The intracerebroventricular (ICV) administration of ouabain (a ENT1 Na  ENT1END (+)/K(+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human bipolar mania. Clinical studies have shown that bipolar disorder may be related to mitochondrial dysfunction. Herein, we investigated the behavioral and biochemical effects induced by the ICV administration of ouabain in rats. To achieve this aim, the effects of ouabain injection immediately after and 7 days following a single ICV administration (at concentrations of 10(-2) and 10(-3)M) on locomotion was measured using the open-field test. Additionally, thiobarbituric acid reactive substances (TBARSs) and superoxide production were measured in submitochondrial particles of the prefrontal cortex, hippocampus, striatum and amygdala. Our findings demonstrated that ouabain at 10(-2) and 10(-3)M induced ENT2 hyperlocomotion ENT2END in rats, and this response remained up to 7 days following a single ICV injection
1	ENT1 Pain ENT1END on injection (80 vs. 20%, p < 0.01) and thrombophlebitis (93.3 vs. 6.6%, p < 0.001) occurred more frequently with AM149 than with ENT2 Disoprivan ENT2END
1	01) and ENT1 thrombophlebitis  ENT1END (93.3 vs. 6.6%, p < 0.001) occurred more frequently with AM149 than with ENT2 Disoprivan ENT2END
0	The patient's observations were within normal limits, he was administered ENT1 oxygen ENT1END via a face mask and glyceryl trinitrate (GTN). Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by atropine sulphate and a fluid challenge. There was no further deterioration in the patient's condition during transport to hospital. There are very few documented case like this in the prehospital scientific literature. The cause appears to be the Bezold-Jarish reflex, stimulation of the ventricular walls which in turn decreases sympathetic outflow from the vasomotor centre. Prehospital care providers who are managing any patient with a ENT2 syncopal episode ENT2END that fails to recover within a reasonable time frame should consider the Bezold-Jarisch reflex as the cause and manage the patient accordingly
0	Several minutes after the ENT1 GTN  ENT1END the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by atropine sulphate and a fluid challenge. There was no further deterioration in the patient's condition during transport to hospital. There are very few documented case like this in the prehospital scientific literature. The cause appears to be the Bezold-Jarish reflex, stimulation of the ventricular walls which in turn decreases sympathetic outflow from the vasomotor centre. Prehospital care providers who are managing any patient with a ENT2 syncopal episode ENT2END that fails to recover within a reasonable time frame should consider the Bezold-Jarisch reflex as the cause and manage the patient accordingly
0	Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by ENT1 atropine sulphate  ENT1END and a fluid challenge. There was no further deterioration in the patient's condition during transport to hospital. There are very few documented case like this in the prehospital scientific literature. The cause appears to be the Bezold-Jarish reflex, stimulation of the ventricular walls which in turn decreases sympathetic outflow from the vasomotor centre. Prehospital care providers who are managing any patient with a ENT2 syncopal episode ENT2END that fails to recover within a reasonable time frame should consider the Bezold-Jarisch reflex as the cause and manage the patient accordingly
0	A male in his sixties with no history of cardiac chest pain awoke with ENT1 chest pain  ENT1END following an afternoon sleep. The patient did not self medicate. The patient's observations were within normal limits, he was administered ENT2 oxygen ENT2END via a face mask and glyceryl trinitrate (GTN)
0	A dramatic drop in blood pressure following prehospital ENT1 GTN ENT1END  administration.A male in his sixties with no history of cardiac ENT2 chest pain ENT2END awoke with chest pain following an afternoon sleep
0	A male in his sixties with no history of cardiac chest pain awoke with ENT1 chest pain  ENT1END  following an afternoon sleep. The patient did not self medicate. The patient's observations were within normal limits, he was administered oxygen via a face mask and glyceryl trinitrate (GTN). Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by ENT2 atropine sulphate ENT2END and a fluid challenge
1	The patient's observations were within normal limits, he was administered ENT1 oxygen ENT1END  via a face mask and glyceryl trinitrate (GTN). Several minutes after the GTN the patient experienced a sudden ENT2 drop in blood pressure ENT2END and heart rate, this was rectified by atropine sulphate and a fluid challenge
1	A dramatic ENT1 drop in blood pressure  ENT1END  following prehospital ENT2 GTN ENT2END administration
0	Several minutes after the GTN the patient experienced a sudden ENT1 drop in blood pressure  ENT1END  and heart rate, this was rectified by ENT2 atropine sulphate ENT2END and a fluid challenge
1	These data indicate that adult mouse atrial and ventricular cardiomyocytes do not synthesize DNA in response to ENT1 isoproterenol ENT1END induced ENT2 cardiac hypertrophy ENT2END
0	Assessment of cardiomyocyte DNA synthesis during ENT1 hypertrophy ENT1END  in adult mice.The ability of cardiomyocytes to synthesize DNA in response to experimentally induced cardiac hypertrophy was assessed in adult mice. ENT2 Isoproterenol ENT2END delivered by osmotic minipump implantation in adult C3Heb/FeJ mice resulted in a 46% increase in heart weight and a 19
0	ENT1 Convulsion  ENT1END  following intravenous ENT2 fluorescein ENT2END angiography
1	Convulsion following intravenous ENT1 fluorescein  ENT1END  angiography. ENT2 Tonic-clonic seizures ENT2END followed intravenous fluorescein injection for fundus angiography in a 47-year-old male
1	METHODS: Newborn piglets received ENT1 levobupivacaine ENT1END until ENT2 cardiovascular collapse ENT2END occurred
0	BACKGROUND: The optimal dosing regimens of lipid emulsion, ENT1 epinephrine  ENT1END  or both are not yet determined in neonates in cases of local anaesthetic systemic toxicity (LAST). METHODS: Newborn piglets received levobupivacaine until ENT2 cardiovascular collapse ENT2END occurred
0	Resuscitation with lipid, epinephrine, or both in ENT1 levobupivacaine  ENT1END -induced ENT2 cardiac toxicity ENT2END in newborn piglets
0	Resuscitation with lipid, ENT1 epinephrine  ENT1END , or both in levobupivacaine-induced ENT2 cardiac toxicity ENT2END in newborn piglets
0	BACKGROUND: The optimal dosing regimens of lipid emulsion, epinephrine, or both are not yet determined in neonates in cases of local anaesthetic systemic ENT1 toxicity  ENT1END (LAST). METHODS: Newborn piglets received ENT2 levobupivacaine ENT2END until cardiovascular collapse occurred
0	BACKGROUND: The optimal dosing regimens of lipid emulsion, ENT1 epinephrine  ENT1END , or both are not yet determined in neonates in cases of local anaesthetic systemic ENT2 toxicity ENT2END (LAST)
0	METHODS: Newborn piglets received ENT1 levobupivacaine ENT1END  until cardiovascular collapse occurred. Standard cardiopulmonary resuscitation was started and electrocardiogram (ECG) was monitored for ventricular tachycardia, ENT2 fibrillation ENT2END , or QRS prolongation
0	Standard cardiopulmonary resuscitation was started and electrocardiogram (ECG) was monitored for ventricular tachycardia, ENT1 fibrillation ENT1END , or QRS prolongation. Piglets were then randomly allocated to four groups: control (saline), Intralipid( ) alone, ENT2 epinephrine ENT2END alone, or a combination of Intralipd plus epinephrine
0	METHODS: Newborn piglets received ENT1 levobupivacaine ENT1END  until cardiovascular collapse occurred. Standard cardiopulmonary resuscitation was started and electrocardiogram (ECG) was monitored for ENT2 ventricular tachycardia ENT2END , fibrillation, or QRS prolongation
0	Standard cardiopulmonary resuscitation was started and electrocardiogram (ECG) was monitored for ENT1 ventricular tachycardia  ENT1END , fibrillation, or QRS prolongation. Piglets were then randomly allocated to four groups: control (saline), Intralipid( ) alone, ENT2 epinephrine ENT2END alone, or a combination of Intralipd plus epinephrine
0	On the 49th day of terbinafine therapy, he was brought to the emergency room for a decrease of his global health status, ENT1 confusion ENT1END and falls. The electrocardiogram revealed a 37 beats/min sinus bradycardia. A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and terbinafine. The heart rate ameliorated first with a decrease in the dose of metoprolol. It was subsequently changed to ENT2 bisoprolol ENT2END and the heart rate remained normal
0	On the 49th day of ENT1 terbinafine  ENT1END therapy, he was brought to the emergency room for a decrease of his global health status, ENT2 confusion ENT2END and falls
0	A 63 year-old Caucasian man on ENT1 metoprolol  ENT1END 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis. On the 49th day of terbinafine therapy, he was brought to the emergency room for a decrease of his global health status, ENT2 confusion ENT2END and falls
0	A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's ENT1 sinus bradycardia  ENT1END and the drug interaction between metoprolol and terbinafine. The heart rate ameliorated first with a decrease in the dose of metoprolol. It was subsequently changed to ENT2 bisoprolol ENT2END and the heart rate remained normal
0	To report a ENT1 sinus bradycardia ENT1END induced by metoprolol and ENT2 terbinafine ENT2END drug-drug interaction and its management
0	To report a ENT1 sinus bradycardia ENT1END  induced by ENT2 metoprolol ENT2END and terbinafine drug-drug interaction and its management
0	A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for ENT1 onychomycosis  ENT1END  On the 49th day of terbinafine therapy, he was brought to the emergency room for a decrease of his global health status, confusion and falls. The electrocardiogram revealed a 37 beats/min sinus bradycardia. A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and terbinafine. The heart rate ameliorated first with a decrease in the dose of metoprolol. It was subsequently changed to ENT2 bisoprolol ENT2END and the heart rate remained normal
0	A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral ENT1 terbinafine  ENT1END 250 mg/day for ENT2 onychomycosis ENT2END
0	A 63 year-old Caucasian man on ENT1 metoprolol  ENT1END  200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for ENT2 onychomycosis ENT2END
0	A score of 7 on the Naranjo ENT1 adverse drug reaction  ENT1END probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and terbinafine. The heart rate ameliorated first with a decrease in the dose of metoprolol. It was subsequently changed to ENT2 bisoprolol ENT2END and the heart rate remained normal
0	A score of 7 on the Naranjo ENT1 adverse drug reaction ENT1END  probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and ENT2 terbinafine ENT2END
0	A score of 7 on the Naranjo ENT1 adverse drug reaction ENT1END  probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between ENT2 metoprolol ENT2END and terbinafine
1	A metoprolol- ENT1 terbinafine  ENT1END  combination induced ENT2 bradycardia ENT2END
1	A ENT1 metoprolol  ENT1END -terbinafine combination induced ENT2 bradycardia ENT2END
0	A 63 year-old Caucasian man on metoprolol 200 mg/day for stable ENT1 coronary artery disease  ENT1END was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis. On the 49th day of terbinafine therapy, he was brought to the emergency room for a decrease of his global health status, confusion and falls. The electrocardiogram revealed a 37 beats/min sinus bradycardia. A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and terbinafine. The heart rate ameliorated first with a decrease in the dose of metoprolol. It was subsequently changed to ENT2 bisoprolol ENT2END and the heart rate remained normal
0	A 63 year-old Caucasian man on metoprolol 200 mg/day for stable ENT1 coronary artery disease  ENT1END  was prescribed a 90-day course of oral ENT2 terbinafine ENT2END 250 mg/day for onychomycosis
0	A 63 year-old Caucasian man on ENT1 metoprolol  ENT1END  200 mg/day for stable ENT2 coronary artery disease ENT2END was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis
1	PRACTICAL IMPLICATIONS: As much as 15% of ENT1 lithium ENT1END treated patients become ENT2 hypercalcemic ENT2END
0	PRACTICAL IMPLICATIONS: As much as 15% of lithium-treated patients become ENT1 hypercalcemic ENT1END . By routinely monitoring serum ENT2 calcium ENT2END levels, healthcare providers can improve the quality of life of this patient group
0	CONCLUSION: ENT1 Primary hyperparathyroidism ENT1END is a rare but potentially life-threatening side effect of long-term ENT2 lithium ENT2END therapy
0	PURPOSE: This paper reviews the effect of chronic lithium therapy on serum ENT1 calcium  ENT1END level and parathyroid glands, its pathogenesis, and treatment options. We examined the case of a lithium-treated patient who had recurrent hypercalcemia to better understand the disease process. CONCLUSION: ENT2 Primary hyperparathyroidism ENT2END is a rare but potentially life-threatening side effect of long-term lithium therapy
1	Long-term ENT1 lithium  ENT1END  therapy leading to ENT2 hyperparathyroidism ENT2END : a case report
0	Long-term lithium therapy leading to ENT1 hyperparathyroidism  ENT1END : a case report.PURPOSE: This paper reviews the effect of chronic lithium therapy on serum ENT2 calcium ENT2END level and parathyroid glands, its pathogenesis, and treatment options
0	CONCLUSION: In patients with FHF and cerebral edema from ENT1 acetaminophen ENT1END overdose, prolonged therapeutic ENT2 hypothermia ENT2END could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery
0	Initial evaluation confirmed FHF from ENT1 acetaminophen ENT1END and cerebral edema. The patient was treated with hyperosmolar therapy, ENT2 hyperventilation ENT2END , sedation, and chemical paralysis
1	At re-warming, patient had resolution of her cerebral edema and ENT1 intracranial hypertension  ENT1END  At discharge, she had complete recovery of neurological and hepatic functions. CONCLUSION: In patients with FHF and cerebral edema from ENT2 acetaminophen ENT2END overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery
0	RESULTS: Our patient was admitted to the MICU after being found unresponsive with presumed ENT1 toxicity ENT1END from ENT2 acetaminophen ENT2END which was ingested over a 2-day period
1	Initial evaluation confirmed FHF from ENT1 acetaminophen ENT1END  and ENT2 cerebral edema ENT2END
0	CONCLUSION: In patients with FHF and cerebral edema from ENT1 acetaminophen ENT1END  ENT2 overdose ENT2END , prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery
1	METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with ENT1 FHF ENT1END from ENT2 acetaminophen ENT2END and resultant cerebral edema
0	Initial evaluation confirmed FHF from ENT1 acetaminophen ENT1END  and cerebral edema. The patient was treated with hyperosmolar therapy, hyperventilation, sedation, and chemical ENT2 paralysis ENT2END
0	Three patients had acute viral myocarditis, one had a ENT1 carbamazepine ENT1END induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock. All patients were continuously monitored with central venous and arterial catheters in addition to routine noninvasive monitoring. An introducer sheath, a pacemaker, and sterile pacing wires were made readily available for the patients, should the need arise to terminate resistant cardiac ENT2 dysrhythmias ENT2END
0	Three patients had acute viral myocarditis, one had a ENT1 carbamazepine ENT1END -induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock. All patients were continuously monitored with central venous and arterial catheters in addition to routine noninvasive monitoring. An introducer sheath, a pacemaker, and sterile pacing wires were made readily available for the patients, should the need arise to terminate resistant cardiac dysrhythmias. All patients developed cardiocirculatory arrest associated with extreme ENT2 hypotension ENT2END and dysrhythmias within the first 48 hours of their admission to the pediatric intensive care unit (PICU)
0	We describe the cardiopulmonary resuscitation efforts on five patients who presented in acute circulatory failure from ENT1 myocardial dysfunction  ENT1END  Three patients had acute viral myocarditis, one had a ENT2 carbamazepine ENT2END -induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock
0	Three patients had acute viral myocarditis, one had a ENT1 carbamazepine ENT1END -induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute ENT2 cardiogenic shock ENT2END
1	Three patients had acute viral myocarditis, one had a ENT1 carbamazepine ENT1END -induced acute ENT2 eosinophilic myocarditis ENT2END , and one had cardiac hemosiderosis resulting in acute cardiogenic shock
1	Three patients had acute viral ENT1 myocarditis  ENT1END  one had a ENT2 carbamazepine ENT2END -induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock
0	We describe the cardiopulmonary resuscitation efforts on five patients who presented in acute ENT1 circulatory failure  ENT1END from myocardial dysfunction. Three patients had acute viral myocarditis, one had a ENT2 carbamazepine ENT2END -induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock
0	Significant clinical manifestations have included confusion, papilledema, ENT1 somnolence ENT1END  exacerbation of motor deficits, and sharp increase in seizure activity. These abnormalities resolved rapidly after initiation of high-dose intravenous ENT2 dexamethasone ENT2END therapy
0	This developed a median of 9 days after initiation of high-dose ENT1 etoposide  ENT1END therapy. Significant clinical manifestations have included confusion, papilledema, ENT2 somnolence ENT2END , exacerbation of motor deficits, and sharp increase in seizure activity
0	These abnormalities resolved rapidly after initiation of high-dose intravenous ENT1 dexamethasone ENT1END  therapy. In all patients, computerized tomographic (CT) brain scans demonstrated stability in tumor size and peritumor edema when compared with pretransplant scans. This complication appears to represent a significant new toxicity of high-dose etoposide therapy for ENT2 malignant glioma ENT2END
0	Acute neurologic dysfunction after high-dose etoposide therapy for ENT1 malignant glioma  ENT1END . ENT2 Etoposide ENT2END (VP-16-213) has been used in the treatment of many solid tumors and hematologic malignancies
0	These abnormalities resolved rapidly after initiation of high-dose intravenous ENT1 dexamethasone ENT1END  therapy. In all patients, computerized tomographic (CT) brain scans demonstrated stability in tumor size and peritumor edema when compared with pretransplant scans. This complication appears to represent a significant new ENT2 toxicity ENT2END of high-dose etoposide therapy for malignant glioma
0	This complication appears to represent a significant new ENT1 toxicity ENT1END  of high-dose ENT2 etoposide ENT2END therapy for malignant glioma
0	These abnormalities resolved rapidly after initiation of high-dose intravenous ENT1 dexamethasone ENT1END  therapy. In all patients, computerized tomographic (CT) brain scans demonstrated stability in ENT2 tumor ENT2END size and peritumor edema when compared with pretransplant scans
0	Etoposide ( ENT1 VP-16-213 ENT1END  has been used in the treatment of many solid ENT2 tumors ENT2END and hematologic malignancies
0	Significant clinical manifestations have included ENT1 confusion  ENT1END  papilledema, somnolence, exacerbation of motor deficits, and sharp increase in seizure activity. These abnormalities resolved rapidly after initiation of high-dose intravenous ENT2 dexamethasone ENT2END therapy
1	This developed a median of 9 days after initiation of high-dose ENT1 etoposide  ENT1END  therapy. Significant clinical manifestations have included ENT2 confusion ENT2END , papilledema, somnolence, exacerbation of motor deficits, and sharp increase in seizure activity
0	In six of eight patients (75%) who we treated for recurrent or resistant glioma, sudden severe ENT1 neurologic deterioration  ENT1END occurred. This developed a median of 9 days after initiation of high-dose etoposide therapy. Significant clinical manifestations have included confusion, papilledema, somnolence, exacerbation of motor deficits, and sharp increase in seizure activity. These abnormalities resolved rapidly after initiation of high-dose intravenous ENT2 dexamethasone ENT2END therapy
0	ENT1 Acute neurologic dysfunction  ENT1END  after high-dose ENT2 etoposide ENT2END therapy for malignant glioma
0	Significant clinical manifestations have included confusion, ENT1 papilledema  ENT1END  somnolence, exacerbation of motor deficits, and sharp increase in seizure activity. These abnormalities resolved rapidly after initiation of high-dose intravenous ENT2 dexamethasone ENT2END therapy
1	This developed a median of 9 days after initiation of high-dose ENT1 etoposide  ENT1END  therapy. Significant clinical manifestations have included confusion, ENT2 papilledema ENT2END , somnolence, exacerbation of motor deficits, and sharp increase in seizure activity
0	Etoposide (VP-16-213) has been used in the treatment of many solid tumors and ENT1 hematologic malignancies  ENT1END  When used in high doses and in conjunction with autologous bone marrow transplantation, this agent has activity against several treatment-resistant cancers including malignant glioma. In six of eight patients (75%) who we treated for recurrent or resistant glioma, sudden severe neurologic deterioration occurred. This developed a median of 9 days after initiation of high-dose etoposide therapy. Significant clinical manifestations have included confusion, papilledema, somnolence, exacerbation of motor deficits, and sharp increase in seizure activity. These abnormalities resolved rapidly after initiation of high-dose intravenous ENT2 dexamethasone ENT2END therapy
0	Etoposide ( ENT1 VP-16-213  ENT1END ) has been used in the treatment of many solid tumors and ENT2 hematologic malignancies ENT2END
0	Significant clinical manifestations have included confusion, papilledema, somnolence, exacerbation of motor deficits, and sharp increase in ENT1 seizure  ENT1END activity. These abnormalities resolved rapidly after initiation of high-dose intravenous ENT2 dexamethasone ENT2END therapy
1	This developed a median of 9 days after initiation of high-dose ENT1 etoposide  ENT1END  therapy. Significant clinical manifestations have included confusion, papilledema, somnolence, exacerbation of motor deficits, and sharp increase in ENT2 seizure ENT2END activity
0	These abnormalities resolved rapidly after initiation of high-dose intravenous ENT1 dexamethasone ENT1END  therapy. In all patients, computerized tomographic (CT) brain scans demonstrated stability in tumor size and peritumor ENT2 edema ENT2END when compared with pretransplant scans
0	In all patients, computerized tomographic (CT) brain scans demonstrated stability in tumor size and peritumor ENT1 edema  ENT1END  when compared with pretransplant scans. This complication appears to represent a significant new toxicity of high-dose ENT2 etoposide ENT2END therapy for malignant glioma
1	Thereafter, seizures were induced by ENT1 pilocarpine ENT1END injections in trained and non-trained control groups. During the acute period of ENT2 status epilepticus ENT2END , we measured: (1) the latency of the first motor sign, (2) the intensity of seizures, (3) the time when it occurred within the 6-h observation period, and (4) the time when the acute period ended
1	Physical training decreases susceptibility to subsequent ENT1 pilocarpine  ENT1END -induced ENT2 seizures ENT2END in the rat
0	Physical training decreases susceptibility to subsequent ENT1 pilocarpine ENT1END -induced seizures in the rat.Regular motor activity has many benefits for mental and physical condition but its implications for ENT2 epilepsy ENT2END are still controversial
0	An integrated characterization of serological, pathological, and functional events in ENT1 doxorubicin  ENT1END -induced ENT2 cardiotoxicity ENT2END
0	25 mg/kg ENT1 DOX ENT1END weekly for 8 weeks followed by a 4 week off-dosing "recovery" period. Electron microscopy of the myocardium revealed subcellular degeneration and marked mitochondrial changes after a single dose. Histopathological analysis revealed progressive cardiomyocyte degeneration, ENT2 hypertrophy ENT2END /cytomegaly, and extensive vacuolation after two doses
0	Histopathological analysis revealed progressive cardiomyocyte degeneration, ENT1 hypertrophy ENT1END /cytomegaly, and extensive vacuolation after two doses. Extensive replacement fibrosis (quantified by Sirius red staining) developed during the off-dosing period. Functional indices assessed by cardiac MRI (including left ventricular ejection fraction (LVEF), cardiac output, and E/A ratio) declined progressively, reaching statistical significance after two doses and culminating in "clinical" LV dysfunction by 12 weeks. Significant increases in peak myocardial contrast enhancement and serological cardiac troponin I (cTnI) emerged after eight doses, importantly preceding the LVEF decline to <50%. Troponin I levels positively correlated with delayed and peak ENT2 gadolinium ENT2END contrast enhancement, histopathological grading, and diastolic dysfunction
1	25 mg/kg ENT1 DOX ENT1END  weekly for 8 weeks followed by a 4 week off-dosing "recovery" period. Electron microscopy of the myocardium revealed subcellular degeneration and marked mitochondrial changes after a single dose. Histopathological analysis revealed progressive cardiomyocyte degeneration, hypertrophy/cytomegaly, and extensive vacuolation after two doses. Extensive replacement ENT2 fibrosis ENT2END (quantified by Sirius red staining) developed during the off-dosing period
0	Extensive replacement ENT1 fibrosis  ENT1END  (quantified by Sirius red staining) developed during the off-dosing period. Functional indices assessed by cardiac MRI (including left ventricular ejection fraction (LVEF), cardiac output, and E/A ratio) declined progressively, reaching statistical significance after two doses and culminating in "clinical" LV dysfunction by 12 weeks. Significant increases in peak myocardial contrast enhancement and serological cardiac troponin I (cTnI) emerged after eight doses, importantly preceding the LVEF decline to <50%. Troponin I levels positively correlated with delayed and peak ENT2 gadolinium ENT2END contrast enhancement, histopathological grading, and diastolic dysfunction
0	25 mg/kg ENT1 DOX ENT1END  weekly for 8 weeks followed by a 4 week off-dosing "recovery" period. Electron microscopy of the myocardium revealed ENT2 subcellular degeneration ENT2END and marked mitochondrial changes after a single dose
0	Troponin I levels positively correlated with delayed and peak ENT1 gadolinium ENT1END  contrast enhancement, histopathological grading, and diastolic dysfunction. In summary, subcellular ENT2 cardiomyocyte degeneration ENT2END was the earliest marker, followed by progressive functional decline and histopathological manifestations
0	An integrated characterization of serological, pathological, and functional events in ENT1 doxorubicin ENT1END -induced cardiotoxicity.Many efficacious ENT2 cancer ENT2END treatments cause significant cardiac morbidity, yet biomarkers or functional indices of early damage, which would allow monitoring and intervention, are lacking
0	In this study, we have utilized a rat model of progressive doxorubicin (DOX)-induced cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this ENT1 toxicity  ENT1END  Hannover Wistar rats were dosed with 1.25 mg/kg ENT2 DOX ENT2END weekly for 8 weeks followed by a 4 week off-dosing "recovery" period
1	In this study, we have utilized a rat model of progressive doxorubicin ( ENT1 DOX ENT1END -induced ENT2 cardiomyopathy ENT2END , applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this toxicity
1	25 mg/kg ENT1 DOX ENT1END  weekly for 8 weeks followed by a 4 week off-dosing "recovery" period. Electron microscopy of the myocardium revealed subcellular degeneration and marked mitochondrial changes after a single dose. Histopathological analysis revealed progressive cardiomyocyte degeneration, hypertrophy/cytomegaly, and extensive vacuolation after two doses. Extensive replacement fibrosis (quantified by Sirius red staining) developed during the off-dosing period. Functional indices assessed by cardiac MRI (including left ventricular ejection fraction (LVEF), cardiac output, and E/A ratio) declined progressively, reaching statistical significance after two doses and culminating in "clinical" ENT2 LV dysfunction ENT2END by 12 weeks
0	Functional indices assessed by cardiac MRI (including left ventricular ejection fraction (LVEF), cardiac output, and E/A ratio) declined progressively, reaching statistical significance after two doses and culminating in "clinical" ENT1 LV dysfunction  ENT1END  by 12 weeks. Significant increases in peak myocardial contrast enhancement and serological cardiac troponin I (cTnI) emerged after eight doses, importantly preceding the LVEF decline to <50%. Troponin I levels positively correlated with delayed and peak ENT2 gadolinium ENT2END contrast enhancement, histopathological grading, and diastolic dysfunction
0	Troponin I levels positively correlated with delayed and peak ENT1 gadolinium ENT1END  contrast enhancement, histopathological grading, and ENT2 diastolic dysfunction ENT2END
0	We report on a 14-year-old boy who developed ENT1 acute renal failure ENT1END 2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a ENT2 blood urea nitrogen ENT2END (BUN) concentration of of 147 mg/dl, creatinine of 15
0	We report on a 14-year-old boy who developed ENT1 acute renal failure ENT1END  2 weeks after aortic valve surgery. He was put on ENT2 aspirin ENT2END following surgery and took ibuprofen for fever for nearly a week prior to presentation
0	We report on a 14-year-old boy who developed ENT1 acute renal failure ENT1END  2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, ENT2 creatinine ENT2END of 15
0	We report on a 14-year-old boy who developed ENT1 acute renal failure ENT1END  2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, creatinine of 15.3 mg/dl and serum ENT2 potassium ENT2END of 8
1	We report on a 14-year-old boy who developed ENT1 acute renal failure ENT1END  2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ENT2 ibuprofen ENT2END for fever for nearly a week prior to presentation
0	He was put on aspirin following surgery and took ibuprofen for ENT1 fever ENT1END for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, creatinine of 15.3 mg/dl and serum potassium of 8.7 mEq/l. Dialysis was immediately initiated. A kidney biopsy showed inflammatory infiltrate consistent with ATIN. However, in the tubular basement membrane (TBM), very intense granular deposits of polyclonal IgG and C3 were noted. He needed dialysis for 2 weeks and was treated successfully with ENT2 steroids ENT2END for 6 months
0	He was put on aspirin following surgery and took ibuprofen for ENT1 fever  ENT1END  for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a ENT2 blood urea nitrogen ENT2END (BUN) concentration of of 147 mg/dl, creatinine of 15
0	He was put on ENT1 aspirin  ENT1END  following surgery and took ibuprofen for ENT2 fever ENT2END for nearly a week prior to presentation
0	He was put on aspirin following surgery and took ibuprofen for ENT1 fever  ENT1END  for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, ENT2 creatinine ENT2END of 15
0	He was put on aspirin following surgery and took ibuprofen for ENT1 fever  ENT1END  for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, creatinine of 15.3 mg/dl and serum ENT2 potassium ENT2END of 8
0	He was put on aspirin following surgery and took ENT1 ibuprofen  ENT1END  for ENT2 fever ENT2END for nearly a week prior to presentation
0	He needed dialysis for 2 weeks and was treated successfully with ENT1 steroids ENT1END  for 6 months. His renal recovery and disappearance of ENT2 proteinuria ENT2END took a year
0	He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen ( ENT1 BUN  ENT1END  concentration of of 147 mg/dl, creatinine of 15.3 mg/dl and serum potassium of 8.7 mEq/l. Dialysis was immediately initiated. A kidney biopsy showed inflammatory infiltrate consistent with ATIN. However, in the tubular basement membrane (TBM), very intense granular deposits of polyclonal IgG and C3 were noted. He needed dialysis for 2 weeks and was treated successfully with steroids for 6 months. His renal recovery and disappearance of ENT2 proteinuria ENT2END took a year
0	He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, ENT1 creatinine  ENT1END  of 15.3 mg/dl and serum potassium of 8.7 mEq/l. Dialysis was immediately initiated. A kidney biopsy showed inflammatory infiltrate consistent with ATIN. However, in the tubular basement membrane (TBM), very intense granular deposits of polyclonal IgG and C3 were noted. He needed dialysis for 2 weeks and was treated successfully with steroids for 6 months. His renal recovery and disappearance of ENT2 proteinuria ENT2END took a year
0	3 mg/dl and serum ENT1 potassium  ENT1END  of 8.7 mEq/l. Dialysis was immediately initiated. A kidney biopsy showed inflammatory infiltrate consistent with ATIN. However, in the tubular basement membrane (TBM), very intense granular deposits of polyclonal IgG and C3 were noted. He needed dialysis for 2 weeks and was treated successfully with steroids for 6 months. His renal recovery and disappearance of ENT2 proteinuria ENT2END took a year
0	Acute tubulo-interstitial nephritis (ATIN) is an important cause of acute renal failure resulting from a variety of insults, including immune complex-mediated ENT1 tubulo-interstitial injury  ENT1END  but drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) are a far more frequent cause. Overall, as an entity, ATIN remains under-diagnosed, as symptoms resolve spontaneously if the medication is stopped. We report on a 14-year-old boy who developed acute renal failure 2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a ENT2 blood urea nitrogen ENT2END (BUN) concentration of of 147 mg/dl, creatinine of 15
0	Acute tubulo-interstitial nephritis (ATIN) is an important cause of acute renal failure resulting from a variety of insults, including immune complex-mediated ENT1 tubulo-interstitial injury  ENT1END , but drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) are a far more frequent cause. Overall, as an entity, ATIN remains under-diagnosed, as symptoms resolve spontaneously if the medication is stopped. We report on a 14-year-old boy who developed acute renal failure 2 weeks after aortic valve surgery. He was put on ENT2 aspirin ENT2END following surgery and took ibuprofen for fever for nearly a week prior to presentation
0	Acute tubulo-interstitial nephritis (ATIN) is an important cause of acute renal failure resulting from a variety of insults, including immune complex-mediated ENT1 tubulo-interstitial injury  ENT1END , but drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) are a far more frequent cause. Overall, as an entity, ATIN remains under-diagnosed, as symptoms resolve spontaneously if the medication is stopped. We report on a 14-year-old boy who developed acute renal failure 2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, ENT2 creatinine ENT2END of 15
0	Acute tubulo-interstitial nephritis (ATIN) is an important cause of acute renal failure resulting from a variety of insults, including immune complex-mediated ENT1 tubulo-interstitial injury  ENT1END , but drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) are a far more frequent cause. Overall, as an entity, ATIN remains under-diagnosed, as symptoms resolve spontaneously if the medication is stopped. We report on a 14-year-old boy who developed acute renal failure 2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, creatinine of 15.3 mg/dl and serum ENT2 potassium ENT2END of 8
1	Acute tubulo-interstitial nephritis (ATIN) is an important cause of acute renal failure resulting from a variety of insults, including immune complex-mediated ENT1 tubulo-interstitial injury  ENT1END , but drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) are a far more frequent cause. Overall, as an entity, ATIN remains under-diagnosed, as symptoms resolve spontaneously if the medication is stopped. We report on a 14-year-old boy who developed acute renal failure 2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ENT2 ibuprofen ENT2END for fever for nearly a week prior to presentation
0	He needed dialysis for 2 weeks and was treated successfully with ENT1 steroids ENT1END  for 6 months. His renal recovery and disappearance of proteinuria took a year. In conclusion, this is a first report of NSAIDs-associated ENT2 ATIN ENT2END , showing deposits of granular immune complex present only in the TBM and not in the glomeruli
0	He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen ( ENT1 BUN ENT1END ) concentration of of 147 mg/dl, creatinine of 15.3 mg/dl and serum potassium of 8.7 mEq/l. Dialysis was immediately initiated. A kidney biopsy showed inflammatory infiltrate consistent with ENT2 ATIN ENT2END
0	Overall, as an entity, ENT1 ATIN  ENT1END remains under-diagnosed, as symptoms resolve spontaneously if the medication is stopped. We report on a 14-year-old boy who developed acute renal failure 2 weeks after aortic valve surgery. He was put on ENT2 aspirin ENT2END following surgery and took ibuprofen for fever for nearly a week prior to presentation
0	He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, ENT1 creatinine  ENT1END  of 15.3 mg/dl and serum potassium of 8.7 mEq/l. Dialysis was immediately initiated. A kidney biopsy showed inflammatory infiltrate consistent with ENT2 ATIN ENT2END
0	3 mg/dl and serum ENT1 potassium  ENT1END  of 8.7 mEq/l. Dialysis was immediately initiated. A kidney biopsy showed inflammatory infiltrate consistent with ENT2 ATIN ENT2END
0	Overall, as an entity, ENT1 ATIN  ENT1END  remains under-diagnosed, as symptoms resolve spontaneously if the medication is stopped. We report on a 14-year-old boy who developed acute renal failure 2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ENT2 ibuprofen ENT2END for fever for nearly a week prior to presentation
1	ENT1 Encephalopathy  ENT1END  during ENT2 amitriptyline ENT2END therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression
0	The major determinant of the symptoms may have been ENT1 dopamine ENT1END serotonin imbalance in the central nervous system. The NMS-like ENT2 encephalopathy ENT2END that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects
0	The major determinant of the symptoms may have been dopamine/ ENT1 serotonin  ENT1END imbalance in the central nervous system. The NMS-like ENT2 encephalopathy ENT2END that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects
0	Encephalopathy during ENT1 amitriptyline  ENT1END  therapy: are ENT2 neuroleptic malignant syndrome ENT2END and serotonin syndrome spectrum disorders?This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression
0	The major determinant of the symptoms may have been ENT1 dopamine ENT1END /serotonin imbalance in the central nervous system. The ENT2 NMS ENT2END -like encephalopathy that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects
0	The major determinant of the symptoms may have been dopamine/ ENT1 serotonin  ENT1END  imbalance in the central nervous system. The ENT2 NMS ENT2END -like encephalopathy that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects
0	Encephalopathy during ENT1 amitriptyline  ENT1END  therapy: are neuroleptic malignant syndrome and ENT2 serotonin syndrome ENT2END spectrum disorders?This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression
0	This patient could have been diagnosed as having either neuroleptic malignant syndrome (NMS) or serotonin syndrome ( ENT1 SS  ENT1END . The major determinant of the symptoms may have been ENT2 dopamine ENT2END /serotonin imbalance in the central nervous system
0	This patient could have been diagnosed as having either neuroleptic malignant syndrome (NMS) or serotonin syndrome ( ENT1 SS  ENT1END ). The major determinant of the symptoms may have been dopamine ENT2 serotonin ENT2END imbalance in the central nervous system
0	Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?This report describes a case of encephalopathy developed in the course of ENT1 amitriptyline ENT1END therapy, during a remission of ENT2 unipolar depression ENT2END
0	Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of ENT1 unipolar depression  ENT1END . This patient could have been diagnosed as having either neuroleptic malignant syndrome (NMS) or serotonin syndrome (SS). The major determinant of the symptoms may have been ENT2 dopamine ENT2END /serotonin imbalance in the central nervous system
0	Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of ENT1 unipolar depression  ENT1END . This patient could have been diagnosed as having either neuroleptic malignant syndrome (NMS) or serotonin syndrome (SS). The major determinant of the symptoms may have been dopamine ENT2 serotonin ENT2END imbalance in the central nervous system
0	contrast material to enable diagnosis of ureteric stones or obstruction in patients with ENT1 HIV infection ENT1END who receive ENT2 indinavir ENT2END therapy
1	OBJECTIVE: We describe the unique CT features of ENT1 ureteric calculi ENT1END in six HIV-infected patients receiving ENT2 indinavir ENT2END , the most commonly used HIV protease inhibitor, which is associated with an increased incidence of urolithiasis
0	OBJECTIVE: We describe the unique CT features of ureteric calculi in six HIV-infected patients receiving indinavir, the most commonly used HIV protease inhibitor, which is associated with an increased incidence of ENT1 urolithiasis ENT1END  CONCLUSION: Ureteric obstruction caused by precipitated ENT2 indinavir ENT2END crystals may be difficult to diagnose with unenhanced CT
0	CONCLUSION: ENT1 Ureteric obstruction  ENT1END caused by precipitated ENT2 indinavir ENT2END crystals may be difficult to diagnose with unenhanced CT
1	CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after ENT1 pilocarpine ENT1END induced ENT2 SE ENT2END
0	CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after ENT1 pilocarpine ENT1END -induced SE. ENT2 Seizures ENT2END also result in changes to CCR2 receptor expression in neurons and astrocytes
0	In addition, rats that experienced SE exhibited CCR2-labeling in populations of ENT1 hypertrophied  ENT1END astrocytes, especially in CA1 and dentate gyrus. These CCR2+ astroctytes were not observed in control rats. Examination of CCL2 expression showed that it was elevated in the hippocampus following SE. CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after ENT2 pilocarpine ENT2END -induced SE
0	Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following ENT1 pilocarpine ENT1END -induced status epilepticus.BACKGROUND: ENT2 Neuroinflammation ENT2END occurs after seizures and is implicated in epileptogenesis
0	The ENT1 ischemia ENT1END probably induced by coronary artery spasm was reversed by ENT2 nitroglycerin ENT2END and calcium blocking agents
0	We report a case of myocardial ischemia induced by ENT1 cocaine  ENT1END  The ENT2 ischemia ENT2END probably induced by coronary artery spasm was reversed by nitroglycerin and calcium blocking agents
0	The ENT1 ischemia ENT1END  probably induced by coronary artery spasm was reversed by nitroglycerin and ENT2 calcium ENT2END blocking agents
0	The ischemia probably induced by ENT1 coronary artery spasm  ENT1END was reversed by ENT2 nitroglycerin ENT2END and calcium blocking agents
1	We report a case of myocardial ischemia induced by ENT1 cocaine  ENT1END . The ischemia probably induced by ENT2 coronary artery spasm ENT2END was reversed by nitroglycerin and calcium blocking agents
0	The ischemia probably induced by ENT1 coronary artery spasm  ENT1END  was reversed by nitroglycerin and ENT2 calcium ENT2END blocking agents
0	We report a case of ENT1 myocardial ischemia  ENT1END induced by cocaine. The ischemia probably induced by coronary artery spasm was reversed by ENT2 nitroglycerin ENT2END and calcium blocking agents
1	ENT1 Cocaine  ENT1END  induced ENT2 myocardial ischemia ENT2END
0	We report a case of ENT1 myocardial ischemia  ENT1END  induced by cocaine. The ischemia probably induced by coronary artery spasm was reversed by nitroglycerin and ENT2 calcium ENT2END blocking agents
1	Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through ENT1 valproic acid ENT1END induced ENT2 hyperammonemia ENT2END
1	Reversible ENT1 valproic acid  ENT1END -induced ENT2 dementia ENT2END : a case report
0	Reversible ENT1 valproic acid ENT1END induced dementia was documented in a 21-year-old man with ENT2 epilepsy ENT2END who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies
0	Active ENT1 vasculitis ENT1END was noted in 36.3% patients at baseline and 0% at 3 years of follow-up. More than 20% (47.61-67.2%) reduction in central retinal thickness was noted in all patients with cystoid macular edema at 6 months, 1 year, 2 years, and 3 years postimplant. At baseline, 54.5% patients were on immunomodulatory agents. This percentage decreased to 45.45, 44.4, and 14.28% at 1 year, 2 years, and 3 years postimplant, respectively. Adverse events included increased intraocular pressure (54.5%) and cataract formation (100%). CONCLUSION: The data suggest that ENT2 fluocinolone acetonide ENT2END implant (0
0	CONCLUSION: The data suggest that ENT1 fluocinolone acetonide ENT1END  implant (0.59 mg) helps to control ENT2 inflammation ENT2END in otherwise treatment-refractory cases of birdshot retinochoroidopathy
0	2%) reduction in central retinal thickness was noted in all patients with ENT1 cystoid macular edema  ENT1END at 6 months, 1 year, 2 years, and 3 years postimplant. At baseline, 54.5% patients were on immunomodulatory agents. This percentage decreased to 45.45, 44.4, and 14.28% at 1 year, 2 years, and 3 years postimplant, respectively. Adverse events included increased intraocular pressure (54.5%) and cataract formation (100%). CONCLUSION: The data suggest that ENT2 fluocinolone acetonide ENT2END implant (0
0	Treatment outcomes of interest were noted at baseline, before ENT1 fluocinolone acetonide ENT1END implant, and then at 6 months, 1 year, 2 years, 3 years, and beyond 3 years. Disease activity markers, including signs of ocular inflammation, evidence of ENT2 retinal vasculitis ENT2END , Swedish interactive threshold algorithm-short wavelength automated perimetry Humphrey visual field analysis, electroretinographic parameters, and optical coherence tomography were recorded
1	5%) and ENT1 cataract  ENT1END formation (100%). CONCLUSION: The data suggest that ENT2 fluocinolone acetonide ENT2END implant (0
1	Adverse events included ENT1 increased intraocular pressure  ENT1END (54.5%) and cataract formation (100%). CONCLUSION: The data suggest that ENT2 fluocinolone acetonide ENT2END implant (0
0	Safety and efficacy of ENT1 fluocinolone acetonide  ENT1END  intravitreal implant (0.59 mg) in ENT2 birdshot retinochoroidopathy ENT2END
0	ENT1 Glibenclamide  ENT1END -sensitive ENT2 hypotension ENT2END produced by helodermin assessed in the rat
1	Oxyhemoglobin did not affect helodermin-induced hypotension, whereas it shortened the duration of acetylcholine ( ENT1 ACh ENT1END -produced ENT2 hypotension ENT2END
0	EDRF (endothelium-derived relaxing factor)/ ENT1 nitric oxide ENT1END does not seem to play an important role in the peptide-produced ENT2 hypotension ENT2END
0	These findings suggest that helodermin-produced ENT1 hypotension  ENT1END is partly attributable to the activation of glibenclamide-sensitive K+ channels (K( ENT2 ATP ENT2END ) channels), which presumably exist on arterial smooth muscle cells
1	ENT1 Hypotension ENT1END induced by both peptides was significantly attenuated by glibenclamide, which abolished a ENT2 levcromakalim ENT2END -produced decrease in arterial blood pressure
1	Oxyhemoglobin did not affect ENT1 helodermin ENT1END induced ENT2 hypotension ENT2END , whereas it shortened the duration of acetylcholine (ACh)-produced hypotension
0	These findings suggest that helodermin-produced ENT1 hypotension ENT1END  is partly attributable to the activation of glibenclamide-sensitive ENT2 K ENT2END + channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells
0	Glibenclamide-sensitive ENT1 hypotension  ENT1END  produced by helodermin assessed in the rat.The effects of helodermin, a basic 35- ENT2 amino acid ENT2END peptide isolated from the venom of a lizard salivary gland, on arterial blood pressure and heart rate were examined in the rat, focusing on the possibility that activation of ATP sensitive K+ (K(ATP)) channels is involved in the responses
1	The incidence of abductor paralysis after ENT1 Botox ENT1END injection for ENT2 ADSD ENT2END was 0
0	METHODS: Patients that received ENT1 Botox ENT1END injections for ENT2 spasmodic dysphonia ENT2END between January 2000 and October 2009 were evaluated
0	Reported adverse effects include a period of breathiness, ENT1 throat pain ENT1END  and difficulty with swallowing liquids. Here we report multiple cases of bilateral abductor paralysis following ENT2 Botox ENT2END injections for ADSD, a complication previously unreported
0	Abductor ENT1 paralysis  ENT1END  after ENT2 botox ENT2END injection for adductor spasmodic dysphonia
0	Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of ENT1 tumor ENT1END cells; stereologic analysis revealed a 4.5- to 6.7-times higher concentration of reduced ENT2 silver ENT2END grains over nuclei than cytoplasm of these cells
0	Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary ENT1 diethylstilbesterol  ENT1END induced renal carcinomas in three hamsters. Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of ENT2 tumor ENT2END cells; stereologic analysis revealed a 4
0	Radiolabelling, following the in vivo injection of 3H-17 beta ENT1 estradiol  ENT1END  was increased only over the nuclei of ENT2 tumor ENT2END cells; stereologic analysis revealed a 4
0	ENT1 Estrogen  ENT1END binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced renal carcinomas in three hamsters. Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of ENT2 tumor ENT2END cells; stereologic analysis revealed a 4
0	Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced ENT1 renal carcinomas  ENT1END in three hamsters. Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of tumor cells; stereologic analysis revealed a 4.5- to 6.7-times higher concentration of reduced ENT2 silver ENT2END grains over nuclei than cytoplasm of these cells
1	Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary ENT1 diethylstilbesterol  ENT1END  induced ENT2 renal carcinomas ENT2END in three hamsters
0	Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced ENT1 renal carcinomas  ENT1END  in three hamsters. Radiolabelling, following the in vivo injection of 3H-17 beta ENT2 estradiol ENT2END , was increased only over the nuclei of tumor cells; stereologic analysis revealed a 4
0	Autoradiographic evidence of estrogen binding sites in nuclei of diethylstilbesterol induced hamster ENT1 renal carcinomas ENT1END ENT2 Estrogen ENT2END binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced renal carcinomas in three hamsters
0	ENT1 Rifampicin ENT1END was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like ENT2 nausea ENT2END , vomiting and fever with chills and rigors
1	ENT1 Acute renal failure  ENT1END  due to ENT2 rifampicin ENT2END
0	ENT1 Rifampicin ENT1END  was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like nausea, vomiting and ENT2 fever ENT2END with chills and rigors
0	Acute renal failure due to ENT1 rifampicin ENT1END .A 23-year-old male patient with bacteriologically proven ENT2 pulmonary tuberculosis ENT2END was treated with the various regimens of antituberculosis drugs for nearly 15 months
0	ENT1 Rifampicin ENT1END  was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like nausea, ENT2 vomiting ENT2END and fever with chills and rigors
0	The results suggest that increased brain serotoninergic transmission with ENT1 fluoxetine ENT1END may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating ENT2 parkinsonian ENT2END motor disability
0	05) of ENT1 apomorphine ENT1END induced dyskinesias without modification of ENT2 parkinsonian ENT2END motor disability
0	We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with ENT1 Parkinson's disease ENT1END after an acute challenge with the mixed ENT2 dopamine ENT2END agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days
0	We evaluated the severity of motor disability and dyskinesias in seven ENT1 levodopa  ENT1END responsive patients with ENT2 Parkinson's disease ENT2END after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days
1	Levodopa-induced ENT1 dyskinesias  ENT1END  are improved by ENT2 fluoxetine ENT2END
1	05) of ENT1 apomorphine ENT1END -induced ENT2 dyskinesias ENT2END without modification of parkinsonian motor disability
0	The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or ENT1 dopamine ENT1END agonist-induced ENT2 dyskinesias ENT2END without aggravating parkinsonian motor disability
0	ENT1 Levodopa  ENT1END -induced ENT2 dyskinesias ENT2END are improved by fluoxetine
0	The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of dystonic dyskinesias (onset- and end-of-dose dyskinesias) and in the upper limbs during ENT1 choreic mid-dose dyskinesias  ENT1END  The results suggest that increased brain serotoninergic transmission with ENT2 fluoxetine ENT2END may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability
0	05) of ENT1 apomorphine  ENT1END -induced dyskinesias without modification of parkinsonian motor disability. The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of dystonic dyskinesias (onset- and end-of-dose dyskinesias) and in the upper limbs during ENT2 choreic mid-dose dyskinesias ENT2END
0	The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of dystonic dyskinesias (onset- and end-of-dose dyskinesias) and in the upper limbs during ENT1 choreic mid-dose dyskinesias  ENT1END . The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or ENT2 dopamine ENT2END agonist-induced dyskinesias without aggravating parkinsonian motor disability
0	The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of dystonic dyskinesias (onset- and end-of-dose dyskinesias) and in the upper limbs during ENT1 choreic mid-dose dyskinesias ENT1END . The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce ENT2 levodopa ENT2END - or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability
0	The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of ENT1 dystonic dyskinesias  ENT1END (onset- and end-of-dose dyskinesias) and in the upper limbs during choreic mid-dose dyskinesias. The results suggest that increased brain serotoninergic transmission with ENT2 fluoxetine ENT2END may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability
0	05) of ENT1 apomorphine  ENT1END -induced dyskinesias without modification of parkinsonian motor disability. The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of ENT2 dystonic dyskinesias ENT2END (onset- and end-of-dose dyskinesias) and in the upper limbs during choreic mid-dose dyskinesias
0	The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of ENT1 dystonic dyskinesias  ENT1END  (onset- and end-of-dose dyskinesias) and in the upper limbs during choreic mid-dose dyskinesias. The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or ENT2 dopamine ENT2END agonist-induced dyskinesias without aggravating parkinsonian motor disability
0	The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of ENT1 dystonic dyskinesias  ENT1END  (onset- and end-of-dose dyskinesias) and in the upper limbs during choreic mid-dose dyskinesias. The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce ENT2 levodopa ENT2END - or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability
0	Levodopa-induced dyskinesias are improved by ENT1 fluoxetine ENT1END .We evaluated the severity of ENT2 motor disability ENT2END and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days
0	05) of ENT1 apomorphine ENT1END -induced dyskinesias without modification of parkinsonian ENT2 motor disability ENT2END
0	The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or ENT1 dopamine ENT1END  agonist-induced dyskinesias without aggravating parkinsonian ENT2 motor disability ENT2END
0	We evaluated the severity of ENT1 motor disability  ENT1END  and dyskinesias in seven ENT2 levodopa ENT2END -responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days
0	In 5 consecutive patients with ENT1 rheumatoid arthritis ENT1END who received intravenous high-dose ENT2 methylprednisolone ENT2END (MP) therapy (1 g daily for 2 or 3 consecutive days), a decline in pulse rate was observed, most pronounced on day 4
0	Electrocardiographic registrations showed ENT1 sinus bradycardia ENT1END in all cases. No significant changes in plasma concentrations of electrolytes were found. Careful observation of patients receiving high-dose ENT2 MP ENT2END is recommended
0	High-dose ENT1 MP ENT1END may be contraindicated in patients with known ENT2 heart disease ENT2END
1	ENT1 Bradycardia  ENT1END  after high-dose intravenous ENT2 methylprednisolone ENT2END therapy
1	A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with ENT1 fluvastatin ENT1END  Patient presented with complaints of increasing ENT2 nausea ENT2END , anorexia, and upper abdominal pain
0	Although ENT1 statins  ENT1END are generally well-tolerated drugs, recent cases of drug-induced liver injury associated with their use have been reported. A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with fluvastatin. Patient presented with complaints of increasing ENT2 nausea ENT2END , anorexia, and upper abdominal pain
0	Patient presented with complaints of increasing ENT1 nausea ENT1END , anorexia, and upper abdominal pain. His laboratory values showed elevated ENT2 creatine ENT2END kinase and transaminases
1	A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with ENT1 fluvastatin ENT1END . Patient presented with complaints of increasing nausea, ENT2 anorexia ENT2END , and upper abdominal pain
0	Although ENT1 statins  ENT1END  are generally well-tolerated drugs, recent cases of drug-induced liver injury associated with their use have been reported. A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with fluvastatin. Patient presented with complaints of increasing nausea, ENT2 anorexia ENT2END , and upper abdominal pain
0	Patient presented with complaints of increasing nausea, ENT1 anorexia  ENT1END , and upper abdominal pain. His laboratory values showed elevated ENT2 creatine ENT2END kinase and transaminases
1	ENT1 Drug-Induced Acute Liver Injury  ENT1END  Within 12 Hours After ENT2 Fluvastatin ENT2END Therapy
0	Although ENT1 statins ENT1END  are generally well-tolerated drugs, recent cases of ENT2 drug-induced liver injury ENT2END associated with their use have been reported
0	A 52-year-old Chinese man reported with ENT1 liver damage  ENT1END  which appeared 12 hours after beginning treatment with fluvastatin. Patient presented with complaints of increasing nausea, anorexia, and upper abdominal pain. His laboratory values showed elevated ENT2 creatine ENT2END kinase and transaminases
1	A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with ENT1 fluvastatin ENT1END . Patient presented with complaints of increasing nausea, anorexia, and upper ENT2 abdominal pain ENT2END
0	Although ENT1 statins  ENT1END  are generally well-tolerated drugs, recent cases of drug-induced liver injury associated with their use have been reported. A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with fluvastatin. Patient presented with complaints of increasing nausea, anorexia, and upper ENT2 abdominal pain ENT2END
0	Patient presented with complaints of increasing nausea, anorexia, and upper ENT1 abdominal pain  ENT1END . His laboratory values showed elevated ENT2 creatine ENT2END kinase and transaminases
0	This report of torsade de pointes ventricular tachycardia during intermittent ENT1 dobutamine ENT1END supports the hypothesis that unpredictable fatal ENT2 arrhythmias ENT2END may occur even with low doses and in patients with no history of significant rhythm disturbances
0	Torsade de pointes ventricular tachycardia during low dose intermittent ENT1 dobutamine  ENT1END  treatment in a patient with ENT2 dilated cardiomyopathy ENT2END and congestive heart failure
0	This report of torsade de pointes ENT1 ventricular tachycardia  ENT1END during intermittent ENT2 dobutamine ENT2END supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances
0	The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed ENT1 QT prolongation ENT1END and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) ENT2 dobutamine ENT2END
0	Torsade de pointes ventricular tachycardia during low dose intermittent ENT1 dobutamine  ENT1END  treatment in a patient with dilated cardiomyopathy and ENT2 congestive heart failure ENT2END
1	5 mcg/kg per min) ENT1 dobutamine ENT1END . This report of ENT2 torsade de pointes ENT2END ventricular tachycardia during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances
0	There was no change in hepatic tissue total ENT1 glutathione ENT1END following intestinal ENT2 ischemia ENT2END -reperfusion injury
0	There was no change in hepatic tissue total glutathione following intestinal ENT1 ischemia ENT1END -reperfusion injury. ENT2 Oxidized glutathione ENT2END (GSSG) increased significantly following 30 and 60 min of reperfusion
0	This study was undertaken to determine whether oxidants are associated with the ENT1 hepatic injury ENT1END and to determine the relative value of several indirect methods of assessing oxidant exposure in vivo. Rats were subjected to a standardized intestinal ischemia-reperfusion injury. Hepatic tissue was assayed for lipid peroxidation products and ENT2 oxidized and reduced glutathione ENT2END
0	This study was undertaken to determine whether oxidants are associated with the ENT1 hepatic injury ENT1END  and to determine the relative value of several indirect methods of assessing oxidant exposure in vivo. Rats were subjected to a standardized intestinal ischemia-reperfusion injury. Hepatic tissue was assayed for lipid peroxidation products and ENT2 oxidized and reduced glutathione ENT2END
0	There was no change in hepatic tissue total ENT1 glutathione  ENT1END  following intestinal ischemia- ENT2 reperfusion injury ENT2END
1	There was no change in hepatic tissue total glutathione following intestinal ischemia- ENT1 reperfusion injury  ENT1END . ENT2 Oxidized glutathione ENT2END (GSSG) increased significantly following 30 and 60 min of reperfusion
0	Reperfusion of ischemic intestine results in acute ENT1 liver dysfunction  ENT1END characterized by hepatocellular enzyme release into plasma, reduction in bile flow rate, and neutrophil sequestration within the liver. The pathophysiology underlying this acute hepatic injury is unknown. This study was undertaken to determine whether oxidants are associated with the hepatic injury and to determine the relative value of several indirect methods of assessing oxidant exposure in vivo. Rats were subjected to a standardized intestinal ischemia-reperfusion injury. Hepatic tissue was assayed for lipid peroxidation products and ENT2 oxidized and reduced glutathione ENT2END
0	Reperfusion of ischemic intestine results in acute ENT1 liver dysfunction  ENT1END  characterized by hepatocellular enzyme release into plasma, reduction in bile flow rate, and neutrophil sequestration within the liver. The pathophysiology underlying this acute hepatic injury is unknown. This study was undertaken to determine whether oxidants are associated with the hepatic injury and to determine the relative value of several indirect methods of assessing oxidant exposure in vivo. Rats were subjected to a standardized intestinal ischemia-reperfusion injury. Hepatic tissue was assayed for lipid peroxidation products and ENT2 oxidized and reduced glutathione ENT2END
0	Nephropathy caused by Chinese herbs has previously been reported, usually involving the use of ENT1 aristolochic acids ENT1END  We report a 23-year-old woman who developed ENT2 acute renal failure ENT2END following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb)
0	Although a causal relationship between the use of an ENT1 anthraquinone ENT1END containing herbal agent and ENT2 renal injury ENT2END remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained renal failure
1	The ENT1 renal injury ENT1END was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, ENT2 diclofenac ENT2END
1	We report a 23-year-old woman who developed ENT1 acute renal failure ENT1END  following prolonged use of a proprietary ENT2 Chinese herbal ENT2END slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb)
0	Nephropathy caused by Chinese herbs has previously been reported, usually involving the use of ENT1 aristolochic acids ENT1END . We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb). The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac. Renal pathology was that of hypocellular interstitial fibrosis. Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular atrophy was still evident histologically 4 months later. Although a causal relationship between the use of an anthraquinone-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained ENT2 renal failure ENT2END
0	Although a causal relationship between the use of an ENT1 anthraquinone  ENT1END -containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained ENT2 renal failure ENT2END
0	The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, ENT1 diclofenac  ENT1END . Renal pathology was that of hypocellular interstitial fibrosis. Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular atrophy was still evident histologically 4 months later. Although a causal relationship between the use of an anthraquinone-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained ENT2 renal failure ENT2END
0	We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary ENT1 Chinese herbal  ENT1END  slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb). The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac. Renal pathology was that of hypocellular interstitial fibrosis. Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular atrophy was still evident histologically 4 months later. Although a causal relationship between the use of an anthraquinone-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained ENT2 renal failure ENT2END
0	ENT1 Nephropathy  ENT1END caused by Chinese herbs has previously been reported, usually involving the use of ENT2 aristolochic acids ENT2END
0	Although a causal relationship between the use of an ENT1 anthraquinone ENT1END -containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial ENT2 nephropathy ENT2END should be considered in patients who present with unexplained renal failure
0	The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, ENT1 diclofenac  ENT1END . Renal pathology was that of hypocellular interstitial fibrosis. Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular atrophy was still evident histologically 4 months later. Although a causal relationship between the use of an anthraquinone-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial ENT2 nephropathy ENT2END should be considered in patients who present with unexplained renal failure
0	ENT1 Nephropathy ENT1END  caused by ENT2 Chinese herbs ENT2END has previously been reported, usually involving the use of aristolochic acids
0	Nephropathy caused by Chinese herbs has previously been reported, usually involving the use of ENT1 aristolochic acids ENT1END . We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb). The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac. Renal pathology was that of hypocellular interstitial fibrosis. Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular ENT2 atrophy ENT2END was still evident histologically 4 months later
0	Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular ENT1 atrophy  ENT1END  was still evident histologically 4 months later. Although a causal relationship between the use of an ENT2 anthraquinone ENT2END -containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained renal failure
0	The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, ENT1 diclofenac  ENT1END . Renal pathology was that of hypocellular interstitial fibrosis. Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular ENT2 atrophy ENT2END was still evident histologically 4 months later
0	We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary ENT1 Chinese herbal  ENT1END  slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb). The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac. Renal pathology was that of hypocellular interstitial fibrosis. Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular ENT2 atrophy ENT2END was still evident histologically 4 months later
0	Nephropathy caused by Chinese herbs has previously been reported, usually involving the use of ENT1 aristolochic acids ENT1END . We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb). The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac. Renal pathology was that of hypocellular interstitial ENT2 fibrosis ENT2END
0	Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial ENT1 fibrosis  ENT1END and tubular atrophy was still evident histologically 4 months later. Although a causal relationship between the use of an ENT2 anthraquinone ENT2END -containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained renal failure
0	The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, ENT1 diclofenac  ENT1END . Renal pathology was that of hypocellular interstitial ENT2 fibrosis ENT2END
0	We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary ENT1 Chinese herbal  ENT1END  slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb). The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac. Renal pathology was that of hypocellular interstitial ENT2 fibrosis ENT2END
1	Reduced ENT1 cardiotoxicity  ENT1END  of ENT2 doxorubicin ENT2END given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat
0	A rat model was used to evaluate the general acute toxicity and the late ENT1 cardiotoxicity ENT1END of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates. In these HPMA copolymers, DOX was covalently bound via peptide linkages that were either non-biodegradable (Gly-Gly) or degradable by lysosomal proteinases (Gly-Phe-Leu-Gly). In addition, one biodegradable conjugate containing ENT2 galactosamine ENT2END was used; this residue was targeted to the liver
0	A rat model was used to evaluate the general acute toxicity and the late ENT1 cardiotoxicity  ENT1END  of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates. In these HPMA copolymers, DOX was covalently bound via peptide linkages that were either non-biodegradable (Gly-Gly) or degradable by lysosomal proteinases ( ENT2 Gly-Phe-Leu-Gly ENT2END )
0	Reduced ENT1 cardiotoxicity  ENT1END  of doxorubicin given in the form of ENT2 N-(2-hydroxypropyl)methacrylamide ENT2END conjugates: and experimental study in the rat
0	A rat model was used to evaluate the general acute ENT1 toxicity ENT1END and the late cardiotoxicity of 4 mg/kg ENT2 doxorubicin ENT2END (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates
0	A rat model was used to evaluate the general acute ENT1 toxicity  ENT1END  and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates. In these HPMA copolymers, DOX was covalently bound via peptide linkages that were either non-biodegradable (Gly-Gly) or degradable by lysosomal proteinases (Gly-Phe-Leu-Gly). In addition, one biodegradable conjugate containing ENT2 galactosamine ENT2END was used; this residue was targeted to the liver
0	A rat model was used to evaluate the general acute ENT1 toxicity ENT1END  and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates. In these HPMA copolymers, DOX was covalently bound via peptide linkages that were either non-biodegradable (Gly-Gly) or degradable by lysosomal proteinases ENT2 Gly-Phe-Leu-Gly ENT2END )
0	Reduced cardiotoxicity of doxorubicin given in the form of ENT1 N-(2-hydroxypropyl)methacrylamide  ENT1END  conjugates: and experimental study in the rat.A rat model was used to evaluate the general acute ENT2 toxicity ENT2END and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates
0	Both CSSEPs as central and NMPs as peripheral correlates of ENT1 pain ENT1END were obtained in response to the ENT2 CO2 ENT2END stimuli
1	METHODS: According to a double-blind, randomised, controlled, threefold cross-over design, 18 healthy subjects (11 males, 7 females; mean age 26 years) received either placebo, 400 mg ibuprofen, or 800 mg ENT1 ibuprofen ENT1END  Phasic ENT2 pain ENT2END was applied by means of short pulses of CO2 to the nasal mucosa (stimulus duration 500 ms, interval approximately 60 s), and tonic pain was induced in the nasal cavity by means of dry air of controlled temperature, humidity and flow rate (22 degrees C, 0% relative humidity, 145 ml
0	A muscarinic receptor blocker, atropine, disrupted haloperidol-induced ENT1 catalepsy ENT1END  Intracranial injection of an ENT2 acetylcholine ENT2END -synthesis inhibitor, hemicholinium, prevented the catalepsy that is usually induced by haloperidol
0	Intracranial injection of an acetylcholine-synthesis inhibitor, ENT1 hemicholinium ENT1END  prevented the ENT2 catalepsy ENT2END that is usually induced by haloperidol
0	Experiments in mice tested previous evidence that activation of cholinergic systems promotes catalepsy and that cholinergic mechanisms need to be intact for full expression of ENT1 neuroleptic ENT1END induced ENT2 catalepsy ENT2END
0	A muscarinic receptor blocker, ENT1 atropine  ENT1END  disrupted haloperidol-induced ENT2 catalepsy ENT2END
1	Large doses of the cholinomimetic, ENT1 pilocarpine ENT1END  could induce ENT2 catalepsy ENT2END when peripheral cholinergic receptors were blocked
1	Evidence for a cholinergic role in ENT1 haloperidol  ENT1END -induced ENT2 catalepsy ENT2END
1	A case of ENT1 isotretinoin embryopathy ENT1END  with bilateral anotia and Taussig-Bing malformation.We report a newborn infant with multiple congenital anomalies (anotia and Taussig-Bing malformation) due to exposure to ENT2 isotretinoin ENT2END within the first trimester
0	A case of ENT1 isotretinoin embryopathy ENT1END  with bilateral anotia and Taussig-Bing malformation.We report a newborn infant with multiple congenital anomalies (anotia and Taussig-Bing malformation) due to exposure to isotretinoin within the first trimester. In this paper we aim to draw to the fact that caution is needed when prescribing ENT2 vitamin A ENT2END -containing drugs to women of childbearing years
1	We report a newborn infant with multiple congenital anomalies ( ENT1 anotia  ENT1END and Taussig-Bing malformation) due to exposure to ENT2 isotretinoin ENT2END within the first trimester
0	We report a newborn infant with multiple congenital anomalies ( ENT1 anotia  ENT1END  and Taussig-Bing malformation) due to exposure to isotretinoin within the first trimester. In this paper we aim to draw to the fact that caution is needed when prescribing ENT2 vitamin A ENT2END -containing drugs to women of childbearing years
1	We report a newborn infant with multiple congenital anomalies (anotia and ENT1 Taussig-Bing malformation  ENT1END  due to exposure to ENT2 isotretinoin ENT2END within the first trimester
0	We report a newborn infant with multiple congenital anomalies (anotia and ENT1 Taussig-Bing malformation  ENT1END ) due to exposure to isotretinoin within the first trimester. In this paper we aim to draw to the fact that caution is needed when prescribing ENT2 vitamin A ENT2END -containing drugs to women of childbearing years
1	Their cardiac tissues were processed for light microscopy, after which ENT1 cardiomyocyte damage ENT1END was evaluated according to Billingham (in Cancer Treat Rep 62(6):865-872, 1978). Microscopic evaluation revealed that treatment with ENT2 DOX ENT2END alone induced significant cardiac damage in comparison to the saline control group (P<0
0	The semisynthetic ENT1 flavonoid  ENT1END monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties. Because of the relatively short final half-life of monoHER (about 30 min), it is expected that the time interval between monoHER and DOX might be of influence on the cardioprotective effect of monoHER. Therefore, the aim of the present study was to investigate this possible effect. METHODS: Six groups of 6 BALB/c mice were treated with saline, DOX alone or DOX (4 mg/kg i.v.) preceded by monoHER (500 mg/kg i.p.) with an interval of 10, 30, 60 or 120 min. After a 6-week treatment period and additional observation for 2 weeks, the mice were sacrificed. Their cardiac tissues were processed for light microscopy, after which ENT2 cardiomyocyte damage ENT2END was evaluated according to Billingham (in Cancer Treat Rep 62(6):865-872, 1978)
0	) preceded by ENT1 monoHER  ENT1END (500 mg/kg i.p.) with an interval of 10, 30, 60 or 120 min. After a 6-week treatment period and additional observation for 2 weeks, the mice were sacrificed. Their cardiac tissues were processed for light microscopy, after which ENT2 cardiomyocyte damage ENT2END was evaluated according to Billingham (in Cancer Treat Rep 62(6):865-872, 1978)
0	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and ENT1 iron  ENT1END chelating properties. Because of the relatively short final half-life of monoHER (about 30 min), it is expected that the time interval between monoHER and DOX might be of influence on the cardioprotective effect of monoHER. Therefore, the aim of the present study was to investigate this possible effect. METHODS: Six groups of 6 BALB/c mice were treated with saline, DOX alone or DOX (4 mg/kg i.v.) preceded by monoHER (500 mg/kg i.p.) with an interval of 10, 30, 60 or 120 min. After a 6-week treatment period and additional observation for 2 weeks, the mice were sacrificed. Their cardiac tissues were processed for light microscopy, after which ENT2 cardiomyocyte damage ENT2END was evaluated according to Billingham (in Cancer Treat Rep 62(6):865-872, 1978)
0	Their cardiac tissues were processed for light microscopy, after which cardiomyocyte damage was evaluated according to Billingham (in ENT1 Cancer  ENT1END Treat Rep 62(6):865-872, 1978). Microscopic evaluation revealed that treatment with ENT2 DOX ENT2END alone induced significant cardiac damage in comparison to the saline control group (P<0
0	The semisynthetic ENT1 flavonoid  ENT1END  monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties. Because of the relatively short final half-life of monoHER (about 30 min), it is expected that the time interval between monoHER and DOX might be of influence on the cardioprotective effect of monoHER. Therefore, the aim of the present study was to investigate this possible effect. METHODS: Six groups of 6 BALB/c mice were treated with saline, DOX alone or DOX (4 mg/kg i.v.) preceded by monoHER (500 mg/kg i.p.) with an interval of 10, 30, 60 or 120 min. After a 6-week treatment period and additional observation for 2 weeks, the mice were sacrificed. Their cardiac tissues were processed for light microscopy, after which cardiomyocyte damage was evaluated according to Billingham (in ENT2 Cancer ENT2END Treat Rep 62(6):865-872, 1978)
0	) preceded by ENT1 monoHER  ENT1END  (500 mg/kg i.p.) with an interval of 10, 30, 60 or 120 min. After a 6-week treatment period and additional observation for 2 weeks, the mice were sacrificed. Their cardiac tissues were processed for light microscopy, after which cardiomyocyte damage was evaluated according to Billingham (in ENT2 Cancer ENT2END Treat Rep 62(6):865-872, 1978)
0	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and ENT1 iron  ENT1END  chelating properties. Because of the relatively short final half-life of monoHER (about 30 min), it is expected that the time interval between monoHER and DOX might be of influence on the cardioprotective effect of monoHER. Therefore, the aim of the present study was to investigate this possible effect. METHODS: Six groups of 6 BALB/c mice were treated with saline, DOX alone or DOX (4 mg/kg i.v.) preceded by monoHER (500 mg/kg i.p.) with an interval of 10, 30, 60 or 120 min. After a 6-week treatment period and additional observation for 2 weeks, the mice were sacrificed. Their cardiac tissues were processed for light microscopy, after which cardiomyocyte damage was evaluated according to Billingham (in ENT2 Cancer ENT2END Treat Rep 62(6):865-872, 1978)
0	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against ENT1 DOX ENT1END induced ENT2 cardiotoxicity ENT2END through its radical scavenging and iron chelating properties
0	The semisynthetic ENT1 flavonoid  ENT1END  monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced ENT2 cardiotoxicity ENT2END through its radical scavenging and iron chelating properties
0	PURPOSE: Despite its well-known ENT1 cardiotoxicity ENT1END  the anthracyclin doxorubicin (DOX) continues to be an effective and widely used chemotherapeutic agent. DOX-induced cardiac damage presumably results from the formation of free radicals by DOX. Reactive ENT2 oxygen ENT2END species particularly affect the cardiac myocytes because these cells seem to have a relatively poor antioxidant defense system
0	The semisynthetic flavonoid monohydroxyethylrutoside ( ENT1 monoHER  ENT1END  showed cardioprotection against DOX-induced ENT2 cardiotoxicity ENT2END through its radical scavenging and iron chelating properties
0	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced ENT1 cardiotoxicity  ENT1END  through its radical scavenging and ENT2 iron ENT2END chelating properties
0	ENT1 DOX ENT1END induced ENT2 cardiac damage ENT2END presumably results from the formation of free radicals by DOX
0	DOX-induced ENT1 cardiac damage  ENT1END  presumably results from the formation of free radicals by DOX. Reactive oxygen species particularly affect the cardiac myocytes because these cells seem to have a relatively poor antioxidant defense system. The semisynthetic ENT2 flavonoid ENT2END monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties
0	DOX-induced ENT1 cardiac damage  ENT1END  presumably results from the formation of free radicals by DOX. Reactive ENT2 oxygen ENT2END species particularly affect the cardiac myocytes because these cells seem to have a relatively poor antioxidant defense system
0	DOX-induced ENT1 cardiac damage ENT1END  presumably results from the formation of free radicals by DOX. Reactive oxygen species particularly affect the cardiac myocytes because these cells seem to have a relatively poor antioxidant defense system. The semisynthetic flavonoid ENT2 monohydroxyethylrutoside ENT2END (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties
0	DOX-induced ENT1 cardiac damage  ENT1END  presumably results from the formation of free radicals by DOX. Reactive oxygen species particularly affect the cardiac myocytes because these cells seem to have a relatively poor antioxidant defense system. The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and ENT2 iron ENT2END chelating properties
1	Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with I-131 HA are not the initiating factor in ENT1 doxorubicin ENT1END ENT2 cardiotoxicity ENT2END
0	Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with ENT1 I-131 HA  ENT1END are not the initiating factor in doxorubicin ENT2 cardiotoxicity ENT2END
0	Human corticotropin-releasing hormone and thyrotropin-releasing hormone modulate the ENT1 hypercapnic ENT1END  ventilatory response in humans.Human corticotropin-releasing hormone (hCRH) and thyrotropin-releasing hormone (TRH) are known to stimulate ventilation after i.v. administration in humans. In a placebo-controlled, single-blind study we aimed to clarify if both peptides act by altering central chemosensitivity. Two subsequent CO2-rebreathing tests were performed in healthy young volunteers. During the first test 0.9% ENT2 NaCl ENT2END was given i
1	The ENT1 CO2 ENT1END response curves in the control group were nearly identical. The results indicate an additive effect of both releasing hormones on the ENT2 hypercapnic ENT2END ventilatory response in humans, presumably independent of central chemosensitivity
0	Human corticotropin-releasing hormone and ENT1 thyrotropin  ENT1END -releasing hormone modulate the ENT2 hypercapnic ENT2END ventilatory response in humans
0	Human corticotropin-releasing hormone and thyrotropin-releasing hormone modulate the ENT1 hypercapnic ENT1END  ventilatory response in humans.Human ENT2 corticotropin ENT2END -releasing hormone (hCRH) and thyrotropin-releasing hormone (TRH) are known to stimulate ventilation after i
0	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal ENT1 methimazole ENT1END associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described. The literature related to antithyroid drug side effects and the mechanisms for their occurrence are reviewed and the efficacy and complications of thyroidectomy and radioiodine compared to those of antithyroid drugs. It is concluded that in most circumstances 131I is the therapy of choice for ENT2 hyperthyroidism ENT2END
0	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of ENT1 propylthiouracil  ENT1END associated lupus-like syndrome are described. The literature related to antithyroid drug side effects and the mechanisms for their occurrence are reviewed and the efficacy and complications of thyroidectomy and radioiodine compared to those of antithyroid drugs. It is concluded that in most circumstances 131I is the therapy of choice for ENT2 hyperthyroidism ENT2END
0	Two cases of propylthiouracil-associated acute ENT1 hepatitis  ENT1END  one case of fatal ENT2 methimazole ENT2END -associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described
1	Two cases of ENT1 propylthiouracil  ENT1END associated acute ENT2 hepatitis ENT2END , one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described
0	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal ENT1 methimazole ENT1END -associated hepatocellular necrosis and one case of propylthiouracil-associated ENT2 lupus-like syndrome ENT2END are described
1	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of ENT1 propylthiouracil  ENT1END -associated ENT2 lupus-like syndrome ENT2END are described
1	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal ENT1 methimazole ENT1END -associated ENT2 hepatocellular necrosis ENT2END and one case of propylthiouracil-associated lupus-like syndrome are described
0	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated ENT1 hepatocellular necrosis  ENT1END  and one case of ENT2 propylthiouracil ENT2END -associated lupus-like syndrome are described
1	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, ENT1 anemia ENT1END in 12 patients, thrombocytopenia in 11 patients, and neutropenic fever in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal ENT2 doxorubicin ENT2END , leading to treatment discontinuation in three patients
1	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, ENT1 anemia ENT1END  in 12 patients, thrombocytopenia in 11 patients, and neutropenic fever in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal doxorubicin, leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENT2 carboplatin ENT2END and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
1	Four patients had five infusion-related reactions during the infusion of liposomal ENT1 doxorubicin ENT1END , leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included ENT2 nausea ENT2END in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients
1	Grade > or = 2 nonhematologic toxicity included ENT1 nausea  ENT1END  in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENT2 carboplatin ENT2END and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
0	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, thrombocytopenia in 11 patients, and ENT1 neutropenic fever  ENT1END in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal ENT2 doxorubicin ENT2END , leading to treatment discontinuation in three patients
0	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, thrombocytopenia in 11 patients, and ENT1 neutropenic fever  ENT1END  in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal doxorubicin, leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENT2 carboplatin ENT2END and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
0	Four patients had five infusion-related reactions during the infusion of liposomal ENT1 doxorubicin ENT1END , leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic ENT2 toxicity ENT2END included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients
0	METHODS: The combination of ENT1 carboplatin ENT1END (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and ENT2 toxicity ENT2END profile
1	Four patients had five infusion-related reactions during the infusion of liposomal ENT1 doxorubicin ENT1END , leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, ENT2 emesis ENT2END in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, ENT1 emesis  ENT1END  in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENT2 carboplatin ENT2END and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, ENT1 weight loss ENT1END in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of carboplatin and liposomal ENT2 doxorubicin ENT2END has modest activity in patients with recurrent cervical carcinoma
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, ENT1 weight loss  ENT1END  in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENT2 carboplatin ENT2END and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
1	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, ENT1 thrombocytopenia  ENT1END in 11 patients, and neutropenic fever in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal ENT2 doxorubicin ENT2END , leading to treatment discontinuation in three patients
1	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, ENT1 thrombocytopenia  ENT1END  in 11 patients, and neutropenic fever in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal doxorubicin, leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENT2 carboplatin ENT2END and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
0	Phase II study of carboplatin and liposomal ENT1 doxorubicin  ENT1END  in patients with recurrent ENT2 squamous cell carcinoma of the cervix ENT2END
0	BACKGROUND: The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent ENT1 cervical carcinoma  ENT1END  METHODS: The combination of ENT2 carboplatin ENT2END (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile
0	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, ENT1 hand-foot syndrome  ENT1END in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of carboplatin and liposomal ENT2 doxorubicin ENT2END has modest activity in patients with recurrent cervical carcinoma
0	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, ENT1 hand-foot syndrome  ENT1END  in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENT2 carboplatin ENT2END and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
0	Phase II study of carboplatin and liposomal ENT1 doxorubicin  ENT1END  in patients with recurrent ENT2 squamous cell carcinoma of the cervix ENT2END
0	Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent ENT1 squamous cell carcinoma of the cervix ENT1END .BACKGROUND: The activity of the combination of ENT2 carboplatin ENT2END and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, ENT1 constipation  ENT1END in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of carboplatin and liposomal ENT2 doxorubicin ENT2END has modest activity in patients with recurrent cervical carcinoma
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, ENT1 constipation  ENT1END  in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENT2 carboplatin ENT2END and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
0	Four patients had five infusion-related reactions during the infusion of liposomal ENT1 doxorubicin ENT1END , leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or ENT2 stomatitis ENT2END in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients
0	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or ENT1 stomatitis  ENT1END  in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENT2 carboplatin ENT2END and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and ENT1 skin reactions  ENT1END in 3 patients. CONCLUSIONS: The combination of carboplatin and liposomal ENT2 doxorubicin ENT2END has modest activity in patients with recurrent cervical carcinoma
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and ENT1 skin reactions  ENT1END  in 3 patients. CONCLUSIONS: The combination of ENT2 carboplatin ENT2END and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
1	Four patients had five infusion-related reactions during the infusion of liposomal ENT1 doxorubicin ENT1END , leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, ENT2 mucositis ENT2END and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, ENT1 mucositis  ENT1END  and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENT2 carboplatin ENT2END and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
0	The main toxic effect was ENT1 myelosuppression  ENT1END  with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, thrombocytopenia in 11 patients, and neutropenic fever in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal ENT2 doxorubicin ENT2END , leading to treatment discontinuation in three patients
0	METHODS: The combination of ENT1 carboplatin  ENT1END  (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile. RESULTS: Twenty-nine patients were assessable for response, and 35 patients were assessable for toxicity. The overall response rate was 38%, the median time to response was 10 weeks, the median duration of response was 26 weeks, and the median survival was 37 weeks. The main toxic effect was ENT2 myelosuppression ENT2END , with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, thrombocytopenia in 11 patients, and neutropenic fever in 3 patients
1	Four patients had five infusion-related reactions during the infusion of liposomal ENT1 doxorubicin ENT1END , leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, ENT2 fatigue ENT2END in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, ENT1 fatigue  ENT1END  in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENT2 carboplatin ENT2END and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
1	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, thrombocytopenia in 11 patients, and ENT1 neutropenic fever  ENT1END in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal ENT2 doxorubicin ENT2END , leading to treatment discontinuation in three patients
1	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, thrombocytopenia in 11 patients, and ENT1 neutropenic fever  ENT1END  in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal doxorubicin, leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENT2 carboplatin ENT2END and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
1	The ENT1 Dimer-X ENT1END group had a higher incidence of ENT2 nausea ENT2END and dizziness
0	Comparative study: Endografine ( ENT1 diatrizoate  ENT1END ), Vasurix polyvidone (acetrizoate), Dimer-X (iocarmate) and Hexabrix (ioxaglate) in hysterosalpingography.Side effects of hysterosalpingography with Dimer-X, Hexabrix, Vasurix polyvidone and Endografine in 142 consecutive patients, receiving one of the four tested media were evaluated from replies to postal questionnaires. The Dimer-X group had a higher incidence of ENT2 nausea ENT2END and dizziness
0	The Dimer-X group had a higher incidence of ENT1 nausea ENT1END  and dizziness. The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. Hexabrix and ENT2 Vasurix polyvidone ENT2END are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
0	The Dimer-X group had a higher incidence of ENT1 nausea ENT1END  and dizziness. The ENT2 Endografine ENT2END group had a higher incidence of abdominal pain
0	The Dimer-X group had a higher incidence of ENT1 nausea ENT1END  and dizziness. The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. Hexabrix and Vasurix polyvidone are considered the best ENT2 contrast media ENT2END for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
0	The Dimer-X group had a higher incidence of ENT1 nausea ENT1END  and dizziness. The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. ENT2 Hexabrix ENT2END and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
0	The ENT1 Dimer-X ENT1END  group had a higher incidence of nausea and dizziness. The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. Hexabrix and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low ENT2 toxicity ENT2END Hexabrix should be preferred
0	Comparative study: Endografine ( ENT1 diatrizoate  ENT1END ), Vasurix polyvidone (acetrizoate), Dimer-X (iocarmate) and Hexabrix (ioxaglate) in hysterosalpingography.Side effects of hysterosalpingography with Dimer-X, Hexabrix, Vasurix polyvidone and Endografine in 142 consecutive patients, receiving one of the four tested media were evaluated from replies to postal questionnaires. The Dimer-X group had a higher incidence of nausea and dizziness. The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. Hexabrix and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low ENT2 toxicity ENT2END Hexabrix should be preferred
0	Hexabrix and ENT1 Vasurix polyvidone  ENT1END  are considered the best contrast media for hysterosalpingography and perhaps because of its low ENT2 toxicity ENT2END Hexabrix should be preferred
0	The ENT1 Endografine  ENT1END  group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. Hexabrix and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low ENT2 toxicity ENT2END Hexabrix should be preferred
0	Hexabrix and Vasurix polyvidone are considered the best ENT1 contrast media  ENT1END  for hysterosalpingography and perhaps because of its low ENT2 toxicity ENT2END Hexabrix should be preferred
0	Hexabrix and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low ENT1 toxicity ENT1END  ENT2 Hexabrix ENT2END should be preferred
0	The ENT1 Dimer-X ENT1END  group had a higher incidence of nausea and dizziness. The Endografine group had a higher incidence of ENT2 abdominal pain ENT2END
0	Comparative study: Endografine ( ENT1 diatrizoate  ENT1END ), Vasurix polyvidone (acetrizoate), Dimer-X (iocarmate) and Hexabrix (ioxaglate) in hysterosalpingography.Side effects of hysterosalpingography with Dimer-X, Hexabrix, Vasurix polyvidone and Endografine in 142 consecutive patients, receiving one of the four tested media were evaluated from replies to postal questionnaires. The Dimer-X group had a higher incidence of nausea and dizziness. The Endografine group had a higher incidence of ENT2 abdominal pain ENT2END
0	The Endografine group had a higher incidence of ENT1 abdominal pain  ENT1END . These differences occur especially in the age groups under 30 years. Hexabrix and ENT2 Vasurix polyvidone ENT2END are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
1	The ENT1 Endografine  ENT1END  group had a higher incidence of ENT2 abdominal pain ENT2END
0	The Endografine group had a higher incidence of ENT1 abdominal pain  ENT1END . These differences occur especially in the age groups under 30 years. Hexabrix and Vasurix polyvidone are considered the best ENT2 contrast media ENT2END for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
0	The Endografine group had a higher incidence of ENT1 abdominal pain  ENT1END . These differences occur especially in the age groups under 30 years. ENT2 Hexabrix ENT2END and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
1	The ENT1 Dimer-X ENT1END  group had a higher incidence of nausea and ENT2 dizziness ENT2END
0	Comparative study: Endografine ( ENT1 diatrizoate  ENT1END ), Vasurix polyvidone (acetrizoate), Dimer-X (iocarmate) and Hexabrix (ioxaglate) in hysterosalpingography.Side effects of hysterosalpingography with Dimer-X, Hexabrix, Vasurix polyvidone and Endografine in 142 consecutive patients, receiving one of the four tested media were evaluated from replies to postal questionnaires. The Dimer-X group had a higher incidence of nausea and ENT2 dizziness ENT2END
0	The Dimer-X group had a higher incidence of nausea and ENT1 dizziness  ENT1END . The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. Hexabrix and ENT2 Vasurix polyvidone ENT2END are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
0	The Dimer-X group had a higher incidence of nausea and ENT1 dizziness  ENT1END . The ENT2 Endografine ENT2END group had a higher incidence of abdominal pain
0	The Dimer-X group had a higher incidence of nausea and ENT1 dizziness  ENT1END . The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. Hexabrix and Vasurix polyvidone are considered the best ENT2 contrast media ENT2END for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
0	The Dimer-X group had a higher incidence of nausea and ENT1 dizziness  ENT1END . The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. ENT2 Hexabrix ENT2END and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
0	ENT1 5-Fluorouracil ENT1END ENT2 cardiotoxicity ENT2END induced by alpha-fluoro-beta-alanine
0	As the precordial pain in this patient was considered to have been due to 5-FU-induced ENT1 cardiotoxicity ENT1END  the administration of 5-FU was abandoned. Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on ENT2 dihydropyrimidine ENT2END dehydrogenase, which catalyzes the degradative of 5-FU into FBAL
0	5-Fluorouracil cardiotoxicity induced by ENT1 alpha-fluoro-beta-alanine  ENT1END . ENT2 Cardiotoxicity ENT2END is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies
0	Cardiotoxicity is a rare complication occurring during 5-fluorouracil ( ENT1 5-FU ENT1END  treatment for ENT2 malignancies ENT2END
0	5-Fluorouracil cardiotoxicity induced by ENT1 alpha-fluoro-beta-alanine  ENT1END .Cardiotoxicity is a rare complication occurring during 5-fluorouracil (5-FU) treatment for ENT2 malignancies ENT2END
0	We herein report the case of a 70-year-old man with ENT1 5-FU ENT1END induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed. The patient, who had unresectable ENT2 colon cancer ENT2END metastases to the liver and lung, was referred to us for chemotherapy from an affiliated hospital; he had no cardiac history
0	The patient, who had unresectable ENT1 colon cancer  ENT1END  metastases to the liver and lung, was referred to us for chemotherapy from an affiliated hospital; he had no cardiac history. After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml. Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5-FU. As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned. Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on ENT2 dihydropyrimidine ENT2END dehydrogenase, which catalyzes the degradative of 5-FU into FBAL
0	We herein report the case of a 70-year-old man with 5-FU-induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine ( ENT1 FBAL  ENT1END  was observed. The patient, who had unresectable ENT2 colon cancer ENT2END metastases to the liver and lung, was referred to us for chemotherapy from an affiliated hospital; he had no cardiac history
0	Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on dihydropyrimidine dehydrogenase, which catalyzes the degradative of ENT1 5-FU ENT1END into FBAL. The serum FBAL concentration subsequently decreased to 352 ng/ml, the same as the value measured on the first day of S-1 administration. Thereafter, no ENT2 cardiac symptoms ENT2END were observed
0	Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on ENT1 dihydropyrimidine  ENT1END  dehydrogenase, which catalyzes the degradative of 5-FU into FBAL. The serum FBAL concentration subsequently decreased to 352 ng/ml, the same as the value measured on the first day of S-1 administration. Thereafter, no ENT2 cardiac symptoms ENT2END were observed
0	The serum ENT1 FBAL  ENT1END concentration subsequently decreased to 352 ng/ml, the same as the value measured on the first day of S-1 administration. Thereafter, no ENT2 cardiac symptoms ENT2END were observed
1	Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of ENT1 5-FU ENT1END  As the ENT2 precordial pain ENT2END in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned
0	As the ENT1 precordial pain  ENT1END  in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned. Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on ENT2 dihydropyrimidine ENT2END dehydrogenase, which catalyzes the degradative of 5-FU into FBAL
0	After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum ENT1 FBAL ENT1END concentration of 1955 ng/ml. Both the ENT2 precordial pain ENT2END and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5-FU
1	After admission, the patient received a continuous intravenous infusion of ENT1 5-FU ENT1END (1000 mg/day), during which precordial pain with ENT2 right bundle branch block ENT2END occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml
0	After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with ENT1 right bundle branch block  ENT1END  occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml. Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5-FU. As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned. Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on ENT2 dihydropyrimidine ENT2END dehydrogenase, which catalyzes the degradative of 5-FU into FBAL
0	After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with ENT1 right bundle branch block  ENT1END  occurred concomitantly with a high serum ENT2 FBAL ENT2END concentration of 1955 ng/ml
0	Indomethacin induced ENT1 hypotension ENT1END  in sodium and volume depleted rats.After a single oral dose of 4 mg/kg indomethacin (IDM) to sodium and volume depleted rats plasma renin activity (PRA) and systolic blood pressure fell significantly within four hours. In sodium repleted animals indomethacin did not change systolic blood pressure (BP) although plasma renin activity was decreased. Thus, indomethacin by inhibition of ENT2 prostaglandin ENT2END synthesis may diminish the blood pressure maintaining effect of the stimulated renin-angiotensin system in sodium and volume depletion
0	Indomethacin induced ENT1 hypotension  ENT1END  in sodium and volume depleted rats.After a single oral dose of 4 mg/kg indomethacin (IDM) to sodium and volume depleted rats plasma renin activity (PRA) and systolic blood pressure fell significantly within four hours. In sodium repleted animals indomethacin did not change systolic blood pressure (BP) although plasma renin activity was decreased. Thus, indomethacin by inhibition of prostaglandin synthesis may diminish the blood pressure maintaining effect of the stimulated renin- ENT2 angiotensin ENT2END system in sodium and volume depletion
1	ENT1 Indomethacin  ENT1END  induced ENT2 hypotension ENT2END in sodium and volume depleted rats
0	Indomethacin induced ENT1 hypotension  ENT1END  in ENT2 sodium ENT2END and volume depleted rats
0	Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide ( ENT1 CCK-8 ENT1END NS) enhanced the latency of ENT2 seizures ENT2END induced by picrotoxin in mice
0	Structure-activity and dose-effect relationships of the antagonism of picrotoxin-induced ENT1 seizures  ENT1END  by ENT2 cholecystokinin ENT2END , fragments and analogues of cholecystokinin in mice
1	Structure-activity and dose-effect relationships of the antagonism of ENT1 picrotoxin  ENT1END -induced ENT2 seizures ENT2END by cholecystokinin, fragments and analogues of cholecystokinin in mice
0	Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of ENT1 seizures ENT1END  induced by picrotoxin in mice. Experiments with N- and C-terminal fragments revealed that the C-terminal tetrapeptide (CCK-5-8) was the active centre of the CCK octapeptide molecule. The analogues CCK-8-SE and CCK-8-NS (dose range 0.2-6.4 mumol/kg) and ENT2 caerulein ENT2END dose range 0
0	2 mumol/kg and larger doses of the reference drug, ENT1 diazepam ENT1END  totally prevented picrotoxin-induced ENT2 seizures ENT2END and mortality
0	Blood pressure was manipulated by one of the following schedules during 120 min of reperfusion: Control, normotensive reperfusion; 90/hypertension (90/HTN), blood pressure was increased by 35 mm Hg during the initial 90 min of reperfusion only; 15/hypertension (15/HTN), normotensive reperfusion for 30 min followed by 15 min of ENT1 hypertension ENT1END and 75 min of normotension. Part A, for eight rats in each group brain injury was evaluated by staining tissue using ENT2 2,3,5-triphenyltetrazolium chloride ENT2END and edema was evaluated by microgravimetry
1	Focal cerebral ischemia in rats: effect of ENT1 phenylephrine  ENT1END -induced ENT2 hypertension ENT2END during reperfusion
0	ENT1 Evans Blue  ENT1END (mug g-1 of brain tissue) was greater in the 90/ ENT2 HTN ENT2END group (24
0	After 180 min of temporary ENT1 middle cerebral artery occlusion  ENT1END in spontaneously hypertensive rats, the effect of phenylephrine-induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined. Blood pressure was manipulated by one of the following schedules during 120 min of reperfusion: Control, normotensive reperfusion; 90/hypertension (90/HTN), blood pressure was increased by 35 mm Hg during the initial 90 min of reperfusion only; 15/hypertension (15/HTN), normotensive reperfusion for 30 min followed by 15 min of hypertension and 75 min of normotension. Part A, for eight rats in each group brain injury was evaluated by staining tissue using ENT2 2,3,5-triphenyltetrazolium chloride ENT2END and edema was evaluated by microgravimetry
0	After 180 min of temporary ENT1 middle cerebral artery occlusion ENT1END  in spontaneously hypertensive rats, the effect of ENT2 phenylephrine ENT2END -induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined
0	Part A, for eight rats in each group brain injury was evaluated by staining tissue using ENT1 2,3,5-triphenyltetrazolium chloride ENT1END  and ENT2 edema ENT2END was evaluated by microgravimetry
0	After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of ENT1 phenylephrine  ENT1END -induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined. Blood pressure was manipulated by one of the following schedules during 120 min of reperfusion: Control, normotensive reperfusion; 90/hypertension (90/HTN), blood pressure was increased by 35 mm Hg during the initial 90 min of reperfusion only; 15/hypertension (15/HTN), normotensive reperfusion for 30 min followed by 15 min of hypertension and 75 min of normotension. Part A, for eight rats in each group brain injury was evaluated by staining tissue using 2,3,5-triphenyltetrazolium chloride and ENT2 edema ENT2END was evaluated by microgravimetry
0	ENT1 Evans Blue ENT1END  (mug g-1 of brain tissue) was greater in the 90/HTN group (24.4 +/- 6.0) versus the control group (12.3 +/- 4.1), which was in turn greater than the 15/HTN group (7.3 +/- 3.2). This study supports a hypothesis that during reperfusion, a short interval of hypertension decreases brain injury and ENT2 edema ENT2END ; and that sustained hypertension increases the risk of vasogenic edema
0	Part A, for eight rats in each group brain injury was evaluated by staining tissue using ENT1 2,3,5-triphenyltetrazolium chloride ENT1END  and edema was evaluated by microgravimetry. Part B, for eight different rats in each group blood-brain barrier permeability was evaluated by measuring the amount and extent of extravasation of Evans Blue dye. Brain injury (percentage of the ischemic hemisphere) was less in the 15/HTN group (16 +/- 6, mean +/- SD) versus the 90/HTN group (30 +/- 6), which was in turn less than the control group (42 +/- 5). Specific gravity was greater in the 15/HTN group (1.043 +/- 0.002) versus the 90/HTN (1.036 +/- 0.003) and control (1.037 +/- 0.003) groups. Evans Blue (mug g-1 of brain tissue) was greater in the 90/HTN group (24.4 +/- 6.0) versus the control group (12.3 +/- 4.1), which was in turn greater than the 15/HTN group (7.3 +/- 3.2). This study supports a hypothesis that during reperfusion, a short interval of hypertension decreases brain injury and edema; and that sustained hypertension increases the risk of ENT2 vasogenic edema ENT2END
0	ENT1 Evans Blue  ENT1END  (mug g-1 of brain tissue) was greater in the 90/HTN group (24.4 +/- 6.0) versus the control group (12.3 +/- 4.1), which was in turn greater than the 15/HTN group (7.3 +/- 3.2). This study supports a hypothesis that during reperfusion, a short interval of hypertension decreases brain injury and edema; and that sustained hypertension increases the risk of ENT2 vasogenic edema ENT2END
0	Part A, for eight rats in each group brain injury was evaluated by staining tissue using ENT1 2,3,5-triphenyltetrazolium chloride ENT1END  and edema was evaluated by microgravimetry. Part B, for eight different rats in each group blood-brain barrier permeability was evaluated by measuring the amount and extent of extravasation of Evans Blue dye. Brain injury (percentage of the ENT2 ischemic hemisphere ENT2END ) was less in the 15/HTN group (16 +/- 6, mean +/- SD) versus the 90/HTN group (30 +/- 6), which was in turn less than the control group (42 +/- 5)
0	Focal ENT1 cerebral ischemia  ENT1END  in rats: effect of ENT2 phenylephrine ENT2END -induced hypertension during reperfusion
0	Brain injury (percentage of the ENT1 ischemic hemisphere  ENT1END ) was less in the 15/HTN group (16 +/- 6, mean +/- SD) versus the 90/HTN group (30 +/- 6), which was in turn less than the control group (42 +/- 5). Specific gravity was greater in the 15/HTN group (1.043 +/- 0.002) versus the 90/HTN (1.036 +/- 0.003) and control (1.037 +/- 0.003) groups. ENT2 Evans Blue ENT2END (mug g-1 of brain tissue) was greater in the 90/HTN group (24
0	Part A, for eight rats in each group ENT1 brain injury  ENT1END was evaluated by staining tissue using ENT2 2,3,5-triphenyltetrazolium chloride ENT2END and edema was evaluated by microgravimetry
0	After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of ENT1 phenylephrine ENT1END -induced hypertension on ENT2 ischemic brain injury ENT2END and blood-brain barrier permeability was determined
0	ENT1 Evans Blue ENT1END  (mug g-1 of brain tissue) was greater in the 90/HTN group (24.4 +/- 6.0) versus the control group (12.3 +/- 4.1), which was in turn greater than the 15/HTN group (7.3 +/- 3.2). This study supports a hypothesis that during reperfusion, a short interval of hypertension decreases ENT2 brain injury ENT2END and edema; and that sustained hypertension increases the risk of vasogenic edema
0	Lithium inhibits IMPase and ENT1 valproate ENT1END inhibits MIP synthase. This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine-induced ENT2 seizures ENT2END model
0	This study shows that ENT1 MIP  ENT1END synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine-induced ENT2 seizures ENT2END model
0	This study shows that MIP synthase inhibition does not replicate or augment the effects of ENT1 lithium  ENT1END in the inositol sensitive pilocarpine-induced ENT2 seizures ENT2END model
1	This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive ENT1 pilocarpine  ENT1END induced ENT2 seizures ENT2END model
0	This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the ENT1 inositol  ENT1END sensitive pilocarpine-induced ENT2 seizures ENT2END model
1	In this study, we evaluate the role DRD2 plays in ENT1 chlorpromazine ENT1END induced ENT2 EPS ENT2END in schizophrenic patients
0	In this study, we evaluate the role DRD2 plays in ENT1 chlorpromazine ENT1END -induced EPS in ENT2 schizophrenic ENT2END patients
0	Clinicians need to be aware of prescribing concomitant medications that increase the risk of ENT1 myopathy ENT1END or inhibit the CYP3A4 enzyme. Our case suggests that troponin elevation could be associated with ENT2 statin ENT2END induced rhabdomyolysis, which may warrant further studies
0	This particular case is of interest as rhabdomyolysis only occurred after an increase in the dose of ENT1 clarithromycin  ENT1END  The patient developed raised cardiac biomarkers without any obvious cardiac issues, a phenomenon that has been linked to rhabdomyolysis previously. To date, there has been no reported effect of rhabdomyolysis on the structure and function of cardiac muscle. Clinicians need to be aware of prescribing concomitant medications that increase the risk of ENT2 myopathy ENT2END or inhibit the CYP3A4 enzyme
1	Our case suggests that troponin elevation could be associated with ENT1 statin ENT1END  induced ENT2 rhabdomyolysis ENT2END , which may warrant further studies
1	This particular case is of interest as ENT1 rhabdomyolysis  ENT1END only occurred after an increase in the dose of ENT2 clarithromycin ENT2END
1	The acute cytolytic hepatitis occurred rapidly after meloxicam administration and was associated with the development of antinuclear antibodies suggesting a ENT1 hypersensitivity ENT1END mechanism. This first case of ENT2 meloxicam ENT2END related liver toxicity demonstrates the potential of this drug to induce hepatic damage
1	We report the case of a female patient with rheumatoid arthritis who developed acute cytolytic ENT1 hepatitis ENT1END due to ENT2 meloxicam ENT2END
0	We report the case of a female patient with ENT1 rheumatoid arthritis  ENT1END who developed acute cytolytic hepatitis due to ENT2 meloxicam ENT2END
1	ENT1 Methoxamine ENT1END evoked non-significant increases in MUP and diastolic blood pressure but caused a significant rise in systolic blood pressure and significant fall in heart rate at maximum dosage. Systemic side effects including piloerection, ENT2 headache ENT2END , and cold extremities were experienced in all subjects
1	ENT1 Methoxamine ENT1END  evoked non-significant increases in MUP and diastolic blood pressure but caused ENT2 a significant rise in systolic blood pressure ENT2END and significant fall in heart rate at maximum dosage
0	Effect of ENT1 methoxamine  ENT1END  on maximum urethral pressure in women with genuine ENT2 stress incontinence ENT2END : a placebo-controlled, double-blind crossover study
1	Participation of a bulbospinal serotonergic pathway in the rat brain in ENT1 clonidine  ENT1END -induced ENT2 hypotension ENT2END and bradycardia
0	The effects of microinjection of clonidine (1-10 micrograms in 1 microliter) into a region adjacent to the ventrolateral surface of the medulla oblongata on cardiovascular function were assessed in ENT1 urethane ENT1END anesthetized rats. Intramedullary administration of clonidine, but not saline vehicle, caused a dose-dependent decrease in both the mean arterial pressure and the heart rate. The clonidine-induced ENT2 hypotension ENT2END was antagonized by prior spinal transection, but not bilateral vagotomy
0	The clonidine-induced ENT1 hypotension ENT1END  was antagonized by prior spinal transection, but not bilateral vagotomy. On the other hand, the clonidine-induced bradycardia was antagonized by prior bilateral vagotomy, but not spinal transection. Furthermore, selective destruction of the spinal ENT2 5-HT ENT2END nerves, produced by bilateral spinal injection of 5,7-dihydroxytryptamine, reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats
0	Furthermore, selective destruction of the spinal 5-HT nerves, produced by bilateral spinal injection of ENT1 5,7-dihydroxytryptamine ENT1END  reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats. The data indicate that a bulbospinal serotonergic pathway is involved in development of clonidine-induced ENT2 hypotension ENT2END and bradycardia
1	On the other hand, the ENT1 clonidine ENT1END induced ENT2 bradycardia ENT2END was antagonized by prior bilateral vagotomy, but not spinal transection
0	Participation of a bulbospinal serotonergic pathway in the rat brain in clonidine-induced hypotension and ENT1 bradycardia  ENT1END .The effects of microinjection of clonidine (1-10 micrograms in 1 microliter) into a region adjacent to the ventrolateral surface of the medulla oblongata on cardiovascular function were assessed in ENT2 urethane ENT2END -anesthetized rats
0	On the other hand, the clonidine-induced ENT1 bradycardia  ENT1END  was antagonized by prior bilateral vagotomy, but not spinal transection. Furthermore, selective destruction of the spinal ENT2 5-HT ENT2END nerves, produced by bilateral spinal injection of 5,7-dihydroxytryptamine, reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats
0	Furthermore, selective destruction of the spinal 5-HT nerves, produced by bilateral spinal injection of ENT1 5,7-dihydroxytryptamine ENT1END , reduced the magnitude of the vasodepressor or the ENT2 bradycardiac ENT2END responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats
0	On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, ENT1 paroxetine ENT1END 40 mg/day, and flecainide 100 mg twice daily. Flecainide had been started 2 weeks prior for ENT2 atrial fibrillation ENT2END
0	On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, ENT1 levothyroxine  ENT1END 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily. Flecainide had been started 2 weeks prior for ENT2 atrial fibrillation ENT2END
0	Flecainide had been started 2 weeks prior for ENT1 atrial fibrillation ENT1END . Laboratory test findings on admission were notable only for a flecainide plasma concentration of 1360 microg/L (reference range 200-1000). A metabolic drug interaction between flecainide and paroxetine, which the patient had been taking for more than 5 years, was considered. Paroxetine was discontinued and the dose of flecainide was reduced to 50 mg twice daily. Her delirium resolved 3 days later. DISCUSSION: Flecainide and pharmacologically similar agents that interact with ENT2 sodium ENT2END channels may cause delirium in susceptible patients
0	On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, ENT1 pantoprazole  ENT1END 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily. Flecainide had been started 2 weeks prior for ENT2 atrial fibrillation ENT2END
0	On admission the patient was taking carvedilol 12 mg twice daily, ENT1 warfarin  ENT1END 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily. Flecainide had been started 2 weeks prior for ENT2 atrial fibrillation ENT2END
0	On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, ENT1 folic acid  ENT1END 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily. Flecainide had been started 2 weeks prior for ENT2 atrial fibrillation ENT2END
0	On admission the patient was taking ENT1 carvedilol  ENT1END 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily. Flecainide had been started 2 weeks prior for ENT2 atrial fibrillation ENT2END
0	ENT1 Flecainide  ENT1END had been started 2 weeks prior for ENT2 atrial fibrillation ENT2END
0	Because ENT1 toxicity ENT1END may occur when flecainide is prescribed with ENT2 paroxetine ENT2END and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors
0	DISCUSSION: Flecainide and pharmacologically similar agents that interact with ENT1 sodium  ENT1END  channels may cause delirium in susceptible patients. A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium. According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. CONCLUSIONS: Supratherapeutic flecainide plasma concentrations may cause delirium. Because ENT2 toxicity ENT2END may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors
0	Because ENT1 toxicity ENT1END  may occur when ENT2 flecainide ENT2END is prescribed with paroxetine and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors
0	OBJECTIVE: To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with ENT1 paroxetine ENT1END  CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of ENT2 confusion ENT2END and paranoia over the past several days
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of ENT1 confusion  ENT1END  and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, ENT2 levothyroxine ENT2END 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of ENT1 confusion  ENT1END  and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, ENT2 pantoprazole ENT2END 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of ENT1 confusion  ENT1END  and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, ENT2 warfarin ENT2END 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of ENT1 confusion  ENT1END  and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, ENT2 folic acid ENT2END 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of ENT1 confusion  ENT1END  and paranoia over the past several days. On admission the patient was taking ENT2 carvedilol ENT2END 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	OBJECTIVE: To describe a case of ENT1 flecainide  ENT1END induced delirium associated with a pharmacokinetic drug interaction with paroxetine. CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of ENT2 confusion ENT2END and paranoia over the past several days
1	Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with ENT1 paroxetine ENT1END .OBJECTIVE: To describe a case of flecainide-induced ENT2 delirium ENT2END associated with a pharmacokinetic drug interaction with paroxetine
0	OBJECTIVE: To describe a case of flecainide-induced ENT1 delirium  ENT1END  associated with a pharmacokinetic drug interaction with paroxetine. CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, ENT2 levothyroxine ENT2END 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	DISCUSSION: Flecainide and pharmacologically similar agents that interact with ENT1 sodium ENT1END  channels may cause ENT2 delirium ENT2END in susceptible patients
0	OBJECTIVE: To describe a case of flecainide-induced ENT1 delirium  ENT1END  associated with a pharmacokinetic drug interaction with paroxetine. CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, ENT2 pantoprazole ENT2END 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	OBJECTIVE: To describe a case of flecainide-induced ENT1 delirium  ENT1END  associated with a pharmacokinetic drug interaction with paroxetine. CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, ENT2 warfarin ENT2END 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	OBJECTIVE: To describe a case of flecainide-induced ENT1 delirium  ENT1END  associated with a pharmacokinetic drug interaction with paroxetine. CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, ENT2 folic acid ENT2END 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	OBJECTIVE: To describe a case of flecainide-induced ENT1 delirium  ENT1END  associated with a pharmacokinetic drug interaction with paroxetine. CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and paranoia over the past several days. On admission the patient was taking ENT2 carvedilol ENT2END 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
1	OBJECTIVE: To describe a case of ENT1 flecainide  ENT1END -induced ENT2 delirium ENT2END associated with a pharmacokinetic drug interaction with paroxetine
0	OBJECTIVE: To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with ENT1 paroxetine ENT1END . CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and ENT2 paranoia ENT2END over the past several days
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and ENT1 paranoia  ENT1END  over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, ENT2 levothyroxine ENT2END 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and ENT1 paranoia  ENT1END  over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, ENT2 pantoprazole ENT2END 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and ENT1 paranoia  ENT1END  over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, ENT2 warfarin ENT2END 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and ENT1 paranoia  ENT1END  over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, ENT2 folic acid ENT2END 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and ENT1 paranoia  ENT1END  over the past several days. On admission the patient was taking ENT2 carvedilol ENT2END 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	OBJECTIVE: To describe a case of ENT1 flecainide  ENT1END -induced delirium associated with a pharmacokinetic drug interaction with paroxetine. CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and ENT2 paranoia ENT2END over the past several days
1	Two cats had transient ENT1 lethargy ENT1END and inappetence. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that ENT2 levetiracetam ENT2END is well tolerated in cats and may be useful as an adjunct to phenobarbital treatment in cats with idiopathic epilepsy
0	Two cats had transient ENT1 lethargy ENT1END  and inappetence. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that levetiracetam is well tolerated in cats and may be useful as an adjunct to ENT2 phenobarbital ENT2END treatment in cats with idiopathic epilepsy
0	Median seizure frequency prior to treatment with ENT1 levetiracetam ENT1END (2.1 ENT2 seizures ENT2END /mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0
0	42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in ENT1 seizure  ENT1END frequency of >or=50%). Two cats had transient lethargy and inappetence. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that levetiracetam is well tolerated in cats and may be useful as an adjunct to ENT2 phenobarbital ENT2END treatment in cats with idiopathic epilepsy
0	ENT1 Levetiracetam  ENT1END  as an adjunct to phenobarbital treatment in cats with suspected ENT2 idiopathic epilepsy ENT2END
0	CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that levetiracetam is well tolerated in cats and may be useful as an adjunct to ENT1 phenobarbital ENT1END  treatment in cats with ENT2 idiopathic epilepsy ENT2END
1	Baboon syndrome induced by ENT1 ketoconazole ENT1END .A 27-year-old male patient presented with a ENT2 maculopapular eruption ENT2END on the flexural areas and buttocks after using oral ketoconazole
0	Three young infants, all of birth weight < 1,500 g, experienced myoclonus following the intravenous administration of ENT1 lorazepam ENT1END  The potential ENT2 neurotoxic ENT2END effects of the drug (and its vehicle) in this population are discussed
1	ENT1 Myoclonus  ENT1END  associated with ENT2 lorazepam ENT2END therapy in very-low-birth-weight infants
0	A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became ENT1 hypotensive ENT1END during ENT2 halothane ENT2END anaesthesia
1	Intraoperative bradycardia and ENT1 hypotension  ENT1END  associated with ENT2 timolol ENT2END and pilocarpine eye drops
1	It is postulated that this action may have been enhanced during halothane anaesthesia with resultant bradycardia and ENT1 hypotension ENT1END  ENT2 Pilocarpine ENT2END may have had a contributory effect
0	It is postulated that this action may have been enhanced during ENT1 halothane ENT1END anaesthesia with resultant ENT2 bradycardia ENT2END and hypotension
1	A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and ENT1 timolol maleate ENT1END eye drops, developed a ENT2 bradycardia ENT2END and became hypotensive during halothane anaesthesia
1	It is postulated that this action may have been enhanced during halothane anaesthesia with resultant ENT1 bradycardia  ENT1END  and hypotension. ENT2 Pilocarpine ENT2END may have had a contributory effect
0	OBJECTIVES: To determine the frequency of and possible factors related to contrast-induced nephropathy (CIN) in hospitalised patients with ENT1 cancer  ENT1END  METHODS: Ninety adult patients were enrolled. Patients with risk factors for acute renal failure were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum creatinine ( ENT2 Cr ENT2END ) of 0
0	OBJECTIVES: To determine the frequency of and possible factors related to contrast-induced nephropathy (CIN) in hospitalised patients with ENT1 cancer ENT1END . METHODS: Ninety adult patients were enrolled. Patients with risk factors for acute renal failure were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum ENT2 creatinine ENT2END (Cr) of 0
0	5-times more frequently in patients with ENT1 cancer  ENT1END who had undergone recent chemotherapy. Hypertension and the combination of bevacizumab/ ENT2 irinotecan ENT2END may be additional risk factors for CIN development
0	Incidence of ENT1 contrast  ENT1END -induced nephropathy in hospitalised patients with ENT2 cancer ENT2END
0	Patients with risk factors for ENT1 acute renal failure ENT1END were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum creatinine ENT2 Cr ENT2END ) of 0
0	Patients with risk factors for ENT1 acute renal failure  ENT1END  were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum ENT2 creatinine ENT2END (Cr) of 0
0	Patients with risk factors for ENT1 acute renal failure ENT1END  were excluded. Blood samples were examined the day before ENT2 contrast ENT2END -enhanced computed tomography (CT) and serially for 3 days thereafter
0	5 mg/dl or more, or elevation of ENT1 Cr ENT1END to 25 % over baseline. Relationships between CIN and possible risk factors were investigated. RESULTS: CIN was detected in 18/90 (20 %) patients. CIN developed in 25.5 % patients who underwent chemotherapy and in 11 % patients who did not (P = 0.1). CIN more frequently developed in patients who had undergone CT within 45 days after the last chemotherapy (P = 0.005); it was also an independent risk factor (P = 0.017). CIN was significantly more after treatment with bevacizumab/irinotecan (P = 0.021) and in patients with ENT2 hypertension ENT2END (P = 0
0	CIN was defined as an increase in serum ENT1 creatinine  ENT1END  (Cr) of 0.5 mg/dl or more, or elevation of Cr to 25 % over baseline. Relationships between CIN and possible risk factors were investigated. RESULTS: CIN was detected in 18/90 (20 %) patients. CIN developed in 25.5 % patients who underwent chemotherapy and in 11 % patients who did not (P = 0.1). CIN more frequently developed in patients who had undergone CT within 45 days after the last chemotherapy (P = 0.005); it was also an independent risk factor (P = 0.017). CIN was significantly more after treatment with bevacizumab/irinotecan (P = 0.021) and in patients with ENT2 hypertension ENT2END (P = 0
0	CIN was significantly more after treatment with bevacizumab/ ENT1 irinotecan  ENT1END (P = 0.021) and in patients with ENT2 hypertension ENT2END (P = 0
0	ENT1 Hypertension ENT1END and the combination of bevacizumab/irinotecan may be additional risk factors for CIN development. KEY POINTS: . ENT2 Contrast ENT2END -induced nephropathy (CIN) is a concern for oncological patients undergoing CT
0	OBJECTIVES: To determine the frequency of and possible factors related to contrast-induced ENT1 nephropathy ENT1END (CIN) in hospitalised patients with cancer. METHODS: Ninety adult patients were enrolled. Patients with risk factors for acute renal failure were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum creatinine ENT2 Cr ENT2END ) of 0
0	OBJECTIVES: To determine the frequency of and possible factors related to contrast-induced ENT1 nephropathy  ENT1END  (CIN) in hospitalised patients with cancer. METHODS: Ninety adult patients were enrolled. Patients with risk factors for acute renal failure were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum ENT2 creatinine ENT2END (Cr) of 0
1	Hypertension and the combination of bevacizumab/ ENT1 irinotecan ENT1END  may be additional risk factors for CIN development. KEY POINTS: . Contrast-induced ENT2 nephropathy ENT2END (CIN) is a concern for oncological patients undergoing CT
1	Incidence of ENT1 contrast  ENT1END -induced ENT2 nephropathy ENT2END in hospitalised patients with cancer
0	This case further supports the concern about ENT1 thromboembolic ENT1END complications associated with ATRA therapy in APL patients. The patients, a 43-year-old man, presented all the signs and symptoms of APL and was included in a treatment protocol with ATRA. After 10 days of treatment, he developed acute renal failure that was completely reversible after complete remission of APL was achieved and therapy discontinued. We conclude that ATRA is a valid therapeutic choice for patients with APL, although the procoagulant tendency is not completely corrected. Thrombotic events, however, could be avoided by using low-dose ENT2 heparin ENT2END
0	A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and ENT1 tranexamic acid  ENT1END has been described recently. We report a case of acute renal failure in an APL patient treated with ATRA alone. This case further supports the concern about ENT2 thromboembolic ENT2END complications associated with ATRA therapy in APL patients
0	This case further supports the concern about ENT1 thromboembolic ENT1END  complications associated with ENT2 ATRA ENT2END therapy in APL patients
0	After 10 days of treatment, he developed ENT1 acute renal failure  ENT1END that was completely reversible after complete remission of APL was achieved and therapy discontinued. We conclude that ATRA is a valid therapeutic choice for patients with APL, although the procoagulant tendency is not completely corrected. Thrombotic events, however, could be avoided by using low-dose ENT2 heparin ENT2END
0	A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and ENT1 tranexamic acid ENT1END  has been described recently. We report a case of ENT2 acute renal failure ENT2END in an APL patient treated with ATRA alone
1	Thrombotic complications in acute promyelocytic leukemia during ENT1 all-trans-retinoic acid ENT1END  therapy.A case of ENT2 acute renal failure ENT2END , due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently
0	We conclude that ATRA is a valid therapeutic choice for patients with ENT1 APL  ENT1END  although the procoagulant tendency is not completely corrected. Thrombotic events, however, could be avoided by using low-dose ENT2 heparin ENT2END
0	A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia ( ENT1 APL  ENT1END  treated with all-trans-retinoic acid (ATRA) and ENT2 tranexamic acid ENT2END has been described recently
0	This case further supports the concern about thromboembolic complications associated with ENT1 ATRA ENT1END  therapy in ENT2 APL ENT2END patients
0	ENT1 Thrombotic  ENT1END events, however, could be avoided by using low-dose ENT2 heparin ENT2END
0	ENT1 Thrombotic  ENT1END  complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy.A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and ENT2 tranexamic acid ENT2END has been described recently
1	ENT1 Thrombotic  ENT1END  complications in acute promyelocytic leukemia during ENT2 all-trans-retinoic acid ENT2END therapy
0	Takotsubo syndrome (or apical ballooning syndrome) secondary to ENT1 Zolmitriptan ENT1END .Takotsubo syndrome (TS), also known as broken heart syndrome, is characterized by left ventricle apical ballooning with elevated cardiac biomarkers and electrocardiographic changes suggestive of an ENT2 acute coronary syndrome ENT2END (ie, ST-segment elevation, T wave inversions, and pathologic Q waves)
0	Takotsubo syndrome (or apical ballooning syndrome) secondary to ENT1 Zolmitriptan ENT1END .Takotsubo syndrome (TS), also known as broken heart syndrome, is characterized by left ventricle apical ballooning with elevated cardiac biomarkers and electrocardiographic changes suggestive of an acute coronary syndrome (ie, ST-segment elevation, T wave inversions, and pathologic Q waves). We report a case of 54-year-old woman with medical history of ENT2 mitral valve prolapse ENT2END and migraines, who was admitted to the hospital for substernal chest pain and electrocardiogram demonstrated 1/2 mm ST-segment elevation in leads II, III, aVF, V5, and V6 and positive troponin I
0	Detailed history obtained retrospectively revealed that the patient took ENT1 zolmitriptan ENT1END sparingly only when she had ENT2 migraines ENT2END
1	Takotsubo syndrome (or apical ballooning syndrome) secondary to ENT1 Zolmitriptan  ENT1END . ENT2 Takotsubo syndrome ENT2END (TS), also known as broken heart syndrome, is characterized by left ventricle apical ballooning with elevated cardiac biomarkers and electrocardiographic changes suggestive of an acute coronary syndrome (ie, ST-segment elevation, T wave inversions, and pathologic Q waves)
0	We report a case of 54-year-old woman with medical history of mitral valve prolapse and migraines, who was admitted to the hospital for substernal ENT1 chest pain  ENT1END and electrocardiogram demonstrated 1/2 mm ST-segment elevation in leads II, III, aVF, V5, and V6 and positive troponin I. Emergent coronary angiogram revealed normal coronary arteries with moderately reduced left ventricular ejection fraction with wall motion abnormalities consistent with TS. Detailed history obtained retrospectively revealed that the patient took ENT2 zolmitriptan ENT2END sparingly only when she had migraines
1	Extensive literature search revealed multiple cases of ENT1 coronary artery vasospasm ENT1END secondary to ENT2 zolmitriptan ENT2END , but none of the cases were associated with TS
1	This case contributes to the previous observations that non-metastasizing hepatic neoplasms and ENT1 peliosis ENT1END can develop in patients with androgen- and ENT2 corticosteroid ENT2END -treated Fanconi's anemia
1	This case contributes to the previous observations that non-metastasizing hepatic neoplasms and ENT1 peliosis ENT1END  can develop in patients with ENT2 androgen ENT2END - and corticosteroid-treated Fanconi's anemia
1	ENT1 Hepatocellular carcinoma  ENT1END  in Fanconi's anemia treated with androgen and ENT2 corticosteroid ENT2END
1	ENT1 Hepatocellular carcinoma  ENT1END  in Fanconi's anemia treated with ENT2 androgen ENT2END and corticosteroid
0	The case of an 11-year-old boy is reported who was known to have Fanconi's anemia for 3 years and was treated with androgens, ENT1 corticosteroids ENT1END and transfusions. Two weeks before his death he was readmitted because of aplastic crisis with ENT2 septicemia ENT2END and marked abnormalities in liver function and died of hemorrhagic bronchopneumonia
0	The case of an 11-year-old boy is reported who was known to have Fanconi's anemia for 3 years and was treated with ENT1 androgens  ENT1END  corticosteroids and transfusions. Two weeks before his death he was readmitted because of aplastic crisis with ENT2 septicemia ENT2END and marked abnormalities in liver function and died of hemorrhagic bronchopneumonia
0	The case of an 11-year-old boy is reported who was known to have Fanconi's anemia for 3 years and was treated with androgens, ENT1 corticosteroids ENT1END  and transfusions. Two weeks before his death he was readmitted because of aplastic crisis with septicemia and marked abnormalities in liver function and died of ENT2 hemorrhagic bronchopneumonia ENT2END
0	The case of an 11-year-old boy is reported who was known to have Fanconi's anemia for 3 years and was treated with ENT1 androgens  ENT1END , corticosteroids and transfusions. Two weeks before his death he was readmitted because of aplastic crisis with septicemia and marked abnormalities in liver function and died of ENT2 hemorrhagic bronchopneumonia ENT2END
0	This case contributes to the previous observations that non-metastasizing ENT1 hepatic neoplasms  ENT1END and peliosis can develop in patients with androgen- and ENT2 corticosteroid ENT2END -treated Fanconi's anemia
0	This case contributes to the previous observations that non-metastasizing ENT1 hepatic neoplasms  ENT1END  and peliosis can develop in patients with ENT2 androgen ENT2END - and corticosteroid-treated Fanconi's anemia
0	This case contributes to the previous observations that non-metastasizing hepatic neoplasms and peliosis can develop in patients with androgen- and ENT1 corticosteroid ENT1END -treated ENT2 Fanconi's anemia ENT2END
0	Hepatocellular carcinoma in ENT1 Fanconi's anemia  ENT1END  treated with ENT2 androgen ENT2END and corticosteroid
0	Given the lifelong nature of hypertension, there is a need to evaluate the long-term efficacy and tolerability of higher doses of combination anti- ENT1 hypertensive ENT1END therapies. OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or ENT2 hydrochlorothiazide ENT2END (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension
0	Given the lifelong nature of hypertension, there is a need to evaluate the long-term efficacy and tolerability of higher doses of combination anti- ENT1 hypertensive ENT1END  therapies. OBJECTIVE: This study investigated the efficacy and tolerability of ENT2 valsartan ENT2END (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension
1	CONCLUSIONS: In this study population, combination therapies with VAL/HCTZ were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less ENT1 hypokalemia ENT1END than ENT2 HCTZ ENT2END alone
0	The incidence of ENT1 hypokalemia ENT1END was lower with ENT2 VAL ENT2END /HCTZ combinations (1
0	OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide ( ENT1 HCTZ ENT1END -monotherapy and higher-dose combinations in patients with ENT2 essential hypertension ENT2END
0	OBJECTIVE: This study investigated the efficacy and tolerability of valsartan ( ENT1 VAL  ENT1END  or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with ENT2 essential hypertension ENT2END
0	Lidocaine, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning ENT1 arrhythmias ENT1END between 15 and 45 minutes after the administration of ENT2 lidocaine ENT2END (p less than 0
1	During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the ENT1 lidocaine ENT1END group, ENT2 hypotension ENT2END occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine
0	The average plasma lidocaine level 10 minutes after administration for patients without a myocardial infarction was significantly higher than that for patients with an acute ENT1 infarction ENT1END  The mean plasma ENT2 lidocaine ENT2END level of patients on beta-blocking agents was no different from that in patients not on beta blocking agents
0	During the 1 hour after administration of the drug the incidence of ventricular fibrillation or sustained ENT1 ventricular tachycardia ENT1END among the 204 patients with acute myocardial infarction was low, 1.5%. ENT2 Lidocaine ENT2END , given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine (p less than 0
0	Four hundred two patients with suspected myocardial infarction seen within 6 hours of the onset of symptoms entered a double-blind randomized trial of ENT1 lidocaine ENT1END vs placebo. During the 1 hour after administration of the drug the incidence of ENT2 ventricular fibrillation ENT2END or sustained ventricular tachycardia among the 204 patients with acute myocardial infarction was low, 1
0	During the 1 hour after administration of the drug the incidence of ventricular fibrillation or sustained ventricular tachycardia among the 204 patients with acute ENT1 myocardial infarction  ENT1END was low, 1.5%. ENT2 Lidocaine ENT2END , given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine (p less than 0
0	During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from ENT1 asystole ENT1END  three of whom had had ENT2 lidocaine ENT2END
0	ENT1 Bort ENT1END dex was an effective salvage treatment for ENT2 MM ENT2END patients, particularly for those in first relapse
0	Bort- ENT1 dex  ENT1END was an effective salvage treatment for ENT2 MM ENT2END patients, particularly for those in first relapse
1	The most relevant adverse event was ENT1 peripheral neuropathy ENT1END  which occurred in 78 % of the patients (grade II, 38 %; grade III, 21 %) and led to treatment discontinuation in 6 %. With a median follow up of 22 months, median time to progression, progression-free survival (PFS) and overall survival (OS) were 8.9, 8.7, and 22 months, respectively. Prolonged PFS and OS were observed in patients achieving CR and receiving ENT2 bort ENT2END -dex a single line of prior therapy
1	The median number of bort- ENT1 dex  ENT1END cycles was 6, up to a maximum of 12 cycles. On an intention-to-treat basis, 55 % of the patients achieved at least partial response, including 19 % CR and 35 % achieved at least very good partial response. Median durations of response, time to next therapy and treatment-free interval were 8, 11.2, and 5.1 months, respectively. The most relevant adverse event was ENT2 peripheral neuropathy ENT2END , which occurred in 78 % of the patients (grade II, 38 %; grade III, 21 %) and led to treatment discontinuation in 6 %
0	Intracerebroventricular injection of ethacrynic acid (50% ENT1 convulsive ENT1END dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and ENT2 acetylcholine ENT2END in mouse brain
0	These effects were completely antagonized by pretreatment with a glutamate/ ENT1 N-methyl-D-aspartate ENT1END antagonist, aminophosphonovaleric acid. In ethacrynic acid-induced ENT2 convulsions ENT2END , these neurotransmitter systems may be differentially modulated, probably through activation of glutaminergic neurons in the brain
0	Intracerebroventricular injection of ethacrynic acid (50% ENT1 convulsive ENT1END  dose; 50 micrograms/mouse) accelerated the synthesis/turnover of ENT2 5-hydroxytryptamine ENT2END (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain
0	Intracerebroventricular injection of ethacrynic acid (50% ENT1 convulsive ENT1END  dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of ENT2 gamma-aminobutyric acid ENT2END and acetylcholine in mouse brain
1	Intracerebroventricular injection of ENT1 ethacrynic acid  ENT1END (50% ENT2 convulsive ENT2END dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain
0	These effects were completely antagonized by pretreatment with a ENT1 glutamate  ENT1END N-methyl-D-aspartate antagonist, aminophosphonovaleric acid. In ethacrynic acid-induced ENT2 convulsions ENT2END , these neurotransmitter systems may be differentially modulated, probably through activation of glutaminergic neurons in the brain
0	In the media of the saphenous artery and its distal branch, vasoconstriction induced by ENT1 L-norepinephrine ENT1END produced many cell-to-cell ENT2 hernias ENT2END within 15 minutes
1	Medial changes in arterial ENT1 spasm  ENT1END  induced by ENT2 L-norepinephrine ENT2END
0	Exclusion criteria were any preexisting predisposing factor for delirium or other potentially confounding ENT1 neurological dysfunctions ENT1END  Patients were assessed daily using the confusion assessment method for the ICU scale for 3 days after the surgical procedure. Early postoperative delirium incidence risk factors were then assessed through three different multiple regression models. RESULTS: According to the confusion assessment method for the ICU scale, 28 % of patients were diagnosed with early postoperative delirium. The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to ENT2 propofol ENT2END (57
0	Exclusion criteria were any preexisting predisposing factor for delirium or other potentially confounding ENT1 neurological dysfunctions ENT1END . Patients were assessed daily using the confusion assessment method for the ICU scale for 3 days after the surgical procedure. Early postoperative delirium incidence risk factors were then assessed through three different multiple regression models. RESULTS: According to the confusion assessment method for the ICU scale, 28 % of patients were diagnosed with early postoperative delirium. The use of ENT2 thiopentone ENT2END was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57
0	Patients were assessed daily using the ENT1 confusion  ENT1END assessment method for the ICU scale for 3 days after the surgical procedure. Early postoperative delirium incidence risk factors were then assessed through three different multiple regression models. RESULTS: According to the confusion assessment method for the ICU scale, 28 % of patients were diagnosed with early postoperative delirium. The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to ENT2 propofol ENT2END (57
0	Patients were assessed daily using the ENT1 confusion  ENT1END  assessment method for the ICU scale for 3 days after the surgical procedure. Early postoperative delirium incidence risk factors were then assessed through three different multiple regression models. RESULTS: According to the confusion assessment method for the ICU scale, 28 % of patients were diagnosed with early postoperative delirium. The use of ENT2 thiopentone ENT2END was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57
0	The use of thiopentone was significantly associated with an eight-fold-higher risk for ENT1 delirium  ENT1END compared to ENT2 propofol ENT2END (57
1	The use of ENT1 thiopentone  ENT1END  was significantly associated with an eight-fold-higher risk for ENT2 delirium ENT2END compared to propofol (57
0	The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to ENT1 propofol ENT1END  (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02). CONCLUSION: In this study early ENT2 postoperative delirium ENT2END was found to be a very common complication after major surgery, even in a population without known risk factors
1	RESULTS: According to the confusion assessment method for the ICU scale, 28 % of patients were diagnosed with early ENT1 postoperative delirium  ENT1END  The use of ENT2 thiopentone ENT2END was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57
0	We report a case about a female with essential ENT1 hypertension ENT1END on drug treatment with ENT2 amlodipine ENT2END developed loss of taste sensation
1	Is Dysguesia Going to be a Rare or a Common Side-effect of Amlodipine?A very rare side-effect of ENT1 amlodipine ENT1END is ENT2 dysguesia ENT2END
0	We report a case about a female with essential hypertension on drug treatment with ENT1 amlodipine ENT1END  developed ENT2 loss of taste sensation ENT2END
0	METHODS: Retrospective chart review including clinical data and EEG recordings was done on five patients, admitted to MD Anderson ENT1 Cancer ENT1END Center between years 2009 and 2012, who developed ENT2 ifosfamide ENT2END related acute encephalopathy
0	BACKGROUND: ENT1 Ifosfamide ENT1END is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas, ENT2 lymphoma ENT2END , gynecologic and testicular cancers
1	RESULTS: All five patients experienced symptoms of encephalopathy soon after (within 12 h-2 days) receiving ENT1 ifosfamide ENT1END  Two patients developed generalized convulsions while one patient developed continuous ENT2 non-convulsive status epilepticus ENT2END (NCSE) that required ICU admission and intubation
1	RESULTS: All five patients experienced symptoms of encephalopathy soon after (within 12 h-2 days) receiving ENT1 ifosfamide ENT1END . Two patients developed generalized ENT2 convulsions ENT2END while one patient developed continuous non-convulsive status epilepticus (NCSE) that required ICU admission and intubation
0	ENT1 Ifosfamide  ENT1END  related ENT2 encephalopathy ENT2END : the need for a timely EEG evaluation
0	BACKGROUND: ENT1 Ifosfamide ENT1END  is an alkylating agent useful in the treatment of a wide range of cancers including ENT2 sarcomas ENT2END , lymphoma, gynecologic and testicular cancers
0	The best clinical effect was found with ENT1 terbutaline ENT1END  Both anti-asthmatic and ENT2 tremorgenic ENT2END effects of procaterol were dose-related
1	Both anti-asthmatic and ENT1 tremorgenic ENT1END  effects of ENT2 procaterol ENT2END were dose-related
0	Procaterol and ENT1 terbutaline  ENT1END  in ENT2 bronchial asthma ENT2END
0	Procaterol, a new beta-2 adrenoceptor stimulant, was studied in a double-blind, placebo-controlled, cross-over trial in patients with ENT1 bronchial asthma ENT1END  Oral ENT2 procaterol ENT2END 50 micrograms b
0	OBJECTIVE: Diazinon, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined ENT1 diazinon ENT1END associated ENT2 cancer ENT2END risk
0	Incidence of solid ENT1 tumours  ENT1END  among pesticide applicators exposed to the ENT2 organophosphate ENT2END insecticide diazinon in the Agricultural Health Study: an updated analysis
0	02) and IW days of ENT1 diazinon ENT1END use (RR=1.41; 95% CI 0.98 to 2.04; Ptrend=0.08). ENT2 Kidney cancer ENT2END (N=94) risks were non-significantly elevated (RRLT days=1
0	OBJECTIVE: Diazinon, a common ENT1 organophosphate  ENT1END insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk. We used updated diazinon exposure and cancer incidence information to evaluate solid tumour risk in the AHS. METHODS: Male pesticide applicators in Iowa and North Carolina reported lifetime diazinon use at enrolment (1993-1997) and follow-up (1998-2005); cancer incidence was assessed through 2010(North Carolina)/2011(Iowa). Among applicators with usage information sufficient to evaluate exposure-response patterns, we used Poisson regression to estimate adjusted rate ratios (RRs) and 95% CI for cancer sites with >10 exposed cases for both lifetime (LT) exposure days and intensity-weighted (IW) lifetime exposure days (accounting for factors impacting exposure). RESULTS: We observed elevated lung cancer risks (N=283) among applicators with the greatest number of LT (RR=1.60; 95% CI 1.11 to 2.31; Ptrend=0.02) and IW days of diazinon use (RR=1.41; 95% CI 0.98 to 2.04; Ptrend=0.08). ENT2 Kidney cancer ENT2END (N=94) risks were non-significantly elevated (RRLT days=1
1	CONCLUSIONS: Our updated evaluation of ENT1 diazinon ENT1END provides additional evidence of an association with ENT2 lung cancer ENT2END risk
0	OBJECTIVE: Diazinon, a common ENT1 organophosphate ENT1END  insecticide with genotoxic properties, was previously associated with ENT2 lung cancer ENT2END in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk
0	50), as were risks for aggressive ENT1 prostate cancer  ENT1END (N=656). CONCLUSIONS: Our updated evaluation of ENT2 diazinon ENT2END provides additional evidence of an association with lung cancer risk
0	OBJECTIVE: Diazinon, a common ENT1 organophosphate  ENT1END  insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk. We used updated diazinon exposure and cancer incidence information to evaluate solid tumour risk in the AHS. METHODS: Male pesticide applicators in Iowa and North Carolina reported lifetime diazinon use at enrolment (1993-1997) and follow-up (1998-2005); cancer incidence was assessed through 2010(North Carolina)/2011(Iowa). Among applicators with usage information sufficient to evaluate exposure-response patterns, we used Poisson regression to estimate adjusted rate ratios (RRs) and 95% CI for cancer sites with >10 exposed cases for both lifetime (LT) exposure days and intensity-weighted (IW) lifetime exposure days (accounting for factors impacting exposure). RESULTS: We observed elevated lung cancer risks (N=283) among applicators with the greatest number of LT (RR=1.60; 95% CI 1.11 to 2.31; Ptrend=0.02) and IW days of diazinon use (RR=1.41; 95% CI 0.98 to 2.04; Ptrend=0.08). Kidney cancer (N=94) risks were non-significantly elevated (RRLT days=1.77; 95% CI 0.90 to 3.51; Ptrend=0.09; RRIW days 1.37; 95% CI 0.64 to 2.92; Ptrend=0.50), as were risks for aggressive ENT2 prostate cancer ENT2END (N=656)
0	The results revealed that the adult offspring kidneys in the PCE group exhibited ENT1 glomerulosclerosis ENT1END as well as interstitial fibrosis, accompanied by elevated levels of serum ENT2 creatinine ENT2END and urine protein
0	The results revealed that the adult offspring kidneys in the PCE group exhibited ENT1 glomerulosclerosis ENT1END  as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein. Renal ENT2 angiotensin II ENT2END receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased
0	Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/ ENT1 tyrosine ENT1END kinase receptor (c-Ret) signaling pathway. These results demonstrated that PCE could induce dysplasia of fetal kidneys as well as ENT2 glomerulosclerosis ENT2END of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis
0	Low functional programming of renal AT2R mediates the developmental origin of ENT1 glomerulosclerosis  ENT1END  in adult offspring induced by prenatal ENT2 caffeine ENT2END exposure
0	A rat model of ENT1 IUGR  ENT1END was established by PCE, male fetuses and adult offspring at the age of postnatal week 24 were euthanized. The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum ENT2 creatinine ENT2END and urine protein
0	A rat model of ENT1 IUGR  ENT1END  was established by PCE, male fetuses and adult offspring at the age of postnatal week 24 were euthanized. The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein. Renal ENT2 angiotensin II ENT2END receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased
0	A rat model of ENT1 IUGR  ENT1END  was established by PCE, male fetuses and adult offspring at the age of postnatal week 24 were euthanized. The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein. Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased. The fetal kidneys in the PCE group displayed an enlarged Bowman's space and a shrunken glomerular tuft, accompanied by a reduced cortex width and an increase in the nephrogenic zone/cortical zone ratio. Observation by electronic microscope revealed structural damage of podocytes; the reduced expression level of podocyte marker genes, nephrin and podocin, was also detected by q-PCR. Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF) ENT2 tyrosine ENT2END kinase receptor (c-Ret) signaling pathway
1	UNASSIGNED: Our previous study has indicated that prenatal ENT1 caffeine ENT1END exposure (PCE) could induce ENT2 intrauterine growth retardation ENT2END (IUGR) of offspring
0	The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as ENT1 interstitial fibrosis  ENT1END  accompanied by elevated levels of serum ENT2 creatinine ENT2END and urine protein
0	The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as ENT1 interstitial fibrosis  ENT1END , accompanied by elevated levels of serum creatinine and urine protein. Renal ENT2 angiotensin II ENT2END receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased
0	The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as ENT1 interstitial fibrosis  ENT1END , accompanied by elevated levels of serum creatinine and urine protein. Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased. The fetal kidneys in the PCE group displayed an enlarged Bowman's space and a shrunken glomerular tuft, accompanied by a reduced cortex width and an increase in the nephrogenic zone/cortical zone ratio. Observation by electronic microscope revealed structural damage of podocytes; the reduced expression level of podocyte marker genes, nephrin and podocin, was also detected by q-PCR. Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF) ENT2 tyrosine ENT2END kinase receptor (c-Ret) signaling pathway
1	UNASSIGNED: Our previous study has indicated that prenatal ENT1 caffeine  ENT1END  exposure (PCE) could induce intrauterine growth retardation (IUGR) of offspring. Recent research suggested that IUGR is a risk factor for glomerulosclerosis. However, whether PCE could induce glomerulosclerosis and its underlying mechanisms remain unknown. This study aimed to demonstrate the induction to glomerulosclerosis in adult offspring by PCE and its intrauterine programming mechanisms. A rat model of IUGR was established by PCE, male fetuses and adult offspring at the age of postnatal week 24 were euthanized. The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as ENT2 interstitial fibrosis ENT2END , accompanied by elevated levels of serum creatinine and urine protein
0	The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum ENT1 creatinine ENT1END  and urine protein. Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased. The fetal kidneys in the PCE group displayed an enlarged Bowman's space and a shrunken glomerular tuft, accompanied by a reduced cortex width and an increase in the nephrogenic zone/cortical zone ratio. Observation by electronic microscope revealed structural damage of podocytes; the reduced expression level of podocyte marker genes, nephrin and podocin, was also detected by q-PCR. Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway. These results demonstrated that PCE could induce ENT2 dysplasia of fetal kidneys ENT2END as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis
0	Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal ENT1 angiotensin II  ENT1END receptor type 1a (AT1aR)/AT2R expression ratio was increased. The fetal kidneys in the PCE group displayed an enlarged Bowman's space and a shrunken glomerular tuft, accompanied by a reduced cortex width and an increase in the nephrogenic zone/cortical zone ratio. Observation by electronic microscope revealed structural damage of podocytes; the reduced expression level of podocyte marker genes, nephrin and podocin, was also detected by q-PCR. Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway. These results demonstrated that PCE could induce ENT2 dysplasia of fetal kidneys ENT2END as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis
0	Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/ ENT1 tyrosine  ENT1END  kinase receptor (c-Ret) signaling pathway. These results demonstrated that PCE could induce ENT2 dysplasia of fetal kidneys ENT2END as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis
1	51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and ENT1 L-DOPA ENT1END induced ENT2 dyskinesias ENT2END
0	51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, ENT1 rigidity  ENT1END  and ENT2 L-DOPA ENT2END -induced dyskinesias
0	51 patients with medically refractory ENT1 Parkinson's disease  ENT1END underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and ENT2 L-DOPA ENT2END -induced dyskinesias
0	51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of ENT1 bradykinesia  ENT1END  rigidity, and ENT2 L-DOPA ENT2END -induced dyskinesias
0	Univariate analysis showed that the risk factors associated with ENT1 seizures ENT1END after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total ENT2 bilirubin ENT2END after surgery, and trough TAC level
1	High PELD and Child-Pugh scores before LT and high post-operative serum Tbil may be contributory risk factors for ENT1 TAC ENT1END related ENT2 seizures ENT2END
0	Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total ENT1 bilirubin  ENT1END  after surgery, and trough TAC level. Multivariate analysis showed that trough TAC level was the only independent risk factor associated with the seizures. All children who experienced seizures survived with good graft function and remained seizure-free without anti- ENT2 epileptic ENT2END drugs over a mean follow-up period of 33
0	All children who experienced seizures survived with good graft function and remained seizure-free without anti- ENT1 epileptic ENT1END  drugs over a mean follow-up period of 33.7 + 14.6 months. High trough ENT2 TAC ENT2END level was the predominant factor that contributed to seizures in the early post-operative period after pediatric LT
0	All exhibited generalized ENT1 tonic-clonic seizures  ENT1END within the first two wk after LT. Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total ENT2 bilirubin ENT2END after surgery, and trough TAC level
0	All exhibited generalized ENT1 tonic-clonic seizures ENT1END  within the first two wk after LT. Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough ENT2 TAC ENT2END level
0	Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric ENT1 end-stage liver disease  ENT1END score before surgery, Child-Pugh score before surgery, serum total ENT2 bilirubin ENT2END after surgery, and trough TAC level
0	Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric ENT1 end-stage liver disease  ENT1END  score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough ENT2 TAC ENT2END level
0	We describe three patients in whom severe, life-threatening ENT1 hyperkalemia ENT1END and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin. This complication may result from an inhibition of ENT2 prostaglandin ENT2END synthesis and consequent hyporeninemic hypoaidosteronism
0	We describe three patients in whom severe, life-threatening ENT1 hyperkalemia ENT1END  and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin. This complication may result from an inhibition of prostaglandin synthesis and consequent hyporeninemic hypoaidosteronism. Careful attention to renal function and ENT2 potassium ENT2END balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication
1	ENT1 Indomethacin  ENT1END -induced ENT2 hyperkalemia ENT2END in three patients with gouty arthritis
0	This complication may result from an inhibition of ENT1 prostaglandin ENT1END  synthesis and consequent ENT2 hyporeninemic hypoaidosteronism ENT2END
0	This complication may result from an inhibition of prostaglandin synthesis and consequent ENT1 hyporeninemic hypoaidosteronism  ENT1END . Careful attention to renal function and ENT2 potassium ENT2END balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication
0	This complication may result from an inhibition of prostaglandin synthesis and consequent ENT1 hyporeninemic hypoaidosteronism ENT1END . Careful attention to renal function and potassium balance in patients receiving ENT2 indomethacin ENT2END or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication
0	This complication may result from an inhibition of ENT1 prostaglandin ENT1END  synthesis and consequent hyporeninemic hypoaidosteronism. Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with ENT2 diabetes mellitus ENT2END or preexisting renal disease, will help prevent this potentially serious complication
0	Careful attention to renal function and ENT1 potassium  ENT1END  balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with ENT2 diabetes mellitus ENT2END or preexisting renal disease, will help prevent this potentially serious complication
0	Careful attention to renal function and potassium balance in patients receiving ENT1 indomethacin  ENT1END  or other nonsteroidal anti-inflammatory agents, particularly in those patients with ENT2 diabetes mellitus ENT2END or preexisting renal disease, will help prevent this potentially serious complication
0	We describe three patients in whom severe, life-threatening hyperkalemia and ENT1 renal insufficiency  ENT1END developed after treatment of acute gouty arthritis with indomethacin. This complication may result from an inhibition of ENT2 prostaglandin ENT2END synthesis and consequent hyporeninemic hypoaidosteronism
0	We describe three patients in whom severe, life-threatening hyperkalemia and ENT1 renal insufficiency  ENT1END  developed after treatment of acute gouty arthritis with indomethacin. This complication may result from an inhibition of prostaglandin synthesis and consequent hyporeninemic hypoaidosteronism. Careful attention to renal function and ENT2 potassium ENT2END balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication
1	We describe three patients in whom severe, life-threatening hyperkalemia and ENT1 renal insufficiency ENT1END  developed after treatment of acute gouty arthritis with ENT2 indomethacin ENT2END
0	This complication may result from an inhibition of ENT1 prostaglandin ENT1END  synthesis and consequent hyporeninemic hypoaidosteronism. Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting ENT2 renal disease ENT2END , will help prevent this potentially serious complication
0	Careful attention to renal function and ENT1 potassium  ENT1END  balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting ENT2 renal disease ENT2END , will help prevent this potentially serious complication
0	Careful attention to renal function and potassium balance in patients receiving ENT1 indomethacin  ENT1END  or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting ENT2 renal disease ENT2END , will help prevent this potentially serious complication
0	We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute ENT1 gouty arthritis  ENT1END with indomethacin. This complication may result from an inhibition of ENT2 prostaglandin ENT2END synthesis and consequent hyporeninemic hypoaidosteronism
0	We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute ENT1 gouty arthritis  ENT1END  with indomethacin. This complication may result from an inhibition of prostaglandin synthesis and consequent hyporeninemic hypoaidosteronism. Careful attention to renal function and ENT2 potassium ENT2END balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication
0	We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute ENT1 gouty arthritis  ENT1END  with ENT2 indomethacin ENT2END
0	After transfer to an internal ward, we noted ENT1 aphasia ENT1END and weakness of his left limbs. After MRI, we found cerebral ischemic infarction. CONCLUSION: Those using methadone and ENT2 heroin ENT2END simultaneously may increase risk of rhabdomyolysis and ischemic stroke
0	After transfer to an internal ward, we noted ENT1 aphasia ENT1END  and weakness of his left limbs. After MRI, we found cerebral ischemic infarction. CONCLUSION: Those using ENT2 methadone ENT2END and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke
1	Hypotheses of ENT1 heroin ENT1END related ENT2 rhabdomyolysis ENT2END and stroke in heroin abusers are discussed
1	CONCLUSION: Those using methadone and heroin simultaneously may increase risk of ENT1 rhabdomyolysis ENT1END and ischemic stroke. Patients under ENT2 methadone ENT2END maintenance therapy should be warned regarding these serious adverse events
0	After transfer to an internal ward, we noted aphasia and ENT1 weakness  ENT1END of his left limbs. After MRI, we found cerebral ischemic infarction. CONCLUSION: Those using methadone and ENT2 heroin ENT2END simultaneously may increase risk of rhabdomyolysis and ischemic stroke
0	After transfer to an internal ward, we noted aphasia and ENT1 weakness  ENT1END  of his left limbs. After MRI, we found cerebral ischemic infarction. CONCLUSION: Those using ENT2 methadone ENT2END and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke
0	In the ICU, we found rhabdomyolysis, acute renal failure and acute ENT1 respiratory failure  ENT1END  After transfer to an internal ward, we noted aphasia and weakness of his left limbs. After MRI, we found cerebral ischemic infarction. CONCLUSION: Those using methadone and ENT2 heroin ENT2END simultaneously may increase risk of rhabdomyolysis and ischemic stroke
0	In the ICU, we found rhabdomyolysis, acute renal failure and acute ENT1 respiratory failure  ENT1END . After transfer to an internal ward, we noted aphasia and weakness of his left limbs. After MRI, we found cerebral ischemic infarction. CONCLUSION: Those using ENT2 methadone ENT2END and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke
1	Hypotheses of heroin-related rhabdomyolysis and ENT1 stroke ENT1END in ENT2 heroin ENT2END abusers are discussed
1	Patients under ENT1 methadone  ENT1END  maintenance therapy should be warned regarding these serious adverse events. Hypotheses of heroin-related rhabdomyolysis and ENT2 stroke ENT2END in heroin abusers are discussed
0	Rhabdomyolysis and brain ENT1 ischemic stroke  ENT1END  in a ENT2 heroin ENT2END -dependent male under methadone maintenance therapy
0	CONCLUSION: Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ENT1 ischemic stroke  ENT1END  Patients under ENT2 methadone ENT2END maintenance therapy should be warned regarding these serious adverse events
0	In the ICU, we found rhabdomyolysis, ENT1 acute renal failure  ENT1END and acute respiratory failure. After transfer to an internal ward, we noted aphasia and weakness of his left limbs. After MRI, we found cerebral ischemic infarction. CONCLUSION: Those using methadone and ENT2 heroin ENT2END simultaneously may increase risk of rhabdomyolysis and ischemic stroke
0	He had used heroin since age 20, and had used 150 mg ENT1 methadone  ENT1END daily for 6 months. He was found unconsciousness at home and was sent to our hospital. In the ER, his opiate level was 4497 ng/ml. In the ICU, we found rhabdomyolysis, ENT2 acute renal failure ENT2END and acute respiratory failure
0	He had used ENT1 heroin ENT1END since age 20, and had used 150 mg methadone daily for 6 months. He was found ENT2 unconsciousness ENT2END at home and was sent to our hospital
0	He had used heroin since age 20, and had used 150 mg ENT1 methadone  ENT1END  daily for 6 months. He was found ENT2 unconsciousness ENT2END at home and was sent to our hospital
0	Rhabdomyolysis and brain ischemic stroke in a ENT1 heroin ENT1END -dependent male under methadone maintenance therapy.OBJECTIVE: There are several complications associated with ENT2 heroin abuse ENT2END , some of which are life-threatening
0	OBJECTIVE: There are several complications associated with ENT1 heroin abuse ENT1END , some of which are life-threatening. ENT2 Methadone ENT2END may aggravate this problem
0	For patients in sinus rhythm and ENT1 heart failure ENT1END the situation is less clear. ENT2 Digoxin ENT2END has a narrow therapeutic:toxic ratio and concentrations are affected by a number of drugs
1	Also, ENT1 digoxin ENT1END has undesirable effects such as increasing peripheral resistance and myocardial demands, and causing ENT2 arrhythmias ENT2END
0	In patients with ENT1 atrial fibrillation ENT1END ENT2 digoxin ENT2END is beneficial for ventricular rate control
0	Pooled analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that digoxin may increase mortality after myocardial infarction ( ENT1 MI ENT1END . ENT2 Angiotensin ENT2END -converting enzyme (ACE) inhibitors should be used first as they are safer, do not require blood level monitoring, modify progression of disease, relieve symptoms, improve exercise tolerance and reduce mortality
0	Pooled analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that ENT1 digoxin ENT1END may increase mortality after ENT2 myocardial infarction ENT2END (MI)
1	After angiography by the venous route in patient n degree 1 a biphasic reaction with an immediate reaction (dyspnea, loss of consciousness) and delayed macro-papular rash appeared, whilst patient n degree 2 developed a generalised sensation of heat, persistent ENT1 pain ENT1END at the site of injection immediately and a generalised macro-papular reaction after 24 hours. The skin tests revealed positive delayed reactions of 24 hours and 48 hours by IDR and patch tests to only some ENT2 PRC ENT2END with common chains in their structures
1	The authors report two observations on patients with delayed reactions in whom intradermoreactions (IDR) and patch tests to a series of ionic and non ionic ENT1 PRC ENT1END were studied. After angiography by the venous route in patient n degree 1 a biphasic reaction with an immediate reaction (dyspnea, loss of consciousness) and delayed ENT2 macro-papular rash ENT2END appeared, whilst patient n degree 2 developed a generalised sensation of heat, persistent pain at the site of injection immediately and a generalised macro-papular reaction after 24 hours
1	The authors report two observations on patients with delayed reactions in whom intradermoreactions (IDR) and patch tests to a series of ionic and non ionic ENT1 PRC ENT1END  were studied. After angiography by the venous route in patient n degree 1 a biphasic reaction with an immediate reaction (dyspnea, ENT2 loss of consciousness ENT2END ) and delayed macro-papular rash appeared, whilst patient n degree 2 developed a generalised sensation of heat, persistent pain at the site of injection immediately and a generalised macro-papular reaction after 24 hours
0	The skin tests revealed positive delayed reactions of 24 hours and 48 hours by IDR and patch tests to only some ENT1 PRC ENT1END  with common chains in their structures. The positive skin tests are in favour of immunological reactions and may help in diagnosis of ENT2 allergy ENT2END in the patients
1	The authors report two observations on patients with delayed reactions in whom intradermoreactions (IDR) and patch tests to a series of ionic and non ionic ENT1 PRC  ENT1END  were studied. After angiography by the venous route in patient n degree 1 a biphasic reaction with an immediate reaction ( ENT2 dyspnea ENT2END , loss of consciousness) and delayed macro-papular rash appeared, whilst patient n degree 2 developed a generalised sensation of heat, persistent pain at the site of injection immediately and a generalised macro-papular reaction after 24 hours
0	Oxidative stress is involved in several processes including cancer, aging and ENT1 cardiovascular disease ENT1END  and has been shown to potentiate the therapeutic effect of drugs such as ENT2 doxorubicin ENT2END
0	ENT1 Hydroxytyrosol  ENT1END  ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.Oxidative stress is involved in several processes including cancer, aging and ENT2 cardiovascular disease ENT2END , and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin
0	Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in ENT1 doxorubicin  ENT1END -induced ENT2 cardiotoxicity ENT2END in rats with breast cancer
0	Herein, we investigate whether doxorubicin-associated chronic ENT1 cardiac toxicity ENT1END can be ameliorated with the antioxidant ENT2 hydroxytyrosol ENT2END in rats with breast cancer
0	Hydroxytyrosol ameliorates oxidative stress and ENT1 mitochondrial dysfunction  ENT1END  in ENT2 doxorubicin ENT2END -induced cardiotoxicity in rats with breast cancer
0	ENT1 Hydroxytyrosol  ENT1END  ameliorates oxidative stress and ENT2 mitochondrial dysfunction ENT2END in doxorubicin-induced cardiotoxicity in rats with breast cancer
0	Oxidative stress is involved in several processes including ENT1 cancer  ENT1END  aging and cardiovascular disease, and has been shown to potentiate the therapeutic effect of drugs such as ENT2 doxorubicin ENT2END
0	ENT1 Hydroxytyrosol  ENT1END  ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.Oxidative stress is involved in several processes including ENT2 cancer ENT2END , aging and cardiovascular disease, and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin
0	Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in ENT1 doxorubicin  ENT1END -induced cardiotoxicity in rats with ENT2 breast cancer ENT2END
0	Herein, we investigate whether doxorubicin-associated chronic cardiac toxicity can be ameliorated with the antioxidant ENT1 hydroxytyrosol ENT1END  in rats with ENT2 breast cancer ENT2END
1	This study demonstrates that hydroxytyrosol protect rat ENT1 heart damage ENT1END provoked by ENT2 doxorubicin ENT2END decreasing oxidative damage and mitochondrial alterations
0	5mg/kg, 5days/week), doxorubicin (1mg/kg/week), and doxorubicin plus ENT1 hydroxytyrosol ENT1END  ENT2 Cardiac disturbances ENT2END at the cellular and mitochondrial level, mitochondrial electron transport chain complexes I-IV and apoptosis-inducing factor, and oxidative stress markers have been analyzed
1	CONCLUSIONS: Evidence is mounting that relates early-life ENT1 iAs ENT1END exposure and ENT2 cancer ENT2END development later in life
0	Mechanisms Underlying Latent Disease Risk Associated with Early-Life ENT1 Arsenic ENT1END  Exposure: Current Research Trends and Scientific Gaps.BACKGROUND: Millions of individuals worldwide, particularly those living in rural and developing areas, are exposed to harmful levels of inorganic arsenic (iAs) in their drinking water. Inorganic As exposure during key developmental periods is associated with a variety of adverse health effects including those that are evident in adulthood. There is considerable interest in identifying the molecular mechanisms that relate early-life iAs exposure to the development of these latent diseases, particularly in relationship to ENT2 cancer ENT2END
1	These findings demonstrate for the first time that a single high dose of ENT1 METH ENT1END induces long-lasting ENT2 depressive ENT2END -like behaviour in mice associated with a persistent disruption of frontostriatal dopaminergic and serotonergic homoeostasis
0	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and ENT1 serotonin ENT1END  observed at both 3 and 49 days post-administration. In parallel, another neurochemical feature of ENT2 depression ENT2END --astroglial dysfunction--was unaffected in the cortex and the striatal levels of the astrocytic protein marker, glial fibrillary acidic protein, were only transiently increased at 3 days
0	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and ENT1 HVA  ENT1END  tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration. In parallel, another neurochemical feature of ENT2 depression ENT2END --astroglial dysfunction--was unaffected in the cortex and the striatal levels of the astrocytic protein marker, glial fibrillary acidic protein, were only transiently increased at 3 days
0	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, ENT1 DOPAC  ENT1END and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration. In parallel, another neurochemical feature of ENT2 depression ENT2END --astroglial dysfunction--was unaffected in the cortex and the striatal levels of the astrocytic protein marker, glial fibrillary acidic protein, were only transiently increased at 3 days
0	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of ENT1 dopamine  ENT1END  DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration. In parallel, another neurochemical feature of ENT2 depression ENT2END --astroglial dysfunction--was unaffected in the cortex and the striatal levels of the astrocytic protein marker, glial fibrillary acidic protein, were only transiently increased at 3 days
0	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, ENT1 tyrosine  ENT1END hydroxylase and serotonin, observed at both 3 and 49 days post-administration. In parallel, another neurochemical feature of ENT2 depression ENT2END --astroglial dysfunction--was unaffected in the cortex and the striatal levels of the astrocytic protein marker, glial fibrillary acidic protein, were only transiently increased at 3 days
0	A single ENT1 neurotoxic  ENT1END  dose of ENT2 methamphetamine ENT2END induces a long-lasting depressive-like behaviour in mice
0	A single ENT1 neurotoxic  ENT1END  dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal. However, it is currently unknown if the acute toxic dosage of METH also causes a long-lasting depressive phenotype and persistent monoaminergic deficits. Thus, we now assessed the depressive-like behaviour in mice at early and long-term periods following a single high METH dose (30 mg/kg, i.p.). METH did not alter the motor function and procedural memory of mice as assessed by swimming speed and escape latency to find the platform in a cued version of the water maze task. However, METH significantly increased the immobility time in the tail suspension test at 3 and 49 days post-administration. This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and ENT2 serotonin ENT2END , observed at both 3 and 49 days post-administration
0	A single ENT1 neurotoxic  ENT1END  dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal. However, it is currently unknown if the acute toxic dosage of METH also causes a long-lasting depressive phenotype and persistent monoaminergic deficits. Thus, we now assessed the depressive-like behaviour in mice at early and long-term periods following a single high METH dose (30 mg/kg, i.p.). METH did not alter the motor function and procedural memory of mice as assessed by swimming speed and escape latency to find the platform in a cued version of the water maze task. However, METH significantly increased the immobility time in the tail suspension test at 3 and 49 days post-administration. This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and ENT2 HVA ENT2END , tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration
0	A single ENT1 neurotoxic  ENT1END  dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal. However, it is currently unknown if the acute toxic dosage of METH also causes a long-lasting depressive phenotype and persistent monoaminergic deficits. Thus, we now assessed the depressive-like behaviour in mice at early and long-term periods following a single high METH dose (30 mg/kg, i.p.). METH did not alter the motor function and procedural memory of mice as assessed by swimming speed and escape latency to find the platform in a cued version of the water maze task. However, METH significantly increased the immobility time in the tail suspension test at 3 and 49 days post-administration. This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, ENT2 DOPAC ENT2END and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration
0	A single ENT1 neurotoxic  ENT1END  dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal. However, it is currently unknown if the acute toxic dosage of METH also causes a long-lasting depressive phenotype and persistent monoaminergic deficits. Thus, we now assessed the depressive-like behaviour in mice at early and long-term periods following a single high METH dose (30 mg/kg, i.p.). METH did not alter the motor function and procedural memory of mice as assessed by swimming speed and escape latency to find the platform in a cued version of the water maze task. However, METH significantly increased the immobility time in the tail suspension test at 3 and 49 days post-administration. This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of ENT2 dopamine ENT2END , DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration
0	A single ENT1 neurotoxic  ENT1END  dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal. However, it is currently unknown if the acute toxic dosage of METH also causes a long-lasting depressive phenotype and persistent monoaminergic deficits. Thus, we now assessed the depressive-like behaviour in mice at early and long-term periods following a single high METH dose (30 mg/kg, i.p.). METH did not alter the motor function and procedural memory of mice as assessed by swimming speed and escape latency to find the platform in a cued version of the water maze task. However, METH significantly increased the immobility time in the tail suspension test at 3 and 49 days post-administration. This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, ENT2 tyrosine ENT2END hydroxylase and serotonin, observed at both 3 and 49 days post-administration
0	Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates ENT1 isoproterenol  ENT1END -induced acute ENT2 myocardial injury ENT2END in rats
0	The protective role of ENT1 betaine ENT1END on ENT2 myocardial damage ENT2END was further confirmed by histopathological examination
1	Oral administration of betaine (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left ENT1 ventricular remodeling ENT1END  Western blot analysis showed that ENT2 isoproterenol ENT2END -induced phosphorylation of STAT3 was maintained or further enhanced by betaine treatment in myocardium
0	Oral administration of ENT1 betaine  ENT1END (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left ENT2 ventricular remodeling ENT2END
1	In summary, our results showed that betaine pretreatment attenuated ENT1 isoproterenol ENT1END induced acute ENT2 myocardial ischemia ENT2END via the regulation of STAT3 and apoptotic pathways
0	The present study was designed to investigate the cardioprotective effects of ENT1 betaine ENT1END on acute ENT2 myocardial ischemia ENT2END induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect
0	Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the ENT1 MK-801 ENT1END treated group, the pyramidal cells of hippocampus appeared darker than normal. In all treatments, granule cells of the dentate gyrus were not affected. 4. These results indicate that ENT2 status epilepticus ENT2END induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism
0	ENT1 Pentobarbital  ENT1END  scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal. In all treatments, granule cells of the dentate gyrus were not affected. 4. These results indicate that ENT2 status epilepticus ENT2END induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism
0	These results indicate that ENT1 status epilepticus ENT1END  induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory ENT2 NMDA ENT2END receptor-mediated mechanism
1	These results indicate that ENT1 status epilepticus ENT1END  induced by ENT2 pilocarpine ENT2END is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism
0	Pentobarbital, ENT1 scopolamine  ENT1END and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal. In all treatments, granule cells of the dentate gyrus were not affected. 4. These results indicate that ENT2 status epilepticus ENT2END induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism
1	Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic ENT1 seizure ENT1END  ENT2 MK-801 ENT2END treatment augmented the electrographic seizure induced by pilocarpine
0	Intraperitoneal injection of pilocarpine (400 mg/kg) induced ENT1 tonic and clonic seizure ENT1END  Scopolamine (10 mg/kg) and ENT2 pentobarbital ENT2END (5 mg/kg) prevented development of pilocarpine-induced behavioral seizure but MK-801 (0
1	The authors examined the anticonvulsant effects of MK-801 on the ENT1 pilocarpine ENT1END induced ENT2 seizure ENT2END model
0	Intraperitoneal injection of pilocarpine (400 mg/kg) induced ENT1 tonic and clonic seizure ENT1END . ENT2 Scopolamine ENT2END (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of pilocarpine-induced behavioral seizure but MK-801 (0
0	Pentobarbital, scopolamine and ENT1 MK-801 ENT1END protected the ENT2 brain damage ENT2END by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal
0	ENT1 Pentobarbital  ENT1END , scopolamine and MK-801 protected the ENT2 brain damage ENT2END by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal
0	These results indicate that status epilepticus induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause ENT1 brain damage  ENT1END through an excitatory ENT2 NMDA ENT2END receptor-mediated mechanism
0	Pentobarbital, scopolamine and MK-801 protected the ENT1 brain damage ENT1END  by ENT2 pilocarpine ENT2END , though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal
0	Pentobarbital, ENT1 scopolamine  ENT1END  and MK-801 protected the ENT2 brain damage ENT2END by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal
0	Pilocarpine produced ENT1 neuronal death  ENT1END in the hippocampus, which showed pyknotic changes. Pentobarbital, scopolamine and ENT2 MK-801 ENT2END protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal
0	Pilocarpine produced ENT1 neuronal death  ENT1END  in the hippocampus, which showed pyknotic changes. ENT2 Pentobarbital ENT2END , scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal
0	Pilocarpine produced ENT1 neuronal death  ENT1END  in the hippocampus, which showed pyknotic changes. Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal. In all treatments, granule cells of the dentate gyrus were not affected. 4. These results indicate that status epilepticus induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory ENT2 NMDA ENT2END receptor-mediated mechanism
1	ENT1 Pilocarpine  ENT1END produced ENT2 neuronal death ENT2END in the hippocampus, which showed pyknotic changes
0	Pilocarpine produced ENT1 neuronal death  ENT1END  in the hippocampus, which showed pyknotic changes. Pentobarbital, ENT2 scopolamine ENT2END and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal
1	A case of fatal ENT1 aplastic anemia ENT1END due to ENT2 carbamazepine ENT2END treatment in an epileptic woman is reported
0	Despite concerns of fatal ENT1 bone marrow toxicity ENT1END due to ENT2 carbamazepine ENT2END , this is only the fourth documented and published report
0	A case of fatal aplastic anemia due to ENT1 carbamazepine ENT1END  treatment in an ENT2 epileptic ENT2END woman is reported
0	The case discussed herein initially appeared to be neurogenic diabetes insipidus ( ENT1 DI ENT1END  secondary to a traumatic brain injury. The nursing staff, by reviewing the patient's health history with his family, discovered a history of polydipsia and long-standing ENT2 lithium ENT2END use
0	The nursing staff, by reviewing the patient's health history with his family, discovered a history of ENT1 polydipsia  ENT1END and long-standing ENT2 lithium ENT2END use
0	By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his ENT1 lithium ENT1END induced nephrogenic DI and developed neurogenic DI secondary to ENT2 brain trauma ENT2END
1	By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his ENT1 lithium ENT1END -induced ENT2 nephrogenic DI ENT2END and developed neurogenic DI secondary to brain trauma
0	3-3% of diet weight) of certain amino derivatives of ENT1 caproate ENT1END resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, ENT2 glucosuria ENT2END
0	3-3% of diet weight) of certain ENT1 amino  ENT1END derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, ENT2 glucosuria ENT2END
0	3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, ENT1 glucosuria ENT1END . Effective compounds included norleucine, norvaline, glutamate, epsilon-aminocaproate, ENT2 methionine ENT2END , and leucine
0	3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated ENT1 glucose  ENT1END tolerance curve and, occasionally, ENT2 glucosuria ENT2END
0	3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, ENT1 glucosuria ENT1END . Effective compounds included norleucine, norvaline, ENT2 glutamate ENT2END , epsilon-aminocaproate, methionine, and leucine
0	3-3% of diet weight) of certain amino derivatives of ENT1 caproate ENT1END  resulted in ENT2 hyperglycemia ENT2END , an elevated glucose tolerance curve and, occasionally, glucosuria
1	ENT1 Hyperglycemic  ENT1END  effect of ENT2 amino ENT2END compounds structurally related to caproate in rats
0	3-3% of diet weight) of certain amino derivatives of caproate resulted in ENT1 hyperglycemia  ENT1END , an elevated glucose tolerance curve and, occasionally, glucosuria. Effective compounds included norleucine, norvaline, glutamate, epsilon-aminocaproate, ENT2 methionine ENT2END , and leucine
0	3-3% of diet weight) of certain amino derivatives of caproate resulted in ENT1 hyperglycemia  ENT1END , an elevated ENT2 glucose ENT2END tolerance curve and, occasionally, glucosuria
0	3-3% of diet weight) of certain amino derivatives of caproate resulted in ENT1 hyperglycemia  ENT1END , an elevated glucose tolerance curve and, occasionally, glucosuria. Effective compounds included norleucine, norvaline, ENT2 glutamate ENT2END , epsilon-aminocaproate, methionine, and leucine
1	Inhibition of nuclear factor-kappaB activation attenuates ENT1 tubulointerstitial nephritis  ENT1END  induced by ENT2 gentamicin ENT2END
0	Treatment with ENT1 PDTC ENT1END reduced the functional and structural changes induced by gentamicin. CONCLUSIONS: These data show that inhibition of NF-kappaB activation attenuates ENT2 tubulointerstitial nephritis ENT2END induced by gentamicin
0	RESULTS: Gentamicin-treated rats presented a transitory increase in plasma ENT1 creatinine  ENT1END levels. Increased ED-1, MAP kinases and NF-kappaB staining were also observed in the renal cortex from all gentamicin-treated rats compared to control (p < 0.05). The animals killed on day 30 also presented fibrosis in the renal cortex despite the recovery of renal function. Treatment with PDTC reduced the functional and structural changes induced by gentamicin. CONCLUSIONS: These data show that inhibition of NF-kappaB activation attenuates ENT2 tubulointerstitial nephritis ENT2END induced by gentamicin
0	Inhibition of nuclear factor-kappaB activation attenuates ENT1 tubulointerstitial nephritis ENT1END  induced by gentamicin.BACKGROUND: Animals treated with gentamicin can show residual areas of interstitial fibrosis in the renal cortex. This study investigated the expression of nuclear factor-kappaB (NF-kappaB), mitogen-activated protein (MAP) kinases and macrophages in the renal cortex and structural and functional renal changes of rats treated with gentamicin or gentamicin + pyrrolidine dithiocarbamate (PDTC), an NF-kappaB inhibitor. METHODS: 38 female Wistar rats were injected with gentamicin, 40 mg/kg, twice a day for 9 days, 38 with gentamicin + PDTC, and 28 with 0.15 M ENT2 NaCl ENT2END solution
0	BACKGROUND: Animals treated with ENT1 gentamicin ENT1END can show residual areas of interstitial ENT2 fibrosis ENT2END in the renal cortex
0	The animals killed on day 30 also presented ENT1 fibrosis  ENT1END in the renal cortex despite the recovery of renal function. Treatment with ENT2 PDTC ENT2END reduced the functional and structural changes induced by gentamicin
0	RESULTS: Gentamicin-treated rats presented a transitory increase in plasma ENT1 creatinine  ENT1END  levels. Increased ED-1, MAP kinases and NF-kappaB staining were also observed in the renal cortex from all gentamicin-treated rats compared to control (p < 0.05). The animals killed on day 30 also presented ENT2 fibrosis ENT2END in the renal cortex despite the recovery of renal function
0	BACKGROUND: Animals treated with gentamicin can show residual areas of interstitial ENT1 fibrosis  ENT1END  in the renal cortex. This study investigated the expression of nuclear factor-kappaB (NF-kappaB), mitogen-activated protein (MAP) kinases and macrophages in the renal cortex and structural and functional renal changes of rats treated with gentamicin or gentamicin + pyrrolidine dithiocarbamate (PDTC), an NF-kappaB inhibitor. METHODS: 38 female Wistar rats were injected with gentamicin, 40 mg/kg, twice a day for 9 days, 38 with gentamicin + PDTC, and 28 with 0.15 M ENT2 NaCl ENT2END solution
1	Five patients complained of ENT1 paresthesias ENT1END and leg cramps. After ENT2 thalidomide ENT2END treatment, sural SAP amplitude recovered in 3 patients
1	ENT1 Thalidomide  ENT1END  and ENT2 sensory neurotoxicity ENT2END : a neurophysiological study
1	Five patients complained of paresthesias and leg ENT1 cramps  ENT1END  After ENT2 thalidomide ENT2END treatment, sural SAP amplitude recovered in 3 patients
0	The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the ENT1 neurotoxic ENT1END potential of ENT2 thalidomide ENT2END and the recovery capacity of sensory fibres after discontinuation of treatment
0	The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus ( ENT1 CLE ENT1END  treated with ENT2 thalidomide ENT2END and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment
0	Persistent sterile leukocyturia is associated with impaired renal function in ENT1 human immunodeficiency virus type 1-infected  ENT1END  children treated with ENT2 indinavir ENT2END
0	DESIGN: A prospective study to monitor indinavir-related nephrotoxicity in a cohort of 30 ENT1 human immunodeficiency virus type 1-infected ENT1END children treated with indinavir. METHODS: Urinary pH, albumin, ENT2 creatinine ENT2END , the presence of erythrocytes, leukocytes, bacteria and crystals, and culture were analyzed every 3 months for 96 weeks
0	The impairment of the renal function in these children occurred in the absence of clinical symptoms of ENT1 nephrolithiasis ENT1END  ENT2 Indinavir ENT2END -associated nephrotoxicity must be monitored closely, especially in children with risk factors such as persistent sterile leukocyturia, age <5
0	Children with persistent sterile leukocyturia more frequently had an increase in serum ENT1 creatinine  ENT1END levels of >50% above normal. Younger children have an additional risk for renal complications. The impairment of the renal function in these children occurred in the absence of clinical symptoms of ENT2 nephrolithiasis ENT2END
1	DESIGN: A prospective study to monitor ENT1 indinavir ENT1END related ENT2 nephrotoxicity ENT2END in a cohort of 30 human immunodeficiency virus type 1-infected children treated with indinavir
0	In 4 children, indinavir was discontinued because of ENT1 nephrotoxicity ENT1END  Subsequently, the serum ENT2 creatinine ENT2END levels decreased, the urine albumin/creatinine ratios returned to zero, and the leukocyturia disappeared within 3 months
1	Steady-state pharmacokinetics of indinavir were done at week 4 after the initiation of ENT1 indinavir ENT1END  RESULTS: The cumulative incidence of persistent sterile leukocyturia (> or =75 cells/ micro L in at least 2 consecutive visits) after 96 weeks was 53%. Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin/creatinine ratio and by microscopic ENT2 hematuria ENT2END
0	Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin/ ENT1 creatinine  ENT1END ratio and by microscopic ENT2 hematuria ENT2END
0	075mg/kg dose of ENT1 Fazadinium ENT1END  did not influence the occurrence of scoline ENT2 pain ENT2END
0	Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or ENT1 bromide ENT1END , affected the incidence of scoline ENT2 pain ENT2END
0	075mg/kg dose of Fazadinium) did not influence the occurrence of scoline ENT1 pain  ENT1END . Neither the type of induction agent ( ENT2 Althesin ENT2END or Thiopentone) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain
0	075mg/kg dose of Fazadinium) did not influence the occurrence of scoline ENT1 pain ENT1END . Neither the type of induction agent (Althesin or ENT2 Thiopentone ENT2END ) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain
1	Contrary to an earlier report by Coxon, ENT1 scoline ENT1END ENT2 pain ENT2END occurs in African negroes
0	Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used ( ENT1 chloride  ENT1END or bromide), affected the incidence of scoline ENT2 pain ENT2END
0	The abolition of muscle ENT1 fasciculations  ENT1END (by 0.075mg/kg dose of ENT2 Fazadinium ENT2END ) did not influence the occurrence of scoline pain
0	The abolition of muscle ENT1 fasciculations  ENT1END  (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain. Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or ENT2 bromide ENT2END ), affected the incidence of scoline pain
0	The abolition of muscle ENT1 fasciculations ENT1END  (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain. Neither the type of induction agent ENT2 Althesin ENT2END or Thiopentone) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain
0	The abolition of muscle ENT1 fasciculations  ENT1END  (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain. Neither the type of induction agent (Althesin or ENT2 Thiopentone ENT2END ) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain
1	The abolition of muscle ENT1 fasciculations ENT1END  (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of ENT2 scoline ENT2END pain
0	The abolition of muscle ENT1 fasciculations ENT1END  (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain. Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used ENT2 chloride ENT2END or bromide), affected the incidence of scoline pain
1	Previous studies indicate that ENT1 ecstasy ENT1END users have marked and persistent neurocognitive and ENT2 sleep-related impairments ENT2END
1	We suggest that ecstasy-associated dysfunction in fronto-temporal circuitry may underlie overnight consolidation ENT1 memory impairments ENT1END in regular ENT2 ecstasy ENT2END users
0	If confirmed in controlled trials, the long-term results of this open, non-randomized study might indicate that the analgesic effect of ENT1 capsaicin ENT1END in ENT2 PHN ENT2END is mediated by both interference with neuropeptide metabolism and morphological changes (perhaps degeneration) of nociceptive afferents
1	025% ENT1 capsaicin ENT1END cream for 8 weeks. During therapy the patients rated their ENT2 pain ENT2END on a visual analogue scale (VAS) and a verbal outcome scale
1	8%) discontinued therapy due to side-effects such as intolerable ENT1 capsaicin ENT1END induced burning sensations (4) or ENT2 mastitis ENT2END (1); 15 (38
0	In a series of five experiments, the modulating role of naloxone on a scopolamine-induced ENT1 retention deficit ENT1END in a passive avoidance paradigm was investigated in mice. Scopolamine, but not ENT2 methyl scopolamine ENT2END (1 and 3 mg/kg), induced an amnesia as measured by latency and duration parameters
0	In a series of five experiments, the modulating role of ENT1 naloxone  ENT1END on a scopolamine-induced ENT2 retention deficit ENT2END in a passive avoidance paradigm was investigated in mice
0	3, 1, 3, and 10 mg/kg) injected prior to training attenuated the ENT1 retention deficit ENT1END with a peak of activity at 3 mg/kg. The effect of naloxone could be antagonized with ENT2 morphine ENT2END (1, 3, and 10 mg/kg), demonstrating the opioid specificity of the naloxone effect
0	In a series of five experiments, the modulating role of naloxone on a ENT1 scopolamine  ENT1END induced ENT2 retention deficit ENT2END in a passive avoidance paradigm was investigated in mice
0	Scopolamine, but not ENT1 methyl scopolamine ENT1END  (1 and 3 mg/kg), induced an ENT2 amnesia ENT2END as measured by latency and duration parameters
0	Reversal of scopolamine-induced ENT1 amnesia  ENT1END  of passive avoidance by pre- and post-training ENT2 naloxone ENT2END
0	The effect of naloxone could be antagonized with ENT1 morphine ENT1END  (1, 3, and 10 mg/kg), demonstrating the opioid specificity of the naloxone effect. Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the scopolamine-induced ENT2 amnesia ENT2END
1	Reversal of ENT1 scopolamine  ENT1END -induced ENT2 amnesia ENT2END of passive avoidance by pre- and post-training naloxone
0	Scopolamine, but not ENT1 methyl scopolamine ENT1END  (1 and 3 mg/kg), induced an amnesia as measured by latency and duration parameters. Naloxone (0.3, 1, 3, and 10 mg/kg) injected prior to training attenuated the retention deficit with a peak of activity at 3 mg/kg. The effect of naloxone could be antagonized with morphine (1, 3, and 10 mg/kg), demonstrating the opioid specificity of the naloxone effect. Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the scopolamine-induced amnesia. Control experiments indicated that neither an increase in ENT2 pain ENT2END sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit
0	Control experiments indicated that neither an increase in ENT1 pain ENT1END  sensitivity (pre-training ENT2 naloxone ENT2END ) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit
0	The effect of naloxone could be antagonized with ENT1 morphine  ENT1END  (1, 3, and 10 mg/kg), demonstrating the opioid specificity of the naloxone effect. Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the scopolamine-induced amnesia. Control experiments indicated that neither an increase in ENT2 pain ENT2END sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit
0	Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the ENT1 scopolamine  ENT1END induced amnesia. Control experiments indicated that neither an increase in ENT2 pain ENT2END sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit
0	A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of timolol maleate and 25 mg of ENT1 hydrochlorothiazide ENT1END  administered twice daily for one month to ENT2 hypertensive ENT2END patients
0	A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of ENT1 timolol maleate  ENT1END and 25 mg of hydrochlorothiazide, administered twice daily for one month to ENT2 hypertensive ENT2END patients
1	Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of timolol- ENT1 hydrochlorothiazide ENT1END therapy (P less than 0.01, both comparisons). Age, race, and sex appeared to have no influence on the decrease in blood pressure. The antihypertensive effect of the drug was greater in patients with more severe hypertension. Overall, 1,453 patients experienced a total of 2,658 adverse events, the most common being fatigue, dizziness, and ENT2 weakness ENT2END
1	Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of ENT1 timolol  ENT1END hydrochlorothiazide therapy (P less than 0.01, both comparisons). Age, race, and sex appeared to have no influence on the decrease in blood pressure. The antihypertensive effect of the drug was greater in patients with more severe hypertension. Overall, 1,453 patients experienced a total of 2,658 adverse events, the most common being fatigue, dizziness, and ENT2 weakness ENT2END
1	Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of timolol- ENT1 hydrochlorothiazide ENT1END  therapy (P less than 0.01, both comparisons). Age, race, and sex appeared to have no influence on the decrease in blood pressure. The antihypertensive effect of the drug was greater in patients with more severe hypertension. Overall, 1,453 patients experienced a total of 2,658 adverse events, the most common being ENT2 fatigue ENT2END , dizziness, and weakness
1	Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of ENT1 timolol  ENT1END -hydrochlorothiazide therapy (P less than 0.01, both comparisons). Age, race, and sex appeared to have no influence on the decrease in blood pressure. The antihypertensive effect of the drug was greater in patients with more severe hypertension. Overall, 1,453 patients experienced a total of 2,658 adverse events, the most common being ENT2 fatigue ENT2END , dizziness, and weakness
1	Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of timolol- ENT1 hydrochlorothiazide ENT1END  therapy (P less than 0.01, both comparisons). Age, race, and sex appeared to have no influence on the decrease in blood pressure. The antihypertensive effect of the drug was greater in patients with more severe hypertension. Overall, 1,453 patients experienced a total of 2,658 adverse events, the most common being fatigue, ENT2 dizziness ENT2END , and weakness
1	Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of ENT1 timolol  ENT1END -hydrochlorothiazide therapy (P less than 0.01, both comparisons). Age, race, and sex appeared to have no influence on the decrease in blood pressure. The antihypertensive effect of the drug was greater in patients with more severe hypertension. Overall, 1,453 patients experienced a total of 2,658 adverse events, the most common being fatigue, ENT2 dizziness ENT2END , and weakness
0	OBJECTIVE: To determine the maximum tolerated dose (MTD) of carbetocin (a long-acting synthetic analogue of ENT1 oxytocin ENT1END , when administered immediately after vaginal delivery at term. MATERIALS AND METHODS: Carbetocin was given as an intramuscular injection immediately after the birth of the infant in 45 healthy women with normal singleton pregnancies who delivered vaginally at term. Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg carbetocin were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: ENT2 hyper- or hypotension ENT2END (three), severe abdominal pain (0), vomiting (0) and retained placenta (four)
1	Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg ENT1 carbetocin  ENT1END were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: ENT2 hyper- or hypotension ENT2END (three), severe abdominal pain (0), vomiting (0) and retained placenta (four)
0	OBJECTIVE: To determine the maximum tolerated dose (MTD) of carbetocin (a long-acting synthetic analogue of ENT1 oxytocin ENT1END ), when administered immediately after vaginal delivery at term. MATERIALS AND METHODS: Carbetocin was given as an intramuscular injection immediately after the birth of the infant in 45 healthy women with normal singleton pregnancies who delivered vaginally at term. Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg carbetocin were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: ENT2 hyper- or hypotension ENT2END (three), severe abdominal pain (0), vomiting (0) and retained placenta (four)
1	Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg ENT1 carbetocin  ENT1END  were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: ENT2 hyper- or hypotension ENT2END (three), severe abdominal pain (0), vomiting (0) and retained placenta (four)
0	OBJECTIVE: To determine the maximum tolerated dose (MTD) of carbetocin (a long-acting synthetic analogue of ENT1 oxytocin ENT1END ), when administered immediately after vaginal delivery at term. MATERIALS AND METHODS: Carbetocin was given as an intramuscular injection immediately after the birth of the infant in 45 healthy women with normal singleton pregnancies who delivered vaginally at term. Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg carbetocin were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: hyper- or hypotension (three), severe abdominal pain (0), ENT2 vomiting ENT2END (0) and retained placenta (four)
1	Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg ENT1 carbetocin  ENT1END  were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: hyper- or hypotension (three), severe abdominal pain (0), ENT2 vomiting ENT2END (0) and retained placenta (four)
0	OBJECTIVE: To determine the maximum tolerated dose (MTD) of carbetocin (a long-acting synthetic analogue of ENT1 oxytocin ENT1END ), when administered immediately after vaginal delivery at term. MATERIALS AND METHODS: Carbetocin was given as an intramuscular injection immediately after the birth of the infant in 45 healthy women with normal singleton pregnancies who delivered vaginally at term. Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg carbetocin were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: hyper- or hypotension (three), severe ENT2 abdominal pain ENT2END (0), vomiting (0) and retained placenta (four)
1	Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg ENT1 carbetocin  ENT1END  were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: hyper- or hypotension (three), severe ENT2 abdominal pain ENT2END (0), vomiting (0) and retained placenta (four)
0	OBJECTIVE: To determine the maximum tolerated dose (MTD) of carbetocin (a long-acting synthetic analogue of ENT1 oxytocin ENT1END ), when administered immediately after vaginal delivery at term. MATERIALS AND METHODS: Carbetocin was given as an intramuscular injection immediately after the birth of the infant in 45 healthy women with normal singleton pregnancies who delivered vaginally at term. Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg carbetocin were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: hyper- or hypotension (three), severe abdominal pain (0), vomiting (0) and ENT2 retained placenta ENT2END (four)
1	Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg ENT1 carbetocin  ENT1END  were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: hyper- or hypotension (three), severe abdominal pain (0), vomiting (0) and ENT2 retained placenta ENT2END (four)
0	OBJECTIVE: To determine the maximum tolerated dose (MTD) of carbetocin (a long-acting synthetic analogue of ENT1 oxytocin ENT1END ), when administered immediately after vaginal delivery at term. MATERIALS AND METHODS: Carbetocin was given as an intramuscular injection immediately after the birth of the infant in 45 healthy women with normal singleton pregnancies who delivered vaginally at term. Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg carbetocin were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: hyper- or hypotension (three), severe abdominal pain (0), vomiting (0) and retained placenta (four). Serious adverse events occurred in seven women: six cases with ENT2 blood loss ENT2END > or = 1000 ml, four cases of manual placenta removal, five cases of additional oxytocics administration and five cases of blood transfusion
1	Four out of six cases with ENT1 blood loss ENT1END > or = 1000 ml occurred in the 200 microg group. The majority of additional administration of oxytocics (4/5) and blood transfusion (3/5) occurred in the dose groups of 200 microg. All retained placentae were found in the group of 200 microg. CONCLUSION: The MTD was calculated to be at 200 microg ENT2 carbetocin ENT2END
0	Serum levels of ENT1 tumor ENT1END necrosis factor-alpha and interferon-gamma were also determined by ELISA. RESULTS: Serum sFas was significantly increased in patients with acute liver failure (median, 26.8 U/mL; range, 6.9-52.7 U/mL) compared to the normal controls (median, 8.6 U/mL; range, 6.5-12.0 U/mL, P < 0.0001). Levels were significantly greater in patients with acute liver failure due to ENT2 paracetamol ENT2END overdose (median, 28
0	A significant correlation was observed between serum sFas levels and ENT1 aspartate ENT1END aminotransferase (r = 0.613, P < 0.01). CONCLUSIONS: The increased concentration of sFas in serum of patients with acute liver failure may reflect activation of Fas-mediated apoptosis in the liver and this together with increased ENT2 tumor ENT2END necrosis factor-alpha may be an important factor in liver cell loss
0	Levels were significantly greater in patients with acute liver failure due to ENT1 paracetamol ENT1END  overdose (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E ENT2 hepatitis ENT2END (median, 12
0	7 U/mL, n = 17) than those due to non-A to E ENT1 hepatitis  ENT1END  (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01). There was no relationship of sFas to eventual outcome in the patients. A significant correlation was observed between serum sFas levels and ENT2 aspartate ENT2END aminotransferase (r = 0
0	Increased serum soluble Fas in patients with acute liver failure due to ENT1 paracetamol ENT1END ENT2 overdose ENT2END
0	Levels were significantly greater in patients with acute liver failure due to paracetamol ENT1 overdose  ENT1END (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E hepatitis (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01). There was no relationship of sFas to eventual outcome in the patients. A significant correlation was observed between serum sFas levels and ENT2 aspartate ENT2END aminotransferase (r = 0
0	Serum levels of tumor ENT1 necrosis  ENT1END factor-alpha and interferon-gamma were also determined by ELISA. RESULTS: Serum sFas was significantly increased in patients with acute liver failure (median, 26.8 U/mL; range, 6.9-52.7 U/mL) compared to the normal controls (median, 8.6 U/mL; range, 6.5-12.0 U/mL, P < 0.0001). Levels were significantly greater in patients with acute liver failure due to ENT2 paracetamol ENT2END overdose (median, 28
0	A significant correlation was observed between serum sFas levels and ENT1 aspartate ENT1END  aminotransferase (r = 0.613, P < 0.01). CONCLUSIONS: The increased concentration of sFas in serum of patients with acute liver failure may reflect activation of Fas-mediated apoptosis in the liver and this together with increased tumor ENT2 necrosis ENT2END factor-alpha may be an important factor in liver cell loss
1	Increased serum soluble Fas in patients with ENT1 acute liver failure  ENT1END  due to ENT2 paracetamol ENT2END overdose
0	A significant correlation was observed between serum sFas levels and ENT1 aspartate ENT1END  aminotransferase (r = 0.613, P < 0.01). CONCLUSIONS: The increased concentration of sFas in serum of patients with ENT2 acute liver failure ENT2END may reflect activation of Fas-mediated apoptosis in the liver and this together with increased tumor necrosis factor-alpha may be an important factor in liver cell loss
1	ENT1 Toxic hepatitis  ENT1END  induced by ENT2 disulfiram ENT2END in a non-alcoholic
0	The mechanism whereby the ENT1 hepatitis ENT1END was induced is not known. However, the patient tolerated well an alternative reverse transcriptase inhibitor, ENT2 2'3' dideoxyinosine ENT2END
1	ENT1 Zidovudine  ENT1END -induced ENT2 hepatitis ENT2END
0	However, the patient tolerated well an alternative reverse transcriptase inhibitor, ENT1 2'3' dideoxyinosine ENT1END . Physicians caring for patients with ENT2 AIDS ENT2END should be aware of this hitherto rarely reported complication
0	A case of acute hepatitis induced by ENT1 zidovudine ENT1END in a 38-year-old patient with ENT2 AIDS ENT2END is presented
0	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of ENT1 lidocaine ENT1END in patients with cocaine-associated MI was not associated with significant ENT2 cardiovascular or central nervous system toxicity ENT2END
0	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with ENT1 cocaine  ENT1END associated MI was not associated with significant ENT2 cardiovascular or central nervous system toxicity ENT2END
0	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine ENT1 toxicity  ENT1END  the use of ENT2 lidocaine ENT2END in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity
0	CONCLUSION: Despite theoretical concerns that lidocaine may enhance ENT1 cocaine ENT1END ENT2 toxicity ENT2END , the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity
0	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of ENT1 lidocaine ENT1END  in patients with cocaine-associated MI was not associated with significant ENT2 cardiovascular or central nervous system toxicity ENT2END
0	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with ENT1 cocaine  ENT1END -associated MI was not associated with significant ENT2 cardiovascular or central nervous system toxicity ENT2END
0	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ENT1 ventricular tachycardia ENT1END  or ventricular fibrillation; or experienced seizures after administration of ENT2 lidocaine ENT2END (95% confidence interval, 0% to 11%)
0	RESULTS: Of 29 patients who received lidocaine in the setting of ENT1 cocaine  ENT1END associated MI, no patient died; exhibited bradydysrhythmias, ENT2 ventricular tachycardia ENT2END , or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%)
0	RESULTS: Of 29 patients who received ENT1 lidocaine ENT1END in the setting of cocaine-associated MI, no patient died; exhibited ENT2 bradydysrhythmias ENT2END , ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%)
0	RESULTS: Of 29 patients who received lidocaine in the setting of ENT1 cocaine  ENT1END -associated MI, no patient died; exhibited ENT2 bradydysrhythmias ENT2END , ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%)
0	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ENT1 ventricular fibrillation  ENT1END  or experienced seizures after administration of ENT2 lidocaine ENT2END (95% confidence interval, 0% to 11%)
0	RESULTS: Of 29 patients who received lidocaine in the setting of ENT1 cocaine  ENT1END -associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ENT2 ventricular fibrillation ENT2END ; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%)
0	PARTICIPANTS: Patients with cocaine-associated ENT1 MI ENT1END who received ENT2 lidocaine ENT2END in the emergency department
1	PARTICIPANTS: Patients with ENT1 cocaine  ENT1END associated ENT2 MI ENT2END who received lidocaine in the emergency department
0	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced ENT1 seizures  ENT1END after administration of ENT2 lidocaine ENT2END (95% confidence interval, 0% to 11%)
0	RESULTS: Of 29 patients who received lidocaine in the setting of ENT1 cocaine  ENT1END -associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced ENT2 seizures ENT2END after administration of lidocaine (95% confidence interval, 0% to 11%)
0	In a 38-year-old male patient suffering from a severe ENT1 postzosteric ENT1END trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia. The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on ENT2 muscarine ENT2END receptors
0	In a 38-year-old male patient suffering from a severe ENT1 postzosteric ENT1END  trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia. The heart rate was back to normal within 12 hours upon administration of ENT2 orciprenaline ENT2END under cardiac monitoring in an intensive care unit
0	In a 38-year-old male patient suffering from a severe ENT1 postzosteric ENT1END  trigeminal neuralgia, intravenous application of 10 mg ENT2 biperiden lactate ENT2END led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia
0	Bradycardia due to ENT1 biperiden  ENT1END .In a 38-year-old male patient suffering from a severe ENT2 postzosteric ENT2END trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia
0	In a 38-year-old male patient suffering from a severe ENT1 postzosteric ENT1END  trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia. The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of ENT2 atropine ENT2END -like drugs on muscarine receptors
0	In a 38-year-old male patient suffering from a severe postzosteric ENT1 trigeminal neuralgia  ENT1END  intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia. The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on ENT2 muscarine ENT2END receptors
0	In a 38-year-old male patient suffering from a severe postzosteric ENT1 trigeminal neuralgia  ENT1END , intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia. The heart rate was back to normal within 12 hours upon administration of ENT2 orciprenaline ENT2END under cardiac monitoring in an intensive care unit
0	In a 38-year-old male patient suffering from a severe postzosteric ENT1 trigeminal neuralgia  ENT1END , intravenous application of 10 mg ENT2 biperiden lactate ENT2END led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia
0	Bradycardia due to ENT1 biperiden  ENT1END .In a 38-year-old male patient suffering from a severe postzosteric ENT2 trigeminal neuralgia ENT2END , intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia
0	In a 38-year-old male patient suffering from a severe postzosteric ENT1 trigeminal neuralgia  ENT1END , intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia. The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of ENT2 atropine ENT2END -like drugs on muscarine receptors
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and ENT1 dysphagia  ENT1END  The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on ENT2 muscarine ENT2END receptors
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and ENT1 dysphagia  ENT1END . The heart rate was back to normal within 12 hours upon administration of ENT2 orciprenaline ENT2END under cardiac monitoring in an intensive care unit
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg ENT1 biperiden lactate  ENT1END  led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and ENT2 dysphagia ENT2END
1	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and ENT1 dysphagia ENT1END . The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by ENT2 biperiden ENT2END is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and ENT1 dysphagia  ENT1END . The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of ENT2 atropine ENT2END -like drugs on muscarine receptors
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, ENT1 dysarthria  ENT1END  and dysphagia. The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on ENT2 muscarine ENT2END receptors
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, ENT1 dysarthria  ENT1END , and dysphagia. The heart rate was back to normal within 12 hours upon administration of ENT2 orciprenaline ENT2END under cardiac monitoring in an intensive care unit
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg ENT1 biperiden lactate  ENT1END  led to a long-lasting paradoxical reaction characterized by considerable bradycardia, ENT2 dysarthria ENT2END , and dysphagia
1	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, ENT1 dysarthria  ENT1END , and dysphagia. The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by ENT2 biperiden ENT2END is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, ENT1 dysarthria  ENT1END , and dysphagia. The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of ENT2 atropine ENT2END -like drugs on muscarine receptors
0	ENT1 Bradycardia  ENT1END induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on ENT2 muscarine ENT2END receptors
0	The heart rate was back to normal within 12 hours upon administration of ENT1 orciprenaline  ENT1END  under cardiac monitoring in an intensive care unit. ENT2 Bradycardia ENT2END induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg ENT1 biperiden lactate ENT1END  led to a long-lasting paradoxical reaction characterized by considerable ENT2 bradycardia ENT2END , dysarthria, and dysphagia
1	ENT1 Bradycardia  ENT1END  due to ENT2 biperiden ENT2END
0	ENT1 Bradycardia  ENT1END  induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of ENT2 atropine ENT2END -like drugs on muscarine receptors
0	A 69-year-old man operated for acute cholecystitis under ENT1 methoxyflurane ENT1END anesthesia developed postoperatively a ENT2 hepatic insufficiency syndrome ENT2END and renal tubular acidosis
1	ENT1 Hepatitis  ENT1END  and renal tubular acidosis after anesthesia with ENT2 methoxyflurane ENT2END
0	A 69-year-old man operated for acute cholecystitis under ENT1 methoxyflurane ENT1END  anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis. Massive ENT2 bleeding ENT2END appeared during surgery which lasted for six hours
0	A 69-year-old man operated for ENT1 acute cholecystitis  ENT1END under ENT2 methoxyflurane ENT2END anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis
1	Hepatitis and ENT1 renal tubular acidosis  ENT1END  after anesthesia with ENT2 methoxyflurane ENT2END
0	Although the patient recovered, he experienced permanent vision and hearing loss, as well as ENT1 end-stage renal disease ENT1END  CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with ENT2 argatroban ENT2END and CDT with alteplase
0	Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENT1 warfarin  ENT1END for long-term anticoagulation. Although the patient recovered, he experienced permanent vision and hearing loss, as well as ENT2 end-stage renal disease ENT2END
1	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and ENT1 pulmonary embolism ENT1END secondary to ENT2 heparin ENT2END -induced thrombocytopenia
0	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and ENT1 pulmonary embolism ENT1END  secondary to heparin-induced thrombocytopenia. A continuous i.v. infusion of ENT2 argatroban ENT2END was initiated, and the patient was managed on the general medical floor
0	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to ENT1 heparin ENT1END -induced thrombocytopenia. A continuous i.v. infusion of argatroban was initiated, and the patient was managed on the general medical floor. After one week of therapy, he was transferred to the intensive care unit with cardiopulmonary compromise related to ENT2 superior vena cava (SVC) syndrome ENT2END
0	CONCLUSION: A 63-year-old man with renal amyloidosis and ENT1 SVC syndrome  ENT1END secondary to HITT was successfully treated with ENT2 argatroban ENT2END and CDT with alteplase
0	Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENT1 warfarin  ENT1END  for long-term anticoagulation. Although the patient recovered, he experienced permanent vision and hearing loss, as well as end-stage renal disease. CONCLUSION: A 63-year-old man with renal amyloidosis and ENT2 SVC syndrome ENT2END secondary to HITT was successfully treated with argatroban and CDT with alteplase
0	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral ENT1 upper-extremity deep venous thrombosis  ENT1END (DVT) and pulmonary embolism secondary to ENT2 heparin ENT2END -induced thrombocytopenia
0	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral ENT1 upper-extremity deep venous thrombosis  ENT1END  (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia. A continuous i.v. infusion of ENT2 argatroban ENT2END was initiated, and the patient was managed on the general medical floor
1	Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with ENT1 heparin  ENT1END -induced ENT2 thrombocytopenia ENT2END with thrombosis
0	PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis ( ENT1 HITT ENT1END  and was treated with ENT2 argatroban ENT2END plus catheter-directed thrombolysis (CDT) with alteplase is presented
0	Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENT1 warfarin ENT1END  for long-term anticoagulation. Although the patient recovered, he experienced permanent vision and hearing loss, as well as end-stage renal disease. CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to ENT2 HITT ENT2END was successfully treated with argatroban and CDT with alteplase
0	PURPOSE: The case of an oncology patient who developed ENT1 heparin ENT1END induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented. SUMMARY: A 63-year-old Caucasian man with renal ENT2 amyloidosis ENT2END undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia
0	CONCLUSION: A 63-year-old man with renal ENT1 amyloidosis  ENT1END and SVC syndrome secondary to HITT was successfully treated with ENT2 argatroban ENT2END and CDT with alteplase
0	Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENT1 warfarin  ENT1END  for long-term anticoagulation. Although the patient recovered, he experienced permanent vision and hearing loss, as well as end-stage renal disease. CONCLUSION: A 63-year-old man with renal ENT2 amyloidosis ENT2END and SVC syndrome secondary to HITT was successfully treated with argatroban and CDT with alteplase
0	Alteplase was discontinued, and the patient was reinitiated on ENT1 argatroban ENT1END  ultimately, he was transitioned to warfarin for long-term anticoagulation. Although the patient recovered, he experienced permanent ENT2 vision and hearing loss ENT2END , as well as end-stage renal disease
0	Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENT1 warfarin  ENT1END  for long-term anticoagulation. Although the patient recovered, he experienced permanent ENT2 vision and hearing loss ENT2END , as well as end-stage renal disease
0	Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with ENT1 heparin  ENT1END -induced thrombocytopenia with ENT2 thrombosis ENT2END
0	PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis ( ENT1 HITT  ENT1END  and was treated with ENT2 argatroban ENT2END plus catheter-directed thrombolysis (CDT) with alteplase is presented
0	Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENT1 warfarin ENT1END  for long-term anticoagulation. Although the patient recovered, he experienced permanent vision and hearing loss, as well as end-stage renal disease. CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to ENT2 HITT ENT2END was successfully treated with argatroban and CDT with alteplase
0	Alteplase was discontinued, and the patient was reinitiated on ENT1 argatroban ENT1END ; ultimately, he was transitioned to warfarin for long-term anticoagulation. Although the patient recovered, he experienced permanent ENT2 vision and hearing loss ENT2END , as well as end-stage renal disease
0	Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENT1 warfarin  ENT1END  for long-term anticoagulation. Although the patient recovered, he experienced permanent ENT2 vision and hearing loss ENT2END , as well as end-stage renal disease
1	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis ( ENT1 DVT  ENT1END  and pulmonary embolism secondary to ENT2 heparin ENT2END -induced thrombocytopenia
0	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis ( ENT1 DVT  ENT1END ) and pulmonary embolism secondary to heparin-induced thrombocytopenia. A continuous i.v. infusion of ENT2 argatroban ENT2END was initiated, and the patient was managed on the general medical floor
0	Use of argatroban and catheter-directed ENT1 thrombolysis  ENT1END  with alteplase in an oncology patient with ENT2 heparin ENT2END -induced thrombocytopenia with thrombosis
0	Use of ENT1 argatroban  ENT1END  and catheter-directed ENT2 thrombolysis ENT2END with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis
0	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to ENT1 heparin ENT1END -induced thrombocytopenia. A continuous i.v. infusion of argatroban was initiated, and the patient was managed on the general medical floor. After one week of therapy, he was transferred to the intensive care unit with cardiopulmonary compromise related to superior vena cava (SVC) syndrome. A percutaneous mechanical thrombectomy and CDT with alteplase were attempted, but the procedure was aborted due to ENT2 epistaxis ENT2END
0	The ENT1 epistaxis ENT1END resolved the next day, and the patient was restarted on ENT2 argatroban ENT2END
0	The ENT1 epistaxis  ENT1END  resolved the next day, and the patient was restarted on argatroban. A second percutaneous mechanical thrombectomy was performed six days later and resulted in partial revascularization of the SVC and central veins. Postthrombectomy continuous CDT with alteplase was commenced while argatroban was withheld, and complete patency of the SVC and central veins was achieved after three days of therapy. Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENT2 warfarin ENT2END for long-term anticoagulation
1	A case of bilateral ENT1 optic neuropathy  ENT1END  in a patient on ENT2 tacrolimus ENT2END (FK506) therapy after liver transplantation
0	ENT1 Deterioration of vision ENT1END occurred despite discontinuation of the ENT2 tacrolimus ENT2END
0	RESULTS: The patient had episodic deterioration of vision in both eyes, with clinical features resembling ENT1 ischemic optic neuropathies  ENT1END  Deterioration of vision occurred despite discontinuation of the ENT2 tacrolimus ENT2END
0	4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from ENT1 malignancy ENT1END  Cyclical low-dose oestrogen therapy with 7--13 days of ENT2 progestagen ENT2END does not seem to increase the risk of endometrial hyperplasia or carcinoma
0	Two courses of 21 days of 5 mg ENT1 norethisterone  ENT1END daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from ENT2 malignancy ENT2END
0	4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from ENT1 malignancy ENT1END . Cyclical low-dose ENT2 oestrogen ENT2END therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma
0	The treatment regimens are described in 74 patients with ENT1 endometrial disease ENT1END among 850 climacteric women receiving oestrogen therapy. Cystic hyperplasia was associated with unopposed oestrogen therapy without ENT2 progestagen ENT2END
0	The treatment regimens are described in 74 patients with ENT1 endometrial disease  ENT1END  among 850 climacteric women receiving oestrogen therapy. Cystic hyperplasia was associated with unopposed oestrogen therapy without progestagen. Two courses of 21 days of 5 mg ENT2 norethisterone ENT2END daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia
0	Prevention and treatment of ENT1 endometrial disease  ENT1END  in climacteric women receiving ENT2 oestrogen ENT2END therapy
0	Cystic ENT1 hyperplasia  ENT1END was associated with unopposed oestrogen therapy without ENT2 progestagen ENT2END
0	Two courses of 21 days of 5 mg ENT1 norethisterone ENT1END  daily caused reversion to normal in all 57 cases of cystic ENT2 hyperplasia ENT2END and 6 of the 8 cases of atypical hyperplasia
1	The treatment regimens are described in 74 patients with endometrial disease among 850 climacteric women receiving ENT1 oestrogen  ENT1END therapy. Cystic ENT2 hyperplasia ENT2END was associated with unopposed oestrogen therapy without progestagen
0	Cyclical low-dose oestrogen therapy with 7--13 days of ENT1 progestagen ENT1END  does not seem to increase the risk of endometrial hyperplasia or ENT2 carcinoma ENT2END
0	Two courses of 21 days of 5 mg ENT1 norethisterone  ENT1END  daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy. Cyclical low-dose oestrogen therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or ENT2 carcinoma ENT2END
0	Cyclical low-dose ENT1 oestrogen  ENT1END  therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or ENT2 carcinoma ENT2END
0	Cyclical low-dose oestrogen therapy with 7--13 days of ENT1 progestagen ENT1END  does not seem to increase the risk of ENT2 endometrial hyperplasia ENT2END or carcinoma
0	Two courses of 21 days of 5 mg ENT1 norethisterone  ENT1END  daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy. Cyclical low-dose oestrogen therapy with 7--13 days of progestagen does not seem to increase the risk of ENT2 endometrial hyperplasia ENT2END or carcinoma
0	Cyclical low-dose ENT1 oestrogen  ENT1END  therapy with 7--13 days of progestagen does not seem to increase the risk of ENT2 endometrial hyperplasia ENT2END or carcinoma
0	Cystic hyperplasia was associated with unopposed oestrogen therapy without ENT1 progestagen ENT1END . Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of ENT2 endometrial carcinoma ENT2END referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy
0	Two courses of 21 days of 5 mg ENT1 norethisterone  ENT1END  daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of ENT2 endometrial carcinoma ENT2END referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy
0	4 cases of ENT1 endometrial carcinoma ENT1END  referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed ENT2 oestrogen ENT2END therapy and the difficulty in distinguishing severe hyperplasia from malignancy
1	Only a handful of cases of ENT1 ATRA ENT1END induced ENT2 myositis ENT2END in children have been reported, and none in the radiology literature
0	All-trans retinoic acid-induced inflammatory myositis in a patient with ENT1 acute promyelocytic leukemia  ENT1END . ENT2 All-trans retinoic acid ENT2END (ATRA), a component of standard therapy for acute promyelocytic leukemia (APL), is associated with potentially serious but treatable adverse effects involving numerous organ systems, including rare skeletal muscle involvement
1	The patient developed acute encephalopathy evidenced by behavioral changes, ENT1 aphasia ENT1END  incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, dexamethasone, and ENT2 polyethylene glycol-asparaginase ENT2END were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, ENT1 aphasia ENT1END , incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, ENT2 dexamethasone ENT2END , and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, ENT1 aphasia ENT1END , incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. ENT2 Vincristine ENT2END , dexamethasone, and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, ENT1 aphasia ENT1END , incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal ENT2 cytarabine ENT2END
0	ENT1 Acute encephalopathy  ENT1END  and cerebral vasospasm after multiagent chemotherapy including ENT2 PEG-asparaginase ENT2END and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia
0	The patient developed ENT1 acute encephalopathy  ENT1END evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, ENT2 dexamethasone ENT2END , and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
0	The patient developed ENT1 acute encephalopathy  ENT1END  evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. ENT2 Vincristine ENT2END , dexamethasone, and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
0	ENT1 Acute encephalopathy  ENT1END  and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal ENT2 cytarabine ENT2END for the treatment of acute lymphoblastic leukemia
0	Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including ENT1 PEG-asparaginase  ENT1END  and intrathecal cytarabine for the treatment of ENT2 acute lymphoblastic leukemia ENT2END
0	A 7-year-old girl with an unusual reaction to induction chemotherapy for precursor B-cell acute lymphoblastic leukemia ( ENT1 ALL  ENT1END  is described. The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, ENT2 dexamethasone ENT2END , and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
0	A 7-year-old girl with an unusual reaction to induction chemotherapy for precursor B-cell acute lymphoblastic leukemia ( ENT1 ALL  ENT1END ) is described. The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. ENT2 Vincristine ENT2END , dexamethasone, and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
0	Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal ENT1 cytarabine  ENT1END  for the treatment of ENT2 acute lymphoblastic leukemia ENT2END
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided ENT1 weakness  ENT1END with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, dexamethasone, and ENT2 polyethylene glycol-asparaginase ENT2END were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided ENT1 weakness  ENT1END  with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, ENT2 dexamethasone ENT2END , and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided ENT1 weakness  ENT1END  with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. ENT2 Vincristine ENT2END , dexamethasone, and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided ENT1 weakness  ENT1END  with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal ENT2 cytarabine ENT2END
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, ENT1 incontinence  ENT1END  visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, dexamethasone, and ENT2 polyethylene glycol-asparaginase ENT2END were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, ENT1 incontinence  ENT1END , visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, ENT2 dexamethasone ENT2END , and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, ENT1 incontinence  ENT1END , visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. ENT2 Vincristine ENT2END , dexamethasone, and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, ENT1 incontinence  ENT1END , visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal ENT2 cytarabine ENT2END
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, ENT1 visual hallucinations  ENT1END  and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, dexamethasone, and ENT2 polyethylene glycol-asparaginase ENT2END were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, ENT1 visual hallucinations  ENT1END , and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, ENT2 dexamethasone ENT2END , and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, ENT1 visual hallucinations  ENT1END , and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. ENT2 Vincristine ENT2END , dexamethasone, and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, ENT1 visual hallucinations  ENT1END , and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal ENT2 cytarabine ENT2END
1	Acute encephalopathy and ENT1 cerebral vasospasm  ENT1END  after multiagent chemotherapy including ENT2 PEG-asparaginase ENT2END and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse ENT1 cerebral vasospasm  ENT1END on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, ENT2 dexamethasone ENT2END , and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse ENT1 cerebral vasospasm  ENT1END  on magnetic resonance angiography after the administration of intrathecal cytarabine. ENT2 Vincristine ENT2END , dexamethasone, and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	Acute encephalopathy and ENT1 cerebral vasospasm  ENT1END  after multiagent chemotherapy including PEG-asparaginase and intrathecal ENT2 cytarabine ENT2END for the treatment of acute lymphoblastic leukemia
0	Gemfibrozil-lovastatin therapy for primary ENT1 hyperlipoproteinemias ENT1END .The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had atherosclerotic vascular disease). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) cholesterol less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4.5 mg/dl) with diet plus a single drug, gemfibrozil (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 ENT2 creatine ENT2END phosphokinase levels measured
0	Gemfibrozil-lovastatin therapy for primary ENT1 hyperlipoproteinemias ENT1END .The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had atherosclerotic vascular disease). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) cholesterol less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4.5 mg/dl) with diet plus a single drug, gemfibrozil (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, ENT2 triglyceride ENT2END levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7
0	Gemfibrozil-lovastatin therapy for primary ENT1 hyperlipoproteinemias ENT1END .The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had atherosclerotic vascular disease). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) ENT2 cholesterol ENT2END less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4
0	Gemfibrozil- ENT1 lovastatin  ENT1END  therapy for primary ENT2 hyperlipoproteinemias ENT2END
0	ENT1 Gemfibrozil  ENT1END -lovastatin therapy for primary ENT2 hyperlipoproteinemias ENT2END
0	ENT1 Myositis ENT1END  attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high ENT2 creatine ENT2END phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria
0	With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, ENT1 triglyceride  ENT1END  levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. ENT2 Myositis ENT2END , attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria
0	With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL ENT1 cholesterol  ENT1END ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. ENT2 Myositis ENT2END , attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria
1	2 g/day)- ENT1 lovastatin  ENT1END (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. ENT2 Myositis ENT2END , attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria
1	5 mg/dl) with diet plus a single drug, ENT1 gemfibrozil  ENT1END (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. ENT2 Myositis ENT2END , attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria
0	Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high ENT1 creatine ENT1END  phosphokinase (769 U/liter); no patients had ENT2 rhabdomyolysis ENT2END or myoglobinuria
0	With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, ENT1 triglyceride  ENT1END  levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had ENT2 rhabdomyolysis ENT2END or myoglobinuria
0	With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL ENT1 cholesterol  ENT1END  ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had ENT2 rhabdomyolysis ENT2END or myoglobinuria
0	2 g/day)- ENT1 lovastatin  ENT1END  (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had ENT2 rhabdomyolysis ENT2END or myoglobinuria
0	5 mg/dl) with diet plus a single drug, ENT1 gemfibrozil  ENT1END  (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had ENT2 rhabdomyolysis ENT2END or myoglobinuria
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed ENT1 hyperlipidemia  ENT1END (68% of whom had atherosclerotic vascular disease). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) cholesterol less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4.5 mg/dl) with diet plus a single drug, gemfibrozil (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 ENT2 creatine ENT2END phosphokinase levels measured
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed ENT1 hyperlipidemia  ENT1END  (68% of whom had atherosclerotic vascular disease). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) cholesterol less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4.5 mg/dl) with diet plus a single drug, gemfibrozil (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, ENT2 triglyceride ENT2END levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed ENT1 hyperlipidemia  ENT1END  (68% of whom had atherosclerotic vascular disease). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) ENT2 cholesterol ENT2END less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil- ENT1 lovastatin  ENT1END treatment in 80 patients with primary mixed ENT2 hyperlipidemia ENT2END (68% of whom had atherosclerotic vascular disease)
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, ENT1 gemfibrozil  ENT1END lovastatin treatment in 80 patients with primary mixed ENT2 hyperlipidemia ENT2END (68% of whom had atherosclerotic vascular disease)
0	Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high ENT1 creatine ENT1END  phosphokinase (769 U/liter); no patients had rhabdomyolysis or ENT2 myoglobinuria ENT2END
0	With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, ENT1 triglyceride  ENT1END  levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or ENT2 myoglobinuria ENT2END
0	With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL ENT1 cholesterol  ENT1END  ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or ENT2 myoglobinuria ENT2END
0	2 g/day)- ENT1 lovastatin  ENT1END  (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or ENT2 myoglobinuria ENT2END
0	5 mg/dl) with diet plus a single drug, ENT1 gemfibrozil  ENT1END  (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or ENT2 myoglobinuria ENT2END
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had ENT1 atherosclerotic vascular disease  ENT1END . Because ideal lipid targets were not reached (low-density lipoprotein (LDL) cholesterol less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4.5 mg/dl) with diet plus a single drug, gemfibrozil (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 ENT2 creatine ENT2END phosphokinase levels measured
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had ENT1 atherosclerotic vascular disease  ENT1END ). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) cholesterol less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4.5 mg/dl) with diet plus a single drug, gemfibrozil (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, ENT2 triglyceride ENT2END levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had ENT1 atherosclerotic vascular disease  ENT1END ). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) ENT2 cholesterol ENT2END less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil- ENT1 lovastatin  ENT1END  treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had ENT2 atherosclerotic vascular disease ENT2END )
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, ENT1 gemfibrozil  ENT1END -lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had ENT2 atherosclerotic vascular disease ENT2END )
1	7e exhibits a high reversal of ENT1 catalepsy ENT1END induced by ENT2 haloperidol ENT2END indicating its atypical antipsychotic nature
0	63) for ENT1 paracetamol ENT1END  and 0.94 (0.57-1.56) for nonaspirin NSAIDs. The risk of ESRD associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular ENT2 nephropathy ENT2END as underlying disease [2
0	76) for ENT1 pyrazolones  ENT1END  0.80 (0.39-1.63) for paracetamol, and 0.94 (0.57-1.56) for nonaspirin NSAIDs. The risk of ESRD associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular ENT2 nephropathy ENT2END as underlying disease [2
0	The risk of ESRD associated with ENT1 aspirin  ENT1END was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular ENT2 nephropathy ENT2END as underlying disease [2
0	63) for ENT1 paracetamol ENT1END , and 0.94 (0.57-1.56) for nonaspirin NSAIDs. The risk of ENT2 ESRD ENT2END associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [2
0	76) for ENT1 pyrazolones  ENT1END , 0.80 (0.39-1.63) for paracetamol, and 0.94 (0.57-1.56) for nonaspirin NSAIDs. The risk of ENT2 ESRD ENT2END associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [2
1	The risk of ENT1 ESRD  ENT1END  associated with ENT2 aspirin ENT2END was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [2
1	BACKGROUND: In dogs, a large amount of intravenous ENT1 cocaine ENT1END causes a profound ENT2 deterioration of left ventricular (LV) systolic function ENT2END and an increase in LV end-diastolic pressure
0	This study was done to assess the influence of a high intracoronary ENT1 cocaine ENT1END concentration on LV systolic and diastolic function in humans. METHODS AND RESULTS: In 20 patients (14 men and 6 women aged 39 to 72 years) referred for cardiac catheterization for the evaluation of ENT2 chest pain ENT2END , we measured heart rate, systemic arterial pressure, LV pressure and its first derivative (dP/dt), and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15-minute intracoronary infusion of saline (n=10, control subjects) or cocaine hydrochloride 1 mg/min (n=10)
1	Two cases of ENT1 propylthiouracil ENT1END induced ENT2 liver damage ENT2END have been observed
1	Two cases of ENT1 propylthiouracil ENT1END -induced liver damage have been observed. The first case is of an acute type of damage, proven by rechallenge; the second presents a clinical and histologic picture resembling ENT2 chronic active hepatitis ENT2END , with spontaneous remission
1	OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon ENT1 carboplatin ENT1END chemotherapy. METHODS: We noted ENT2 abnormal ocular motility ENT2END in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin
1	CONCLUSIONS: Subtenon ENT1 carboplatin ENT1END chemotherapy is associated with significant ENT2 fibrosis ENT2END of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult
0	The enucleations were technically difficult and hazardous for globe ENT1 rupture  ENT1END because of extensive orbital soft tissue adhesions. CONCLUSIONS: Subtenon ENT2 carboplatin ENT2END chemotherapy is associated with significant fibrosis of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult
0	METHODS: We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon ENT1 carboplatin ENT1END  During ocular manipulation under general anesthesia, we assessed their eyes by forced duction testing, comparing ocular motility after ENT2 tumor ENT2END control with ocular motility at diagnosis
0	Subtenon ENT1 carboplatin ENT1END is not free of ENT2 toxicity ENT2END , and its use is best restricted to specific indications
0	Histopathological examination revealed many lipophages in the periorbital fat surrounding the optic nerve in 1 eye, indicative of phagocytosis of previously existing fat cells and suggesting prior fat ENT1 necrosis  ENT1END  The enucleations were technically difficult and hazardous for globe rupture because of extensive orbital soft tissue adhesions. CONCLUSIONS: Subtenon ENT2 carboplatin ENT2END chemotherapy is associated with significant fibrosis of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult
0	Ocular motility changes after subtenon ENT1 carboplatin  ENT1END  chemotherapy for ENT2 retinoblastoma ENT2END
1	No subject reported side effects of oxitropium, as compared to three subjects reporting ENT1 nausea ENT1END  vomiting and tremors after ENT2 theophylline ENT2END
0	No subject reported side effects of ENT1 oxitropium  ENT1END  as compared to three subjects reporting ENT2 nausea ENT2END , vomiting and tremors after theophylline
1	No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and ENT1 tremors  ENT1END after ENT2 theophylline ENT2END
0	No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and ENT1 tremors ENT1END  after theophylline. ENT2 Oxitropium ENT2END proves to be a valuable alternative to theophylline in nocturnal asthma, since it is equally potent, safer and does not require the titration of dosage
1	No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, ENT1 vomiting  ENT1END and tremors after ENT2 theophylline ENT2END
0	No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, ENT1 vomiting  ENT1END  and tremors after theophylline. ENT2 Oxitropium ENT2END proves to be a valuable alternative to theophylline in nocturnal asthma, since it is equally potent, safer and does not require the titration of dosage
0	Comparison of the effect of oxitropium bromide and of slow-release ENT1 theophylline  ENT1END  on nocturnal ENT2 asthma ENT2END
0	Comparison of the effect of ENT1 oxitropium bromide  ENT1END  and of slow-release theophylline on nocturnal ENT2 asthma ENT2END
1	Twenty-one reports of antimicrobial-induced ENT1 mania ENT1END were found in the literature. There were 6 cases implicating clarithromycin, 13 implicating ENT2 isoniazid ENT2END , and 1 case each implicating erythromycin and amoxicillin
1	Twenty-one reports of antimicrobial-induced ENT1 mania ENT1END  were found in the literature. There were 6 cases implicating clarithromycin, 13 implicating isoniazid, and 1 case each implicating erythromycin and ENT2 amoxicillin ENT2END
1	ENT1 Cotrimoxazole ENT1END  metronidazole, and erythromycin were involved in 15 reported ENT2 manic ENT2END episodes
1	Cases reported by the FDA showed clarithromycin and ENT1 ciprofloxacin ENT1END to be the most frequently associated with the development of ENT2 mania ENT2END
1	Cotrimoxazole, metronidazole, and erythromycin were involved in 15 reported ENT1 manic ENT1END  episodes. Cases reported by the FDA showed ENT2 clarithromycin ENT2END and ciprofloxacin to be the most frequently associated with the development of mania
1	4%) cases, and ENT1 ofloxacin  ENT1END in 10 (12%) cases. Cotrimoxazole, metronidazole, and erythromycin were involved in 15 reported ENT2 manic ENT2END episodes
1	Cotrimoxazole, metronidazole, and ENT1 erythromycin  ENT1END were involved in 15 reported ENT2 manic ENT2END episodes
1	Cotrimoxazole, ENT1 metronidazole  ENT1END  and erythromycin were involved in 15 reported ENT2 manic ENT2END episodes
0	Rats treated with 500 ppm ENT1 quinacrine hydrochloride ENT1END in the diet all developed a high incidence of left atrial thrombosis. The lesion was associated with cardiac hypertrophy and dilatation and focal ENT2 myocardial degeneration ENT2END
0	The lesion was associated with cardiac hypertrophy and dilatation and focal ENT1 myocardial degeneration ENT1END . Rats died from cardiac hypertrophy with severe acute and chronic congestion of the lungs, liver, and other organs. Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm ENT2 sodium nitrite ENT2END simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis
1	Rats treated with 500 ppm ENT1 quinacrine hydrochloride ENT1END  in the diet all developed a high incidence of left atrial thrombosis. The lesion was associated with ENT2 cardiac hypertrophy ENT2END and dilatation and focal myocardial degeneration
0	Rats died from ENT1 cardiac hypertrophy  ENT1END with severe acute and chronic congestion of the lungs, liver, and other organs. Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm ENT2 sodium nitrite ENT2END simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis
0	Seventy percent of rats given 250 ppm ENT1 quinacrine hydrochloride ENT1END and 1,000 ppm sodium nitrite simultaneously in the diet had ENT2 thrombosis ENT2END of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis
0	Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm ENT1 sodium nitrite  ENT1END  simultaneously in the diet had ENT2 thrombosis ENT2END of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis
1	Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have ENT1 atrial thrombosis ENT1END  Sodium nitrite in combination with ENT2 quinacrine hydrochloride ENT2END appeared to have no additional effect
0	Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have ENT1 atrial thrombosis ENT1END . ENT2 Sodium nitrite ENT2END in combination with quinacrine hydrochloride appeared to have no additional effect
0	All of the patients' plasma blood urea nitrogen ( ENT1 BUN ENT1END  and creatinine levels were measured on the second and seventh day after the administration of intravenous contrast material. RESULTS: The basal creatinine levels were similar for all three groups (p > 0.05). Among a total of 60 patients included in the study, 16 patients developed ENT2 acute renal failure ENT2END (ARF) on the second day after contrast material was injected (26
0	The number of patients who developed ENT1 ARF ENT1END on the second day after the injection in the first group was five (25%), in the second group was six (30%) and the third group was five (25%) (p > 0.05). CONCLUSION: There was no significant difference between isotonic ENT2 sodium chloride ENT2END , sodium bicarbonate and isotonic sodium chloride with diltiazem application in prevention of CIN
0	RESULTS: The basal ENT1 creatinine  ENT1END levels were similar for all three groups (p > 0.05). Among a total of 60 patients included in the study, 16 patients developed ENT2 acute renal failure ENT2END (ARF) on the second day after contrast material was injected (26
0	The first group of patients was administered isotonic sodium chloride; the second group was administered a solution that of 5% ENT1 dextrose  ENT1END and sodium bicarbonate, while the third group was administered isotonic sodium chloride before and after the contrast injection. The third group received an additional injection of diltiazem the day before and first 2 days after the contrast injection. All of the patients' plasma blood urea nitrogen (BUN) and creatinine levels were measured on the second and seventh day after the administration of intravenous contrast material. RESULTS: The basal creatinine levels were similar for all three groups (p > 0.05). Among a total of 60 patients included in the study, 16 patients developed ENT2 acute renal failure ENT2END (ARF) on the second day after contrast material was injected (26
0	The number of patients who developed ENT1 ARF ENT1END  on the second day after the injection in the first group was five (25%), in the second group was six (30%) and the third group was five (25%) (p > 0.05). CONCLUSION: There was no significant difference between isotonic sodium chloride, sodium bicarbonate and isotonic sodium chloride with ENT2 diltiazem ENT2END application in prevention of CIN
1	Among a total of 60 patients included in the study, 16 patients developed acute renal failure ( ENT1 ARF ENT1END  on the second day after ENT2 contrast ENT2END material was injected (26
0	The number of patients who developed ENT1 ARF ENT1END  on the second day after the injection in the first group was five (25%), in the second group was six (30%) and the third group was five (25%) (p > 0.05). CONCLUSION: There was no significant difference between isotonic sodium chloride, ENT2 sodium bicarbonate ENT2END and isotonic sodium chloride with diltiazem application in prevention of CIN
0	Comparison of effects of isotonic ENT1 sodium chloride  ENT1END  with diltiazem in prevention of contrast-induced ENT2 nephropathy ENT2END
0	INTRODUCTION AND OBJECTIVE: Contrast-induced ENT1 nephropathy ENT1END (CIN) significantly increases the morbidity and mortality of patients. The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a ENT2 calcium ENT2END channel blocker, in preventing CIN
0	INTRODUCTION AND OBJECTIVE: Contrast-induced ENT1 nephropathy ENT1END  (CIN) significantly increases the morbidity and mortality of patients. The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN. MATERIALS AND METHODS: Our study included patients who were administered 30-60 mL of iodinated contrast agent for percutaneous coronary angiography (PCAG), all with ENT2 creatinine ENT2END values between 1
0	INTRODUCTION AND OBJECTIVE: Contrast-induced ENT1 nephropathy  ENT1END  (CIN) significantly increases the morbidity and mortality of patients. The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN. MATERIALS AND METHODS: Our study included patients who were administered 30-60 mL of iodinated contrast agent for percutaneous coronary angiography (PCAG), all with creatinine values between 1.1 and 3.1 mg/dL. Patients were divided into three groups and each group had 20 patients. The first group of patients was administered isotonic sodium chloride; the second group was administered a solution that of 5% ENT2 dextrose ENT2END and sodium bicarbonate, while the third group was administered isotonic sodium chloride before and after the contrast injection
0	Comparison of effects of isotonic sodium chloride with ENT1 diltiazem  ENT1END  in prevention of contrast-induced ENT2 nephropathy ENT2END
0	Comparison of effects of isotonic sodium chloride with diltiazem in prevention of ENT1 contrast  ENT1END -induced ENT2 nephropathy ENT2END
0	INTRODUCTION AND OBJECTIVE: Contrast-induced ENT1 nephropathy ENT1END  (CIN) significantly increases the morbidity and mortality of patients. The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with ENT2 sodium bicarbonate ENT2END infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN
0	The present experiments were performed to study the effect of the ENT1 flavonoid ENT1END apigenin (20 mg/kg intraperitoneally (i.p.), 1 h before acquisition), on 24 h retention performance and forgetting of a step-through passive avoidance task, in young male Wistar rats. There were no differences between saline- and apigenin-treated groups in the 24 h retention trial. Furthermore, apigenin did not prevent the amnesia induced by scopolamine (1mg/kg, i.p., 30 min before the acquisition). The saline- and apigenin-treated rats that did not step through into the dark compartment during the cut-off time (540 s) were retested weekly for up to eight weeks. In the saline treated group, the first significant decline in passive avoidance response was observed at four weeks, and complete ENT2 memory loss ENT2END was found five weeks after the acquisition of the passive avoidance task
0	In the saline treated group, the first significant decline in passive avoidance response was observed at four weeks, and complete ENT1 memory loss ENT1END  was found five weeks after the acquisition of the passive avoidance task. At the end of the experimental period, 60% of the animals treated with ENT2 apigenin ENT2END still did not step through
0	Furthermore, apigenin did not prevent the amnesia induced by ENT1 scopolamine  ENT1END (1mg/kg, i.p., 30 min before the acquisition). The saline- and apigenin-treated rats that did not step through into the dark compartment during the cut-off time (540 s) were retested weekly for up to eight weeks. In the saline treated group, the first significant decline in passive avoidance response was observed at four weeks, and complete ENT2 memory loss ENT2END was found five weeks after the acquisition of the passive avoidance task
0	The present experiments were performed to study the effect of the ENT1 flavonoid ENT1END  apigenin (20 mg/kg intraperitoneally (i.p.), 1 h before acquisition), on 24 h retention performance and forgetting of a step-through passive avoidance task, in young male Wistar rats. There were no differences between saline- and apigenin-treated groups in the 24 h retention trial. Furthermore, apigenin did not prevent the ENT2 amnesia ENT2END induced by scopolamine (1mg/kg, i
0	Furthermore, ENT1 apigenin  ENT1END did not prevent the ENT2 amnesia ENT2END induced by scopolamine (1mg/kg, i
1	Furthermore, apigenin did not prevent the ENT1 amnesia  ENT1END  induced by ENT2 scopolamine ENT2END (1mg/kg, i
0	Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, ENT1 nausea ENT1END  palpitations, restlessness, and tremors in the patients compared with healthy subjects. In the patients, but not the healthy subjects, these symptoms were significantly correlated with plasma caffeine levels. Seventy-one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks. Caffeine did not alter plasma MHPG levels in either the healthy subjects or patients. Caffeine increased plasma cortisol levels equally in the patient and healthy groups. Because caffeine is an ENT2 adenosine ENT2END receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol ( ENT1 MHPG  ENT1END  and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, ENT2 nausea ENT2END , palpitations, restlessness, and tremors in the patients compared with healthy subjects
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and ENT1 cortisol  ENT1END were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, ENT2 nausea ENT2END , palpitations, restlessness, and tremors in the patients compared with healthy subjects
1	ENT1 Caffeine  ENT1END produced significantly greater increases in subject-rated anxiety, nervousness, fear, ENT2 nausea ENT2END , palpitations, restlessness, and tremors in the patients compared with healthy subjects
0	Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, ENT1 restlessness  ENT1END  and tremors in the patients compared with healthy subjects. In the patients, but not the healthy subjects, these symptoms were significantly correlated with plasma caffeine levels. Seventy-one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks. Caffeine did not alter plasma MHPG levels in either the healthy subjects or patients. Caffeine increased plasma cortisol levels equally in the patient and healthy groups. Because caffeine is an ENT2 adenosine ENT2END receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol ( ENT1 MHPG  ENT1END ) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, ENT2 restlessness ENT2END , and tremors in the patients compared with healthy subjects
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and ENT1 cortisol  ENT1END  were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, ENT2 restlessness ENT2END , and tremors in the patients compared with healthy subjects
0	ENT1 Caffeine  ENT1END  produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, ENT2 restlessness ENT2END , and tremors in the patients compared with healthy subjects
0	Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have ENT1 abnormalities in neuronal systems ENT1END involving ENT2 adenosine ENT2END
0	Caffeine did not alter plasma ENT1 MHPG  ENT1END levels in either the healthy subjects or patients. Caffeine increased plasma cortisol levels equally in the patient and healthy groups. Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have ENT2 abnormalities in neuronal systems ENT2END involving adenosine
0	Caffeine increased plasma ENT1 cortisol  ENT1END levels equally in the patient and healthy groups. Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have ENT2 abnormalities in neuronal systems ENT2END involving adenosine
0	Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have ENT1 abnormalities in neuronal systems ENT1END  involving adenosine. Patients with anxiety disorders may benefit by avoiding ENT2 caffeine ENT2END -containing foods and beverages
0	Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving ENT1 adenosine ENT1END . Patients with ENT2 anxiety disorders ENT2END may benefit by avoiding caffeine-containing foods and beverages
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol ( ENT1 MHPG ENT1END ) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated ENT2 anxiety ENT2END , nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and ENT1 cortisol  ENT1END  were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated ENT2 anxiety ENT2END , nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects
1	Patients with ENT1 anxiety disorders  ENT1END  may benefit by avoiding ENT2 caffeine ENT2END -containing foods and beverages
0	Because caffeine is an ENT1 adenosine ENT1END  receptor antagonist, these results suggest that some ENT2 panic disorder ENT2END patients may have abnormalities in neuronal systems involving adenosine
0	Seventy-one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during ENT1 panic attacks  ENT1END  Caffeine did not alter plasma ENT2 MHPG ENT2END levels in either the healthy subjects or patients
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and ENT1 cortisol ENT1END  were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with ENT2 panic attacks ENT2END or panic disorder
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or ENT1 panic disorder ENT1END ENT2 Caffeine ENT2END produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol ( ENT1 MHPG ENT1END ) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for ENT2 agoraphobia ENT2END with panic attacks or panic disorder
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and ENT1 cortisol  ENT1END  were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for ENT2 agoraphobia ENT2END with panic attacks or panic disorder
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for ENT1 agoraphobia  ENT1END  with panic attacks or panic disorder. ENT2 Caffeine ENT2END produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects
0	Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and ENT1 tremors  ENT1END in the patients compared with healthy subjects. In the patients, but not the healthy subjects, these symptoms were significantly correlated with plasma caffeine levels. Seventy-one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks. Caffeine did not alter plasma MHPG levels in either the healthy subjects or patients. Caffeine increased plasma cortisol levels equally in the patient and healthy groups. Because caffeine is an ENT2 adenosine ENT2END receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol ( ENT1 MHPG  ENT1END ) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and ENT2 tremors ENT2END in the patients compared with healthy subjects
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and ENT1 cortisol  ENT1END  were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and ENT2 tremors ENT2END in the patients compared with healthy subjects
1	ENT1 Caffeine  ENT1END  produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and ENT2 tremors ENT2END in the patients compared with healthy subjects
0	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined ENT1 beta adrenergic and muscarinic receptors blockade ENT1END but drug-induced ENT2 tachycardia ENT2END was abolished
0	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined ENT1 beta adrenergic and muscarinic receptors blockade  ENT1END but drug-induced ENT2 tachycardia ENT2END was abolished
1	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced ENT1 tachycardia ENT1END  was abolished. When circumflex artery blood flow was maintained constant, the increases in CxAD induced by ENT2 cromakalim ENT2END (10 micrograms/kg), pinacidil (30 micrograms/kg) and nitroglycerin (10 micrograms/kg) were reduced by 68 +/- 7, 54 +/- 9 and 1 +/- 1%, respectively
0	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced ENT1 tachycardia ENT1END  was abolished. When circumflex artery blood flow was maintained constant, the increases in CxAD induced by cromakalim (10 micrograms/kg), pinacidil (30 micrograms/kg) and ENT2 nitroglycerin ENT2END (10 micrograms/kg) were reduced by 68 +/- 7, 54 +/- 9 and 1 +/- 1%, respectively
1	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and ENT1 pinacidil  ENT1END were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced ENT2 tachycardia ENT2END was abolished
0	Vasodilation of large and small coronary vessels and ENT1 hypotension  ENT1END induced by cromakalim and pinacidil were not affected by prior combined ENT2 beta adrenergic and muscarinic receptors blockade ENT2END but drug-induced tachycardia was abolished
0	Vasodilation of large and small coronary vessels and ENT1 hypotension  ENT1END  induced by cromakalim and pinacidil were not affected by prior combined ENT2 beta adrenergic and muscarinic receptors blockade ENT2END but drug-induced tachycardia was abolished
1	Vasodilation of large and small coronary vessels and ENT1 hypotension ENT1END  induced by ENT2 cromakalim ENT2END and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished
0	Vasodilation of large and small coronary vessels and ENT1 hypotension  ENT1END  induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished. When circumflex artery blood flow was maintained constant, the increases in CxAD induced by cromakalim (10 micrograms/kg), pinacidil (30 micrograms/kg) and ENT2 nitroglycerin ENT2END (10 micrograms/kg) were reduced by 68 +/- 7, 54 +/- 9 and 1 +/- 1%, respectively
1	Vasodilation of large and small coronary vessels and ENT1 hypotension  ENT1END  induced by cromakalim and ENT2 pinacidil ENT2END were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished
0	ENT1 Flushing ENT1END was the most common adverse event, reported by 18% of patients and leading to discontinuation by 6%. Incidence of increased ENT2 aspartate ENT2END aminotransferase and/or alanine aminotransferase >3 times the upper limit of normal was <0
0	ENT1 Flushing ENT1END  was the most common adverse event, reported by 18% of patients and leading to discontinuation by 6%. Incidence of increased aspartate aminotransferase and/or ENT2 alanine ENT2END aminotransferase >3 times the upper limit of normal was <0
0	ENT1 Flushing ENT1END  was the most common adverse event, reported by 18% of patients and leading to discontinuation by 6%. Incidence of increased aspartate aminotransferase and/or alanine aminotransferase >3 times the upper limit of normal was <0.3%. An increase of ENT2 creatine ENT2END phosphokinase to >5 times the upper limit of normal occurred in 0
1	Compliance to ENT1 niacin extended-release/lovastatin  ENT1END was 77%, with 3,245 patients completing the study. Patients in the southeast and those enrolled by endocrinologists had the lowest compliance and highest adverse event rates. ENT2 Flushing ENT2END was the most common adverse event, reported by 18% of patients and leading to discontinuation by 6%
0	Incidence of increased ENT1 aspartate ENT1END  aminotransferase and/or alanine aminotransferase >3 times the upper limit of normal was <0.3%. An increase of creatine phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of drug-induced ENT2 myopathy ENT2END were observed
0	Patients were treated with 1 tablet (500 mg of niacin extended-release/20 mg of ENT1 lovastatin ENT1END  once nightly for 4 weeks and then 2 tablets for 8 weeks. Patients also received dietary counseling, educational materials, and reminders to call a toll-free number that provided further education about dyslipidemia and niacin extended-release/lovastatin. Primary end points were study compliance, increases in liver transaminases to >3 times the upper limit of normal, and clinical ENT2 myopathy ENT2END
0	Incidence of increased aspartate aminotransferase and/or ENT1 alanine  ENT1END  aminotransferase >3 times the upper limit of normal was <0.3%. An increase of creatine phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of drug-induced ENT2 myopathy ENT2END were observed
0	Patients were treated with 1 tablet (500 mg of ENT1 niacin  ENT1END extended-release/20 mg of lovastatin) once nightly for 4 weeks and then 2 tablets for 8 weeks. Patients also received dietary counseling, educational materials, and reminders to call a toll-free number that provided further education about dyslipidemia and niacin extended-release/lovastatin. Primary end points were study compliance, increases in liver transaminases to >3 times the upper limit of normal, and clinical ENT2 myopathy ENT2END
0	An increase of ENT1 creatine  ENT1END  phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of drug-induced ENT2 myopathy ENT2END were observed
0	24% of patients, and no cases of drug-induced ENT1 myopathy ENT1END  were observed. ENT2 Niacin extended-release/lovastatin ENT2END 1,000/40 mg, dosed as initial therapy, was associated with good compliance and safety and had very low incidences of increased liver and muscle enzymes
0	Niacin extended-release/lovastatin is a new combination product approved for treatment of primary ENT1 hypercholesterolemia  ENT1END and mixed dyslipidemia. This open-labeled, multicenter study evaluated the safety of bedtime niacin extended-release/lovastatin when dosed as initial therapy and patient compliance to treatment in various clinical practice settings. A total of 4,499 patients with dyslipidemia requiring drug intervention was enrolled at 1,081 sites. Patients were treated with 1 tablet (500 mg of niacin extended-release/20 mg of ENT2 lovastatin ENT2END ) once nightly for 4 weeks and then 2 tablets for 8 weeks
0	Niacin extended-release/lovastatin is a new combination product approved for treatment of primary ENT1 hypercholesterolemia  ENT1END  and mixed dyslipidemia. This open-labeled, multicenter study evaluated the safety of bedtime niacin extended-release/lovastatin when dosed as initial therapy and patient compliance to treatment in various clinical practice settings. A total of 4,499 patients with dyslipidemia requiring drug intervention was enrolled at 1,081 sites. Patients were treated with 1 tablet (500 mg of ENT2 niacin ENT2END extended-release/20 mg of lovastatin) once nightly for 4 weeks and then 2 tablets for 8 weeks
0	ENT1 Niacin extended-release/lovastatin  ENT1END is a new combination product approved for treatment of primary ENT2 hypercholesterolemia ENT2END and mixed dyslipidemia
0	A total of 4,499 patients with ENT1 dyslipidemia  ENT1END requiring drug intervention was enrolled at 1,081 sites. Patients were treated with 1 tablet (500 mg of niacin extended-release/20 mg of ENT2 lovastatin ENT2END ) once nightly for 4 weeks and then 2 tablets for 8 weeks
0	A total of 4,499 patients with ENT1 dyslipidemia  ENT1END  requiring drug intervention was enrolled at 1,081 sites. Patients were treated with 1 tablet (500 mg of ENT2 niacin ENT2END extended-release/20 mg of lovastatin) once nightly for 4 weeks and then 2 tablets for 8 weeks
0	Patients also received dietary counseling, educational materials, and reminders to call a toll-free number that provided further education about ENT1 dyslipidemia ENT1END and ENT2 niacin extended-release/lovastatin ENT2END
0	We studied 212 ENT1 RRMM ENT1END patients who received RD in RW. Objective response (>PR (partial response)) rate was 77.4 % (complete response (CR), 20.2 %). Median time to first and best response was 2 and 5 months, respectively. Median time to CR when RD was given as 2nd or >2(nd)-line treatment at 4 and 11 months, respectively. Quality of response was independent of previous lines of therapies or previous exposure to thalidomide or ENT2 bortezomib ENT2END
0	We studied 212 ENT1 RRMM ENT1END  patients who received ENT2 RD ENT2END in RW
0	We studied 212 ENT1 RRMM ENT1END  patients who received RD in RW. Objective response (>PR (partial response)) rate was 77.4 % (complete response (CR), 20.2 %). Median time to first and best response was 2 and 5 months, respectively. Median time to CR when RD was given as 2nd or >2(nd)-line treatment at 4 and 11 months, respectively. Quality of response was independent of previous lines of therapies or previous exposure to ENT2 thalidomide ENT2END or bortezomib
0	"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek ENT1 Myeloma  ENT1END  Study Group. ENT2 Lenalidomide ENT2END and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition
0	Quality of response was independent of previous lines of therapies or previous exposure to thalidomide or ENT1 bortezomib ENT1END . Median duration of response was 34.4 months, and it was higher in patients who received RD until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients (myelosuppression in 49.4 %) and 12.7 % of patients needed hospitalization. Peripheral neuropathy was observed only in 2.5 % of patients and ENT2 deep vein thrombosis ENT2END in 5
1	5 % of patients and ENT1 deep vein thrombosis ENT1END  in 5.7 %. Dose reductions were needed in 31 % of patients and permanent discontinuation in 38.9 %. Median time to treatment discontinuation was 16.8 months. Performance status (PS) and initial lenalidomide dose predicted for treatment discontinuation. Extra-medullary relapses occurred in 3.8 % of patients. Our study confirms that ENT2 RD ENT2END is effective and safe in RRMM in the RW; it produces durable responses especially in patients who continue on treatment till progression and improves humoral immunity even in patients with stable disease
0	Quality of response was independent of previous lines of therapies or previous exposure to ENT1 thalidomide  ENT1END  or bortezomib. Median duration of response was 34.4 months, and it was higher in patients who received RD until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients (myelosuppression in 49.4 %) and 12.7 % of patients needed hospitalization. Peripheral neuropathy was observed only in 2.5 % of patients and ENT2 deep vein thrombosis ENT2END in 5
1	5 % of patients and ENT1 deep vein thrombosis ENT1END  in 5.7 %. Dose reductions were needed in 31 % of patients and permanent discontinuation in 38.9 %. Median time to treatment discontinuation was 16.8 months. Performance status (PS) and initial ENT2 lenalidomide ENT2END dose predicted for treatment discontinuation
0	Quality of response was independent of previous lines of therapies or previous exposure to thalidomide or ENT1 bortezomib  ENT1END . Median duration of response was 34.4 months, and it was higher in patients who received RD until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients ( ENT2 myelosuppression ENT2END in 49
1	4 months, and it was higher in patients who received ENT1 RD ENT1END until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients ENT2 myelosuppression ENT2END in 49
0	Quality of response was independent of previous lines of therapies or previous exposure to ENT1 thalidomide ENT1END  or bortezomib. Median duration of response was 34.4 months, and it was higher in patients who received RD until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients ENT2 myelosuppression ENT2END in 49
1	4 months, and it was higher in patients who received ENT1 RD ENT1END until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients ENT2 myelosuppression ENT2END in 49
0	Quality of response was independent of previous lines of therapies or previous exposure to thalidomide or ENT1 bortezomib ENT1END . Median duration of response was 34.4 months, and it was higher in patients who received RD until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients (myelosuppression in 49.4 %) and 12.7 % of patients needed hospitalization. ENT2 Peripheral neuropathy ENT2END was observed only in 2
1	4 months, and it was higher in patients who received ENT1 RD  ENT1END  until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients (myelosuppression in 49.4 %) and 12.7 % of patients needed hospitalization. ENT2 Peripheral neuropathy ENT2END was observed only in 2
0	Quality of response was independent of previous lines of therapies or previous exposure to ENT1 thalidomide  ENT1END  or bortezomib. Median duration of response was 34.4 months, and it was higher in patients who received RD until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients (myelosuppression in 49.4 %) and 12.7 % of patients needed hospitalization. ENT2 Peripheral neuropathy ENT2END was observed only in 2
1	ENT1 Peripheral neuropathy  ENT1END  was observed only in 2.5 % of patients and deep vein thrombosis in 5.7 %. Dose reductions were needed in 31 % of patients and permanent discontinuation in 38.9 %. Median time to treatment discontinuation was 16.8 months. Performance status (PS) and initial ENT2 lenalidomide ENT2END dose predicted for treatment discontinuation
0	Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with ENT1 streptozotocin ENT1END .Basic and clinical research has demonstrated that ENT2 dementia ENT2END of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells
0	Long-term oral ENT1 galactose  ENT1END  treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin.Basic and clinical research has demonstrated that ENT2 dementia ENT2END of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells
0	Basic and clinical research has demonstrated that ENT1 dementia ENT1END  of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased ENT2 glucose ENT2END transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells
0	One month of oral galactose treatment initiated immediately after the STZ-icv administration, successfully prevented development of the ENT1 STZ ENT1END icv-induced cognitive deficits. Beneficial effect of oral galactose was independent of the rat age and of the galactose dose ranging from 100 to 300 mg/kg/day. Additionally, oral galactose administration led to the appearance of galactose in the blood. The increase of galactose concentration in the cerebrospinal fluid was several times lower after oral than after parenteral administration of the same galactose dose. Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with ENT2 glucose hypometabolism ENT2END in AD
0	Oral ENT1 galactose  ENT1END exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with ENT2 glucose hypometabolism ENT2END in AD
1	We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on ENT1 cognitive deficits ENT1END in ENT2 streptozotocin ENT2END -induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively
1	Long-term oral ENT1 galactose  ENT1END  treatment prevents ENT2 cognitive deficits ENT2END in male Wistar rats treated intracerebroventricularly with streptozotocin
0	Long-term oral galactose treatment prevents ENT1 cognitive deficits  ENT1END  in male Wistar rats treated intracerebroventricularly with streptozotocin.Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased ENT2 glucose ENT2END transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells
1	Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with ENT1 streptozotocin ENT1END .Basic and clinical research has demonstrated that dementia of sporadic ENT2 Alzheimer's disease ENT2END (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells
0	Oral ENT1 galactose ENT1END  exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in ENT2 AD ENT2END
1	Basic and clinical research has demonstrated that dementia of sporadic ENT1 Alzheimer's disease  ENT1END  (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased ENT2 glucose ENT2END transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells
0	Exclusively parenteral daily injections of galactose induce ENT1 memory deterioration  ENT1END in rodents and are used to generate animal aging model, but the effects of oral galactose treatment on cognitive functions have never been tested. We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in ENT2 streptozotocin ENT2END -induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively
0	Exclusively parenteral daily injections of ENT1 galactose  ENT1END induce ENT2 memory deterioration ENT2END in rodents and are used to generate animal aging model, but the effects of oral galactose treatment on cognitive functions have never been tested
0	An alternative source of energy is d-galactose (the C-4-epimer of d-glucose) which is transported into the brain by insulin-independent GLUT3 transporter where it might be metabolized to ENT1 glucose  ENT1END via the Leloir pathway. Exclusively parenteral daily injections of galactose induce ENT2 memory deterioration ENT2END in rodents and are used to generate animal aging model, but the effects of oral galactose treatment on cognitive functions have never been tested
0	There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and ENT1 necrosis ENT1END in ENT2 VCM ENT2END -treated rats more than those of the control and the erdosteine groups
0	VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased ENT1 superoxide  ENT1END dismutase (SOD) and catalase (CAT) activities. Erdosteine administration with VCM injections caused significantly decreased renal MDA and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone. Erdosteine showed histopathological protection against VCM-induced nephrotoxicity. There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and ENT2 necrosis ENT2END in VCM-treated rats more than those of the control and the erdosteine groups
0	Erdosteine administration with VCM injections caused significantly decreased renal ENT1 MDA  ENT1END and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone. Erdosteine showed histopathological protection against VCM-induced nephrotoxicity. There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and ENT2 necrosis ENT2END in VCM-treated rats more than those of the control and the erdosteine groups
0	There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and ENT1 necrosis ENT1END  in VCM-treated rats more than those of the control and the ENT2 erdosteine ENT2END groups
0	In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced ENT1 nephrotoxicity ENT1END : protection by erdosteine.The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive ENT2 oxygen ENT2END species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats
1	It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the ENT1 VCM ENT1END induced ENT2 kidney damage ENT2END both at the biochemical and histological levels
0	VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of ENT1 renal tubular injury  ENT1END  excretion but decreased ENT2 superoxide ENT2END dismutase (SOD) and catalase (CAT) activities
0	VCM administration to control rats significantly increased renal malondialdehyde ( ENT1 MDA  ENT1END  and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of ENT2 renal tubular injury ENT2END ) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities
0	In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced ENT1 nephrotoxicity  ENT1END : protection by ENT2 erdosteine ENT2END
0	There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, ENT1 atrophy  ENT1END  desquamation, and necrosis in ENT2 VCM ENT2END -treated rats more than those of the control and the erdosteine groups
0	VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased ENT1 superoxide  ENT1END  dismutase (SOD) and catalase (CAT) activities. Erdosteine administration with VCM injections caused significantly decreased renal MDA and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone. Erdosteine showed histopathological protection against VCM-induced nephrotoxicity. There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, ENT2 atrophy ENT2END , desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups
0	Erdosteine administration with VCM injections caused significantly decreased renal ENT1 MDA  ENT1END  and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone. Erdosteine showed histopathological protection against VCM-induced nephrotoxicity. There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, ENT2 atrophy ENT2END , desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups
0	There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, ENT1 atrophy  ENT1END , desquamation, and necrosis in VCM-treated rats more than those of the control and the ENT2 erdosteine ENT2END groups
0	Treatment of ENT1 ovarian cancer  ENT1END  with a combination of cis-platinum, ENT2 adriamycin ENT2END , cyclophosphamide and hexamethylmelamine
0	Treatment of ENT1 ovarian cancer  ENT1END  with a combination of cis-platinum, adriamycin, ENT2 cyclophosphamide ENT2END and hexamethylmelamine
0	During the last 2 1/2 years, 38 patients with ENT1 ovarian cancer  ENT1END were treated with a combination of cisplatinum ( ENT2 CPDD ENT2END ), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days
0	Treatment of ENT1 ovarian cancer  ENT1END  with a combination of ENT2 cis-platinum ENT2END , adriamycin, cyclophosphamide and hexamethylmelamine
0	Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and ENT1 hexamethylmelamine  ENT1END .During the last 2 1/2 years, 38 patients with ENT2 ovarian cancer ENT2END were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days
1	Hematologic toxicity was moderate and with reversible ENT1 anemia ENT1END developing in 71% of patients. Gastrointestinal side effects from ENT2 CPDD ENT2END were universal
0	Hematologic toxicity was moderate and with reversible ENT1 anemia ENT1END  developing in 71% of patients. Gastrointestinal side effects from CPDD were universal. ENT2 HMM ENT2END gastrointestinal toxicity necessitated discontinuation of the drug in 5 patients
1	Gastrointestinal side effects from ENT1 CPDD ENT1END  were universal. HMM gastrointestinal toxicity necessitated discontinuation of the drug in 5 patients. Severe ENT2 nephrotoxicity ENT2END was observed in 2 patients but was reversible
0	ENT1 HMM  ENT1END  gastrointestinal toxicity necessitated discontinuation of the drug in 5 patients. Severe ENT2 nephrotoxicity ENT2END was observed in 2 patients but was reversible
1	Gastrointestinal side effects from ENT1 CPDD ENT1END  were universal. HMM ENT2 gastrointestinal toxicity ENT2END necessitated discontinuation of the drug in 5 patients
0	ENT1 HMM ENT1END ENT2 gastrointestinal toxicity ENT2END necessitated discontinuation of the drug in 5 patients
0	ENT1 Hematologic toxicity  ENT1END was moderate and with reversible anemia developing in 71% of patients. Gastrointestinal side effects from ENT2 CPDD ENT2END were universal
0	ENT1 Hematologic toxicity  ENT1END  was moderate and with reversible anemia developing in 71% of patients. Gastrointestinal side effects from CPDD were universal. ENT2 HMM ENT2END gastrointestinal toxicity necessitated discontinuation of the drug in 5 patients
0	These rats are also highly susceptible to develop ENT1 papillary necrosis ENT1END with analgesic administration. We used homozygous (jj) and phenotypically normal heterozygous (jJ) animals. Four groups of rats (n = 7) were studied: jj and jJ rats treated either with ENT2 aspirin ENT2END 300 mg/kg every other day or sham-treated
0	We examined the potential role of ENT1 prostaglandins  ENT1END in the development of analgesic nephropathy in the Gunn strain of rat. The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla. These rats are also highly susceptible to develop ENT2 papillary necrosis ENT2END with analgesic administration
0	ENT1 Salicylate  ENT1END  nephropathy in the Gunn rat: potential role of prostaglandins.We examined the potential role of prostaglandins in the development of analgesic nephropathy in the Gunn strain of rat. The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla. These rats are also highly susceptible to develop ENT2 papillary necrosis ENT2END with analgesic administration
0	The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase, leading to marked ENT1 bilirubin  ENT1END deposition in renal medulla and papilla. These rats are also highly susceptible to develop ENT2 papillary necrosis ENT2END with analgesic administration
0	Aspirin treatment reduced PGE2 synthesis in all regions, but outer medullary ENT1 PGE2 ENT1END remained higher in jj (18 +/- 3) than jJ rats (9 +/- 2) (p less than 0.05). PGF2 alpha was also significantly higher in the outer medulla of jj rats with and without aspirin administration (p less than 0.05). The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ). These results suggest that enhanced prostaglandin synthesis contributes to maintenance of renal function and morphological integrity, and that inhibition of prostaglandin synthesis may lead to ENT2 pathological renal medullary lesions ENT2END and deterioration of renal function
0	ENT1 PGF2 alpha  ENT1END was also significantly higher in the outer medulla of jj rats with and without aspirin administration (p less than 0.05). The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ). These results suggest that enhanced prostaglandin synthesis contributes to maintenance of renal function and morphological integrity, and that inhibition of prostaglandin synthesis may lead to ENT2 pathological renal medullary lesions ENT2END and deterioration of renal function
0	005 compared to either sham-treated jj or ENT1 aspirin  ENT1END treated jJ). These results suggest that enhanced prostaglandin synthesis contributes to maintenance of renal function and morphological integrity, and that inhibition of prostaglandin synthesis may lead to ENT2 pathological renal medullary lesions ENT2END and deterioration of renal function
0	These results suggest that enhanced prostaglandin synthesis contributes to maintenance of renal function and morphological integrity, and that inhibition of ENT1 prostaglandin  ENT1END synthesis may lead to ENT2 pathological renal medullary lesions ENT2END and deterioration of renal function
0	01); increased serum ENT1 creatinine  ENT1END (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ). These results suggest that enhanced prostaglandin synthesis contributes to maintenance of renal function and morphological integrity, and that inhibition of prostaglandin synthesis may lead to ENT2 pathological renal medullary lesions ENT2END and deterioration of renal function
0	Aspirin treatment reduced PGE2 synthesis in all regions, but outer medullary ENT1 PGE2 ENT1END  remained higher in jj (18 +/- 3) than jJ rats (9 +/- 2) (p less than 0.05). PGF2 alpha was also significantly higher in the outer medulla of jj rats with and without aspirin administration (p less than 0.05). The changes in renal prostaglandin synthesis were accompanied by evidence of ENT2 renal damage ENT2END in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0
0	ENT1 PGF2 alpha  ENT1END  was also significantly higher in the outer medulla of jj rats with and without aspirin administration (p less than 0.05). The changes in renal prostaglandin synthesis were accompanied by evidence of ENT2 renal damage ENT2END in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0
1	The changes in renal prostaglandin synthesis were accompanied by evidence of ENT1 renal damage ENT1END  in ENT2 aspirin ENT2END -treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0
0	We examined the potential role of ENT1 prostaglandins ENT1END  in the development of analgesic ENT2 nephropathy ENT2END in the Gunn strain of rat
0	ENT1 Salicylate ENT1END ENT2 nephropathy ENT2END in the Gunn rat: potential role of prostaglandins
0	We examined the potential role of prostaglandins in the development of analgesic ENT1 nephropathy  ENT1END  in the Gunn strain of rat. The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase, leading to marked ENT2 bilirubin ENT2END deposition in renal medulla and papilla
0	The changes in renal prostaglandin synthesis were accompanied by evidence of ENT1 renal damage  ENT1END  in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum ENT2 creatinine ENT2END (p less than 0
0	Aspirin treatment reduced PGE2 synthesis in all regions, but outer medullary ENT1 PGE2 ENT1END  remained higher in jj (18 +/- 3) than jJ rats (9 +/- 2) (p less than 0.05). PGF2 alpha was also significantly higher in the outer medulla of jj rats with and without aspirin administration (p less than 0.05). The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of ENT2 hematuria ENT2END (p less than 0
0	ENT1 PGF2 alpha  ENT1END  was also significantly higher in the outer medulla of jj rats with and without aspirin administration (p less than 0.05). The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of ENT2 hematuria ENT2END (p less than 0
0	The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in ENT1 aspirin  ENT1END -treated jj but not jJ rats as evidenced by: increased incidence and severity of ENT2 hematuria ENT2END (p less than 0
0	The changes in renal ENT1 prostaglandin  ENT1END synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of ENT2 hematuria ENT2END (p less than 0
0	The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of ENT1 hematuria  ENT1END  (p less than 0.01); increased serum ENT2 creatinine ENT2END (p less than 0
0	The homozygous Gunn rats have unconjugated ENT1 hyperbilirubinemia  ENT1END due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla. These rats are also highly susceptible to develop papillary necrosis with analgesic administration. We used homozygous (jj) and phenotypically normal heterozygous (jJ) animals. Four groups of rats (n = 7) were studied: jj and jJ rats treated either with ENT2 aspirin ENT2END 300 mg/kg every other day or sham-treated
0	We examined the potential role of ENT1 prostaglandins  ENT1END  in the development of analgesic nephropathy in the Gunn strain of rat. The homozygous Gunn rats have unconjugated ENT2 hyperbilirubinemia ENT2END due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla
0	ENT1 Salicylate  ENT1END  nephropathy in the Gunn rat: potential role of prostaglandins.We examined the potential role of prostaglandins in the development of analgesic nephropathy in the Gunn strain of rat. The homozygous Gunn rats have unconjugated ENT2 hyperbilirubinemia ENT2END due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla
0	The homozygous Gunn rats have unconjugated ENT1 hyperbilirubinemia  ENT1END  due to the absence of glucuronyl transferase, leading to marked ENT2 bilirubin ENT2END deposition in renal medulla and papilla
1	OBJECTIVE: This study describes associations of ozone and fine ENT1 particulate matter ENT1END with ENT2 Parkinson's disease ENT2END observed among farmers in North Carolina and Iowa
1	RESULTS: We observed positive associations of ENT1 Parkinson's disease ENT1END with ENT2 ozone ENT2END (odds ratio = 1
1	CONCLUSIONS: ENT1 Indomethacin ENT1END resulted in histopathologic findings typical of interstitial cystitis, such as leaky bladder epithelium and mucosal ENT2 mastocytosis ENT2END
0	0001) and penetration of ENT1 lanthanum nitrate  ENT1END through intercellular areas of the epithelium. Furthermore, the difference in mast cell counts between the high and therapeutic dose groups was also statistically significant (P <0.0001). CONCLUSIONS: Indomethacin resulted in histopathologic findings typical of interstitial cystitis, such as leaky bladder epithelium and mucosal ENT2 mastocytosis ENT2END
0	OBJECTIVES: To evaluate the morphologic changes in rat urothelium induced by ENT1 indomethacin ENT1END  Nonsteroidal anti-inflammatory drug-induced ENT2 cystitis ENT2END is a poorly recognized and under-reported condition
0	Nonsteroidal anti-inflammatory drug-induced ENT1 cystitis ENT1END  is a poorly recognized and under-reported condition. In addition to ENT2 tiaprofenic acid ENT2END , indomethacin has been reported to be associated with this condition
0	0001) and penetration of ENT1 lanthanum nitrate ENT1END  through intercellular areas of the epithelium. Furthermore, the difference in mast cell counts between the high and therapeutic dose groups was also statistically significant (P <0.0001). CONCLUSIONS: Indomethacin resulted in histopathologic findings typical of interstitial cystitis, such as leaky bladder epithelium and mucosal mastocytosis. The true incidence of nonsteroidal anti-inflammatory drug-induced ENT2 cystitis ENT2END in humans must be clarified by prospective clinical trials
1	CONCLUSIONS: ENT1 Indomethacin ENT1END  resulted in histopathologic findings typical of ENT2 interstitial cystitis ENT2END , such as leaky bladder epithelium and mucosal mastocytosis
0	0001) and penetration of ENT1 lanthanum nitrate  ENT1END  through intercellular areas of the epithelium. Furthermore, the difference in mast cell counts between the high and therapeutic dose groups was also statistically significant (P <0.0001). CONCLUSIONS: Indomethacin resulted in histopathologic findings typical of ENT2 interstitial cystitis ENT2END , such as leaky bladder epithelium and mucosal mastocytosis
0	55 s in 13 patients, bradycardia less than 40 beats/min in 6 patients, dizziness and general ENT1 fatigue ENT1END in 1 patient each. In 4 of 13 patients with QT prolongation, Tdp occurred. The major triggering factors of Tdp were hypokalemia and sudden decrease in heart rate. There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with Tdp. CONCLUSION: Careful observation of serum ENT2 potassium ENT2END concentration and the ECG should always be done during Bpd administration, particularly in elderly patients
1	55 s in 13 patients, bradycardia less than 40 beats/min in 6 patients, dizziness and general ENT1 fatigue ENT1END  in 1 patient each. In 4 of 13 patients with QT prolongation, Tdp occurred. The major triggering factors of Tdp were hypokalemia and sudden decrease in heart rate. There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with Tdp. CONCLUSION: Careful observation of serum potassium concentration and the ECG should always be done during ENT2 Bpd ENT2END administration, particularly in elderly patients
0	The major triggering factors of Tdp were ENT1 hypokalemia  ENT1END and sudden decrease in heart rate. There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with Tdp. CONCLUSION: Careful observation of serum ENT2 potassium ENT2END concentration and the ECG should always be done during Bpd administration, particularly in elderly patients
0	The major triggering factors of Tdp were ENT1 hypokalemia  ENT1END  and sudden decrease in heart rate. There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with Tdp. CONCLUSION: Careful observation of serum potassium concentration and the ECG should always be done during ENT2 Bpd ENT2END administration, particularly in elderly patients
0	In 4 of 13 patients with ENT1 QT prolongation  ENT1END  Tdp occurred. The major triggering factors of Tdp were hypokalemia and sudden decrease in heart rate. There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with Tdp. CONCLUSION: Careful observation of serum ENT2 potassium ENT2END concentration and the ECG should always be done during Bpd administration, particularly in elderly patients
1	ENT1 Bpd ENT1END was administered to 459 patients (361 males, 63+/-12 years old) comprising 378 AF and 81 AFL cases. Mean left ventricular ejection fraction and atrial dimension (LAD) were 66+/-11% and 40+/-6 mm, respectively. Adverse effects were observed in 19 patients (4%) during an average follow-up of 20 months. There was marked ENT2 QT prolongation ENT2END greater than 0
1	There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with ENT1 Tdp  ENT1END  CONCLUSION: Careful observation of serum ENT2 potassium ENT2END concentration and the ECG should always be done during Bpd administration, particularly in elderly patients
1	However, serious adverse effects, including torsade de pointes ( ENT1 Tdp ENT1END , have been reported. METHODS AND RESULTS: Adverse effects of ENT2 Bpd ENT2END requiring discontinuation of treatment were evaluated
0	Clinical evaluation of adverse effects during ENT1 bepridil  ENT1END  administration for ENT2 atrial fibrillation and flutter ENT2END
0	Clinical evaluation of adverse effects during ENT1 bepridil  ENT1END  administration for ENT2 atrial fibrillation and flutter ENT2END
0	55 s in 13 patients, ENT1 bradycardia  ENT1END less than 40 beats/min in 6 patients, dizziness and general fatigue in 1 patient each. In 4 of 13 patients with QT prolongation, Tdp occurred. The major triggering factors of Tdp were hypokalemia and sudden decrease in heart rate. There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with Tdp. CONCLUSION: Careful observation of serum ENT2 potassium ENT2END concentration and the ECG should always be done during Bpd administration, particularly in elderly patients
1	ENT1 Bpd  ENT1END  was administered to 459 patients (361 males, 63+/-12 years old) comprising 378 AF and 81 AFL cases. Mean left ventricular ejection fraction and atrial dimension (LAD) were 66+/-11% and 40+/-6 mm, respectively. Adverse effects were observed in 19 patients (4%) during an average follow-up of 20 months. There was marked QT prolongation greater than 0.55 s in 13 patients, ENT2 bradycardia ENT2END less than 40 beats/min in 6 patients, dizziness and general fatigue in 1 patient each
0	55 s in 13 patients, bradycardia less than 40 beats/min in 6 patients, ENT1 dizziness  ENT1END and general fatigue in 1 patient each. In 4 of 13 patients with QT prolongation, Tdp occurred. The major triggering factors of Tdp were hypokalemia and sudden decrease in heart rate. There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with Tdp. CONCLUSION: Careful observation of serum ENT2 potassium ENT2END concentration and the ECG should always be done during Bpd administration, particularly in elderly patients
1	ENT1 Bpd  ENT1END  was administered to 459 patients (361 males, 63+/-12 years old) comprising 378 AF and 81 AFL cases. Mean left ventricular ejection fraction and atrial dimension (LAD) were 66+/-11% and 40+/-6 mm, respectively. Adverse effects were observed in 19 patients (4%) during an average follow-up of 20 months. There was marked QT prolongation greater than 0.55 s in 13 patients, bradycardia less than 40 beats/min in 6 patients, ENT2 dizziness ENT2END and general fatigue in 1 patient each
1	CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or ENT1 propofol ENT1END  Providers should similarly consider the likelihood of ENT2 hypotension ENT2END or bradycardia before starting either sedative
1	CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive ENT1 dexmedetomidine  ENT1END or propofol. Providers should similarly consider the likelihood of ENT2 hypotension ENT2END or bradycardia before starting either sedative
1	CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or ENT1 propofol ENT1END . Providers should similarly consider the likelihood of hypotension or ENT2 bradycardia ENT2END before starting either sedative
1	CONCLUSIONS: Severe hypotension and ENT1 bradycardia  ENT1END occur at similar prevalence in neurocritical care patients who receive ENT2 dexmedetomidine ENT2END or propofol
1	Intravascular hemolysis leading to ENT1 acute renal failure ENT1END following ENT2 rifampin ENT2END therapy is extremely rare
0	Intravascular hemolysis leading to acute renal failure following ENT1 rifampin ENT1END  therapy is extremely rare. Two patients with ENT2 leprosy ENT2END who developed hemolysis and acute renal failure following rifampin are reported
1	Renal failure is a rare complication associated with the use of ENT1 rifampin ENT1END  Intravascular ENT2 hemolysis ENT2END leading to acute renal failure following rifampin therapy is extremely rare
0	Intravascular hemolysis and acute renal failure following intermittent ENT1 rifampin  ENT1END  therapy. ENT2 Renal failure ENT2END is a rare complication associated with the use of rifampin
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, ENT1 colorectal cancer ENT1END  ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENT2 progestogens ENT2END ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, ENT1 colorectal cancer  ENT1END , ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT ( ENT2 oestrogens ENT2END with or without progestogens) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	It has also been used for the management and prevention of ENT1 cardiovascular disease  ENT1END  osteoporosis and dementia in older women but the evidence supporting its use for these indications is largely observational. OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENT2 progestogens ENT2END ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	Among women with ENT1 cardiovascular disease ENT1END  long-term use of combined continuous HT significantly increased the risk of venous thromboembolism. No trials focussed specifically on younger women. However, one trial analysed subgroups of 2839 relatively healthy 50 to 59 year-old women taking combined continuous HT and 1637 taking ENT2 oestrogen ENT2END -only HT, versus similar-sized placebo groups
1	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, ENT1 gallbladder disease  ENT1END  cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENT2 progestogens ENT2END ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	In relatively healthy women, combined continuous HT significantly increased the risk of venous thromboembolism or coronary event (after one year's use), stroke (after 3 years), breast cancer (after 5 years) and ENT1 gallbladder disease ENT1END  Long-term ENT2 oestrogen ENT2END -only HT also significantly increased the risk of stroke and gallbladder disease
0	Long-term ENT1 oestrogen ENT1END -only HT also significantly increased the risk of stroke and gallbladder disease. Overall, the only statistically significant benefits of HT were a decreased incidence of fractures and ENT2 colon cancer ENT2END with long-term use
0	It has also been used for the management and prevention of cardiovascular disease, ENT1 osteoporosis  ENT1END and dementia in older women but the evidence supporting its use for these indications is largely observational. OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENT2 progestogens ENT2END ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	It has also been used for the management and prevention of cardiovascular disease, ENT1 osteoporosis ENT1END  and dementia in older women but the evidence supporting its use for these indications is largely observational. OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT ENT2 oestrogens ENT2END with or without progestogens) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, ENT1 breast cancer  ENT1END  colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENT2 progestogens ENT2END ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	In relatively healthy women, combined continuous HT significantly increased the risk of venous thromboembolism or coronary event (after one year's use), stroke (after 3 years), ENT1 breast cancer  ENT1END (after 5 years) and gallbladder disease. Long-term ENT2 oestrogen ENT2END -only HT also significantly increased the risk of stroke and gallbladder disease
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, ENT1 endometrial cancer  ENT1END  gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENT2 progestogens ENT2END ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, ENT1 endometrial cancer ENT1END , gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT ENT2 oestrogens ENT2END with or without progestogens) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	However, one trial analysed subgroups of 2839 relatively healthy 50 to 59 year-old women taking combined continuous HT and 1637 taking ENT1 oestrogen ENT1END -only HT, versus similar-sized placebo groups. The only significantly increased risk reported was for venous thromboembolism in women taking combined continuous HT; their absolute risk remained very low. AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of ENT2 chronic disease ENT2END
0	BACKGROUND: Hormone therapy (HT) is widely used for controlling ENT1 menopausal symptoms  ENT1END  It has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women but the evidence supporting its use for these indications is largely observational. OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENT2 progestogens ENT2END ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	BACKGROUND: Hormone therapy (HT) is widely used for controlling ENT1 menopausal symptoms ENT1END . It has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women but the evidence supporting its use for these indications is largely observational. OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT ENT2 oestrogens ENT2END with or without progestogens) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, ENT1 stroke  ENT1END  transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENT2 progestogens ENT2END ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	Long-term ENT1 oestrogen ENT1END -only HT also significantly increased the risk of ENT2 stroke ENT2END and gallbladder disease
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ENT1 ovarian cancer  ENT1END  endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENT2 progestogens ENT2END ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ENT1 ovarian cancer ENT1END , endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT ENT2 oestrogens ENT2END with or without progestogens) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, ENT1 dementia  ENT1END  fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENT2 progestogens ENT2END ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	Among relatively healthy women over 65 years taking continuous combined HT, there was a statistically significant increase in the incidence of ENT1 dementia  ENT1END  Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thromboembolism. No trials focussed specifically on younger women. However, one trial analysed subgroups of 2839 relatively healthy 50 to 59 year-old women taking combined continuous HT and 1637 taking ENT2 oestrogen ENT2END -only HT, versus similar-sized placebo groups
0	OBJECTIVES: To assess the effect of long-term HT on mortality, ENT1 heart disease  ENT1END  venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENT2 progestogens ENT2END ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	OBJECTIVES: To assess the effect of long-term HT on mortality, ENT1 heart disease ENT1END , venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT ENT2 oestrogens ENT2END with or without progestogens) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, ENT1 fractures  ENT1END and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENT2 progestogens ENT2END ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	Long-term ENT1 oestrogen ENT1END -only HT also significantly increased the risk of stroke and gallbladder disease. Overall, the only statistically significant benefits of HT were a decreased incidence of ENT2 fractures ENT2END and colon cancer with long-term use
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, ENT1 transient ischaemic attacks  ENT1END  breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENT2 progestogens ENT2END ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, ENT1 transient ischaemic attacks ENT1END , breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT ENT2 oestrogens ENT2END with or without progestogens) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	However, one trial analysed subgroups of 2839 relatively healthy 50 to 59 year-old women taking combined continuous HT and 1637 taking ENT1 oestrogen ENT1END -only HT, versus similar-sized placebo groups. The only significantly increased risk reported was for ENT2 venous thromboembolism ENT2END in women taking combined continuous HT; their absolute risk remained very low
0	These data suggest a protective role for the central ENT1 dopamine ENT1END blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of ENT2 seizures ENT2END
1	Haloperidol decreased the incidence of ENT1 cocaine ENT1END induced ENT2 seizures ENT2END at the two highest doses, but the lowering of the mortality rate did not reach statistical significance at any dose
0	These data suggest a protective role for the central dopamine blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of ENT1 seizures ENT1END . In contrast, ENT2 haloperidol ENT2END demonstrated an ability to reduce cocaine-induced seizures without significantly reducing mortality
1	Haloperidol failed to prevent ENT1 amphetamine ENT1END induced ENT2 seizures ENT2END , but did lower the mortality rate at most doses tested
0	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENT1 necrosis ENT1END and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture. In addition, maleate treatment reduced oxygen consumption in ENT2 ADP ENT2END -stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate
0	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, ENT1 sodium  ENT1END  neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENT2 necrosis ENT2END and apoptosis of tubular cells on 24 h
0	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENT1 necrosis ENT1END  and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. Maleate induced cell damage and reactive ENT2 oxygen ENT2END species (ROS) production in LLC-PK1 cells in culture
0	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, ENT1 glucose  ENT1END  sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENT2 necrosis ENT2END and apoptosis of tubular cells on 24 h
0	The potential protective effect of the dietary antioxidant ENT1 curcumin  ENT1END (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated. Tubular proteinuria and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats. Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENT2 necrosis ENT2END and apoptosis of tubular cells on 24 h
0	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENT1 necrosis ENT1END  and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture. In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using ENT2 malate ENT2END /glutamate as substrate
1	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENT1 necrosis ENT1END  and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. ENT2 Maleate ENT2END induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture
0	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENT1 necrosis  ENT1END  and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture. In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate/ ENT2 glutamate ENT2END as substrate
0	In addition, maleate treatment reduced oxygen consumption in ENT1 ADP ENT1END -stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate. The activities of both complex I and aconitase were also diminished. All the above-described alterations were prevented by curcumin. It is concluded that curcumin is able to attenuate in vivo maleate-induced ENT2 nephropathy ENT2END and in vitro cell damage
0	Maleate-induced ENT1 renal injury  ENT1END included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, ENT2 sodium ENT2END , neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h
0	Curcumin prevents maleate-induced ENT1 nephrotoxicity  ENT1END : relation to hemodynamic alterations, oxidative stress, mitochondrial ENT2 oxygen ENT2END consumption and activity of respiratory complex I
0	Maleate-induced ENT1 renal injury  ENT1END  included increase in renal vascular resistance and in the urinary excretion of total protein, ENT2 glucose ENT2END , sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h
0	ENT1 Curcumin  ENT1END  prevents maleate-induced ENT2 nephrotoxicity ENT2END : relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I
0	In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using ENT1 malate  ENT1END /glutamate as substrate. The activities of both complex I and aconitase were also diminished. All the above-described alterations were prevented by curcumin. It is concluded that curcumin is able to attenuate in vivo maleate-induced ENT2 nephropathy ENT2END and in vitro cell damage
1	It is concluded that curcumin is able to attenuate in vivo ENT1 maleate  ENT1END induced ENT2 nephropathy ENT2END and in vitro cell damage
0	In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate/ ENT1 glutamate  ENT1END  as substrate. The activities of both complex I and aconitase were also diminished. All the above-described alterations were prevented by curcumin. It is concluded that curcumin is able to attenuate in vivo maleate-induced ENT2 nephropathy ENT2END and in vitro cell damage
0	Tubular ENT1 proteinuria  ENT1END and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats. Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture. In addition, maleate treatment reduced oxygen consumption in ENT2 ADP ENT2END -stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate
0	Tubular ENT1 proteinuria  ENT1END  and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats. Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, ENT2 sodium ENT2END , neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h
0	Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial ENT1 oxygen  ENT1END  consumption and activity of respiratory complex I.The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated. Tubular ENT2 proteinuria ENT2END and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats
0	Tubular ENT1 proteinuria  ENT1END  and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats. Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, ENT2 glucose ENT2END , sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h
0	The potential protective effect of the dietary antioxidant ENT1 curcumin  ENT1END  (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated. Tubular ENT2 proteinuria ENT2END and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats
0	Tubular ENT1 proteinuria  ENT1END  and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats. Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture. In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using ENT2 malate ENT2END /glutamate as substrate
1	The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by ENT1 maleate  ENT1END was evaluated. Tubular ENT2 proteinuria ENT2END and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats
0	Tubular ENT1 proteinuria  ENT1END  and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats. Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture. In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate ENT2 glutamate ENT2END as substrate
0	Myopathy due to lack of ENT1 vitamin E ENT1END and ENT2 myopathy ENT2END induced by certain viruses have much in common anatomically and pathologically with the human form
0	The authors conclude by affirming the undoubted efficacy of the anabolizing ENT1 steroids ENT1END in experimental ENT2 myopathic disease ENT2END , but they have reservations as to the transfer of the results into the human field, where high dosage cannot be carried out continuously because of the effects of the drug on virility; because the tissue injury too often occurs at an irreversible stage vis-a-vis the "regeneration" of the muscle tissue; and finally because the dystrophic injurious agent is certainly not the lack of vitamin E but something as yet unknown
0	The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent ( ENT1 Dianabol ENT1END  CIBA) at high doses in rats rendered ENT2 myopathic ENT2END by a diet deficient in vitamin E
1	The authors induced ENT1 myodystrophy ENT1END in the rat by giving it a diet lacking in ENT2 vitamin E ENT2END
0	The authors induced ENT1 myodystrophy ENT1END  in the rat by giving it a diet lacking in vitamin E. The pharmacological characteristics of vitamin E and the degenerative changes brought about by its deficiency, especially in the muscles, are illustrated. It is thus confirmed that the histological characteristics of myopathic rat muscle induced experimentally are extraordinarily similar to those of human myopathy as confirmed during biopsies performed at the Orthopaedic Traumatological Centre, Florence. The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing ENT2 steroids ENT2END have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E
1	The authors induced ENT1 myodystrophy ENT1END  in the rat by giving it a diet lacking in vitamin E. The pharmacological characteristics of vitamin E and the degenerative changes brought about by its deficiency, especially in the muscles, are illustrated. It is thus confirmed that the histological characteristics of myopathic rat muscle induced experimentally are extraordinarily similar to those of human myopathy as confirmed during biopsies performed at the Orthopaedic Traumatological Centre, Florence. The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent ENT2 Dianabol ENT2END , CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E
0	After ENT1 dipyridamole ENT1END  ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the ENT2 INF-MI ENT2END group and 61% of the total population
0	After ENT1 dipyridamole ENT1END , ENT2 ischemic ENT2END ST-segment depression (0
0	After ENT1 dipyridamole ENT1END , ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ENT2 ANT-MI ENT2END group, 63% of the INF-MI group and 61% of the total population
1	The data suggest that the ENT1 dipyridamole ENT1END induced ENT2 myocardial ischemia ENT2END is caused by the inhomogenous distribution of myocardial blood flow
0	After ENT1 dipyridamole  ENT1END , ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non- ENT2 MI ENT2END group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population
0	After ENT1 dipyridamole ENT1END , ischemic ST-segment ENT2 depression ENT2END (0
0	Non-invasive detection of ENT1 coronary artery disease  ENT1END  by body surface electrocardiographic mapping after ENT2 dipyridamole ENT2END infusion
0	Aconitine-induced Ca2+ overload causes ENT1 arrhythmia ENT1END  and triggers apoptosis through p38 MAPK signaling pathway in rats.Aconitine is a major bioactive diterpenoid alkaloid with high content derived from herbal aconitum plants. Emerging evidence indicates that voltage-dependent ENT2 Na ENT2END (+) channels have pivotal roles in the cardiotoxicity of aconitine
0	We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused ENT1 arrhythmia  ENT1END in conscious freely moving rats. To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats. The results showed that aconitine resulted in myocardial injury and reduced NRVMs viability dose-dependently. To confirm the pro-apoptotic effects, we performed flow cytometric detection, cardiac histology, transmission electron microscopy and terminal deoxynucleotidyl transferase-mediated dUTP- ENT2 biotin ENT2END nick end labeling assay
0	We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused ENT1 arrhythmia ENT1END  in conscious freely moving rats. To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured ENT2 lactate ENT2END dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
1	ENT1 Aconitine  ENT1END -induced Ca2+ overload causes ENT2 arrhythmia ENT2END and triggers apoptosis through p38 MAPK signaling pathway in rats
0	Aconitine-induced ENT1 Ca  ENT1END 2+ overload causes ENT2 arrhythmia ENT2END and triggers apoptosis through p38 MAPK signaling pathway in rats
0	Emerging evidence indicates that voltage-dependent ENT1 Na ENT1END (+) channels have pivotal roles in the cardiotoxicity of aconitine. However, no reports are available on the role of Ca(2+) in aconitine ENT2 poisoning ENT2END
0	In this study, we explored the importance of pathological Ca(2+) signaling in aconitine ENT1 poisoning  ENT1END in vitro and in vivo. We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats. To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats. The results showed that aconitine resulted in myocardial injury and reduced NRVMs viability dose-dependently. To confirm the pro-apoptotic effects, we performed flow cytometric detection, cardiac histology, transmission electron microscopy and terminal deoxynucleotidyl transferase-mediated dUTP ENT2 biotin ENT2END nick end labeling assay
0	In this study, we explored the importance of pathological Ca(2+) signaling in aconitine ENT1 poisoning  ENT1END  in vitro and in vivo. We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats. To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured ENT2 lactate ENT2END dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
1	However, no reports are available on the role of Ca(2+) in ENT1 aconitine ENT1END ENT2 poisoning ENT2END
0	However, no reports are available on the role of ENT1 Ca  ENT1END 2+) in aconitine ENT2 poisoning ENT2END
0	Emerging evidence indicates that voltage-dependent ENT1 Na ENT1END (+) channels have pivotal roles in the ENT2 cardiotoxicity ENT2END of aconitine
0	Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the ENT1 cardiotoxicity  ENT1END  of aconitine. However, no reports are available on the role of Ca(2+) in aconitine poisoning. In this study, we explored the importance of pathological Ca(2+) signaling in aconitine poisoning in vitro and in vivo. We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats. To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured ENT2 lactate ENT2END dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
1	Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the ENT1 cardiotoxicity ENT1END  of ENT2 aconitine ENT2END
0	Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the ENT1 cardiotoxicity  ENT1END  of aconitine. However, no reports are available on the role of ENT2 Ca ENT2END (2+) in aconitine poisoning
0	Emerging evidence indicates that voltage-dependent ENT1 Na ENT1END (+) channels have pivotal roles in the cardiotoxicity of aconitine. However, no reports are available on the role of Ca(2+) in aconitine poisoning. In this study, we explored the importance of pathological Ca(2+) signaling in aconitine poisoning in vitro and in vivo. We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats. To investigate effects of aconitine on myocardial injury, we performed ENT2 cytotoxicity ENT2END assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
0	To investigate effects of aconitine on myocardial injury, we performed ENT1 cytotoxicity  ENT1END  assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats. The results showed that aconitine resulted in myocardial injury and reduced NRVMs viability dose-dependently. To confirm the pro-apoptotic effects, we performed flow cytometric detection, cardiac histology, transmission electron microscopy and terminal deoxynucleotidyl transferase-mediated dUTP ENT2 biotin ENT2END nick end labeling assay
0	To investigate effects of aconitine on myocardial injury, we performed ENT1 cytotoxicity  ENT1END  assay in neonatal rat ventricular myocytes (NRVMs), as well as measured ENT2 lactate ENT2END dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
0	To investigate effects of ENT1 aconitine  ENT1END on myocardial injury, we performed ENT2 cytotoxicity ENT2END assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
0	We found that ENT1 Ca  ENT1END 2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats. To investigate effects of aconitine on myocardial injury, we performed ENT2 cytotoxicity ENT2END assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
0	Emerging evidence indicates that voltage-dependent ENT1 Na ENT1END (+) channels have pivotal roles in the cardiotoxicity of aconitine. However, no reports are available on the role of Ca(2+) in aconitine poisoning. In this study, we explored the importance of pathological Ca(2+) signaling in aconitine poisoning in vitro and in vivo. We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats. To investigate effects of aconitine on ENT2 myocardial injury ENT2END , we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
0	The results showed that aconitine resulted in ENT1 myocardial injury  ENT1END and reduced NRVMs viability dose-dependently. To confirm the pro-apoptotic effects, we performed flow cytometric detection, cardiac histology, transmission electron microscopy and terminal deoxynucleotidyl transferase-mediated dUTP ENT2 biotin ENT2END nick end labeling assay
0	To investigate effects of aconitine on ENT1 myocardial injury  ENT1END , we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured ENT2 lactate ENT2END dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
0	To investigate effects of ENT1 aconitine  ENT1END  on ENT2 myocardial injury ENT2END , we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
0	We found that ENT1 Ca  ENT1END (2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats. To investigate effects of aconitine on ENT2 myocardial injury ENT2END , we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
1	Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in ENT1 Gentamicin  ENT1END -induced ENT2 Nephropathy ENT2END
0	The present study was aimed to determine whether there is an altered regulation of tubular transporters in gentamicin-induced ENT1 nephropathy ENT1END  Sprague-Dawley male rats (200~250 g) were subcutaneously injected with gentamicin (100 mg/kg per day) for 7 days, and the expression of tubular transporters was determined by immunoblotting and immunohistochemistry. The mRNA and protein expression of OAT was also determined. Gentamicin-treated rats exhibited significantly decreased ENT2 creatinine ENT2END clearance along with increased plasma creatinine levels
0	Decreased Expression of Na/ ENT1 K  ENT1END -ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced ENT2 Nephropathy ENT2END
0	Decreased Expression of ENT1 Na  ENT1END /K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced ENT2 Nephropathy ENT2END
1	Liver-specific ablation of integrin-linked kinase in mice results in enhanced and prolonged cell proliferation and ENT1 hepatomegaly  ENT1END  after ENT2 phenobarbital ENT2END administration
0	RESULTS: While the ENT1 CAN ENT1END and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of ENT2 impaired memory ENT2END and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern
0	CONCLUSIONS: Given this record of ENT1 impaired memory ENT1END  and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ENT2 ecstasy ENT2END users is a major cause for concern
0	RESULTS: While the ENT1 CAN  ENT1END and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of ENT2 impaired memory ENT2END and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern
0	RESULTS: While the ENT1 CAN  ENT1END and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of ENT2 impaired memory ENT2END and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern
0	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/ ENT1 alcohol  ENT1END nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA). Participants completed a drug history questionnaire, Beck Depression Inventory, Barratt Impulsiveness Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures. RESULTS: While the CAN and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of ENT2 impaired memory ENT2END and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern
0	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine ( ENT1 CAN ENT1END , non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA). Participants completed a drug history questionnaire, Beck ENT2 Depression ENT2END Inventory, Barratt Impulsiveness Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures
1	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX- ENT1 MDMA  ENT1END . Participants completed a drug history questionnaire, Beck ENT2 Depression ENT2END Inventory, Barratt Impulsiveness Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures
0	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine ( ENT1 CAN  ENT1END , non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA). Participants completed a drug history questionnaire, Beck ENT2 Depression ENT2END Inventory, Barratt Impulsiveness Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures
0	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine ( ENT1 CAN  ENT1END , non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA). Participants completed a drug history questionnaire, Beck ENT2 Depression ENT2END Inventory, Barratt Impulsiveness Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures
0	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/ ENT1 alcohol  ENT1END /nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA). Participants completed a drug history questionnaire, Beck ENT2 Depression ENT2END Inventory, Barratt Impulsiveness Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures
0	Participants completed a drug history questionnaire, Beck Depression Inventory, Barratt ENT1 Impulsiveness  ENT1END Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures. RESULTS: While the ENT2 CAN ENT2END and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures
1	CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, ENT1 impulsiveness  ENT1END  and sleep disturbance, the prognosis for the current generation of ENT2 ecstasy ENT2END users is a major cause for concern
0	Participants completed a drug history questionnaire, Beck Depression Inventory, Barratt ENT1 Impulsiveness  ENT1END  Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures. RESULTS: While the ENT2 CAN ENT2END and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures
0	Participants completed a drug history questionnaire, Beck Depression Inventory, Barratt ENT1 Impulsiveness  ENT1END  Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures. RESULTS: While the ENT2 CAN ENT2END and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures
0	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/ ENT1 alcohol  ENT1END /nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA). Participants completed a drug history questionnaire, Beck Depression Inventory, Barratt ENT2 Impulsiveness ENT2END Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures
0	RESULTS: While the ENT1 CAN ENT1END  and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and ENT2 sleep disturbance ENT2END , the prognosis for the current generation of ecstasy users is a major cause for concern
1	CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and ENT1 sleep disturbance  ENT1END , the prognosis for the current generation of ENT2 ecstasy ENT2END users is a major cause for concern
0	RESULTS: While the ENT1 CAN  ENT1END  and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and ENT2 sleep disturbance ENT2END , the prognosis for the current generation of ecstasy users is a major cause for concern
0	RESULTS: While the ENT1 CAN  ENT1END  and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and ENT2 sleep disturbance ENT2END , the prognosis for the current generation of ecstasy users is a major cause for concern
0	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/ ENT1 alcohol  ENT1END /nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA). Participants completed a drug history questionnaire, Beck Depression Inventory, Barratt Impulsiveness Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures. RESULTS: While the CAN and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and ENT2 sleep disturbance ENT2END , the prognosis for the current generation of ecstasy users is a major cause for concern
0	Anaesthesia with a ENT1 propofol ENT1END infusion and avoidance of serotonin antagonists provided a ENT2 nausea ENT2END -free postoperative course without exacerbation of the depression disorder
0	Anaesthesia with a propofol infusion and avoidance of ENT1 serotonin  ENT1END antagonists provided a ENT2 nausea ENT2END -free postoperative course without exacerbation of the depression disorder
0	A 41-year-old woman with a strong history of postoperative nausea and vomiting presented for abdominal hysterectomy 3 months after a previous anaesthetic where ENT1 ondansetron  ENT1END prophylaxis had been used. She had developed a severe acute major depression disorder almost immediately thereafter, possibly related to the use of a serotonin antagonist. Nine years before she had experienced a self-limited puerperal depressive episode. Anaesthesia with a propofol infusion and avoidance of serotonin antagonists provided a ENT2 nausea ENT2END -free postoperative course without exacerbation of the depression disorder
0	She had developed a severe acute ENT1 major depression disorder  ENT1END almost immediately thereafter, possibly related to the use of a serotonin antagonist. Nine years before she had experienced a self-limited puerperal depressive episode. Anaesthesia with a ENT2 propofol ENT2END infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder
0	She had developed a severe acute ENT1 major depression disorder ENT1END  almost immediately thereafter, possibly related to the use of a ENT2 serotonin ENT2END antagonist
1	A 41-year-old woman with a strong history of postoperative nausea and vomiting presented for abdominal hysterectomy 3 months after a previous anaesthetic where ENT1 ondansetron  ENT1END  prophylaxis had been used. She had developed a severe acute ENT2 major depression disorder ENT2END almost immediately thereafter, possibly related to the use of a serotonin antagonist
0	Nine years before she had experienced a self-limited puerperal ENT1 depressive episode  ENT1END  Anaesthesia with a ENT2 propofol ENT2END infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder
0	Nine years before she had experienced a self-limited puerperal ENT1 depressive episode  ENT1END . Anaesthesia with a propofol infusion and avoidance of ENT2 serotonin ENT2END antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder
0	Acute severe ENT1 depression  ENT1END  following peri-operative ENT2 ondansetron ENT2END
0	A 41-year-old woman with a strong history of ENT1 postoperative nausea and vomiting  ENT1END presented for abdominal hysterectomy 3 months after a previous anaesthetic where ondansetron prophylaxis had been used. She had developed a severe acute major depression disorder almost immediately thereafter, possibly related to the use of a serotonin antagonist. Nine years before she had experienced a self-limited puerperal depressive episode. Anaesthesia with a ENT2 propofol ENT2END infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder
0	A 41-year-old woman with a strong history of ENT1 postoperative nausea and vomiting  ENT1END  presented for abdominal hysterectomy 3 months after a previous anaesthetic where ondansetron prophylaxis had been used. She had developed a severe acute major depression disorder almost immediately thereafter, possibly related to the use of a ENT2 serotonin ENT2END antagonist
0	Acute severe depression following peri-operative ENT1 ondansetron  ENT1END .A 41-year-old woman with a strong history of ENT2 postoperative nausea and vomiting ENT2END presented for abdominal hysterectomy 3 months after a previous anaesthetic where ondansetron prophylaxis had been used
1	5 patients with acute renal failure (3 with ENT1 thrombopenia ENT1END and hemolysis) induced by the reintroduction of ENT2 rifampicin ENT2END are described
0	5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of ENT1 rifampicin ENT1END  are described. No correlation was found between the severity of clinical manifestations and the total dose taken by the patients. In all but 1 patient, antirifampicin antibodies were detected. Antibodies suggested to be of the IgM class were detected in all 3 patients with ENT2 hematological disorders ENT2END
1	5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of ENT1 rifampicin ENT1END  are described. No correlation was found between the severity of clinical manifestations and the total dose taken by the patients. In all but 1 patient, antirifampicin antibodies were detected. Antibodies suggested to be of the IgM class were detected in all 3 patients with hematological disorders. The pattern of non-specific ENT2 acute tubular necrosis ENT2END found in the 2 biopsied patients, indistinguishable from that of ischemic origin, raised the possibility of a vascular-mediated damage
0	Antirifampicin antibodies in acute ENT1 rifampicin ENT1END -associated renal failure.5 patients with ENT2 acute renal failure ENT2END (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described
0	Antirifampicin antibodies in acute ENT1 rifampicin  ENT1END -associated ENT2 renal failure ENT2END
1	5 patients with acute renal failure (3 with thrombopenia and ENT1 hemolysis  ENT1END  induced by the reintroduction of ENT2 rifampicin ENT2END are described
0	001) but none in ENT1 warfarin ENT1END users with ENT2 IS ENT2END /TIA (OR, 1
0	METHODS: We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ENT1 ischemic ENT1END events stratified by antithrombotic use. We also analyzed published and unpublished follow-up data to determine the risk of ICH in antithrombotic users with MB. RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in ENT2 warfarin ENT2END users (P difference=0
0	001) but none in ENT1 warfarin  ENT1END  users with IS/ ENT2 TIA ENT2END (OR, 1
0	METHODS: We performed a systematic review of published and unpublished data from cohorts with ENT1 stroke  ENT1END or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ischemic events stratified by antithrombotic use. We also analyzed published and unpublished follow-up data to determine the risk of ICH in antithrombotic users with MB. RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in ENT2 warfarin ENT2END users (P difference=0
1	CONCLUSIONS: The excess of MB in ENT1 warfarin ENT1END users with ENT2 ICH ENT2END compared to other groups suggests that MB increase the risk of warfarin-associated ICH
0	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of ENT1 Mental Disorders ENT1END  Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral ENT2 caffeine ENT2END challenge test
0	The patients with PD and ENT1 MDP ENT1END were more sensitive to ENT2 caffeine ENT2END than were patients with MD and healthy volunteers
0	ENT1 Caffeine  ENT1END  challenge test in panic disorder and ENT2 depression ENT2END with panic attacks
1	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of ENT1 panic attacks  ENT1END by an oral ENT2 caffeine ENT2END challenge test
0	In a randomized double-blind experiment performed in 2 occasions 7 days apart, 480 mg caffeine and a ENT1 caffeine ENT1END free (placebo) solution were administered in a coffee form and ENT2 anxiety ENT2END scales were applied before and after each test
0	Neither dosage nor serum levels of ENT1 CBZ ENT1END were in a higher range. We consider asterixis to be an easily overlooked sign of ENT2 neurotoxicity ENT2END , which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ
0	We consider asterixis to be an easily overlooked sign of ENT1 neurotoxicity ENT1END , which may occur even at low or moderate dosage levels, if certain drugs as ENT2 lithium ENT2END or clozapine are used in combination with CBZ
0	We consider asterixis to be an easily overlooked sign of ENT1 neurotoxicity ENT1END , which may occur even at low or moderate dosage levels, if certain drugs as lithium or ENT2 clozapine ENT2END are used in combination with CBZ
0	ENT1 Asterixis  ENT1END  induced by ENT2 carbamazepine ENT2END therapy
1	We consider ENT1 asterixis  ENT1END to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as ENT2 lithium ENT2END or clozapine are used in combination with CBZ
1	We consider ENT1 asterixis  ENT1END  to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or ENT2 clozapine ENT2END are used in combination with CBZ
0	In the first case a caesarean section was done one week after replacement of warfarin with ENT1 heparin ENT1END  The baby died of cerebral and pulmonary hemorrhage. The second mother had a male infant by caesarean section. The baby showed warfarin-induced ENT2 embryopathy ENT2END with nasal hypoplasia and stippled epiphyses (chondrodysplasia punctata)
0	The baby showed ENT1 warfarin  ENT1END induced ENT2 embryopathy ENT2END with nasal hypoplasia and stippled epiphyses (chondrodysplasia punctata)
0	In the first case a caesarean section was done one week after replacement of warfarin with ENT1 heparin ENT1END . The baby died of cerebral and pulmonary hemorrhage. The second mother had a male infant by caesarean section. The baby showed warfarin-induced embryopathy with nasal hypoplasia and ENT2 stippled epiphyses ENT2END (chondrodysplasia punctata)
1	The baby showed ENT1 warfarin  ENT1END -induced embryopathy with nasal hypoplasia and ENT2 stippled epiphyses ENT2END (chondrodysplasia punctata)
0	In the first case a caesarean section was done one week after replacement of warfarin with ENT1 heparin ENT1END . The baby died of ENT2 cerebral and pulmonary hemorrhage ENT2END
1	In the first case a caesarean section was done one week after replacement of ENT1 warfarin  ENT1END with heparin. The baby died of ENT2 cerebral and pulmonary hemorrhage ENT2END
0	In the first case a caesarean section was done one week after replacement of warfarin with ENT1 heparin ENT1END . The baby died of ENT2 cerebral and pulmonary hemorrhage ENT2END
1	In the first case a caesarean section was done one week after replacement of ENT1 warfarin  ENT1END  with heparin. The baby died of ENT2 cerebral and pulmonary hemorrhage ENT2END
0	In the first case a caesarean section was done one week after replacement of warfarin with ENT1 heparin ENT1END . The baby died of ENT2 cerebral and pulmonary hemorrhage ENT2END
1	In the first case a caesarean section was done one week after replacement of ENT1 warfarin  ENT1END  with heparin. The baby died of ENT2 cerebral and pulmonary hemorrhage ENT2END
0	In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed ENT1 MM ENT1END  VTD consisted of ENT2 bortezomib ENT2END at a dose of 1
0	In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed ENT1 MM ENT1END . VTD consisted of bortezomib at a dose of 1.3 mg/m(2) and ENT2 dexamethasone ENT2END at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day
0	In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, ENT1 thalidomide  ENT1END  and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed ENT2 MM ENT2END
1	VTD consisted of ENT1 bortezomib ENT1END  at a dose of 1.3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and ENT2 thrombocytopenia ENT2END were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case
1	3 mg/m(2) and ENT1 dexamethasone  ENT1END  at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and ENT2 thrombocytopenia ENT2END were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case
1	3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral ENT1 thalidomide  ENT1END at a dose of 100 mg/day. Grade 3-4 neutropenia and ENT2 thrombocytopenia ENT2END were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case
1	VTD consisted of ENT1 bortezomib ENT1END  at a dose of 1.3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case. ENT2 Peripheral neuropathy ENT2END was common (63 %), but severe grade 3-4 peripheral neuropathy was not observed
1	3 mg/m(2) and ENT1 dexamethasone  ENT1END  at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case. ENT2 Peripheral neuropathy ENT2END was common (63 %), but severe grade 3-4 peripheral neuropathy was not observed
1	3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral ENT1 thalidomide  ENT1END  at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case. ENT2 Peripheral neuropathy ENT2END was common (63 %), but severe grade 3-4 peripheral neuropathy was not observed
1	VTD consisted of ENT1 bortezomib ENT1END  at a dose of 1.3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 ENT2 neutropenia ENT2END and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case
1	3 mg/m(2) and ENT1 dexamethasone  ENT1END  at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 ENT2 neutropenia ENT2END and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case
1	3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral ENT1 thalidomide  ENT1END  at a dose of 100 mg/day. Grade 3-4 ENT2 neutropenia ENT2END and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case
0	VTD consisted of ENT1 bortezomib ENT1END  at a dose of 1.3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to ENT2 cytopenia ENT2END was not required in any case
0	3 mg/m(2) and ENT1 dexamethasone  ENT1END  at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to ENT2 cytopenia ENT2END was not required in any case
0	3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral ENT1 thalidomide  ENT1END  at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to ENT2 cytopenia ENT2END was not required in any case
1	ENT1 Famotidine  ENT1END -associated ENT2 delirium ENT2END
0	ENT1 Famotidine ENT1END is a histamine H2-receptor antagonist used in inpatient settings for prevention of stress ENT2 ulcers ENT2END and is showing increasing popularity because of its low cost
1	As heparin remains one of the most frequently used medications today with potential for ENT1 HIT ENT1END with every ENT2 heparin ENT2END exposure, a close vigilance of platelet counts must be practiced whenever heparin is initiated
0	ENT1 Direct thrombin inhibitors ENT1END are appropriate, evidence-based alternatives to heparin in patients with a history of ENT2 HIT ENT2END , who need to undergo percutaneous coronary intervention
1	HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever ENT1 thrombosis ENT1END occurs after ENT2 heparin ENT2END exposure
0	HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever ENT1 thrombosis ENT1END  occurs after heparin exposure. Early recognition that incorporates the clinical and serologic clues is paramount to timely institution of treatment, as its delay may result in catastrophic outcomes. The treatment of HIT mandates an immediate cessation of all heparin exposure and the institution of an antithrombotic therapy, most commonly using a ENT2 direct thrombin inhibitor ENT2END
0	The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental ENT1 glomerulosclerosis ENT1END  tubulointerstitial injury, or renal cortical malondialdehyde content. In rats with ENT2 PAN ENT2END nephropathy, administration of rhIGF-I increased IGF-I and GH receptor gene expression, without altering the steady state level of IGF-I receptor mRNA
0	The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental ENT1 glomerulosclerosis ENT1END , tubulointerstitial injury, or renal cortical ENT2 malondialdehyde ENT2END content
0	In rats with ENT1 PAN ENT1END  nephropathy, administration of rhIGF-I increased IGF-I and GH receptor gene expression, without altering the steady state level of IGF-I receptor mRNA. In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter weight gain, blood pressure, ENT2 proteinuria ENT2END , GFR, glomerular planar area, renal cortical malondialdehyde content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4)
0	In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter weight gain, blood pressure, ENT1 proteinuria ENT1END , GFR, glomerular planar area, renal cortical ENT2 malondialdehyde ENT2END content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4)
1	Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of growth failure in rats with chronic ENT1 PAN ENT1END ENT2 nephropathy ENT2END
0	The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis, tubulointerstitial injury, or renal cortical ENT1 malondialdehyde ENT1END  content. In rats with PAN ENT2 nephropathy ENT2END , administration of rhIGF-I increased IGF-I and GH receptor gene expression, without altering the steady state level of IGF-I receptor mRNA
0	Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of ENT1 growth failure  ENT1END in rats with chronic ENT2 PAN ENT2END nephropathy
1	A 27-yr-old man developed jaundice 2 wk after exposure to ENT1 thiabendazole ENT1END  Cholestasis persisted for 3 yr, at which time a liver transplant was performed. Two liver biopsy specimens and the hepatectomy specimen were remarkable for almost complete disappearance of interlobular bile ducts. Prominent fibrosis and hepatocellular regeneration were also present; however, the lobular architecture was preserved. This case represents an example of "idiosyncratic" ENT2 drug-induced liver damage ENT2END in which the primary target of injury is the bile duct
0	Progressive ENT1 bile duct injury  ENT1END  after ENT2 thiabendazole ENT2END administration
0	A 27-yr-old man developed ENT1 jaundice  ENT1END 2 wk after exposure to ENT2 thiabendazole ENT2END
0	A 27-yr-old man developed jaundice 2 wk after exposure to ENT1 thiabendazole ENT1END . Cholestasis persisted for 3 yr, at which time a liver transplant was performed. Two liver biopsy specimens and the hepatectomy specimen were remarkable for almost complete disappearance of interlobular bile ducts. Prominent ENT2 fibrosis ENT2END and hepatocellular regeneration were also present; however, the lobular architecture was preserved
1	A 27-yr-old man developed jaundice 2 wk after exposure to ENT1 thiabendazole ENT1END . ENT2 Cholestasis ENT2END persisted for 3 yr, at which time a liver transplant was performed
1	Common > or =grade 3 events were fatigue, dyspnea, stomatitis, ENT1 anemia ENT1END  and thrombocytopenia. Pneumonitis, probably or possibly related, mainly grade 1/2, occurred in 25%. Cox regression analysis of IHC scores found that only phospho AKT (pAKT) was a significant independent predictor of worse PFS. CONCLUSIONS: ENT2 RAD001 ENT2END 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC
0	RAD001, an oral inhibitor of the mammalian target of ENT1 rapamycin ENT1END (mTOR), has shown phase I efficacy in NSCLC. METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity. Primary objective was overall response rate (ORR). Analyses of markers associated with the mTOR pathway were carried out on archival ENT2 tumor ENT2END from a subgroup using immunohistochemistry (IHC) and direct mutation sequencing
0	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one ENT1 platinum  ENT1END based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity. Primary objective was overall response rate (ORR). Analyses of markers associated with the mTOR pathway were carried out on archival ENT2 tumor ENT2END from a subgroup using immunohistochemistry (IHC) and direct mutation sequencing
0	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor ENT1 tyrosine  ENT1END kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity. Primary objective was overall response rate (ORR). Analyses of markers associated with the mTOR pathway were carried out on archival ENT2 tumor ENT2END from a subgroup using immunohistochemistry (IHC) and direct mutation sequencing
0	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received ENT1 RAD001  ENT1END 10 mg/day until progression or unacceptable toxicity. Primary objective was overall response rate (ORR). Analyses of markers associated with the mTOR pathway were carried out on archival ENT2 tumor ENT2END from a subgroup using immunohistochemistry (IHC) and direct mutation sequencing
1	Common > or =grade 3 events were fatigue, dyspnea, ENT1 stomatitis  ENT1END  anemia, and thrombocytopenia. Pneumonitis, probably or possibly related, mainly grade 1/2, occurred in 25%. Cox regression analysis of IHC scores found that only phospho AKT (pAKT) was a significant independent predictor of worse PFS. CONCLUSIONS: ENT2 RAD001 ENT2END 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC
0	RAD001, an oral inhibitor of the mammalian target of ENT1 rapamycin ENT1END  (mTOR), has shown phase I efficacy in NSCLC. METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable ENT2 toxicity ENT2END
0	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one ENT1 platinum  ENT1END  based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable ENT2 toxicity ENT2END
0	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor ENT1 tyrosine  ENT1END  kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable ENT2 toxicity ENT2END
0	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received ENT1 RAD001  ENT1END  10 mg/day until progression or unacceptable ENT2 toxicity ENT2END
0	ENT1 Pneumonitis  ENT1END  probably or possibly related, mainly grade 1/2, occurred in 25%. Cox regression analysis of IHC scores found that only phospho AKT (pAKT) was a significant independent predictor of worse PFS. CONCLUSIONS: ENT2 RAD001 ENT2END 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC
1	Common > or =grade 3 events were fatigue, dyspnea, stomatitis, anemia, and ENT1 thrombocytopenia  ENT1END  Pneumonitis, probably or possibly related, mainly grade 1/2, occurred in 25%. Cox regression analysis of IHC scores found that only phospho AKT (pAKT) was a significant independent predictor of worse PFS. CONCLUSIONS: ENT2 RAD001 ENT2END 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC
1	Common > or =grade 3 events were ENT1 fatigue  ENT1END  dyspnea, stomatitis, anemia, and thrombocytopenia. Pneumonitis, probably or possibly related, mainly grade 1/2, occurred in 25%. Cox regression analysis of IHC scores found that only phospho AKT (pAKT) was a significant independent predictor of worse PFS. CONCLUSIONS: ENT2 RAD001 ENT2END 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC
0	RAD001, an oral inhibitor of the mammalian target of ENT1 rapamycin ENT1END  (mTOR), has shown phase I efficacy in ENT2 NSCLC ENT2END
0	METHODS: Stage IIIb or IV ENT1 NSCLC  ENT1END patients, with two or fewer prior chemotherapy regimens, one ENT2 platinum ENT2END based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity
0	METHODS: Stage IIIb or IV ENT1 NSCLC  ENT1END  patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor ENT2 tyrosine ENT2END kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity
0	BACKGROUND: Treatment options are scarce in pretreated advanced non-small-cell lung cancer ( ENT1 NSCLC ENT1END  patients. ENT2 RAD001 ENT2END , an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in NSCLC
1	Common > or =grade 3 events were fatigue, ENT1 dyspnea  ENT1END  stomatitis, anemia, and thrombocytopenia. Pneumonitis, probably or possibly related, mainly grade 1/2, occurred in 25%. Cox regression analysis of IHC scores found that only phospho AKT (pAKT) was a significant independent predictor of worse PFS. CONCLUSIONS: ENT2 RAD001 ENT2END 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC
0	Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in ENT1 heparin  ENT1END -induced ENT2 thrombocytopenia ENT2END
0	Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced ENT1 thrombocytopenia  ENT1END . ENT2 Argatroban ENT2END is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI)
0	Argatroban prolongs the International Normalized Ratio, and published approaches for monitoring the argatroban-to- ENT1 warfarin ENT1END transition should be followed. Major bleeding with argatroban is 0-10% in the non-interventional setting and 0-5.8% periprocedurally. Argatroban has no specific antidote, and if excessive anticoagulation occurs, argatroban infusion should be stopped or reduced. Improved familiarity of healthcare professionals with argatroban therapy in ENT2 HIT ENT2END , including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e
0	Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of ENT1 thrombosis ENT1END in ENT2 heparin ENT2END -induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI)
0	ENT1 Argatroban  ENT1END  is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of ENT2 thrombosis ENT2END in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI)
0	Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in ENT1 heparin ENT1END -induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI). The objective of this review is to summarize practical considerations of argatroban therapy in HIT. The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds). Contemporary experiences indicate that reduced doses are also needed in patients with conditions associated with hepatic hypoperfusion, e.g. heart failure, yet are unnecessary for renal dysfunction, adult age, sex, race/ethnicity or ENT2 obesity ENT2END
0	heart failure, yet are unnecessary for renal dysfunction, adult age, sex, race/ethnicity or ENT1 obesity ENT1END . ENT2 Argatroban ENT2END 0
0	For PCI, argatroban has not been investigated in hepatically impaired patients; dose adjustment is unnecessary for adult age, sex, race/ethnicity or ENT1 obesity  ENT1END  and lesser doses may be adequate with concurrent glycoprotein IIb/IIIa inhibition. Argatroban prolongs the International Normalized Ratio, and published approaches for monitoring the argatroban-to ENT2 warfarin ENT2END transition should be followed
0	Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in ENT1 heparin ENT1END -induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI). The objective of this review is to summarize practical considerations of argatroban therapy in HIT. The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds). Contemporary experiences indicate that reduced doses are also needed in patients with conditions associated with hepatic hypoperfusion, e.g. heart failure, yet are unnecessary for ENT2 renal dysfunction ENT2END , adult age, sex, race/ethnicity or obesity
0	heart failure, yet are unnecessary for ENT1 renal dysfunction  ENT1END , adult age, sex, race/ethnicity or obesity. ENT2 Argatroban ENT2END 0
0	heart failure, yet are unnecessary for ENT1 renal dysfunction  ENT1END , adult age, sex, race/ethnicity or obesity. Argatroban 0.5-1.2 microg/kg/min typically supports therapeutic aPTTs. The FDA-recommended dose during PCI is 25 microg/kg/min (350 microg/kg initial bolus), adjusted to achieve activated clotting times (ACTs) of 300-450 sec. For PCI, argatroban has not been investigated in hepatically impaired patients; dose adjustment is unnecessary for adult age, sex, race/ethnicity or obesity, and lesser doses may be adequate with concurrent glycoprotein IIb/IIIa inhibition. Argatroban prolongs the International Normalized Ratio, and published approaches for monitoring the argatroban-to ENT2 warfarin ENT2END transition should be followed
0	Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in ENT1 heparin ENT1END -induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI). The objective of this review is to summarize practical considerations of argatroban therapy in HIT. The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds). Contemporary experiences indicate that reduced doses are also needed in patients with conditions associated with hepatic hypoperfusion, e.g. ENT2 heart failure ENT2END , yet are unnecessary for renal dysfunction, adult age, sex, race/ethnicity or obesity
0	ENT1 heart failure  ENT1END , yet are unnecessary for renal dysfunction, adult age, sex, race/ethnicity or obesity. ENT2 Argatroban ENT2END 0
0	ENT1 heart failure  ENT1END , yet are unnecessary for renal dysfunction, adult age, sex, race/ethnicity or obesity. Argatroban 0.5-1.2 microg/kg/min typically supports therapeutic aPTTs. The FDA-recommended dose during PCI is 25 microg/kg/min (350 microg/kg initial bolus), adjusted to achieve activated clotting times (ACTs) of 300-450 sec. For PCI, argatroban has not been investigated in hepatically impaired patients; dose adjustment is unnecessary for adult age, sex, race/ethnicity or obesity, and lesser doses may be adequate with concurrent glycoprotein IIb/IIIa inhibition. Argatroban prolongs the International Normalized Ratio, and published approaches for monitoring the argatroban-to ENT2 warfarin ENT2END transition should be followed
1	Major ENT1 bleeding ENT1END with ENT2 argatroban ENT2END is 0-10% in the non-interventional setting and 0-5
0	Argatroban prolongs the International Normalized Ratio, and published approaches for monitoring the argatroban-to- ENT1 warfarin  ENT1END  transition should be followed. Major ENT2 bleeding ENT2END with argatroban is 0-10% in the non-interventional setting and 0-5
0	Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in ENT1 heparin ENT1END -induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI). The objective of this review is to summarize practical considerations of argatroban therapy in HIT. The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with ENT2 hepatic impairment ENT2END and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1
0	The US FDA-recommended ENT1 argatroban  ENT1END dose in HIT is 2 microg/kg/min (reduced in patients with ENT2 hepatic impairment ENT2END and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1
0	After pretreatment with 3 mg of cyproheptadine, 2 mg ENT1 mianserin ENT1END  or 2 mg chlorpheniramine, only 5 of 105 animals (5%) died after receiving BSA on day +7 (p less than 0.001). Blockade of histamine H1 receptors may reduce mortality in pertussis immunization-induced ENT2 encephalopathy ENT2END in mice
1	Treatment of lethal ENT1 pertussis vaccine  ENT1END  reaction with histamine H1 antagonists.We studied mortality after pertussis immunization in the mouse. Without treatment, 73 of 92 animals (80%) died after injection of bovine serum albumin (BSA) on day +7 of pertussis immunization. After pretreatment with 3 mg of cyproheptadine, 2 mg mianserin, or 2 mg chlorpheniramine, only 5 of 105 animals (5%) died after receiving BSA on day +7 (p less than 0.001). Blockade of histamine H1 receptors may reduce mortality in pertussis immunization-induced ENT2 encephalopathy ENT2END in mice
0	Blockade of ENT1 histamine  ENT1END H1 receptors may reduce mortality in pertussis immunization-induced ENT2 encephalopathy ENT2END in mice
0	After pretreatment with 3 mg of ENT1 cyproheptadine  ENT1END  2 mg mianserin, or 2 mg chlorpheniramine, only 5 of 105 animals (5%) died after receiving BSA on day +7 (p less than 0.001). Blockade of histamine H1 receptors may reduce mortality in pertussis immunization-induced ENT2 encephalopathy ENT2END in mice
0	After pretreatment with 3 mg of cyproheptadine, 2 mg mianserin, or 2 mg ENT1 chlorpheniramine  ENT1END  only 5 of 105 animals (5%) died after receiving BSA on day +7 (p less than 0.001). Blockade of histamine H1 receptors may reduce mortality in pertussis immunization-induced ENT2 encephalopathy ENT2END in mice
0	Without treatment, 73 of 92 animals (80%) died after injection of bovine serum albumin (BSA) on day +7 of ENT1 pertussis  ENT1END immunization. After pretreatment with 3 mg of cyproheptadine, 2 mg ENT2 mianserin ENT2END , or 2 mg chlorpheniramine, only 5 of 105 animals (5%) died after receiving BSA on day +7 (p less than 0
0	Treatment of lethal ENT1 pertussis vaccine ENT1END  reaction with histamine H1 antagonists.We studied mortality after ENT2 pertussis ENT2END immunization in the mouse
0	Blockade of ENT1 histamine ENT1END  H1 receptors may reduce mortality in ENT2 pertussis ENT2END immunization-induced encephalopathy in mice
0	Without treatment, 73 of 92 animals (80%) died after injection of bovine serum albumin (BSA) on day +7 of ENT1 pertussis  ENT1END  immunization. After pretreatment with 3 mg of ENT2 cyproheptadine ENT2END , 2 mg mianserin, or 2 mg chlorpheniramine, only 5 of 105 animals (5%) died after receiving BSA on day +7 (p less than 0
0	Without treatment, 73 of 92 animals (80%) died after injection of bovine serum albumin (BSA) on day +7 of ENT1 pertussis  ENT1END  immunization. After pretreatment with 3 mg of cyproheptadine, 2 mg mianserin, or 2 mg ENT2 chlorpheniramine ENT2END , only 5 of 105 animals (5%) died after receiving BSA on day +7 (p less than 0
1	Recurrent myocardial infarction in a postpartum patient receiving ENT1 bromocriptine  ENT1END . ENT2 Myocardial infarction ENT2END in puerperium is infrequently reported
0	Recurrent myocardial infarction in a postpartum patient receiving ENT1 bromocriptine ENT1END .Myocardial infarction in puerperium is infrequently reported. ENT2 Spasm ENT2END , coronary dissection, or atheromatous etiology has been described
0	The results warrant clinical trials of ENT1 denopamine ENT1END in the treatment of ENT2 cardiac failure ENT2END
1	Improvement by denopamine (TA-064) of ENT1 pentobarbital  ENT1END -induced ENT2 cardiac failure ENT2END in the dog heart-lung preparation
0	No ENT1 arrhythmias ENT1END were induced by these doses of ENT2 denopamine ENT2END
0	Cardiac functions depressed by ENT1 pentobarbital  ENT1END (118 +/- 28 mg; mean value +/- SD) such that cardiac output and maximum rate of rise of left ventricular pressure (LV dP/dt max) had been reduced by about 35% and 26% of the respective controls were improved by denopamine (10-300 micrograms) in a dose-dependent manner. With 100 micrograms denopamine, almost complete restoration of cardiac performance was attained, associated with a slight increase in heart rate. No ENT2 arrhythmias ENT2END were induced by these doses of denopamine
0	Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated ENT1 diabetes insipidus ENT1END after DOCA-salt treatment. Administration of DDAVP which has antidiuretic action but minimal vasopressor effect failed to increase blood pressure to the levels observed after administration of AVP. Furthermore, the pressor action of vasopressin appears to be important in the development of this model of hypertension, since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension. Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension. An unproportional release of vasopressin compared to plasma osmolality may be induced by the absence of an adjusting control of ENT2 angiotensin ENT2END II forming and receptor binding capacity for sodium balance in the brain
0	Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated ENT1 diabetes insipidus ENT1END  after ENT2 DOCA ENT2END -salt treatment
1	Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with ENT1 lithium  ENT1END treated ENT2 diabetes insipidus ENT2END after DOCA-salt treatment
0	Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated ENT1 diabetes insipidus ENT1END  after DOCA-salt treatment. Administration of DDAVP which has antidiuretic action but minimal vasopressor effect failed to increase blood pressure to the levels observed after administration of AVP. Furthermore, the pressor action of vasopressin appears to be important in the development of this model of hypertension, since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension. Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension. An unproportional release of vasopressin compared to plasma osmolality may be induced by the absence of an adjusting control of angiotensin II forming and receptor binding capacity for ENT2 sodium ENT2END balance in the brain
0	Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated ENT1 diabetes insipidus ENT1END  after DOCA-salt treatment. Administration of ENT2 DDAVP ENT2END which has antidiuretic action but minimal vasopressor effect failed to increase blood pressure to the levels observed after administration of AVP
0	ENT1 Vasopressin  ENT1END plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated ENT2 diabetes insipidus ENT2END after DOCA-salt treatment
0	Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in ENT1 hypertension  ENT1END  An unproportional release of vasopressin compared to plasma osmolality may be induced by the absence of an adjusting control of ENT2 angiotensin ENT2END II forming and receptor binding capacity for sodium balance in the brain
1	Vasopressin plays a major role in the pathogenesis of ENT1 DOCA ENT1END salt ENT2 hypertension ENT2END , since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment
0	Vasopressin plays a major role in the pathogenesis of DOCA-salt ENT1 hypertension  ENT1END , since the elevation of blood pressure was not substantial in the rats with ENT2 lithium ENT2END -treated diabetes insipidus after DOCA-salt treatment
0	An unproportional release of vasopressin compared to plasma osmolality may be induced by the absence of an adjusting control of angiotensin II forming and receptor binding capacity for ENT1 sodium ENT1END  balance in the brain. However, the role of vasopressin remains to be determined in human essential ENT2 hypertension ENT2END
0	Vasopressin plays a major role in the pathogenesis of DOCA-salt ENT1 hypertension  ENT1END , since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment. Administration of ENT2 DDAVP ENT2END which has antidiuretic action but minimal vasopressor effect failed to increase blood pressure to the levels observed after administration of AVP
0	Vasopressin as a possible contributor to ENT1 hypertension ENT1END .The role of ENT2 vasopressin ENT2END as a pressor agent to the hypertensive process was examined
0	All 36 patients receiving ENT1 lamivudine ENT1END had a decrease in ENT2 hepatitis B ENT2END virus (HBV) DNA values of >90% (P <
1	Lamivudine is effective in suppressing ENT1 hepatitis B  ENT1END  virus DNA in Chinese ENT2 hepatitis B surface antigen ENT2END carriers: a placebo-controlled trial
0	In some cases, a high serum concentration of ENT1 citalopram ENT1END (> 600 nmol/L) in elderly patients has been associated with increased ENT2 somnolence ENT2END and movement difficulties
0	In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased ENT1 somnolence ENT1END  and movement difficulties. Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus ENT2 desmethylfluoxetine ENT2END ) concentration
0	In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased ENT1 somnolence ENT1END  and movement difficulties. Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total ENT2 fluoxetine ENT2END (fluoxetine plus desmethylfluoxetine) concentration
0	Only a few reports exist, however, on the relationship between the serum concentrations of selective ENT1 serotonin  ENT1END reuptake inhibitors (SSRIs) and their toxic effects. In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased ENT2 somnolence ENT2END and movement difficulties
0	In some cases, a high serum concentration of ENT1 citalopram ENT1END  (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties. Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute ENT2 hyperkinetic ENT2END delirium connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration
0	In this report, we describe a patient with acute ENT1 hyperkinetic  ENT1END  delirium connected with a high serum total fluoxetine (fluoxetine plus ENT2 desmethylfluoxetine ENT2END ) concentration
1	In this report, we describe a patient with acute ENT1 hyperkinetic  ENT1END  delirium connected with a high serum total ENT2 fluoxetine ENT2END (fluoxetine plus desmethylfluoxetine) concentration
0	Only a few reports exist, however, on the relationship between the serum concentrations of selective ENT1 serotonin  ENT1END  reuptake inhibitors (SSRIs) and their toxic effects. In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties. Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute ENT2 hyperkinetic ENT2END delirium connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration
0	In some cases, a high serum concentration of ENT1 citalopram ENT1END  (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties. Widespread cognitive disorders, such as ENT2 delirium ENT2END , have not been previously linked with high blood levels of SSRIs
0	In this report, we describe a patient with acute hyperkinetic ENT1 delirium  ENT1END connected with a high serum total fluoxetine (fluoxetine plus ENT2 desmethylfluoxetine ENT2END ) concentration
1	ENT1 Delirium  ENT1END  during ENT2 fluoxetine ENT2END treatment
0	Only a few reports exist, however, on the relationship between the serum concentrations of selective ENT1 serotonin  ENT1END  reuptake inhibitors (SSRIs) and their toxic effects. In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties. Widespread cognitive disorders, such as ENT2 delirium ENT2END , have not been previously linked with high blood levels of SSRIs
0	In some cases, a high serum concentration of ENT1 citalopram ENT1END  (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties. Widespread ENT2 cognitive disorders ENT2END , such as delirium, have not been previously linked with high blood levels of SSRIs
0	Widespread ENT1 cognitive disorders  ENT1END , such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus ENT2 desmethylfluoxetine ENT2END ) concentration
0	Widespread ENT1 cognitive disorders  ENT1END , such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total ENT2 fluoxetine ENT2END (fluoxetine plus desmethylfluoxetine) concentration
0	Only a few reports exist, however, on the relationship between the serum concentrations of selective ENT1 serotonin  ENT1END  reuptake inhibitors (SSRIs) and their toxic effects. In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties. Widespread ENT2 cognitive disorders ENT2END , such as delirium, have not been previously linked with high blood levels of SSRIs
0	In some cases, a high serum concentration of ENT1 citalopram ENT1END  (> 600 nmol/L) in elderly patients has been associated with increased somnolence and ENT2 movement difficulties ENT2END
0	In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and ENT1 movement difficulties  ENT1END . Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus ENT2 desmethylfluoxetine ENT2END ) concentration
0	In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and ENT1 movement difficulties  ENT1END . Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total ENT2 fluoxetine ENT2END (fluoxetine plus desmethylfluoxetine) concentration
0	Only a few reports exist, however, on the relationship between the serum concentrations of selective ENT1 serotonin  ENT1END  reuptake inhibitors (SSRIs) and their toxic effects. In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and ENT2 movement difficulties ENT2END
0	Suxamethonium-induced ENT1 jaw stiffness ENT1END  and myalgia associated with atypical cholinesterase: case report.An 11-year-old boy was given ENT2 halothane ENT2END , nitrous oxide and oxygen, pancuronium 0
0	An 11-year-old boy was given halothane, nitrous oxide and oxygen, ENT1 pancuronium ENT1END 0.4 mg and suxamethonium 100 mg for induction of anaesthesia. In response to this a marked ENT2 jaw stiffness ENT2END occurred which lasted for two minutes and the anaesthesia were terminated
0	He was found to have atypical plasma cholinesterase with a ENT1 dibucaine ENT1END number of 12, indicating homozygocity. This was verified by study of the family. The case shows that ENT2 prolonged jaw rigidity ENT2END and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium
0	An 11-year-old boy was given halothane, nitrous oxide and ENT1 oxygen  ENT1END  pancuronium 0.4 mg and suxamethonium 100 mg for induction of anaesthesia. In response to this a marked ENT2 jaw stiffness ENT2END occurred which lasted for two minutes and the anaesthesia were terminated
1	ENT1 Suxamethonium  ENT1END -induced ENT2 jaw stiffness ENT2END and myalgia associated with atypical cholinesterase: case report
0	Suxamethonium-induced ENT1 jaw stiffness ENT1END  and myalgia associated with atypical cholinesterase: case report.An 11-year-old boy was given halothane, ENT2 nitrous oxide ENT2END and oxygen, pancuronium 0
0	An 11-year-old boy was given ENT1 halothane ENT1END , nitrous oxide and oxygen, pancuronium 0.4 mg and suxamethonium 100 mg for induction of anaesthesia. In response to this a marked jaw stiffness occurred which lasted for two minutes and the anaesthesia were terminated. Four hours of ENT2 apnoea ENT2END ensued and he suffered generalized severe myalgia lasting for one week
0	An 11-year-old boy was given halothane, nitrous oxide and oxygen, ENT1 pancuronium  ENT1END  0.4 mg and suxamethonium 100 mg for induction of anaesthesia. In response to this a marked jaw stiffness occurred which lasted for two minutes and the anaesthesia were terminated. Four hours of ENT2 apnoea ENT2END ensued and he suffered generalized severe myalgia lasting for one week
0	Four hours of ENT1 apnoea  ENT1END  ensued and he suffered generalized severe myalgia lasting for one week. He was found to have atypical plasma cholinesterase with a ENT2 dibucaine ENT2END number of 12, indicating homozygocity
0	An 11-year-old boy was given halothane, nitrous oxide and ENT1 oxygen  ENT1END , pancuronium 0.4 mg and suxamethonium 100 mg for induction of anaesthesia. In response to this a marked jaw stiffness occurred which lasted for two minutes and the anaesthesia were terminated. Four hours of ENT2 apnoea ENT2END ensued and he suffered generalized severe myalgia lasting for one week
1	4 mg and ENT1 suxamethonium  ENT1END 100 mg for induction of anaesthesia. In response to this a marked jaw stiffness occurred which lasted for two minutes and the anaesthesia were terminated. Four hours of ENT2 apnoea ENT2END ensued and he suffered generalized severe myalgia lasting for one week
0	An 11-year-old boy was given halothane, ENT1 nitrous oxide  ENT1END  and oxygen, pancuronium 0.4 mg and suxamethonium 100 mg for induction of anaesthesia. In response to this a marked jaw stiffness occurred which lasted for two minutes and the anaesthesia were terminated. Four hours of ENT2 apnoea ENT2END ensued and he suffered generalized severe myalgia lasting for one week
0	Suxamethonium-induced jaw stiffness and ENT1 myalgia  ENT1END  associated with atypical cholinesterase: case report.An 11-year-old boy was given ENT2 halothane ENT2END , nitrous oxide and oxygen, pancuronium 0
0	The case shows that prolonged jaw rigidity and ENT1 myalgia ENT1END may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with ENT2 pancuronium ENT2END
0	Four hours of apnoea ensued and he suffered generalized severe ENT1 myalgia  ENT1END lasting for one week. He was found to have atypical plasma cholinesterase with a ENT2 dibucaine ENT2END number of 12, indicating homozygocity
0	Suxamethonium-induced jaw stiffness and ENT1 myalgia  ENT1END  associated with atypical cholinesterase: case report.An 11-year-old boy was given halothane, nitrous oxide and ENT2 oxygen ENT2END , pancuronium 0
1	The case shows that prolonged jaw rigidity and ENT1 myalgia ENT1END  may occur after ENT2 suxamethonium ENT2END in patients with atypical cholinesterase despite pretreatment with pancuronium
0	Suxamethonium-induced jaw stiffness and ENT1 myalgia  ENT1END  associated with atypical cholinesterase: case report.An 11-year-old boy was given halothane, ENT2 nitrous oxide ENT2END and oxygen, pancuronium 0
0	Furthermore, there have been reports of thrombotic microangiopathy precipitated by ENT1 cyclosporine ENT1END in patients with SSc. In this article, we report a patient with ENT2 SRC ENT2END induced by tacrolimus and corticosteroids
0	In this article, we report a patient with ENT1 SRC ENT1END  induced by ENT2 tacrolimus ENT2END and corticosteroids
0	In this article, we report a patient with ENT1 SRC ENT1END  induced by tacrolimus and ENT2 corticosteroids ENT2END
0	Late-onset scleroderma renal crisis induced by tacrolimus and ENT1 prednisolone  ENT1END : a case report. ENT2 Scleroderma renal crisis ENT2END (SRC) is a rare complication of systemic sclerosis (SSc) but can be severe enough to require temporary or permanent renal replacement therapy
1	Furthermore, there have been reports of ENT1 thrombotic microangiopathy  ENT1END precipitated by ENT2 cyclosporine ENT2END in patients with SSc
0	Furthermore, there have been reports of ENT1 thrombotic microangiopathy  ENT1END  precipitated by cyclosporine in patients with SSc. In this article, we report a patient with SRC induced by ENT2 tacrolimus ENT2END and corticosteroids
0	Moderate to high dose ENT1 corticosteroid  ENT1END use is recognized as a major risk factor for SRC. Furthermore, there have been reports of ENT2 thrombotic microangiopathy ENT2END precipitated by cyclosporine in patients with SSc
0	Late-onset scleroderma renal crisis induced by tacrolimus and ENT1 prednisolone  ENT1END : a case report.Scleroderma renal crisis (SRC) is a rare complication of systemic sclerosis (SSc) but can be severe enough to require temporary or permanent renal replacement therapy. Moderate to high dose corticosteroid use is recognized as a major risk factor for SRC. Furthermore, there have been reports of ENT2 thrombotic microangiopathy ENT2END precipitated by cyclosporine in patients with SSc
0	Furthermore, there have been reports of thrombotic microangiopathy precipitated by ENT1 cyclosporine ENT1END  in patients with ENT2 SSc ENT2END
1	The aim of this work is to call attention to the risk of ENT1 tacrolimus ENT1END use in patients with ENT2 SSc ENT2END
1	Furthermore, there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with ENT1 SSc  ENT1END . In this article, we report a patient with SRC induced by tacrolimus and ENT2 corticosteroids ENT2END
0	Late-onset scleroderma renal crisis induced by tacrolimus and ENT1 prednisolone ENT1END : a case report.Scleroderma renal crisis (SRC) is a rare complication of ENT2 systemic sclerosis ENT2END (SSc) but can be severe enough to require temporary or permanent renal replacement therapy
1	ENT1 CYP ENT1END induced ENT2 cystitis ENT2END increased (P < or = 0
0	Previous studies have examined the expression and regulation of ENT1 tyrosine ENT1END kinase receptors (Trks) in micturition reflexes with ENT2 urinary bladder inflammation ENT2END
0	OBJECTIVES: The present study investigates the effects of ENT1 nicotine ENT1END on ENT2 anxiety ENT2END induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice
1	25 mg/kg) pretreatment blocked the caffeine- but not ENT1 pentylenetetrazole ENT1END induced ENT2 anxiety ENT2END
1	CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on ENT1 caffeine ENT1END induced ENT2 anxiety ENT2END is specific to caffeine, instead of a non-specific anxiolytic effect
1	A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and ENT1 levomepromazine ENT1END  In addition to the typical symptoms of ENT2 NMS ENT2END , massive intestinal bleeding was observed during the episode
1	A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome ( ENT1 NMS ENT1END  after administration of ENT2 risperidone ENT2END and levomepromazine
0	A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and ENT1 levomepromazine ENT1END . In addition to the typical symptoms of NMS, massive intestinal ENT2 bleeding ENT2END was observed during the episode
0	A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of ENT1 risperidone  ENT1END  and levomepromazine. In addition to the typical symptoms of NMS, massive intestinal ENT2 bleeding ENT2END was observed during the episode
0	A patient with chronic renal failure ( ENT1 CRF  ENT1END  developed neuroleptic malignant syndrome (NMS) after administration of risperidone and ENT2 levomepromazine ENT2END
0	A patient with chronic renal failure ( ENT1 CRF  ENT1END ) developed neuroleptic malignant syndrome (NMS) after administration of ENT2 risperidone ENT2END and levomepromazine
1	These results support the conclusion that NO plays a role of endogenous convulsant in rat model of ENT1 lindane ENT1END ENT2 seizures ENT2END
0	It evokes ENT1 convulsions ENT1END mainly trough the blockage of ENT2 GABA ENT2END (A) receptors
0	On the contrary, pretreatment with ENT1 L-NAME ENT1END (500, 700 and 900 mg/kg, i.p.) decreased ENT2 convulsion ENT2END incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane (8 mg/kg, i
0	The role of ENT1 nitric oxide  ENT1END  in ENT2 convulsions ENT2END induced by lindane in rats
0	The administration of ENT1 L-arginine ENT1END (600, 800 and 1000 mg/kg, i.p.) in dose-dependent manner significantly increased ENT2 convulsion ENT2END incidence and severity and shortened latency time to first convulsion elicited by lower lindane dose (4 mg/kg, i
0	The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of ENT1 lindane ENT1END induced ENT2 epilepsy ENT2END in male Wistar albino rats
0	It evokes convulsions mainly trough the blockage of ENT1 GABA ENT1END (A) receptors. Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different ENT2 epilepsy ENT2END models
0	Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and ENT1 L-NAME  ENT1END (NOS inhibitor) observed in different ENT2 epilepsy ENT2END models
0	The aim of the current study was to determine the effects of ENT1 NO  ENT1END on the behavioral and EEG characteristics of lindane-induced ENT2 epilepsy ENT2END in male Wistar albino rats
0	The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of lindane-induced ENT1 epilepsy  ENT1END  in male Wistar albino rats. The administration of ENT2 L-arginine ENT2END (600, 800 and 1000 mg/kg, i
1	Support for ENT1 adrenaline ENT1END ENT2 hypertension ENT2END hypothesis: 18 hour pressor effect after 6 hours adrenaline infusion
0	Over the total postinfusion period systolic and diastolic arterial pressure were 6 (SEM 2)% and 7 (2)%, respectively, higher than after ENT1 dextrose  ENT1END infusion (ANOVA, p less than 0.001). Thus, "stress" levels of adrenaline (230 pg/ml) for 6 h cause a delayed and protracted pressor effect. These findings are strong support for the adrenaline- ENT2 hypertension ENT2END hypothesis in man
0	Support for adrenaline- ENT1 hypertension ENT1END  hypothesis: 18 hour pressor effect after 6 hours adrenaline infusion.In a double blind, crossover study 6 h infusions of adrenaline (15 ng/kg/min; 1 ng = 5.458 pmol), ENT2 noradrenaline ENT2END (30 ng/kg/min; 1 ng = 5
1	05 mg/kg of this beta-carboline reduced markedly the increase of [35S]TBPS binding and the ENT1 convulsions ENT1END induced by ENT2 isoniazid ENT2END (200 mg/kg s
0	injection to rats, abecarnil and ENT1 diazepam  ENT1END decreased in a time-dependent and dose-related (0.25-20 mg/kg i.p.) manner [35S]TBPS binding measured ex vivo in the cerebral cortex. Moreover, both drugs at the dose of 0.5 mg/kg antagonized completely the convulsant activity and the increase of [35S]TBPS binding induced by isoniazide (350 mg/kg s.c.) as well as the increase of [35S]TBPS binding induced by foot-shock stress. To better correlate the biochemical and the pharmacological effects, we studied the action of abecarnil on [35S]TBPS binding, exploratory motility and on isoniazid-induced biochemical and pharmacological effects in mice. In these animals, abecarnil produced a paralleled dose-dependent (0.05-1 mg/kg i.p.) reduction of both motor behavior and cortical [35S]TBPS binding. Moreover, 0.05 mg/kg of this beta-carboline reduced markedly the increase of [35S]TBPS binding and the ENT2 convulsions ENT2END induced by isoniazid (200 mg/kg s
0	In these animals, ENT1 abecarnil  ENT1END produced a paralleled dose-dependent (0.05-1 mg/kg i.p.) reduction of both motor behavior and cortical [35S]TBPS binding. Moreover, 0.05 mg/kg of this beta-carboline reduced markedly the increase of [35S]TBPS binding and the ENT2 convulsions ENT2END induced by isoniazid (200 mg/kg s
0	05 mg/kg of this ENT1 beta-carboline  ENT1END reduced markedly the increase of [35S]TBPS binding and the ENT2 convulsions ENT2END induced by isoniazid (200 mg/kg s
0	05 mg/kg of this beta-carboline reduced markedly the increase of ENT1 [35S]TBPS  ENT1END binding and the ENT2 convulsions ENT2END induced by isoniazid (200 mg/kg s
0	We undertook an open-label study using thalidomide 100 mg once daily for up to 6 months in 20 men with androgen-independent ENT1 prostate cancer ENT1END  The mean time of study was 109 days (median 107, range 4-184 days). Patients underwent regular measurement of prostate-specific antigen (PSA), ENT2 urea ENT2END and electrolytes, serum bFGF and VEGF
0	An open-label phase II study of low-dose ENT1 thalidomide  ENT1END  in androgen-independent ENT2 prostate cancer ENT2END
0	An open-label phase II study of low-dose thalidomide in ENT1 androgen  ENT1END -independent ENT2 prostate cancer ENT2END
0	Patients underwent regular measurement of prostate-specific antigen (PSA), ENT1 urea ENT1END  and electrolytes, serum bFGF and VEGF. Three men (15%) showed a decline in serum PSA of at least 50%, sustained throughout treatment. Of 16 men treated for at least 2 months, six (37.5%) showed a fall in absolute PSA by a median of 48%. Increasing levels of serum bFGF and VEGF were associated with progressive disease; five of six men who demonstrated a fall in PSA also showed a decline in bFGF and VEGF levels, and three of four men with a rising PSA showed an increase in both growth factors. Adverse effects included constipation, morning drowsiness, dizziness and ENT2 rash ENT2END , and resulted in withdrawal from the study by three men
1	Adverse effects included constipation, morning drowsiness, dizziness and ENT1 rash ENT1END , and resulted in withdrawal from the study by three men. Evidence of peripheral sensory neuropathy was found in nine of 13 men before treatment. In the seven men who completed six months on ENT2 thalidomide ENT2END , subclinical evidence of peripheral neuropathy was found in four before treatment, but in all seven at repeat testing
0	Patients underwent regular measurement of prostate-specific antigen (PSA), ENT1 urea ENT1END  and electrolytes, serum bFGF and VEGF. Three men (15%) showed a decline in serum PSA of at least 50%, sustained throughout treatment. Of 16 men treated for at least 2 months, six (37.5%) showed a fall in absolute PSA by a median of 48%. Increasing levels of serum bFGF and VEGF were associated with progressive disease; five of six men who demonstrated a fall in PSA also showed a decline in bFGF and VEGF levels, and three of four men with a rising PSA showed an increase in both growth factors. Adverse effects included constipation, morning ENT2 drowsiness ENT2END , dizziness and rash, and resulted in withdrawal from the study by three men
1	Adverse effects included constipation, morning ENT1 drowsiness  ENT1END , dizziness and rash, and resulted in withdrawal from the study by three men. Evidence of peripheral sensory neuropathy was found in nine of 13 men before treatment. In the seven men who completed six months on ENT2 thalidomide ENT2END , subclinical evidence of peripheral neuropathy was found in four before treatment, but in all seven at repeat testing
0	Patients underwent regular measurement of prostate-specific antigen (PSA), ENT1 urea ENT1END  and electrolytes, serum bFGF and VEGF. Three men (15%) showed a decline in serum PSA of at least 50%, sustained throughout treatment. Of 16 men treated for at least 2 months, six (37.5%) showed a fall in absolute PSA by a median of 48%. Increasing levels of serum bFGF and VEGF were associated with progressive disease; five of six men who demonstrated a fall in PSA also showed a decline in bFGF and VEGF levels, and three of four men with a rising PSA showed an increase in both growth factors. Adverse effects included constipation, morning drowsiness, dizziness and rash, and resulted in withdrawal from the study by three men. Evidence of ENT2 peripheral sensory neuropathy ENT2END was found in nine of 13 men before treatment
1	In the seven men who completed six months on ENT1 thalidomide ENT1END , subclinical evidence of ENT2 peripheral neuropathy ENT2END was found in four before treatment, but in all seven at repeat testing
0	The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and ENT1 haematological malignancies  ENT1END  Thalidomide blocks the activity of angiogenic agents including bFGF, VEGF and IL-6. We undertook an open-label study using thalidomide 100 mg once daily for up to 6 months in 20 men with androgen-independent prostate cancer. The mean time of study was 109 days (median 107, range 4-184 days). Patients underwent regular measurement of prostate-specific antigen (PSA), ENT2 urea ENT2END and electrolytes, serum bFGF and VEGF
0	The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and ENT1 haematological malignancies ENT1END . ENT2 Thalidomide ENT2END blocks the activity of angiogenic agents including bFGF, VEGF and IL-6
0	An open-label phase II study of low-dose thalidomide in ENT1 androgen  ENT1END -independent prostate cancer.The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and ENT2 haematological malignancies ENT2END
0	Patients underwent regular measurement of prostate-specific antigen (PSA), ENT1 urea ENT1END  and electrolytes, serum bFGF and VEGF. Three men (15%) showed a decline in serum PSA of at least 50%, sustained throughout treatment. Of 16 men treated for at least 2 months, six (37.5%) showed a fall in absolute PSA by a median of 48%. Increasing levels of serum bFGF and VEGF were associated with progressive disease; five of six men who demonstrated a fall in PSA also showed a decline in bFGF and VEGF levels, and three of four men with a rising PSA showed an increase in both growth factors. Adverse effects included ENT2 constipation ENT2END , morning drowsiness, dizziness and rash, and resulted in withdrawal from the study by three men
1	Adverse effects included ENT1 constipation  ENT1END , morning drowsiness, dizziness and rash, and resulted in withdrawal from the study by three men. Evidence of peripheral sensory neuropathy was found in nine of 13 men before treatment. In the seven men who completed six months on ENT2 thalidomide ENT2END , subclinical evidence of peripheral neuropathy was found in four before treatment, but in all seven at repeat testing
0	Patients underwent regular measurement of prostate-specific antigen (PSA), ENT1 urea ENT1END  and electrolytes, serum bFGF and VEGF. Three men (15%) showed a decline in serum PSA of at least 50%, sustained throughout treatment. Of 16 men treated for at least 2 months, six (37.5%) showed a fall in absolute PSA by a median of 48%. Increasing levels of serum bFGF and VEGF were associated with progressive disease; five of six men who demonstrated a fall in PSA also showed a decline in bFGF and VEGF levels, and three of four men with a rising PSA showed an increase in both growth factors. Adverse effects included constipation, morning drowsiness, ENT2 dizziness ENT2END and rash, and resulted in withdrawal from the study by three men
1	Adverse effects included constipation, morning drowsiness, ENT1 dizziness  ENT1END  and rash, and resulted in withdrawal from the study by three men. Evidence of peripheral sensory neuropathy was found in nine of 13 men before treatment. In the seven men who completed six months on ENT2 thalidomide ENT2END , subclinical evidence of peripheral neuropathy was found in four before treatment, but in all seven at repeat testing
1	Toxicity included embryolethality, teratogenicity, and ENT1 growth retardation ENT1END  Dermal administration of ENT2 S-23121 ENT2END at 800 mg/kg resulted in an increased incidence of embryonic death and ventricular septal defect, but retarded fetal growth was not observed as it was following oral exposure to S-23121
1	BACKGROUND: ENT1 S-53482 ENT1END and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and ENT2 growth retardation ENT2END in rats in conventional oral developmental toxicity studies
1	Dermal administration of ENT1 S-23121 ENT1END  at 800 mg/kg resulted in an increased incidence of embryonic death and ENT2 ventricular septal defect ENT2END , but retarded fetal growth was not observed as it was following oral exposure to S-23121
1	BACKGROUND: ENT1 S-53482 ENT1END  and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ENT2 ventricular septal defects ENT2END and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies
1	BACKGROUND: S-53482 and ENT1 S-23121 ENT1END are N-phenylimide herbicides and produced ENT2 embryolethality ENT2END , teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies
1	BACKGROUND: ENT1 S-53482  ENT1END  and S-23121 are N-phenylimide herbicides and produced ENT2 embryolethality ENT2END , teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies
0	Dermal developmental ENT1 toxicity  ENT1END  of N-phenylimide herbicides in rats.BACKGROUND: S-53482 and ENT2 S-23121 ENT2END are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies
0	Dermal developmental ENT1 toxicity  ENT1END  of N-phenylimide herbicides in rats.BACKGROUND: ENT2 S-53482 ENT2END and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies
1	CONCLUSIONS: Based on the results, S-53482 and ENT1 S-23121 ENT1END were ENT2 teratogenic ENT2END when administered dermally to pregnant rats as were the compounds administered orally
1	CONCLUSIONS: Based on the results, ENT1 S-53482  ENT1END and S-23121 were ENT2 teratogenic ENT2END when administered dermally to pregnant rats as were the compounds administered orally
0	However, it would seem prudent not to use ENT1 mefenamic acid ENT1END in ENT2 hypothyroid ENT2END patients until the hypothyroidism has been corrected
1	ENT1 Mefenamic acid  ENT1END -induced ENT2 neutropenia ENT2END and renal failure in elderly females with hypothyroidism
1	We report ENT1 mefenamic acid ENT1END induced non-oliguric ENT2 renal failure ENT2END and severe neutropenia occurring simultaneously in two elderly females
0	ENT1 Fluoxetine  ENT1END  improves the memory deficits caused by the chemotherapy agent 5-fluorouracil. ENT2 Cancer ENT2END patients who have been treated with systemic adjuvant chemotherapy have described experiencing deteriorations in cognition
0	Fluoxetine improves the memory deficits caused by the chemotherapy agent ENT1 5-fluorouracil ENT1END ENT2 Cancer ENT2END patients who have been treated with systemic adjuvant chemotherapy have described experiencing deteriorations in cognition
0	ENT1 Cancer ENT1END  patients who have been treated with systemic adjuvant chemotherapy have described experiencing deteriorations in cognition. A widely used chemotherapeutic agent, 5-fluorouracil (5-FU), readily crosses the blood-brain barrier and so could have a direct effect on brain function. In particular this anti mitotic drug could reduce cell proliferation in the neurogenic regions of the adult brain. In contrast reports indicate that hippocampal dependent neurogenesis and cognition are enhanced by the ENT2 SSRI ENT2END antidepressant Fluoxetine
0	ENT1 Fluoxetine  ENT1END  improves the ENT2 memory deficits ENT2END caused by the chemotherapy agent 5-fluorouracil
1	Fluoxetine improves the ENT1 memory deficits  ENT1END  caused by the chemotherapy agent ENT2 5-fluorouracil ENT2END
0	Fluoxetine improves the ENT1 memory deficits  ENT1END  caused by the chemotherapy agent 5-fluorouracil.Cancer patients who have been treated with systemic adjuvant chemotherapy have described experiencing deteriorations in cognition. A widely used chemotherapeutic agent, 5-fluorouracil (5-FU), readily crosses the blood-brain barrier and so could have a direct effect on brain function. In particular this anti mitotic drug could reduce cell proliferation in the neurogenic regions of the adult brain. In contrast reports indicate that hippocampal dependent neurogenesis and cognition are enhanced by the ENT2 SSRI ENT2END antidepressant Fluoxetine
0	We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of ENT1 suxamethonium ENT1END  The muscle spasms disappeared spontaneously and the surgery proceeded without further problems. When subsequently questioned, she reported minor symptoms suggesting a ENT2 myotonic condition ENT2END
0	Anaesthetic complications associated with myotonia congenita: case study and comparison with other ENT1 myotonic disorders ENT1END .Myotonia congenita (MC) is caused by a defect in the skeletal muscle ENT2 chloride ENT2END channel function, which may cause sustained membrane depolarisation
0	We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of ENT1 suxamethonium ENT1END . The muscle spasms disappeared spontaneously and the surgery proceeded without further problems. When subsequently questioned, she reported minor symptoms suggesting a myotonic condition. ENT2 Myotonia ENT2END was found on clinical examination and EMG
0	Myotonia congenita (MC) is caused by a defect in the skeletal muscle ENT1 chloride  ENT1END  channel function, which may cause sustained membrane depolarisation. We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of suxamethonium. The muscle spasms disappeared spontaneously and the surgery proceeded without further problems. When subsequently questioned, she reported minor symptoms suggesting a myotonic condition. ENT2 Myotonia ENT2END was found on clinical examination and EMG
0	We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of ENT1 suxamethonium ENT1END . The muscle spasms disappeared spontaneously and the surgery proceeded without further problems. When subsequently questioned, she reported minor symptoms suggesting a myotonic condition. Myotonia was found on clinical examination and EMG. The diagnosis ENT2 MC ENT2END was confirmed genetically
0	Myotonia congenita ( ENT1 MC  ENT1END  is caused by a defect in the skeletal muscle ENT2 chloride ENT2END channel function, which may cause sustained membrane depolarisation
1	We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of ENT1 suxamethonium ENT1END . The ENT2 muscle spasms ENT2END disappeared spontaneously and the surgery proceeded without further problems
0	Myotonia congenita (MC) is caused by a defect in the skeletal muscle ENT1 chloride ENT1END  channel function, which may cause sustained membrane depolarisation. We describe a previously healthy 32-year-old woman who developed a life-threatening ENT2 muscle spasm ENT2END and secondary ventilation difficulties following a preoperative injection of suxamethonium
0	Premedication of ENT1 diazepam ENT1END 10 mg and atropine 0.5 mg was given, and sleep was induced and maintained by intermittent intravenous injections of etomidate 0.1/mg/kg, given whenever the patient would open his eyes on request. A mean overall dose of etomidate 17.4 microgram/kg/min. was required to maintain sleep, but great individual variation occurred, with older patients requiring less drug. The investigation was discontinued after 18 patients because of the frequency and intensity of side-effects, particularly ENT2 pain ENT2END and myoclonia, which caused the technique to be abandoned in two cases
1	The investigation was discontinued after 18 patients because of the frequency and intensity of side-effects, particularly ENT1 pain ENT1END  and myoclonia, which caused the technique to be abandoned in two cases. It is considered unlikely that ENT2 etomidate ENT2END will prove to be the hypnotic of choice for a totally intravenous anesthetic technique in adults because of the high incidence of myoclonia after prolonged administration
0	Premedication of diazepam 10 mg and ENT1 atropine  ENT1END 0.5 mg was given, and sleep was induced and maintained by intermittent intravenous injections of etomidate 0.1/mg/kg, given whenever the patient would open his eyes on request. A mean overall dose of etomidate 17.4 microgram/kg/min. was required to maintain sleep, but great individual variation occurred, with older patients requiring less drug. The investigation was discontinued after 18 patients because of the frequency and intensity of side-effects, particularly ENT2 pain ENT2END and myoclonia, which caused the technique to be abandoned in two cases
0	Premedication of ENT1 diazepam ENT1END  10 mg and atropine 0.5 mg was given, and sleep was induced and maintained by intermittent intravenous injections of etomidate 0.1/mg/kg, given whenever the patient would open his eyes on request. A mean overall dose of etomidate 17.4 microgram/kg/min. was required to maintain sleep, but great individual variation occurred, with older patients requiring less drug. The investigation was discontinued after 18 patients because of the frequency and intensity of side-effects, particularly pain and ENT2 myoclonia ENT2END , which caused the technique to be abandoned in two cases
1	The investigation was discontinued after 18 patients because of the frequency and intensity of side-effects, particularly pain and ENT1 myoclonia  ENT1END , which caused the technique to be abandoned in two cases. It is considered unlikely that ENT2 etomidate ENT2END will prove to be the hypnotic of choice for a totally intravenous anesthetic technique in adults because of the high incidence of myoclonia after prolonged administration
0	Premedication of diazepam 10 mg and ENT1 atropine  ENT1END  0.5 mg was given, and sleep was induced and maintained by intermittent intravenous injections of etomidate 0.1/mg/kg, given whenever the patient would open his eyes on request. A mean overall dose of etomidate 17.4 microgram/kg/min. was required to maintain sleep, but great individual variation occurred, with older patients requiring less drug. The investigation was discontinued after 18 patients because of the frequency and intensity of side-effects, particularly pain and ENT2 myoclonia ENT2END , which caused the technique to be abandoned in two cases
0	DESIGN: Dose response curves for nonsedating doses of morphine and ENT1 CNSB002 ENT1END given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat ENT2 pain ENT2END models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat ENT1 pain ENT1END  models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy. RESULTS: The maximum nonsedating doses were: ENT2 morphine ENT2END , 3
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat ENT1 pain ENT1END  models: ENT2 carrageenan ENT2END -induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat ENT1 pain ENT1END  models: carrageenan-induced paw inflammation and ENT2 streptozotocin ENT2END (STZ)-induced diabetic neuropathy
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a ENT1 sodium  ENT1END channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain. DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat ENT2 pain ENT2END models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced ENT1 diabetic neuropathy ENT1END  RESULTS: The maximum nonsedating doses were: morphine, 3.2 mg/kg; ENT2 CNSB002 ENT2END 10
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced ENT1 diabetic neuropathy  ENT1END . RESULTS: The maximum nonsedating doses were: ENT2 morphine ENT2END , 3
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: ENT1 carrageenan  ENT1END -induced paw inflammation and streptozotocin (STZ)-induced ENT2 diabetic neuropathy ENT2END
1	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin ( ENT1 STZ  ENT1END -induced ENT2 diabetic neuropathy ENT2END
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a ENT1 sodium  ENT1END  channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain. DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced ENT2 diabetic neuropathy ENT2END
0	Studies of synergy between morphine and a novel sodium channel blocker, ENT1 CNSB002  ENT1END , in rat models of inflammatory and ENT2 neuropathic pain ENT2END
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with ENT1 morphine ENT1END in rat models of inflammatory and ENT2 neuropathic pain ENT2END
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and ENT1 neuropathic pain  ENT1END . DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: ENT2 carrageenan ENT2END -induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and ENT1 neuropathic pain  ENT1END . DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and ENT2 streptozotocin ENT2END (STZ)-induced diabetic neuropathy
0	Studies of synergy between morphine and a novel ENT1 sodium  ENT1END  channel blocker, CNSB002, in rat models of inflammatory and ENT2 neuropathic pain ENT2END
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw ENT1 inflammation  ENT1END and streptozotocin (STZ)-induced diabetic neuropathy. RESULTS: The maximum nonsedating doses were: morphine, 3.2 mg/kg; ENT2 CNSB002 ENT2END 10
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw ENT1 inflammation  ENT1END  and streptozotocin (STZ)-induced diabetic neuropathy. RESULTS: The maximum nonsedating doses were: ENT2 morphine ENT2END , 3
1	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: ENT1 carrageenan  ENT1END -induced paw ENT2 inflammation ENT2END and streptozotocin (STZ)-induced diabetic neuropathy
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw ENT1 inflammation  ENT1END  and ENT2 streptozotocin ENT2END (STZ)-induced diabetic neuropathy
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a ENT1 sodium  ENT1END  channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain. DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw ENT2 inflammation ENT2END and streptozotocin (STZ)-induced diabetic neuropathy
0	24) in the STZ-induced ENT1 neuropathy ENT1END model for ENT2 CNSB002 ENT2END and morphine, respectively (mg/kg; mean, SEM)
0	24) in the STZ-induced ENT1 neuropathy ENT1END  model for CNSB002 and ENT2 morphine ENT2END , respectively (mg/kg; mean, SEM)
0	55) in the ENT1 carrageenan ENT1END model and 1.37 (1.23) in the ENT2 neuropathy ENT2END model (mg/kg; mean, SEM)
0	24) in the ENT1 STZ  ENT1END induced ENT2 neuropathy ENT2END model for CNSB002 and morphine, respectively (mg/kg; mean, SEM)
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a ENT1 sodium  ENT1END  channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain. DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy. RESULTS: The maximum nonsedating doses were: morphine, 3.2 mg/kg; CNSB002 10.0 mg/kg; 5.0 mg/kg CNSB002 with morphine 3.2 mg/kg in combination. The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced ENT2 neuropathy ENT2END model for CNSB002 and morphine, respectively (mg/kg; mean, SEM)
0	2 mg/kg) was increased by co-administration with ENT1 CNSB002 ENT1END from 28.0 and 31.7% to 114.6 and 56.9% reversal of ENT2 hyperalgesia ENT2END in the inflammatory and neuropathic models, respectively (P < 0
0	0 mg/kg CNSB002 with ENT1 morphine ENT1END 3.2 mg/kg in combination. The doses calculated to cause 50% reversal of ENT2 hyperalgesia ENT2END (ED50) were 7
1	The doses calculated to cause 50% reversal of ENT1 hyperalgesia ENT1END  (ED50) were 7.54 (1.81) and 4.83 (1.54) in the ENT2 carrageenan ENT2END model and 44
1	The doses calculated to cause 50% reversal of ENT1 hyperalgesia  ENT1END  (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the ENT2 STZ ENT2END -induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM)
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a ENT1 sodium  ENT1END  channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain. DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy. RESULTS: The maximum nonsedating doses were: morphine, 3.2 mg/kg; CNSB002 10.0 mg/kg; 5.0 mg/kg CNSB002 with morphine 3.2 mg/kg in combination. The doses calculated to cause 50% reversal of ENT2 hyperalgesia ENT2END (ED50) were 7
0	Adverse effects included a mildly ENT1 dry mouth ENT1END and a sore throat in 2 patients (2% ENT2 glycopyrrolate ENT2END ), a light headache in 1 patient (1
0	Current options of treatment include oral anticholinergic drugs, the topical application of anticholinergics or ENT1 aluminum chloride  ENT1END  and the injection of botulinum toxin. Thirteen patients have been treated to date with 1.5% or 2% topical glycopyrrolate. All patients had gustatory hyperhidrosis, which interfered with their social activities, after transthroacic endoscopic sympathectomy, and which was associated with compensatory focal hyperhidrosis. After applying topical glycopyrrolate, the subjective effect was excellent (no sweating after eating hot spicy food) in 10 patients (77%), and fair (clearly reduced sweating) in 3 patients (23%). All had reported incidents of being very embarrassed whilst eating hot spicy foods. Adverse effects included a mildly ENT2 dry mouth ENT2END and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1
0	All patients had gustatory hyperhidrosis, which interfered with their social activities, after transthroacic endoscopic sympathectomy, and which was associated with compensatory focal ENT1 hyperhidrosis ENT1END  After applying topical ENT2 glycopyrrolate ENT2END , the subjective effect was excellent (no sweating after eating hot spicy food) in 10 patients (77%), and fair (clearly reduced sweating) in 3 patients (23%)
0	Current options of treatment include oral anticholinergic drugs, the topical application of anticholinergics or ENT1 aluminum chloride  ENT1END , and the injection of botulinum toxin. Thirteen patients have been treated to date with 1.5% or 2% topical glycopyrrolate. All patients had gustatory hyperhidrosis, which interfered with their social activities, after transthroacic endoscopic sympathectomy, and which was associated with compensatory focal ENT2 hyperhidrosis ENT2END
1	Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% ENT1 glycopyrrolate ENT1END ), a light ENT2 headache ENT2END in 1 patient (1
0	Current options of treatment include oral anticholinergic drugs, the topical application of anticholinergics or ENT1 aluminum chloride  ENT1END , and the injection of botulinum toxin. Thirteen patients have been treated to date with 1.5% or 2% topical glycopyrrolate. All patients had gustatory hyperhidrosis, which interfered with their social activities, after transthroacic endoscopic sympathectomy, and which was associated with compensatory focal hyperhidrosis. After applying topical glycopyrrolate, the subjective effect was excellent (no sweating after eating hot spicy food) in 10 patients (77%), and fair (clearly reduced sweating) in 3 patients (23%). All had reported incidents of being very embarrassed whilst eating hot spicy foods. Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% glycopyrrolate), a light ENT2 headache ENT2END in 1 patient (1
0	Treatment of compensatory gustatory hyperhidrosis with topical ENT1 glycopyrrolate  ENT1END . ENT2 Gustatory hyperhidrosis ENT2END is facial sweating usually associated with the eating of hot spicy food or even smelling this food
0	Current options of treatment include oral anticholinergic drugs, the topical application of anticholinergics or ENT1 aluminum chloride ENT1END , and the injection of botulinum toxin. Thirteen patients have been treated to date with 1.5% or 2% topical glycopyrrolate. All patients had ENT2 gustatory hyperhidrosis ENT2END , which interfered with their social activities, after transthroacic endoscopic sympathectomy, and which was associated with compensatory focal hyperhidrosis
1	Adverse effects included a mildly dry mouth and a ENT1 sore throat  ENT1END in 2 patients (2% ENT2 glycopyrrolate ENT2END ), a light headache in 1 patient (1
0	Current options of treatment include oral anticholinergic drugs, the topical application of anticholinergics or ENT1 aluminum chloride  ENT1END , and the injection of botulinum toxin. Thirteen patients have been treated to date with 1.5% or 2% topical glycopyrrolate. All patients had gustatory hyperhidrosis, which interfered with their social activities, after transthroacic endoscopic sympathectomy, and which was associated with compensatory focal hyperhidrosis. After applying topical glycopyrrolate, the subjective effect was excellent (no sweating after eating hot spicy food) in 10 patients (77%), and fair (clearly reduced sweating) in 3 patients (23%). All had reported incidents of being very embarrassed whilst eating hot spicy foods. Adverse effects included a mildly dry mouth and a ENT2 sore throat ENT2END in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1
0	METHODS: Outcomes were examined in patients admitted for possible MI after ENT1 cocaine ENT1END use. All patients underwent a rapid rule-in protocol that included serial sampling of creatine kinase (CK), CK-MB, and cardiac troponin I (cTnI) over eight hours. Outcomes included CK-MB MI (CK-MB >or= 8 ng/mL with a relative index [(CK-MB x 100)/total CK] >or= 4, ENT2 cardiac death ENT2END , and significant coronary disease (>or=50%)
0	All patients underwent a rapid rule-in protocol that included serial sampling of ENT1 creatine  ENT1END kinase (CK), CK-MB, and cardiac troponin I (cTnI) over eight hours. Outcomes included CK-MB MI (CK-MB >or= 8 ng/mL with a relative index [(CK-MB x 100)/total CK] >or= 4, ENT2 cardiac death ENT2END , and significant coronary disease (>or=50%)
0	Baseline electrocardiogram abnormalities and market elevations not associated with ENT1 myocardial necrosis ENT1END make accurate diagnosis of myocardial infarction (MI) difficult in patients with ENT2 cocaine ENT2END -associated chest pain
0	Baseline electrocardiogram abnormalities and market elevations not associated with ENT1 myocardial necrosis  ENT1END  make accurate diagnosis of myocardial infarction (MI) difficult in patients with cocaine-associated chest pain. Troponin sampling may offer greater diagnostic utility in these patients. OBJECTIVE: To assess outcomes based on troponin positivity in patients with cocaine chest pain admitted for exclusion of MI. METHODS: Outcomes were examined in patients admitted for possible MI after cocaine use. All patients underwent a rapid rule-in protocol that included serial sampling of ENT2 creatine ENT2END kinase (CK), CK-MB, and cardiac troponin I (cTnI) over eight hours
1	METHODS: Outcomes were examined in patients admitted for possible ENT1 MI  ENT1END after ENT2 cocaine ENT2END use
0	All patients underwent a rapid rule-in protocol that included serial sampling of ENT1 creatine ENT1END  kinase (CK), CK-MB, and cardiac troponin I (cTnI) over eight hours. Outcomes included CK-MB ENT2 MI ENT2END (CK-MB >or= 8 ng/mL with a relative index [(CK-MB x 100)/total CK] >or= 4, cardiac death, and significant coronary disease (>or=50%)
0	Troponin appears to have an equivalent diagnostic accuracy compared with CK-MB for diagnosing ENT1 necrosis ENT1END in patients with ENT2 cocaine ENT2END -associated chest pain and suspected MI
0	OBJECTIVE: To assess outcomes based on troponin positivity in patients with ENT1 cocaine ENT1END ENT2 chest pain ENT2END admitted for exclusion of MI
0	OBJECTIVE: To assess outcomes based on troponin positivity in patients with cocaine ENT1 chest pain  ENT1END  admitted for exclusion of MI. METHODS: Outcomes were examined in patients admitted for possible MI after cocaine use. All patients underwent a rapid rule-in protocol that included serial sampling of ENT2 creatine ENT2END kinase (CK), CK-MB, and cardiac troponin I (cTnI) over eight hours
0	METHODS: Outcomes were examined in patients admitted for possible MI after ENT1 cocaine ENT1END  use. All patients underwent a rapid rule-in protocol that included serial sampling of creatine kinase (CK), CK-MB, and cardiac troponin I (cTnI) over eight hours. Outcomes included CK-MB MI (CK-MB >or= 8 ng/mL with a relative index [(CK-MB x 100)/total CK] >or= 4, cardiac death, and significant ENT2 coronary disease ENT2END (>or=50%)
0	All patients underwent a rapid rule-in protocol that included serial sampling of ENT1 creatine  ENT1END  kinase (CK), CK-MB, and cardiac troponin I (cTnI) over eight hours. Outcomes included CK-MB MI (CK-MB >or= 8 ng/mL with a relative index [(CK-MB x 100)/total CK] >or= 4, cardiac death, and significant ENT2 coronary disease ENT2END (>or=50%)
0	We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause ENT1 left ventricular dysfunction ENT1END  Seven days of cocaine administration to rats led to an increased ENT2 oxygen ENT2END consumption detected in cardiac fibers, specifically through complex I and complex III
0	We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause ENT1 left ventricular dysfunction ENT1END . Seven days of ENT2 cocaine ENT2END administration to rats led to an increased oxygen consumption detected in cardiac fibers, specifically through complex I and complex III
0	We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause ENT1 left ventricular dysfunction ENT1END . Seven days of cocaine administration to rats led to an increased oxygen consumption detected in cardiac fibers, specifically through complex I and complex III. ROS levels were increased, specifically in interfibrillar mitochondria. In parallel there was a decrease in ENT2 ATP ENT2END synthesis, whereas no difference was observed in subsarcolemmal mitochondria
0	Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant ENT1 MitoQ  ENT1END .The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction. We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause ENT2 left ventricular dysfunction ENT2END
0	The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced ENT1 cardiac dysfunction  ENT1END  We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction. Seven days of cocaine administration to rats led to an increased ENT2 oxygen ENT2END consumption detected in cardiac fibers, specifically through complex I and complex III
1	Mitochondrial impairment contributes to ENT1 cocaine  ENT1END -induced ENT2 cardiac dysfunction ENT2END : Prevention by the targeted antioxidant MitoQ
0	The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced ENT1 cardiac dysfunction  ENT1END . We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction. Seven days of cocaine administration to rats led to an increased oxygen consumption detected in cardiac fibers, specifically through complex I and complex III. ROS levels were increased, specifically in interfibrillar mitochondria. In parallel there was a decrease in ENT2 ATP ENT2END synthesis, whereas no difference was observed in subsarcolemmal mitochondria
0	Mitochondrial impairment contributes to cocaine-induced ENT1 cardiac dysfunction  ENT1END : Prevention by the targeted antioxidant ENT2 MitoQ ENT2END
0	Seven days of cocaine administration to rats led to an increased ENT1 oxygen ENT1END  consumption detected in cardiac fibers, specifically through complex I and complex III. ROS levels were increased, specifically in interfibrillar mitochondria. In parallel there was a decrease in ATP synthesis, whereas no difference was observed in subsarcolemmal mitochondria. This uncoupling effect on oxidative phosphorylation was not detectable after short-term exposure to cocaine, suggesting that these ENT2 mitochondrial abnormalities ENT2END were a late rather than a primary event in the pathological response to cocaine
0	ENT1 Mitochondrial impairment  ENT1END  contributes to ENT2 cocaine ENT2END -induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ
0	In parallel there was a decrease in ENT1 ATP  ENT1END  synthesis, whereas no difference was observed in subsarcolemmal mitochondria. This uncoupling effect on oxidative phosphorylation was not detectable after short-term exposure to cocaine, suggesting that these ENT2 mitochondrial abnormalities ENT2END were a late rather than a primary event in the pathological response to cocaine
0	ENT1 MitoQ ENT1END  a mitochondrial-targeted antioxidant, was shown to completely prevent these ENT2 mitochondrial abnormalities ENT2END as well as cardiac dysfunction characterized here by a diastolic dysfunction studied with a conductance catheter to obtain pressure-volume data
0	We hypothesized that ENT1 cocaine abuse  ENT1END may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction. Seven days of cocaine administration to rats led to an increased ENT2 oxygen ENT2END consumption detected in cardiac fibers, specifically through complex I and complex III
0	The goal of this study was to assess mitochondrial function and ROS production in an experimental model of ENT1 cocaine  ENT1END induced cardiac dysfunction. We hypothesized that ENT2 cocaine abuse ENT2END may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction
0	We hypothesized that ENT1 cocaine abuse  ENT1END  may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction. Seven days of cocaine administration to rats led to an increased oxygen consumption detected in cardiac fibers, specifically through complex I and complex III. ROS levels were increased, specifically in interfibrillar mitochondria. In parallel there was a decrease in ENT2 ATP ENT2END synthesis, whereas no difference was observed in subsarcolemmal mitochondria
0	Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant ENT1 MitoQ  ENT1END .The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction. We hypothesized that ENT2 cocaine abuse ENT2END may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction
0	Bilateral basal ganglia infarcts after the use of cocaine, without concurrent ENT1 heroin ENT1END use, have never been reported. In our patient, transient ENT2 cardiac arrhythmia ENT2END or respiratory dysfunction related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion
0	In our patient, transient ENT1 cardiac arrhythmia ENT1END  or respiratory dysfunction related to ENT2 cocaine ENT2END and/or ethanol use were the most likely causes of cerebral hypoperfusion
0	In our patient, transient ENT1 cardiac arrhythmia ENT1END  or respiratory dysfunction related to cocaine and/or ENT2 ethanol ENT2END use were the most likely causes of cerebral hypoperfusion
0	Bilateral basal ganglia infarcts after the use of cocaine, without concurrent ENT1 heroin ENT1END  use, have never been reported. In our patient, transient cardiac arrhythmia or ENT2 respiratory dysfunction ENT2END related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion
0	In our patient, transient cardiac arrhythmia or ENT1 respiratory dysfunction  ENT1END  related to ENT2 cocaine ENT2END and/or ethanol use were the most likely causes of cerebral hypoperfusion
0	In our patient, transient cardiac arrhythmia or ENT1 respiratory dysfunction  ENT1END  related to cocaine and/or ENT2 ethanol ENT2END use were the most likely causes of cerebral hypoperfusion
1	Drug-related globus pallidus infarctions are most often associated with ENT1 heroin ENT1END  Bilateral ENT2 basal ganglia infarcts ENT2END after the use of cocaine, without concurrent heroin use, have never been reported
0	Bilateral ENT1 basal ganglia infarcts ENT1END  after the use of ENT2 cocaine ENT2END , without concurrent heroin use, have never been reported
0	Bilateral ENT1 haemorrhagic infarction of the globus pallidus  ENT1END  after cocaine and ENT2 alcohol ENT2END intoxication
0	Cocaine is a risk factor for both ENT1 ischemic and haemorrhagic stroke  ENT1END  We present the case of a 31-year-old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use. Drug-related globus pallidus infarctions are most often associated with ENT2 heroin ENT2END
0	ENT1 Cocaine  ENT1END is a risk factor for both ENT2 ischemic and haemorrhagic stroke ENT2END
1	Bilateral haemorrhagic infarction of the globus pallidus after cocaine and ENT1 alcohol  ENT1END  intoxication.Cocaine is a risk factor for both ENT2 ischemic and haemorrhagic stroke ENT2END
0	Cocaine is a risk factor for both ENT1 ischemic and haemorrhagic stroke  ENT1END  We present the case of a 31-year-old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use. Drug-related globus pallidus infarctions are most often associated with ENT2 heroin ENT2END
0	ENT1 Cocaine  ENT1END  is a risk factor for both ENT2 ischemic and haemorrhagic stroke ENT2END
1	Bilateral haemorrhagic infarction of the globus pallidus after cocaine and ENT1 alcohol  ENT1END  intoxication.Cocaine is a risk factor for both ENT2 ischemic and haemorrhagic stroke ENT2END
0	We present the case of a 31-year-old man with bilateral ENT1 ischemia of the globus pallidus  ENT1END after excessive alcohol and intranasal cocaine use. Drug-related globus pallidus infarctions are most often associated with ENT2 heroin ENT2END
1	We present the case of a 31-year-old man with bilateral ENT1 ischemia of the globus pallidus ENT1END  after excessive alcohol and intranasal ENT2 cocaine ENT2END use
0	We present the case of a 31-year-old man with bilateral ENT1 ischemia of the globus pallidus ENT1END  after excessive ENT2 alcohol ENT2END and intranasal cocaine use
0	Bilateral ENT1 haemorrhagic infarction of the globus pallidus  ENT1END  after cocaine and alcohol intoxication.Cocaine is a risk factor for both ischemic and haemorrhagic stroke. We present the case of a 31-year-old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use. Drug-related globus pallidus infarctions are most often associated with ENT2 heroin ENT2END
0	Bilateral ENT1 haemorrhagic infarction of the globus pallidus  ENT1END  after ENT2 cocaine ENT2END and alcohol intoxication
0	Bilateral ENT1 haemorrhagic infarction of the globus pallidus  ENT1END  after cocaine and ENT2 alcohol ENT2END intoxication
0	A 37-year-old Caucasian woman with a history of ENT1 T-cell lymphoblastic lymphoma ENT1END was admitted for relapsed disease. She was originally treated with induction chemotherapy followed by an autologous transplant. She developed relapsed disease 10 months later with leukemic involvement. She was re-induced with nelarabine 1500 mg/m(2) on days 1, 3, and 5 with 1 dose of IT ENT2 cytarabine ENT2END 100 mg on day 2 as central nervous system (CNS) prophylaxis
0	Severe ENT1 nelarabine  ENT1END neurotoxicity in a patient who received concurrent intrathecal (IT) chemotherapy is reported. A 37-year-old Caucasian woman with a history of ENT2 T-cell lymphoblastic lymphoma ENT2END was admitted for relapsed disease
0	Severe nelarabine ENT1 neurotoxicity  ENT1END in a patient who received concurrent intrathecal (IT) chemotherapy is reported. A 37-year-old Caucasian woman with a history of T-cell lymphoblastic lymphoma was admitted for relapsed disease. She was originally treated with induction chemotherapy followed by an autologous transplant. She developed relapsed disease 10 months later with leukemic involvement. She was re-induced with nelarabine 1500 mg/m(2) on days 1, 3, and 5 with 1 dose of IT ENT2 cytarabine ENT2END 100 mg on day 2 as central nervous system (CNS) prophylaxis
0	ENT1 Nelarabine ENT1END ENT2 neurotoxicity ENT2END with concurrent intrathecal chemotherapy: Case report and review of literature
0	She was re-induced with nelarabine 1500 mg/m(2) on days 1, 3, and 5 with 1 dose of IT ENT1 cytarabine ENT1END  100 mg on day 2 as central nervous system (CNS) prophylaxis. At the time of treatment, she was on continuous renal replacement therapy due to sequelae of tumor lysis syndrome (TLS). She tolerated therapy well, entered a complete remission, and recovered her renal function. She received a second cycle of nelarabine without additional IT prophylaxis one month later. A week after this second cycle, she noted numbness in her lower extremities. Predominantly sensory, though also motor and autonomic, ENT2 peripheral neuropathy ENT2END started in her feet, ascended proximally to the mid-thoracic region, and eventually included her distal upper extremities
1	She received a second cycle of ENT1 nelarabine  ENT1END without additional IT prophylaxis one month later. A week after this second cycle, she noted numbness in her lower extremities. Predominantly sensory, though also motor and autonomic, ENT2 peripheral neuropathy ENT2END started in her feet, ascended proximally to the mid-thoracic region, and eventually included her distal upper extremities
0	ENT1 Nelarabine ENT1END was felt to be the cause of her symptoms. Her ENT2 neuropathy ENT2END stabilized and showed slight improvement and ultimately received an unrelated, reduced-intensity allogeneic transplant while in complete remission, but relapsed disease 10 weeks later
0	She was re-induced with nelarabine 1500 mg/m(2) on days 1, 3, and 5 with 1 dose of IT ENT1 cytarabine ENT1END  100 mg on day 2 as central nervous system (CNS) prophylaxis. At the time of treatment, she was on continuous renal replacement therapy due to sequelae of ENT2 tumor lysis syndrome ENT2END (TLS)
0	At the time of treatment, she was on continuous renal replacement therapy due to sequelae of tumor lysis syndrome ( ENT1 TLS  ENT1END . She tolerated therapy well, entered a complete remission, and recovered her renal function. She received a second cycle of ENT2 nelarabine ENT2END without additional IT prophylaxis one month later
0	She developed relapsed disease 10 months later with ENT1 leukemic  ENT1END involvement. She was re-induced with nelarabine 1500 mg/m(2) on days 1, 3, and 5 with 1 dose of IT ENT2 cytarabine ENT2END 100 mg on day 2 as central nervous system (CNS) prophylaxis
0	She developed relapsed disease 10 months later with ENT1 leukemic ENT1END  involvement. She was re-induced with ENT2 nelarabine ENT2END 1500 mg/m(2) on days 1, 3, and 5 with 1 dose of IT cytarabine 100 mg on day 2 as central nervous system (CNS) prophylaxis
0	Signs of ENT1 FZP ENT1END ENT2 toxocity ENT2END in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions
0	Signs of FZP ENT1 toxocity ENT1END  in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions. An interaction between FZP and ENT2 pentylenetetrazol ENT2END (PTZ) was shown by pretreating mice with FZP before PTZ challenge
1	Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and ENT1 convulsions ENT1END  An interaction between ENT2 FZP ENT2END and pentylenetetrazol (PTZ) was shown by pretreating mice with FZP before PTZ challenge
1	Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and ENT1 convulsions  ENT1END . An interaction between FZP and ENT2 pentylenetetrazol ENT2END (PTZ) was shown by pretreating mice with FZP before PTZ challenge
0	Signs of ENT1 FZP ENT1END  toxocity in cats included excessive ENT2 salivation ENT2END , extreme apprehensive behavior, retching, muscle tremors and convulsions
0	Signs of FZP toxocity in cats included excessive ENT1 salivation  ENT1END , extreme apprehensive behavior, retching, muscle tremors and convulsions. An interaction between FZP and ENT2 pentylenetetrazol ENT2END (PTZ) was shown by pretreating mice with FZP before PTZ challenge
0	These results may be relevant to the use of ENT1 FZP ENT1END in clinical situations in which there is increased neural excitability, such as ENT2 epilepsy ENT2END or sedative-hypnotic drug withdrawal
0	An interaction between FZP and pentylenetetrazol (PTZ) was shown by pretreating mice with FZP before ENT1 PTZ  ENT1END challenge. As a function of dose, FZP first protected against convulsions and death. At higher doses, however, convulsions again emerged. These doses of FZP were lower than those that would alone cause convulsions. These results may be relevant to the use of FZP in clinical situations in which there is increased neural excitability, such as ENT2 epilepsy ENT2END or sedative-hypnotic drug withdrawal
0	Toxic actions of flurazepam ( ENT1 FZP ENT1END  were studied in cats, mice and rats. High doses caused an apparent central excitation, most clearly seen as clonic convulsions, superimposed on general ENT2 depression ENT2END
0	Comparing the relative sensitivity to central ENT1 depression  ENT1END and excitation revealed that rats were least likely to have convulsions at doses that did not first cause loss of consciousness, while cats most clearly showed marked central excitatory actions. Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions. An interaction between FZP and ENT2 pentylenetetrazol ENT2END (PTZ) was shown by pretreating mice with FZP before PTZ challenge
0	Comparing the relative sensitivity to central depression and excitation revealed that rats were least likely to have convulsions at doses that did not first cause ENT1 loss of consciousness  ENT1END  while cats most clearly showed marked central excitatory actions. Signs of ENT2 FZP ENT2END toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions
0	Comparing the relative sensitivity to central depression and excitation revealed that rats were least likely to have convulsions at doses that did not first cause ENT1 loss of consciousness  ENT1END , while cats most clearly showed marked central excitatory actions. Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions. An interaction between FZP and ENT2 pentylenetetrazol ENT2END (PTZ) was shown by pretreating mice with FZP before PTZ challenge
0	Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, ENT1 muscle tremors  ENT1END and convulsions. An interaction between ENT2 FZP ENT2END and pentylenetetrazol (PTZ) was shown by pretreating mice with FZP before PTZ challenge
0	Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, ENT1 muscle tremors  ENT1END  and convulsions. An interaction between FZP and ENT2 pentylenetetrazol ENT2END (PTZ) was shown by pretreating mice with FZP before PTZ challenge
0	They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked ENT1 hypersensitivity ENT1END to the pressor effects of infused ENT2 norepinephrine ENT2END
0	They all exhibited markedly reduced plasma ENT1 catecholamines  ENT1END and plasma renin activity in both recumbent and upright positions and had marked ENT2 hypersensitivity ENT2END to the pressor effects of infused norepinephrine
0	They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked ENT1 hypersensitivity ENT1END  to the pressor effects of infused norepinephrine. Treatment with ENT2 propanolol ENT2END administered intravenously (1-5 mg) produced increases in supine and upright blood pressure in 4 of the 5 individuals with rises ranging from 11/6 to 22/11 mmHg
0	They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused ENT1 norepinephrine ENT1END . Treatment with propanolol administered intravenously (1-5 mg) produced increases in supine and upright blood pressure in 4 of the 5 individuals with rises ranging from 11/6 to 22/11 mmHg. Chronic oral administration of propranolol (40-160 mg/day) also elevated the blood pressures of these individuals with increases in the order of 20-35/15-25 mmg being observed. In 1 patient, marked ENT2 hypertension ENT2END was induced by propranolol and the drug had to be withdrawn
0	They all exhibited markedly reduced plasma ENT1 catecholamines  ENT1END  and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused norepinephrine. Treatment with propanolol administered intravenously (1-5 mg) produced increases in supine and upright blood pressure in 4 of the 5 individuals with rises ranging from 11/6 to 22/11 mmHg. Chronic oral administration of propranolol (40-160 mg/day) also elevated the blood pressures of these individuals with increases in the order of 20-35/15-25 mmg being observed. In 1 patient, marked ENT2 hypertension ENT2END was induced by propranolol and the drug had to be withdrawn
1	In 1 patient, marked ENT1 hypertension ENT1END  was induced by ENT2 propranolol ENT2END and the drug had to be withdrawn
0	Five patients with ENT1 idiopathic orthostatic hypotension  ENT1END who had physiologic and biochemical evidence of severe autonomic dysfunction were included in the study. They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused ENT2 norepinephrine ENT2END
0	Five patients with ENT1 idiopathic orthostatic hypotension  ENT1END  who had physiologic and biochemical evidence of severe autonomic dysfunction were included in the study. They all exhibited markedly reduced plasma ENT2 catecholamines ENT2END and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused norepinephrine
0	Use of ENT1 propranolol  ENT1END  in the treatment of ENT2 idiopathic orthostatic hypotension ENT2END
1	Eight patients stopped using ENT1 GTN ENT1END because ENT2 headache ENT2END --attributed to its use--became intolerable
0	Headache was significantly increased by GTN but not by ENT1 DCF  ENT1END  Eight patients stopped using GTN because ENT2 headache ENT2END --attributed to its use--became intolerable
0	The difference in ENT1 pain  ENT1END intensity score (DPI) was the main outcome variable. Both treatments significantly reduced DPI by the 30th minute ( ENT2 GTN ENT2END , -12
0	The difference in ENT1 pain ENT1END  intensity score (DPI) was the main outcome variable. Both treatments significantly reduced DPI by the 30th minute (GTN, -12.8 +/- 17.9; ENT2 DCF ENT2END , -18
0	Primary ENT1 dysmenorrhea ENT1END is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial ENT2 prostaglandins ENT2END ; non-steroidal anti-inflammatory drugs are the first choice for its treatment
0	The aim of the present study was to determine the efficacy of glyceryl trinitrate ( ENT1 GTN ENT1END , an NO donor, in the resolution of primary ENT2 dysmenorrhea ENT2END in comparison with diclofenac (DCF)
0	The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an ENT1 NO  ENT1END donor, in the resolution of primary ENT2 dysmenorrhea ENT2END in comparison with diclofenac (DCF)
0	The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an NO donor, in the resolution of primary ENT1 dysmenorrhea ENT1END  in comparison with ENT2 diclofenac ENT2END (DCF)
0	6 and after two hours: ENT1 GTN ENT1END  -23.7 +/- 20.5; DFC, -59.7 +/- 17.9, p = 0.0001). ENT2 Low back pain ENT2END was also relieved by both drugs
0	ENT1 Low back pain  ENT1END  was also relieved by both drugs. Headache was significantly increased by GTN but not by ENT2 DCF ENT2END
0	However, DCF continued to be effective in reducing ENT1 pelvic pain ENT1END for two hours, whereas ENT2 GTN ENT2END scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12
0	However, ENT1 DCF  ENT1END continued to be effective in reducing ENT2 pelvic pain ENT2END for two hours, whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12
0	Two hundred four people with epilepsy were grouped on the basis of antiepileptic drug therapy (current, previous, or no exposure to ENT1 VGB ENT1END . Groups were matched with respect to age, gender, and ENT2 seizure ENT2END frequency
1	Assessment by conventional static perimetry may neither be sufficiently sensitive nor specific to reliably identify ENT1 retinal toxicity ENT1END associated with ENT2 VGB ENT2END
0	This study investigated the visual defects associated with the antiepileptic drug vigabatrin ( ENT1 VGB ENT1END . Two hundred four people with ENT2 epilepsy ENT2END were grouped on the basis of antiepileptic drug therapy (current, previous, or no exposure to VGB)
1	Assessment of retinal function revealed abnormal responses in 48% of current VGB users and 22% of prior VGB users, but in none of the patients without previous exposure to ENT1 VGB ENT1END  ENT2 Bilateral visual field abnormalities ENT2END are common in the treated epilepsy population, irrespective of drug history
0	Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, ENT1 congestive heart failure ENT1END  deep hypothermic circulatory arrest, duration of aortic cross-clamp and ENT2 tranexamic acid ENT2END
0	Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep ENT1 hypothermic  ENT1END circulatory arrest, duration of aortic cross-clamp and ENT2 tranexamic acid ENT2END
1	The association between ENT1 tranexamic acid  ENT1END  and ENT2 convulsive ENT2END seizures after cardiac surgery: a multivariate analysis in 11 529 patients
0	The association between ENT1 tranexamic acid ENT1END  and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients.Because of a lack of contemporary data regarding seizures after cardiac surgery, we undertook a retrospective analysis of prospectively collected data from 11 529 patients in whom cardiopulmonary bypass was used from January 2004 to December 2010. A convulsive seizure was defined as a transient episode of disturbed brain function characterised by ENT2 abnormal involuntary motor movements ENT2END
0	Convulsive seizures are a serious ENT1 postoperative complication ENT1END after cardiac surgery. As ENT2 tranexamic acid ENT2END is the only modifiable factor, its administration, particularly in doses exceeding 80 mg
0	Tobramycin was given to a total daily dose of 300 mg/m2 and ENT1 carbenicillin ENT1END was given at a dose of 5 gm every four hours. There were 125 infectious episodes in 116 cancer patients receiving myelosuppressive chemotherapy. The overall cure rate was 70%. Pneumonia was the most common infection and 61% of 59 episodes were cured. Gram-negative bacilli were the most common causative organisms and 69% of these infections were cured. The most common pathogen was Klebsiella pneumoniae and this, together with Escherichia coli and Pseudomonas aeruginosa, accounted for 74% of all ENT2 gram-negative bacillary infections ENT2END
0	The most common pathogen was Klebsiella pneumoniae and this, together with Escherichia coli and Pseudomonas aeruginosa, accounted for 74% of all ENT1 gram-negative bacillary infections ENT1END . Response was not influenced by the initial neutrophil count, with a 62% cure rate for 39 episodes associated with severe neutropenia. However, failure of the neutrophil count to increase during therapy adversely affected response. Azotemia was the major side effect recognized, and it occurred in 11% of episodes. Major azotemia (serum ENT2 creatinine ENT2END greater than 2
0	The most common pathogen was Klebsiella pneumoniae and this, together with Escherichia coli and Pseudomonas aeruginosa, accounted for 74% of all ENT1 gram-negative bacillary infections ENT1END . Response was not influenced by the initial neutrophil count, with a 62% cure rate for 39 episodes associated with severe neutropenia. However, failure of the neutrophil count to increase during therapy adversely affected response. Azotemia was the major side effect recognized, and it occurred in 11% of episodes. Major azotemia (serum creatinine greater than 2.5 mg/dl or BUN greater than 50 mg/dl) occurred in only 2%. Azotemia was not related to duration of therapy or serum ENT2 tobramycin ENT2END concentration
0	To overcome the adverse effects of ENT1 neutropenia ENT1END  tobramycin was given by continuous infusion and combined with intermittent ENT2 carbenicillin ENT2END
0	Response was not influenced by the initial neutrophil count, with a 62% cure rate for 39 episodes associated with severe ENT1 neutropenia  ENT1END  However, failure of the neutrophil count to increase during therapy adversely affected response. Azotemia was the major side effect recognized, and it occurred in 11% of episodes. Major azotemia (serum ENT2 creatinine ENT2END greater than 2
0	To overcome the adverse effects of ENT1 neutropenia ENT1END , ENT2 tobramycin ENT2END was given by continuous infusion and combined with intermittent carbenicillin
0	Continuous infusion tobramycin combined with ENT1 carbenicillin  ENT1END  for infections in ENT2 cancer ENT2END patients
0	Continuous infusion ENT1 tobramycin  ENT1END  combined with carbenicillin for infections in ENT2 cancer ENT2END patients
0	Continuous infusion tobramycin combined with ENT1 carbenicillin  ENT1END  for ENT2 infections ENT2END in cancer patients
0	Gram-negative bacilli were the most common causative organisms and 69% of these ENT1 infections  ENT1END were cured. The most common pathogen was Klebsiella pneumoniae and this, together with Escherichia coli and Pseudomonas aeruginosa, accounted for 74% of all gram-negative bacillary infections. Response was not influenced by the initial neutrophil count, with a 62% cure rate for 39 episodes associated with severe neutropenia. However, failure of the neutrophil count to increase during therapy adversely affected response. Azotemia was the major side effect recognized, and it occurred in 11% of episodes. Major azotemia (serum ENT2 creatinine ENT2END greater than 2
0	Continuous infusion ENT1 tobramycin  ENT1END  combined with carbenicillin for ENT2 infections ENT2END in cancer patients
0	Major ENT1 azotemia  ENT1END (serum ENT2 creatinine ENT2END greater than 2
1	ENT1 Azotemia  ENT1END was not related to duration of therapy or serum ENT2 tobramycin ENT2END concentration
0	Tobramycin was given to a total daily dose of 300 mg/m2 and ENT1 carbenicillin ENT1END  was given at a dose of 5 gm every four hours. There were 125 infectious episodes in 116 cancer patients receiving myelosuppressive chemotherapy. The overall cure rate was 70%. ENT2 Pneumonia ENT2END was the most common infection and 61% of 59 episodes were cured
0	The most common pathogen was Klebsiella ENT1 pneumoniae  ENT1END and this, together with Escherichia coli and Pseudomonas aeruginosa, accounted for 74% of all gram-negative bacillary infections. Response was not influenced by the initial neutrophil count, with a 62% cure rate for 39 episodes associated with severe neutropenia. However, failure of the neutrophil count to increase during therapy adversely affected response. Azotemia was the major side effect recognized, and it occurred in 11% of episodes. Major azotemia (serum ENT2 creatinine ENT2END greater than 2
0	ENT1 Tobramycin  ENT1END was given to a total daily dose of 300 mg/m2 and carbenicillin was given at a dose of 5 gm every four hours. There were 125 infectious episodes in 116 cancer patients receiving myelosuppressive chemotherapy. The overall cure rate was 70%. ENT2 Pneumonia ENT2END was the most common infection and 61% of 59 episodes were cured
0	Major azotemia (serum ENT1 creatinine ENT1END  greater than 2.5 mg/dl or BUN greater than 50 mg/dl) occurred in only 2%. Azotemia was not related to duration of therapy or serum tobramycin concentration. This antibiotic regimen showed both therapeutic efficacy and acceptable ENT2 renal toxicity ENT2END for these patients
0	Azotemia was not related to duration of therapy or serum ENT1 tobramycin  ENT1END  concentration. This antibiotic regimen showed both therapeutic efficacy and acceptable ENT2 renal toxicity ENT2END for these patients
1	BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with ENT1 QT prolongation  ENT1END induced by dl- ENT2 sotalol ENT2END and azimilide
0	dl-Sotalol preferentially prolonged action potential duration (APD) in M cells dose-dependently (1 to 100 micromol/L), leading to ENT1 QT prolongation ENT1END and an increase in TDR. ENT2 Azimilide ENT2END , however, significantly prolonged APD and QT interval at concentrations from 0
1	BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes ( ENT1 TdP  ENT1END  with QT prolongation induced by dl ENT2 sotalol ENT2END and azimilide
0	BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes ( ENT1 TdP ENT1END ) with QT prolongation induced by dl-sotalol and ENT2 azimilide ENT2END
0	Phase 2 early afterdepolarization as a trigger of polymorphic ENT1 ventricular tachycardia  ENT1END  in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall.BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl ENT2 sotalol ENT2END and azimilide
0	Phase 2 early afterdepolarization as a trigger of polymorphic ENT1 ventricular tachycardia  ENT1END  in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall.BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and ENT2 azimilide ENT2END
1	708), ENT1 bipolar disorder ENT1END (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy ENT2 methamphetamine ENT2END uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors
0	It was associated with co-morbid ENT1 affective disorder ENT1END  antisocial personality, and heavy ENT2 methamphetamine ENT2END use
0	) for ENT1 methamphetamine ENT1END induced psychosis and other Axis I ENT2 psychiatric disorders ENT2END
1	It was associated with co-morbid affective disorder, ENT1 antisocial personality  ENT1END  and heavy ENT2 methamphetamine ENT2END use
1	The risk and associated factors of ENT1 methamphetamine ENT1END ENT2 psychosis ENT2END in methamphetamine-dependent patients in Malaysia
0	759) and heavy methamphetamine uses were significantly associated with lifetime ENT1 methamphetamine ENT1END induced psychosis after adjusted for other factors. ENT2 Major depressive disorder ENT2END (OR=2
0	Co-morbid major ENT1 depressive disorder  ENT1END (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy ENT2 methamphetamine ENT2END uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors
0	Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine ( ENT1 CBZ ENT1END  and oxcarbazepine (OXC). We have studied the effects of oral treatment with eslicarbazepine acetate on a whole-animal model in which partial ENT2 seizures ENT2END can be elicited repeatedly on different days without changes in threshold or seizure patterns
1	In the animals treated with threshold doses of ENT1 picrotoxin ENT1END  the average number of ENT2 seizures ENT2END was 2
0	Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine ( ENT1 OXC  ENT1END . We have studied the effects of oral treatment with eslicarbazepine acetate on a whole-animal model in which partial ENT2 seizures ENT2END can be elicited repeatedly on different days without changes in threshold or seizure patterns
0	Anticonvulsant effect of eslicarbazepine acetate ( ENT1 BIA 2-093  ENT1END ) on ENT2 seizures ENT2END induced by microperfusion of picrotoxin in the hippocampus of freely moving rats
0	In patients with impaired renal and liver function, and those who need long-term ENT1 pain ENT1END control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENT2 norpethidine ENT2END , resulting in irritability and seizure attack
0	In patients with impaired renal and liver function, and those who need long-term ENT1 pain ENT1END  control, ENT2 pethidine ENT2END may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack
0	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its ENT1 neurotoxic  ENT1END metabolite, ENT2 norpethidine ENT2END , resulting in irritability and seizure attack
0	In patients with impaired renal and liver function, and those who need long-term pain control, ENT1 pethidine  ENT1END  may cause excitatory central nervous system (CNS) effects through its ENT2 neurotoxic ENT2END metabolite, norpethidine, resulting in irritability and seizure attack
0	Common side effects include nausea, ENT1 vomiting  ENT1END and hypotension. In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENT2 norpethidine ENT2END , resulting in irritability and seizure attack
1	Common side effects include nausea, ENT1 vomiting  ENT1END  and hypotension. In patients with impaired renal and liver function, and those who need long-term pain control, ENT2 pethidine ENT2END may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack
0	Common side effects include nausea, vomiting and ENT1 hypotension  ENT1END  In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENT2 norpethidine ENT2END , resulting in irritability and seizure attack
1	Common side effects include nausea, vomiting and ENT1 hypotension  ENT1END . In patients with impaired renal and liver function, and those who need long-term pain control, ENT2 pethidine ENT2END may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack
0	In patients with ENT1 impaired renal and liver function  ENT1END  and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENT2 norpethidine ENT2END , resulting in irritability and seizure attack
0	In patients with ENT1 impaired renal and liver function  ENT1END , and those who need long-term pain control, ENT2 pethidine ENT2END may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack
0	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENT1 norpethidine ENT1END , resulting in ENT2 irritability ENT2END and seizure attack
0	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in ENT1 irritability ENT1END  and seizure attack. On the contrary, though not clinically apparent, ENT2 pethidine ENT2END potentially causes inhibitory impacts on the CNS and impairs normal cerebellar and oculomotor function in the short term
0	ENT1 Cerebellar and oculomotor dysfunction  ENT1END  induced by rapid infusion of pethidine.Pethidine is an opioid that gains its popularity for the effective pain control through acting on the opioid-receptors. However, rapid pain relief sometimes brings about unfavourable side effects that largely limit its clinical utility. Common side effects include nausea, vomiting and hypotension. In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENT2 norpethidine ENT2END , resulting in irritability and seizure attack
0	ENT1 Cerebellar and oculomotor dysfunction  ENT1END  induced by rapid infusion of ENT2 pethidine ENT2END
0	ENT1 Cerebellar and oculomotor dysfunction  ENT1END  induced by rapid infusion of pethidine.Pethidine is an opioid that gains its popularity for the effective pain control through acting on the opioid-receptors. However, rapid pain relief sometimes brings about unfavourable side effects that largely limit its clinical utility. Common side effects include nausea, vomiting and hypotension. In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENT2 norpethidine ENT2END , resulting in irritability and seizure attack
0	ENT1 Cerebellar and oculomotor dysfunction  ENT1END  induced by rapid infusion of ENT2 pethidine ENT2END
0	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENT1 norpethidine ENT1END , resulting in irritability and seizure attack. On the contrary, though not clinically apparent, pethidine potentially causes inhibitory impacts on the CNS and impairs normal cerebellar and oculomotor function in the short term. In this case report, we highlight opioid's inhibitory side effects on the cerebellar structure that causes ENT2 dysmetria ENT2END , dysarthria, reduced smooth pursuit gain and decreased saccadic velocity
1	On the contrary, though not clinically apparent, ENT1 pethidine  ENT1END  potentially causes inhibitory impacts on the CNS and impairs normal cerebellar and oculomotor function in the short term. In this case report, we highlight opioid's inhibitory side effects on the cerebellar structure that causes ENT2 dysmetria ENT2END , dysarthria, reduced smooth pursuit gain and decreased saccadic velocity
0	In patients with ENT1 impaired renal and liver function  ENT1END  and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENT2 norpethidine ENT2END , resulting in irritability and seizure attack
0	In patients with ENT1 impaired renal and liver function  ENT1END , and those who need long-term pain control, ENT2 pethidine ENT2END may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack
0	Common side effects include ENT1 nausea  ENT1END  vomiting and hypotension. In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENT2 norpethidine ENT2END , resulting in irritability and seizure attack
1	Common side effects include ENT1 nausea  ENT1END , vomiting and hypotension. In patients with impaired renal and liver function, and those who need long-term pain control, ENT2 pethidine ENT2END may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack
1	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENT1 norpethidine ENT1END , resulting in irritability and ENT2 seizure ENT2END attack
0	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and ENT1 seizure  ENT1END  attack. On the contrary, though not clinically apparent, ENT2 pethidine ENT2END potentially causes inhibitory impacts on the CNS and impairs normal cerebellar and oculomotor function in the short term
0	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENT1 norpethidine ENT1END , resulting in irritability and seizure attack. On the contrary, though not clinically apparent, pethidine potentially causes inhibitory impacts on the CNS and impairs normal cerebellar and oculomotor function in the short term. In this case report, we highlight opioid's inhibitory side effects on the cerebellar structure that causes dysmetria, ENT2 dysarthria ENT2END , reduced smooth pursuit gain and decreased saccadic velocity
1	On the contrary, though not clinically apparent, ENT1 pethidine  ENT1END  potentially causes inhibitory impacts on the CNS and impairs normal cerebellar and oculomotor function in the short term. In this case report, we highlight opioid's inhibitory side effects on the cerebellar structure that causes dysmetria, ENT2 dysarthria ENT2END , reduced smooth pursuit gain and decreased saccadic velocity
1	The mechanism of doxorubicin ( ENT1 DOX ENT1END -induced ENT2 cardiotoxicity ENT2END remains controversial
0	Increased resistance to the oxidative stress is plausible for the multiple dose of ENT1 DOX ENT1END  Thus, different mechanisms may be involved in acute ENT2 toxicity ENT2END versus chronic toxicity
1	Single dose of ENT1 DOX ENT1END was associated with increased cardiac disarrangement, ENT2 necrosis ENT2END , and DNA damage (strand breaks (SBs) and oxidized pyrimidines) and decreased TAP
0	Single dose of ENT1 DOX ENT1END  was associated with increased ENT2 cardiac disarrangement ENT2END , necrosis, and DNA damage (strand breaks (SBs) and oxidized pyrimidines) and decreased TAP
0	levodopa were examined in ENT1 parkinsonian ENT1END patients with stable and fluctuating responses to levodopa. The magnitude of the hypotensive effect of levodopa was concentration dependent and was fit to an Emax model in fluctuating responders. Stable responders demonstrated a small hypotensive response. Baseline blood pressures were higher in fluctuating patients; a higher baseline blood pressure correlated with greater hypotensive effects. Antiparkinsonian effects of levodopa temporally correlated with blood pressure changes. ENT2 Phenylalanine ENT2END , a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa
0	levodopa were examined in ENT1 parkinsonian ENT1END  patients with stable and fluctuating responses to levodopa. The magnitude of the hypotensive effect of levodopa was concentration dependent and was fit to an Emax model in fluctuating responders. Stable responders demonstrated a small hypotensive response. Baseline blood pressures were higher in fluctuating patients; a higher baseline blood pressure correlated with greater hypotensive effects. Antiparkinsonian effects of levodopa temporally correlated with blood pressure changes. Phenylalanine, a large neutral ENT2 amino acid ENT2END (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa
0	Pharmacodynamics of the hypotensive effect of ENT1 levodopa  ENT1END  in ENT2 parkinsonian ENT2END patients
0	Baseline blood pressures were higher in fluctuating patients; a higher baseline blood pressure correlated with greater ENT1 hypotensive  ENT1END effects. Antiparkinsonian effects of levodopa temporally correlated with blood pressure changes. ENT2 Phenylalanine ENT2END , a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa
0	Phenylalanine, a large neutral ENT1 amino acid ENT1END  (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the ENT2 hypotensive ENT2END and antiparkinsonian effects of levodopa
1	Pharmacodynamics of the ENT1 hypotensive  ENT1END  effect of ENT2 levodopa ENT2END in parkinsonian patients
0	ENT1 Hypoxaemia ENT1END resolved quickly on inhaled ENT2 nitric oxide ENT2END therapy
1	We report three cases of severe ENT1 hypoxaemia ENT1END after ENT2 ibuprofen ENT2END administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation
0	We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of ENT1 patent ductus arteriosus  ENT1END with ibuprofen in premature infants born at less than 28 weeks of gestation. Echocardiography showed severely decreased pulmonary blood flow. Hypoxaemia resolved quickly on inhaled ENT2 nitric oxide ENT2END therapy
0	We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of ENT1 patent ductus arteriosus ENT1END  with ENT2 ibuprofen ENT2END in premature infants born at less than 28 weeks of gestation
0	ENT1 Pulmonary hypertension  ENT1END  after ibuprofen prophylaxis in very preterm infants.We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation. Echocardiography showed severely decreased pulmonary blood flow. Hypoxaemia resolved quickly on inhaled ENT2 nitric oxide ENT2END therapy
1	ENT1 Pulmonary hypertension  ENT1END  after ENT2 ibuprofen ENT2END prophylaxis in very preterm infants
0	This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from ENT1 acute lymphoblastic leukemia ENT1END treated with high-dose ENT2 methotrexate ENT2END
1	This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing ENT1 leukoencephalopathy  ENT1END  which developed from acute lymphoblastic leukemia treated with high-dose ENT2 methotrexate ENT2END
1	This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from acute lymphoblastic leukemia treated with high-dose ENT1 methotrexate ENT1END . In both patients, the enhancement was more pronounced near the base of the brain than at the vertex. Necropsy of the first case revealed loss of myelination and ENT2 necrosis ENT2END of the white matter
1	This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from acute lymphoblastic leukemia treated with high-dose ENT1 methotrexate ENT1END . In both patients, the enhancement was more pronounced near the base of the brain than at the vertex. Necropsy of the first case revealed ENT2 loss of myelination ENT2END and necrosis of the white matter
1	ENT1 Pulmonary edema  ENT1END  and shock after high-dose ENT2 aracytine-C ENT2END for lymphoma; possible role of TNF-alpha and PAF
1	It was characterized by the onset of fever, diarrhea, shock, pulmonary edema, acute renal failure, metabolic acidosis, ENT1 weight gain ENT1END and leukocytosis. Thorough bacteriological screening failed to provide evidence of infection. Sequential biological assays of IL-1, IL-2, TNF and PAF were performed during ENT2 Ara-C ENT2END infusion to ten patients, including the four who developed the syndrome
1	Four out of 23 consecutive patients treated with high-dose ENT1 Ara-C ENT1END for lymphomas in our institution developed a strikingly similar syndrome during the perfusion. It was characterized by the onset of ENT2 fever ENT2END , diarrhea, shock, pulmonary edema, acute renal failure, metabolic acidosis, weight gain and leukocytosis
1	Pulmonary edema and ENT1 shock  ENT1END  after high-dose ENT2 aracytine-C ENT2END for lymphoma; possible role of TNF-alpha and PAF
1	It was characterized by the onset of fever, diarrhea, shock, pulmonary edema, acute renal failure, ENT1 metabolic acidosis  ENT1END  weight gain and leukocytosis. Thorough bacteriological screening failed to provide evidence of infection. Sequential biological assays of IL-1, IL-2, TNF and PAF were performed during ENT2 Ara-C ENT2END infusion to ten patients, including the four who developed the syndrome
0	Thorough bacteriological screening failed to provide evidence of ENT1 infection  ENT1END  Sequential biological assays of IL-1, IL-2, TNF and PAF were performed during ENT2 Ara-C ENT2END infusion to ten patients, including the four who developed the syndrome
1	It was characterized by the onset of fever, diarrhea, shock, pulmonary edema, acute renal failure, metabolic acidosis, weight gain and ENT1 leukocytosis  ENT1END  Thorough bacteriological screening failed to provide evidence of infection. Sequential biological assays of IL-1, IL-2, TNF and PAF were performed during ENT2 Ara-C ENT2END infusion to ten patients, including the four who developed the syndrome
1	Four out of 23 consecutive patients treated with high-dose ENT1 Ara-C ENT1END  for lymphomas in our institution developed a strikingly similar syndrome during the perfusion. It was characterized by the onset of fever, diarrhea, shock, pulmonary edema, ENT2 acute renal failure ENT2END , metabolic acidosis, weight gain and leukocytosis
0	Four out of 23 consecutive patients treated with high-dose ENT1 Ara-C ENT1END  for ENT2 lymphomas ENT2END in our institution developed a strikingly similar syndrome during the perfusion
1	Four out of 23 consecutive patients treated with high-dose ENT1 Ara-C ENT1END  for lymphomas in our institution developed a strikingly similar syndrome during the perfusion. It was characterized by the onset of fever, ENT2 diarrhea ENT2END , shock, pulmonary edema, acute renal failure, metabolic acidosis, weight gain and leukocytosis
0	As TNF and PAF are thought to be involved in the development of septic shock and ENT1 adult respiratory distress syndrome ENT1END  we hypothesize that high-dose ENT2 Ara-C ENT2END may be associated with cytokine release
0	Antitumor effect, ENT1 cardiotoxicity  ENT1END , and nephrotoxicity of ENT2 doxorubicin ENT2END in the IgM solid immunocytoma-bearing LOU/M/WSL rat
0	Complete disappearance of the ENT1 tumor ENT1END was induced with 1.0 mg ENT2 doxorubicin ENT2END /kg
1	0 mg ENT1 doxorubicin ENT1END kg, the serum albumin level decreased from 33.6 +/- 4.1 to 1.5 +/- 0.5 g/liter. ENT2 Ascites ENT2END and hydrothorax were observed simultaneously
1	5 mg ENT1 doxorubicin ENT1END kg, which resulted in ENT2 albuminuria ENT2END and very low serum albumin levels
1	0 mg ENT1 doxorubicin ENT1END /kg, the serum albumin level decreased from 33.6 +/- 4.1 to 1.5 +/- 0.5 g/liter. Ascites and ENT2 hydrothorax ENT2END were observed simultaneously
0	0 mg ENT1 doxorubicin ENT1END /kg, the serum albumin level decreased from 33.6 +/- 4.1 to 1.5 +/- 0.5 g/liter. Ascites and hydrothorax were observed simultaneously. The same experiments were performed with non-tumor-bearing rats, in which no major differences were observed. In conclusion, antitumor activity, cardiotoxicity, and nephrotoxicity were studied simultaneously in the same LOU/M/WSL rat. Albuminuria due to renal damage led to extremely low serum albumin levels, so ascites and hydrothorax were not necessarily a consequence of the observed ENT2 cardiomyopathy ENT2END
0	Antitumor effect, cardiotoxicity, and ENT1 nephrotoxicity  ENT1END  of ENT2 doxorubicin ENT2END in the IgM solid immunocytoma-bearing LOU/M/WSL rat
0	Her medications included desvenlafaxine, and symptoms included ENT1 nausea ENT1END  anxiety and confusion. The serum sodium at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH. Desvenlafaxine was ceased and fluid restriction implemented. After 4 days the sodium increased to 128 mmol/L and fluid restriction was relaxed. During her further 3 weeks inpatient admission the serum sodium ranged from 134 to 137 mmol/L during treatment with ENT2 mirtazapine ENT2END
1	Her medications included ENT1 desvenlafaxine  ENT1END  and symptoms included ENT2 nausea ENT2END , anxiety and confusion
0	Her medications included desvenlafaxine, and symptoms included ENT1 nausea ENT1END , anxiety and confusion. The serum ENT2 sodium ENT2END at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH
0	During her further 3 weeks inpatient admission the serum sodium ranged from 134 to 137 mmol/L during treatment with ENT1 mirtazapine ENT1END . DISCUSSION: SIADH has been widely reported with a range of antidepressants. This case report suggests that desvenlafaxine might cause clinically significant ENT2 hyponatremia ENT2END
1	CASE SUMMARY: A 57-year old female with ENT1 hyponatraemia  ENT1END  Her medications included ENT2 desvenlafaxine ENT2END , and symptoms included nausea, anxiety and confusion
0	CASE SUMMARY: A 57-year old female with ENT1 hyponatraemia  ENT1END . Her medications included desvenlafaxine, and symptoms included nausea, anxiety and confusion. The serum ENT2 sodium ENT2END at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH
0	Her medications included desvenlafaxine, and symptoms included nausea, anxiety and ENT1 confusion  ENT1END  The serum sodium at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH. Desvenlafaxine was ceased and fluid restriction implemented. After 4 days the sodium increased to 128 mmol/L and fluid restriction was relaxed. During her further 3 weeks inpatient admission the serum sodium ranged from 134 to 137 mmol/L during treatment with ENT2 mirtazapine ENT2END
1	Her medications included ENT1 desvenlafaxine  ENT1END , and symptoms included nausea, anxiety and ENT2 confusion ENT2END
0	Her medications included desvenlafaxine, and symptoms included nausea, anxiety and ENT1 confusion  ENT1END . The serum ENT2 sodium ENT2END at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH
0	During her further 3 weeks inpatient admission the serum sodium ranged from 134 to 137 mmol/L during treatment with ENT1 mirtazapine ENT1END . DISCUSSION: ENT2 SIADH ENT2END has been widely reported with a range of antidepressants
1	The serum sodium at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of ENT1 SIADH ENT1END  ENT2 Desvenlafaxine ENT2END was ceased and fluid restriction implemented
0	The serum sodium at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine ENT1 sodium  ENT1END 63 mmol/L, consistent with a diagnosis of ENT2 SIADH ENT2END
0	Her medications included desvenlafaxine, and symptoms included nausea, ENT1 anxiety  ENT1END and confusion. The serum sodium at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH. Desvenlafaxine was ceased and fluid restriction implemented. After 4 days the sodium increased to 128 mmol/L and fluid restriction was relaxed. During her further 3 weeks inpatient admission the serum sodium ranged from 134 to 137 mmol/L during treatment with ENT2 mirtazapine ENT2END
1	Her medications included ENT1 desvenlafaxine  ENT1END , and symptoms included nausea, ENT2 anxiety ENT2END and confusion
0	Her medications included desvenlafaxine, and symptoms included nausea, ENT1 anxiety  ENT1END  and confusion. The serum ENT2 sodium ENT2END at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH
0	For example, the symptoms of ENT1 RLS ENT1END can be dramatically improved by levodopa and ENT2 dopamine ENT2END agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms
0	For example, the symptoms of ENT1 RLS ENT1END  can be dramatically improved by ENT2 levodopa ENT2END and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms
0	Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of ENT1 domperione ENT1END on mirtazapine-associated ENT2 RLS ENT2END
1	To our knowledge, there is no previous report regarding whether domperidone, a peripheral dopamine D2 receptor antagonist, can also induce or aggravate symptoms of ENT1 RLS ENT1END  ENT2 Mirtazapine ENT2END , the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications
0	To our knowledge, there is no previous report regarding whether domperidone, a peripheral ENT1 dopamine ENT1END D2 receptor antagonist, can also induce or aggravate symptoms of RLS. Mirtazapine, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications. The authors report here a depressed patient comorbid with ENT2 postprandial dyspepsia ENT2END who developed RLS after mirtazapine had been added to his domperidone therapy
0	For example, the symptoms of RLS can be dramatically improved by ENT1 levodopa  ENT1END  and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms. To our knowledge, there is no previous report regarding whether domperidone, a peripheral dopamine D2 receptor antagonist, can also induce or aggravate symptoms of RLS. Mirtazapine, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications. The authors report here a depressed patient comorbid with ENT2 postprandial dyspepsia ENT2END who developed RLS after mirtazapine had been added to his domperidone therapy
0	The authors report here a depressed patient comorbid with ENT1 postprandial dyspepsia ENT1END  who developed RLS after mirtazapine had been added to his ENT2 domperidone ENT2END therapy
0	The authors report here a depressed patient comorbid with ENT1 postprandial dyspepsia ENT1END  who developed RLS after ENT2 mirtazapine ENT2END had been added to his domperidone therapy
1	Five cases of encephalitis during treatment of loiasis with ENT1 diethylcarbamazine ENT1END .Five cases of ENT2 encephalitis ENT2END following treatment with diethylcarbamazine (DEC) were observed in Congolese patients with Loa loa filariasis
0	Five cases of encephalitis during treatment of ENT1 loiasis  ENT1END  with ENT2 diethylcarbamazine ENT2END
0	Five cases of encephalitis following treatment with diethylcarbamazine ( ENT1 DEC ENT1END  were observed in Congolese patients with Loa loa ENT2 filariasis ENT2END
1	Pituitary response to luteinizing hormone-releasing hormone during ENT1 haloperidol  ENT1END -induced ENT2 hyperprolactinemia ENT2END
0	9% ENT1 NaCl ENT1END solution. During the course of haloperidol infusions, significant ENT2 hyperprolactinemia ENT2END was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects
1	In six dogs with ENT1 doxorubicin ENT1END induced ENT2 heart failure ENT2END , VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0
0	In six dogs with doxorubicin-induced ENT1 heart failure ENT1END , VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with rheumatic disease, nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with coronary disease (one patient receiving a transplant and three receiving mitral prostheses) (6.3 +/- 1.9 pg/mg protein). The other patients undergoing transplantation had an average ejection fraction of 17% +/- 6% and a VIP level of 8.8 +/- 3.9 pg/mg protein. The hearts without coronary artery disease (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14.1 +/- 7.9 pg/mg protein, and this was greater than in hearts of the patients with coronary disease and the hearts of patients receiving a transplant (P less than 0.05). Myocardial ENT2 catecholamines ENT2END were also determined in 14 subjects; a weak correlation (r = 0
0	Myocardial levels of VIP were assayed before and after the development of ENT1 heart failure ENT1END in two canine models. In the first, ENT2 cobalt ENT2END cardiomyopathy was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0
0	In six dogs with doxorubicin-induced ENT1 heart failure ENT1END , VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with rheumatic disease, nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with coronary disease (one patient receiving a transplant and three receiving mitral prostheses) (6.3 +/- 1.9 pg/mg protein). The other patients undergoing transplantation had an average ejection fraction of 17% +/- 6% and a VIP level of 8.8 +/- 3.9 pg/mg protein. The hearts without coronary artery disease (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14.1 +/- 7.9 pg/mg protein, and this was greater than in hearts of the patients with coronary disease and the hearts of patients receiving a transplant (P less than 0.05). Myocardial catecholamines were also determined in 14 subjects; a weak correlation (r = 0.57, P less than 0.05) between the tissue concentrations of VIP and ENT2 norepinephrine ENT2END was noted
0	In the first, cobalt ENT1 cardiomyopathy  ENT1END was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0.05). In six dogs with ENT2 doxorubicin ENT2END -induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0
1	In the first, ENT1 cobalt ENT1END ENT2 cardiomyopathy ENT2END was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0
0	In six dogs with ENT1 doxorubicin ENT1END -induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with ENT2 rheumatic disease ENT2END , nine with myxomatous degeneration) receiving mitral valve prostheses
0	In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with ENT1 rheumatic disease  ENT1END , nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with coronary disease (one patient receiving a transplant and three receiving mitral prostheses) (6.3 +/- 1.9 pg/mg protein). The other patients undergoing transplantation had an average ejection fraction of 17% +/- 6% and a VIP level of 8.8 +/- 3.9 pg/mg protein. The hearts without coronary artery disease (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14.1 +/- 7.9 pg/mg protein, and this was greater than in hearts of the patients with coronary disease and the hearts of patients receiving a transplant (P less than 0.05). Myocardial ENT2 catecholamines ENT2END were also determined in 14 subjects; a weak correlation (r = 0
0	In the first, ENT1 cobalt  ENT1END  cardiomyopathy was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0.05). In six dogs with doxorubicin-induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with ENT2 rheumatic disease ENT2END , nine with myxomatous degeneration) receiving mitral valve prostheses
0	In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with ENT1 rheumatic disease  ENT1END , nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with coronary disease (one patient receiving a transplant and three receiving mitral prostheses) (6.3 +/- 1.9 pg/mg protein). The other patients undergoing transplantation had an average ejection fraction of 17% +/- 6% and a VIP level of 8.8 +/- 3.9 pg/mg protein. The hearts without coronary artery disease (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14.1 +/- 7.9 pg/mg protein, and this was greater than in hearts of the patients with coronary disease and the hearts of patients receiving a transplant (P less than 0.05). Myocardial catecholamines were also determined in 14 subjects; a weak correlation (r = 0.57, P less than 0.05) between the tissue concentrations of VIP and ENT2 norepinephrine ENT2END was noted
0	In six dogs with ENT1 doxorubicin ENT1END -induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with rheumatic disease, nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with ENT2 coronary disease ENT2END (one patient receiving a transplant and three receiving mitral prostheses) (6
0	9 pg/mg protein, and this was greater than in hearts of the patients with ENT1 coronary disease  ENT1END and the hearts of patients receiving a transplant (P less than 0.05). Myocardial ENT2 catecholamines ENT2END were also determined in 14 subjects; a weak correlation (r = 0
0	In the first, ENT1 cobalt  ENT1END  cardiomyopathy was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0.05). In six dogs with doxorubicin-induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with rheumatic disease, nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with ENT2 coronary disease ENT2END (one patient receiving a transplant and three receiving mitral prostheses) (6
0	9 pg/mg protein, and this was greater than in hearts of the patients with ENT1 coronary disease  ENT1END  and the hearts of patients receiving a transplant (P less than 0.05). Myocardial catecholamines were also determined in 14 subjects; a weak correlation (r = 0.57, P less than 0.05) between the tissue concentrations of VIP and ENT2 norepinephrine ENT2END was noted
0	In six dogs with ENT1 doxorubicin ENT1END -induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with rheumatic disease, nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with coronary disease (one patient receiving a transplant and three receiving mitral prostheses) (6.3 +/- 1.9 pg/mg protein). The other patients undergoing transplantation had an average ejection fraction of 17% +/- 6% and a VIP level of 8.8 +/- 3.9 pg/mg protein. The hearts without ENT2 coronary artery disease ENT2END (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14
0	The hearts without ENT1 coronary artery disease  ENT1END  (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14.1 +/- 7.9 pg/mg protein, and this was greater than in hearts of the patients with coronary disease and the hearts of patients receiving a transplant (P less than 0.05). Myocardial ENT2 catecholamines ENT2END were also determined in 14 subjects; a weak correlation (r = 0
0	In the first, ENT1 cobalt  ENT1END  cardiomyopathy was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0.05). In six dogs with doxorubicin-induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with rheumatic disease, nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with coronary disease (one patient receiving a transplant and three receiving mitral prostheses) (6.3 +/- 1.9 pg/mg protein). The other patients undergoing transplantation had an average ejection fraction of 17% +/- 6% and a VIP level of 8.8 +/- 3.9 pg/mg protein. The hearts without ENT2 coronary artery disease ENT2END (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14
0	The hearts without ENT1 coronary artery disease  ENT1END  (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14.1 +/- 7.9 pg/mg protein, and this was greater than in hearts of the patients with coronary disease and the hearts of patients receiving a transplant (P less than 0.05). Myocardial catecholamines were also determined in 14 subjects; a weak correlation (r = 0.57, P less than 0.05) between the tissue concentrations of VIP and ENT2 norepinephrine ENT2END was noted
0	OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with succimer, a widely used chelating agent for the treatment of ENT1 Pb poisoning ENT1END  RESULTS: ENT2 Pb ENT2END exposure produced lasting impairments in learning, attention, inhibitory control, and arousal regulation, paralleling the areas of dysfunction seen in Pb-exposed children
0	OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with ENT1 succimer  ENT1END  a widely used chelating agent for the treatment of ENT2 Pb poisoning ENT2END
1	RESULTS: ENT1 Pb ENT1END  exposure produced lasting ENT2 impairments in learning, attention, inhibitory control, and arousal regulation ENT2END , paralleling the areas of dysfunction seen in Pb-exposed children
0	RESULTS: Pb exposure produced lasting ENT1 impairments in learning, attention, inhibitory control, and arousal regulation ENT1END , paralleling the areas of dysfunction seen in Pb-exposed children. ENT2 Succimer ENT2END treatment of the Pb-exposed rats significantly improved learning, attention, and arousal regulation, although the efficacy of the treatment varied as a function of the Pb exposure level and the specific functional deficit
1	RESULTS: ENT1 Pb ENT1END  exposure produced lasting ENT2 impairments in learning, attention, inhibitory control, and arousal regulation ENT2END , paralleling the areas of dysfunction seen in Pb-exposed children
0	RESULTS: Pb exposure produced lasting ENT1 impairments in learning, attention, inhibitory control, and arousal regulation  ENT1END , paralleling the areas of dysfunction seen in Pb-exposed children. ENT2 Succimer ENT2END treatment of the Pb-exposed rats significantly improved learning, attention, and arousal regulation, although the efficacy of the treatment varied as a function of the Pb exposure level and the specific functional deficit
0	CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate ENT1 cognitive deficits ENT1END due to ENT2 Pb ENT2END exposure
1	CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate ENT1 cognitive deficits ENT1END  due to Pb exposure. These findings suggest that it may be possible to identify a ENT2 succimer ENT2END treatment protocol that improves cognitive outcomes in Pb-exposed children
0	In contrast, succimer treatment of rats not previously exposed to ENT1 Pb ENT1END produced lasting and pervasive ENT2 cognitive and affective dysfunction ENT2END comparable in magnitude to that produced by the higher Pb exposure regimen
0	In contrast, ENT1 succimer  ENT1END treatment of rats not previously exposed to Pb produced lasting and pervasive ENT2 cognitive and affective dysfunction ENT2END comparable in magnitude to that produced by the higher Pb exposure regimen
0	Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of ENT1 5-fluorouracil  ENT1END  with the complication of dehydration and ENT2 infection ENT2END
0	Among the 32 episodes, 26 (81%) had various degrees of azotemia, 18 (56%) occurred during bacterial infections and 14 (44%) without ENT1 infection ENT1END occurred during periods of dehydration. Higher plasma ENT2 ammonium ENT2END levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0
0	In conclusion, hyperammonemic encephalopathy can occur in patients receiving continuous infusion of ENT1 5-FU ENT1END  Azotemia, body fluid insufficiency and ENT2 bacterial infections ENT2END were frequently found in these patients
0	Higher plasma ENT1 ammonium ENT1END  levels and more rapid onset of hyperammonemia were seen in 18 patients with ENT2 bacterial infections ENT2END (p=0
0	Risk of transient hyperammonemic encephalopathy in ENT1 cancer  ENT1END  patients who received continuous infusion of ENT2 5-fluorouracil ENT2END with the complication of dehydration and infection
0	From 1986 to 1998, 29 ENT1 cancer ENT1END patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil (5-FU) were identified. None of the patients had decompensated liver disease. Onset of hyperammonemic encephalopathy varied from 0.5 to 5 days (mean: 2.6 +/- 1.3 days) after the initiation of chemotherapy. Plasma ENT2 ammonium ENT2END level ranged from 248 to 2387 microg% (mean: 626 +/- 431 microg%)
1	From 1986 to 1998, 29 cancer patients who had 32 episodes of transient ENT1 hyperammonemic encephalopathy ENT1END related to continuous infusion of ENT2 5-fluorouracil ENT2END (5-FU) were identified
0	Higher plasma ENT1 ammonium ENT1END  levels and more rapid onset of ENT2 hyperammonemia ENT2END were seen in 18 patients with bacterial infections (p=0
0	From 1986 to 1998, 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil ( ENT1 5-FU ENT1END  were identified. None of the patients had decompensated ENT2 liver disease ENT2END
0	None of the patients had decompensated ENT1 liver disease  ENT1END . Onset of hyperammonemic encephalopathy varied from 0.5 to 5 days (mean: 2.6 +/- 1.3 days) after the initiation of chemotherapy. Plasma ENT2 ammonium ENT2END level ranged from 248 to 2387 microg% (mean: 626 +/- 431 microg%)
1	From 1986 to 1998, 29 cancer patients who had 32 episodes of transient ENT1 hyperammonemic encephalopathy  ENT1END related to continuous infusion of ENT2 5-fluorouracil ENT2END (5-FU) were identified
0	Onset of ENT1 hyperammonemic encephalopathy  ENT1END varied from 0.5 to 5 days (mean: 2.6 +/- 1.3 days) after the initiation of chemotherapy. Plasma ENT2 ammonium ENT2END level ranged from 248 to 2387 microg% (mean: 626 +/- 431 microg%)
0	Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of ENT1 5-fluorouracil  ENT1END  with the complication of ENT2 dehydration ENT2END and infection
0	Among the 32 episodes, 26 (81%) had various degrees of azotemia, 18 (56%) occurred during bacterial infections and 14 (44%) without infection occurred during periods of ENT1 dehydration  ENT1END  Higher plasma ENT2 ammonium ENT2END levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0
0	In conclusion, hyperammonemic encephalopathy can occur in patients receiving continuous infusion of ENT1 5-FU ENT1END . ENT2 Azotemia ENT2END , body fluid insufficiency and bacterial infections were frequently found in these patients
0	Plasma ENT1 ammonium ENT1END  level ranged from 248 to 2387 microg% (mean: 626 +/- 431 microg%). Among the 32 episodes, 26 (81%) had various degrees of ENT2 azotemia ENT2END , 18 (56%) occurred during bacterial infections and 14 (44%) without infection occurred during periods of dehydration
0	Neither patient developed signs of ENT1 cardiovascular toxicity ENT1END  Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of ENT2 levobupivacaine ENT2END with epinephrine
0	5 microgram/mL, the patients developed grand mal seizures, despite negative aspiration for blood and no clinical signs of intravenous ENT1 epinephrine  ENT1END administration. The seizures were successfully treated with sodium thiopental in addition to succinylcholine in 1 patient. Neither patient developed signs of ENT2 cardiovascular toxicity ENT2END
0	The seizures were successfully treated with ENT1 sodium thiopental  ENT1END in addition to succinylcholine in 1 patient. Neither patient developed signs of ENT2 cardiovascular toxicity ENT2END
0	The seizures were successfully treated with sodium thiopental in addition to ENT1 succinylcholine  ENT1END in 1 patient. Neither patient developed signs of ENT2 cardiovascular toxicity ENT2END
0	Neither patient developed signs of ENT1 cardiovascular toxicity ENT1END . Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of levobupivacaine with epinephrine. CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic ENT2 bupivacaine ENT2END , if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions
0	CONCLUSIONS: Although ENT1 levobupivacaine ENT1END may have a safer ENT2 cardiac toxicity ENT2END profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions
0	Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of levobupivacaine with ENT1 epinephrine  ENT1END  CONCLUSIONS: Although levobupivacaine may have a safer ENT2 cardiac toxicity ENT2END profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions
0	The seizures were successfully treated with ENT1 sodium thiopental  ENT1END  in addition to succinylcholine in 1 patient. Neither patient developed signs of cardiovascular toxicity. Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of levobupivacaine with epinephrine. CONCLUSIONS: Although levobupivacaine may have a safer ENT2 cardiac toxicity ENT2END profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions
0	The seizures were successfully treated with sodium thiopental in addition to ENT1 succinylcholine  ENT1END  in 1 patient. Neither patient developed signs of cardiovascular toxicity. Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of levobupivacaine with epinephrine. CONCLUSIONS: Although levobupivacaine may have a safer ENT2 cardiac toxicity ENT2END profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions
0	CONCLUSIONS: Although levobupivacaine may have a safer ENT1 cardiac toxicity  ENT1END  profile than racemic ENT2 bupivacaine ENT2END , if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions
0	ENT1 Central nervous system toxicity  ENT1END  following the administration of ENT2 levobupivacaine ENT2END for lumbar plexus block: A report of two cases
0	Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of levobupivacaine with ENT1 epinephrine ENT1END . CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions. Plasma concentrations sufficient to result in ENT2 central nervous system toxicity ENT2END did not produce manifestations of cardiac toxicity in these 2 patients
0	The seizures were successfully treated with ENT1 sodium thiopental  ENT1END  in addition to succinylcholine in 1 patient. Neither patient developed signs of cardiovascular toxicity. Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of levobupivacaine with epinephrine. CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions. Plasma concentrations sufficient to result in ENT2 central nervous system toxicity ENT2END did not produce manifestations of cardiac toxicity in these 2 patients
0	The seizures were successfully treated with sodium thiopental in addition to ENT1 succinylcholine  ENT1END  in 1 patient. Neither patient developed signs of cardiovascular toxicity. Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of levobupivacaine with epinephrine. CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions. Plasma concentrations sufficient to result in ENT2 central nervous system toxicity ENT2END did not produce manifestations of cardiac toxicity in these 2 patients
0	CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic ENT1 bupivacaine  ENT1END , if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions. Plasma concentrations sufficient to result in ENT2 central nervous system toxicity ENT2END did not produce manifestations of cardiac toxicity in these 2 patients
0	CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of ENT1 levobupivacaine ENT1END reach the circulation, it will result in ENT2 convulsions ENT2END
0	5 microgram/mL, the patients developed grand mal seizures, despite negative aspiration for blood and no clinical signs of intravenous ENT1 epinephrine ENT1END  administration. The ENT2 seizures ENT2END were successfully treated with sodium thiopental in addition to succinylcholine in 1 patient
0	The ENT1 seizures  ENT1END  were successfully treated with ENT2 sodium thiopental ENT2END in addition to succinylcholine in 1 patient
0	The ENT1 seizures  ENT1END  were successfully treated with sodium thiopental in addition to ENT2 succinylcholine ENT2END in 1 patient
0	CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic ENT1 bupivacaine  ENT1END , if adequate amounts of levobupivacaine reach the circulation, it will result in ENT2 convulsions ENT2END
1	We describe 2 cases of ENT1 grand mal seizures ENT1END following accidental intravascular injection of ENT2 levobupivacaine ENT2END
0	5% with ENT1 epinephrine ENT1END 2.5 microgram/mL, the patients developed ENT2 grand mal seizures ENT2END , despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration
0	5 microgram/mL, the patients developed ENT1 grand mal seizures  ENT1END , despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration. The seizures were successfully treated with ENT2 sodium thiopental ENT2END in addition to succinylcholine in 1 patient
0	5 microgram/mL, the patients developed ENT1 grand mal seizures  ENT1END , despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration. The seizures were successfully treated with sodium thiopental in addition to ENT2 succinylcholine ENT2END in 1 patient
0	Levobupivacaine, the pure S(-) enantiomer of bupivacaine, was developed to improve the cardiac safety profile of ENT1 bupivacaine  ENT1END  We describe 2 cases of ENT2 grand mal seizures ENT2END following accidental intravascular injection of levobupivacaine
0	The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin ( ENT1 ADR ENT1END -induced ENT2 cardiotoxicity ENT2END actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach
0	The purpose of the present study was to determine if elevated reactive oxygen (ROS)/ ENT1 nitrogen  ENT1END species (RNS) reported to be present in adriamycin (ADR)-induced ENT2 cardiotoxicity ENT2END actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach
0	The purpose of the present study was to determine if elevated reactive ENT1 oxygen  ENT1END (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced ENT2 cardiotoxicity ENT2END actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach
0	The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced ENT1 cardiotoxicity ENT1END  actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach. B6C3 mice were treated with a single dose of 20 mg/kg ADR. Ultrastructural damage and levels of ENT2 4-hydroxy-2-nonenal ENT2END (4HNE)-protein adducts and 3-nitrotyrosine (3NT) were analyzed
0	The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced ENT1 cardiotoxicity ENT1END  actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach. B6C3 mice were treated with a single dose of 20 mg/kg ADR. Ultrastructural damage and levels of 4-hydroxy-2-nonenal (4HNE)-protein adducts and ENT2 3-nitrotyrosine ENT2END (3NT) were analyzed
1	Oxidative damage precedes nitrative damage in ENT1 adriamycin  ENT1END -induced cardiac ENT2 mitochondrial injury ENT2END
0	Oxidative damage precedes nitrative damage in adriamycin-induced cardiac ENT1 mitochondrial injury  ENT1END .The purpose of the present study was to determine if elevated reactive oxygen (ROS) ENT2 nitrogen ENT2END species (RNS) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach
0	Oxidative damage precedes nitrative damage in adriamycin-induced cardiac ENT1 mitochondrial injury  ENT1END .The purpose of the present study was to determine if elevated reactive ENT2 oxygen ENT2END (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach
0	Our data showed ADR induced ENT1 4HNE ENT1END protein adducts in mitochondria at the same time point as when ENT2 mitochondrial injury ENT2END initially appeared
0	ENT1 3NT  ENT1END levels were significantly increased in all subcellular compartments at 6 hours and subsequently declined at 24 hours. Our data showed ADR induced 4HNE-protein adducts in mitochondria at the same time point as when ENT2 mitochondrial injury ENT2END initially appeared
0	This dual effect of ENT1 temsirolimus ENT1END on ENT2 tumor ENT2END tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy
1	Moreover, numerous patchy, well-limited fibrotic areas, compatible with post- ENT1 necrotic ENT1END tissue repair, were found after 6-month ENT2 temsirolimus ENT2END therapy
0	However, a 38% remission rate has been recently reported in refractory ENT1 MCL ENT1END treated with ENT2 temsirolimus ENT2END , a mTOR inhibitor
0	Cytostatic and anti-angiogenic effects of ENT1 temsirolimus ENT1END  in refractory mantle cell lymphoma.Mantle cell lymphoma (MCL) is a rare and aggressive type of ENT2 B-cell non-Hodgkin's lymphoma ENT2END
0	Alternatively, ENT1 anemia ENT1END could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of ENT2 phosphatidylserine ENT2END (PS) at the erythrocyte surface and by cell shrinkage
0	The effect of azathioprine on both annexin V binding and forward scatter was significantly blunted in the nominal absence of extracellular ENT1 Ca ENT1END +. CONCLUSIONS: Azathioprine triggers suicidal erythrocyte death, an effect presumably contributing to azathioprine-induced ENT2 anemia ENT2END
0	Alternatively, ENT1 anemia  ENT1END  could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage. METHODS: The present experiments explored whether azathioprine influences eryptosis. According to annexin V binding, erythrocytes from patients indeed showed a significant increase of PS exposure within 1 week of treatment with azathioprine. In a second series, cytosolic Ca2+ activity ( ENT2 Fluo3 ENT2END fluorescence), cell volume (forward scatter), and PS-exposure (annexin V binding) were determined by FACS analysis in erythrocytes from healthy volunteers
1	The side effects of ENT1 azathioprine ENT1END include ENT2 anemia ENT2END , which has been attributed to bone marrow suppression
1	This occlusion occurred after ENT1 EACA ENT1END therapy in a patient with SAH and histopathological documentation of recurrent SAH. The corresponding clinical event was characterized by marked ENT2 hypertension ENT2END and abrupt neurological deterioration
0	Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, ENT1 EACA ENT1END should not be implicated in the pathogenesis of fibrin thrombi in patients with ENT2 disseminated intravascular coagulation ENT2END or other "consumption coagulopathies
0	Recurrent subarachnoid hemorrhage associated with ENT1 aminocaproic acid  ENT1END  therapy and acute renal artery thrombosis. Case report.Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH). Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy. These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena. Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with ENT2 disseminated intravascular coagulation ENT2END or other "consumption coagulopathies
0	" This report describes subtotal ENT1 infarction  ENT1END of the kidney due to thrombosis of a normal renal artery. This occlusion occurred after ENT2 EACA ENT2END therapy in a patient with SAH and histopathological documentation of recurrent SAH
0	Recurrent subarachnoid hemorrhage associated with ENT1 aminocaproic acid  ENT1END  therapy and acute renal artery thrombosis. Case report.Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH). Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy. These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena. Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other "consumption coagulopathies." This report describes subtotal ENT2 infarction ENT2END of the kidney due to thrombosis of a normal renal artery
0	These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with ENT1 EACA ENT1END  or other ENT2 thromboembolic phenomena ENT2END
0	Recurrent subarachnoid hemorrhage associated with ENT1 aminocaproic acid  ENT1END  therapy and acute renal artery thrombosis. Case report.Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH). Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy. These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other ENT2 thromboembolic phenomena ENT2END
1	Although this agent does decrease the frequency of rebleeding, several reports have described ENT1 thrombotic ENT1END complications of ENT2 EACA ENT2END therapy
0	Recurrent subarachnoid hemorrhage associated with ENT1 aminocaproic acid  ENT1END  therapy and acute renal artery thrombosis. Case report.Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH). Although this agent does decrease the frequency of rebleeding, several reports have described ENT2 thrombotic ENT2END complications of EACA therapy
1	This occlusion occurred after ENT1 EACA ENT1END  therapy in a patient with ENT2 SAH ENT2END and histopathological documentation of recurrent SAH
0	Recurrent ENT1 subarachnoid hemorrhage  ENT1END  associated with ENT2 aminocaproic acid ENT2END therapy and acute renal artery thrombosis
1	Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and ENT1 acute renal artery thrombosis  ENT1END . Case report. ENT2 Epsilon aminocaproic acid ENT2END (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH)
0	Recurrent subarachnoid hemorrhage associated with ENT1 aminocaproic acid  ENT1END  therapy and ENT2 acute renal artery thrombosis ENT2END
1	Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of ENT1 EACA ENT1END  therapy. These complications have included clinical deterioration and ENT2 intracranial vascular thrombosis ENT2END in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena
0	Recurrent subarachnoid hemorrhage associated with ENT1 aminocaproic acid  ENT1END  therapy and acute renal artery thrombosis. Case report.Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH). Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy. These complications have included clinical deterioration and ENT2 intracranial vascular thrombosis ENT2END in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena
0	Cholestatic presentation of yellow ENT1 phosphorus ENT1END ENT2 poisoning ENT2END
1	Poisoning with yellow ENT1 phosphorus ENT1END classically manifests with ENT2 acute hepatitis ENT2END leading to acute liver failure which may need liver transplantation
0	We present a case of yellow phosphorus poisoning in which a patient presented with florid clinical features of cholestasis highlighting the fact that cholestasis can rarely be a presenting feature of yellow ENT1 phosphorus ENT1END ENT2 hepatotoxicity ENT2END
1	Poisoning with yellow ENT1 phosphorus ENT1END  classically manifests with acute hepatitis leading to ENT2 acute liver failure ENT2END which may need liver transplantation
1	ENT1 Cholestatic  ENT1END  presentation of yellow ENT2 phosphorus ENT2END poisoning
0	Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ENT1 ischemia ENT1END  Because of the theoretical concern regarding administration of dobutamine in the setting of ENT2 cocaine ENT2END use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain
0	Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ENT1 ischemia ENT1END . Because of the theoretical concern regarding administration of ENT2 dobutamine ENT2END in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain
0	Patients exhibiting signs of continuing ENT1 cocaine ENT1END ENT2 toxicity ENT2END were excluded from the study
0	Because of the theoretical concern regarding administration of ENT1 dobutamine  ENT1END  in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital. Patients were eligible for DSE if they had used cocaine within 24 hours preceding the onset of chest pain and had a normal ECG and tropinin I level. Patients exhibiting signs of continuing cocaine ENT2 toxicity ENT2END were excluded from the study
0	None of the patients experienced signs of exaggerated adrenergic response, which was defined as a systolic blood pressure of greater than 200 mm Hg or the occurrence of tachydysrhythmias (excluding ENT1 sinus tachycardia ENT1END . Further suggesting lack of exaggerated adrenergic response, 13 (65%) of 20 patients required supplemental atropine to reach their target heart rates. CONCLUSION: No exaggerated adrenergic response was detected when dobutamine was administered to patients with ENT2 cocaine ENT2END -related chest pain
0	None of the patients experienced signs of exaggerated adrenergic response, which was defined as a systolic blood pressure of greater than 200 mm Hg or the occurrence of tachydysrhythmias (excluding ENT1 sinus tachycardia ENT1END ). Further suggesting lack of exaggerated adrenergic response, 13 (65%) of 20 patients required supplemental atropine to reach their target heart rates. CONCLUSION: No exaggerated adrenergic response was detected when ENT2 dobutamine ENT2END was administered to patients with cocaine-related chest pain
0	None of the patients experienced signs of exaggerated adrenergic response, which was defined as a systolic blood pressure of greater than 200 mm Hg or the occurrence of tachydysrhythmias (excluding ENT1 sinus tachycardia ENT1END ). Further suggesting lack of exaggerated adrenergic response, 13 (65%) of 20 patients required supplemental ENT2 atropine ENT2END to reach their target heart rates
1	CONCLUSION: No exaggerated adrenergic response was detected when dobutamine was administered to patients with ENT1 cocaine ENT1END -related ENT2 chest pain ENT2END
0	CONCLUSION: No exaggerated adrenergic response was detected when ENT1 dobutamine  ENT1END  was administered to patients with cocaine-related ENT2 chest pain ENT2END
0	Further suggesting lack of exaggerated adrenergic response, 13 (65%) of 20 patients required supplemental ENT1 atropine  ENT1END  to reach their target heart rates. CONCLUSION: No exaggerated adrenergic response was detected when dobutamine was administered to patients with cocaine-related ENT2 chest pain ENT2END
0	Patients exhibiting signs of continuing ENT1 cocaine ENT1END  toxicity were excluded from the study. All patients were admitted to the hospital for serial testing after the DSE testing in the intensive diagnostic and treatment unit. RESULTS: Twenty-four patients were enrolled. Two patients had inadequate resting images, one DSE was terminated because of inferior ENT2 hypokinesis ENT2END , another DSE was terminated because of a rate-related atrial conduction deficit, and 1 patient did not reach the target heart rate
0	Two patients had inadequate resting images, one DSE was terminated because of inferior ENT1 hypokinesis  ENT1END , another DSE was terminated because of a rate-related atrial conduction deficit, and 1 patient did not reach the target heart rate. Thus, 19 patients completed a DSE and reached their target heart rates. None of the patients experienced signs of exaggerated adrenergic response, which was defined as a systolic blood pressure of greater than 200 mm Hg or the occurrence of tachydysrhythmias (excluding sinus tachycardia). Further suggesting lack of exaggerated adrenergic response, 13 (65%) of 20 patients required supplemental atropine to reach their target heart rates. CONCLUSION: No exaggerated adrenergic response was detected when ENT2 dobutamine ENT2END was administered to patients with cocaine-related chest pain
0	Two patients had inadequate resting images, one DSE was terminated because of inferior ENT1 hypokinesis  ENT1END , another DSE was terminated because of a rate-related atrial conduction deficit, and 1 patient did not reach the target heart rate. Thus, 19 patients completed a DSE and reached their target heart rates. None of the patients experienced signs of exaggerated adrenergic response, which was defined as a systolic blood pressure of greater than 200 mm Hg or the occurrence of tachydysrhythmias (excluding sinus tachycardia). Further suggesting lack of exaggerated adrenergic response, 13 (65%) of 20 patients required supplemental ENT2 atropine ENT2END to reach their target heart rates
1	Pubertal exposure to ENT1 Bisphenol A  ENT1END  increases ENT2 anxiety ENT2END -like behavior and decreases acetylcholinesterase activity of hippocampus in adult male mice
0	The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of ENT1 CCK-8 ENT1END on morphine-induced ENT2 memory impairment ENT2END
0	The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on ENT1 morphine  ENT1END induced ENT2 memory impairment ENT2END
0	We have previously reported that ENT1 CCK-8 ENT1END significantly alleviated morphine-induced ENT2 amnesia ENT2END and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals
1	We have previously reported that CCK-8 significantly alleviated ENT1 morphine  ENT1END induced ENT2 amnesia ENT2END and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals
1	Further study is needed to determine the optimal dosage and to identify risk factors that increase individual vulnerability to ENT1 fluoxetine ENT1END induced ENT2 mania ENT2END in adolescents
0	ENT1 Mania ENT1END  associated with fluoxetine treatment in adolescents.Fluoxetine, a selective ENT2 serotonin ENT2END reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent depression
0	Apparent risk factors for the development of mania or hypomania during ENT1 fluoxetine ENT1END pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with ENT2 psychotic ENT2END features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder
0	Fluoxetine, a selective ENT1 serotonin  ENT1END  reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent depression. Generally safe and well tolerated by adults, fluoxetine has been reported to induce mania. The cases of five depressed adolescents, 14-16 years of age, who developed mania during pharmacotherapy with fluoxetine, are reported here. Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with ENT2 psychotic ENT2END features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder
0	Fluoxetine, a selective serotonin reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent ENT1 depression ENT1END  Generally safe and well tolerated by adults, ENT2 fluoxetine ENT2END has been reported to induce mania
0	Fluoxetine, a selective ENT1 serotonin  ENT1END  reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent ENT2 depression ENT2END
0	Apparent risk factors for the development of mania or hypomania during ENT1 fluoxetine ENT1END  pharmacotherapy in this population were the combination of ENT2 attention-deficit hyperactivity disorder ENT2END and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder
0	Fluoxetine, a selective ENT1 serotonin  ENT1END  reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent depression. Generally safe and well tolerated by adults, fluoxetine has been reported to induce mania. The cases of five depressed adolescents, 14-16 years of age, who developed mania during pharmacotherapy with fluoxetine, are reported here. Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of ENT2 attention-deficit hyperactivity disorder ENT2END and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder
0	Apparent risk factors for the development of mania or hypomania during ENT1 fluoxetine ENT1END  pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of ENT2 affective disorder ENT2END , especially bipolar disorder; and a diagnosis of bipolar disorder
0	Fluoxetine, a selective ENT1 serotonin  ENT1END  reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent depression. Generally safe and well tolerated by adults, fluoxetine has been reported to induce mania. The cases of five depressed adolescents, 14-16 years of age, who developed mania during pharmacotherapy with fluoxetine, are reported here. Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of ENT2 affective disorder ENT2END , especially bipolar disorder; and a diagnosis of bipolar disorder
0	The ENT1 trimethaphan ENT1END induced hypotension was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion. Therefore, rostral ventrolateral medulla neurons appear to play a significant role in maintaining ENT2 hypertension ENT2END in conscious spontaneously hypertensive rats
0	We studied the effects of chronic selective neuronal lesion of rostral ventrolateral medulla on mean arterial pressure, heart rate, and neurogenic tone in conscious, unrestrained spontaneously ENT1 hypertensive ENT1END rats. The lesions were placed via bilateral microinjections of 30 nmol/200 nl ENT2 N-methyl-D-aspartic acid ENT2END
1	The ENT1 trimethaphan ENT1END -induced hypotension was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a ENT2 tachycardia ENT2END in sham rats (+33 +/- 12 beats per minute) 1 day postlesion
0	The restimulation of this area with ENT1 N-methyl-D-aspartic acid  ENT1END 15 days postlesion failed to produce a pressor response. One day postlesion, the resting mean arterial pressure was significantly decreased in lesioned rats when compared with sham rats (100 +/- 7 versus 173 +/- 4 mm Hg, p less than 0.05). Fifteen days later, the lesioned group still showed values significantly lower than the sham group (150 +/- 6 versus 167 +/- 5 mm Hg, p less than 0.05). No significant heart rate differences were observed between the sham and lesioned groups. The ganglionic blocker trimethaphan (5 mg/kg i.v.) caused similar reductions in mean arterial pressure in both lesioned and sham groups. The trimethaphan-induced hypotension was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a ENT2 tachycardia ENT2END in sham rats (+33 +/- 12 beats per minute) 1 day postlesion
1	The ENT1 trimethaphan ENT1END -induced ENT2 hypotension ENT2END was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion
0	The restimulation of this area with ENT1 N-methyl-D-aspartic acid  ENT1END  15 days postlesion failed to produce a pressor response. One day postlesion, the resting mean arterial pressure was significantly decreased in lesioned rats when compared with sham rats (100 +/- 7 versus 173 +/- 4 mm Hg, p less than 0.05). Fifteen days later, the lesioned group still showed values significantly lower than the sham group (150 +/- 6 versus 167 +/- 5 mm Hg, p less than 0.05). No significant heart rate differences were observed between the sham and lesioned groups. The ganglionic blocker trimethaphan (5 mg/kg i.v.) caused similar reductions in mean arterial pressure in both lesioned and sham groups. The trimethaphan-induced ENT2 hypotension ENT2END was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion
0	The ENT1 trimethaphan ENT1END -induced hypotension was accompanied by a significant ENT2 bradycardia ENT2END in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion
0	The restimulation of this area with ENT1 N-methyl-D-aspartic acid  ENT1END  15 days postlesion failed to produce a pressor response. One day postlesion, the resting mean arterial pressure was significantly decreased in lesioned rats when compared with sham rats (100 +/- 7 versus 173 +/- 4 mm Hg, p less than 0.05). Fifteen days later, the lesioned group still showed values significantly lower than the sham group (150 +/- 6 versus 167 +/- 5 mm Hg, p less than 0.05). No significant heart rate differences were observed between the sham and lesioned groups. The ganglionic blocker trimethaphan (5 mg/kg i.v.) caused similar reductions in mean arterial pressure in both lesioned and sham groups. The trimethaphan-induced hypotension was accompanied by a significant ENT2 bradycardia ENT2END in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion
1	The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that adenosine plays little, if any, pathophysiological role in ENT1 gentamicin ENT1END induced ENT2 ARF ENT2END
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing ENT1 acute renal failure  ENT1END after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C] ENT2 p-aminohippuric acid ENT2END clearances) and morphological (degree of necrosis) indices
0	However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle (polyethylene glycol and ENT1 NaOH  ENT1END . The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that adenosine plays little, if any, pathophysiological role in gentamicin-induced ENT2 ARF ENT2END
0	Effect of alkylxanthines on gentamicin-induced ENT1 acute renal failure  ENT1END  in the rat. ENT2 Adenosine ENT2END antagonists have been previously shown to be of benefit in some ischaemic and nephrotoxic models of acute renal failure (ARF)
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing ENT1 acute renal failure ENT1END  after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma ENT2 urea ENT2END and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, ENT1 theophylline  ENT1END and enprofylline, were examined in rats developing ENT2 acute renal failure ENT2END after 4 daily injections of gentamicin (200 mg kg-1)
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists ENT1 8-phenyltheophylline  ENT1END  theophylline and enprofylline, were examined in rats developing ENT2 acute renal failure ENT2END after 4 daily injections of gentamicin (200 mg kg-1)
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing ENT1 acute renal failure ENT1END  after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and ENT2 creatinine ENT2END ), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and ENT1 enprofylline  ENT1END  were examined in rats developing ENT2 acute renal failure ENT2END after 4 daily injections of gentamicin (200 mg kg-1)
0	However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle ( ENT1 polyethylene glycol  ENT1END and NaOH). The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that adenosine plays little, if any, pathophysiological role in gentamicin-induced ENT2 ARF ENT2END
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of ENT1 gentamicin ENT1END (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENT2 necrosis ENT2END ) indices
0	Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C] ENT1 p-aminohippuric acid  ENT1END  clearances) and morphological (degree of ENT2 necrosis ENT2END ) indices
0	Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENT1 necrosis  ENT1END ) indices. The various drug treatments produced improvements in some, but not all, measurements of renal function. However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle (polyethylene glycol and ENT2 NaOH ENT2END )
0	In the present study, the effects of three alkylxanthines with different potencies as ENT1 adenosine  ENT1END antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENT2 necrosis ENT2END ) indices
0	Renal function was assessed by biochemical (plasma ENT1 urea  ENT1END  and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENT2 necrosis ENT2END ) indices
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, ENT1 theophylline  ENT1END  and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENT2 necrosis ENT2END ) indices
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists ENT1 8-phenyltheophylline  ENT1END , theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENT2 necrosis ENT2END ) indices
0	Renal function was assessed by biochemical (plasma urea and ENT1 creatinine  ENT1END ), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENT2 necrosis ENT2END ) indices
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and ENT1 enprofylline  ENT1END , were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENT2 necrosis ENT2END ) indices
0	Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENT1 necrosis ENT1END ) indices. The various drug treatments produced improvements in some, but not all, measurements of renal function. However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle ENT2 polyethylene glycol ENT2END and NaOH)
0	Effect of alkylxanthines on ENT1 gentamicin ENT1END -induced acute renal failure in the rat.Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENT2 nephrotoxic ENT2END models of acute renal failure (ARF)
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENT1 nephrotoxic  ENT1END  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C ENT2 p-aminohippuric acid ENT2END clearances) and morphological (degree of necrosis) indices
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENT1 nephrotoxic  ENT1END  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices. The various drug treatments produced improvements in some, but not all, measurements of renal function. However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle (polyethylene glycol and ENT2 NaOH ENT2END )
0	ENT1 Adenosine  ENT1END  antagonists have been previously shown to be of benefit in some ischaemic and ENT2 nephrotoxic ENT2END models of acute renal failure (ARF)
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENT1 nephrotoxic  ENT1END  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma ENT2 urea ENT2END and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENT1 nephrotoxic  ENT1END  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, ENT2 theophylline ENT2END and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1)
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENT1 nephrotoxic  ENT1END  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists ENT2 8-phenyltheophylline ENT2END , theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1)
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENT1 nephrotoxic  ENT1END  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and ENT2 creatinine ENT2END ), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENT1 nephrotoxic  ENT1END  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and ENT2 enprofylline ENT2END , were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1)
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENT1 nephrotoxic ENT1END  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices. The various drug treatments produced improvements in some, but not all, measurements of renal function. However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle ENT2 polyethylene glycol ENT2END and NaOH)
0	Effect of alkylxanthines on ENT1 gentamicin ENT1END -induced acute renal failure in the rat.Adenosine antagonists have been previously shown to be of benefit in some ENT2 ischaemic ENT2END and nephrotoxic models of acute renal failure (ARF)
0	Adenosine antagonists have been previously shown to be of benefit in some ENT1 ischaemic  ENT1END  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C ENT2 p-aminohippuric acid ENT2END clearances) and morphological (degree of necrosis) indices
0	Adenosine antagonists have been previously shown to be of benefit in some ENT1 ischaemic  ENT1END  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices. The various drug treatments produced improvements in some, but not all, measurements of renal function. However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle (polyethylene glycol and ENT2 NaOH ENT2END )
0	ENT1 Adenosine  ENT1END  antagonists have been previously shown to be of benefit in some ENT2 ischaemic ENT2END and nephrotoxic models of acute renal failure (ARF)
0	Adenosine antagonists have been previously shown to be of benefit in some ENT1 ischaemic  ENT1END  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma ENT2 urea ENT2END and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices
0	Adenosine antagonists have been previously shown to be of benefit in some ENT1 ischaemic  ENT1END  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, ENT2 theophylline ENT2END and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1)
0	Adenosine antagonists have been previously shown to be of benefit in some ENT1 ischaemic  ENT1END  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists ENT2 8-phenyltheophylline ENT2END , theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1)
0	Adenosine antagonists have been previously shown to be of benefit in some ENT1 ischaemic  ENT1END  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and ENT2 creatinine ENT2END ), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices
0	Adenosine antagonists have been previously shown to be of benefit in some ENT1 ischaemic  ENT1END  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and ENT2 enprofylline ENT2END , were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1)
0	Adenosine antagonists have been previously shown to be of benefit in some ENT1 ischaemic ENT1END  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices. The various drug treatments produced improvements in some, but not all, measurements of renal function. However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle ENT2 polyethylene glycol ENT2END and NaOH)
1	ENT1 Valproate  ENT1END -induced ENT2 hyperammonemic ENT2END encephalopathy in a renal transplanted patient
0	ENT1 Valproate  ENT1END -induced hyperammonemic ENT2 encephalopathy ENT2END in a renal transplanted patient
0	ENT1 Valproate  ENT1END -induced hyperammonemic encephalopathy in a renal transplanted patient. ENT2 Neurological complications ENT2END after renal transplantation constitute an important cause of morbidity and mortality
1	Here, we describe the case of a 15-year-old girl who was on a long-term therapy with ENT1 valproate ENT1END due to epilepsy and revealed ENT2 impaired consciousness ENT2END with hyperammonemia 12 days after renal transplantation
0	Here, we describe the case of a 15-year-old girl who was on a long-term therapy with ENT1 valproate ENT1END  due to ENT2 epilepsy ENT2END and revealed impaired consciousness with hyperammonemia 12 days after renal transplantation
0	STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known ENT1 CVD ENT1END  Does ENT2 aspirin ENT2END increase gastrointestinal bleeding or hemorrhagic strokes? DATA EXTRACTION: All studies were reviewed, abstracted, and rated for quality by using predefined USPSTF criteria
0	BACKGROUND: Coronary heart disease and ENT1 cerebrovascular disease ENT1END are leading causes of death in the United States. In 2002, the U.S. Preventive Services Task Force (USPSTF) strongly recommended that clinicians discuss ENT2 aspirin ENT2END with adults who are at increased risk for coronary heart disease
0	CONCLUSION: ENT1 Aspirin ENT1END reduces the risk for ENT2 myocardial infarction ENT2END in men and strokes in women
1	Men in these studies experienced fewer myocardial infarctions and women experienced fewer ischemic ENT1 strokes ENT1END  ENT2 Aspirin ENT2END does not seem to affect CVD mortality or all-cause mortality in either men or women
0	Preventive Services Task Force (USPSTF) strongly recommended that clinicians discuss ENT1 aspirin ENT1END  with adults who are at increased risk for ENT2 coronary heart disease ENT2END
1	Men have an increased risk for ENT1 hemorrhagic strokes ENT1END with ENT2 aspirin ENT2END use
0	ENT1 Aspirin ENT1END use increases the risk for serious ENT2 bleeding ENT2END events
1	STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD? Does ENT1 aspirin ENT1END  increase ENT2 gastrointestinal bleeding ENT2END or hemorrhagic strokes? DATA EXTRACTION: All studies were reviewed, abstracted, and rated for quality by using predefined USPSTF criteria
1	Crocin reduced inhibition of ERK activation and ENT1 diazinon ENT1END induced ENT2 hyperlipemia ENT2END and increased levels of LDLr transcript
0	Crocin reduced inhibition of ERK activation and diazinon-induced ENT1 hyperlipemia ENT1END  and increased levels of LDLr transcript. CONCLUSIONS: ENT2 Crocin ENT2END may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression
0	RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, ENT1 triglyceride  ENT1END and LDL. Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript. Crocin reduced inhibition of ERK activation and diazinon-induced ENT2 hyperlipemia ENT2END and increased levels of LDLr transcript
0	RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of ENT1 cholesterol  ENT1END  triglyceride and LDL. Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript. Crocin reduced inhibition of ERK activation and diazinon-induced ENT2 hyperlipemia ENT2END and increased levels of LDLr transcript
0	Subgroups presumed to be at higher risk for ACE inhibitor intolerance (blood pressure, <120 mm Hg; ENT1 creatinine ENT1END  > or =132.6 micromol/L [> or =1.5 mg/dL]; age, > or =70 years; and patients with diabetes) generally tolerated the high-dose strategy. CONCLUSIONS: These findings demonstrate that ACE inhibitor therapy in most patients with ENT2 CHF ENT2END can be successfully titrated to and maintained at high doses, and that more aggressive use of these agents is warranted
0	CONCLUSIONS: These findings demonstrate that ENT1 ACE inhibitor  ENT1END therapy in most patients with ENT2 CHF ENT2END can be successfully titrated to and maintained at high doses, and that more aggressive use of these agents is warranted
0	The present study examines the safety and tolerability of high- compared with low-dose ENT1 lisinopril ENT1END in ENT2 CHF ENT2END
0	0%) or because of renal dysfunction or ENT1 hyperkalemia  ENT1END (2.3%). Doses in more than 90% of randomized patients in the high- and low-dose groups were titrated to their assigned target, and the mean doses of blinded medication in both groups remained similar throughout the study. Withdrawals occurred in 27.1% of the high- and 30.7% of the low-dose groups. Subgroups presumed to be at higher risk for ACE inhibitor intolerance (blood pressure, <120 mm Hg; ENT2 creatinine ENT2END , > or =132
0	RESULTS: Of 405 patients not previously receiving an ENT1 ACE inhibitor  ENT1END  doses in only 4.2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension (2.0%) or because of renal dysfunction or ENT2 hyperkalemia ENT2END (2
1	METHODS: The Assessment of Lisinopril and Survival study was a multicenter, randomized, double-blind trial in which patients with or without previous ACE inhibitor treatment were stabilized receiving medium-dose ENT1 lisinopril  ENT1END (12.5 or 15.0 mg once daily [OD]) for 2 to 4 weeks and then randomized to high- (35.0 or 32.5 mg OD) or low-dose (5.0 or 2.5 mg OD) groups. Patients with New York Heart Association classes II to IV CHF and left ventricular ejection fractions of no greater than 0.30 (n = 3164) were randomized and followed up for a median of 46 months. We examined the occurrence of adverse events and the need for discontinuation and dose reduction during treatment, with a focus on hypotension and renal dysfunction. RESULTS: Of 405 patients not previously receiving an ACE inhibitor, doses in only 4.2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension (2.0%) or because of renal dysfunction or ENT2 hyperkalemia ENT2END (2
0	0%) or because of ENT1 renal dysfunction  ENT1END or hyperkalemia (2.3%). Doses in more than 90% of randomized patients in the high- and low-dose groups were titrated to their assigned target, and the mean doses of blinded medication in both groups remained similar throughout the study. Withdrawals occurred in 27.1% of the high- and 30.7% of the low-dose groups. Subgroups presumed to be at higher risk for ACE inhibitor intolerance (blood pressure, <120 mm Hg; ENT2 creatinine ENT2END , > or =132
0	We examined the occurrence of adverse events and the need for discontinuation and dose reduction during treatment, with a focus on hypotension and ENT1 renal dysfunction  ENT1END  RESULTS: Of 405 patients not previously receiving an ENT2 ACE inhibitor ENT2END , doses in only 4
1	METHODS: The Assessment of Lisinopril and Survival study was a multicenter, randomized, double-blind trial in which patients with or without previous ACE inhibitor treatment were stabilized receiving medium-dose ENT1 lisinopril  ENT1END  (12.5 or 15.0 mg once daily [OD]) for 2 to 4 weeks and then randomized to high- (35.0 or 32.5 mg OD) or low-dose (5.0 or 2.5 mg OD) groups. Patients with New York Heart Association classes II to IV CHF and left ventricular ejection fractions of no greater than 0.30 (n = 3164) were randomized and followed up for a median of 46 months. We examined the occurrence of adverse events and the need for discontinuation and dose reduction during treatment, with a focus on hypotension and ENT2 renal dysfunction ENT2END
0	2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to ENT1 hypotension  ENT1END (2.0%) or because of renal dysfunction or hyperkalemia (2.3%). Doses in more than 90% of randomized patients in the high- and low-dose groups were titrated to their assigned target, and the mean doses of blinded medication in both groups remained similar throughout the study. Withdrawals occurred in 27.1% of the high- and 30.7% of the low-dose groups. Subgroups presumed to be at higher risk for ACE inhibitor intolerance (blood pressure, <120 mm Hg; ENT2 creatinine ENT2END , > or =132
0	We examined the occurrence of adverse events and the need for discontinuation and dose reduction during treatment, with a focus on ENT1 hypotension  ENT1END and renal dysfunction. RESULTS: Of 405 patients not previously receiving an ENT2 ACE inhibitor ENT2END , doses in only 4
1	METHODS: The Assessment of Lisinopril and Survival study was a multicenter, randomized, double-blind trial in which patients with or without previous ACE inhibitor treatment were stabilized receiving medium-dose ENT1 lisinopril  ENT1END  (12.5 or 15.0 mg once daily [OD]) for 2 to 4 weeks and then randomized to high- (35.0 or 32.5 mg OD) or low-dose (5.0 or 2.5 mg OD) groups. Patients with New York Heart Association classes II to IV CHF and left ventricular ejection fractions of no greater than 0.30 (n = 3164) were randomized and followed up for a median of 46 months. We examined the occurrence of adverse events and the need for discontinuation and dose reduction during treatment, with a focus on ENT2 hypotension ENT2END and renal dysfunction
0	Subgroups presumed to be at higher risk for ACE inhibitor intolerance (blood pressure, <120 mm Hg; ENT1 creatinine ENT1END , > or =132.6 micromol/L [> or =1.5 mg/dL]; age, > or =70 years; and patients with ENT2 diabetes ENT2END ) generally tolerated the high-dose strategy
0	5 mg/dL]; age, > or =70 years; and patients with ENT1 diabetes  ENT1END ) generally tolerated the high-dose strategy. CONCLUSIONS: These findings demonstrate that ENT2 ACE inhibitor ENT2END therapy in most patients with CHF can be successfully titrated to and maintained at high doses, and that more aggressive use of these agents is warranted
0	On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of ENT1 CTX ENT1END (divided over 5 days) q 4 wk is tolerable in ENT2 tumor ENT2END -bearing dogs
0	On the basis of the findings reported herein, a dose of 60 mg/m(2) of ENT1 CCNU  ENT1END combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in ENT2 tumor ENT2END -bearing dogs
0	This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide ( ENT1 CTX ENT1END  in dogs with ENT2 lymphoma ENT2END
0	This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with ENT1 lymphoma ENT1END . ENT2 CCNU ENT2END was administered per os (PO) at a targeted dosage of 60 mg/m(2) body surface area on day 0, CTX was administered PO at a targeted dosage of 250 mg/m(2) divided over days 0 through 4, and all dogs received prophylactic antibiotics
0	This retrospective study describes ENT1 toxicity ENT1END associated with a protocol of lomustine (CCNU) and ENT2 cyclophosphamide ENT2END (CTX) in dogs with lymphoma
0	This retrospective study describes ENT1 toxicity ENT1END  associated with a protocol of ENT2 lomustine ENT2END (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma
0	No dogs had evidence of either ENT1 renal toxicity  ENT1END or hemorrhagic cystitis. Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of ENT2 CTX ENT2END (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
0	No dogs had evidence of either ENT1 renal toxicity  ENT1END  or hemorrhagic cystitis. Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of ENT2 CCNU ENT2END combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
0	No dogs had evidence of either renal toxicity or ENT1 hemorrhagic cystitis  ENT1END  Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of ENT2 CTX ENT2END (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
0	No dogs had evidence of either renal toxicity or ENT1 hemorrhagic cystitis  ENT1END . Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of ENT2 CCNU ENT2END combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
0	One dog (3%) developed hematologic changes suggestive of ENT1 hepatotoxicity  ENT1END  No dogs had evidence of either renal toxicity or hemorrhagic cystitis. Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of ENT2 CTX ENT2END (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
0	One dog (3%) developed hematologic changes suggestive of ENT1 hepatotoxicity  ENT1END . No dogs had evidence of either renal toxicity or hemorrhagic cystitis. Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of ENT2 CCNU ENT2END combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
0	No dogs had evidence of either renal toxicity or ENT1 hemorrhagic cystitis  ENT1END  Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of ENT2 CTX ENT2END (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
0	No dogs had evidence of either renal toxicity or ENT1 hemorrhagic cystitis  ENT1END . Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of ENT2 CCNU ENT2END combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
1	Neutropenia was the principal toxic effect, and the overall frequency of grade 4 ENT1 neutropenia  ENT1END after the first treatment of CCNU/ ENT2 CTX ENT2END was 30% (95% confidence interval, 19-43%)
1	Neutropenia was the principal toxic effect, and the overall frequency of grade 4 ENT1 neutropenia ENT1END  after the first treatment of ENT2 CCNU ENT2END /CTX was 30% (95% confidence interval, 19-43%)
1	Sixty patients (age-range one month to 14 years) with other types of epilepsy than infantile spasms were treated with ENT1 clonazepam ENT1END  Disappearance of seizures and normalization of abnormal EEG with disappearance of seizures were recognized in 77% and 50%, respectively. Seizures disappeared in 71% of the patients with generalized seizures and 89% of partial seizures. Improvement of abnormal EEG was noticed in 76% of diffuse paroxysms and in 67% of focal paroxysms. In excellent cases, mean effective dosages were 0.086 +/- 0.021 mg/kg/day in infants and 0.057 +/- 0.022 mg/kg/day in schoolchildren, this difference was statistically significant (p less than 0.005). The incidence of side effects such as drowsiness and ENT2 ataxia ENT2END was only 5%
1	Sixty patients (age-range one month to 14 years) with other types of epilepsy than infantile spasms were treated with ENT1 clonazepam ENT1END . Disappearance of seizures and normalization of abnormal EEG with disappearance of seizures were recognized in 77% and 50%, respectively. Seizures disappeared in 71% of the patients with generalized seizures and 89% of partial seizures. Improvement of abnormal EEG was noticed in 76% of diffuse paroxysms and in 67% of focal paroxysms. In excellent cases, mean effective dosages were 0.086 +/- 0.021 mg/kg/day in infants and 0.057 +/- 0.022 mg/kg/day in schoolchildren, this difference was statistically significant (p less than 0.005). The incidence of side effects such as ENT2 drowsiness ENT2END and ataxia was only 5%
0	Sixty patients (age-range one month to 14 years) with other types of epilepsy than infantile spasms were treated with ENT1 clonazepam ENT1END . Disappearance of ENT2 seizures ENT2END and normalization of abnormal EEG with disappearance of seizures were recognized in 77% and 50%, respectively
0	Sixty patients (age-range one month to 14 years) with other types of epilepsy than ENT1 infantile spasms  ENT1END were treated with ENT2 clonazepam ENT2END
0	ENT1 Clonazepam  ENT1END  monotherapy for ENT2 epilepsy ENT2END in childhood
0	Smoking of ENT1 crack cocaine  ENT1END  as a risk factor for ENT2 HIV infection ENT2END among people who use injection drugs
1	To determine whether the risk of ENT1 HIV seroconversion ENT1END among daily smokers of ENT2 crack cocaine ENT2END changed over time, we used Cox proportional hazards regression and divided the study into 3 periods: May 1, 1996-Nov
0	It was hypothesized that ENT1 progestins ENT1END could equilibrate the effects of the estrogenic stimulation on the mammary and endometrial target tissues of women on hormonal replacement therapy. The treatment schedule consisted of conjugated estrogens (Premarin) 1.25 mg/day for 21 days and Medroxyprogesterone acetate 10 mg/day for 10 days in each month. The mean treatment period was 18 months. During the follow-up period, attention was paid to breast modifications as evidenced by symptomatology, physical examination, and plate thermography. ENT2 Mastodynia ENT2END was reported by 21 patients, and physical examination revealed a light increase in breast firmness in 12 women and a moderate increase in breast nodularity in 2 women
1	25 mg/day for 21 days and ENT1 Medroxyprogesterone acetate  ENT1END 10 mg/day for 10 days in each month. The mean treatment period was 18 months. During the follow-up period, attention was paid to breast modifications as evidenced by symptomatology, physical examination, and plate thermography. ENT2 Mastodynia ENT2END was reported by 21 patients, and physical examination revealed a light increase in breast firmness in 12 women and a moderate increase in breast nodularity in 2 women
1	The treatment schedule consisted of conjugated estrogens ( ENT1 Premarin  ENT1END  1.25 mg/day for 21 days and Medroxyprogesterone acetate 10 mg/day for 10 days in each month. The mean treatment period was 18 months. During the follow-up period, attention was paid to breast modifications as evidenced by symptomatology, physical examination, and plate thermography. ENT2 Mastodynia ENT2END was reported by 21 patients, and physical examination revealed a light increase in breast firmness in 12 women and a moderate increase in breast nodularity in 2 women
0	Themography confirmed the existence of an excessive breast stimulation in 1 women who complained of moderate mastodynia and in 5 of the 7 women who complained of severe ENT1 mastodynia ENT1END  Normalization was obtained by halving the ENT2 estrogen ENT2END dose
0	Hormones and risk of ENT1 breast cancer  ENT1END .This paper reports the results of a study of 50 menopausal women receiving hormonal replacement therapy. The majority (29) had surgical menopause; their mean age was 45.7 years. It was hypothesized that ENT2 progestins ENT2END could equilibrate the effects of the estrogenic stimulation on the mammary and endometrial target tissues of women on hormonal replacement therapy
0	Hormones and risk of ENT1 breast cancer  ENT1END .This paper reports the results of a study of 50 menopausal women receiving hormonal replacement therapy. The majority (29) had surgical menopause; their mean age was 45.7 years. It was hypothesized that progestins could equilibrate the effects of the estrogenic stimulation on the mammary and endometrial target tissues of women on hormonal replacement therapy. The treatment schedule consisted of conjugated estrogens (Premarin) 1.25 mg/day for 21 days and ENT2 Medroxyprogesterone acetate ENT2END 10 mg/day for 10 days in each month
0	Hormones and risk of ENT1 breast cancer ENT1END .This paper reports the results of a study of 50 menopausal women receiving hormonal replacement therapy. The majority (29) had surgical menopause; their mean age was 45.7 years. It was hypothesized that progestins could equilibrate the effects of the estrogenic stimulation on the mammary and endometrial target tissues of women on hormonal replacement therapy. The treatment schedule consisted of ENT2 conjugated estrogens ENT2END (Premarin) 1
0	We investigated the effects of clentiazem, a ENT1 1,5-benzothiazepine ENT1END calcium antagonist, on epinephrine-induced ENT2 cardiomyopathy ENT2END in rats
1	We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on ENT1 epinephrine  ENT1END induced ENT2 cardiomyopathy ENT2END in rats
0	We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced ENT1 cardiomyopathy ENT1END  in rats. With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and fibrosis of the left ventricles were observed. In epinephrine-treated rats, left atrial and left ventricular papillary muscle contractile responses to ENT2 isoproterenol ENT2END were reduced, but responses to calcium were normal or enhanced compared to controls
0	We investigated the effects of ENT1 clentiazem  ENT1END  a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced ENT2 cardiomyopathy ENT2END in rats
0	We investigated the effects of clentiazem, a 1,5-benzothiazepine ENT1 calcium  ENT1END antagonist, on epinephrine-induced ENT2 cardiomyopathy ENT2END in rats
0	We investigated the effects of clentiazem, a ENT1 1,5-benzothiazepine ENT1END  calcium antagonist, on epinephrine-induced cardiomyopathy in rats. With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ENT2 ischemic lesions ENT2END and fibrosis of the left ventricles were observed
0	With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ENT1 ischemic lesions ENT1END  and fibrosis of the left ventricles were observed. In ENT2 epinephrine ENT2END -treated rats, left atrial and left ventricular papillary muscle contractile responses to isoproterenol were reduced, but responses to calcium were normal or enhanced compared to controls
0	05), and attenuated the ventricular ENT1 ischemic lesions ENT1END and fibrosis, in a dose-dependent manner. Left atrial and left ventricular papillary muscle contractile responses to ENT2 isoproterenol ENT2END were reduced compared to controls in groups treated with clentiazem alone, but combined with epinephrine, clentiazem restored left atrial responses and enhanced left ventricular papillary responses to isoproterenol
0	Treatment with ENT1 clentiazem  ENT1END prevented epinephrine-induced death (P < .05), and attenuated the ventricular ENT2 ischemic lesions ENT2END and fibrosis, in a dose-dependent manner
0	We investigated the effects of clentiazem, a 1,5-benzothiazepine ENT1 calcium  ENT1END  antagonist, on epinephrine-induced cardiomyopathy in rats. With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ENT2 ischemic lesions ENT2END and fibrosis of the left ventricles were observed
0	Protective effect of clentiazem against epinephrine-induced ENT1 cardiac injury  ENT1END  in rats.We investigated the effects of clentiazem, a ENT2 1,5-benzothiazepine ENT2END calcium antagonist, on epinephrine-induced cardiomyopathy in rats
0	Protective effect of clentiazem against ENT1 epinephrine  ENT1END -induced ENT2 cardiac injury ENT2END in rats
0	Protective effect of clentiazem against epinephrine-induced ENT1 cardiac injury  ENT1END  in rats.We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced cardiomyopathy in rats. With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and fibrosis of the left ventricles were observed. In epinephrine-treated rats, left atrial and left ventricular papillary muscle contractile responses to ENT2 isoproterenol ENT2END were reduced, but responses to calcium were normal or enhanced compared to controls
0	Protective effect of ENT1 clentiazem  ENT1END  against epinephrine-induced ENT2 cardiac injury ENT2END in rats
0	Protective effect of clentiazem against epinephrine-induced ENT1 cardiac injury  ENT1END  in rats.We investigated the effects of clentiazem, a 1,5-benzothiazepine ENT2 calcium ENT2END antagonist, on epinephrine-induced cardiomyopathy in rats
0	We investigated the effects of clentiazem, a ENT1 1,5-benzothiazepine ENT1END  calcium antagonist, on epinephrine-induced cardiomyopathy in rats. With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and ENT2 fibrosis ENT2END of the left ventricles were observed
0	With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and ENT1 fibrosis  ENT1END  of the left ventricles were observed. In ENT2 epinephrine ENT2END -treated rats, left atrial and left ventricular papillary muscle contractile responses to isoproterenol were reduced, but responses to calcium were normal or enhanced compared to controls
0	05), and attenuated the ventricular ischemic lesions and ENT1 fibrosis  ENT1END  in a dose-dependent manner. Left atrial and left ventricular papillary muscle contractile responses to ENT2 isoproterenol ENT2END were reduced compared to controls in groups treated with clentiazem alone, but combined with epinephrine, clentiazem restored left atrial responses and enhanced left ventricular papillary responses to isoproterenol
0	Treatment with ENT1 clentiazem  ENT1END  prevented epinephrine-induced death (P < .05), and attenuated the ventricular ischemic lesions and ENT2 fibrosis ENT2END , in a dose-dependent manner
0	We investigated the effects of clentiazem, a 1,5-benzothiazepine ENT1 calcium  ENT1END  antagonist, on epinephrine-induced cardiomyopathy in rats. With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and ENT2 fibrosis ENT2END of the left ventricles were observed
0	Anticonvulsant actions of MK-801 on the lithium-pilocarpine model of ENT1 status epilepticus  ENT1END  in rats. ENT2 MK-801 ENT2END , a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two seizure models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone
0	These results suggest that activation of ENT1 NMDA ENT1END receptors plays an important role in ENT2 status epilepticus ENT2END and brain damage in the lithium-pilocarpine model
1	Anticonvulsant actions of MK-801 on the ENT1 lithium  ENT1END -pilocarpine model of ENT2 status epilepticus ENT2END in rats
1	Anticonvulsant actions of MK-801 on the lithium- ENT1 pilocarpine  ENT1END  model of ENT2 status epilepticus ENT2END in rats
0	Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the ENT1 seizures ENT1END  Administration of ENT2 MK-801 ENT2END 30 or 60 min after pilocarpine, i
0	This observation is suggested to be an in vivo demonstration of the conclusion derived from in vitro experiments that MK-801 binding requires agonist-induced opening of the channel sites of the ENT1 NMDA ENT1END receptor. Third, although it is relatively easy to block ENT2 seizures ENT2END induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures
0	Third, although it is relatively easy to block ENT1 seizures ENT1END  induced by ENT2 lithium ENT2END and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures
0	Third, although it is relatively easy to block ENT1 seizures ENT1END  induced by lithium and ENT2 pilocarpine ENT2END by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures
0	Administration of ENT1 MK-801 ENT1END  30 or 60 min after pilocarpine, i.e., during status epilepticus, gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate. These results suggest that activation of NMDA receptors plays an important role in status epilepticus and ENT2 brain damage ENT2END in the lithium-pilocarpine model
0	These results suggest that activation of ENT1 NMDA  ENT1END  receptors plays an important role in status epilepticus and ENT2 brain damage ENT2END in the lithium-pilocarpine model
0	These results suggest that activation of NMDA receptors plays an important role in status epilepticus and ENT1 brain damage ENT1END  in the ENT2 lithium ENT2END -pilocarpine model
0	These results suggest that activation of NMDA receptors plays an important role in status epilepticus and ENT1 brain damage  ENT1END  in the lithium- ENT2 pilocarpine ENT2END model
1	ENT1 Hyperosmolar nonketotic coma  ENT1END  precipitated by ENT2 lithium ENT2END -induced nephrogenic diabetes insipidus
0	A 45-year-old man, with a 10-year history of manic depression treated with lithium, was admitted with ENT1 hyperosmolar, nonketotic coma ENT1END  He gave a five-year history of polyuria and polydipsia, during which time urinalysis had been negative for ENT2 glucose ENT2END
0	A 45-year-old man, with a 10-year history of ENT1 manic depression ENT1END treated with ENT2 lithium ENT2END , was admitted with hyperosmolar, nonketotic coma
0	A 45-year-old man, with a 10-year history of ENT1 manic depression  ENT1END  treated with lithium, was admitted with hyperosmolar, nonketotic coma. He gave a five-year history of polyuria and polydipsia, during which time urinalysis had been negative for ENT2 glucose ENT2END
1	After recovery from hyperglycaemia, he remained polyuric despite normal blood glucose concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be ENT1 lithium ENT1END induced. We hypothesize that when this man developed type 2 diabetes, chronic ENT2 polyuria ENT2END due to nephrogenic diabetes insipidus was sufficient to precipitate hyperosmolar dehydration
0	After recovery from hyperglycaemia, he remained ENT1 polyuric ENT1END despite normal blood ENT2 glucose ENT2END concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be lithium-induced
1	Hyperosmolar nonketotic coma precipitated by ENT1 lithium  ENT1END -induced ENT2 nephrogenic diabetes insipidus ENT2END
0	After recovery from hyperglycaemia, he remained polyuric despite normal blood ENT1 glucose ENT1END  concentrations; water deprivation testing indicated ENT2 nephrogenic diabetes insipidus ENT2END , likely to be lithium-induced
0	After recovery from hyperglycaemia, he remained polyuric despite normal blood glucose concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be ENT1 lithium ENT1END -induced. We hypothesize that when this man developed ENT2 type 2 diabetes ENT2END , chronic polyuria due to nephrogenic diabetes insipidus was sufficient to precipitate hyperosmolar dehydration
0	After recovery from hyperglycaemia, he remained polyuric despite normal blood ENT1 glucose  ENT1END  concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be lithium-induced. We hypothesize that when this man developed ENT2 type 2 diabetes ENT2END , chronic polyuria due to nephrogenic diabetes insipidus was sufficient to precipitate hyperosmolar dehydration
0	A 45-year-old man, with a 10-year history of manic depression treated with ENT1 lithium ENT1END , was admitted with hyperosmolar, nonketotic coma. He gave a five-year history of polyuria and ENT2 polydipsia ENT2END , during which time urinalysis had been negative for glucose
0	He gave a five-year history of polyuria and ENT1 polydipsia  ENT1END , during which time urinalysis had been negative for ENT2 glucose ENT2END
0	After recovery from hyperglycaemia, he remained polyuric despite normal blood glucose concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be ENT1 lithium ENT1END -induced. We hypothesize that when this man developed type 2 diabetes, chronic polyuria due to nephrogenic diabetes insipidus was sufficient to precipitate hyperosmolar ENT2 dehydration ENT2END
0	After recovery from hyperglycaemia, he remained polyuric despite normal blood ENT1 glucose  ENT1END  concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be lithium-induced. We hypothesize that when this man developed type 2 diabetes, chronic polyuria due to nephrogenic diabetes insipidus was sufficient to precipitate hyperosmolar ENT2 dehydration ENT2END
1	Ionizing radiation is capable of inducing the requisite CML-associated t(9:22) translocation ( ENT1 Philadelphia chromosome ENT1END  in appropriate cells in vitro but, thus far, chemicals have not shown this capacity. We have proposed that ENT2 1,3-butadiene ENT2END metabolites be so tested as a reality check on the epidemiological reports
0	ENT1 1,3-Butadiene  ENT1END , ENT2 CML ENT2END and the t(9:22) translocation: A reality check
1	Branch ENT1 retinal vein occlusion  ENT1END  and ENT2 fluoxetine ENT2END
0	A case of branch ENT1 retinal vein occlusion ENT1END associated with fluoxetine-induced secondary hypertension is described. Although an infrequent complication of selective ENT2 serotonin ENT2END reuptake inhibitor therapy, it is important that ophthalmologists are aware that these agents can cause hypertension because this class of drugs is widely prescribed
1	A case of branch retinal vein occlusion associated with ENT1 fluoxetine ENT1END induced secondary ENT2 hypertension ENT2END is described
0	A case of branch retinal vein occlusion associated with fluoxetine-induced secondary ENT1 hypertension  ENT1END  is described. Although an infrequent complication of selective ENT2 serotonin ENT2END reuptake inhibitor therapy, it is important that ophthalmologists are aware that these agents can cause hypertension because this class of drugs is widely prescribed
0	METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, ENT1 rigidity ENT1END  and ENT2 levodopa ENT2END -induced dyskinesias underwent bilateral implantation of electrodes in the STN
0	METHOD: Twenty-three patients suffering from severe ENT1 Parkinson's disease  ENT1END (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and ENT2 levodopa ENT2END -induced dyskinesias underwent bilateral implantation of electrodes in the STN
1	METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and ENT1 levodopa ENT1END -induced ENT2 dyskinesias ENT2END underwent bilateral implantation of electrodes in the STN
0	METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly ENT1 bradykinesia  ENT1END  rigidity, and ENT2 levodopa ENT2END -induced dyskinesias underwent bilateral implantation of electrodes in the STN
0	The subscores for the akinesia, rigidity, ENT1 tremor ENT1END and gait also improved. (p<0.0005). The average ENT2 levodopa ENT2END dose decreased from 813 mg to 359 mg
0	The ENT1 DHEA ENT1END was administered intraperitoneally (ip) for 5 days. Amphetamine (3 mg/kg ip) induced ENT2 hyper ENT2END locomotion, apomorphine (1
0	Amphetamine (3 mg/kg ip) induced ENT1 hyper ENT1END  locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and ENT2 haloperidol ENT2END (1
0	ENT1 Amphetamine  ENT1END (3 mg/kg ip) induced ENT2 hyper ENT2END locomotion, apomorphine (1
0	Amphetamine (3 mg/kg ip) induced ENT1 hyper ENT1END  locomotion, ENT2 apomorphine ENT2END (1
0	CONCLUSION: We observed that ENT1 DHEA ENT1END reduced locomotor activity and increased ENT2 catalepsy ENT2END at both doses, while it had no effect on climbing behavior
1	There was a significant difference between groups in the ENT1 haloperidol ENT1END induced ENT2 catalepsy ENT2END test (p<0
0	Statistical analysis was carried out using Kruskal-Wallis test for hyper locomotion, and one-way ANOVA for climbing and ENT1 catalepsy ENT1END tests. RESULTS: In the ENT2 amphetamine ENT2END -induced locomotion test, there were significant increases in all movements compared with the amphetamine-free group
0	Amphetamine (3 mg/kg ip) induced hyper locomotion, ENT1 apomorphine ENT1END  (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced ENT2 catalepsy ENT2END tests were used as animal models of schizophrenia
0	OBJECTIVE: To examine the effects of dehydroepiandrosterone ( ENT1 DHEA ENT1END  on animal models of ENT2 schizophrenia ENT2END
1	5 mg/kg subcutaneously [sc]) induced climbing, and ENT1 haloperidol ENT1END  (1.5 mg/kg sc) induced catalepsy tests were used as animal models of ENT2 schizophrenia ENT2END
1	Effects of dehydroepiandrosterone in ENT1 amphetamine  ENT1END -induced ENT2 schizophrenia ENT2END models in mice
1	Amphetamine (3 mg/kg ip) induced hyper locomotion, ENT1 apomorphine  ENT1END  (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of ENT2 schizophrenia ENT2END
0	Levodopa is the most effective symptomatic therapy for ENT1 Parkinson's disease ENT1END  but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations. HOMER1 is a protein with pivotal function in ENT2 glutamate ENT2END transmission, which has been related to the pathogenesis of these complications
0	Association of common genetic variants of HOMER1 gene with levodopa adverse effects in ENT1 Parkinson's disease  ENT1END  patients. ENT2 Levodopa ENT2END is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations
0	Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, ENT1 dyskinesia  ENT1END and visual hallucinations. HOMER1 is a protein with pivotal function in ENT2 glutamate ENT2END transmission, which has been related to the pathogenesis of these complications
1	ENT1 Levodopa  ENT1END  is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, ENT2 dyskinesia ENT2END and visual hallucinations
0	Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and ENT1 visual hallucinations  ENT1END  HOMER1 is a protein with pivotal function in ENT2 glutamate ENT2END transmission, which has been related to the pathogenesis of these complications
1	009) and ENT1 visual hallucinations ENT1END (PR=0.515, 95% CI 0.295-0.899, P=0.020). Our data suggest that HOMER1 rs4704559 G allele has a protective role for the development of ENT2 levodopa ENT2END adverse effects
0	Efficacy and safety of ENT1 granisetron  ENT1END , a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of ENT2 nausea ENT2END and vomiting induced by high-dose cisplatin
1	PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of ENT1 cisplatin ENT1END induced ENT2 nausea ENT2END and vomiting
0	Efficacy and safety of granisetron, a selective ENT1 5-hydroxytryptamine  ENT1END -3 receptor antagonist, in the prevention of ENT2 nausea ENT2END and vomiting induced by high-dose cisplatin
1	As ENT1 granisetron ENT1END dose increased, appetite return increased (P = .040). ENT2 Headache ENT2END was the most frequently reported adverse event (20%)
0	ENT1 Headache ENT1END  was the most frequently reported adverse event (20%). CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of granisetron was effective in controlling vomiting in 57% to 60% of patients who received ENT2 cisplatin ENT2END at doses greater than 81 mg/m2 and totally prevented vomiting in 40% to 47% of patients
0	CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of ENT1 granisetron ENT1END was effective in controlling ENT2 vomiting ENT2END in 57% to 60% of patients who received cisplatin at doses greater than 81 mg/m2 and totally prevented vomiting in 40% to 47% of patients
1	PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of ENT1 cisplatin ENT1END -induced nausea and ENT2 vomiting ENT2END
0	Efficacy and safety of granisetron, a selective ENT1 5-hydroxytryptamine  ENT1END -3 receptor antagonist, in the prevention of nausea and ENT2 vomiting ENT2END induced by high-dose cisplatin
0	The cause of ENT1 hyperkalemia ENT1END was considered to be several doses of spiranolactone, an ENT2 aldosterone ENT2END antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor
1	The cause of ENT1 hyperkalemia ENT1END  was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ENT2 ramipril ENT2END , an ACE inhibitor
0	Syncope caused by ENT1 hyperkalemia  ENT1END  during use of a combined therapy with the ENT2 angiotensin ENT2END -converting enzyme inhibitor and spironolactone
0	The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum ENT1 potassium  ENT1END level. The cause of ENT2 hyperkalemia ENT2END was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor
1	The cause of ENT1 hyperkalemia ENT1END  was considered to be several doses of ENT2 spiranolactone ENT2END , an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor
0	ENT1 Syncope  ENT1END  caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an ENT2 aldosterone ENT2END antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor
0	ENT1 Syncope  ENT1END  caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ENT2 ramipril ENT2END , an ACE inhibitor
0	ENT1 Syncope  ENT1END  caused by hyperkalemia during use of a combined therapy with the ENT2 angiotensin ENT2END -converting enzyme inhibitor and spironolactone
0	ENT1 Syncope ENT1END  caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia. The concentration of serum ENT2 potassium ENT2END was high, and normal sinus rhythm was restored after correction of the serum potassium level
0	ENT1 Syncope  ENT1END  caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and ENT2 spironolactone ENT2END
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked ENT1 bradycardia  ENT1END caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an ENT2 aldosterone ENT2END antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked ENT1 bradycardia  ENT1END  caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ENT2 ramipril ENT2END , an ACE inhibitor
0	Syncope caused by hyperkalemia during use of a combined therapy with the ENT1 angiotensin  ENT1END -converting enzyme inhibitor and spironolactone.A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked ENT2 bradycardia ENT2END caused by hyperkalemia
1	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked ENT1 bradycardia  ENT1END  caused by hyperkalemia. The concentration of serum ENT2 potassium ENT2END was high, and normal sinus rhythm was restored after correction of the serum potassium level
0	Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and ENT1 spironolactone  ENT1END .A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked ENT2 bradycardia ENT2END caused by hyperkalemia
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior ENT1 myocardial infarction  ENT1END was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an ENT2 aldosterone ENT2END antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior ENT1 myocardial infarction  ENT1END  was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ENT2 ramipril ENT2END , an ACE inhibitor
0	Syncope caused by hyperkalemia during use of a combined therapy with the ENT1 angiotensin  ENT1END -converting enzyme inhibitor and spironolactone.A 76 year-old woman with a history of coronary artery bypass grafting and prior ENT2 myocardial infarction ENT2END was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior ENT1 myocardial infarction  ENT1END  was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia. The concentration of serum ENT2 potassium ENT2END was high, and normal sinus rhythm was restored after correction of the serum potassium level
0	Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and ENT1 spironolactone  ENT1END .A 76 year-old woman with a history of coronary artery bypass grafting and prior ENT2 myocardial infarction ENT2END was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia
0	The cause of hyperkalemia was considered to be several doses of spiranolactone, an ENT1 aldosterone ENT1END  antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor. This case is a good example of electrolyte imbalance causing acute life-threatening cardiac events. Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild ENT2 renal disturbance ENT2END
0	The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ENT1 ramipril  ENT1END , an ACE inhibitor. This case is a good example of electrolyte imbalance causing acute life-threatening cardiac events. Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild ENT2 renal disturbance ENT2END
0	Syncope caused by hyperkalemia during use of a combined therapy with the ENT1 angiotensin  ENT1END -converting enzyme inhibitor and spironolactone.A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor. This case is a good example of electrolyte imbalance causing acute life-threatening cardiac events. Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild ENT2 renal disturbance ENT2END
0	Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with ENT1 potassium  ENT1END sparing agents and who have mild ENT2 renal disturbance ENT2END
0	The cause of hyperkalemia was considered to be several doses of ENT1 spiranolactone  ENT1END , an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor. This case is a good example of electrolyte imbalance causing acute life-threatening cardiac events. Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild ENT2 renal disturbance ENT2END
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with ENT1 loss of consciousness  ENT1END due to marked bradycardia caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an ENT2 aldosterone ENT2END antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with ENT1 loss of consciousness  ENT1END  due to marked bradycardia caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ENT2 ramipril ENT2END , an ACE inhibitor
0	Syncope caused by hyperkalemia during use of a combined therapy with the ENT1 angiotensin  ENT1END -converting enzyme inhibitor and spironolactone.A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with ENT2 loss of consciousness ENT2END due to marked bradycardia caused by hyperkalemia
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with ENT1 loss of consciousness  ENT1END  due to marked bradycardia caused by hyperkalemia. The concentration of serum ENT2 potassium ENT2END was high, and normal sinus rhythm was restored after correction of the serum potassium level
0	Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and ENT1 spironolactone  ENT1END .A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with ENT2 loss of consciousness ENT2END due to marked bradycardia caused by hyperkalemia
1	1/0, ENT1 hand-foot syndrome ENT1END 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose ENT2 5-FU ENT2END /FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	1/0, ENT1 hand-foot syndrome ENT1END  12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%). It may serve as an alternative to ENT2 cisplatin ENT2END -containing regimens; however, it has to be considered that possibly HUS may occur
1	1/0, ENT1 hand-foot syndrome  ENT1END  12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/ ENT2 FA ENT2END /MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	1/0, ENT1 hand-foot syndrome  ENT1END  12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/ ENT2 MMC ENT2END is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	1, ENT1 vomitus  ENT1END 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose ENT2 5-FU ENT2END /FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	1, ENT1 vomitus  ENT1END  24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%). It may serve as an alternative to ENT2 cisplatin ENT2END -containing regimens; however, it has to be considered that possibly HUS may occur
1	1, ENT1 vomitus  ENT1END  24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU ENT2 FA ENT2END /MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	1, ENT1 vomitus  ENT1END  24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA ENT2 MMC ENT2END is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	1, ENT1 thrombocytopenia  ENT1END 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose ENT2 5-FU ENT2END /FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	1, ENT1 thrombocytopenia  ENT1END  33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%). It may serve as an alternative to ENT2 cisplatin ENT2END -containing regimens; however, it has to be considered that possibly HUS may occur
1	1, ENT1 thrombocytopenia  ENT1END  33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU ENT2 FA ENT2END /MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	1, ENT1 thrombocytopenia  ENT1END  33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA ENT2 MMC ENT2END is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	Two patients developed hemolytic-uremic syndrome ( ENT1 HUS  ENT1END . CONCLUSIONS: High-dose ENT2 5-FU ENT2END /FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	It may serve as an alternative to ENT1 cisplatin ENT1END -containing regimens; however, it has to be considered that possibly ENT2 HUS ENT2END may occur
1	Two patients developed hemolytic-uremic syndrome ( ENT1 HUS  ENT1END ). CONCLUSIONS: High-dose 5-FU ENT2 FA ENT2END /MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	Two patients developed hemolytic-uremic syndrome ( ENT1 HUS  ENT1END ). CONCLUSIONS: High-dose 5-FU/FA ENT2 MMC ENT2END is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	In a previous phase II study with 3-weekly bolus ENT1 5-FU ENT1END  FA and mitomycin C (MMC) we found a low ENT2 toxicity ENT2END rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival
0	The worst ENT1 toxicities  ENT1END (%) observed were (CTC-NCI 1/2/3): leukopenia 45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%). It may serve as an alternative to ENT2 cisplatin ENT2END -containing regimens; however, it has to be considered that possibly HUS may occur
0	In a previous phase II study with 3-weekly bolus 5-FU, ENT1 FA  ENT1END and mitomycin C (MMC) we found a low ENT2 toxicity ENT2END rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival
0	In a previous phase II study with 3-weekly bolus 5-FU, FA and mitomycin C ( ENT1 MMC  ENT1END  we found a low ENT2 toxicity ENT2END rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival
1	0, ENT1 stomatitis  ENT1END 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose ENT2 5-FU ENT2END /FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	0, ENT1 stomatitis  ENT1END  18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%). It may serve as an alternative to ENT2 cisplatin ENT2END -containing regimens; however, it has to be considered that possibly HUS may occur
1	0, ENT1 stomatitis  ENT1END  18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU ENT2 FA ENT2END /MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	0, ENT1 stomatitis  ENT1END  18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA ENT2 MMC ENT2END is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	The worst toxicities (%) observed were (CTC-NCI 1/2/3): ENT1 leukopenia  ENT1END 45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose ENT2 5-FU ENT2END /FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	The worst toxicities (%) observed were (CTC-NCI 1/2/3): ENT1 leukopenia  ENT1END  45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%). It may serve as an alternative to ENT2 cisplatin ENT2END -containing regimens; however, it has to be considered that possibly HUS may occur
1	The worst toxicities (%) observed were (CTC-NCI 1/2/3): ENT1 leukopenia  ENT1END  45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU ENT2 FA ENT2END /MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	The worst toxicities (%) observed were (CTC-NCI 1/2/3): ENT1 leukopenia  ENT1END  45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA ENT2 MMC ENT2END is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	PATIENTS AND METHODS: From February, 1998 to September, 2000 we recruited 33 patients with ENT1 AGC ENT1END to receive weekly 24-hour ENT2 5-FU ENT2END 2,600 mg/m(2) preceded by 2-hour FA 500 mg/m(2) for 6 weeks, followed by a 2-week rest period
0	CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for ENT1 AGC  ENT1END (objective response rate 54.6%). It may serve as an alternative to ENT2 cisplatin ENT2END -containing regimens; however, it has to be considered that possibly HUS may occur
0	CONCLUSIONS: High-dose 5-FU/ ENT1 FA  ENT1END /MMC is an effective and well-tolerated outpatient regimen for ENT2 AGC ENT2END (objective response rate 54
0	High-dose 5-fluorouracil / folinic acid in combination with three-weekly ENT1 mitomycin C  ENT1END  in the treatment of advanced ENT2 gastric cancer ENT2END
1	1/0, ENT1 diarrhea  ENT1END 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose ENT2 5-FU ENT2END /FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	1/0, ENT1 diarrhea  ENT1END  36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%). It may serve as an alternative to ENT2 cisplatin ENT2END -containing regimens; however, it has to be considered that possibly HUS may occur
1	1/0, ENT1 diarrhea  ENT1END  36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU ENT2 FA ENT2END /MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	1/0, ENT1 diarrhea  ENT1END  36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA ENT2 MMC ENT2END is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	We report a case of acute interstitial nephritis (AIN) due to nicergoline ( ENT1 Sermion ENT1END . A 50-year-old patient admitted to our hospital for ENT2 fever ENT2END and acute renal failure
0	A 50-year-old patient admitted to our hospital for ENT1 fever ENT1END  and acute renal failure. Before admission, he had been taking nicergoline and ENT2 bendazac lysine ENT2END due to retinal vein occlusion at ophthalmologic department
0	arthralgia and ENT1 fever ENT1END  and laboratory findings (i.e. eosinophilia and renal failure) suggested AIN, and which was confirmed by pathologic findings on renal biopsy. A lymphocyte transformation test demonstrated a positive result against nicergoline. Treatment was consisted of withdrawal of nicergoline and intravenous ENT2 methylprednisolone ENT2END , and his renal function was completely recovered
0	Before admission, he had been taking ENT1 nicergoline ENT1END and bendazac lysine due to retinal vein occlusion at ophthalmologic department. Thereafter, he experienced intermittent fever and ENT2 skin rash ENT2END
0	Before admission, he had been taking nicergoline and ENT1 bendazac lysine  ENT1END  due to retinal vein occlusion at ophthalmologic department. Thereafter, he experienced intermittent fever and ENT2 skin rash ENT2END
0	Thereafter, he experienced intermittent fever and ENT1 skin rash  ENT1END . On admission, clinical symptoms (i.e. arthralgia and fever) and laboratory findings (i.e. eosinophilia and renal failure) suggested AIN, and which was confirmed by pathologic findings on renal biopsy. A lymphocyte transformation test demonstrated a positive result against nicergoline. Treatment was consisted of withdrawal of nicergoline and intravenous ENT2 methylprednisolone ENT2END , and his renal function was completely recovered
1	We report a case of acute interstitial nephritis ( ENT1 AIN ENT1END  due to ENT2 nicergoline ENT2END (Sermion)
0	We report a case of acute interstitial nephritis ( ENT1 AIN  ENT1END ) due to nicergoline (Sermion). A 50-year-old patient admitted to our hospital for fever and acute renal failure. Before admission, he had been taking nicergoline and ENT2 bendazac lysine ENT2END due to retinal vein occlusion at ophthalmologic department
0	Treatment was consisted of withdrawal of nicergoline and intravenous ENT1 methylprednisolone ENT1END , and his renal function was completely recovered. To our knowledge, this is the first report of nicergoline-associated ENT2 AIN ENT2END
1	eosinophilia and ENT1 renal failure ENT1END  suggested AIN, and which was confirmed by pathologic findings on renal biopsy. A lymphocyte transformation test demonstrated a positive result against ENT2 nicergoline ENT2END
0	Before admission, he had been taking nicergoline and ENT1 bendazac lysine  ENT1END  due to retinal vein occlusion at ophthalmologic department. Thereafter, he experienced intermittent fever and skin rash. On admission, clinical symptoms (i.e. arthralgia and fever) and laboratory findings (i.e. eosinophilia and ENT2 renal failure ENT2END ) suggested AIN, and which was confirmed by pathologic findings on renal biopsy
0	eosinophilia and ENT1 renal failure  ENT1END ) suggested AIN, and which was confirmed by pathologic findings on renal biopsy. A lymphocyte transformation test demonstrated a positive result against nicergoline. Treatment was consisted of withdrawal of nicergoline and intravenous ENT2 methylprednisolone ENT2END , and his renal function was completely recovered
1	Before admission, he had been taking ENT1 nicergoline ENT1END  and bendazac lysine due to retinal vein occlusion at ophthalmologic department. Thereafter, he experienced intermittent fever and skin rash. On admission, clinical symptoms (i.e. ENT2 arthralgia ENT2END and fever) and laboratory findings (i
0	Before admission, he had been taking nicergoline and ENT1 bendazac lysine  ENT1END  due to retinal vein occlusion at ophthalmologic department. Thereafter, he experienced intermittent fever and skin rash. On admission, clinical symptoms (i.e. ENT2 arthralgia ENT2END and fever) and laboratory findings (i
0	ENT1 arthralgia  ENT1END  and fever) and laboratory findings (i.e. eosinophilia and renal failure) suggested AIN, and which was confirmed by pathologic findings on renal biopsy. A lymphocyte transformation test demonstrated a positive result against nicergoline. Treatment was consisted of withdrawal of nicergoline and intravenous ENT2 methylprednisolone ENT2END , and his renal function was completely recovered
0	Before admission, he had been taking ENT1 nicergoline ENT1END  and bendazac lysine due to ENT2 retinal vein occlusion ENT2END at ophthalmologic department
0	Before admission, he had been taking nicergoline and ENT1 bendazac lysine  ENT1END  due to ENT2 retinal vein occlusion ENT2END at ophthalmologic department
0	A 50-year-old patient admitted to our hospital for fever and ENT1 acute renal failure  ENT1END  Before admission, he had been taking ENT2 nicergoline ENT2END and bendazac lysine due to retinal vein occlusion at ophthalmologic department
0	A 50-year-old patient admitted to our hospital for fever and ENT1 acute renal failure  ENT1END . Before admission, he had been taking nicergoline and ENT2 bendazac lysine ENT2END due to retinal vein occlusion at ophthalmologic department
1	ENT1 eosinophilia  ENT1END and renal failure) suggested AIN, and which was confirmed by pathologic findings on renal biopsy. A lymphocyte transformation test demonstrated a positive result against ENT2 nicergoline ENT2END
0	Before admission, he had been taking nicergoline and ENT1 bendazac lysine  ENT1END  due to retinal vein occlusion at ophthalmologic department. Thereafter, he experienced intermittent fever and skin rash. On admission, clinical symptoms (i.e. arthralgia and fever) and laboratory findings (i.e. ENT2 eosinophilia ENT2END and renal failure) suggested AIN, and which was confirmed by pathologic findings on renal biopsy
0	ENT1 eosinophilia  ENT1END  and renal failure) suggested AIN, and which was confirmed by pathologic findings on renal biopsy. A lymphocyte transformation test demonstrated a positive result against nicergoline. Treatment was consisted of withdrawal of nicergoline and intravenous ENT2 methylprednisolone ENT2END , and his renal function was completely recovered
0	Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to ENT1 sodium pentobarbital ENT1END suggest the existence of a heretofore undescribed ENT2 cardiomyopathic disorder ENT2END induced by chronic barium exposure
0	Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed ENT1 cardiomyopathic disorder ENT1END  induced by chronic ENT2 barium ENT2END exposure
0	The lack of a similar response to ketamine and ENT1 xylazine  ENT1END anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response. Other myocardial pathophysiologic and metabolic changes induced by barium were manifest, irrespective of the anesthetic employed. The contractile element shortening velocity of the cardiac muscle fibers was significantly slower in both groups of barium-treated rats relative to the control groups, irrespective of the anesthetic regimen. Similarly, significant disturbances in myocardial energy metabolism were detected in the barium-exposed rats which were consistent with the reduced contractile element shortening velocity. In addition, the excitability of the cardiac conduction system was depressed preferentially in the atrioventricular nodal region of hearts from barium-exposed rats. Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed ENT2 cardiomyopathic disorder ENT2END induced by chronic barium exposure
0	The lack of a similar response to ENT1 ketamine  ENT1END and xylazine anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response. Other myocardial pathophysiologic and metabolic changes induced by barium were manifest, irrespective of the anesthetic employed. The contractile element shortening velocity of the cardiac muscle fibers was significantly slower in both groups of barium-treated rats relative to the control groups, irrespective of the anesthetic regimen. Similarly, significant disturbances in myocardial energy metabolism were detected in the barium-exposed rats which were consistent with the reduced contractile element shortening velocity. In addition, the excitability of the cardiac conduction system was depressed preferentially in the atrioventricular nodal region of hearts from barium-exposed rats. Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed ENT2 cardiomyopathic disorder ENT2END induced by chronic barium exposure
0	Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant barium-induced ENT1 disturbances within the cardiovascular system ENT1END  The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital. Under ENT2 barbiturate ENT2END anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats
0	ENT1 Cardiovascular dysfunction  ENT1END  and hypersensitivity to ENT2 sodium pentobarbital ENT2END induced by chronic barium chloride ingestion
0	ENT1 Cardiovascular dysfunction  ENT1END  and hypersensitivity to sodium pentobarbital induced by chronic ENT2 barium chloride ENT2END ingestion
0	Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant ENT1 barium  ENT1END induced ENT2 disturbances within the cardiovascular system ENT2END
0	Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant barium-induced ENT1 disturbances within the cardiovascular system  ENT1END . The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital. Under barbiturate anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats. The lack of a similar response to ketamine and ENT2 xylazine ENT2END anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response
0	Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant barium-induced ENT1 disturbances within the cardiovascular system  ENT1END . The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital. Under barbiturate anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats. The lack of a similar response to ENT2 ketamine ENT2END and xylazine anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response
0	The most distinctive aspect of the barium effect was a demonstrated ENT1 hypersensitivity  ENT1END of the cardiovascular system to sodium pentobarbital. Under ENT2 barbiturate ENT2END anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats
0	Cardiovascular dysfunction and ENT1 hypersensitivity  ENT1END  to ENT2 sodium pentobarbital ENT2END induced by chronic barium chloride ingestion
0	Cardiovascular dysfunction and ENT1 hypersensitivity  ENT1END  to sodium pentobarbital induced by chronic ENT2 barium chloride ENT2END ingestion
0	The most distinctive aspect of the ENT1 barium  ENT1END effect was a demonstrated ENT2 hypersensitivity ENT2END of the cardiovascular system to sodium pentobarbital
0	The most distinctive aspect of the barium effect was a demonstrated ENT1 hypersensitivity  ENT1END  of the cardiovascular system to sodium pentobarbital. Under barbiturate anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats. The lack of a similar response to ketamine and ENT2 xylazine ENT2END anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response
0	The most distinctive aspect of the barium effect was a demonstrated ENT1 hypersensitivity  ENT1END  of the cardiovascular system to sodium pentobarbital. Under barbiturate anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats. The lack of a similar response to ENT2 ketamine ENT2END and xylazine anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response
0	Barium-supplemented Long-Evans hooded rats were characterized by a persistent ENT1 hypertension  ENT1END that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment. Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant barium-induced disturbances within the cardiovascular system. The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital. Under ENT2 barbiturate ENT2END anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats
0	Cardiovascular dysfunction and hypersensitivity to ENT1 sodium pentobarbital  ENT1END  induced by chronic barium chloride ingestion.Barium-supplemented Long-Evans hooded rats were characterized by a persistent ENT2 hypertension ENT2END that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment
1	Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic ENT1 barium chloride  ENT1END  ingestion.Barium-supplemented Long-Evans hooded rats were characterized by a persistent ENT2 hypertension ENT2END that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment
0	Barium-supplemented Long-Evans hooded rats were characterized by a persistent ENT1 hypertension ENT1END  that was evident after 1 month of ENT2 barium ENT2END (100 micrograms/ml mineral fortified water) treatment
0	Barium-supplemented Long-Evans hooded rats were characterized by a persistent ENT1 hypertension  ENT1END  that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment. Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant barium-induced disturbances within the cardiovascular system. The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital. Under barbiturate anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats. The lack of a similar response to ketamine and ENT2 xylazine ENT2END anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response
0	Barium-supplemented Long-Evans hooded rats were characterized by a persistent ENT1 hypertension  ENT1END  that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment. Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant barium-induced disturbances within the cardiovascular system. The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital. Under barbiturate anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats. The lack of a similar response to ENT2 ketamine ENT2END and xylazine anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response
0	Overall, the altered cardiac contractility and excitability characteristics, the myocardial ENT1 metabolic disturbances  ENT1END  and the hypersensitivity of the cardiovascular system to ENT2 sodium pentobarbital ENT2END suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure
0	In addition, the excitability of the cardiac conduction system was depressed preferentially in the atrioventricular nodal region of hearts from ENT1 barium  ENT1END exposed rats. Overall, the altered cardiac contractility and excitability characteristics, the myocardial ENT2 metabolic disturbances ENT2END , and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure
0	The lack of a similar response to ketamine and ENT1 xylazine  ENT1END  anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response. Other myocardial pathophysiologic and metabolic changes induced by barium were manifest, irrespective of the anesthetic employed. The contractile element shortening velocity of the cardiac muscle fibers was significantly slower in both groups of barium-treated rats relative to the control groups, irrespective of the anesthetic regimen. Similarly, significant disturbances in myocardial energy metabolism were detected in the barium-exposed rats which were consistent with the reduced contractile element shortening velocity. In addition, the excitability of the cardiac conduction system was depressed preferentially in the atrioventricular nodal region of hearts from barium-exposed rats. Overall, the altered cardiac contractility and excitability characteristics, the myocardial ENT2 metabolic disturbances ENT2END , and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure
0	The lack of a similar response to ENT1 ketamine  ENT1END  and xylazine anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response. Other myocardial pathophysiologic and metabolic changes induced by barium were manifest, irrespective of the anesthetic employed. The contractile element shortening velocity of the cardiac muscle fibers was significantly slower in both groups of barium-treated rats relative to the control groups, irrespective of the anesthetic regimen. Similarly, significant disturbances in myocardial energy metabolism were detected in the barium-exposed rats which were consistent with the reduced contractile element shortening velocity. In addition, the excitability of the cardiac conduction system was depressed preferentially in the atrioventricular nodal region of hearts from barium-exposed rats. Overall, the altered cardiac contractility and excitability characteristics, the myocardial ENT2 metabolic disturbances ENT2END , and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure
0	A 77-year-old woman with refractory ENT1 multiple myeloma ENT1END was treated with a 4-day continuous intravenous infusion of vincristine and ENT2 doxorubicin ENT2END and 4 days of oral dexamethasone
0	Syndrome of inappropriate secretion of antidiuretic hormone after infusional ENT1 vincristine  ENT1END .A 77-year-old woman with refractory ENT2 multiple myeloma ENT2END was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone
0	A 77-year-old woman with refractory ENT1 multiple myeloma ENT1END  was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral ENT2 dexamethasone ENT2END
0	A 77-year-old woman with refractory ENT1 multiple myeloma ENT1END  was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone. Nine days after her second cycle she presented with lethargy and weakness associated with hyponatremia. Evaluation revealed the syndrome of inappropriate secretion of antidiuretic hormone, which was attributed to the vincristine infusion. After normal serum ENT2 sodium ENT2END levels returned, further doxorubicin and dexamethasone chemotherapy without vincristine did not produce this complication
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and ENT1 doxorubicin ENT1END  and 4 days of oral dexamethasone. Nine days after her second cycle she presented with ENT2 lethargy ENT2END and weakness associated with hyponatremia
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of ENT1 vincristine  ENT1END and doxorubicin and 4 days of oral dexamethasone. Nine days after her second cycle she presented with ENT2 lethargy ENT2END and weakness associated with hyponatremia
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral ENT1 dexamethasone  ENT1END . Nine days after her second cycle she presented with ENT2 lethargy ENT2END and weakness associated with hyponatremia
0	Nine days after her second cycle she presented with ENT1 lethargy  ENT1END  and weakness associated with hyponatremia. Evaluation revealed the syndrome of inappropriate secretion of antidiuretic hormone, which was attributed to the vincristine infusion. After normal serum ENT2 sodium ENT2END levels returned, further doxorubicin and dexamethasone chemotherapy without vincristine did not produce this complication
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and ENT1 doxorubicin ENT1END  and 4 days of oral dexamethasone. Nine days after her second cycle she presented with lethargy and ENT2 weakness ENT2END associated with hyponatremia
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of ENT1 vincristine  ENT1END  and doxorubicin and 4 days of oral dexamethasone. Nine days after her second cycle she presented with lethargy and ENT2 weakness ENT2END associated with hyponatremia
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral ENT1 dexamethasone  ENT1END . Nine days after her second cycle she presented with lethargy and ENT2 weakness ENT2END associated with hyponatremia
0	Nine days after her second cycle she presented with lethargy and ENT1 weakness  ENT1END  associated with hyponatremia. Evaluation revealed the syndrome of inappropriate secretion of antidiuretic hormone, which was attributed to the vincristine infusion. After normal serum ENT2 sodium ENT2END levels returned, further doxorubicin and dexamethasone chemotherapy without vincristine did not produce this complication
0	Evaluation revealed the ENT1 syndrome of inappropriate secretion of antidiuretic hormone ENT1END  which was attributed to the vincristine infusion. After normal serum sodium levels returned, further ENT2 doxorubicin ENT2END and dexamethasone chemotherapy without vincristine did not produce this complication
1	ENT1 Syndrome of inappropriate secretion of antidiuretic hormone  ENT1END  after infusional ENT2 vincristine ENT2END
0	Evaluation revealed the ENT1 syndrome of inappropriate secretion of antidiuretic hormone ENT1END , which was attributed to the vincristine infusion. After normal serum sodium levels returned, further doxorubicin and ENT2 dexamethasone ENT2END chemotherapy without vincristine did not produce this complication
0	Evaluation revealed the ENT1 syndrome of inappropriate secretion of antidiuretic hormone  ENT1END , which was attributed to the vincristine infusion. After normal serum ENT2 sodium ENT2END levels returned, further doxorubicin and dexamethasone chemotherapy without vincristine did not produce this complication
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and ENT1 doxorubicin ENT1END  and 4 days of oral dexamethasone. Nine days after her second cycle she presented with lethargy and weakness associated with ENT2 hyponatremia ENT2END
0	Nine days after her second cycle she presented with lethargy and weakness associated with ENT1 hyponatremia ENT1END . Evaluation revealed the syndrome of inappropriate secretion of antidiuretic hormone, which was attributed to the ENT2 vincristine ENT2END infusion
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral ENT1 dexamethasone  ENT1END . Nine days after her second cycle she presented with lethargy and weakness associated with ENT2 hyponatremia ENT2END
0	Nine days after her second cycle she presented with lethargy and weakness associated with ENT1 hyponatremia  ENT1END . Evaluation revealed the syndrome of inappropriate secretion of antidiuretic hormone, which was attributed to the vincristine infusion. After normal serum ENT2 sodium ENT2END levels returned, further doxorubicin and dexamethasone chemotherapy without vincristine did not produce this complication
1	ENT1 Penicillamine  ENT1END -related ENT2 lichenoid dermatitis ENT2END and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities
0	Penicillamine-related ENT1 lichenoid dermatitis ENT1END  and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.Wilson's disease is an autosomal recessive disorder of hepatic ENT2 copper ENT2END metabolism with consequent copper accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders
0	During the follow-up of our patient, penicillamine was interrupted after the appearance of a ENT1 lichenoid dermatitis ENT1END  and ENT2 zinc acetate ENT2END permitted to continue the successful treatment of the patient without side-effects
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent ENT1 hepatic, neurologic and psychiatric disorders ENT1END  We report a case of Wilson's disease with chronic liver disease; moreover, in our patient, presenting also with high levels of state anxiety without depression, 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, ENT2 penicillamine ENT2END was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent ENT1 copper  ENT1END accumulation and toxicity in many tissues and consequent ENT2 hepatic, neurologic and psychiatric disorders ENT2END
0	Penicillamine-related lichenoid dermatitis and utility of ENT1 zinc acetate  ENT1END  in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent ENT2 hepatic, neurologic and psychiatric disorders ENT2END
0	ENT1 Penicillamine ENT1END -related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and ENT2 toxicity ENT2END in many tissues and consequent hepatic, neurologic and psychiatric disorders
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent ENT1 copper  ENT1END  accumulation and ENT2 toxicity ENT2END in many tissues and consequent hepatic, neurologic and psychiatric disorders
0	Penicillamine-related lichenoid dermatitis and utility of ENT1 zinc acetate  ENT1END  in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and ENT2 toxicity ENT2END in many tissues and consequent hepatic, neurologic and psychiatric disorders
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent ENT1 hepatic, neurologic and psychiatric disorders  ENT1END  We report a case of Wilson's disease with chronic liver disease; moreover, in our patient, presenting also with high levels of state anxiety without depression, 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, ENT2 penicillamine ENT2END was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent ENT1 copper  ENT1END  accumulation and toxicity in many tissues and consequent ENT2 hepatic, neurologic and psychiatric disorders ENT2END
0	Penicillamine-related lichenoid dermatitis and utility of ENT1 zinc acetate  ENT1END  in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent ENT2 hepatic, neurologic and psychiatric disorders ENT2END
0	ENT1 Penicillamine  ENT1END -related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, ENT2 anxiety ENT2END and SPECT abnormalities
0	Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, ENT1 anxiety  ENT1END  and SPECT abnormalities.Wilson's disease is an autosomal recessive disorder of hepatic ENT2 copper ENT2END metabolism with consequent copper accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders
0	Penicillamine-related lichenoid dermatitis and utility of ENT1 zinc acetate  ENT1END  in a Wilson disease patient with hepatic presentation, ENT2 anxiety ENT2END and SPECT abnormalities
0	We report a case of Wilson's disease with ENT1 chronic liver disease  ENT1END  moreover, in our patient, presenting also with high levels of state anxiety without depression, 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, ENT2 penicillamine ENT2END was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent ENT1 copper  ENT1END  accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders. We report a case of Wilson's disease with ENT2 chronic liver disease ENT2END ; moreover, in our patient, presenting also with high levels of state anxiety without depression, 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe
0	We report a case of Wilson's disease with ENT1 chronic liver disease  ENT1END ; moreover, in our patient, presenting also with high levels of state anxiety without depression, 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, penicillamine was interrupted after the appearance of a lichenoid dermatitis, and ENT2 zinc acetate ENT2END permitted to continue the successful treatment of the patient without side-effects
0	Since most of Wilson's disease ENT1 penicillamine ENT1END treated patients do not seem to develop this ENT2 skin lesion ENT2END , it could be conceivable that a specific genetic factor is involved in drug response
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent ENT1 copper  ENT1END  accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders. We report a case of Wilson's disease with chronic liver disease; moreover, in our patient, presenting also with high levels of state anxiety without depression, 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, penicillamine was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects. In our case the therapy with zinc acetate represented an effective treatment for a Wilson's disease patient in which penicillamine-related side effects appeared. The safety of the zinc acetate allowed us to avoid other potentially toxic chelating drugs; this observation is in line with the growing evidence on the efficacy of the drug in the treatment of Wilson's disease. Since most of Wilson's disease penicillamine-treated patients do not seem to develop this ENT2 skin lesion ENT2END , it could be conceivable that a specific genetic factor is involved in drug response
0	The safety of the ENT1 zinc acetate  ENT1END allowed us to avoid other potentially toxic chelating drugs; this observation is in line with the growing evidence on the efficacy of the drug in the treatment of Wilson's disease. Since most of Wilson's disease penicillamine-treated patients do not seem to develop this ENT2 skin lesion ENT2END , it could be conceivable that a specific genetic factor is involved in drug response
0	Since most of ENT1 Wilson's disease ENT1END ENT2 penicillamine ENT2END -treated patients do not seem to develop this skin lesion, it could be conceivable that a specific genetic factor is involved in drug response
0	ENT1 Wilson's disease  ENT1END is an autosomal recessive disorder of hepatic ENT2 copper ENT2END metabolism with consequent copper accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders
0	Penicillamine-related lichenoid dermatitis and utility of ENT1 zinc acetate  ENT1END  in a ENT2 Wilson disease ENT2END patient with hepatic presentation, anxiety and SPECT abnormalities
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent ENT1 hepatic, neurologic and psychiatric disorders  ENT1END  We report a case of Wilson's disease with chronic liver disease; moreover, in our patient, presenting also with high levels of state anxiety without depression, 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, ENT2 penicillamine ENT2END was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent ENT1 copper  ENT1END  accumulation and toxicity in many tissues and consequent ENT2 hepatic, neurologic and psychiatric disorders ENT2END
0	Penicillamine-related lichenoid dermatitis and utility of ENT1 zinc acetate  ENT1END  in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent ENT2 hepatic, neurologic and psychiatric disorders ENT2END
0	We report a case of Wilson's disease with chronic liver disease; moreover, in our patient, presenting also with high levels of state anxiety without ENT1 depression  ENT1END  99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, ENT2 penicillamine ENT2END was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent ENT1 copper  ENT1END  accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders. We report a case of Wilson's disease with chronic liver disease; moreover, in our patient, presenting also with high levels of state anxiety without ENT2 depression ENT2END , 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe
0	We report a case of Wilson's disease with chronic liver disease; moreover, in our patient, presenting also with high levels of state anxiety without ENT1 depression  ENT1END , 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, penicillamine was interrupted after the appearance of a lichenoid dermatitis, and ENT2 zinc acetate ENT2END permitted to continue the successful treatment of the patient without side-effects
1	BACKGROUND: ENT1 Acetaminophen ENT1END induced ENT2 hepatotoxicity ENT2END is the most common cause of acute liver failure (ALF) in the UK
1	AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for ENT1 acetaminophen ENT1END induced ENT2 ALF ENT2END (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34)
0	AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease ( ENT1 CLD ENT1END  n=34). RESULTS: ENT2 Acetaminophen ENT2END -induced ALF patients undergoing LT had a greater severity of pre-LT illness reflected by higher Acute Physiology and Chronic Health Evaluation II scores and requirement for organ support compared with the other two groups
0	We report the case of a 35-year-old patient suffering from ENT1 schizo-affective disorder ENT1END since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and ENT2 lithium ENT2END (1200 mg/day) (serum lithium=0
0	We report the case of a 35-year-old patient suffering from ENT1 schizo-affective disorder ENT1END  since the age of 19 years, treated by a combination of first-generation antipsychotics, ENT2 zuclopenthixol ENT2END (100 mg/day) and lithium (1200 mg/day) (serum lithium=0
0	Paradoxical severe agitation induced by add-on high-doses ENT1 quetiapine  ENT1END  in ENT2 schizo-affective disorder ENT2END
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum ENT1 lithium ENT1END 0.85 mEq/l). This patient had no associated personality disorder (particularly no antisocial disorder) and no substance abuse disorder. Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder. The diagnoses of ENT2 manic ENT2END shift and akathisia were dismissed
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, ENT1 zuclopenthixol  ENT1END  (100 mg/day) and lithium (1200 mg/day) (serum lithium=0.85 mEq/l). This patient had no associated personality disorder (particularly no antisocial disorder) and no substance abuse disorder. Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder. The diagnoses of ENT2 manic ENT2END shift and akathisia were dismissed
0	The diagnoses of ENT1 manic ENT1END  shift and akathisia were dismissed. The withdrawal and the gradual reintroduction of ENT2 quetiapine ENT2END 2 weeks later, which led to another severe agitation, enabled us to attribute the agitation specifically to quetiapine
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum ENT1 lithium ENT1END =0.85 mEq/l). This patient had no associated personality disorder (particularly no antisocial disorder) and no ENT2 substance abuse disorder ENT2END
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, ENT1 zuclopenthixol  ENT1END  (100 mg/day) and lithium (1200 mg/day) (serum lithium=0.85 mEq/l). This patient had no associated personality disorder (particularly no antisocial disorder) and no ENT2 substance abuse disorder ENT2END
0	This patient had no associated personality disorder (particularly no antisocial disorder) and no ENT1 substance abuse disorder ENT1END . Within the 48 h following the gradual introduction of ENT2 quetiapine ENT2END (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum ENT1 lithium ENT1END =0.85 mEq/l). This patient had no associated personality disorder (particularly no ENT2 antisocial disorder ENT2END ) and no substance abuse disorder
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, ENT1 zuclopenthixol  ENT1END  (100 mg/day) and lithium (1200 mg/day) (serum lithium=0.85 mEq/l). This patient had no associated personality disorder (particularly no ENT2 antisocial disorder ENT2END ) and no substance abuse disorder
0	This patient had no associated personality disorder (particularly no ENT1 antisocial disorder  ENT1END ) and no substance abuse disorder. Within the 48 h following the gradual introduction of ENT2 quetiapine ENT2END (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum ENT1 lithium ENT1END =0.85 mEq/l). This patient had no associated personality disorder (particularly no antisocial disorder) and no substance abuse disorder. Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe ENT2 agitation ENT2END without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder
0	Paradoxical severe ENT1 agitation  ENT1END  induced by add-on high-doses quetiapine in schizo-affective disorder.We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, ENT2 zuclopenthixol ENT2END (100 mg/day) and lithium (1200 mg/day) (serum lithium=0
1	The withdrawal and the gradual reintroduction of quetiapine 2 weeks later, which led to another severe agitation, enabled us to attribute the ENT1 agitation ENT1END specifically to ENT2 quetiapine ENT2END
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum ENT1 lithium ENT1END =0.85 mEq/l). This patient had no associated personality disorder (particularly no antisocial disorder) and no substance abuse disorder. Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder. The diagnoses of manic shift and ENT2 akathisia ENT2END were dismissed
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, ENT1 zuclopenthixol  ENT1END  (100 mg/day) and lithium (1200 mg/day) (serum lithium=0.85 mEq/l). This patient had no associated personality disorder (particularly no antisocial disorder) and no substance abuse disorder. Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder. The diagnoses of manic shift and ENT2 akathisia ENT2END were dismissed
0	The diagnoses of manic shift and ENT1 akathisia  ENT1END  were dismissed. The withdrawal and the gradual reintroduction of ENT2 quetiapine ENT2END 2 weeks later, which led to another severe agitation, enabled us to attribute the agitation specifically to quetiapine
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum ENT1 lithium ENT1END =0.85 mEq/l). This patient had no associated ENT2 personality disorder ENT2END (particularly no antisocial disorder) and no substance abuse disorder
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, ENT1 zuclopenthixol  ENT1END  (100 mg/day) and lithium (1200 mg/day) (serum lithium=0.85 mEq/l). This patient had no associated ENT2 personality disorder ENT2END (particularly no antisocial disorder) and no substance abuse disorder
0	Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or ENT1 personality disorder  ENT1END  The diagnoses of manic shift and akathisia were dismissed. The withdrawal and the gradual reintroduction of ENT2 quetiapine ENT2END 2 weeks later, which led to another severe agitation, enabled us to attribute the agitation specifically to quetiapine
0	Increase in intragastric pressure during suxamethonium-induced ENT1 muscle fasciculations  ENT1END  in children: inhibition by ENT2 alfentanil ENT2END
0	Anaesthesia was induced with ENT1 thiopentone ENT1END 5 mg kg-1. The incidence and intensity of ENT2 muscle fasciculations ENT2END caused by suxamethonium were significantly greater in the control than in the alfentanil group
1	Increase in intragastric pressure during ENT1 suxamethonium  ENT1END -induced ENT2 muscle fasciculations ENT2END in children: inhibition by alfentanil
0	The intragastric pressure during ENT1 muscle fasciculations ENT1END was significantly higher in the control group (16 +/- 0.7 (SEM) cm ENT2 H2O ENT2END ) than in the alfentanil group (7
1	Both isomers of propranolol were capable of preventing adrenaline-induced ENT1 cardiac arrhythmias ENT1END in cats anaesthetized with ENT2 halothane ENT2END , but the mean dose of (-)-propranolol was 0
0	(+)-Propranolol had no effect on fatty acid mobilization but significantly reduced the increments in both ENT1 lactate  ENT1END and glucose.4. Both isomers of propranolol possessed similar depressant potency on isolated atrial muscle taken from guinea-pigs.5. The isomers of propranolol exhibited similar local anaesthetic potencies on an isolated frog nerve preparation at a level approximately three times that of procaine. The racemic compound was significantly less potent than either isomer.6. Both isomers of propranolol were capable of preventing adrenaline-induced ENT2 cardiac arrhythmias ENT2END in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0
0	Blockade of ENT1 arrhythmias ENT1END with both isomers was surmountable by increasing the dose of adrenaline.7. Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ENT2 ouabain ENT2END in anaesthetized cats and dogs
0	(+)-Propranolol had no effect on fatty acid mobilization but significantly reduced the increments in both lactate and ENT1 glucose  ENT1END 4. Both isomers of propranolol possessed similar depressant potency on isolated atrial muscle taken from guinea-pigs.5. The isomers of propranolol exhibited similar local anaesthetic potencies on an isolated frog nerve preparation at a level approximately three times that of procaine. The racemic compound was significantly less potent than either isomer.6. Both isomers of propranolol were capable of preventing adrenaline-induced ENT2 cardiac arrhythmias ENT2END in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0
1	Both isomers of propranolol were capable of preventing ENT1 adrenaline  ENT1END induced ENT2 cardiac arrhythmias ENT2END in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0
0	The isomers of propranolol exhibited similar local anaesthetic potencies on an isolated frog nerve preparation at a level approximately three times that of ENT1 procaine  ENT1END  The racemic compound was significantly less potent than either isomer.6. Both isomers of propranolol were capable of preventing adrenaline-induced ENT2 cardiac arrhythmias ENT2END in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0
0	The biological properties of the optical isomers of propranolol and their effects on ENT1 cardiac arrhythmias ENT1END .1. The optical isomers of propranolol have been compared for their beta-blocking and antiarrhythmic activities.2. In blocking the positive inotropic and chronotropic responses to ENT2 isoprenaline ENT2END , (+)-propranolol had less than one hundredth the potency of (-)-propranolol
0	(+)-Propranolol had no effect on ENT1 fatty acid  ENT1END mobilization but significantly reduced the increments in both lactate and glucose.4. Both isomers of propranolol possessed similar depressant potency on isolated atrial muscle taken from guinea-pigs.5. The isomers of propranolol exhibited similar local anaesthetic potencies on an isolated frog nerve preparation at a level approximately three times that of procaine. The racemic compound was significantly less potent than either isomer.6. Both isomers of propranolol were capable of preventing adrenaline-induced ENT2 cardiac arrhythmias ENT2END in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0
0	The biological properties of the optical isomers of ENT1 propranolol  ENT1END  and their effects on ENT2 cardiac arrhythmias ENT2END
0	Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with ENT1 halothane ENT1END , but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg. At the effective dose level of (+)-propranolol there was a significant prolongation of the PR interval of the electrocardiogram. Blockade of arrhythmias with both isomers was surmountable by increasing the dose of adrenaline.7. Both isomers of propranolol were also capable of reversing ENT2 ventricular tachycardia ENT2END caused by ouabain in anaesthetized cats and dogs
1	Both isomers of propranolol were also capable of reversing ENT1 ventricular tachycardia  ENT1END  caused by ENT2 ouabain ENT2END in anaesthetized cats and dogs
0	Blockade of arrhythmias with both isomers was surmountable by increasing the dose of ENT1 adrenaline  ENT1END 7. Both isomers of propranolol were also capable of reversing ENT2 ventricular tachycardia ENT2END caused by ouabain in anaesthetized cats and dogs
0	The isomers of propranolol exhibited similar local anaesthetic potencies on an isolated frog nerve preparation at a level approximately three times that of ENT1 procaine  ENT1END . The racemic compound was significantly less potent than either isomer.6. Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg. At the effective dose level of (+)-propranolol there was a significant prolongation of the PR interval of the electrocardiogram. Blockade of arrhythmias with both isomers was surmountable by increasing the dose of adrenaline.7. Both isomers of propranolol were also capable of reversing ENT2 ventricular tachycardia ENT2END caused by ouabain in anaesthetized cats and dogs
0	Both isomers of ENT1 propranolol  ENT1END were also capable of reversing ENT2 ventricular tachycardia ENT2END caused by ouabain in anaesthetized cats and dogs
1	ENT1 Thoracic hematomyelia  ENT1END  secondary to ENT2 coumadin ENT2END anticoagulant therapy: a case report
1	In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin ( ENT1 STZ ENT1END  induced ENT2 memory impaired ENT2END rats was explored
0	In experiment set up 1: ENT1 Memory deficit ENT1END was found in Morris water maze test on 14-16 days after STZ (ICV; 3mg/Kg) administration. STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and neuroinflammation. STZ also significantly increased the level of ROS, nitrite, ENT2 Ca ENT2END (2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity
0	In experiment set up 1: ENT1 Memory deficit ENT1END  was found in Morris water maze test on 14-16 days after STZ (ICV; 3mg/Kg) administration. STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and neuroinflammation. STZ also significantly increased the level of ROS, ENT2 nitrite ENT2END , Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity
0	In the present study the role of glial activation and post synaptic ENT1 toxicity ENT1END in ICV ENT2 Streptozotocin ENT2END (STZ) induced memory impaired rats was explored
0	STZ also significantly increased the level of ROS, nitrite, ENT1 Ca ENT1END (2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and ENT2 excitotoxicity ENT2END
0	STZ also significantly increased the level of ROS, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and ENT1 excitotoxicity ENT1END . Increased expression and activity of Caspase-3 was also observed in STZ treated rat which specify apoptotic cell death in hippocampus and cortex. STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity. Oral treatment with ENT2 Memantine ENT2END (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain
0	STZ also significantly increased the level of ROS, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and ENT1 excitotoxicity ENT1END . Increased expression and activity of Caspase-3 was also observed in STZ treated rat which specify apoptotic cell death in hippocampus and cortex. STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity. Oral treatment with Memantine (10mg/kg) and ENT2 Ibuprofen ENT2END (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain
0	STZ also significantly increased the level of ROS, ENT1 nitrite  ENT1END , Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and ENT2 excitotoxicity ENT2END
0	Present study clearly suggests that glial activation and post synaptic ENT1 neurotoxicity ENT1END are the key factors in ENT2 STZ ENT2END induced memory impairment and neuronal cell death
0	On the other hand, apoptotic marker, synaptic markers, mitochondrial activity and ENT1 Ca  ENT1END 2+) levels remained unaffected. Collective data indicates that neuroinflammatory process and oxidative stress occurs earlier to apoptosis and does not affect memory function. Present study clearly suggests that glial activation and post synaptic ENT2 neurotoxicity ENT2END are the key factors in STZ induced memory impairment and neuronal cell death
0	STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic ENT1 neurotoxicity  ENT1END  Oral treatment with ENT2 Memantine ENT2END (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain
0	STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic ENT1 neurotoxicity  ENT1END . Oral treatment with Memantine (10mg/kg) and ENT2 Ibuprofen ENT2END (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain
0	Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic ENT1 neurotoxicity ENT1END in rat brain. Further, in experiment set up 2: where memory function was not affected i.e. 7-9 days after STZ treatment. The level of GFAP, CD11b, TNF-a, ROS and ENT2 nitrite ENT2END levels were increased
1	STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and ENT1 neuroinflammation ENT1END  ENT2 STZ ENT2END also significantly increased the level of ROS, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity
0	STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and ENT1 neuroinflammation  ENT1END . STZ also significantly increased the level of ROS, nitrite, ENT2 Ca ENT2END (2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity
0	Oral treatment with ENT1 Memantine ENT1END  (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain. Further, in experiment set up 2: where memory function was not affected i.e. 7-9 days after STZ treatment. The level of GFAP, CD11b, TNF-a, ROS and nitrite levels were increased. On the other hand, apoptotic marker, synaptic markers, mitochondrial activity and Ca(2+) levels remained unaffected. Collective data indicates that ENT2 neuroinflammatory ENT2END process and oxidative stress occurs earlier to apoptosis and does not affect memory function
0	Oral treatment with Memantine (10mg/kg) and ENT1 Ibuprofen  ENT1END  (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain. Further, in experiment set up 2: where memory function was not affected i.e. 7-9 days after STZ treatment. The level of GFAP, CD11b, TNF-a, ROS and nitrite levels were increased. On the other hand, apoptotic marker, synaptic markers, mitochondrial activity and Ca(2+) levels remained unaffected. Collective data indicates that ENT2 neuroinflammatory ENT2END process and oxidative stress occurs earlier to apoptosis and does not affect memory function
0	STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and ENT1 neuroinflammation  ENT1END . STZ also significantly increased the level of ROS, ENT2 nitrite ENT2END , Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity
0	The selective deficit in fear recognition accuracy manifested by the RC group cannot be explained by the subacute effects of cocaine, or ENT1 ecstasy ENT1END  because recent and less recent users of these drugs within this group were similarly impaired. Possible parallels between RC users and ENT2 psychopaths ENT2END with respect to impaired fear recognition, amygdala dysfunction, and etiology are discussed
0	The selective deficit in fear recognition accuracy manifested by the RC group cannot be explained by the subacute effects of ENT1 cocaine  ENT1END  or ecstasy, because recent and less recent users of these drugs within this group were similarly impaired. Possible parallels between RC users and ENT2 psychopaths ENT2END with respect to impaired fear recognition, amygdala dysfunction, and etiology are discussed
0	The selective ENT1 deficit in fear recognition  ENT1END accuracy manifested by the RC group cannot be explained by the subacute effects of cocaine, or ENT2 ecstasy ENT2END , because recent and less recent users of these drugs within this group were similarly impaired
1	ENT1 Impaired fear recognition  ENT1END  in regular recreational ENT2 cocaine ENT2END users
1	Administration of flutamide, letrozole or ENT1 tamoxifen ENT1END significantly ENT2 impaired the memory ENT2END in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment
0	AIM: To study the effects of testosterone on streptozotocin (STZ)-induced ENT1 memory impairment ENT1END in male rats. METHODS: Adult male Wistar rats were intracerebroventricularly (icv) infused with STZ (750 ug) on d 1 and d 3, and a passive avoidance task was assessed 2 weeks after the first injection of STZ. Castration surgery was performed in another group of rats, and the passive avoidance task was assessed 4 weeks after the operation. Testosterone (1 mg.kg(-1).d(-1), sc), the ENT2 androgen ENT2END receptor antagonist flutamide (10 mg
0	Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced ENT1 memory impairment ENT1END  CONCLUSION: ENT2 Testosterone ENT2END administration ameliorates STZ- and castration-induced memory impairment in male Wistar rats
1	AIM: To study the effects of testosterone on streptozotocin ( ENT1 STZ  ENT1END -induced ENT2 memory impairment ENT2END in male rats
1	Administration of flutamide, ENT1 letrozole  ENT1END or tamoxifen significantly ENT2 impaired the memory ENT2END in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment
1	Administration of ENT1 flutamide  ENT1END  letrozole or tamoxifen significantly ENT2 impaired the memory ENT2END in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment
0	AIM: To study the effects of testosterone on streptozotocin (STZ)-induced ENT1 memory impairment ENT1END  in male rats. METHODS: Adult male Wistar rats were intracerebroventricularly (icv) infused with STZ (750 ug) on d 1 and d 3, and a passive avoidance task was assessed 2 weeks after the first injection of STZ. Castration surgery was performed in another group of rats, and the passive avoidance task was assessed 4 weeks after the operation. Testosterone (1 mg.kg(-1).d(-1), sc), the androgen receptor antagonist flutamide (10 mg.kg(-1).d(-1), ip), the ENT2 estrogen ENT2END receptor antagonist tamoxifen (1 mg
0	A 54-year-old man with severe left ventricular dysfunction due to ENT1 dilated cardiomyopathy ENT1END was referred to our hospital for symptomatic incessant sustained ventricular tachycardia (VT). After the administration of nifekalant hydrochloride, sustained VT was terminated. An alternate class III agent, sotalol, was also effective for the prevention of VT. However, one month after switching over nifekalant to sotalol, a short duration of ST elevation was documented in ECG monitoring at almost the same time for three consecutive days. ST elevation with chest discomfort disappeared since he began taking long-acting ENT2 diltiazem ENT2END
0	ENT1 Sotalol  ENT1END -induced coronary spasm in a patient with ENT2 dilated cardiomyopathy ENT2END associated with sustained ventricular tachycardia
0	A 54-year-old man with severe left ventricular dysfunction due to ENT1 dilated cardiomyopathy ENT1END  was referred to our hospital for symptomatic incessant sustained ventricular tachycardia (VT). After the administration of ENT2 nifekalant hydrochloride ENT2END , sustained VT was terminated
0	A 54-year-old man with severe left ENT1 ventricular dysfunction  ENT1END due to dilated cardiomyopathy was referred to our hospital for symptomatic incessant sustained ventricular tachycardia (VT). After the administration of nifekalant hydrochloride, sustained VT was terminated. An alternate class III agent, sotalol, was also effective for the prevention of VT. However, one month after switching over nifekalant to sotalol, a short duration of ST elevation was documented in ECG monitoring at almost the same time for three consecutive days. ST elevation with chest discomfort disappeared since he began taking long-acting ENT2 diltiazem ENT2END
0	ENT1 Sotalol  ENT1END -induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia.A 54-year-old man with severe left ENT2 ventricular dysfunction ENT2END due to dilated cardiomyopathy was referred to our hospital for symptomatic incessant sustained ventricular tachycardia (VT)
0	A 54-year-old man with severe left ENT1 ventricular dysfunction  ENT1END  due to dilated cardiomyopathy was referred to our hospital for symptomatic incessant sustained ventricular tachycardia (VT). After the administration of ENT2 nifekalant hydrochloride ENT2END , sustained VT was terminated
0	An alternate class III agent, sotalol, was also effective for the prevention of ENT1 VT  ENT1END  However, one month after switching over nifekalant to sotalol, a short duration of ST elevation was documented in ECG monitoring at almost the same time for three consecutive days. ST elevation with chest discomfort disappeared since he began taking long-acting ENT2 diltiazem ENT2END
0	An alternate class III agent, ENT1 sotalol  ENT1END  was also effective for the prevention of ENT2 VT ENT2END
0	After the administration of ENT1 nifekalant hydrochloride ENT1END , sustained ENT2 VT ENT2END was terminated
0	ST elevation with chest discomfort disappeared since he began taking long-acting ENT1 diltiazem ENT1END . ENT2 Coronary vasospasm ENT2END may be induced by the non-selective beta-blocking properties of sotalol
1	ENT1 Sotalol  ENT1END -induced ENT2 coronary spasm ENT2END in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia
0	However, one month after switching over ENT1 nifekalant  ENT1END to sotalol, a short duration of ST elevation was documented in ECG monitoring at almost the same time for three consecutive days. ST elevation with chest discomfort disappeared since he began taking long-acting diltiazem. ENT2 Coronary vasospasm ENT2END may be induced by the non-selective beta-blocking properties of sotalol
1	The current study identified the optimal dose of rocuronium to prevent ENT1 succinylcholine ENT1END induced ENT2 fasciculation ENT2END and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine
0	Optimal precurarizing dose of ENT1 rocuronium  ENT1END  to decrease ENT2 fasciculation ENT2END and myalgia following succinylcholine administration
1	Optimal precurarizing dose of rocuronium to decrease fasciculation and ENT1 myalgia  ENT1END  following ENT2 succinylcholine ENT2END administration
0	RESULTS: The incidence and severity of visible muscle fasciculation was significantly less with increasing the amount of precurarizing dose of ENT1 rocuronium ENT1END (P < 0.001). Those of ENT2 myalgia ENT2END tend to decrease according to increasing the amount of precurarizing dose of rocuronium, but there was no significance (P = 0
0	Butyrylcholinesterase deficiency is characterized by prolonged ENT1 apnea ENT1END after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with ENT2 butyrylthiocholine ENT2END (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype
0	Butyrylcholinesterase deficiency is characterized by prolonged ENT1 apnea ENT1END  after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and ENT2 benzoylcholine ENT2END , and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype
1	Butyrylcholinesterase deficiency is characterized by prolonged ENT1 apnea ENT1END  after the use of muscle relaxants (suxamethonium or ENT2 mivacurium ENT2END ) in patients who have mutations in the BCHE gene
0	Butyrylcholinesterase deficiency is characterized by prolonged ENT1 apnea ENT1END  after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of ENT2 dibucaine ENT2END and fluoride numbers fit with heterozygous atypical silent genotype
1	Val204Asp) causes loss of activity and prolonged ENT1 apnea  ENT1END  with ENT2 suxamethonium ENT2END
0	Butyrylcholinesterase deficiency is characterized by prolonged ENT1 apnea ENT1END  after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and ENT2 fluoride ENT2END numbers fit with heterozygous atypical silent genotype
0	ENT1 Butyrylcholinesterase deficiency  ENT1END is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with ENT2 butyrylthiocholine ENT2END (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype
0	ENT1 Butyrylcholinesterase deficiency  ENT1END  is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and ENT2 benzoylcholine ENT2END , and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype
1	ENT1 Butyrylcholinesterase deficiency  ENT1END  is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or ENT2 mivacurium ENT2END ) in patients who have mutations in the BCHE gene
0	ENT1 Butyrylcholinesterase deficiency  ENT1END  is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of ENT2 dibucaine ENT2END and fluoride numbers fit with heterozygous atypical silent genotype
1	Val204Asp) causes loss of activity and prolonged apnea with ENT1 suxamethonium ENT1END ENT2 Butyrylcholinesterase deficiency ENT2END is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene
0	ENT1 Butyrylcholinesterase deficiency  ENT1END  is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and ENT2 fluoride ENT2END numbers fit with heterozygous atypical silent genotype
1	A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent ENT1 albuterol ENT1END (INA) treatments is reported. Forty matched pairs of patients with asthma are compared. CNA was administered for a mean of 11 +/- 10 hr. The incidence of ENT2 cardiac dysrhythmias ENT2END was similar between groups
0	A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent ENT1 albuterol ENT1END  (INA) treatments is reported. Forty matched pairs of patients with asthma are compared. CNA was administered for a mean of 11 +/- 10 hr. The incidence of cardiac dysrhythmias was similar between groups. Symptomatic ENT2 hypokalemia ENT2END did not occur
0	Continuously nebulized ENT1 albuterol  ENT1END  in severe exacerbations of ENT2 asthma ENT2END in adults: a case-controlled study
0	The severity of ENT1 pain ENT1END due to etomidate injection, mean arterial pressure, heart rate, and adverse effects were also evaluated. RESULTS: Study results showed that myoclonus incidence was 85%, 40%, 70%, and 25% in Group NP, Group F, Group M, and Group FM, respectively, and were significantly lower in Group F and Group FM. CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and ENT2 midazolam ENT2END was effective in preventing etomidate-induced myoclonus
0	The severity of ENT1 pain ENT1END  due to ENT2 etomidate ENT2END injection, mean arterial pressure, heart rate, and adverse effects were also evaluated
0	The severity of ENT1 pain ENT1END  due to etomidate injection, mean arterial pressure, heart rate, and adverse effects were also evaluated. RESULTS: Study results showed that myoclonus incidence was 85%, 40%, 70%, and 25% in Group NP, Group F, Group M, and Group FM, respectively, and were significantly lower in Group F and Group FM. CONCLUSIONS: We conclude that pretreatment with ENT2 fentanyl ENT2END or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus
0	BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and ENT1 midazolam ENT1END to prevent etomidate-induced ENT2 myoclonus ENT2END
1	Prevention of ENT1 etomidate  ENT1END -induced ENT2 myoclonus ENT2END : which is superior: Fentanyl, midazolam, or a combination? A Retrospective comparative study
0	Prevention of etomidate-induced ENT1 myoclonus  ENT1END : which is superior: ENT2 Fentanyl ENT2END , midazolam, or a combination? A Retrospective comparative study
0	kg-1 (Group M), and ENT1 midazolam ENT1END 0.015 mg.kg-1 + fentanyl 0.5 ug.kg-1 (Group FM). Patients who received the same anesthetic procedure were selected: 2 minutes after intravenous injections of the pretreatment drugs, anesthesia is induced with 0.3 mg.kg-1 etomidate injected intravenously over a period of 20-30 seconds. ENT2 Myoclonic movements ENT2END are evaluated, which were observed and graded according to clinical severity during the 2 minutes after etomidate injection
0	kg-1 ENT1 etomidate  ENT1END injected intravenously over a period of 20-30 seconds. ENT2 Myoclonic movements ENT2END are evaluated, which were observed and graded according to clinical severity during the 2 minutes after etomidate injection
0	kg-1 + ENT1 fentanyl  ENT1END 0.5 ug.kg-1 (Group FM). Patients who received the same anesthetic procedure were selected: 2 minutes after intravenous injections of the pretreatment drugs, anesthesia is induced with 0.3 mg.kg-1 etomidate injected intravenously over a period of 20-30 seconds. ENT2 Myoclonic movements ENT2END are evaluated, which were observed and graded according to clinical severity during the 2 minutes after etomidate injection
0	Rhabdomyolysis in a ENT1 hepatitis C virus infected  ENT1END  patient treated with ENT2 telaprevir ENT2END and simvastatin
0	Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and ENT1 simvastatin ENT1END .A 46-year old man with a chronic ENT2 hepatitis C virus infection ENT2END received triple therapy with ribavirin, pegylated interferon and telaprevir
0	A 46-year old man with a chronic ENT1 hepatitis C virus infection ENT1END  received triple therapy with ribavirin, ENT2 pegylated interferon ENT2END and telaprevir
0	A 46-year old man with a chronic ENT1 hepatitis C virus infection ENT1END  received triple therapy with ENT2 ribavirin ENT2END , pegylated interferon and telaprevir
0	A 46-year old man with a chronic ENT1 hepatitis C virus infection ENT1END  received triple therapy with ribavirin, pegylated interferon and telaprevir. The patient also received simvastatin. One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed rhabdomyolysis. At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected. The ENT2 creatine ENT2END kinase peaked at 62,246 IU/L and the patient was treated with intravenous normal saline
0	Simvastatin plasma concentration increased 30 times in this patient and statin induced ENT1 muscle toxicity ENT1END is related to the concentration of the statin in blood. In conclusion, with this case we illustrate that ENT2 telaprevir ENT2END as well as statins are susceptible to clinical relevant drug-drug interactions
1	Simvastatin plasma concentration increased 30 times in this patient and ENT1 statin  ENT1END induced ENT2 muscle toxicity ENT2END is related to the concentration of the statin in blood
0	Fourteen days after hospitalization, ENT1 creatine  ENT1END kinase level had returned to 230 IU/L and the patient was discharged. Telaprevir was considered the probable causative agent of an interaction with simvastatin according to the Drug Interaction Probability Scale. The interaction is due to inhibition of CYP3A4-mediated simvastatin clearance. Simvastatin plasma concentration increased 30 times in this patient and statin induced ENT2 muscle toxicity ENT2END is related to the concentration of the statin in blood
0	A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and ENT1 telaprevir ENT1END  The patient also received simvastatin. One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed rhabdomyolysis. At admission simvastatin and all antiviral drugs were discontinued because ENT2 toxicity ENT2END due to a drug-drug interaction was suspected
0	At admission ENT1 simvastatin  ENT1END and all antiviral drugs were discontinued because ENT2 toxicity ENT2END due to a drug-drug interaction was suspected
0	A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, ENT1 pegylated interferon  ENT1END  and telaprevir. The patient also received simvastatin. One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed rhabdomyolysis. At admission simvastatin and all antiviral drugs were discontinued because ENT2 toxicity ENT2END due to a drug-drug interaction was suspected
0	A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ENT1 ribavirin  ENT1END , pegylated interferon and telaprevir. The patient also received simvastatin. One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed rhabdomyolysis. At admission simvastatin and all antiviral drugs were discontinued because ENT2 toxicity ENT2END due to a drug-drug interaction was suspected
0	At admission simvastatin and all antiviral drugs were discontinued because ENT1 toxicity  ENT1END  due to a drug-drug interaction was suspected. The ENT2 creatine ENT2END kinase peaked at 62,246 IU/L and the patient was treated with intravenous normal saline
1	ENT1 Rhabdomyolysis  ENT1END  in a hepatitis C virus infected patient treated with ENT2 telaprevir ENT2END and simvastatin
1	One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed ENT1 rhabdomyolysis  ENT1END  At admission ENT2 simvastatin ENT2END and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected
0	A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, ENT1 pegylated interferon  ENT1END  and telaprevir. The patient also received simvastatin. One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed ENT2 rhabdomyolysis ENT2END
0	ENT1 Rhabdomyolysis  ENT1END  in a hepatitis C virus infected patient treated with telaprevir and simvastatin.A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ENT2 ribavirin ENT2END , pegylated interferon and telaprevir
0	One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed ENT1 rhabdomyolysis  ENT1END . At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected. The ENT2 creatine ENT2END kinase peaked at 62,246 IU/L and the patient was treated with intravenous normal saline
0	One day after experimental myocardial infarction, six additional ENT1 halothane ENT1END anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared. After 45 min, 1 mg/kg bupivacaine was injected over 5 min, again followed by 4 micrograms.kg-1.min-1 epinephrine. In these dogs, the prodysrhythmic response to epinephrine was also mitigated by preceding bupivacaine. Bupivacaine antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous postinfarct ENT2 dysrhythmias ENT2END
0	Since bupivacaine and ENT1 epinephrine ENT1END may both precipitate ENT2 dysrhythmias ENT2END , circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine
0	Since bupivacaine and epinephrine may both precipitate ENT1 dysrhythmias ENT1END , circulating ENT2 bupivacaine ENT2END during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine
0	One day after experimental ENT1 myocardial infarction  ENT1END  six additional ENT2 halothane ENT2END -anesthetized dogs received 4 micrograms
0	We therefore examined whether bupivacaine alters the dysrhythmogenicity of subsequent administration of ENT1 epinephrine ENT1END in conscious, healthy dogs and in anesthetized dogs with ENT2 myocardial infarction ENT2END
0	Epinephrine shortened QT less after ENT1 bupivacaine  ENT1END than in control animals. One day after experimental ENT2 myocardial infarction ENT2END , six additional halothane-anesthetized dogs received 4 micrograms
0	One day after experimental myocardial infarction, six additional ENT1 halothane ENT1END -anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until ENT2 VT ENT2END appeared
1	min-1 ENT1 epinephrine  ENT1END until ENT2 VT ENT2END appeared
0	In the bupivacaine groups, epinephrine caused fewer prodysrhythmic effects than without ENT1 bupivacaine ENT1END  ENT2 VT ENT2END appeared in fewer dogs and at a later time, and there were more sinoatrial beats and less ectopies
0	Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or ENT1 diltiazem ENT1END  In the presence of ENT2 coronary artery stenosis ENT2END , 3-min periods of intracoronary ISO infusion (10 ng/kg/min) increased heart rate and maximal rate of left ventricular pressure rise, which resulted in a decrease in percentage segmental shortening and ST-segment elevation of the epicardial electrocardiogram
0	Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial ENT1 coronary stenosis ENT1END .Effects of CD-832 on ENT2 isoproterenol ENT2END (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem
0	Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial ENT1 coronary stenosis ENT1END .Effects of ENT2 CD-832 ENT2END on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem
0	Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for ENT1 nifedipine  ENT1END or diltiazem. In the presence of ENT2 coronary artery stenosis ENT2END , 3-min periods of intracoronary ISO infusion (10 ng/kg/min) increased heart rate and maximal rate of left ventricular pressure rise, which resulted in a decrease in percentage segmental shortening and ST-segment elevation of the epicardial electrocardiogram
0	Effects of a new ENT1 calcium  ENT1END  antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial ENT2 coronary stenosis ENT2END
0	01) at 3 min after ISO infusion with ENT1 stenosis ENT1END  ENT2 Diltiazem ENT2END (30 micrograms/kg/min) also prevented the decrease in percentage segmental shortening from 34 +/- 14% to 63 +/- 18% of the control value (P <
0	After the control ENT1 ISO ENT1END infusion with ENT2 stenosis ENT2END was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion
0	01) at 3 min after ISO infusion with ENT1 stenosis ENT1END  These data show that ENT2 CD-832 ENT2END improves myocardial ischemia during ISO infusion with stenosis and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832
0	After the control ISO infusion with ENT1 stenosis ENT1END  was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), ENT2 nifedipine ENT2END (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion
0	Effects of a new ENT1 calcium  ENT1END  antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem. In the presence of coronary artery stenosis, 3-min periods of intracoronary ISO infusion (10 ng/kg/min) increased heart rate and maximal rate of left ventricular pressure rise, which resulted in a decrease in percentage segmental shortening and ST-segment elevation of the epicardial electrocardiogram. After the control ISO infusion with ENT2 stenosis ENT2END was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion
0	Effects of CD-832 on isoproterenol (ISO)-induced ENT1 myocardial ischemia  ENT1END were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or ENT2 diltiazem ENT2END
1	These data show that CD-832 improves ENT1 myocardial ischemia ENT1END during ENT2 ISO ENT2END infusion with stenosis and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832
0	These data show that ENT1 CD-832  ENT1END  improves ENT2 myocardial ischemia ENT2END during ISO infusion with stenosis and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832
0	Effects of CD-832 on isoproterenol (ISO)-induced ENT1 myocardial ischemia  ENT1END  were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for ENT2 nifedipine ENT2END or diltiazem
0	Effects of a new ENT1 calcium  ENT1END  antagonist, CD-832, on isoproterenol-induced ENT2 myocardial ischemia ENT2END in dogs with partial coronary stenosis
1	ENT1 Amiodarone  ENT1END -induced ENT2 myxoedema coma ENT2END
0	The 24 hour excretion of ENT1 iodine ENT1END was 3657 (mcg (25-756 ( mcg). The only two cases of amiodarone-induced ENT2 myxoedema coma ENT2END in the literature report patient death despite supportive therapy and thyroid hormone replacement
0	The patient was maintained on ENT1 levothyroxine  ENT1END 175 (g POorally daily. A thyroid ultrasound showed diffuse heterogeneity. The 24 hour excretion of iodine was 3657 (mcg (25-756 ( mcg). The only two cases of amiodarone-induced ENT2 myxoedema coma ENT2END in the literature report patient death despite supportive therapy and thyroid hormone replacement
0	Amiodarone-induced ENT1 myxoedema coma ENT1END .A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free thyroxine (FT4) was <0.2 ng/dL (nl. 0.8-1.8 ng/dL). He received intravenous fluids, vasopressor therapy and stress dose ENT2 steroids ENT2END ; he was intubated and admitted to the intensive care unit
1	A 62-year-old man was found to have bradycardia, ENT1 hypothermia ENT1END and respiratory failure 3 weeks after initiation of ENT2 amiodarone ENT2END therapy for atrial fibrillation
0	A 62-year-old man was found to have bradycardia, ENT1 hypothermia ENT1END  and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free ENT2 thyroxine ENT2END (FT4) was <0
0	A 62-year-old man was found to have bradycardia, ENT1 hypothermia  ENT1END  and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free thyroxine (FT4) was <0.2 ng/dL (nl. 0.8-1.8 ng/dL). He received intravenous fluids, vasopressor therapy and stress dose ENT2 steroids ENT2END ; he was intubated and admitted to the intensive care unit
0	This case represents the most thoroughly investigated case of ENT1 amiodarone ENT1END induced myxoedema coma with a history significant for subclinical ENT2 thyroid disease ENT2END
0	The 24 hour excretion of ENT1 iodine  ENT1END  was 3657 (mcg (25-756 ( mcg). The only two cases of amiodarone-induced myxoedema coma in the literature report patient death despite supportive therapy and thyroid hormone replacement. This case represents the most thoroughly investigated case of amiodarone-induced myxoedema coma with a history significant for subclinical ENT2 thyroid disease ENT2END
0	The patient was maintained on ENT1 levothyroxine  ENT1END  175 (g POorally daily. A thyroid ultrasound showed diffuse heterogeneity. The 24 hour excretion of iodine was 3657 (mcg (25-756 ( mcg). The only two cases of amiodarone-induced myxoedema coma in the literature report patient death despite supportive therapy and thyroid hormone replacement. This case represents the most thoroughly investigated case of amiodarone-induced myxoedema coma with a history significant for subclinical ENT2 thyroid disease ENT2END
1	ENT1 Amiodarone ENT1END -induced myxoedema coma.A 62-year-old man was found to have ENT2 bradycardia ENT2END , hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation
0	A 62-year-old man was found to have ENT1 bradycardia  ENT1END , hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free ENT2 thyroxine ENT2END (FT4) was <0
0	A 62-year-old man was found to have ENT1 bradycardia  ENT1END , hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free thyroxine (FT4) was <0.2 ng/dL (nl. 0.8-1.8 ng/dL). He received intravenous fluids, vasopressor therapy and stress dose ENT2 steroids ENT2END ; he was intubated and admitted to the intensive care unit
0	A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of ENT1 amiodarone ENT1END  therapy for ENT2 atrial fibrillation ENT2END
0	A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for ENT1 atrial fibrillation  ENT1END . Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free ENT2 thyroxine ENT2END (FT4) was <0
0	A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for ENT1 atrial fibrillation  ENT1END . Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free thyroxine (FT4) was <0.2 ng/dL (nl. 0.8-1.8 ng/dL). He received intravenous fluids, vasopressor therapy and stress dose ENT2 steroids ENT2END ; he was intubated and admitted to the intensive care unit
1	A 62-year-old man was found to have bradycardia, hypothermia and ENT1 respiratory failure  ENT1END 3 weeks after initiation of ENT2 amiodarone ENT2END therapy for atrial fibrillation
0	A 62-year-old man was found to have bradycardia, hypothermia and ENT1 respiratory failure  ENT1END  3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free ENT2 thyroxine ENT2END (FT4) was <0
0	A 62-year-old man was found to have bradycardia, hypothermia and ENT1 respiratory failure  ENT1END  3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free thyroxine (FT4) was <0.2 ng/dL (nl. 0.8-1.8 ng/dL). He received intravenous fluids, vasopressor therapy and stress dose ENT2 steroids ENT2END ; he was intubated and admitted to the intensive care unit
1	ENT1 Amiodarone  ENT1END -induced ENT2 myxoedema coma ENT2END
0	The 24 hour excretion of ENT1 iodine ENT1END  was 3657 (mcg (25-756 ( mcg). The only two cases of amiodarone-induced ENT2 myxoedema coma ENT2END in the literature report patient death despite supportive therapy and thyroid hormone replacement
0	The patient was maintained on ENT1 levothyroxine  ENT1END  175 (g POorally daily. A thyroid ultrasound showed diffuse heterogeneity. The 24 hour excretion of iodine was 3657 (mcg (25-756 ( mcg). The only two cases of amiodarone-induced ENT2 myxoedema coma ENT2END in the literature report patient death despite supportive therapy and thyroid hormone replacement
0	Amiodarone-induced ENT1 myxoedema coma  ENT1END .A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free thyroxine (FT4) was <0.2 ng/dL (nl. 0.8-1.8 ng/dL). He received intravenous fluids, vasopressor therapy and stress dose ENT2 steroids ENT2END ; he was intubated and admitted to the intensive care unit
0	A large population-based follow-up study of trimethoprim-sulfamethoxazole, ENT1 trimethoprim  ENT1END , and cephalexin for uncommon serious ENT2 drug toxicity ENT2END
0	A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and ENT1 cephalexin  ENT1END  for uncommon serious ENT2 drug toxicity ENT2END
0	A large population-based follow-up study of ENT1 trimethoprim-sulfamethoxazole  ENT1END , trimethoprim, and cephalexin for uncommon serious ENT2 drug toxicity ENT2END
0	2/100,000) and those prescribed ENT1 trimethoprim ENT1END alone (3.8/100,000). The risk for those prescribed cephalexin was somewhat lower (2.0/100,000). Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with ENT2 erythema multiforme ENT2END and Stevens-Johnson syndrome, four were exposed to TMP-SMZ
0	The risk for those prescribed ENT1 cephalexin  ENT1END was somewhat lower (2.0/100,000). Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with ENT2 erythema multiforme ENT2END and Stevens-Johnson syndrome, four were exposed to TMP-SMZ
0	Only five patients experienced blood disorders, one of whom was exposed to ENT1 TMP-SMZ  ENT1END  of seven with ENT2 erythema multiforme ENT2END and Stevens-Johnson syndrome, four were exposed to TMP-SMZ
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed ENT1 trimethoprim ENT1END alone, and 196,397 prescribed cephalexin, to estimate the risk of serious ENT2 liver, blood, skin, and renal disorders ENT2END resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed ENT1 cephalexin  ENT1END  to estimate the risk of serious ENT2 liver, blood, skin, and renal disorders ENT2END resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole ( ENT1 TMP-SMZ  ENT1END , 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious ENT2 liver, blood, skin, and renal disorders ENT2END resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed ENT1 trimethoprim ENT1END  alone, and 196,397 prescribed cephalexin, to estimate the risk of serious ENT2 liver, blood, skin, and renal disorders ENT2END resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed ENT1 cephalexin  ENT1END , to estimate the risk of serious ENT2 liver, blood, skin, and renal disorders ENT2END resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole ( ENT1 TMP-SMZ  ENT1END ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious ENT2 liver, blood, skin, and renal disorders ENT2END resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed ENT1 trimethoprim ENT1END  alone, and 196,397 prescribed cephalexin, to estimate the risk of serious ENT2 liver, blood, skin, and renal disorders ENT2END resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed ENT1 cephalexin  ENT1END , to estimate the risk of serious ENT2 liver, blood, skin, and renal disorders ENT2END resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole ( ENT1 TMP-SMZ  ENT1END ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious ENT2 liver, blood, skin, and renal disorders ENT2END resulting in referral or hospitalization associated with these drugs
0	2/100,000) and those prescribed ENT1 trimethoprim ENT1END  alone (3.8/100,000). The risk for those prescribed cephalexin was somewhat lower (2.0/100,000). Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and ENT2 Stevens-Johnson syndrome ENT2END , four were exposed to TMP-SMZ
1	The one case of ENT1 toxic epidermal necrolysis ENT1END occurred in a patient who took ENT2 cephalexin ENT2END
1	Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to ENT1 TMP-SMZ  ENT1END  The one case of ENT2 toxic epidermal necrolysis ENT2END occurred in a patient who took cephalexin
1	The risk of clinically important idiopathic ENT1 liver disease  ENT1END was similar for persons prescribed TMP-SMZ (5.2/100,000) and those prescribed ENT2 trimethoprim ENT2END alone (3
1	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed ENT1 cephalexin ENT1END , to estimate the risk of serious ENT2 liver, blood, skin, and renal disorders ENT2END resulting in referral or hospitalization associated with these drugs
1	The risk of clinically important idiopathic ENT1 liver disease ENT1END  was similar for persons prescribed ENT2 TMP-SMZ ENT2END (5
0	Longitudinal association of ENT1 alcohol  ENT1END  use with ENT2 HIV disease ENT2END progression and psychological health of women with HIV
1	The participants had physical examination, medical record extraction, and venipuncture, CD4+T-cell counts determination, measurement of depression symptoms (using the self-report Center for Epidemiological Studies- ENT1 Depression ENT1END Scale), and ENT2 alcohol ENT2END use assessment at enrollment, and semiannually until March 2000
0	This study shows that ENT1 busulfan ENT1END ENT2 neurotoxicity ENT2END is dose-dependent in children and efficiently prevented by clonazepam
0	This study shows that busulfan ENT1 neurotoxicity ENT1END  is dose-dependent in children and efficiently prevented by ENT2 clonazepam ENT2END
0	5 years) receiving high-dose busulfan in combined chemotherapy before bone marrow transplantation for malignant solid ENT1 tumors ENT1END  brain tumors excluded. ENT2 Busulfan ENT2END was given p
0	Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without ENT1 central nervous system disease ENT1END under 600 mg/m2 ENT2 busulfan ENT2END with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1
0	Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without ENT1 central nervous system disease ENT1END  under 600 mg/m2 busulfan with ENT2 clonazepam ENT2END :busulfan cerebrospinal fluid:plasma ratio was 1
1	5%) developed ENT1 seizures ENT1END during the 4 days of the ENT2 busulfan ENT2END course or within 24 h after the last dosing
0	5%) developed ENT1 seizures ENT1END  during the 4 days of the busulfan course or within 24 h after the last dosing. When the total busulfan dose was taken into account, there was a significant difference in terms of neurotoxicity incidence among patients under 16 mg/kg (1 of 57, 1.7%) and patients under 600 mg/m2 (6 of 39, 15.4%) (P less than 0.02). Twenty-seven patients were given a 600-mg/m2 busulfan total dose with continuous i.v. infusion of ENT2 clonazepam ENT2END ; none had any neurological symptoms
0	infusion of clonazepam; none had any ENT1 neurological symptoms ENT1END  ENT2 Busulfan ENT2END levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg/m2 busulfan with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1
0	infusion of ENT1 clonazepam  ENT1END ; none had any ENT2 neurological symptoms ENT2END
0	5 years) receiving high-dose busulfan in combined chemotherapy before bone marrow transplantation for malignant solid tumors, ENT1 brain tumors  ENT1END excluded. ENT2 Busulfan ENT2END was given p
0	In the absence of ENT1 amiodarone ENT1END therapy, a second bladder irrigation did not induce TdP despite hypokalemia and ENT2 hypomagnesemia ENT2END
0	Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including hypokalemia and ENT1 digoxin  ENT1END excess. Transient prolongation of the QT during bladder irrigation prompted the episode of TdP. It is well known that bradycardia exacerbates acquired TdP. The authors speculate that the increased vagal tone during bladder irrigation, a vagal maneuver, in the context of amiodarone therapy resulted in amiodarone-induced proarrhythmia. In the absence of amiodarone therapy, a second bladder irrigation did not induce TdP despite hypokalemia and ENT2 hypomagnesemia ENT2END
1	ENT1 Amiodarone  ENT1END -induced ENT2 torsade de pointes ENT2END during bladder irrigation: an unusual presentation--a case report
0	Consistent with other reports this case of ENT1 TdP  ENT1END occurred in the context of multiple exacerbating factors including hypokalemia and ENT2 digoxin ENT2END excess
0	In the absence of ENT1 amiodarone ENT1END  therapy, a second bladder irrigation did not induce TdP despite ENT2 hypokalemia ENT2END and hypomagnesemia
0	Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including ENT1 hypokalemia  ENT1END and ENT2 digoxin ENT2END excess
0	It is well known that ENT1 bradycardia ENT1END exacerbates acquired TdP. The authors speculate that the increased vagal tone during bladder irrigation, a vagal maneuver, in the context of ENT2 amiodarone ENT2END therapy resulted in amiodarone-induced proarrhythmia
0	Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including hypokalemia and ENT1 digoxin  ENT1END  excess. Transient prolongation of the QT during bladder irrigation prompted the episode of TdP. It is well known that ENT2 bradycardia ENT2END exacerbates acquired TdP
1	ENT1 Linezolid  ENT1END -induced ENT2 optic neuropathy ENT2END
0	ENT1 Ethambutol ENT1END induced ENT2 toxic optic neuropathy ENT2END was suspected and tablet ethambutol was withdrawn
0	ENT1 Deterioration of vision ENT1END occurred despite withdrawal of ethambutol. Discontinuation of ENT2 linezolid ENT2END resulted in marked improvement of vision
0	Ethambutol-induced toxic optic neuropathy was suspected and tablet ENT1 ethambutol  ENT1END was withdrawn. ENT2 Deterioration of vision ENT2END occurred despite withdrawal of ethambutol
0	A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including ENT1 linezolid ENT1END and ethambutol for ENT2 extensively drug-resistant tuberculosis ENT2END (XDR-TB) presented to us with painless progressive loss of vision in both eyes
0	A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ENT1 ethambutol  ENT1END for ENT2 extensively drug-resistant tuberculosis ENT2END (XDR-TB) presented to us with painless progressive loss of vision in both eyes
1	Color vision was defective and fundus examination revealed ENT1 optic disc edema  ENT1END in both eyes. Ethambutol-induced toxic optic neuropathy was suspected and tablet ethambutol was withdrawn. Deterioration of vision occurred despite withdrawal of ethambutol. Discontinuation of ENT2 linezolid ENT2END resulted in marked improvement of vision
0	Color vision was defective and fundus examination revealed ENT1 optic disc edema  ENT1END  in both eyes. ENT2 Ethambutol ENT2END -induced toxic optic neuropathy was suspected and tablet ethambutol was withdrawn
0	We describe a case of progressive ENT1 loss of vision ENT1END associated with ENT2 linezolid ENT2END therapy
0	A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ENT1 ethambutol ENT1END  for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive ENT2 loss of vision ENT2END in both eyes
1	The effects on ENT1 isoproterenol ENT1END ENT2 tachycardia ENT2END were determined before and after atropine (0
0	The effects on isoproterenol ENT1 tachycardia ENT1END  were determined before and after ENT2 atropine ENT2END (0
0	We compared the effects of single doses of 50 mg ENT1 atenolol ENT1END (cardioselective), 40 mg propranolol (nonselective), and placebo on both exercise- and isoproterenol-induced ENT2 tachycardia ENT2END in two experiments involving nine normal subjects
0	We compared the effects of single doses of 50 mg atenolol (cardioselective), 40 mg ENT1 propranolol  ENT1END (nonselective), and placebo on both exercise- and isoproterenol-induced ENT2 tachycardia ENT2END in two experiments involving nine normal subjects
0	25 per cent to 2 per cent, their vehicle, and 1 per cent silver sulphadiazine (AgSD) cream, an antimicrobial agent frequently used for topical treatment of ENT1 burn ENT1END wounds. The other site was always treated with ENT2 AgSD ENT2END cream
0	Effective topical antimicrobial agents decrease infection and mortality in ENT1 burn ENT1END patients. ENT2 Chlorhexidine phosphanilate ENT2END (CHP), a new broad-spectrum antimicrobial agent, has been evaluated as a topical burn wound dressing in cream form, but preliminary clinical trials reported that it was painful upon application
0	Effective topical antimicrobial agents decrease ENT1 infection ENT1END and mortality in burn patients. Chlorhexidine phosphanilate (CHP), a new broad-spectrum antimicrobial agent, has been evaluated as a topical burn wound dressing in cream form, but preliminary clinical trials reported that it was painful upon application. This study compared various concentrations of CHP to determine if a tolerable concentration could be identified with retention of antimicrobial efficacy. Twenty-nine burn patients, each with two similar burns which could be separately treated, were given pairs of treatments at successive 12-h intervals over a 3-day period. One burn site was treated with each of four different CHP concentrations, from 0.25 per cent to 2 per cent, their vehicle, and 1 per cent ENT2 silver sulphadiazine ENT2END (AgSD) cream, an antimicrobial agent frequently used for topical treatment of burn wounds
0	Effective topical antimicrobial agents decrease ENT1 infection  ENT1END  and mortality in burn patients. ENT2 Chlorhexidine phosphanilate ENT2END (CHP), a new broad-spectrum antimicrobial agent, has been evaluated as a topical burn wound dressing in cream form, but preliminary clinical trials reported that it was painful upon application
0	25 per cent CHP cream was closest to ENT1 AgSD ENT1END in ENT2 pain ENT2END tolerance; however, none of the treatments differed statistically from AgSD or from each other
1	25 per cent ENT1 CHP  ENT1END cream was closest to AgSD in ENT2 pain ENT2END tolerance; however, none of the treatments differed statistically from AgSD or from each other
1	Loss of endothelial cell-derived nitric oxide ( ENT1 NO ENT1END  in ENT2 hypertension ENT2END is a hallmark of arterial dysfunction
0	Maximum contraction of vena cava to ENT1 norepinephrine ENT1END (37% control) also was reduced but no change in response to ET-1 was observed. Mean circulatory filling pressure, an in vivo measure of venomotor tone, was not elevated in LNNA ENT2 hypertension ENT2END at 1 or 2 weeks after LNNA
0	Similarly, ganglionic blockade with ENT1 hexamethonium ENT1END caused a significantly greater fall in LNNA ENT2 hypertensive ENT2END rats (76 +/- 9 mm Hg) compared with control rats (35 +/- 10 mm Hg)
0	Mean circulatory filling pressure, an in vivo measure of venomotor tone, was not elevated in ENT1 LNNA ENT1END ENT2 hypertension ENT2END at 1 or 2 weeks after LNNA
0	Mean circulatory filling pressure, an in vivo measure of venomotor tone, was not elevated in LNNA ENT1 hypertension ENT1END  at 1 or 2 weeks after LNNA. The superoxide scavenger ENT2 tempol ENT2END (30, 100, and 300 micromol kg(-1), IV) did not change arterial pressure in control rats but caused a dose-dependent decrease in LNNA rats (-18 +/- 8, -26 +/- 15, and -54 +/- 11 mm Hg)
0	Mean circulatory filling pressure, an in vivo measure of venomotor tone, was not elevated in LNNA ENT1 hypertension ENT1END  at 1 or 2 weeks after LNNA. The ENT2 superoxide ENT2END scavenger tempol (30, 100, and 300 micromol kg(-1), IV) did not change arterial pressure in control rats but caused a dose-dependent decrease in LNNA rats (-18 +/- 8, -26 +/- 15, and -54 +/- 11 mm Hg)
0	Loss of endothelial cell-derived nitric oxide ( ENT1 NO ENT1END ) in hypertension is a hallmark of ENT2 arterial dysfunction ENT2END
0	Loss of endothelial cell-derived nitric oxide (NO) in hypertension is a hallmark of ENT1 arterial dysfunction ENT1END . Experimental hypertension created by the removal of NO, however, involves mechanisms in addition to decreased arterial vasodilator activity. These include augmented endothelin-1 (ET-1) release, increased sympathetic nervous system activity, and elevated tissue oxidative stress. We hypothesized that increased venous smooth muscle (venomotor) tone plays a role in ENT2 Nomega-nitro-L-arginine ENT2END (LNNA) hypertension through these mechanisms
0	Hypercalcemia, ENT1 arrhythmia ENT1END , and mood stabilizers.Recent findings in a bipolar patient receiving maintenance ENT2 lithium ENT2END therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia
1	Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with ENT1 lithium ENT1END associated ENT2 hypercalcemia ENT2END
0	Thus, two control groups were generated: group C1, which included age- and sex-comparable ENT1 lithium ENT1END treated ENT2 bipolar ENT2END normocalcemic patients, and group C2, which included bipolar normocalcemic patients treated with anticonvulsant mood stabilizers
0	After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non- ENT1 lithium ENT1END treated patients with hypercalcemias related to ENT2 malignancies ENT2END and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B)
0	Recent findings in a bipolar patient receiving maintenance ENT1 lithium ENT1END  therapy who developed hypercalcemia and severe ENT2 bradyarrhythmia ENT2END prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia
0	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as ENT1 venous thrombosis ENT1END not otherwise specified. The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ENT2 ethinyloestradiol ENT2END than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	FINDINGS: 85 women met the inclusion criteria for VTE, two of whom were users of ENT1 progestagen ENT1END only OCs. Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as ENT2 deep-vein thrombosis ENT2END , 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified
0	BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens ENT1 gestodene ENT1END or desogestrel than in users of OCs containing second-generation progestagens. However, confounding and bias in the design of these studies may have affected the findings. The aim of our study was to re-examine the association between risk of VTE and OC use with a different study design and analysis to avoid some of the bias and confounding of the earlier studies. METHODS: We used computer records of patients from 143 general practices in the UK. The study was based on the medical records of about 540,000 women born between 1941 and 1981. All women who had a recorded diagnosis of ENT2 deep-vein thrombosis ENT2END , venous thrombosis not otherwise specified, or pulmonary embolus during the study period, and who had been treated with an anticoagulant were identified as potential cases of VTE
0	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as ENT1 venous thrombosis ENT1END  not otherwise specified. The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation ENT2 progestagens ENT2END , the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as ENT1 venous thrombosis ENT1END  not otherwise specified. The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation progestagens, the risk of VTE was higher in users of ENT2 desogestrel ENT2END with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	Of the 83 cases of VTE associated with use of combined ENT1 OCs  ENT1END  43 were recorded as ENT2 deep-vein thrombosis ENT2END , 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified
0	Among users of third-generation progestagens, the risk of ENT1 VTE  ENT1END was higher in users of desogestrel with 20 g ENT2 ethinyloestradiol ENT2END than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	FINDINGS: 85 women met the inclusion criteria for ENT1 VTE  ENT1END  two of whom were users of ENT2 progestagen ENT2END -only OCs
0	Among users of third-generation progestagens, the risk of ENT1 VTE ENT1END  was higher in users of desogestrel with 20 g ethinyloestradiol than in users of ENT2 gestodene ENT2END or desogestrel with 30 g ethinyloestradiol
0	Among users of third-generation ENT1 progestagens  ENT1END , the risk of ENT2 VTE ENT2END was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	Among users of third-generation progestagens, the risk of ENT1 VTE  ENT1END  was higher in users of ENT2 desogestrel ENT2END with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol
1	The aim of our study was to re-examine the association between risk of ENT1 VTE ENT1END and ENT2 OC ENT2END use with a different study design and analysis to avoid some of the bias and confounding of the earlier studies
0	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary ENT1 thrombosis  ENT1END  and five as venous thrombosis not otherwise specified. The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ENT2 ethinyloestradiol ENT2END than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	FINDINGS: 85 women met the inclusion criteria for VTE, two of whom were users of ENT1 progestagen  ENT1END -only OCs. Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary ENT2 thrombosis ENT2END , and five as venous thrombosis not otherwise specified
0	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary ENT1 thrombosis  ENT1END , and five as venous thrombosis not otherwise specified. The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of ENT2 gestodene ENT2END or desogestrel with 30 g ethinyloestradiol
0	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary ENT1 thrombosis  ENT1END , and five as venous thrombosis not otherwise specified. The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation ENT2 progestagens ENT2END , the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary ENT1 thrombosis  ENT1END , and five as venous thrombosis not otherwise specified. The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation progestagens, the risk of VTE was higher in users of ENT2 desogestrel ENT2END with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	Of the 83 cases of VTE associated with use of combined ENT1 OCs  ENT1END , 43 were recorded as deep-vein thrombosis, 35 as pulmonary ENT2 thrombosis ENT2END , and five as venous thrombosis not otherwise specified
0	The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the ENT1 cardiotoxic ENT1END effect of high doses of isoproterenol (ISO) was investigated in rats. Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared. The myocardial content of catecholamines was estimated in these 8 day diabetic rats. The ENT2 norepinephrine ENT2END content was significantly increased while epinephrine remained unchanged
0	The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the ENT1 cardiotoxic ENT1END  effect of high doses of isoproterenol (ISO) was investigated in rats. Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared. The myocardial content of ENT2 catecholamines ENT2END was estimated in these 8 day diabetic rats
0	The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the ENT1 cardiotoxic ENT1END  effect of high doses of isoproterenol (ISO) was investigated in rats. Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood ENT2 glucose ENT2END after insulin treatment appeared
0	The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the ENT1 cardiotoxic ENT1END  effect of high doses of isoproterenol (ISO) was investigated in rats. Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared. The myocardial content of catecholamines was estimated in these 8 day diabetic rats. The norepinephrine content was significantly increased while ENT2 epinephrine ENT2END remained unchanged
0	Acute insulin treatment normalizes the resistance to the ENT1 cardiotoxic  ENT1END  effect of ENT2 isoproterenol ENT2END in streptozotocin diabetic rats
0	The acute effect of insulin treatment on the earlier reported protective effect of ENT1 streptozotocin  ENT1END diabetes against the ENT2 cardiotoxic ENT2END effect of high doses of isoproterenol (ISO) was investigated in rats
0	The myocardial content of catecholamines was estimated in these 8 day ENT1 diabetic  ENT1END rats. The ENT2 norepinephrine ENT2END content was significantly increased while epinephrine remained unchanged
0	The rapid reversion after insulin treatment excludes the possibility that streptozotocin in itself causes the ISO resistance and points towards a direct insulin effect on myocardial ENT1 catecholamine ENT1END sensitivity in ENT2 diabetic ENT2END rats
0	006) to the slope of the fall in blood ENT1 glucose  ENT1END  after insulin treatment appeared. The myocardial content of catecholamines was estimated in these 8 day ENT2 diabetic ENT2END rats
0	The myocardial content of catecholamines was estimated in these 8 day ENT1 diabetic  ENT1END  rats. The norepinephrine content was significantly increased while ENT2 epinephrine ENT2END remained unchanged
0	Acute insulin treatment normalizes the resistance to the cardiotoxic effect of ENT1 isoproterenol  ENT1END  in streptozotocin ENT2 diabetic ENT2END rats
1	Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in ENT1 streptozotocin ENT1END ENT2 diabetic ENT2END rats
0	Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced ENT1 fibrosis  ENT1END in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared. The myocardial content of catecholamines was estimated in these 8 day diabetic rats. The ENT2 norepinephrine ENT2END content was significantly increased while epinephrine remained unchanged
0	Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced ENT1 fibrosis  ENT1END  in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared. The myocardial content of ENT2 catecholamines ENT2END was estimated in these 8 day diabetic rats
0	Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced ENT1 fibrosis  ENT1END  in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood ENT2 glucose ENT2END after insulin treatment appeared
0	Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced ENT1 fibrosis  ENT1END  in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared. The myocardial content of catecholamines was estimated in these 8 day diabetic rats. The norepinephrine content was significantly increased while ENT2 epinephrine ENT2END remained unchanged
1	Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ENT1 ISO  ENT1END induced ENT2 fibrosis ENT2END in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0
0	Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in ENT1 streptozotocin  ENT1END  diabetic rats. A morphometric study of isoproterenol induced myocardial ENT2 fibrosis ENT2END
0	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced ENT1 hyperactivity ENT1END seems to be connected to both quinine- and ENT2 4-aminopyridine ENT2END -sensitive K(+)-channels
0	Quinine is known to block voltage-, calcium- and ENT1 ATP ENT1END sensitive K(+)-channels while 4-aminopyridine is known to block voltage-sensitive K(+)-channels. 2. In the counterbalanced method, quinine attenuated morphine-induced place preference, whereas 4-aminopyridine was ineffective. In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary ENT2 hyperactivity ENT2END
1	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas ENT1 morphine  ENT1END induced ENT2 hyperactivity ENT2END seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels
0	Quinine is known to block voltage-, ENT1 calcium  ENT1END  and ATP-sensitive K(+)-channels while 4-aminopyridine is known to block voltage-sensitive K(+)-channels. 2. In the counterbalanced method, quinine attenuated morphine-induced place preference, whereas 4-aminopyridine was ineffective. In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary ENT2 hyperactivity ENT2END
0	In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both ENT1 K  ENT1END +)-channel blockers prevented morphine-induced secondary ENT2 hyperactivity ENT2END
0	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced ENT1 hyperactivity ENT1END  seems to be connected to both ENT2 quinine ENT2END - and 4-aminopyridine-sensitive K(+)-channels
0	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced ENT1 hypoactivity  ENT1END whereas morphine-induced hyperactivity seems to be connected to both quinine- and ENT2 4-aminopyridine ENT2END -sensitive K(+)-channels
0	Quinine is known to block voltage-, calcium- and ENT1 ATP ENT1END -sensitive K(+)-channels while 4-aminopyridine is known to block voltage-sensitive K(+)-channels. 2. In the counterbalanced method, quinine attenuated morphine-induced place preference, whereas 4-aminopyridine was ineffective. In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced ENT2 hypoactivity ENT2END , but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity
0	In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected ENT1 morphine  ENT1END induced ENT2 hypoactivity ENT2END , but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity
0	Quinine is known to block voltage-, ENT1 calcium  ENT1END - and ATP-sensitive K(+)-channels while 4-aminopyridine is known to block voltage-sensitive K(+)-channels. 2. In the counterbalanced method, quinine attenuated morphine-induced place preference, whereas 4-aminopyridine was ineffective. In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced ENT2 hypoactivity ENT2END , but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity
0	In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced ENT1 hypoactivity  ENT1END , but both ENT2 K ENT2END (+)-channel blockers prevented morphine-induced secondary hyperactivity
0	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced ENT1 hypoactivity  ENT1END  whereas morphine-induced hyperactivity seems to be connected to both ENT2 quinine ENT2END - and 4-aminopyridine-sensitive K(+)-channels
0	It is widely used in folk medicine to treat ENT1 skin diseases ENT1END in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, ENT2 aspartate ENT2END and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	Garcinielliptone FC ( ENT1 GFC  ENT1END  isolated from hexanic fraction seed extract of species Platonia insignis Mart. It is widely used in folk medicine to treat ENT2 skin diseases ENT2END in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases
0	It is widely used in folk medicine to treat ENT1 skin diseases  ENT1END  in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid ( ENT2 r-aminobutyric acid ENT2END (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat ENT1 skin diseases ENT1END  in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on ENT2 amino acid ENT2END (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat ENT1 skin diseases ENT1END  in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and ENT2 glutathione ENT2END ) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in ENT1 pilocarpine  ENT1END -induced seizures.Garcinielliptone FC (GFC) isolated from hexanic fraction seed extract of species Platonia insignis Mart. It is widely used in folk medicine to treat ENT2 skin diseases ENT2END in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases
0	It is widely used in folk medicine to treat ENT1 skin diseases ENT1END  in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), ENT2 glutamine ENT2END , aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and ENT1 inflammatory diseases  ENT1END  However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, ENT2 aspartate ENT2END and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and ENT1 inflammatory diseases ENT1END . However, there is no research on ENT2 GFC ENT2END effects in the central nervous system of rodents
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and ENT1 inflammatory diseases ENT1END . However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid ENT2 r-aminobutyric acid ENT2END (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and ENT1 inflammatory diseases  ENT1END . However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on ENT2 amino acid ENT2END (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and ENT1 inflammatory diseases  ENT1END . However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and ENT2 glutathione ENT2END ) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in ENT1 pilocarpine  ENT1END -induced seizures.Garcinielliptone FC (GFC) isolated from hexanic fraction seed extract of species Platonia insignis Mart. It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and ENT2 inflammatory diseases ENT2END
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and ENT1 inflammatory diseases  ENT1END . However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), ENT2 glutamine ENT2END , aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, ENT1 aspartate ENT1END  and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after ENT2 seizures ENT2END
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after ENT1 seizures ENT1END . ENT2 GFC ENT2END produced an increased latency to first seizure, at doses 25mg/kg (20
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on ENT1 seizure ENT1END parameters to determine their anticonvulsant activity and its effects on amino acid ENT2 r-aminobutyric acid ENT2END (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on ENT1 seizure  ENT1END  parameters to determine their anticonvulsant activity and its effects on ENT2 amino acid ENT2END (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and ENT1 glutathione  ENT1END ) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after ENT2 seizures ENT2END
1	Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in ENT1 pilocarpine  ENT1END -induced ENT2 seizures ENT2END
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on ENT1 seizure  ENT1END  parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), ENT2 glutamine ENT2END , aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat ENT1 diarrheas  ENT1END and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, ENT2 aspartate ENT2END and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat ENT1 diarrheas  ENT1END  and inflammatory diseases. However, there is no research on ENT2 GFC ENT2END effects in the central nervous system of rodents
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat ENT1 diarrheas ENT1END  and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid ENT2 r-aminobutyric acid ENT2END (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat ENT1 diarrheas  ENT1END  and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on ENT2 amino acid ENT2END (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat ENT1 diarrheas  ENT1END  and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and ENT2 glutathione ENT2END ) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in ENT1 pilocarpine  ENT1END -induced seizures.Garcinielliptone FC (GFC) isolated from hexanic fraction seed extract of species Platonia insignis Mart. It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat ENT2 diarrheas ENT2END and inflammatory diseases
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat ENT1 diarrheas  ENT1END  and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), ENT2 glutamine ENT2END , aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	In ENT1 aspartate ENT1END  glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with GFC75 plus P400 when compared with seized mice. Hippocampus mice treated with GFC75 plus P400 showed an increase in AChE activity (63.30%) when compared with seized mice. The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced ENT2 status epilepticus ENT2END , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals
0	The results indicate that ENT1 GFC  ENT1END can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced ENT2 status epilepticus ENT2END , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals
0	The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced ENT1 status epilepticus ENT1END , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals. In conclusion, our data suggest that GFC may influence in epileptogenesis and promote anticonvulsant actions in pilocarpine model by modulating the ENT2 GABA ENT2END and glutamate contents and of AChE activity in seized mice hippocampus
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on ENT1 amino acid  ENT1END  (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures. GFC produced an increased latency to first seizure, at doses 25mg/kg (20.12 + 2.20 min), 50mg/kg (20.95 + 2.21 min) or 75 mg/kg (23.43 + 1.99 min) when compared with seized mice. In addition, GABA content of mice hippocampus treated with GFC75 plus P400 showed an increase of 46.90% when compared with seized mice. In aspartate, glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with GFC75 plus P400 when compared with seized mice. Hippocampus mice treated with GFC75 plus P400 showed an increase in AChE activity (63.30%) when compared with seized mice. The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced ENT2 status epilepticus ENT2END , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and ENT1 glutathione  ENT1END ) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures. GFC produced an increased latency to first seizure, at doses 25mg/kg (20.12 + 2.20 min), 50mg/kg (20.95 + 2.21 min) or 75 mg/kg (23.43 + 1.99 min) when compared with seized mice. In addition, GABA content of mice hippocampus treated with GFC75 plus P400 showed an increase of 46.90% when compared with seized mice. In aspartate, glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with GFC75 plus P400 when compared with seized mice. Hippocampus mice treated with GFC75 plus P400 showed an increase in AChE activity (63.30%) when compared with seized mice. The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced ENT2 status epilepticus ENT2END , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals
1	The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of ENT1 pilocarpine  ENT1END induced ENT2 status epilepticus ENT2END , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals
0	The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced ENT1 status epilepticus ENT1END , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals. In conclusion, our data suggest that GFC may influence in epileptogenesis and promote anticonvulsant actions in pilocarpine model by modulating the GABA and ENT2 glutamate ENT2END contents and of AChE activity in seized mice hippocampus
1	We conclude that ENT1 coronary artery or myocardial disease ENT1END is common (38%) in young asymptomatic chronic ENT2 cocaine ENT2END users
0	Finally, resting and peak exercise ENT1 abnormal left ventricular filling  ENT1END was detected in 38 and 35% of patients as compared to 19 and 9% of controls, respectively (p = 0.11 and 0.02, respectively). We conclude that coronary artery or myocardial disease is common (38%) in young asymptomatic chronic ENT2 cocaine ENT2END users
0	Prevalence of ENT1 heart disease  ENT1END  in asymptomatic chronic ENT2 cocaine ENT2END users
1	We conclude that ENT1 coronary artery or myocardial disease  ENT1END is common (38%) in young asymptomatic chronic ENT2 cocaine ENT2END users
1	Anaesthesia was maintained with intermittent ENT1 etomidate ENT1END in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous ENT2 pain ENT2END occurred in 68% of patients and 50% had redness, pain or swelling related to the injection site, in some cases lasting up to three weeks after anaesthesia
0	Unpremedicated patients were given ENT1 fentanyl  ENT1END 1 microgram/kg followed by etomidate 0.3 mg/kg. Anaesthesia was maintained with intermittent etomidate in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous ENT2 pain ENT2END occurred in 68% of patients and 50% had redness, pain or swelling related to the injection site, in some cases lasting up to three weeks after anaesthesia
1	Anaesthesia was maintained with intermittent ENT1 etomidate ENT1END  in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous pain occurred in 68% of patients and 50% had redness, pain or swelling related to the injection site, in some cases lasting up to three weeks after anaesthesia. Skeletal movements occurred in 50% of patients; 30% experienced ENT2 respiratory upset ENT2END , one sufficiently severe to necessitate abandoning the technique
0	Unpremedicated patients were given ENT1 fentanyl  ENT1END  1 microgram/kg followed by etomidate 0.3 mg/kg. Anaesthesia was maintained with intermittent etomidate in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous pain occurred in 68% of patients and 50% had redness, pain or swelling related to the injection site, in some cases lasting up to three weeks after anaesthesia. Skeletal movements occurred in 50% of patients; 30% experienced ENT2 respiratory upset ENT2END , one sufficiently severe to necessitate abandoning the technique
1	Anaesthesia was maintained with intermittent ENT1 etomidate ENT1END  in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous pain occurred in 68% of patients and 50% had redness, pain or swelling related to the injection site, in some cases lasting up to three weeks after anaesthesia. Skeletal movements occurred in 50% of patients; 30% experienced respiratory upset, one sufficiently severe to necessitate abandoning the technique. Nausea and ENT2 vomiting ENT2END occurred in 40% and 25% had disturbing emergence psychoses
1	Anaesthesia was maintained with intermittent ENT1 etomidate ENT1END  in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous pain occurred in 68% of patients and 50% had redness, pain or swelling related to the injection site, in some cases lasting up to three weeks after anaesthesia. Skeletal movements occurred in 50% of patients; 30% experienced respiratory upset, one sufficiently severe to necessitate abandoning the technique. Nausea and vomiting occurred in 40% and 25% had disturbing emergence ENT2 psychoses ENT2END
1	Anaesthesia was maintained with intermittent ENT1 etomidate ENT1END  in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous pain occurred in 68% of patients and 50% had redness, pain or swelling related to the injection site, in some cases lasting up to three weeks after anaesthesia. Skeletal movements occurred in 50% of patients; 30% experienced respiratory upset, one sufficiently severe to necessitate abandoning the technique. ENT2 Nausea ENT2END and vomiting occurred in 40% and 25% had disturbing emergence psychoses
0	Anaesthesia was maintained with intermittent ENT1 etomidate ENT1END  in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous pain occurred in 68% of patients and 50% had redness, pain or ENT2 swelling ENT2END related to the injection site, in some cases lasting up to three weeks after anaesthesia
0	Unpremedicated patients were given ENT1 fentanyl  ENT1END  1 microgram/kg followed by etomidate 0.3 mg/kg. Anaesthesia was maintained with intermittent etomidate in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous pain occurred in 68% of patients and 50% had redness, pain or ENT2 swelling ENT2END related to the injection site, in some cases lasting up to three weeks after anaesthesia
0	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and ENT1 status epilepticus ENT1END  Electroencephalographic and behavioral monitoring revealed a profound reduction of the threshold for pilocarpine-induced convulsions. Morphological analysis of frontal forebrain sections with light microscopy revealed seizure-related damage to the hippocampal formation, thalamus, amygdala, olfactory cortex, substantia nigra and neocortex, which is typically observed with pilocarpine in doses exceeding 350 mg/kg. Bilateral intrastriatal injections of isoniazid did not augment seizures produced by pilocarpine, 200 mg/kg. Application of an irreversible inhibitor of GABA transaminase, ENT2 gamma-vinyl-GABA ENT2END (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg
0	In animals pretreated with microinjections of ENT1 isoniazid  ENT1END  150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and ENT2 status epilepticus ENT2END
0	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the ENT1 GABA  ENT1END synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and ENT2 status epilepticus ENT2END
0	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of ENT1 pilocarpine  ENT1END  100 and 200 mg/kg, resulted in severe motor limbic seizures and ENT2 status epilepticus ENT2END
0	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, ENT1 L-glutamic acid  ENT1END decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and ENT2 status epilepticus ENT2END
0	Susceptibility to ENT1 seizures  ENT1END  produced by pilocarpine in rats after microinjection of isoniazid or ENT2 gamma-vinyl-GABA ENT2END into the substantia nigra
0	Bilateral intrastriatal injections of ENT1 isoniazid ENT1END did not augment ENT2 seizures ENT2END produced by pilocarpine, 200 mg/kg
0	The results demonstrate that the threshold for pilocarpine-induced ENT1 seizures ENT1END in rats is subjected to the regulation of the ENT2 GABA ENT2END -mediated synaptic inhibition within the substantia nigra
1	The results demonstrate that the threshold for ENT1 pilocarpine  ENT1END induced ENT2 seizures ENT2END in rats is subjected to the regulation of the GABA-mediated synaptic inhibition within the substantia nigra
0	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, ENT1 L-glutamic acid ENT1END  decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic ENT2 seizures ENT2END and status epilepticus
0	This treatment was also sufficient to protect animals from the occurrence of ENT1 brain damage ENT1END  Microinjections of ENT2 gamma-vinyl-GABA ENT2END , 5 micrograms, into the dorsal striatum, bilaterally, failed to prevent the development of convulsions produced by pilocarpine, 380 mg/kg
0	Bilateral intrastriatal injections of ENT1 isoniazid  ENT1END  did not augment seizures produced by pilocarpine, 200 mg/kg. Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg. This treatment was also sufficient to protect animals from the occurrence of ENT2 brain damage ENT2END
0	Application of an irreversible inhibitor of ENT1 GABA  ENT1END transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg. This treatment was also sufficient to protect animals from the occurrence of ENT2 brain damage ENT2END
0	Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by ENT1 pilocarpine  ENT1END  380 mg/kg. This treatment was also sufficient to protect animals from the occurrence of ENT2 brain damage ENT2END
0	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, ENT1 L-glutamic acid  ENT1END  decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus. Electroencephalographic and behavioral monitoring revealed a profound reduction of the threshold for pilocarpine-induced convulsions. Morphological analysis of frontal forebrain sections with light microscopy revealed seizure-related damage to the hippocampal formation, thalamus, amygdala, olfactory cortex, substantia nigra and neocortex, which is typically observed with pilocarpine in doses exceeding 350 mg/kg. Bilateral intrastriatal injections of isoniazid did not augment seizures produced by pilocarpine, 200 mg/kg. Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg. This treatment was also sufficient to protect animals from the occurrence of ENT2 brain damage ENT2END
0	Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or ENT1 gamma-vinyl-GABA ENT1END  into the substantia nigra.Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of ENT2 temporal lobe epilepsy ENT2END and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain
0	Susceptibility to seizures produced by pilocarpine in rats after microinjection of ENT1 isoniazid  ENT1END  or gamma-vinyl-GABA into the substantia nigra.Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of ENT2 temporal lobe epilepsy ENT2END and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain
0	Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of ENT1 temporal lobe epilepsy ENT1END  and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain. In the present study, the effects of manipulating the activity of the ENT2 gamma-aminobutyric acid ENT2END (GABA)-mediated synaptic inhibition within the substantia nigra on seizures produced by pilocarpine in rats, were investigated
0	ENT1 Pilocarpine  ENT1END  given intraperitoneally to rats, reproduces the neuropathological sequelae of ENT2 temporal lobe epilepsy ENT2END and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain
0	Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of ENT1 temporal lobe epilepsy  ENT1END  and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain. In the present study, the effects of manipulating the activity of the gamma-aminobutyric acid (GABA)-mediated synaptic inhibition within the substantia nigra on seizures produced by pilocarpine in rats, were investigated. In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, ENT2 L-glutamic acid ENT2END decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus
0	Among the patients with 1 year of follow-up, ENT1 NVP ENT1END therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05). ENT2 Anemia ENT2END and hepatitis often occur within 12 weeks of initiating generic HAART
0	Clinically significant ENT1 anemia ENT1END (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with ENT2 alanine ENT2END aminotransferase > 5 times upper limits of normal) in 3
0	1%), and AZT + ENT1 3TC  ENT1END + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant ENT2 anemia ENT2END (hemoglobin <7 g/dL) was observed in 5
0	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and ENT1 d4T  ENT1END therapy with developing peripheral neuropathy (p < 0.05). ENT2 Anemia ENT2END and hepatitis often occur within 12 weeks of initiating generic HAART
0	1%), and AZT + 3TC + ENT1 EFV  ENT1END (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant ENT2 anemia ENT2END (hemoglobin <7 g/dL) was observed in 5
0	1%), and ENT1 AZT  ENT1END + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant ENT2 anemia ENT2END (hemoglobin <7 g/dL) was observed in 5
1	Among the patients with 1 year of follow-up, ENT1 NVP ENT1END  therapy was significantly associated with developing ENT2 rash ENT2END and d4T therapy with developing peripheral neuropathy (p < 0
0	The most common adverse events and median CD4 at time of event were ENT1 rash  ENT1END (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with ENT2 alanine ENT2END aminotransferase > 5 times upper limits of normal) in 3
0	1%), and AZT + ENT1 3TC  ENT1END  + EFV (5.4%). The most common adverse events and median CD4 at time of event were ENT2 rash ENT2END (15
0	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing ENT1 rash  ENT1END  and ENT2 d4T ENT2END therapy with developing peripheral neuropathy (p < 0
0	1%), and AZT + 3TC + ENT1 EFV  ENT1END  (5.4%). The most common adverse events and median CD4 at time of event were ENT2 rash ENT2END (15
0	1%), and ENT1 AZT  ENT1END  + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were ENT2 rash ENT2END (15
0	Women were significantly more likely to experience ENT1 lactic acidosis  ENT1END  while men were significantly more likely to experience immune reconstitution syndrome (p < 0.05). Among the patients with 1 year of follow-up, ENT2 NVP ENT2END therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0
0	4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with ENT1 alanine  ENT1END  aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience ENT2 lactic acidosis ENT2END , while men were significantly more likely to experience immune reconstitution syndrome (p < 0
0	1%), and AZT + ENT1 3TC  ENT1END  + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience ENT2 lactic acidosis ENT2END , while men were significantly more likely to experience immune reconstitution syndrome (p < 0
0	Women were significantly more likely to experience ENT1 lactic acidosis  ENT1END , while men were significantly more likely to experience immune reconstitution syndrome (p < 0.05). Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and ENT2 d4T ENT2END therapy with developing peripheral neuropathy (p < 0
0	1%), and AZT + 3TC + ENT1 EFV  ENT1END  (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience ENT2 lactic acidosis ENT2END , while men were significantly more likely to experience immune reconstitution syndrome (p < 0
0	1%), and ENT1 AZT  ENT1END  + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience ENT2 lactic acidosis ENT2END , while men were significantly more likely to experience immune reconstitution syndrome (p < 0
0	To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 ENT1 HIV-infected ENT1END individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India. The most common regimens were 3TC + d4T + ENT2 nevirapine ENT2END (NVP) (54
0	To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 ENT1 HIV-infected  ENT1END  individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India. The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with ENT2 alanine ENT2END aminotransferase > 5 times upper limits of normal) in 3
0	To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 ENT1 HIV-infected ENT1END  individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India. The most common regimens were ENT2 3TC ENT2END + d4T + nevirapine (NVP) (54
0	To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 ENT1 HIV-infected ENT1END  individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India. The most common regimens were 3TC + ENT2 d4T ENT2END + nevirapine (NVP) (54
0	To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 ENT1 HIV-infected ENT1END  individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India. The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + ENT2 efavirenz ENT2END (EFV) (20
0	To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 ENT1 HIV-infected ENT1END  individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India. The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), ENT2 zidovudine ENT2END (AZT) + 3TC + NVP (14
0	Among the patients with 1 year of follow-up, ENT1 NVP ENT1END  therapy was significantly associated with developing rash and d4T therapy with developing ENT2 peripheral neuropathy ENT2END (p < 0
0	2%; CD4, 285 cells/microL) and ENT1 peripheral neuropathy  ENT1END (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with ENT2 alanine ENT2END aminotransferase > 5 times upper limits of normal) in 3
0	1%), and AZT + ENT1 3TC  ENT1END  + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and ENT2 peripheral neuropathy ENT2END (9
1	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and ENT1 d4T  ENT1END  therapy with developing ENT2 peripheral neuropathy ENT2END (p < 0
0	1%), and AZT + 3TC + ENT1 EFV  ENT1END  (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and ENT2 peripheral neuropathy ENT2END (9
0	1%), and ENT1 AZT  ENT1END  + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and ENT2 peripheral neuropathy ENT2END (9
0	Among the patients with 1 year of follow-up, ENT1 NVP ENT1END  therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05). Anemia and hepatitis often occur within 12 weeks of initiating generic HAART. Frequent and early monitoring for these ENT2 toxicities ENT2END is warranted in developing countries where generic HAART is increasingly available
0	4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with ENT1 alanine  ENT1END  aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience immune reconstitution syndrome (p < 0.05). Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05). Anemia and hepatitis often occur within 12 weeks of initiating generic HAART. Frequent and early monitoring for these ENT2 toxicities ENT2END is warranted in developing countries where generic HAART is increasingly available
0	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and ENT1 d4T  ENT1END  therapy with developing peripheral neuropathy (p < 0.05). Anemia and hepatitis often occur within 12 weeks of initiating generic HAART. Frequent and early monitoring for these ENT2 toxicities ENT2END is warranted in developing countries where generic HAART is increasingly available
0	Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience ENT1 immune reconstitution syndrome  ENT1END (p < 0.05). Among the patients with 1 year of follow-up, ENT2 NVP ENT2END therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0
0	4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with ENT1 alanine  ENT1END  aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience ENT2 immune reconstitution syndrome ENT2END (p < 0
0	1%), and AZT + ENT1 3TC  ENT1END  + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience ENT2 immune reconstitution syndrome ENT2END (p < 0
0	Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience ENT1 immune reconstitution syndrome  ENT1END  (p < 0.05). Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and ENT2 d4T ENT2END therapy with developing peripheral neuropathy (p < 0
0	1%), and AZT + 3TC + ENT1 EFV  ENT1END  (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience ENT2 immune reconstitution syndrome ENT2END (p < 0
0	1%), and ENT1 AZT  ENT1END  + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience ENT2 immune reconstitution syndrome ENT2END (p < 0
0	Among the patients with 1 year of follow-up, ENT1 NVP ENT1END  therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05). Anemia and ENT2 hepatitis ENT2END often occur within 12 weeks of initiating generic HAART
0	4% of patients (CD4, 165 cells/microL) and ENT1 hepatitis  ENT1END (clinical jaundice with ENT2 alanine ENT2END aminotransferase > 5 times upper limits of normal) in 3
0	1%), and AZT + ENT1 3TC  ENT1END  + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and ENT2 hepatitis ENT2END (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3
0	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and ENT1 d4T  ENT1END  therapy with developing peripheral neuropathy (p < 0.05). Anemia and ENT2 hepatitis ENT2END often occur within 12 weeks of initiating generic HAART
0	1%), and AZT + 3TC + ENT1 EFV  ENT1END  (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and ENT2 hepatitis ENT2END (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3
0	1%), and ENT1 AZT  ENT1END  + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and ENT2 hepatitis ENT2END (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3
0	4% of patients (CD4, 165 cells/microL) and hepatitis (clinical ENT1 jaundice  ENT1END with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience immune reconstitution syndrome (p < 0.05). Among the patients with 1 year of follow-up, ENT2 NVP ENT2END therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0
0	4% of patients (CD4, 165 cells/microL) and hepatitis (clinical ENT1 jaundice  ENT1END  with ENT2 alanine ENT2END aminotransferase > 5 times upper limits of normal) in 3
0	1%), and AZT + ENT1 3TC  ENT1END  + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical ENT2 jaundice ENT2END with alanine aminotransferase > 5 times upper limits of normal) in 3
0	5%), 3TC + ENT1 d4T  ENT1END + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical ENT2 jaundice ENT2END with alanine aminotransferase > 5 times upper limits of normal) in 3
0	1%), and AZT + 3TC + ENT1 EFV  ENT1END  (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical ENT2 jaundice ENT2END with alanine aminotransferase > 5 times upper limits of normal) in 3
0	1%), and ENT1 AZT  ENT1END  + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical ENT2 jaundice ENT2END with alanine aminotransferase > 5 times upper limits of normal) in 3
0	Alternating sinus rhythm and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for ENT1 angina ENT1END with 80 mg ENT2 propranolol ENT2END daily
1	Alternating sinus rhythm and intermittent sinoatrial block induced by ENT1 propranolol  ENT1END . ENT2 Alternating sinus rhythm ENT2END and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg propranolol daily
0	ENT1 Atropine ENT1END 1 mg given intravenously resulted in shortening of all P-P intervals without changing the rhythm. The abnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2/1 ENT2 S-A block ENT2END was seen
1	Alternating sinus rhythm and intermittent ENT1 sinoatrial block  ENT1END  induced by ENT2 propranolol ENT2END
0	ENT1 Atropine ENT1END  1 mg given intravenously resulted in shortening of all P-P intervals without changing the rhythm. The abnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2/1 S-A block was seen. This was accepted as evidence for propranolol being the cause of this ENT2 conduction disorder ENT2END
0	This was accepted as evidence for ENT1 propranolol  ENT1END being the cause of this ENT2 conduction disorder ENT2END
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENT1 penicillin ENT1END are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, ENT2 pupillary abnormalities ENT2END , and conjunctival hemorrhages with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENT1 epinephrine  ENT1END  or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, ENT2 pupillary abnormalities ENT2END , and conjunctival hemorrhages with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENT1 lidocaine  ENT1END  epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, ENT2 pupillary abnormalities ENT2END , and conjunctival hemorrhages with edema
0	Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting ENT1 corticosteroid  ENT1END  suspensions in combination with other drugs: I. Clinical studies.Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, ENT2 pupillary abnormalities ENT2END , and conjunctival hemorrhages with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with ENT1 methylprednisolone acetate  ENT1END in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, ENT2 pupillary abnormalities ENT2END , and conjunctival hemorrhages with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENT1 penicillin ENT1END  are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked visual loss, constricted visual fields, optic nerve pallor, vascular attenuation, and ENT2 chorioretinal atrophy ENT2END
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENT1 epinephrine  ENT1END , or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked visual loss, constricted visual fields, optic nerve pallor, vascular attenuation, and ENT2 chorioretinal atrophy ENT2END
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENT1 lidocaine  ENT1END , epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked visual loss, constricted visual fields, optic nerve pallor, vascular attenuation, and ENT2 chorioretinal atrophy ENT2END
0	Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting ENT1 corticosteroid  ENT1END  suspensions in combination with other drugs: I. Clinical studies.Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked visual loss, constricted visual fields, optic nerve pallor, vascular attenuation, and ENT2 chorioretinal atrophy ENT2END
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with ENT1 methylprednisolone acetate  ENT1END  in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked visual loss, constricted visual fields, optic nerve pallor, vascular attenuation, and ENT2 chorioretinal atrophy ENT2END
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENT1 penicillin ENT1END  are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked ENT2 visual loss ENT2END , constricted visual fields, optic nerve pallor, vascular attenuation, and chorioretinal atrophy
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENT1 epinephrine  ENT1END , or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked ENT2 visual loss ENT2END , constricted visual fields, optic nerve pallor, vascular attenuation, and chorioretinal atrophy
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENT1 lidocaine  ENT1END , epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked ENT2 visual loss ENT2END , constricted visual fields, optic nerve pallor, vascular attenuation, and chorioretinal atrophy
0	Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting ENT1 corticosteroid  ENT1END  suspensions in combination with other drugs: I. Clinical studies.Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked ENT2 visual loss ENT2END , constricted visual fields, optic nerve pallor, vascular attenuation, and chorioretinal atrophy
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with ENT1 methylprednisolone acetate  ENT1END  in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked ENT2 visual loss ENT2END , constricted visual fields, optic nerve pallor, vascular attenuation, and chorioretinal atrophy
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with ENT1 blindness  ENT1END following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENT2 penicillin ENT2END are reported
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with ENT1 blindness  ENT1END  following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENT2 epinephrine ENT2END , or penicillin are reported
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with ENT1 blindness  ENT1END  following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENT2 lidocaine ENT2END , epinephrine, or penicillin are reported
0	Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting ENT1 corticosteroid  ENT1END  suspensions in combination with other drugs: I. Clinical studies.Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with ENT2 blindness ENT2END following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with ENT1 blindness  ENT1END  following head and neck soft-tissue injection with ENT2 methylprednisolone acetate ENT2END in combination with lidocaine, epinephrine, or penicillin are reported
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENT1 penicillin ENT1END  are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with ENT2 edema ENT2END
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENT1 epinephrine  ENT1END , or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with ENT2 edema ENT2END
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENT1 lidocaine  ENT1END , epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with ENT2 edema ENT2END
0	Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting ENT1 corticosteroid  ENT1END  suspensions in combination with other drugs: I. Clinical studies.Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with ENT2 edema ENT2END
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with ENT1 methylprednisolone acetate  ENT1END  in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with ENT2 edema ENT2END
0	Two well-documented cases of bilateral ENT1 retinal artery and choriocapillaris occlusions  ENT1END with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENT2 penicillin ENT2END are reported
0	Two well-documented cases of bilateral ENT1 retinal artery and choriocapillaris occlusions  ENT1END  with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENT2 epinephrine ENT2END , or penicillin are reported
0	Two well-documented cases of bilateral ENT1 retinal artery and choriocapillaris occlusions  ENT1END  with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENT2 lidocaine ENT2END , epinephrine, or penicillin are reported
0	Bilateral ENT1 retinal artery and choriocapillaris occlusion  ENT1END  following the injection of long-acting ENT2 corticosteroid ENT2END suspensions in combination with other drugs: I
1	Two well-documented cases of bilateral ENT1 retinal artery and choriocapillaris occlusions  ENT1END  with blindness following head and neck soft-tissue injection with ENT2 methylprednisolone acetate ENT2END in combination with lidocaine, epinephrine, or penicillin are reported
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENT1 penicillin ENT1END  are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival ENT2 hemorrhages ENT2END with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENT1 epinephrine  ENT1END , or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival ENT2 hemorrhages ENT2END with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENT1 lidocaine  ENT1END , epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival ENT2 hemorrhages ENT2END with edema
0	Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting ENT1 corticosteroid  ENT1END  suspensions in combination with other drugs: I. Clinical studies.Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival ENT2 hemorrhages ENT2END with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with ENT1 methylprednisolone acetate  ENT1END  in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival ENT2 hemorrhages ENT2END with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENT1 penicillin ENT1END  are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze ENT2 palsy ENT2END , pupillary abnormalities, and conjunctival hemorrhages with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENT1 epinephrine  ENT1END , or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze ENT2 palsy ENT2END , pupillary abnormalities, and conjunctival hemorrhages with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENT1 lidocaine  ENT1END , epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze ENT2 palsy ENT2END , pupillary abnormalities, and conjunctival hemorrhages with edema
0	Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting ENT1 corticosteroid  ENT1END  suspensions in combination with other drugs: I. Clinical studies.Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze ENT2 palsy ENT2END , pupillary abnormalities, and conjunctival hemorrhages with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with ENT1 methylprednisolone acetate  ENT1END  in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze ENT2 palsy ENT2END , pupillary abnormalities, and conjunctival hemorrhages with edema
0	Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during ENT1 epirubicine ENT1END -based chemotherapy.AIMS: To investigate whether alterations of ENT2 myocardial strain ENT2END and high-sensitive cardiac troponin T (cTnT) could predict future cardiac dysfunction in patients after epirubicin exposure
1	METHODS: Seventy-five patients with non-Hodgkin lymphoma treated with ENT1 epirubicin ENT1END were studied. Blood collection and echocardiography were performed at baseline, 1 day after the third cycle, and 1 day after completion of chemotherapy. Patients were studied using echocardiography during follow-up. Global longitudinal (GLS), circumferential (GCS), and radial strain (GRS) were calculated using speckle tracking echocardiography. Left ventricular ejection fraction was analysed by real-time 3D echocardiography. Cardiotoxicity was defined as a reduction of the LVEF of >5% to <55% with symptoms of ENT2 heart failure ENT2END or an asymptomatic reduction of the LVEF of >10% to <55%
0	The decrease in GLS remained the only independent predictor of ENT1 cardiotoxicity ENT1END (P = 0.000). CONCLUSIONS: GLS combined with cTnT may provide a reliable and non-invasive method to predict cardiac dysfunction in patients receiving ENT2 anthracycline ENT2END -based chemotherapy
1	Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of ENT1 cardiotoxicity  ENT1END  during ENT2 epirubicine ENT2END -based chemotherapy
0	CONCLUSIONS: GLS combined with cTnT may provide a reliable and non-invasive method to predict ENT1 cardiac dysfunction  ENT1END in patients receiving ENT2 anthracycline ENT2END -based chemotherapy
0	AIMS: To investigate whether alterations of myocardial strain and high-sensitive cardiac troponin T (cTnT) could predict future ENT1 cardiac dysfunction ENT1END in patients after ENT2 epirubicin ENT2END exposure
0	METHODS: Seventy-five patients with ENT1 non-Hodgkin lymphoma  ENT1END treated with ENT2 epirubicin ENT2END were studied
1	All animals suffered tonic ENT1 convulsions ENT1END at 18.3 +/- 1.4 min after ENT2 lindane ENT2END administration
0	We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of ENT1 GABA ENT1END  dopamine and its metabolites in 7 brain areas at the onset of ENT2 seizures ENT2END
0	All animals suffered tonic ENT1 convulsions ENT1END  at 18.3 +/- 1.4 min after lindane administration. The concentration of GABA was only slightly but significantly decreased in the colliculi without modifications in the other areas. The concentration of dopamine was increased in the mesencephalon and that of its metabolite ENT2 DOPAC ENT2END was also increased in the mesencephalon and the striatum
0	We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, ENT1 dopamine  ENT1END and its metabolites in 7 brain areas at the onset of ENT2 seizures ENT2END
0	Lindane ( ENT1 gamma-hexachlorocyclohexane ENT1END  is an organochlorine insecticide with known ENT2 neurotoxic ENT2END effects
0	Convulsant effect of lindane and regional brain concentration of ENT1 GABA  ENT1END  and dopamine.Lindane (gamma-hexachlorocyclohexane) is an organochlorine insecticide with known ENT2 neurotoxic ENT2END effects
0	Lindane (gamma-hexachlorocyclohexane) is an organochlorine insecticide with known ENT1 neurotoxic  ENT1END  effects. Its mechanism of action is not well understood although it has been proposed that lindane acts as a non-competitive antagonist at the gamma-aminobutyric acid (GABA)-A receptor. We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, dopamine and its metabolites in 7 brain areas at the onset of seizures. All animals suffered tonic convulsions at 18.3 +/- 1.4 min after lindane administration. The concentration of GABA was only slightly but significantly decreased in the colliculi without modifications in the other areas. The concentration of dopamine was increased in the mesencephalon and that of its metabolite ENT2 DOPAC ENT2END was also increased in the mesencephalon and the striatum
0	Convulsant effect of lindane and regional brain concentration of GABA and ENT1 dopamine  ENT1END .Lindane (gamma-hexachlorocyclohexane) is an organochlorine insecticide with known ENT2 neurotoxic ENT2END effects
0	Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body ENT1 weight loss ENT1END  The inability of ENT2 amiodarone ENT2END to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 hepatoma cells indicates that the effects of amiodarone on the function of this receptor were indirect
0	Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for ENT1 fatty acid  ENT1END oxidation, lipoprotein assembly, and lipid transport. Many of these genes are regulated by the peroxisome proliferator-activated receptor-alpha (PPARalpha), a ligand-activated nuclear hormone receptor transcription factor. The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene. Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body ENT2 weight loss ENT2END
0	Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum ENT1 triglycerides  ENT1END and glucose. Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for fatty acid oxidation, lipoprotein assembly, and lipid transport. Many of these genes are regulated by the peroxisome proliferator-activated receptor-alpha (PPARalpha), a ligand-activated nuclear hormone receptor transcription factor. The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene. Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body ENT2 weight loss ENT2END
0	Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and ENT1 glucose  ENT1END  Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for fatty acid oxidation, lipoprotein assembly, and lipid transport. Many of these genes are regulated by the peroxisome proliferator-activated receptor-alpha (PPARalpha), a ligand-activated nuclear hormone receptor transcription factor. The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene. Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body ENT2 weight loss ENT2END
1	These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against ENT1 amiodarone ENT1END induced ENT2 hepatotoxicity ENT2END
0	Amiodarone, an efficacious and widely used antiarrhythmic agent, has been reported to cause ENT1 hepatotoxicity  ENT1END in some patients. To gain insight into the mechanism of this unwanted effect, mice were administered various doses of amiodarone and examined for changes in hepatic histology and gene regulation. Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose. Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for ENT2 fatty acid ENT2END oxidation, lipoprotein assembly, and lipid transport
0	Amiodarone, an efficacious and widely used antiarrhythmic agent, has been reported to cause ENT1 hepatotoxicity  ENT1END  in some patients. To gain insight into the mechanism of this unwanted effect, mice were administered various doses of amiodarone and examined for changes in hepatic histology and gene regulation. Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum ENT2 triglycerides ENT2END and glucose
0	Amiodarone, an efficacious and widely used antiarrhythmic agent, has been reported to cause ENT1 hepatotoxicity  ENT1END  in some patients. To gain insight into the mechanism of this unwanted effect, mice were administered various doses of amiodarone and examined for changes in hepatic histology and gene regulation. Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and ENT2 glucose ENT2END
0	The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 ENT1 hepatoma ENT1END cells indicates that the effects of ENT2 amiodarone ENT2END on the function of this receptor were indirect
0	Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for ENT1 fatty acid  ENT1END  oxidation, lipoprotein assembly, and lipid transport. Many of these genes are regulated by the peroxisome proliferator-activated receptor-alpha (PPARalpha), a ligand-activated nuclear hormone receptor transcription factor. The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene. Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body weight loss. The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 ENT2 hepatoma ENT2END cells indicates that the effects of amiodarone on the function of this receptor were indirect
0	Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum ENT1 triglycerides  ENT1END  and glucose. Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for fatty acid oxidation, lipoprotein assembly, and lipid transport. Many of these genes are regulated by the peroxisome proliferator-activated receptor-alpha (PPARalpha), a ligand-activated nuclear hormone receptor transcription factor. The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene. Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body weight loss. The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 ENT2 hepatoma ENT2END cells indicates that the effects of amiodarone on the function of this receptor were indirect
0	Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and ENT1 glucose  ENT1END . Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for fatty acid oxidation, lipoprotein assembly, and lipid transport. Many of these genes are regulated by the peroxisome proliferator-activated receptor-alpha (PPARalpha), a ligand-activated nuclear hormone receptor transcription factor. The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene. Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body weight loss. The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 ENT2 hepatoma ENT2END cells indicates that the effects of amiodarone on the function of this receptor were indirect
1	ENT1 Amiodarone ENT1END induced ENT2 hepatomegaly ENT2END , hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose
0	Amiodarone induced ENT1 hepatomegaly  ENT1END , hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose. Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for ENT2 fatty acid ENT2END oxidation, lipoprotein assembly, and lipid transport
0	Amiodarone induced ENT1 hepatomegaly  ENT1END , hepatocyte microvesicular lipid accumulation, and a significant decrease in serum ENT2 triglycerides ENT2END and glucose
0	Amiodarone induced ENT1 hepatomegaly  ENT1END , hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and ENT2 glucose ENT2END
0	After the withdrawal of ENT1 VPA ENT1END therapy, our patient showed a significant ENT2 weight loss ENT2END , a decrease of body mass index, and normalization of metabolic and endocrine parameters; moreover, ultrasound measurements showed a complete normalization
1	We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed obesity during ENT1 VPA ENT1END treatment. Laboratory data revealed ENT2 hyperinsulinemia ENT2END with insulin resistance
1	Laboratory data revealed hyperinsulinemia with ENT1 insulin resistance  ENT1END  After the withdrawal of ENT2 VPA ENT2END therapy, our patient showed a significant weight loss, a decrease of body mass index, and normalization of metabolic and endocrine parameters; moreover, ultrasound measurements showed a complete normalization
1	ENT1 Nonalcoholic fatty liver disease  ENT1END  during ENT2 valproate ENT2END therapy
0	Valproic acid ( ENT1 VPA ENT1END  is effective for the treatment of many types of ENT2 epilepsy ENT2END , but its use can be associated with an increase in body weight
1	We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed ENT1 obesity  ENT1END during ENT2 VPA ENT2END treatment
0	All adenosine receptor agonists significantly ENT1 decreased the locomotor activity ENT1END in mice, and the effects were dose-dependent. It seems that adenosine A1 and A2 receptors might be involved in this reaction. Moreover, all adenosine receptor agonists: 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680), A2A receptor agonist, N6-cyclopentyladenosine (CPA), A1 receptor agonist, and ENT2 5'-N-ethylcarboxamidoadenosine ENT2END (NECA), A2/A1 receptor agonist significantly and dose-dependently decreased cocaine-induced locomotor activity
0	All ENT1 adenosine  ENT1END receptor agonists significantly ENT2 decreased the locomotor activity ENT2END in mice, and the effects were dose-dependent
1	The influence of adenosine receptor agonists and antagonists on cocaine-and ENT1 amphetamine  ENT1END induced hyperactivity was examined in mice. All adenosine receptor agonists significantly ENT2 decreased the locomotor activity ENT2END in mice, and the effects were dose-dependent
1	The influence of adenosine receptor agonists and antagonists on ENT1 cocaine  ENT1END and amphetamine-induced hyperactivity was examined in mice. All adenosine receptor agonists significantly ENT2 decreased the locomotor activity ENT2END in mice, and the effects were dose-dependent
1	All adenosine receptor agonists significantly ENT1 decreased the locomotor activity ENT1END  in mice, and the effects were dose-dependent. It seems that adenosine A1 and A2 receptors might be involved in this reaction. Moreover, all adenosine receptor agonists: 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680), A2A receptor agonist, N6-cyclopentyladenosine (CPA), A1 receptor agonist, and 5'-N-ethylcarboxamidoadenosine (NECA), A2/A1 receptor agonist significantly and dose-dependently decreased cocaine-induced locomotor activity. CPA reduced cocaine action at the doses which, given alone, did not influence motility, while CGS 21680 and NECA decreased the action of cocaine at the doses which, given alone, decreased locomotor activity in animals. These results suggest the involvement of both adenosine receptors in the action of cocaine although agonists of A1 receptors seem to have stronger influence on it. The selective blockade of A2 adenosine receptor by ENT2 DMPX ENT2END (3,7-dimethyl-1-propargylxanthine) significantly enhanced cocaine-induced locomotor activity of animals
0	All adenosine receptor agonists significantly ENT1 decreased the locomotor activity ENT1END  in mice, and the effects were dose-dependent. It seems that adenosine A1 and A2 receptors might be involved in this reaction. Moreover, all adenosine receptor agonists: 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680), A2A receptor agonist, ENT2 N6-cyclopentyladenosine ENT2END (CPA), A1 receptor agonist, and 5'-N-ethylcarboxamidoadenosine (NECA), A2/A1 receptor agonist significantly and dose-dependently decreased cocaine-induced locomotor activity
0	All adenosine receptor agonists significantly ENT1 decreased the locomotor activity ENT1END  in mice, and the effects were dose-dependent. It seems that adenosine A1 and A2 receptors might be involved in this reaction. Moreover, all adenosine receptor agonists: ENT2 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine ENT2END (CGS 21680), A2A receptor agonist, N6-cyclopentyladenosine (CPA), A1 receptor agonist, and 5'-N-ethylcarboxamidoadenosine (NECA), A2/A1 receptor agonist significantly and dose-dependently decreased cocaine-induced locomotor activity
0	The influence of adenosine receptor agonists and antagonists on cocaine-and amphetamine-induced ENT1 hyperactivity  ENT1END was examined in mice. All adenosine receptor agonists significantly decreased the locomotor activity in mice, and the effects were dose-dependent. It seems that adenosine A1 and A2 receptors might be involved in this reaction. Moreover, all adenosine receptor agonists: 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680), A2A receptor agonist, N6-cyclopentyladenosine (CPA), A1 receptor agonist, and ENT2 5'-N-ethylcarboxamidoadenosine ENT2END (NECA), A2/A1 receptor agonist significantly and dose-dependently decreased cocaine-induced locomotor activity
0	Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced ENT1 hyperactivity ENT1END .The influence of ENT2 adenosine ENT2END receptor agonists and antagonists on cocaine-and amphetamine-induced hyperactivity was examined in mice
0	Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than ENT1 amphetamine  ENT1END -induced ENT2 hyperactivity ENT2END
0	Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced ENT1 hyperactivity  ENT1END  The selective blockade of A2 adenosine receptors (DMPX) and non-selective blockade of adenosine receptors ( ENT2 caffeine ENT2END ) significantly increased the action of amphetamine in the locomotor activity test
0	ENT1 Cocaine  ENT1END -induced ENT2 hyperactivity ENT2END is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity
0	CPT ( ENT1 8-cyclopentyltheophylline ENT1END --A1 receptor antagonist, did not show any influence in this test. Similarly, all adenosine receptor agonists decreased amphetamine-induced ENT2 hyperactivity ENT2END , but at the higher doses than those which were active in cocaine-induced hyperactivity
0	Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced ENT1 hyperactivity  ENT1END . The selective blockade of A2 adenosine receptors ( ENT2 DMPX ENT2END ) and non-selective blockade of adenosine receptors (caffeine) significantly increased the action of amphetamine in the locomotor activity test
0	The influence of adenosine receptor agonists and antagonists on cocaine-and amphetamine-induced ENT1 hyperactivity  ENT1END  was examined in mice. All adenosine receptor agonists significantly decreased the locomotor activity in mice, and the effects were dose-dependent. It seems that adenosine A1 and A2 receptors might be involved in this reaction. Moreover, all adenosine receptor agonists: 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680), A2A receptor agonist, ENT2 N6-cyclopentyladenosine ENT2END (CPA), A1 receptor agonist, and 5'-N-ethylcarboxamidoadenosine (NECA), A2/A1 receptor agonist significantly and dose-dependently decreased cocaine-induced locomotor activity
0	The influence of adenosine receptor agonists and antagonists on cocaine-and amphetamine-induced ENT1 hyperactivity  ENT1END  was examined in mice. All adenosine receptor agonists significantly decreased the locomotor activity in mice, and the effects were dose-dependent. It seems that adenosine A1 and A2 receptors might be involved in this reaction. Moreover, all adenosine receptor agonists: ENT2 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine ENT2END (CGS 21680), A2A receptor agonist, N6-cyclopentyladenosine (CPA), A1 receptor agonist, and 5'-N-ethylcarboxamidoadenosine (NECA), A2/A1 receptor agonist significantly and dose-dependently decreased cocaine-induced locomotor activity
1	ENT1 Adrenaline ENT1END induced ENT2 hypertension ENT2END was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving adrenaline for 30 s
0	Adrenaline-induced ENT1 hypertension ENT1END  was used to destroy the BBB, which was evaluated using ENT2 triphenyltetrazolium ENT2END (TTC) staining of the brain slices just after giving adrenaline for 30 s
0	After ENT1 adrenaline ENT1END infusion for 30 s, there were large unstained areas in the left brain in right-pawed animals, and vice versa in left-pawed animals. Similar results were obtained in ENT2 seizure ENT2END -induced breakdown of BBB
0	In normal rats, the whole brain sections exhibited complete staining with ENT1 TTC  ENT1END  After adrenaline infusion for 30 s, there were large unstained areas in the left brain in right-pawed animals, and vice versa in left-pawed animals. Similar results were obtained in ENT2 seizure ENT2END -induced breakdown of BBB
0	We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the ENT1 emergency department ENT1END with near-syncope. The boy had been treated with intravenous ENT2 methyldopa ENT2END during a trauma admission seven weeks prior to presentation
0	We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the ENT1 emergency department ENT1END  with near-syncope. The boy had been treated with intravenous methyldopa during a trauma admission seven weeks prior to presentation. Evaluation revealed a hemoglobin of three grams, 3+ Coombs' test with polyspecific anti-human globulin and monospecific IgG reagents, and a warm reacting autoantibody. Transfusion and ENT2 corticosteroid ENT2END therapy resulted in a complete recovery of the patient
1	ENT1 Methyldopa  ENT1END -induced ENT2 hemolytic anemia ENT2END in a 15 year old presenting as near-syncope
0	Transfusion and ENT1 corticosteroid ENT1END  therapy resulted in a complete recovery of the patient. Emergency physicians treating children must be aware of this syndrome in order to diagnose and treat it correctly. A brief review of autoimmune and drug-induced ENT2 hemolytic anemias ENT2END is provided
0	ENT1 Methyldopa ENT1END causes an ENT2 autoimmune hemolytic anemia ENT2END in a small percentage of patients who take the drug
0	Methyldopa causes an ENT1 autoimmune hemolytic anemia  ENT1END  in a small percentage of patients who take the drug. We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the emergency department with near-syncope. The boy had been treated with intravenous methyldopa during a trauma admission seven weeks prior to presentation. Evaluation revealed a hemoglobin of three grams, 3+ Coombs' test with polyspecific anti-human globulin and monospecific IgG reagents, and a warm reacting autoantibody. Transfusion and ENT2 corticosteroid ENT2END therapy resulted in a complete recovery of the patient
0	The boy had been treated with intravenous ENT1 methyldopa ENT1END  during a ENT2 trauma ENT2END admission seven weeks prior to presentation
0	The boy had been treated with intravenous methyldopa during a ENT1 trauma  ENT1END  admission seven weeks prior to presentation. Evaluation revealed a hemoglobin of three grams, 3+ Coombs' test with polyspecific anti-human globulin and monospecific IgG reagents, and a warm reacting autoantibody. Transfusion and ENT2 corticosteroid ENT2END therapy resulted in a complete recovery of the patient
0	Methyldopa-induced hemolytic anemia in a 15 year old presenting as near- ENT1 syncope  ENT1END . ENT2 Methyldopa ENT2END is an antihypertensive medication which is available generically and under the trade name Aldomet that is widely prescribed in the adult population and infrequently used in children
0	We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the emergency department with near- ENT1 syncope  ENT1END  The boy had been treated with intravenous methyldopa during a trauma admission seven weeks prior to presentation. Evaluation revealed a hemoglobin of three grams, 3+ Coombs' test with polyspecific anti-human globulin and monospecific IgG reagents, and a warm reacting autoantibody. Transfusion and ENT2 corticosteroid ENT2END therapy resulted in a complete recovery of the patient
0	The mean ENT1 H ENT1END concentration during hypotension in the inspiratory gas was 0.7 +/- 0.1 vol%, the mean E concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%. In addition, the patients received fentanyl and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENT2 tachy- or bradycardia ENT2END
0	In addition, the patients received fentanyl and ENT1 d-tubocurarine  ENT1END  The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENT2 tachy- or bradycardia ENT2END
0	During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the ENT1 isoflurane ENT1END group. After hypotension there was no rebound phenomenon in either blood pressure or heart rate. These results indicate that labetalol induces easily adjustable hypotension without compensatory ENT2 tachycardia ENT2END and rebound hypertension
0	In addition, the patients received ENT1 fentanyl  ENT1END and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENT2 tachy- or bradycardia ENT2END
0	During hypotension, the heart rate was stable without ENT1 tachy- or bradycardia ENT1END . The operating conditions regarding bleeding were estimated in a double-blind manner, and did not differ significantly between the groups. During hypotension, the serum ENT2 creatinine ENT2END concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group
0	These results indicate that ENT1 labetalol  ENT1END induces easily adjustable hypotension without compensatory ENT2 tachycardia ENT2END and rebound hypertension
0	1 vol%, the mean ENT1 E  ENT1END concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%. In addition, the patients received fentanyl and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENT2 tachy- or bradycardia ENT2END
0	The mean ENT1 H ENT1END  concentration during hypotension in the inspiratory gas was 0.7 +/- 0.1 vol%, the mean E concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%. In addition, the patients received fentanyl and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without tachy- or bradycardia. The operating conditions regarding ENT2 bleeding ENT2END were estimated in a double-blind manner, and did not differ significantly between the groups
0	In addition, the patients received fentanyl and ENT1 d-tubocurarine  ENT1END . The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without tachy- or bradycardia. The operating conditions regarding ENT2 bleeding ENT2END were estimated in a double-blind manner, and did not differ significantly between the groups
0	The operating conditions regarding ENT1 bleeding  ENT1END  were estimated in a double-blind manner, and did not differ significantly between the groups. During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the ENT2 isoflurane ENT2END group
0	In addition, the patients received ENT1 fentanyl  ENT1END  and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without tachy- or bradycardia. The operating conditions regarding ENT2 bleeding ENT2END were estimated in a double-blind manner, and did not differ significantly between the groups
0	The operating conditions regarding ENT1 bleeding  ENT1END  were estimated in a double-blind manner, and did not differ significantly between the groups. During hypotension, the serum ENT2 creatinine ENT2END concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group
0	The initial dose of ENT1 labetalol  ENT1END for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without tachy- or bradycardia. The operating conditions regarding ENT2 bleeding ENT2END were estimated in a double-blind manner, and did not differ significantly between the groups
0	1 vol%, the mean ENT1 E  ENT1END  concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%. In addition, the patients received fentanyl and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without tachy- or bradycardia. The operating conditions regarding ENT2 bleeding ENT2END were estimated in a double-blind manner, and did not differ significantly between the groups
0	During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the ENT1 isoflurane ENT1END  group. After hypotension there was no rebound phenomenon in either blood pressure or heart rate. These results indicate that labetalol induces easily adjustable hypotension without compensatory tachycardia and rebound ENT2 hypertension ENT2END
0	During hypotension, the serum ENT1 creatinine  ENT1END  concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group. After hypotension there was no rebound phenomenon in either blood pressure or heart rate. These results indicate that labetalol induces easily adjustable hypotension without compensatory tachycardia and rebound ENT2 hypertension ENT2END
0	These results indicate that ENT1 labetalol  ENT1END  induces easily adjustable hypotension without compensatory tachycardia and rebound ENT2 hypertension ENT2END
1	The mean ENT1 H ENT1END  concentration during ENT2 hypotension ENT2END in the inspiratory gas was 0
0	In addition, the patients received fentanyl and ENT1 d-tubocurarine ENT1END . The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During ENT2 hypotension ENT2END , the heart rate was stable without tachy- or bradycardia
1	During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the ENT1 isoflurane ENT1END  group. After ENT2 hypotension ENT2END there was no rebound phenomenon in either blood pressure or heart rate
0	In addition, the patients received ENT1 fentanyl  ENT1END  and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During ENT2 hypotension ENT2END , the heart rate was stable without tachy- or bradycardia
0	During ENT1 hypotension  ENT1END  the serum ENT2 creatinine ENT2END concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group
1	Deliberate ENT1 hypotension  ENT1END  induced by ENT2 labetalol ENT2END with halothane, enflurane or isoflurane for middle-ear surgery
1	Deliberate ENT1 hypotension  ENT1END  induced by labetalol with halothane, ENT2 enflurane ENT2END or isoflurane for middle-ear surgery
0	The mean ENT1 H ENT1END  concentration during hypotension in the inspiratory gas was 0.7 +/- 0.1 vol%, the mean E concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%. In addition, the patients received fentanyl and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENT2 tachy- or bradycardia ENT2END
0	In addition, the patients received fentanyl and ENT1 d-tubocurarine  ENT1END . The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENT2 tachy- or bradycardia ENT2END
0	2 vol%, and the mean ENT1 I  ENT1END concentration 1.0 +/- 0.1 vol%. In addition, the patients received fentanyl and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENT2 tachy- or bradycardia ENT2END
0	In addition, the patients received ENT1 fentanyl  ENT1END  and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENT2 tachy- or bradycardia ENT2END
0	During hypotension, the heart rate was stable without ENT1 tachy- or bradycardia  ENT1END . The operating conditions regarding bleeding were estimated in a double-blind manner, and did not differ significantly between the groups. During hypotension, the serum ENT2 creatinine ENT2END concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group
0	The initial dose of ENT1 labetalol  ENT1END  for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENT2 tachy- or bradycardia ENT2END
0	1 vol%, the mean ENT1 E  ENT1END  concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%. In addition, the patients received fentanyl and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENT2 tachy- or bradycardia ENT2END
0	Skin tests and in vitro lymphocyte stimulation revealed that the patient was sensitized to cephalothin and also to ENT1 ampicillin ENT1END  Careful investigation of drug-induced ENT2 hemolytic anemias ENT2END reveals the complexity of the immune mechanisms involved
1	ENT1 Cephalothin  ENT1END -induced immune ENT2 hemolytic anemia ENT2END
0	A patient with ENT1 renal disease  ENT1END developed Coombs-positive hemolytic anemia while receiving cephalothin therapy. An anti-cephalothin IgG antibody was detected in the patient's serum and in the eluates from her erythrocytes. In addition, nonimmunologic binding of normal and patient's serum proteins to her own and cephalothin-coated normal red cells was demonstrated. Skin tests and in vitro lymphocyte stimulation revealed that the patient was sensitized to cephalothin and also to ENT2 ampicillin ENT2END
0	ENT1 Cephalothin  ENT1END -induced immune hemolytic anemia.A patient with ENT2 renal disease ENT2END developed Coombs-positive hemolytic anemia while receiving cephalothin therapy
1	It is characterized by its intense urotoxic action, leading to ENT1 hemorrhagic cystitis ENT1END  This side effect of ENT2 IFO ENT2END raises the requirement for the co-administration with sodium 2-sulfanylethanesulfonate (Mesna) aiming to avoid or minimize this effect
0	Ifosfamide (IFO) is an alkylating ENT1 nitrogen  ENT1END mustard, administrated as an antineoplasmic agent. It is characterized by its intense urotoxic action, leading to ENT2 hemorrhagic cystitis ENT2END
0	It is characterized by its intense urotoxic action, leading to ENT1 hemorrhagic cystitis ENT1END . This side effect of IFO raises the requirement for the co-administration with ENT2 sodium 2-sulfanylethanesulfonate ENT2END (Mesna) aiming to avoid or minimize this effect
0	Mesna significantly reduces ENT1 IFO ENT1END s ENT2 genotoxicity ENT2END , while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug
0	ENT1 Mesna  ENT1END significantly reduces IFO's ENT2 genotoxicity ENT2END , while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug
1	It is characterized by its intense urotoxic action, leading to ENT1 hemorrhagic cystitis  ENT1END  This side effect of ENT2 IFO ENT2END raises the requirement for the co-administration with sodium 2-sulfanylethanesulfonate (Mesna) aiming to avoid or minimize this effect
0	Ifosfamide (IFO) is an alkylating ENT1 nitrogen  ENT1END  mustard, administrated as an antineoplasmic agent. It is characterized by its intense urotoxic action, leading to ENT2 hemorrhagic cystitis ENT2END
0	It is characterized by its intense urotoxic action, leading to ENT1 hemorrhagic cystitis  ENT1END . This side effect of IFO raises the requirement for the co-administration with ENT2 sodium 2-sulfanylethanesulfonate ENT2END (Mesna) aiming to avoid or minimize this effect
0	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti- ENT1 tumor ENT1END therapy with ENT2 IFO ENT2END
0	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti- ENT1 tumor ENT1END  therapy with IFO. Depletion of sulfhydryl (SH) groups has been reported from cell culture, animal and clinical studies. In this work the effect of CAA on human proximal tubule cells in primary culture (hRPTEC) was investigated. Toxicity of CAA was determined by protein content, cell number, LDH release, ENT2 trypan blue ENT2END exclusion assay and caspase-3 activity
0	Chloroacetaldehyde as a sulfhydryl reagent: the role of critical ENT1 thiol  ENT1END  groups in ifosfamide nephropathy.Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti ENT2 tumor ENT2END therapy with IFO
0	Chloroacetaldehyde ( ENT1 CAA  ENT1END  is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti ENT2 tumor ENT2END therapy with IFO
0	Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its ENT1 toxicity ENT1END on hRPTEC. This effect can be reduced by acidification. Therefore, urinary acidification could be an option to prevent ENT2 IFO ENT2END nephropathy in patients
0	ENT1 Toxicity  ENT1END of CAA was determined by protein content, cell number, LDH release, ENT2 trypan blue ENT2END exclusion assay and caspase-3 activity
0	ENT1 Toxicity ENT1END  of CAA was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity. Free thiols were measured by the method of Ellman. CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in necrosis markers. CAA but not acrolein inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B. Caspase activation by ENT2 cisplatin ENT2END was inhibited by CAA
0	Thus, CAA directly reacts with cellular protein and non-protein ENT1 thiols  ENT1END  mediating its ENT2 toxicity ENT2END on hRPTEC
0	ENT1 Toxicity ENT1END  of ENT2 CAA ENT2END was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity
0	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and ENT1 cysteine  ENT1END protease inhibition in living cells. Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its ENT2 toxicity ENT2END on hRPTEC
0	ENT1 Toxicity ENT1END  of CAA was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity. Free thiols were measured by the method of Ellman. CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in necrosis markers. CAA but not ENT2 acrolein ENT2END inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B
0	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on ENT1 necrosis  ENT1END markers, thiol depletion and cysteine protease inhibition in living cells. Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its toxicity on hRPTEC. This effect can be reduced by acidification. Therefore, urinary acidification could be an option to prevent ENT2 IFO ENT2END nephropathy in patients
0	Toxicity of CAA was determined by protein content, cell number, LDH release, ENT1 trypan blue ENT1END  exclusion assay and caspase-3 activity. Free thiols were measured by the method of Ellman. CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in ENT2 necrosis ENT2END markers
0	CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in ENT1 necrosis  ENT1END  markers. CAA but not acrolein inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B. Caspase activation by ENT2 cisplatin ENT2END was inhibited by CAA
0	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on ENT1 necrosis ENT1END  markers, ENT2 thiol ENT2END depletion and cysteine protease inhibition in living cells
0	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of ENT1 CAA  ENT1END on ENT2 necrosis ENT2END markers, thiol depletion and cysteine protease inhibition in living cells
0	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on ENT1 necrosis  ENT1END  markers, thiol depletion and ENT2 cysteine ENT2END protease inhibition in living cells
0	CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in ENT1 necrosis  ENT1END  markers. CAA but not ENT2 acrolein ENT2END inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B
1	Therefore, urinary acidification could be an option to prevent ENT1 IFO ENT1END  ENT2 nephropathy ENT2END in patients
0	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for ENT1 renal damage  ENT1END following anti-tumor therapy with IFO. Depletion of sulfhydryl (SH) groups has been reported from cell culture, animal and clinical studies. In this work the effect of CAA on human proximal tubule cells in primary culture (hRPTEC) was investigated. Toxicity of CAA was determined by protein content, cell number, LDH release, ENT2 trypan blue ENT2END exclusion assay and caspase-3 activity
0	Chloroacetaldehyde as a sulfhydryl reagent: the role of critical ENT1 thiol  ENT1END  groups in ifosfamide ENT2 nephropathy ENT2END
0	Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide ENT1 nephropathy  ENT1END . ENT2 Chloroacetaldehyde ENT2END (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO
0	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and ENT1 cysteine  ENT1END  protease inhibition in living cells. Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its toxicity on hRPTEC. This effect can be reduced by acidification. Therefore, urinary acidification could be an option to prevent IFO ENT2 nephropathy ENT2END in patients
1	In conclusion, we believe that physicians should carefully consider the risk of drug-induced ENT1 hepatic injury ENT1END when ENT2 clopidogrel ENT2END is prescribed
1	The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of ENT1 gingival hyperplasia ENT1END in 2 of the 13 patients. Our findings indicate that sustained-release ENT2 nifedipine ENT2END is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia
1	Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with ENT1 cyclosporin A ENT1END  but that these patients should be monitored for ENT2 gingival hyperplasia ENT2END
0	The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in ENT1 blood urea nitrogen  ENT1END levels in 9 of the 13 patients and development of ENT2 gingival hyperplasia ENT2END in 2 of the 13 patients
0	Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a ENT1 calcium  ENT1END channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs. Seven of the 13 patients had exhibited a subclinical hypertensive state before cyclosporin A therapy. Both systolic and diastolic blood pressures of these 13 patients were decreased significantly after 4 weeks of nifedipine therapy, and blood pressure was maintained within the normal range thereafter for 25 months. The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of ENT2 gingival hyperplasia ENT2END in 2 of the 13 patients
0	Our findings indicate that sustained-release ENT1 nifedipine ENT1END  is useful for ENT2 hypertensive ENT2END psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia
1	Long-term efficacy and adverse event of nifedipine sustained-release tablets for ENT1 cyclosporin A  ENT1END -induced ENT2 hypertension ENT2END in patients with psoriasis
0	The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in ENT1 blood urea nitrogen  ENT1END  levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients. Our findings indicate that sustained-release nifedipine is useful for ENT2 hypertensive ENT2END psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia
0	Thirteen psoriatic patients with ENT1 hypertension  ENT1END during the course of cyclosporin A therapy were treated for 25 months with a ENT2 calcium ENT2END channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs
0	Our findings indicate that sustained-release ENT1 nifedipine ENT1END  is useful for hypertensive ENT2 psoriatic ENT2END patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia
0	Long-term efficacy and adverse event of nifedipine sustained-release tablets for ENT1 cyclosporin A  ENT1END -induced hypertension in patients with ENT2 psoriasis ENT2END
0	The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in ENT1 blood urea nitrogen  ENT1END  levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients. Our findings indicate that sustained-release nifedipine is useful for hypertensive ENT2 psoriatic ENT2END patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia
0	Thirteen ENT1 psoriatic  ENT1END patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a ENT2 calcium ENT2END channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs
1	To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to ENT1 status epilepticus ENT1END induced by ENT2 pilocarpine ENT2END (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS
0	To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to ENT1 status epilepticus ENT1END  induced by pilocarpine (Pilo), previously injected or not with ENT2 cycloheximide ENT2END (CHX), which has been shown to inhibit MFS
0	PURPOSE: GAP43 has been thought to be linked with mossy fiber sprouting (MFS) in various experimental models of ENT1 epilepsy  ENT1END  To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by ENT2 pilocarpine ENT2END (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS
0	Growth-associated protein 43 expression in hippocampal molecular layer of chronic ENT1 epileptic  ENT1END  rats treated with ENT2 cycloheximide ENT2END
1	The influence of d-ribose on ENT1 adriamycin ENT1END induced ENT2 myocardiopathy ENT2END in rats was studied
0	The influence of ENT1 d-ribose  ENT1END on adriamycin-induced ENT2 myocardiopathy ENT2END in rats was studied
0	D-ribose in the multiple doses of 200 mg/kg did not influence ENT1 ADR ENT1END ENT2 cardiotoxicity ENT2END
0	Adriamycin in the cumulative dose of 25 mg/kg evoked fully developed ENT1 cardiac toxicity ENT1END  ENT2 D-ribose ENT2END in the multiple doses of 200 mg/kg did not influence ADR cardiotoxicity
0	PATIENTS: We investigated 102 untreated patients with ENT1 hyperthyroidism ENT1END due to Graves' disease for the presence of MPO-ANCA, and for the development vasculitis after starting ENT2 PTU ENT2END therapy
1	In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher ENT1 fever ENT1END  oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping ENT2 PTU ENT2END therapy, and the MPO-ANCA titre decreased to 20
0	Nevertheless, there have been no studies on the temporal relationship between the appearance of MPO-ANCA and ENT1 vasculitis ENT1END during ENT2 PTU ENT2END therapy, or on the incidence of MPO-ANCA in untreated Graves' disease patients
0	Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in ENT1 Graves' disease  ENT1END  patients treated with ENT2 propylthiouracil ENT2END and the relationship between MPO-ANCA and clinical manifestations
0	0 U/ml, respectively, despite continued ENT1 PTU ENT1END therapy, but no ENT2 vasculitic disorders ENT2END developed
1	In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, ENT1 oral ulcers  ENT1END and polyarthralgia, but the symptoms resolved 2 weeks after stopping ENT2 PTU ENT2END therapy, and the MPO-ANCA titre decreased to 20
1	In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and ENT1 polyarthralgia  ENT1END  but the symptoms resolved 2 weeks after stopping ENT2 PTU ENT2END therapy, and the MPO-ANCA titre decreased to 20
0	5 mg/kg/min propofol in intralipid (Group P), ENT1 propofol ENT1END in medialipid (Group L), or saline (Group C) over 20 min. Thereafter, 2 mg/kg/min bupivacaine 0.5% was infused. We recorded time to first ENT2 dysrhythmia ENT2END occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption
0	Thereafter, 2 mg/kg/min ENT1 bupivacaine  ENT1END 0.5% was infused. We recorded time to first ENT2 dysrhythmia ENT2END occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption
0	METHODS: Rats were anaesthetised with ENT1 ketamine  ENT1END and were given 0.5 mg/kg/min propofol in intralipid (Group P), propofol in medialipid (Group L), or saline (Group C) over 20 min. Thereafter, 2 mg/kg/min bupivacaine 0.5% was infused. We recorded time to first ENT2 dysrhythmia ENT2END occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption
0	Pre-treatment of bupivacaine-induced ENT1 cardiovascular depression  ENT1END  using different lipid formulations of ENT2 propofol ENT2END
0	Pre-treatment of ENT1 bupivacaine  ENT1END -induced ENT2 cardiovascular depression ENT2END using different lipid formulations of propofol
0	Pre-treatment of bupivacaine-induced ENT1 cardiovascular depression  ENT1END  using different lipid formulations of propofol.BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity. The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced cardiotoxicity. METHODS: Rats were anaesthetised with ENT2 ketamine ENT2END and were given 0
0	BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of ENT1 propofol ENT1END may alleviate bupivacaine-induced ENT2 cardiotoxicity ENT2END
1	CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of ENT1 bupivacaine ENT1END induced ENT2 cardiotoxic ENT2END effects as well as reduced plasma bupivacaine levels
0	The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced ENT1 cardiotoxicity  ENT1END  METHODS: Rats were anaesthetised with ENT2 ketamine ENT2END and were given 0
0	5 mg/kg/min propofol in intralipid (Group P), ENT1 propofol ENT1END  in medialipid (Group L), or saline (Group C) over 20 min. Thereafter, 2 mg/kg/min bupivacaine 0.5% was infused. We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to ENT2 asystole ENT2END and total amount of bupivacaine consumption
1	We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to ENT1 asystole ENT1END  and total amount of ENT2 bupivacaine ENT2END consumption
0	METHODS: Rats were anaesthetised with ENT1 ketamine  ENT1END  and were given 0.5 mg/kg/min propofol in intralipid (Group P), propofol in medialipid (Group L), or saline (Group C) over 20 min. Thereafter, 2 mg/kg/min bupivacaine 0.5% was infused. We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to ENT2 asystole ENT2END and total amount of bupivacaine consumption
1	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, ENT1 heparin ENT1END associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and ENT2 alopecia ENT2END will be discussed in this article
1	Important untoward effects of heparin therapy including heparin-induced ENT1 thrombocytopenia ENT1END ENT2 heparin ENT2END -associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article
1	Heparin-induced thrombocytopenia, paradoxical ENT1 thromboembolism  ENT1END , and other side effects of ENT2 heparin ENT2END therapy
1	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, ENT1 heparin ENT1END -associated ENT2 osteoporosis ENT2END , eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article
1	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, ENT1 heparin ENT1END -associated osteoporosis, ENT2 eosinophilia ENT2END , skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article
1	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, ENT1 heparin ENT1END -associated osteoporosis, eosinophilia, ENT2 skin reactions ENT2END , allergic reactions other than thrombocytopenia and alopecia will be discussed in this article
1	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, ENT1 heparin ENT1END -associated osteoporosis, eosinophilia, skin reactions, ENT2 allergic reactions ENT2END other than thrombocytopenia and alopecia will be discussed in this article
1	This study examined the frequency of atrioventricular (AV) dissociation and accelerated junctional rhythms in 59 patients receiving oral ENT1 verapamil ENT1END  ENT2 Accelerated junctional rhythms ENT2END and AV dissociation were frequent in patients with supraventricular tachyarrhythmias, particularly AV nodal reentry
0	Accelerated junctional rhythms and AV dissociation were frequent in patients with ENT1 supraventricular tachyarrhythmias ENT1END  particularly AV nodal reentry. ENT2 Verapamil ENT2END administration to these patients led to an asymptomatic increase in activity of these junctional pacemakers
0	In patients with various ENT1 chest pain ENT1END syndromes, ENT2 verapamil ENT2END neither increased the frequency of junctional rhythms nor suppressed their role as escape rhythms under physiologically appropriate circumstances
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group ENT1 angiotensin ENT1END converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced ENT2 nephrotic ENT2END rats
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside ( ENT1 PAN  ENT1END  - induced ENT2 nephrotic ENT2END rats
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced ENT1 nephrotic  ENT1END  rats. Nephrosis was induced by injection of PAN (15mg/100g body weight) in male Sprague-Dawley (SD) rats. Four groups were used, i) the PAN group (14), ii) PAN/ ENT2 temocapril ENT2END (13), iii) temocapril (14) and iv) untreated controls (15)
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group ENT1 angiotensin ENT1END  converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular ENT2 hypertrophy ENT2END and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular ENT1 hypertrophy ENT1END  and prevented glomerulosclerosis in chronic ENT2 puromycin aminonucleoside ENT2END (PAN) - induced nephrotic rats
0	The purpose of the present study was to determine whether chronic administration of ENT1 temocapril  ENT1END  a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular ENT2 hypertrophy ENT2END and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats
0	Temocapril, a long-acting non-SH group ENT1 angiotensin  ENT1END  converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside ENT2 nephrosis ENT2END
1	It appears that temocapril was effective in retarding renal progression and protected renal function in ENT1 PAN ENT1END ENT2 neprotic ENT2END rats
0	It appears that ENT1 temocapril  ENT1END was effective in retarding renal progression and protected renal function in PAN ENT2 neprotic ENT2END rats
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group ENT1 angiotensin ENT1END  converting enzyme (ACE) inhibitor, reduced ENT2 proteinuria ENT2END , inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats
1	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced ENT1 proteinuria  ENT1END , inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic ENT2 puromycin aminonucleoside ENT2END (PAN) - induced nephrotic rats
0	ENT1 Temocapril ENT1END did not attenuate ENT2 proteinuria ENT2END at 8 days, but it did markedly lower it from weeks 4 to 20
0	Temocapril, a long-acting non-SH group ENT1 angiotensin  ENT1END  converting enzyme inhibitor, modulates ENT2 glomerular injury ENT2END in chronic puromycin aminonucleoside nephrosis
0	Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates ENT1 glomerular injury  ENT1END  in chronic ENT2 puromycin aminonucleoside ENT2END nephrosis
0	ENT1 Temocapril  ENT1END , a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates ENT2 glomerular injury ENT2END in chronic puromycin aminonucleoside nephrosis
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group ENT1 angiotensin ENT1END  converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented ENT2 glomerulosclerosis ENT2END in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented ENT1 glomerulosclerosis  ENT1END  in chronic ENT2 puromycin aminonucleoside ENT2END (PAN) - induced nephrotic rats
0	ENT1 Temocapril ENT1END  did not attenuate proteinuria at 8 days, but it did markedly lower it from weeks 4 to 20. The ENT2 glomerulosclerosis ENT2END index (GSI) was 6
0	ENT1 Angiotensin-converting enzyme (ACE) inhibitors ENT1END  used to treat hypertension and ENT2 congestive heart failure ENT2END , were introduced in Europe in the middle of the eighties, and the use of these drugs has increased progressively
0	Adverse reactions to drugs are well recognized as a cause of acute or chronic ENT1 urticaria  ENT1END  and angio-oedema. ENT2 Angiotensin-converting enzyme (ACE) inhibitors ENT2END , used to treat hypertension and congestive heart failure, were introduced in Europe in the middle of the eighties, and the use of these drugs has increased progressively
0	ENT1 Angiotensin-converting enzyme (ACE) inhibitors ENT1END , used to treat ENT2 hypertension ENT2END and congestive heart failure, were introduced in Europe in the middle of the eighties, and the use of these drugs has increased progressively
1	Soon after the introduction of ENT1 ACE inhibitors ENT1END  acute bouts of ENT2 angio-oedema ENT2END were reported in association with the use of these drugs
0	We conclude that the CYA cardiotoxicity correlates with ENT1 CYA ENT1END dosage as calculated by body surface area, and that patients with ENT2 aplastic anemia ENT2END and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1
0	Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of ENT1 CYA ENT1END ENT2 cardiotoxicity ENT2END correlated with the dose per body surface area
0	We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and ENT1 immunodeficiencies ENT1END can be effectively prepared for bone marrow grafting at a ENT2 CYA ENT2END dose of 1
0	Eighty patients who were to receive CYA 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, ENT1 Wiskott-Aldrich syndrome ENT1END  or severe combined immunodeficiency syndrome. Fourteen of 84 (17%) patients had symptoms and signs consistent with ENT2 CYA ENT2END cardiotoxicity within ten days of receiving 1 to 4 doses of CYA
0	55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose ENT1 CYA ENT1END dosage is calculated based on weight. This study reaffirms the principle that drug ENT2 toxicity ENT2END correlates with dose per body surface area
0	Eighty patients who were to receive CYA 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, Wiskott-Aldrich syndrome, or ENT1 severe combined immunodeficiency syndrome  ENT1END  Fourteen of 84 (17%) patients had symptoms and signs consistent with ENT2 CYA ENT2END cardiotoxicity within ten days of receiving 1 to 4 doses of CYA
1	Six of the 14 patients died with ENT1 congestive heart failure ENT1END  The dose of ENT2 CYA ENT2END per body surface area was calculated for all patients and the patients were divided into two groups based on daily CYA dose: Group 1, CYA less than or equal to 1
1	Twelve asthmatic patients (FEV1, 81 +/- 4% predicted), requiring only occasional inhaled beta-agonists as their sole therapy, were given a 14-day treatment with high dose inhaled salbutamol (HDS), 4,000 micrograms daily, low dose inhaled ENT1 salbutamol ENT1END (LDS), 800 micrograms daily, or placebo (PI) by metered-dose inhaler in a double-blind, randomized crossover design. During the 14-day run-in and during washout periods, inhaled beta-agonists were withheld and ipratropium bromide was substituted for rescue purposes. At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), ENT2 tremor ENT2END , and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms)
0	At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), ENT1 tremor  ENT1END , and metabolic ( ENT2 K ENT2END , Glu) responses were measured at each step (from 100 to 4,000 micrograms)
0	At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), ENT1 tremor ENT1END , and metabolic (K, ENT2 Glu ENT2END ) responses were measured at each step (from 100 to 4,000 micrograms)
0	During the 14-day run-in and during washout periods, inhaled beta-agonists were withheld and ENT1 ipratropium bromide  ENT1END was substituted for rescue purposes. At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), ENT2 tremor ENT2END , and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms)
0	Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled ENT1 salbutamol  ENT1END  in ENT2 asthmatics ENT2END
0	Twelve ENT1 asthmatic ENT1END patients (FEV1, 81 +/- 4% predicted), requiring only occasional inhaled beta-agonists as their sole therapy, were given a 14-day treatment with high dose inhaled salbutamol (HDS), 4,000 micrograms daily, low dose inhaled salbutamol (LDS), 800 micrograms daily, or placebo (PI) by metered-dose inhaler in a double-blind, randomized crossover design. During the 14-day run-in and during washout periods, inhaled beta-agonists were withheld and ipratropium bromide was substituted for rescue purposes. At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic ENT2 K ENT2END , Glu) responses were measured at each step (from 100 to 4,000 micrograms)
0	Twelve ENT1 asthmatic  ENT1END  patients (FEV1, 81 +/- 4% predicted), requiring only occasional inhaled beta-agonists as their sole therapy, were given a 14-day treatment with high dose inhaled salbutamol (HDS), 4,000 micrograms daily, low dose inhaled salbutamol (LDS), 800 micrograms daily, or placebo (PI) by metered-dose inhaler in a double-blind, randomized crossover design. During the 14-day run-in and during washout periods, inhaled beta-agonists were withheld and ipratropium bromide was substituted for rescue purposes. At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic (K, ENT2 Glu ENT2END ) responses were measured at each step (from 100 to 4,000 micrograms)
0	Twelve ENT1 asthmatic  ENT1END  patients (FEV1, 81 +/- 4% predicted), requiring only occasional inhaled beta-agonists as their sole therapy, were given a 14-day treatment with high dose inhaled salbutamol (HDS), 4,000 micrograms daily, low dose inhaled salbutamol (LDS), 800 micrograms daily, or placebo (PI) by metered-dose inhaler in a double-blind, randomized crossover design. During the 14-day run-in and during washout periods, inhaled beta-agonists were withheld and ENT2 ipratropium bromide ENT2END was substituted for rescue purposes
1	Diffuse skeletal ENT1 pain  ENT1END  after administration of ENT2 alendronate ENT2END
0	CONCLUSION: We conclude that patients with osteoporosis can report ENT1 pain ENT1END  and ENT2 bisphosphonate ENT2END -related pain should also be considered before ascribing this complaint to osteoporosis
0	ENT1 Alendronate ENT1END  a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women. Side effects are relatively few and prominently gastrointestinal. ENT2 Musculoskeletal pain ENT2END may be an important side effect in these patients
0	BACKGROUND: Osteoporosis is caused by bone resorption in excess of bone formation, and ENT1 bisphosphonates  ENT1END  are used to inhibit bone resorption. Alendronate, a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women. Side effects are relatively few and prominently gastrointestinal. ENT2 Musculoskeletal pain ENT2END may be an important side effect in these patients
0	Diffuse skeletal pain after administration of ENT1 alendronate ENT1END .BACKGROUND: ENT2 Osteoporosis ENT2END is caused by bone resorption in excess of bone formation, and bisphosphonates, are used to inhibit bone resorption
0	CONCLUSION: We conclude that patients with ENT1 osteoporosis  ENT1END can report pain, and ENT2 bisphosphonate ENT2END -related pain should also be considered before ascribing this complaint to osteoporosis
0	There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid ( ENT1 5-HIAA ENT1END  in the AN after 6-months of ENT2 hyperprolactinemia ENT2END and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia
0	After 6 months of ENT1 hyperprolactinemia ENT1END  ENT2 dopamine ENT2END (DA) concentrations in the median eminence (ME) increased by 84% over the control group
1	However, DA response was lost if a 9-month long ENT1 haloperidol ENT1END induced ENT2 hyperprolactinemia ENT2END was followed by a 1 1/2 month-long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule
0	However, DA response was lost if a 9-month long haloperidol-induced ENT1 hyperprolactinemia ENT1END  was followed by a 1 1/2 month-long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule. There was no change in the levels of DA, norepinephrine (NE), ENT2 serotonin ENT2END (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia
0	However, DA response was lost if a 9-month long haloperidol-induced ENT1 hyperprolactinemia ENT1END  was followed by a 1 1/2 month-long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule. There was no change in the levels of DA, ENT2 norepinephrine ENT2END (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia
0	We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given ENT1 Imipramine ENT1END to control a behavior disorder. It was determined later that this patient's ENT2 tumor ENT2END was recurring at the time of her hypertensive episode
0	It was determined later that this patient's ENT1 tumor ENT1END  was recurring at the time of her hypertensive episode. Since she had no blood pressure elevation at initial diagnosis and none following discontinuation of the Imipramine (when she was in florid relapse), we believe that this drug rather than her underlying disease alone caused her hypertension. The mechanism for this reaction is believed to be increased levels of vasoactive ENT2 catecholamines ENT2END due to interference of their physiologic inactivation by Imipramine
1	Hypertension in neuroblastoma induced by ENT1 imipramine  ENT1END . ENT2 Hypertension ENT2END is a well-known finding in some patients with neuroblastoma
0	Since she had no blood pressure elevation at initial diagnosis and none following discontinuation of the Imipramine (when she was in florid relapse), we believe that this drug rather than her underlying disease alone caused her ENT1 hypertension  ENT1END  The mechanism for this reaction is believed to be increased levels of vasoactive ENT2 catecholamines ENT2END due to interference of their physiologic inactivation by Imipramine
0	We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given ENT1 Imipramine ENT1END  to control a ENT2 behavior disorder ENT2END
0	We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given Imipramine to control a ENT1 behavior disorder  ENT1END . It was determined later that this patient's tumor was recurring at the time of her hypertensive episode. Since she had no blood pressure elevation at initial diagnosis and none following discontinuation of the Imipramine (when she was in florid relapse), we believe that this drug rather than her underlying disease alone caused her hypertension. The mechanism for this reaction is believed to be increased levels of vasoactive ENT2 catecholamines ENT2END due to interference of their physiologic inactivation by Imipramine
0	Hypertension in ENT1 neuroblastoma  ENT1END  induced by ENT2 imipramine ENT2END
0	The mechanism for this reaction is believed to be increased levels of vasoactive ENT1 catecholamines ENT1END  due to interference of their physiologic inactivation by Imipramine. From this experience, we urge extreme caution in the use of tricyclic antidepressants in children with active ENT2 neuroblastoma ENT2END
1	We report a case of hypersensitivity myocarditis secondary to administration of ENT1 carbamazepine ENT1END  Acute ENT2 hypersensitivity ENT2END myocarditis was not suspected clinically, and the diagnosis was made post-mortem
1	Fatal ENT1 carbamazepine  ENT1END  induced ENT2 fulminant eosinophilic ENT2END (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis
1	Clinically, death was due to ENT1 cardiogenic shock ENT1END  To best of our knowledge this is the second case of fatal ENT2 carbamazepine ENT2END induced myocarditis reported in English literature
1	To best of our knowledge this is the second case of fatal ENT1 carbamazepine ENT1END  induced ENT2 myocarditis ENT2END reported in English literature
1	Transmural ENT1 myocardial infarction  ENT1END  with ENT2 sumatriptan ENT2END
0	We describe a 47-year-old woman with an acute myocardial infarction after administration of ENT1 sumatriptan ENT1END 6 mg subcutaneously for cluster headache. The patient had no history of underlying ENT2 ischaemic heart disease ENT2END or Prinzmetal's angina
0	We describe a 47-year-old woman with an acute myocardial infarction after administration of ENT1 sumatriptan ENT1END  6 mg subcutaneously for cluster headache. The patient had no history of underlying ischaemic heart disease or ENT2 Prinzmetal's angina ENT2END
0	We describe a 47-year-old woman with an acute myocardial infarction after administration of ENT1 sumatriptan ENT1END  6 mg subcutaneously for ENT2 cluster headache ENT2END
0	), no effects were observed in ENT1 convulsions ENT1END induced by ENT2 N-methyl-D-aspartate ENT2END , picrotoxin, or electroshock in Slc:ddY mice
0	, respectively, while that of ENT1 flunarizine ENT1END was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic ENT2 convulsions ENT2END induced by pentylenetetrazole (85 mg/kg, s
1	) or ENT1 bemegride  ENT1END (40 mg/kg, s.c.), no effects were observed in ENT2 convulsions ENT2END induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice
1	Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic ENT1 convulsions ENT1END  induced by ENT2 pentylenetetrazole ENT2END (85 mg/kg, s
0	S-312, S-312-d, but not S-312-l, L-type ENT1 calcium  ENT1END channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic ENT2 convulsions ENT2END induced by pentylenetetrazole (85 mg/kg, s
0	Although moderate anticonvulsant effects of ENT1 S-312-d  ENT1END in higher doses were observed against the clonic ENT2 convulsions ENT2END induced by pentylenetetrazole (85 mg/kg, s
1	), no effects were observed in ENT1 convulsions ENT1END  induced by N-methyl-D-aspartate, ENT2 picrotoxin ENT2END , or electroshock in Slc:ddY mice
0	), no effects were observed in convulsions induced by ENT1 N-methyl-D-aspartate ENT1END , picrotoxin, or electroshock in Slc:ddY mice. S-312-d may be useful in the therapy of certain types of human ENT2 epilepsy ENT2END
0	, respectively, while that of ENT1 flunarizine  ENT1END  was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice. S-312-d may be useful in the therapy of certain types of human ENT2 epilepsy ENT2END
0	) or ENT1 bemegride  ENT1END  (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice. S-312-d may be useful in the therapy of certain types of human ENT2 epilepsy ENT2END
0	Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by ENT1 pentylenetetrazole  ENT1END  (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice. S-312-d may be useful in the therapy of certain types of human ENT2 epilepsy ENT2END
0	S-312, S-312-d, but not S-312-l, L-type ENT1 calcium  ENT1END  channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice. S-312-d may be useful in the therapy of certain types of human ENT2 epilepsy ENT2END
0	ENT1 S-312-d  ENT1END may be useful in the therapy of certain types of human ENT2 epilepsy ENT2END
0	), no effects were observed in convulsions induced by N-methyl-D-aspartate, ENT1 picrotoxin  ENT1END , or electroshock in Slc:ddY mice. S-312-d may be useful in the therapy of certain types of human ENT2 epilepsy ENT2END
0	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the ENT1 audiogenic tonic convulsions  ENT1END in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by ENT2 N-methyl-D-aspartate ENT2END , picrotoxin, or electroshock in Slc:ddY mice
0	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the ENT1 audiogenic tonic convulsions  ENT1END  in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of ENT2 flunarizine ENT2END was 34
0	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the ENT1 audiogenic tonic convulsions  ENT1END  in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or ENT2 bemegride ENT2END (40 mg/kg, s
0	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the ENT1 audiogenic tonic convulsions  ENT1END  in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by ENT2 pentylenetetrazole ENT2END (85 mg/kg, s
0	S-312, S-312-d, but not S-312-l, L-type ENT1 calcium  ENT1END  channel antagonists, showed anticonvulsant effects on the ENT2 audiogenic tonic convulsions ENT2END in DBA/2 mice; and their ED50 values were 18
0	S-312, ENT1 S-312-d  ENT1END  but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the ENT2 audiogenic tonic convulsions ENT2END in DBA/2 mice; and their ED50 values were 18
0	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the ENT1 audiogenic tonic convulsions  ENT1END  in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, ENT2 picrotoxin ENT2END , or electroshock in Slc:ddY mice
1	A total of 261 adverse ocular reactions occurred in 237 patients who received ENT1 isotretinoin ENT1END  a commonly used drug in the treatment of severe cystic acne. Blepharoconjunctivitis, subjective complaints of dry eyes, blurred vision, contact lens intolerance, and ENT2 photodermatitis ENT2END are reversible side effects
0	ENT1 Isotretinoin ENT1END is contraindicated in pregnancy because of the many reported ENT2 congenital abnormalities ENT2END after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia)
1	A total of 261 adverse ocular reactions occurred in 237 patients who received ENT1 isotretinoin ENT1END , a commonly used drug in the treatment of severe cystic acne. ENT2 Blepharoconjunctivitis ENT2END , subjective complaints of dry eyes, blurred vision, contact lens intolerance, and photodermatitis are reversible side effects
1	More serious ocular adverse reactions include ENT1 papilledema  ENT1END  pseudotumor cerebri, and white or gray subepithelial corneal opacities; all of these are reversible if the drug is discontinued. Reported cases of decreased dark adaptation are under investigation. ENT2 Isotretinoin ENT2END is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia)
1	More serious ocular adverse reactions include papilledema, pseudotumor cerebri, and white or gray subepithelial ENT1 corneal opacities  ENT1END  all of these are reversible if the drug is discontinued. Reported cases of decreased dark adaptation are under investigation. ENT2 Isotretinoin ENT2END is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia)
1	A total of 261 adverse ocular reactions occurred in 237 patients who received ENT1 isotretinoin ENT1END , a commonly used drug in the treatment of severe cystic acne. Blepharoconjunctivitis, subjective complaints of dry eyes, ENT2 blurred vision ENT2END , contact lens intolerance, and photodermatitis are reversible side effects
1	A total of 261 adverse ocular reactions occurred in 237 patients who received ENT1 isotretinoin ENT1END , a commonly used drug in the treatment of severe cystic acne. Blepharoconjunctivitis, subjective complaints of ENT2 dry eyes ENT2END , blurred vision, contact lens intolerance, and photodermatitis are reversible side effects
0	ENT1 Isotretinoin ENT1END  is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital ENT2 hypertelorism ENT2END , and optic nerve hypoplasia)
1	More serious ocular adverse reactions include papilledema, ENT1 pseudotumor cerebri  ENT1END  and white or gray subepithelial corneal opacities; all of these are reversible if the drug is discontinued. Reported cases of decreased dark adaptation are under investigation. ENT2 Isotretinoin ENT2END is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia)
0	A total of 261 adverse ocular reactions occurred in 237 patients who received ENT1 isotretinoin ENT1END , a commonly used drug in the treatment of severe cystic ENT2 acne ENT2END
0	ENT1 Isotretinoin ENT1END  is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including ENT2 microphthalmos ENT2END , orbital hypertelorism, and optic nerve hypoplasia)
0	ENT1 Isotretinoin ENT1END  is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and ENT2 optic nerve hypoplasia ENT2END )
0	BACKGROUND: Reports of severe bradyarrhythmia during ENT1 amiodarone ENT1END therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ENT2 ventricular arrhythmias ENT2END
0	BACKGROUND: Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ENT1 ventricular arrhythmias ENT1END . METHODS: A study cohort of 8,770 patients age > or =65 years with a new diagnosis of AF was identified from a provincewide database of Quebec residents with a myocardial infarction (MI) between 1991 and 1999. Using a nested case-control design, 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to ENT2 sotalol ENT2END , Class I antiarrhythmic agents, beta-blockers, calcium channel blockers, and digoxin
0	BACKGROUND: Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ENT1 ventricular arrhythmias ENT1END . METHODS: A study cohort of 8,770 patients age > or =65 years with a new diagnosis of AF was identified from a provincewide database of Quebec residents with a myocardial infarction (MI) between 1991 and 1999. Using a nested case-control design, 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to sotalol, Class I antiarrhythmic agents, beta-blockers, calcium channel blockers, and ENT2 digoxin ENT2END
0	BACKGROUND: Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ENT1 ventricular arrhythmias ENT1END . METHODS: A study cohort of 8,770 patients age > or =65 years with a new diagnosis of AF was identified from a provincewide database of Quebec residents with a myocardial infarction (MI) between 1991 and 1999. Using a nested case-control design, 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to sotalol, Class I antiarrhythmic agents, beta-blockers, ENT2 calcium ENT2END channel blockers, and digoxin
0	CONCLUSIONS: This study suggests that the use of ENT1 amiodarone ENT1END in elderly patients with AF and a previous ENT2 MI ENT2END increases the risk of bradyarrhythmia requiring a permanent pacemaker
0	METHODS: A study cohort of 8,770 patients age > or =65 years with a new diagnosis of AF was identified from a provincewide database of Quebec residents with a myocardial infarction ( ENT1 MI  ENT1END  between 1991 and 1999. Using a nested case-control design, 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to ENT2 sotalol ENT2END , Class I antiarrhythmic agents, beta-blockers, calcium channel blockers, and digoxin
0	ENT1 Digoxin  ENT1END was the only other medication associated with an increased risk of pacemaker insertion (OR: 1.78, 95% CI: 1.37 to 2.31). CONCLUSIONS: This study suggests that the use of amiodarone in elderly patients with AF and a previous ENT2 MI ENT2END increases the risk of bradyarrhythmia requiring a permanent pacemaker
0	METHODS: A study cohort of 8,770 patients age > or =65 years with a new diagnosis of AF was identified from a provincewide database of Quebec residents with a myocardial infarction ( ENT1 MI  ENT1END ) between 1991 and 1999. Using a nested case-control design, 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to sotalol, Class I antiarrhythmic agents, beta-blockers, ENT2 calcium ENT2END channel blockers, and digoxin
0	OBJECTIVES: The aim of this study was to determine whether the use of ENT1 amiodarone ENT1END in patients with ENT2 atrial fibrillation ENT2END (AF) increases the risk of bradyarrhythmia requiring a permanent pacemaker
0	METHODS: A study cohort of 8,770 patients age > or =65 years with a new diagnosis of ENT1 AF  ENT1END was identified from a provincewide database of Quebec residents with a myocardial infarction (MI) between 1991 and 1999. Using a nested case-control design, 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to ENT2 sotalol ENT2END , Class I antiarrhythmic agents, beta-blockers, calcium channel blockers, and digoxin
0	ENT1 Digoxin ENT1END  was the only other medication associated with an increased risk of pacemaker insertion (OR: 1.78, 95% CI: 1.37 to 2.31). CONCLUSIONS: This study suggests that the use of amiodarone in elderly patients with ENT2 AF ENT2END and a previous MI increases the risk of bradyarrhythmia requiring a permanent pacemaker
0	METHODS: A study cohort of 8,770 patients age > or =65 years with a new diagnosis of ENT1 AF  ENT1END  was identified from a provincewide database of Quebec residents with a myocardial infarction (MI) between 1991 and 1999. Using a nested case-control design, 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to sotalol, Class I antiarrhythmic agents, beta-blockers, ENT2 calcium ENT2END channel blockers, and digoxin
1	BACKGROUND: Reports of severe ENT1 bradyarrhythmia  ENT1END during ENT2 amiodarone ENT2END therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ventricular arrhythmias
0	Using a nested case-control design, 477 cases of ENT1 bradyarrhythmia  ENT1END requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to ENT2 sotalol ENT2END , Class I antiarrhythmic agents, beta-blockers, calcium channel blockers, and digoxin
0	ENT1 Digoxin ENT1END  was the only other medication associated with an increased risk of pacemaker insertion (OR: 1.78, 95% CI: 1.37 to 2.31). CONCLUSIONS: This study suggests that the use of amiodarone in elderly patients with AF and a previous MI increases the risk of ENT2 bradyarrhythmia ENT2END requiring a permanent pacemaker
0	Using a nested case-control design, 477 cases of ENT1 bradyarrhythmia  ENT1END  requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to sotalol, Class I antiarrhythmic agents, beta-blockers, ENT2 calcium ENT2END channel blockers, and digoxin
0	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and ENT1 perioral dermatitis ENT1END  We report on rosaceiform dermatitis as a complication of treatment with ENT2 tacrolimus ENT2END ointment
0	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in ENT1 steroid  ENT1END aggravated rosacea and ENT2 perioral dermatitis ENT2END
1	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated ENT1 rosacea  ENT1END and perioral dermatitis. We report on rosaceiform dermatitis as a complication of treatment with ENT2 tacrolimus ENT2END ointment
0	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in ENT1 steroid  ENT1END -aggravated ENT2 rosacea ENT2END and perioral dermatitis
0	Induction of rosaceiform dermatitis during treatment of ENT1 facial inflammatory dermatoses  ENT1END  with ENT2 tacrolimus ENT2END ointment
0	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in ENT1 steroid ENT1END -aggravated rosacea and perioral dermatitis. We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment. OBSERVATIONS: Six adult patients with ENT2 inflammatory facial dermatoses ENT2END were treated with tacrolimus ointment because of the ineffectiveness of standard treatments
0	In 1 patient with eyelid ENT1 eczema ENT1END  rosaceiform periocular dermatitis gradually appeared after 3 weeks of treatment. In 1 patient with atopic dermatitis, telangiectatic and papular rosacea insidiously appeared after 5 months of treatment. CONCLUSIONS: Our observations suggest that the spectrum of rosaceiform dermatitis as a complication of treatment with ENT2 tacrolimus ENT2END ointment is heterogeneous
0	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in ENT1 steroid  ENT1END -aggravated rosacea and perioral dermatitis. We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment. OBSERVATIONS: Six adult patients with inflammatory facial dermatoses were treated with tacrolimus ointment because of the ineffectiveness of standard treatments. Within 2 to 3 weeks of initially effective and well-tolerated treatment, 3 patients with a history of rosacea and 1 with a history of acne experienced sudden worsening with pustular rosaceiform lesions. Biopsy revealed an abundance of Demodex mites in 2 of these patients. In 1 patient with eyelid ENT2 eczema ENT2END , rosaceiform periocular dermatitis gradually appeared after 3 weeks of treatment
0	In 1 patient with ENT1 atopic dermatitis  ENT1END  telangiectatic and papular rosacea insidiously appeared after 5 months of treatment. CONCLUSIONS: Our observations suggest that the spectrum of rosaceiform dermatitis as a complication of treatment with ENT2 tacrolimus ENT2END ointment is heterogeneous
0	OBSERVATIONS: Six adult patients with inflammatory facial dermatoses were treated with ENT1 tacrolimus ENT1END ointment because of the ineffectiveness of standard treatments. Within 2 to 3 weeks of initially effective and well-tolerated treatment, 3 patients with a history of rosacea and 1 with a history of ENT2 acne ENT2END experienced sudden worsening with pustular rosaceiform lesions
0	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in ENT1 steroid  ENT1END -aggravated rosacea and perioral dermatitis. We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment. OBSERVATIONS: Six adult patients with inflammatory facial dermatoses were treated with tacrolimus ointment because of the ineffectiveness of standard treatments. Within 2 to 3 weeks of initially effective and well-tolerated treatment, 3 patients with a history of rosacea and 1 with a history of ENT2 acne ENT2END experienced sudden worsening with pustular rosaceiform lesions
0	We report on rosaceiform ENT1 dermatitis  ENT1END as a complication of treatment with ENT2 tacrolimus ENT2END ointment
0	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in ENT1 steroid  ENT1END -aggravated rosacea and perioral dermatitis. We report on rosaceiform ENT2 dermatitis ENT2END as a complication of treatment with tacrolimus ointment
1	A case of nontraumatic ENT1 dissecting aneurysm ENT1END of the basilar artery in association with hypertension, smoke, and ENT2 oral contraceptives ENT2END is reported in a young female patient with a locked-in syndrome
0	A case of nontraumatic dissecting aneurysm of the basilar artery in association with hypertension, smoke, and ENT1 oral contraceptives ENT1END  is reported in a young female patient with a ENT2 locked-in syndrome ENT2END
0	A case of nontraumatic dissecting aneurysm of the basilar artery in association with ENT1 hypertension  ENT1END  smoke, and ENT2 oral contraceptives ENT2END is reported in a young female patient with a locked-in syndrome
0	PURPOSE: To determine the natural history of visual field defects in a group of patients known to have Vigabatrin-associated changes who elected to continue the medication because of good ENT1 seizure ENT1END control. METHODS: All patients taking ENT2 Vigabatrin ENT2END alone or in combination with other antiepileptic drugs for at least 5 years (range 5-12 years) were entered into a visual surveillance programme
0	These data give support to the hypothesis that the pathogenesis of ENT1 Vigabatrin ENT1END associated visual field defects may be an idiosyncratic adverse drug reaction rather than dose-dependent ENT2 toxicity ENT2END
1	The natural history of ENT1 Vigabatrin  ENT1END  associated ENT2 visual field defects ENT2END in patients electing to continue their medication
0	The role of methotrexate contaminants, local folate deficiency, and cranial irradiation in the pathogenesis of intrathecal ENT1 methotrexate ENT1END ENT2 toxicity ENT2END is unclear
1	ENT1 Paraplegia  ENT1END  following intrathecal ENT2 methotrexate ENT2END : report of a case and review of the literature
0	The role of ENT1 methotrexate ENT1END contaminants, local ENT2 folate deficiency ENT2END , and cranial irradiation in the pathogenesis of intrathecal methotrexate toxicity is unclear
0	The role of methotrexate contaminants, local folate deficiency, and cranial irradiation in the pathogenesis of intrathecal ENT1 methotrexate ENT1END  toxicity is unclear. The incidence of ENT2 neurotoxicity ENT2END may be reduced by employing lower doses of methotrexate in the presence of central nervous system leukemia, in older children and adults, and in the presence of epidural leakage
0	The incidence of neurotoxicity may be reduced by employing lower doses of ENT1 methotrexate ENT1END in the presence of ENT2 central nervous system leukemia ENT2END , in older children and adults, and in the presence of epidural leakage
1	ENT1 Ethambutol ENT1END is known to cause optic neuropathy and, more rarely, axonal ENT2 polyneuropathy ENT2END
1	We characterize the clinical, neurophysiological, and neuroimaging findings in a 72-year-old man who developed visual loss and ENT1 paresthesias ENT1END after 11 weeks of exposure to a supratherapeutic dose of ENT2 ethambutol ENT2END
0	Optochiasmatic and ENT1 peripheral neuropathy  ENT1END  due to ENT2 ethambutol ENT2END overtreatment
0	This case demonstrates the selective vulnerability of the anterior visual pathways and peripheral nerves to ENT1 ethambutol ENT1END ENT2 toxicity ENT2END
1	We characterize the clinical, neurophysiological, and neuroimaging findings in a 72-year-old man who developed ENT1 visual loss  ENT1END and paresthesias after 11 weeks of exposure to a supratherapeutic dose of ENT2 ethambutol ENT2END
1	ENT1 Ethambutol ENT1END  is known to cause ENT2 optic neuropathy ENT2END and, more rarely, axonal polyneuropathy
1	ENT1 Metronidazole  ENT1END -induced ENT2 encephalopathy ENT2END : an uncommon scenario
0	The diagnosis of ENT1 metronidazole ENT1END ENT2 toxicity ENT2END was made by the MRI findings and supported clinically
1	Typical S-T/T changes occurred in the insulin-group but in none of the ENT1 propranolol ENT1END insulin group. ENT2 Hypertension ENT2END in diabetics prone to hypoglycaemia attacks should not be treated with beta-blockers because these drugs may cause a sharp rise in blood-pressure in such patients
0	Modification by ENT1 propranolol  ENT1END  of cardiovascular effects of induced ENT2 hypoglycaemia ENT2END
0	Typical S-T/T changes occurred in the insulin-group but in none of the ENT1 propranolol ENT1END -insulin group. Hypertension in ENT2 diabetics ENT2END prone to hypoglycaemia attacks should not be treated with beta-blockers because these drugs may cause a sharp rise in blood-pressure in such patients
0	Postoperatively, she was given a patient-controlled analgesia device delivering boluses of ENT1 diamorphine ENT1END 0.5 mg and droperidol 0.025 mg. Whilst using the device she gradually became anxious, the feeling worsening after each bolus. The diagnosis of droperidol-induced ENT2 psychological disturbance ENT2END was not made straight away although on subsequent close questioning the patient gave a very clear history
1	A case of postoperative ENT1 anxiety  ENT1END  due to low dose ENT2 droperidol ENT2END used with patient-controlled analgesia
0	CONCLUSION: In this open trial, ENT1 galantamine ENT1END was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly ENT2 aggression ENT2END , behavioral dyscontrol, and inattention
1	Overall, galantamine was well-tolerated, with no significant adverse effects apart from ENT1 headaches  ENT1END in one patient. CONCLUSION: In this open trial, ENT2 galantamine ENT2END was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly aggression, behavioral dyscontrol, and inattention
0	CONCLUSION: In this open trial, ENT1 galantamine ENT1END  was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly aggression, behavioral dyscontrol, and ENT2 inattention ENT2END
0	A prospective, open-label trial of ENT1 galantamine  ENT1END  in ENT2 autistic disorder ENT2END
0	CONCLUSION: In this open trial, ENT1 galantamine ENT1END  was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly aggression, ENT2 behavioral dyscontrol ENT2END , and inattention
0	ENT1 Viracept  ENT1END  and ENT2 irregular heartbeat ENT2END warning
1	A group of doctors in Boston warn that the protease inhibitor ENT1 Viracept ENT1END may cause an irregular heart beat, known as ENT2 bradycardia ENT2END , in people with HIV
1	Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating ENT1 lithium ENT1END induced ENT2 polyuria ENT2END
0	Urinary ENT1 sodium ENT1END  potassium and calcium were elevated in lithium-fed WT but not in lithium-fed PKCa KO mice. Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe ENT2 polyuria ENT2END associated with lithium therapy
0	The decreased capacity to concentrate urine is likely due to lithium acutely disrupting the cAMP pathway and chronically reducing ENT1 urea  ENT1END transporter (UT-A1) and water channel (AQP2) expression in the inner medulla. Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating lithium-induced ENT2 polyuria ENT2END
0	Urinary sodium, potassium and ENT1 calcium  ENT1END were elevated in lithium-fed WT but not in lithium-fed PKCa KO mice. Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe ENT2 polyuria ENT2END associated with lithium therapy
0	Urinary sodium, ENT1 potassium  ENT1END and calcium were elevated in lithium-fed WT but not in lithium-fed PKCa KO mice. Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe ENT2 polyuria ENT2END associated with lithium therapy
0	The decreased capacity to concentrate urine is likely due to lithium acutely disrupting the ENT1 cAMP  ENT1END pathway and chronically reducing urea transporter (UT-A1) and water channel (AQP2) expression in the inner medulla. Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating lithium-induced ENT2 polyuria ENT2END
1	Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in ENT1 lithium ENT1END induced ENT2 NDI ENT2END , and prevents the development of the severe polyuria associated with lithium therapy
0	Urinary ENT1 sodium  ENT1END , potassium and calcium were elevated in lithium-fed WT but not in lithium-fed PKCa KO mice. Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced ENT2 NDI ENT2END , and prevents the development of the severe polyuria associated with lithium therapy
0	Lithium, an effective antipsychotic, induces nephrogenic diabetes insipidus ( ENT1 NDI  ENT1END  in  40% of patients. The decreased capacity to concentrate urine is likely due to lithium acutely disrupting the cAMP pathway and chronically reducing ENT2 urea ENT2END transporter (UT-A1) and water channel (AQP2) expression in the inner medulla
0	Urinary sodium, potassium and ENT1 calcium  ENT1END  were elevated in lithium-fed WT but not in lithium-fed PKCa KO mice. Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced ENT2 NDI ENT2END , and prevents the development of the severe polyuria associated with lithium therapy
0	Urinary sodium, ENT1 potassium  ENT1END  and calcium were elevated in lithium-fed WT but not in lithium-fed PKCa KO mice. Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced ENT2 NDI ENT2END , and prevents the development of the severe polyuria associated with lithium therapy
0	Lithium, an effective antipsychotic, induces nephrogenic diabetes insipidus ( ENT1 NDI  ENT1END ) in  40% of patients. The decreased capacity to concentrate urine is likely due to lithium acutely disrupting the ENT2 cAMP ENT2END pathway and chronically reducing urea transporter (UT-A1) and water channel (AQP2) expression in the inner medulla
1	RESULTS: A total of 76 cases of ENT1 hyponatremia ENT1END and/or SIADH associated with ENT2 vincristine ENT2END use were identified
0	Approximately 75% of the patients were receiving treatment for leukemia or ENT1 lymphoma ENT1END  Among the 39 reports that included information on race, the racial distribution was: 1 Black, 3 Caucasian, and 35 Asian. CONCLUSION: Our data suggest that Asian patients may be at increased risk of hyponatremia and/or SIADH associated with ENT2 vincristine ENT2END use
1	Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of Vincristine: an over-representation of Asians?PURPOSE: This retrospective study used a pharmaceutical company's global safety database to determine the reporting rate of hyponatremia and/or syndrome of inappropriate secretion of anti-diuretic hormone ( ENT1 SIADH ENT1END  among ENT2 vincristine ENT2END -treated patients and to explore the possibility of at-risk population subgroups
0	RESULTS: A total of 76 cases of hyponatremia and/or SIADH associated with ENT1 vincristine ENT1END  use were identified. The overall reporting rate was estimated to be 1.3/100,000 treated patients. The average age of patients was 35.6 +/- 28.3 years, and 62% were males. Approximately 75% of the patients were receiving treatment for ENT2 leukemia ENT2END or lymphoma
0	8 x 10(10) pyocin type 6 Pseudomonas organisms in monkeys given ENT1 vincristine sulfate ENT1END 4 days previously resulted in fatal ENT2 infection ENT2END in 11 of 14 monkeys, whereas none of four receiving Pseudomonas alone died
0	ENT1 Leukocytosis ENT1END was observed in all monkeys. Intravenous or intratracheal inoculation of 2.0 to 2.5 mg of ENT2 vincristine sulfate ENT2END was followed by leukopenia in 4 to 5 days
1	5 mg of ENT1 vincristine sulfate ENT1END  was followed by ENT2 leukopenia ENT2END in 4 to 5 days
1	Effect of ENT1 vincristine sulfate  ENT1END  on ENT2 Pseudomonas infections ENT2END in monkeys
1	8 x 10(10) pyocin type 6 Pseudomonas organisms in monkeys given ENT1 vincristine sulfate ENT1END  4 days previously resulted in fatal infection in 11 of 14 monkeys, whereas none of four receiving Pseudomonas alone died. These studies suggest that an antimetabolite-induced leukopenia predisposes to severe Pseudomonas ENT2 sepsis ENT2END and that such monkeys may serve as a biological model for study of comparative efficacy of antimicrobial agents
0	Cardiac symptoms, including hypotension, developed in three patients with advanced ENT1 colorectal carcinoma ENT1END while being treated with cisplatin (CDDP) and ENT2 5-fluorouracil ENT2END (5-FU)
0	Cardiac symptoms, including hypotension, developed in three patients with advanced ENT1 colorectal carcinoma ENT1END  while being treated with ENT2 cisplatin ENT2END (CDDP) and 5-fluorouracil (5-FU)
1	Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil ( ENT1 5-FU ENT1END . In two patients, hypotension was associated with severe ENT2 left ventricular dysfunction ENT2END
1	Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin ( ENT1 CDDP  ENT1END  and 5-fluorouracil (5-FU). In two patients, hypotension was associated with severe ENT2 left ventricular dysfunction ENT2END
0	The presentation and cardiac evaluation (hemodynamic, echocardiographic, and scintigraphic) of these patients suggest new manifestations of ENT1 5-FU ENT1END ENT2 cardiotoxicity ENT2END that may be influenced by CDDP
0	The presentation and cardiac evaluation (hemodynamic, echocardiographic, and scintigraphic) of these patients suggest new manifestations of 5-FU ENT1 cardiotoxicity ENT1END  that may be influenced by ENT2 CDDP ENT2END
1	Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil ( ENT1 5-FU ENT1END ). In two patients, ENT2 hypotension ENT2END was associated with severe left ventricular dysfunction
1	Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin ( ENT1 CDDP  ENT1END ) and 5-fluorouracil (5-FU). In two patients, ENT2 hypotension ENT2END was associated with severe left ventricular dysfunction
0	ENT1 Creatine ENT1END kinase levels were normal prior to daptomycin therapy and were not reassessed. DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute ENT2 interstitial nephritis ENT2END and relapsing bacteremia
0	DISCUSSION: ENT1 Daptomycin  ENT1END was initiated in our patient secondary to possible nafcillin-induced acute ENT2 interstitial nephritis ENT2END and relapsing bacteremia
1	DISCUSSION: Daptomycin was initiated in our patient secondary to possible ENT1 nafcillin  ENT1END induced acute ENT2 interstitial nephritis ENT2END and relapsing bacteremia
0	OBJECTIVE: To report a case of ENT1 methicillin ENT1END sensitive Staphylococcus aureus (MSSA) ENT2 bacteremia ENT2END with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) ENT1 bacteremia  ENT1END  with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/ ENT2 tazobactam ENT2END
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) ENT1 bacteremia ENT1END  with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, ENT2 levofloxacin ENT2END , and piperacillin/tazobactam
0	ENT1 Creatine ENT1END  kinase levels were normal prior to daptomycin therapy and were not reassessed. DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing ENT2 bacteremia ENT2END
0	aureus susceptible to ENT1 oxacillin ENT1END  Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10. The patient experienced relapsing MSSA ENT2 bacteremia ENT2END on day 9, increasing the suspicion for a central nervous system (CNS) infection
0	CONCLUSIONS: High-dose ENT1 daptomycin ENT1END may be an alternative option for MSSA ENT2 bacteremia ENT2END with or without a CNS source in patients who have failed or cannot tolerate standard therapy
0	On day 8, the patient developed acute renal failure (serum ENT1 creatinine  ENT1END 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10. The patient experienced relapsing MSSA ENT2 bacteremia ENT2END on day 9, increasing the suspicion for a central nervous system (CNS) infection
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) ENT1 bacteremia ENT1END  with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with ENT2 vancomycin ENT2END , levofloxacin, and piperacillin/tazobactam
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) ENT1 bacteremia ENT1END  with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and ENT2 piperacillin ENT2END /tazobactam
0	DISCUSSION: Daptomycin was initiated in our patient secondary to possible ENT1 nafcillin  ENT1END -induced acute interstitial nephritis and relapsing ENT2 bacteremia ENT2END
0	The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) ENT1 infection  ENT1END  Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16. Daptomycin serum and CSF trough concentrations were 11.21 ug/mL and 0.52 ug/mL, respectively, prior to the third dose. Lumbar puncture results were inconclusive and no further blood cultures were positive for MSSA. ENT2 Creatine ENT2END kinase levels were normal prior to daptomycin therapy and were not reassessed
0	aureus susceptible to ENT1 oxacillin  ENT1END . Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10. The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) ENT2 infection ENT2END
0	The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) ENT1 infection ENT1END . Nafcillin was discontinued and ENT2 daptomycin ENT2END 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16
0	On day 8, the patient developed acute renal failure (serum ENT1 creatinine  ENT1END  1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10. The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) ENT2 infection ENT2END
0	The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) ENT1 infection ENT1END . ENT2 Nafcillin ENT2END was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16
0	OBJECTIVE: To report a case of ENT1 methicillin ENT1END -sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENT2 weakness ENT2END and presumed health-care-associated pneumonia shown on chest radiograph
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENT1 weakness  ENT1END  and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin ENT2 tazobactam ENT2END
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENT1 weakness  ENT1END  and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, ENT2 levofloxacin ENT2END , and piperacillin/tazobactam
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENT1 weakness  ENT1END  and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to ENT2 oxacillin ENT2END
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose ENT1 daptomycin  ENT1END assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENT2 weakness ENT2END and presumed health-care-associated pneumonia shown on chest radiograph
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENT1 weakness  ENT1END  and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum ENT2 creatinine ENT2END 1
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENT1 weakness  ENT1END  and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with ENT2 vancomycin ENT2END , levofloxacin, and piperacillin/tazobactam
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENT1 weakness  ENT1END  and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and ENT2 piperacillin ENT2END /tazobactam
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENT1 weakness ENT1END  and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to ENT2 nafcillin ENT2END on day 4
0	Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/ ENT1 tazobactam ENT1END . Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed ENT2 acute renal failure ENT2END (serum creatinine 1
0	Treatment was empirically initiated with vancomycin, ENT1 levofloxacin  ENT1END , and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed ENT2 acute renal failure ENT2END (serum creatinine 1
0	aureus susceptible to ENT1 oxacillin  ENT1END . Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed ENT2 acute renal failure ENT2END (serum creatinine 1
0	On day 8, the patient developed ENT1 acute renal failure  ENT1END  (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10. The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection. Nafcillin was discontinued and ENT2 daptomycin ENT2END 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16
0	On day 8, the patient developed ENT1 acute renal failure  ENT1END  (serum ENT2 creatinine ENT2END 1
0	Treatment was empirically initiated with ENT1 vancomycin  ENT1END , levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed ENT2 acute renal failure ENT2END (serum creatinine 1
0	Treatment was empirically initiated with vancomycin, levofloxacin, and ENT1 piperacillin  ENT1END /tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed ENT2 acute renal failure ENT2END (serum creatinine 1
0	Empiric antibiotic treatment was narrowed to ENT1 nafcillin  ENT1END  on day 4. On day 8, the patient developed ENT2 acute renal failure ENT2END (serum creatinine 1
0	Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/ ENT1 tazobactam ENT1END . Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENT2 cardiac arrest ENT2END on day 10
0	Treatment was empirically initiated with vancomycin, ENT1 levofloxacin  ENT1END , and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENT2 cardiac arrest ENT2END on day 10
0	The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENT1 cardiac arrest  ENT1END  on day 10. The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection. Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16. Daptomycin serum and CSF trough concentrations were 11.21 ug/mL and 0.52 ug/mL, respectively, prior to the third dose. Lumbar puncture results were inconclusive and no further blood cultures were positive for MSSA. ENT2 Creatine ENT2END kinase levels were normal prior to daptomycin therapy and were not reassessed
0	aureus susceptible to ENT1 oxacillin  ENT1END . Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENT2 cardiac arrest ENT2END on day 10
0	The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENT1 cardiac arrest  ENT1END  on day 10. The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection. Nafcillin was discontinued and ENT2 daptomycin ENT2END 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16
0	On day 8, the patient developed acute renal failure (serum ENT1 creatinine  ENT1END  1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENT2 cardiac arrest ENT2END on day 10
0	Treatment was empirically initiated with ENT1 vancomycin  ENT1END , levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENT2 cardiac arrest ENT2END on day 10
0	Treatment was empirically initiated with vancomycin, levofloxacin, and ENT1 piperacillin  ENT1END /tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENT2 cardiac arrest ENT2END on day 10
0	The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENT1 cardiac arrest  ENT1END  on day 10. The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection. ENT2 Nafcillin ENT2END was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16
0	OBJECTIVE: To report a case of ENT1 methicillin ENT1END -sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENT2 pneumonia ENT2END shown on chest radiograph
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENT1 pneumonia  ENT1END  shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin ENT2 tazobactam ENT2END
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENT1 pneumonia  ENT1END  shown on chest radiograph. Treatment was empirically initiated with vancomycin, ENT2 levofloxacin ENT2END , and piperacillin/tazobactam
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENT1 pneumonia  ENT1END  shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to ENT2 oxacillin ENT2END
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose ENT1 daptomycin  ENT1END  assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENT2 pneumonia ENT2END shown on chest radiograph
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENT1 pneumonia  ENT1END  shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum ENT2 creatinine ENT2END 1
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENT1 pneumonia  ENT1END  shown on chest radiograph. Treatment was empirically initiated with ENT2 vancomycin ENT2END , levofloxacin, and piperacillin/tazobactam
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENT1 pneumonia  ENT1END  shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and ENT2 piperacillin ENT2END /tazobactam
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENT1 pneumonia  ENT1END  shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to ENT2 nafcillin ENT2END on day 4
0	Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus ENT1 meningitis  ENT1END .OBJECTIVE: To report a case of ENT2 methicillin ENT2END -sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA ENT1 meningitis  ENT1END treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin ENT2 tazobactam ENT2END
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA ENT1 meningitis  ENT1END  treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, ENT2 levofloxacin ENT2END , and piperacillin/tazobactam
0	Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected ENT1 meningitis  ENT1END and was continued until the patient's death on day 16. Daptomycin serum and CSF trough concentrations were 11.21 ug/mL and 0.52 ug/mL, respectively, prior to the third dose. Lumbar puncture results were inconclusive and no further blood cultures were positive for MSSA. ENT2 Creatine ENT2END kinase levels were normal prior to daptomycin therapy and were not reassessed
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA ENT1 meningitis  ENT1END  treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to ENT2 oxacillin ENT2END
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA ENT1 meningitis  ENT1END  treated with high-dose ENT2 daptomycin ENT2END assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations
0	On day 8, the patient developed acute renal failure (serum ENT1 creatinine  ENT1END  1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10. The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection. Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected ENT2 meningitis ENT2END and was continued until the patient's death on day 16
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA ENT1 meningitis  ENT1END  treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with ENT2 vancomycin ENT2END , levofloxacin, and piperacillin/tazobactam
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA ENT1 meningitis  ENT1END  treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and ENT2 piperacillin ENT2END /tazobactam
0	ENT1 Nafcillin  ENT1END  was discontinued and daptomycin 9 mg/kg daily was initiated for suspected ENT2 meningitis ENT2END and was continued until the patient's death on day 16
0	005), and systemic ENT1 fungal infections ENT1END occurred only in the liver transplant group. Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of ENT2 cyclosporine ENT2END patients and 76% of Aza patients
0	ENT1 Aza  ENT1END patients had significantly more staphylococcal infections than all other transplant groups (P less than 0.005), and systemic ENT2 fungal infections ENT2END occurred only in the liver transplant group
0	Serological evidence for ENT1 Epstein Barr Virus infection ENT1END was found in 20% of 65 ENT2 cyclosporine ENT2END patients studied
0	Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of ENT1 Aza  ENT1END patients. Of the cyclosporine patients, 15% had symptoms related to CMV infection. Serological evidence for ENT2 Epstein Barr Virus infection ENT2END was found in 20% of 65 cyclosporine patients studied
0	Renal patients on ENT1 cyclosporine ENT1END had the fewest ENT2 bacteremias ENT2END
0	All others received cyclosporine and ENT1 prednisone  ENT1END  The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients. Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients. There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths. Renal patients on cyclosporine had the fewest ENT2 bacteremias ENT2END
0	There were no infectious deaths in renal transplant patients on cyclosporine or ENT1 Aza  ENT1END  but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths. Renal patients on cyclosporine had the fewest ENT2 bacteremias ENT2END
1	Heart and liver patients had more ENT1 infections ENT1END than ENT2 cyclosporine ENT2END renal patients but fewer infections than the Aza renal patients
0	All others received cyclosporine and ENT1 prednisone ENT1END . The randomized Aza patients had more overall ENT2 infections ENT2END (P less than 0
1	There were no infectious deaths in renal transplant patients on cyclosporine or ENT1 Aza ENT1END , but ENT2 infection ENT2END played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths
0	Of the ENT1 cyclosporine ENT1END patients, 15% had symptoms related to ENT2 CMV infection ENT2END
0	Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of ENT1 Aza  ENT1END  patients. Of the cyclosporine patients, 15% had symptoms related to ENT2 CMV infection ENT2END
0	Pulmonary infections were less common in ENT1 cyclosporine ENT1END treated renal patients than in Aza-treated patients (P less than 0.05). Aza patients had significantly more ENT2 staphylococcal infections ENT2END than all other transplant groups (P less than 0
0	ENT1 Aza  ENT1END  patients had significantly more ENT2 staphylococcal infections ENT2END than all other transplant groups (P less than 0
0	Renal patients on ENT1 cyclosporine ENT1END  had the fewest bacteremias. Analysis of site of infection showed a preponderance of ENT2 abdominal infections ENT2END in liver patients, intrathoracic infections in heart patients, and urinary tract infections in renal patients
0	All others received cyclosporine and ENT1 prednisone  ENT1END . The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients. Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients. There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths. Renal patients on cyclosporine had the fewest bacteremias. Analysis of site of infection showed a preponderance of ENT2 abdominal infections ENT2END in liver patients, intrathoracic infections in heart patients, and urinary tract infections in renal patients
0	Analysis of site of infection showed a preponderance of ENT1 abdominal infections ENT1END  in liver patients, intrathoracic infections in heart patients, and urinary tract infections in renal patients. Pulmonary infections were less common in cyclosporine-treated renal patients than in ENT2 Aza ENT2END -treated patients (P less than 0
0	Serological evidence for Epstein Barr Virus infection was found in 20% of 65 ENT1 cyclosporine ENT1END  patients studied. Three had associated symptoms, and one developed a ENT2 lymphoma ENT2END
0	Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of ENT1 Aza  ENT1END  patients. Of the cyclosporine patients, 15% had symptoms related to CMV infection. Serological evidence for Epstein Barr Virus infection was found in 20% of 65 cyclosporine patients studied. Three had associated symptoms, and one developed a ENT2 lymphoma ENT2END
0	Analysis of site of infection showed a preponderance of abdominal infections in liver patients, intrathoracic infections in heart patients, and ENT1 urinary tract infections  ENT1END in renal patients. Pulmonary infections were less common in ENT2 cyclosporine ENT2END -treated renal patients than in Aza-treated patients (P less than 0
0	All others received cyclosporine and ENT1 prednisone  ENT1END . The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients. Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients. There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths. Renal patients on cyclosporine had the fewest bacteremias. Analysis of site of infection showed a preponderance of abdominal infections in liver patients, intrathoracic infections in heart patients, and ENT2 urinary tract infections ENT2END in renal patients
0	Analysis of site of infection showed a preponderance of abdominal infections in liver patients, intrathoracic infections in heart patients, and ENT1 urinary tract infections  ENT1END  in renal patients. Pulmonary infections were less common in cyclosporine-treated renal patients than in ENT2 Aza ENT2END -treated patients (P less than 0
0	Patients were managed with ENT1 cyclosporine ENT1END and azathioprine. No prophylaxis with antilymphocyte globulin was used. Steroids were given to 39% of patients for refractory rejection, but weaning was always attempted and generally successful (64%). Five patients (14%) received maintenance steroids. Four patients died in the perioperative period and one died 4 months later. There have been no deaths related to rejection or ENT2 infection ENT2END
0	Freedom from serious ENT1 infections ENT1END was 83% at 1 month and 65% at 1 year. Cytomegalovirus infections were treated successfully with ENT2 ganciclovir ENT2END in 11 patients
0	Five patients (14%) received maintenance ENT1 steroids  ENT1END  Four patients died in the perioperative period and one died 4 months later. There have been no deaths related to rejection or ENT2 infection ENT2END
0	Patients were managed with cyclosporine and ENT1 azathioprine  ENT1END  No prophylaxis with antilymphocyte globulin was used. Steroids were given to 39% of patients for refractory rejection, but weaning was always attempted and generally successful (64%). Five patients (14%) received maintenance steroids. Four patients died in the perioperative period and one died 4 months later. There have been no deaths related to rejection or ENT2 infection ENT2END
0	Cytomegalovirus infections were treated successfully with ENT1 ganciclovir ENT1END  in 11 patients. No impairment of growth was observed in children who underwent transplantation compared with a control population. Twenty-one patients (60%) have undergone annual catheterizations and no sign of graft atherosclerosis has been observed. Seizures occurred in five patients (14%) and ENT2 hypertension ENT2END was treated in 10 patients (28%)
0	Indications for transplantation were ENT1 idiopathic cardiomyopathy ENT1END (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and ENT2 doxorubicin ENT2END cardiomyopathy (5%)
0	Indications for transplantation were ENT1 idiopathic cardiomyopathy  ENT1END  (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with ENT2 cyclosporine ENT2END and azathioprine
0	Pediatric heart transplantation without chronic maintenance ENT1 steroids  ENT1END .From 1986 to February 1993, 40 children aged 2 months to 18 years (average age 10.4 +/- 5.8 years) underwent heart transplantation. Indications for transplantation were ENT2 idiopathic cardiomyopathy ENT2END (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%)
0	Indications for transplantation were ENT1 idiopathic cardiomyopathy  ENT1END  (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with cyclosporine and ENT2 azathioprine ENT2END
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), ENT1 hypertrophic cardiomyopathy  ENT1END (5%), valvular heart disease (3%), and ENT2 doxorubicin ENT2END cardiomyopathy (5%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), ENT1 hypertrophic cardiomyopathy  ENT1END  (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with ENT2 cyclosporine ENT2END and azathioprine
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), ENT1 hypertrophic cardiomyopathy ENT1END  (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with cyclosporine and azathioprine. No prophylaxis with antilymphocyte globulin was used. ENT2 Steroids ENT2END were given to 39% of patients for refractory rejection, but weaning was always attempted and generally successful (64%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), ENT1 hypertrophic cardiomyopathy  ENT1END  (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with cyclosporine and ENT2 azathioprine ENT2END
1	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and ENT1 doxorubicin ENT1END  ENT2 cardiomyopathy ENT2END (5%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin ENT1 cardiomyopathy  ENT1END  (5%). Patients were managed with ENT2 cyclosporine ENT2END and azathioprine
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin ENT1 cardiomyopathy  ENT1END  (5%). Patients were managed with cyclosporine and azathioprine. No prophylaxis with antilymphocyte globulin was used. ENT2 Steroids ENT2END were given to 39% of patients for refractory rejection, but weaning was always attempted and generally successful (64%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin ENT1 cardiomyopathy  ENT1END  (5%). Patients were managed with cyclosporine and ENT2 azathioprine ENT2END
0	ENT1 Cytomegalovirus infections  ENT1END were treated successfully with ENT2 ganciclovir ENT2END in 11 patients
0	Cytomegalovirus infections were treated successfully with ENT1 ganciclovir ENT1END  in 11 patients. No impairment of growth was observed in children who underwent transplantation compared with a control population. Twenty-one patients (60%) have undergone annual catheterizations and no sign of graft atherosclerosis has been observed. ENT2 Seizures ENT2END occurred in five patients (14%) and hypertension was treated in 10 patients (28%)
0	Cytomegalovirus infections were treated successfully with ENT1 ganciclovir ENT1END  in 11 patients. No impairment of growth was observed in children who underwent transplantation compared with a control population. Twenty-one patients (60%) have undergone annual catheterizations and no sign of graft ENT2 atherosclerosis ENT2END has been observed
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), ENT1 valvular heart disease  ENT1END (3%), and ENT2 doxorubicin ENT2END cardiomyopathy (5%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), ENT1 valvular heart disease  ENT1END  (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with ENT2 cyclosporine ENT2END and azathioprine
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), ENT1 valvular heart disease  ENT1END  (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with cyclosporine and azathioprine. No prophylaxis with antilymphocyte globulin was used. ENT2 Steroids ENT2END were given to 39% of patients for refractory rejection, but weaning was always attempted and generally successful (64%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), ENT1 valvular heart disease  ENT1END  (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with cyclosporine and ENT2 azathioprine ENT2END
0	Indications for transplantation were idiopathic cardiomyopathy (52%), ENT1 congenital heart disease  ENT1END (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and ENT2 doxorubicin ENT2END cardiomyopathy (5%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), ENT1 congenital heart disease  ENT1END  (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with ENT2 cyclosporine ENT2END and azathioprine
0	Pediatric heart transplantation without chronic maintenance ENT1 steroids  ENT1END .From 1986 to February 1993, 40 children aged 2 months to 18 years (average age 10.4 +/- 5.8 years) underwent heart transplantation. Indications for transplantation were idiopathic cardiomyopathy (52%), ENT2 congenital heart disease ENT2END (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), ENT1 congenital heart disease  ENT1END  (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with cyclosporine and ENT2 azathioprine ENT2END
0	Cytomegalovirus infections were treated successfully with ENT1 ganciclovir ENT1END  in 11 patients. No impairment of growth was observed in children who underwent transplantation compared with a control population. Twenty-one patients (60%) have undergone annual catheterizations and no sign of graft atherosclerosis has been observed. Seizures occurred in five patients (14%) and hypertension was treated in 10 patients (28%). No patient was disabled and no ENT2 lymphoproliferative disorder ENT2END was observed
0	METHODS: The effect of pretreatment with trazodone on ENT1 dexamphetamine ENT1END  and apomorphine-induced ENT2 oral stereotypies ENT2END , on catalepsy induced by haloperidol and apomorphine (0
0	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced ENT1 oral stereotypies ENT1END , on catalepsy induced by ENT2 haloperidol ENT2END and apomorphine (0
0	The antidepressant trazodone is a ENT1 5-HT  ENT1END 2A/2C receptor antagonist. OBJECTIVES: To evaluate the effect of trazodone treatment on behaviors dependent on the functional status of the nigrostriatal DAergic system. METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced ENT2 oral stereotypies ENT2END , on catalepsy induced by haloperidol and apomorphine (0
0	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced ENT1 oral stereotypies ENT1END , on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and ENT2 fluoxetine ENT2END -induced penile erections was studied in rats
0	METHODS: The effect of pretreatment with ENT1 trazodone  ENT1END on dexamphetamine- and apomorphine-induced ENT2 oral stereotypies ENT2END , on catalepsy induced by haloperidol and apomorphine (0
0	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced ENT1 oral stereotypies ENT1END , on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ENT2 ergometrine ENT2END -induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats
0	Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on ENT1 dopamine  ENT1END -dependent behaviors in rats.RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission. The antidepressant trazodone is a 5-HT 2A/2C receptor antagonist. OBJECTIVES: To evaluate the effect of trazodone treatment on behaviors dependent on the functional status of the nigrostriatal DAergic system. METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced ENT2 oral stereotypies ENT2END , on catalepsy induced by haloperidol and apomorphine (0
0	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and ENT1 apomorphine  ENT1END induced ENT2 oral stereotypies ENT2END , on catalepsy induced by haloperidol and apomorphine (0
0	induced ENT1 catalepsy ENT1END and antagonized apomorphine and ENT2 dexamphetamine ENT2END stereotypies
1	trazodone enhanced dexamphetamine stereotypy, and antagonized ENT1 haloperidol ENT1END ENT2 catalepsy ENT2END , ergometrine-induced WDS behavior and fluoxetine-induced penile erections
0	We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by ENT1 5-HT ENT1END  and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol ENT2 catalepsy ENT2END
0	trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol ENT1 catalepsy ENT1END , ergometrine-induced WDS behavior and ENT2 fluoxetine ENT2END -induced penile erections
0	We also investigated whether ENT1 trazodone ENT1END induces ENT2 catalepsy ENT2END in rats
0	trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol ENT1 catalepsy ENT1END , ENT2 ergometrine ENT2END -induced WDS behavior and fluoxetine-induced penile erections
0	Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on ENT1 dopamine ENT1END -dependent behaviors in rats.RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission. The antidepressant trazodone is a 5-HT 2A/2C receptor antagonist. OBJECTIVES: To evaluate the effect of trazodone treatment on behaviors dependent on the functional status of the nigrostriatal DAergic system. METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on ENT2 catalepsy ENT2END induced by haloperidol and apomorphine (0
1	induced ENT1 catalepsy ENT1END  and antagonized ENT2 apomorphine ENT2END and dexamphetamine stereotypies
0	Recurrence rates of ventricular tachyarrhythmias are high despite complete suppression of the ENT1 arrhythmia ENT1END during programmed stimulation. Therefore programmed electrical stimulation in the case of ENT2 d,l-sotalol ENT2END seems to be of limited prognostic value
0	Eighty-one consecutive patients (54 with coronary artery disease, and 20 with ENT1 dilated cardiomyopathy ENT1END  with inducible sustained ventricular tachycardia or ventricular fibrillation received oral ENT2 d,l-sotalol ENT2END to prevent induction of the ventricular tachyarrhythmia
0	Efficacy and proarrhythmia with the use of ENT1 d,l-sotalol  ENT1END  for sustained ENT2 ventricular tachyarrhythmias ENT2END
0	Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ENT1 ventricular fibrillation  ENT1END received oral ENT2 d,l-sotalol ENT2END to prevent induction of the ventricular tachyarrhythmia
0	One female patient with stable ENT1 cardiac disease ENT1END had recurrent torsades de pointes after 2 years of successful treatment with ENT2 d,l-sotalol ENT2END
0	This study prospectively evaluated the clinical efficacy, the incidence of torsades de pointes, and the presumable risk factors for torsades de pointes in patients treated with ENT1 d,l-sotalol ENT1END for sustained ventricular tachyarrhythmias. Eighty-one consecutive patients (54 with ENT2 coronary artery disease ENT2END , and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia
1	One female patient with stable cardiac disease had recurrent torsades de pointes after 2 years of successful treatment with ENT1 d,l-sotalol ENT1END . ENT2 Torsades de pointes ENT2END occurred early during treatment even with low doses of oral d,l-sotalol
0	Patients were asked about dysphagia and evaluated with the Unified ENT1 Parkinson's Disease ENT1END Rating Scale Parts II and III and the Hoehn and Yahr scale. Deglutition was assessed using modified ENT2 barium ENT2END swallow with videofluoroscopy
0	The aim of this study was to characterize the oropharyngeal dynamics in ENT1 PD ENT1END patients with and without ENT2 levodopa ENT2END -induced dyskinesia
0	Deglutition was assessed using modified ENT1 barium ENT1END  swallow with videofluoroscopy. Nondyskinetic patients, but not the ENT2 dyskinetic ENT2END ones, showed less oropharyngeal swallowing efficiency (OPSE) for liquid food than controls (Dunnett, P = 0
1	The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without ENT1 levodopa ENT1END -induced ENT2 dyskinesia ENT2END
0	Patients were asked about ENT1 dysphagia  ENT1END and evaluated with the Unified Parkinson's Disease Rating Scale Parts II and III and the Hoehn and Yahr scale. Deglutition was assessed using modified ENT2 barium ENT2END swallow with videofluoroscopy
0	Our results suggest a role for ENT1 levodopa ENT1END in the oral phase of deglutition and confirm that ENT2 dysphagia ENT2END is not a good predictor of deglutition alterations in PD
0	ENT1 Gastrointestinal abnormalities  ENT1END in Parkinson's disease (PD) have been known for almost two centuries, but many aspects concerning their pathophysiology have not been completely clarified. The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without levodopa-induced dyskinesia. Fifteen dyskinetic, 12 nondyskinetic patients, and a control group were included. Patients were asked about dysphagia and evaluated with the Unified Parkinson's Disease Rating Scale Parts II and III and the Hoehn and Yahr scale. Deglutition was assessed using modified ENT2 barium ENT2END swallow with videofluoroscopy
0	ENT1 Gastrointestinal abnormalities  ENT1END  in Parkinson's disease (PD) have been known for almost two centuries, but many aspects concerning their pathophysiology have not been completely clarified. The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without ENT2 levodopa ENT2END -induced dyskinesia
0	ENT1 Swallowing abnormalities  ENT1END  and dyskinesia in Parkinson's disease.Gastrointestinal abnormalities in Parkinson's disease (PD) have been known for almost two centuries, but many aspects concerning their pathophysiology have not been completely clarified. The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without levodopa-induced dyskinesia. Fifteen dyskinetic, 12 nondyskinetic patients, and a control group were included. Patients were asked about dysphagia and evaluated with the Unified Parkinson's Disease Rating Scale Parts II and III and the Hoehn and Yahr scale. Deglutition was assessed using modified ENT2 barium ENT2END swallow with videofluoroscopy
0	ENT1 Swallowing abnormalities  ENT1END  and dyskinesia in Parkinson's disease.Gastrointestinal abnormalities in Parkinson's disease (PD) have been known for almost two centuries, but many aspects concerning their pathophysiology have not been completely clarified. The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without ENT2 levodopa ENT2END -induced dyskinesia
0	Nefiracetam is a novel ENT1 pyrrolidone ENT1END derivative which attenuates scopolamine-induced ENT2 learning and post-training consolidation deficits ENT2END
0	Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced ENT1 learning and post-training consolidation deficits  ENT1END . Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism. A step-down passive avoidance paradigm was employed and nefiracetam (3 mg/kg) and apomorphine (0.5 mg/kg) were given alone or in combination during training and at the 10-12h post-training period of consolidation. Co-administration of nefiracetam and apomorphine during training or 10h thereafter produced no significant anti-amnesic effect. However, administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post-training time and the converse was also true. These effects were not mediated by a dopaminergic mechanism as nefiracetam, at millimolar concentrations, failed to displace either [3H]SCH 23390 or [3H] ENT2 spiperone ENT2END binding from D1 or D2 dopamine receptor subtypes, respectively
1	Nefiracetam is a novel pyrrolidone derivative which attenuates ENT1 scopolamine  ENT1END induced ENT2 learning and post-training consolidation deficits ENT2END
0	ENT1 Nefiracetam  ENT1END is a novel pyrrolidone derivative which attenuates scopolamine-induced ENT2 learning and post-training consolidation deficits ENT2END
0	Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced ENT1 learning and post-training consolidation deficits  ENT1END . Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism. A step-down passive avoidance paradigm was employed and nefiracetam (3 mg/kg) and apomorphine (0.5 mg/kg) were given alone or in combination during training and at the 10-12h post-training period of consolidation. Co-administration of nefiracetam and apomorphine during training or 10h thereafter produced no significant anti-amnesic effect. However, administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post-training time and the converse was also true. These effects were not mediated by a dopaminergic mechanism as nefiracetam, at millimolar concentrations, failed to displace either [3H] ENT2 SCH 23390 ENT2END or [3H]spiperone binding from D1 or D2 dopamine receptor subtypes, respectively
0	Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced ENT1 learning and post-training consolidation deficits ENT1END . Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism. A step-down passive avoidance paradigm was employed and nefiracetam (3 mg/kg) and apomorphine (0.5 mg/kg) were given alone or in combination during training and at the 10-12h post-training period of consolidation. Co-administration of nefiracetam and apomorphine during training or 10h thereafter produced no significant anti-amnesic effect. However, administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post-training time and the converse was also true. These effects were not mediated by a dopaminergic mechanism as nefiracetam, at millimolar concentrations, failed to displace either [3H]SCH 23390 or [3H]spiperone binding from D1 or D2 ENT2 dopamine ENT2END receptor subtypes, respectively
0	Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced ENT1 learning and post-training consolidation deficits ENT1END . Given that ENT2 apomorphine ENT2END inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism
0	Nefiracetam (DM-9384) reverses apomorphine-induced ENT1 amnesia  ENT1END  of a passive avoidance response: delayed emergence of the memory retention effects.Nefiracetam is a novel ENT2 pyrrolidone ENT2END derivative which attenuates scopolamine-induced learning and post-training consolidation deficits
0	However, administration of nefiracetam during training completely reversed the ENT1 amnesia  ENT1END induced by apomorphine at the 10h post-training time and the converse was also true. These effects were not mediated by a dopaminergic mechanism as nefiracetam, at millimolar concentrations, failed to displace either [3H]SCH 23390 or [3H ENT2 spiperone ENT2END binding from D1 or D2 dopamine receptor subtypes, respectively
0	Nefiracetam (DM-9384) reverses apomorphine-induced ENT1 amnesia  ENT1END  of a passive avoidance response: delayed emergence of the memory retention effects.Nefiracetam is a novel pyrrolidone derivative which attenuates ENT2 scopolamine ENT2END -induced learning and post-training consolidation deficits
0	Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of ENT1 nefiracetam ENT1END to attenuate ENT2 amnesia ENT2END induced by dopaminergic agonism
0	However, administration of nefiracetam during training completely reversed the ENT1 amnesia  ENT1END  induced by apomorphine at the 10h post-training time and the converse was also true. These effects were not mediated by a dopaminergic mechanism as nefiracetam, at millimolar concentrations, failed to displace either [3H ENT2 SCH 23390 ENT2END or [3H]spiperone binding from D1 or D2 dopamine receptor subtypes, respectively
0	However, administration of nefiracetam during training completely reversed the ENT1 amnesia  ENT1END  induced by apomorphine at the 10h post-training time and the converse was also true. These effects were not mediated by a dopaminergic mechanism as nefiracetam, at millimolar concentrations, failed to displace either [3H]SCH 23390 or [3H]spiperone binding from D1 or D2 ENT2 dopamine ENT2END receptor subtypes, respectively
1	Nefiracetam (DM-9384) reverses ENT1 apomorphine  ENT1END -induced ENT2 amnesia ENT2END of a passive avoidance response: delayed emergence of the memory retention effects
0	Differential effects of ENT1 1,4-dihydropyridine ENT1END  calcium channel blockers: therapeutic implications.Increasing recognition of the importance of calcium in the pathogenesis of ENT2 cardiovascular disease ENT2END has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases
0	Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of ENT1 cardiovascular diseases ENT1END  The favorable efficacy and tolerability profiles of these agents make them attractive therapeutic modalities. Clinical applications of calcium channel blockers parallel their tissue selectivity. In contrast to verapamil and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, ENT2 nifedipine ENT2END controls angina and hypertension with minimal depression of cardiac function
0	Increasing recognition of the importance of ENT1 calcium  ENT1END in the pathogenesis of ENT2 cardiovascular disease ENT2END has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases
0	Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of ENT1 cardiovascular diseases ENT1END . The favorable efficacy and tolerability profiles of these agents make them attractive therapeutic modalities. Clinical applications of calcium channel blockers parallel their tissue selectivity. In contrast to ENT2 verapamil ENT2END and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue
0	Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of ENT1 cardiovascular diseases ENT1END . The favorable efficacy and tolerability profiles of these agents make them attractive therapeutic modalities. Clinical applications of calcium channel blockers parallel their tissue selectivity. In contrast to verapamil and ENT2 diltiazem ENT2END , which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue
0	Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of ENT1 calcium channel blocking agents  ENT1END for treatment of a variety of ENT2 cardiovascular diseases ENT2END
0	Once or twice daily dosage possible with ENT1 nitrendipine ENT1END and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of ENT2 hypertension ENT2END
0	As the first ENT1 dihydropyridine ENT1END available for use in the United States, nifedipine controls angina and ENT2 hypertension ENT2END with minimal depression of cardiac function
0	As the first dihydropyridine available for use in the United States, ENT1 nifedipine  ENT1END  controls angina and ENT2 hypertension ENT2END with minimal depression of cardiac function
0	Increasing recognition of the importance of ENT1 calcium  ENT1END  in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases. The favorable efficacy and tolerability profiles of these agents make them attractive therapeutic modalities. Clinical applications of calcium channel blockers parallel their tissue selectivity. In contrast to verapamil and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and ENT2 hypertension ENT2END with minimal depression of cardiac function
0	In contrast to ENT1 verapamil  ENT1END  and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and ENT2 hypertension ENT2END with minimal depression of cardiac function
0	Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of ENT1 hypertension ENT1END . The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes ENT2 nimodipine ENT2END potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke
0	Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of ENT1 hypertension ENT1END . The coronary vasodilating properties of ENT2 nisoldipine ENT2END have led to the investigation of this agent for use in angina
0	In contrast to verapamil and ENT1 diltiazem  ENT1END , which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and ENT2 hypertension ENT2END with minimal depression of cardiac function
0	As the first dihydropyridine available for use in the United States, nifedipine controls angina and ENT1 hypertension ENT1END  with minimal depression of cardiac function. Additional members of this group of ENT2 calcium channel blockers ENT2END have been studied for a variety of indications for which they may offer advantages over current therapy
0	Once or twice daily dosage possible with ENT1 nitrendipine ENT1END  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in ENT2 angina ENT2END
0	As the first ENT1 dihydropyridine ENT1END  available for use in the United States, nifedipine controls ENT2 angina ENT2END and hypertension with minimal depression of cardiac function
0	As the first dihydropyridine available for use in the United States, ENT1 nifedipine  ENT1END  controls ENT2 angina ENT2END and hypertension with minimal depression of cardiac function
0	Increasing recognition of the importance of ENT1 calcium  ENT1END  in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases. The favorable efficacy and tolerability profiles of these agents make them attractive therapeutic modalities. Clinical applications of calcium channel blockers parallel their tissue selectivity. In contrast to verapamil and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls ENT2 angina ENT2END and hypertension with minimal depression of cardiac function
0	In contrast to ENT1 verapamil  ENT1END  and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls ENT2 angina ENT2END and hypertension with minimal depression of cardiac function
0	The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in ENT1 angina  ENT1END . Selectivity for the cerebrovascular bed makes ENT2 nimodipine ENT2END potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke
0	The coronary vasodilating properties of ENT1 nisoldipine  ENT1END  have led to the investigation of this agent for use in ENT2 angina ENT2END
0	In contrast to verapamil and ENT1 diltiazem  ENT1END , which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls ENT2 angina ENT2END and hypertension with minimal depression of cardiac function
0	As the first dihydropyridine available for use in the United States, nifedipine controls ENT1 angina  ENT1END  and hypertension with minimal depression of cardiac function. Additional members of this group of ENT2 calcium channel blockers ENT2END have been studied for a variety of indications for which they may offer advantages over current therapy
0	Once or twice daily dosage possible with ENT1 nitrendipine ENT1END  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, ENT2 nausea ENT2END , anorexia, and dizziness being the more common adverse effects
0	In general, the ENT1 dihydropyridine  ENT1END calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, ENT2 nausea ENT2END , anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENT1 nifedipine  ENT1END  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, ENT2 nausea ENT2END , anorexia, and dizziness being the more common adverse effects
0	Selectivity for the cerebrovascular bed makes ENT1 nimodipine  ENT1END  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, ENT2 nausea ENT2END , anorexia, and dizziness being the more common adverse effects
0	The coronary vasodilating properties of ENT1 nisoldipine  ENT1END  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, ENT2 nausea ENT2END , anorexia, and dizziness being the more common adverse effects
1	In general, the dihydropyridine ENT1 calcium channel blockers  ENT1END are usually well tolerated, with headache, facial flushing, palpitations, edema, ENT2 nausea ENT2END , anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENT1 nitrendipine ENT1END  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, ENT2 anorexia ENT2END , and dizziness being the more common adverse effects
0	In general, the ENT1 dihydropyridine  ENT1END  calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, ENT2 anorexia ENT2END , and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENT1 nifedipine  ENT1END  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, ENT2 anorexia ENT2END , and dizziness being the more common adverse effects
0	Selectivity for the cerebrovascular bed makes ENT1 nimodipine  ENT1END  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, ENT2 anorexia ENT2END , and dizziness being the more common adverse effects
0	The coronary vasodilating properties of ENT1 nisoldipine  ENT1END  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, ENT2 anorexia ENT2END , and dizziness being the more common adverse effects
1	In general, the dihydropyridine ENT1 calcium channel blockers  ENT1END  are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, ENT2 anorexia ENT2END , and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENT1 nitrendipine ENT1END  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, ENT2 migraine headache ENT2END , dementia, and stroke
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, ENT1 migraine headache  ENT1END , dementia, and stroke. In general, the ENT2 dihydropyridine ENT2END calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENT1 nifedipine  ENT1END  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, ENT2 migraine headache ENT2END , dementia, and stroke
0	In contrast to ENT1 verapamil  ENT1END  and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, ENT2 migraine headache ENT2END , dementia, and stroke
0	Selectivity for the cerebrovascular bed makes ENT1 nimodipine  ENT1END  potentially useful in the treatment of subarachnoid hemorrhage, ENT2 migraine headache ENT2END , dementia, and stroke
0	The coronary vasodilating properties of ENT1 nisoldipine  ENT1END  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, ENT2 migraine headache ENT2END , dementia, and stroke
0	In contrast to verapamil and ENT1 diltiazem  ENT1END , which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, ENT2 migraine headache ENT2END , dementia, and stroke
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, ENT1 migraine headache  ENT1END , dementia, and stroke. In general, the dihydropyridine ENT2 calcium channel blockers ENT2END are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENT1 nitrendipine ENT1END  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with ENT2 headache ENT2END , facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	In general, the ENT1 dihydropyridine  ENT1END  calcium channel blockers are usually well tolerated, with ENT2 headache ENT2END , facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENT1 nifedipine  ENT1END  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with ENT2 headache ENT2END , facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Selectivity for the cerebrovascular bed makes ENT1 nimodipine  ENT1END  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with ENT2 headache ENT2END , facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	The coronary vasodilating properties of ENT1 nisoldipine  ENT1END  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with ENT2 headache ENT2END , facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
1	In general, the dihydropyridine ENT1 calcium channel blockers  ENT1END  are usually well tolerated, with ENT2 headache ENT2END , facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENT1 nitrendipine ENT1END  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of ENT2 subarachnoid hemorrhage ENT2END , migraine headache, dementia, and stroke
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of ENT1 subarachnoid hemorrhage  ENT1END , migraine headache, dementia, and stroke. In general, the ENT2 dihydropyridine ENT2END calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENT1 nifedipine  ENT1END  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of ENT2 subarachnoid hemorrhage ENT2END , migraine headache, dementia, and stroke
0	In contrast to ENT1 verapamil  ENT1END  and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of ENT2 subarachnoid hemorrhage ENT2END , migraine headache, dementia, and stroke
0	Selectivity for the cerebrovascular bed makes ENT1 nimodipine  ENT1END  potentially useful in the treatment of ENT2 subarachnoid hemorrhage ENT2END , migraine headache, dementia, and stroke
0	The coronary vasodilating properties of ENT1 nisoldipine  ENT1END  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of ENT2 subarachnoid hemorrhage ENT2END , migraine headache, dementia, and stroke
0	In contrast to verapamil and ENT1 diltiazem  ENT1END , which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of ENT2 subarachnoid hemorrhage ENT2END , migraine headache, dementia, and stroke
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of ENT1 subarachnoid hemorrhage  ENT1END , migraine headache, dementia, and stroke. In general, the dihydropyridine ENT2 calcium channel blockers ENT2END are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENT1 nitrendipine ENT1END  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, ENT2 edema ENT2END , nausea, anorexia, and dizziness being the more common adverse effects
0	In general, the ENT1 dihydropyridine  ENT1END  calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, ENT2 edema ENT2END , nausea, anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENT1 nifedipine  ENT1END  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, ENT2 edema ENT2END , nausea, anorexia, and dizziness being the more common adverse effects
0	Selectivity for the cerebrovascular bed makes ENT1 nimodipine  ENT1END  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, ENT2 edema ENT2END , nausea, anorexia, and dizziness being the more common adverse effects
0	The coronary vasodilating properties of ENT1 nisoldipine  ENT1END  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, ENT2 edema ENT2END , nausea, anorexia, and dizziness being the more common adverse effects
1	In general, the dihydropyridine ENT1 calcium channel blockers  ENT1END  are usually well tolerated, with headache, facial flushing, palpitations, ENT2 edema ENT2END , nausea, anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENT1 nitrendipine ENT1END  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENT2 stroke ENT2END
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENT1 stroke  ENT1END . In general, the ENT2 dihydropyridine ENT2END calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENT1 nifedipine  ENT1END  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENT2 stroke ENT2END
0	In contrast to ENT1 verapamil  ENT1END  and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENT2 stroke ENT2END
0	Selectivity for the cerebrovascular bed makes ENT1 nimodipine  ENT1END  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENT2 stroke ENT2END
0	The coronary vasodilating properties of ENT1 nisoldipine  ENT1END  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENT2 stroke ENT2END
0	In contrast to verapamil and ENT1 diltiazem  ENT1END , which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENT2 stroke ENT2END
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENT1 stroke  ENT1END . In general, the dihydropyridine ENT2 calcium channel blockers ENT2END are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENT1 nitrendipine ENT1END  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENT2 dementia ENT2END , and stroke
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENT1 dementia  ENT1END , and stroke. In general, the ENT2 dihydropyridine ENT2END calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENT1 nifedipine  ENT1END  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENT2 dementia ENT2END , and stroke
0	In contrast to ENT1 verapamil  ENT1END  and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENT2 dementia ENT2END , and stroke
0	Selectivity for the cerebrovascular bed makes ENT1 nimodipine  ENT1END  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENT2 dementia ENT2END , and stroke
0	The coronary vasodilating properties of ENT1 nisoldipine  ENT1END  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENT2 dementia ENT2END , and stroke
0	In contrast to verapamil and ENT1 diltiazem  ENT1END , which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENT2 dementia ENT2END , and stroke
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENT1 dementia  ENT1END , and stroke. In general, the dihydropyridine ENT2 calcium channel blockers ENT2END are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENT1 nitrendipine ENT1END  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial ENT2 flushing ENT2END , palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	In general, the ENT1 dihydropyridine  ENT1END  calcium channel blockers are usually well tolerated, with headache, facial ENT2 flushing ENT2END , palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENT1 nifedipine  ENT1END  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial ENT2 flushing ENT2END , palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Selectivity for the cerebrovascular bed makes ENT1 nimodipine  ENT1END  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial ENT2 flushing ENT2END , palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	The coronary vasodilating properties of ENT1 nisoldipine  ENT1END  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial ENT2 flushing ENT2END , palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
1	In general, the dihydropyridine ENT1 calcium channel blockers  ENT1END  are usually well tolerated, with headache, facial ENT2 flushing ENT2END , palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENT1 nitrendipine ENT1END  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and ENT2 dizziness ENT2END being the more common adverse effects
0	In general, the ENT1 dihydropyridine  ENT1END  calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and ENT2 dizziness ENT2END being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENT1 nifedipine  ENT1END  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and ENT2 dizziness ENT2END being the more common adverse effects
0	Selectivity for the cerebrovascular bed makes ENT1 nimodipine  ENT1END  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and ENT2 dizziness ENT2END being the more common adverse effects
0	The coronary vasodilating properties of ENT1 nisoldipine  ENT1END  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and ENT2 dizziness ENT2END being the more common adverse effects
1	In general, the dihydropyridine ENT1 calcium channel blockers  ENT1END  are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and ENT2 dizziness ENT2END being the more common adverse effects
0	Damage of substantia nigra pars reticulata during ENT1 pilocarpine ENT1END -induced status epilepticus in the rat: immunohistochemical study of neurons, astrocytes and serum-protein extravasation.The substantia nigra has a gating function controlling the spread of ENT2 epileptic seizure ENT2END activity
0	The substantia nigra has a gating function controlling the spread of ENT1 epileptic seizure ENT1END  activity. Additionally, in models of prolonged status epilepticus the pars reticulata of substantia nigra (SNR) suffers from a massive lesion which may arise from a massive metabolic derangement and hyperexcitation developing in the activated SNR. In this study, status epilepticus was induced by systemic injection of pilocarpine in rats. The neuropathology of SNR was investigated using immunohistochemical techniques with the major emphasis on the time-course of changes in neurons and astrocytes. Animals surviving 20, 30, 40, 60 min, 2, 3, 6 hours, 1, 2, and 3 days after induction of status epilepticus were perfusion-fixed, and brains processed for immunohistochemical staining of SNR. Nissl-staining and antibodies against the neuron-specific ENT2 calcium ENT2END -binding protein, parvalbumin, served to detect neuronal damage in SNR
0	In this study, status epilepticus was induced by systemic injection of ENT1 pilocarpine ENT1END in rats. The neuropathology of SNR was investigated using immunohistochemical techniques with the major emphasis on the time-course of changes in neurons and astrocytes. Animals surviving 20, 30, 40, 60 min, 2, 3, 6 hours, 1, 2, and 3 days after induction of status epilepticus were perfusion-fixed, and brains processed for immunohistochemical staining of SNR. Nissl-staining and antibodies against the neuron-specific calcium-binding protein, parvalbumin, served to detect ENT2 neuronal damage ENT2END in SNR
0	Nissl-staining and antibodies against the neuron-specific ENT1 calcium  ENT1END -binding protein, parvalbumin, served to detect ENT2 neuronal damage ENT2END in SNR
1	Damage of substantia nigra pars reticulata during ENT1 pilocarpine  ENT1END -induced ENT2 status epilepticus ENT2END in the rat: immunohistochemical study of neurons, astrocytes and serum-protein extravasation
0	Animals surviving 20, 30, 40, 60 min, 2, 3, 6 hours, 1, 2, and 3 days after induction of ENT1 status epilepticus  ENT1END were perfusion-fixed, and brains processed for immunohistochemical staining of SNR. Nissl-staining and antibodies against the neuron-specific ENT2 calcium ENT2END -binding protein, parvalbumin, served to detect neuronal damage in SNR
0	Antibodies against the astroglia-specific cytoskeletal protein, glial fibrillary acidic protein (GFAP), and against the glial ENT1 calcium ENT1END binding protein, S-100 protein, were used to assess the status of astrocytes. Immunohistochemical staining for serum-albumin and immunoglobulins in brain tissue was taken as indicator of blood-brain barrier disturbances and vasogenic edema formation. Immunohistochemical staining indicated loss of GFAP-staining already at 30 min after induction of ENT2 seizures ENT2END in an oval focus situated in the center of SNR while sparing medial and lateral aspects
0	In this study, status epilepticus was induced by systemic injection of ENT1 pilocarpine ENT1END  in rats. The neuropathology of SNR was investigated using immunohistochemical techniques with the major emphasis on the time-course of changes in neurons and astrocytes. Animals surviving 20, 30, 40, 60 min, 2, 3, 6 hours, 1, 2, and 3 days after induction of status epilepticus were perfusion-fixed, and brains processed for immunohistochemical staining of SNR. Nissl-staining and antibodies against the neuron-specific calcium-binding protein, parvalbumin, served to detect neuronal damage in SNR. Antibodies against the astroglia-specific cytoskeletal protein, glial fibrillary acidic protein (GFAP), and against the glial calcium-binding protein, S-100 protein, were used to assess the status of astrocytes. Immunohistochemical staining for serum-albumin and immunoglobulins in brain tissue was taken as indicator of blood-brain barrier disturbances and ENT2 vasogenic edema ENT2END formation
0	Antibodies against the astroglia-specific cytoskeletal protein, glial fibrillary acidic protein (GFAP), and against the glial ENT1 calcium  ENT1END -binding protein, S-100 protein, were used to assess the status of astrocytes. Immunohistochemical staining for serum-albumin and immunoglobulins in brain tissue was taken as indicator of blood-brain barrier disturbances and ENT2 vasogenic edema ENT2END formation
1	ENT1 Damage of substantia nigra pars reticulata  ENT1END  during ENT2 pilocarpine ENT2END -induced status epilepticus in the rat: immunohistochemical study of neurons, astrocytes and serum-protein extravasation
0	Additionally, in models of prolonged status epilepticus the pars reticulata of substantia nigra (SNR) suffers from a massive lesion which may arise from a massive ENT1 metabolic derangement  ENT1END and hyperexcitation developing in the activated SNR. In this study, status epilepticus was induced by systemic injection of ENT2 pilocarpine ENT2END in rats
0	Additionally, in models of prolonged status epilepticus the pars reticulata of substantia nigra (SNR) suffers from a massive lesion which may arise from a massive ENT1 metabolic derangement  ENT1END  and hyperexcitation developing in the activated SNR. In this study, status epilepticus was induced by systemic injection of pilocarpine in rats. The neuropathology of SNR was investigated using immunohistochemical techniques with the major emphasis on the time-course of changes in neurons and astrocytes. Animals surviving 20, 30, 40, 60 min, 2, 3, 6 hours, 1, 2, and 3 days after induction of status epilepticus were perfusion-fixed, and brains processed for immunohistochemical staining of SNR. Nissl-staining and antibodies against the neuron-specific ENT2 calcium ENT2END -binding protein, parvalbumin, served to detect neuronal damage in SNR
1	CONCLUSIONS: ENT1 QT interval prolongation ENT1END in ENT2 methadone ENT2END maintenance patients hospitalized in a tertiary care center is a frequent finding
0	Methadone dose, presence of cytochrome P-450 3A4 inhibitors, ENT1 potassium ENT1END level, and liver function contribute to ENT2 QT prolongation ENT2END
0	6%) in the ENT1 methadone ENT1END group presented ENT2 torsades de pointes ENT2END
0	6%) in the methadone group presented ENT1 torsades de pointes  ENT1END . QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P<.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function. CONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, ENT2 potassium ENT2END level, and liver function contribute to QT prolongation
0	8% of QTc variability to ENT1 methadone ENT1END dose, cytochrome P-450 3A4 drug-drug interactions, ENT2 hypokalemia ENT2END , and altered liver function
0	8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, ENT1 hypokalemia  ENT1END , and altered liver function. CONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, ENT2 potassium ENT2END level, and liver function contribute to QT prolongation
0	Nociceptin/orphanin FQ and ENT1 nocistatin  ENT1END  on ENT2 learning and memory impairment ENT2END induced by scopolamine in mice
0	Nociceptin/ ENT1 orphanin FQ  ENT1END  and nocistatin on ENT2 learning and memory impairment ENT2END induced by scopolamine in mice
1	Nociceptin/orphanin FQ and nocistatin on ENT1 learning and memory impairment  ENT1END  induced by ENT2 scopolamine ENT2END in mice
0	Nociceptin/orphanin FQ and ENT1 nocistatin  ENT1END  on ENT2 learning and memory impairment ENT2END induced by scopolamine in mice
0	Nociceptin/ ENT1 orphanin FQ  ENT1END  and nocistatin on ENT2 learning and memory impairment ENT2END induced by scopolamine in mice
1	Nociceptin/orphanin FQ and nocistatin on ENT1 learning and memory impairment  ENT1END  induced by ENT2 scopolamine ENT2END in mice
0	On the other hand, ENT1 nocistatin ENT1END is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced ENT2 allodynia ENT2END and hyperalgesia
0	On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks ENT1 nociceptin  ENT1END induced ENT2 allodynia ENT2END and hyperalgesia
0	Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by ENT1 scopolamine  ENT1END  in mice.1. Nociceptin, also known as orphanin FQ, is an endogenous ligand for the orphan opioid receptor-like receptor 1 (ORL1) and involves in various functions in the central nervous system (CNS). On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced ENT2 allodynia ENT2END and hyperalgesia
0	Thirty-six nonobese subjects with schizophrenia or ENT1 schizoaffective disorder ENT1END  matched by body mass index and treated with either clozapine, olanzapine, or ENT2 risperidone ENT2END , were included in the analysis
0	Thirty-six nonobese subjects with schizophrenia or ENT1 schizoaffective disorder ENT1END , matched by body mass index and treated with either ENT2 clozapine ENT2END , olanzapine, or risperidone, were included in the analysis
0	Thirty-six nonobese subjects with schizophrenia or ENT1 schizoaffective disorder ENT1END , matched by body mass index and treated with either clozapine, ENT2 olanzapine ENT2END , or risperidone, were included in the analysis
0	Patients Fifty subjects signed informed consent and 41 underwent the frequently sampled intravenous ENT1 glucose  ENT1END tolerance test. Thirty-six nonobese subjects with schizophrenia or ENT2 schizoaffective disorder ENT2END , matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis
0	001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant ENT1 insulin resistance ENT1END compared with subjects who were treated with ENT2 risperidone ENT2END (clozapine vs risperidone, t(33) = -4
1	Patients taking ENT1 clozapine ENT1END and olanzapine must be examined for ENT2 insulin resistance ENT2END and its consequences
1	Patients taking clozapine and ENT1 olanzapine  ENT1END must be examined for ENT2 insulin resistance ENT2END and its consequences
0	MAIN OUTCOME MEASURES: Fasting plasma glucose and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of ENT1 insulin resistance ENT1END  and ENT2 glucose ENT2END effectiveness
0	BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for ENT1 diabetes ENT1END  OBJECTIVE: To study the 2 drugs most clearly implicated (clozapine and olanzapine) and ENT2 risperidone ENT2END using a frequently sampled intravenous glucose tolerance test
0	BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for ENT1 diabetes  ENT1END . OBJECTIVE: To study the 2 drugs most clearly implicated ( ENT2 clozapine ENT2END and olanzapine) and risperidone using a frequently sampled intravenous glucose tolerance test
0	BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for ENT1 diabetes ENT1END . OBJECTIVE: To study the 2 drugs most clearly implicated (clozapine and ENT2 olanzapine ENT2END ) and risperidone using a frequently sampled intravenous glucose tolerance test
0	BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting ENT1 glucose  ENT1END metabolism or simply increasing known risk factors for ENT2 diabetes ENT2END
0	Thirty-six nonobese subjects with ENT1 schizophrenia  ENT1END or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or ENT2 risperidone ENT2END , were included in the analysis
0	Thirty-six nonobese subjects with ENT1 schizophrenia  ENT1END  or schizoaffective disorder, matched by body mass index and treated with either ENT2 clozapine ENT2END , olanzapine, or risperidone, were included in the analysis
0	Thirty-six nonobese subjects with ENT1 schizophrenia  ENT1END  or schizoaffective disorder, matched by body mass index and treated with either clozapine, ENT2 olanzapine ENT2END , or risperidone, were included in the analysis
0	ENT1 Glucose  ENT1END  metabolism in patients with ENT2 schizophrenia ENT2END treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis
0	ENT1 Amiodarone  ENT1END is an anti- ENT2 arrhythmic ENT2END drug for life-threatening tachycardia, but various adverse effects have been reported
0	76 g/day) after treatment with ENT1 amiodarone ENT1END for a long time. The lung mass was highly suspected to be ENT2 lung cancer ENT2END on CT and positron emission tomography, but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra-alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies, indicating that it was an amiodarone-related lesion
1	ENT1 Amiodarone  ENT1END -related pulmonary mass and unique ENT2 membranous glomerulonephritis ENT2END in a patient with valvular heart disease: Diagnostic pitfall and new findings
0	Autoimmune diseases, ENT1 viral hepatitis ENT1END  malignant neoplasms or other diseases with a known relationship to membranous glomerulonephritis were not found. The present case highlights the possibility that differential diagnosis between an ENT2 amiodarone ENT2END -related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment
0	5 cm in diameter) and ENT1 proteinuria  ENT1END (2.76 g/day) after treatment with ENT2 amiodarone ENT2END for a long time
0	The present case highlights the possibility that differential diagnosis between an ENT1 amiodarone ENT1END -related pulmonary lesion and a ENT2 neoplasm ENT2END can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment
0	ENT1 Autoimmune diseases  ENT1END  viral hepatitis, malignant neoplasms or other diseases with a known relationship to membranous glomerulonephritis were not found. The present case highlights the possibility that differential diagnosis between an ENT2 amiodarone ENT2END -related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment
0	ENT1 Amiodarone ENT1END  is an anti-arrhythmic drug for life-threatening ENT2 tachycardia ENT2END , but various adverse effects have been reported
1	The lung mass was highly suspected to be lung cancer on CT and positron emission tomography, but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra-alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies, indicating that it was an ENT1 amiodarone ENT1END related lesion. In addition, the lung tissue had unevenly distributed ENT2 hemosiderin ENT2END deposition, and abnormally tortuous capillaries were seen in the mass and in heavily hemosiderotic lung portions outside the mass
0	Amiodarone-related pulmonary mass and unique membranous glomerulonephritis in a patient with ENT1 valvular heart disease  ENT1END : Diagnostic pitfall and new findings ENT2 Amiodarone ENT2END is an anti-arrhythmic drug for life-threatening tachycardia, but various adverse effects have been reported
1	ENT1 Amiodarone  ENT1END -related ENT2 pulmonary mass ENT2END and unique membranous glomerulonephritis in a patient with valvular heart disease: Diagnostic pitfall and new findings
0	17 required ENT1 epinephrine ENT1END infusion to treat ENT2 hypotension ENT2END
0	Blood pressure, heart rate, respiratory rate and ENT1 oxygen ENT1END saturation were monitored over 1 hour. RESULTS: Three patients (8.1%) in the unilateral group and 5 (13.5%) in the conventional group developed ENT2 hypotension ENT2END , P= 0
1	5% hyperbaric ENT1 bupivacaine  ENT1END through a 25-gauge spinal needle. Patients in the unilateral group were maintained in the lateral position for 15 minutes following spinal injection while those in the conventional group were turned supine immediately after injection. Blood pressure, heart rate, respiratory rate and oxygen saturation were monitored over 1 hour. RESULTS: Three patients (8.1%) in the unilateral group and 5 (13.5%) in the conventional group developed ENT2 hypotension ENT2END , P= 0
0	Cardiovascular diseases ( ENT1 CVDs ENT1END  are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and ENT2 angiotensin ENT2END -converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENT1 CVDs ENT1END ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, ENT2 aspartate ENT2END transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENT1 CVDs ENT1END ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue ENT2 malondialdehyde ENT2END (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENT1 CVDs ENT1END ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum ENT2 lactate ENT2END dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENT1 CVDs ENT1END ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and ENT2 nitric oxide ENT2END levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENT1 CVDs ENT1END ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05). Pretreatment with S. virgaurea extract for 5 weeks at a dose of 250 mg/kg followed by isoproterenol injection significantly prevented the observed alterations. ENT2 Captopril ENT2END (50 mg/kg/day, given orally), an inhibitor of angiotensin-converting enzyme used as a standard cardioprotective drug, was used as a positive control in this study
0	Cardiovascular diseases ( ENT1 CVDs ENT1END ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, ENT2 alanine ENT2END transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENT1 CVDs ENT1END ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total ENT2 cholesterol ENT2END , triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENT1 CVDs ENT1END ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, ENT2 creatine ENT2END phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENT1 CVDs ENT1END ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, ENT2 triglycerides ENT2END , free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENT1 CVDs ENT1END ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on ENT2 isoproterenol ENT2END -induced cardiotoxicity in rats
0	Cardiovascular diseases ( ENT1 CVDs ENT1END ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum ENT2 fatty acid ENT2END , cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENT1 CVDs ENT1END ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of ENT2 glutathione ENT2END and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENT1 CVDs ENT1END ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and ENT2 superoxide ENT2END dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENT1 cardiotoxicity  ENT1END in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and ENT2 angiotensin ENT2END -converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENT1 cardiotoxicity  ENT1END  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, ENT2 aspartate ENT2END transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENT1 cardiotoxicity  ENT1END  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue ENT2 malondialdehyde ENT2END (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENT1 cardiotoxicity  ENT1END  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum ENT2 lactate ENT2END dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENT1 cardiotoxicity  ENT1END  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and ENT2 nitric oxide ENT2END levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENT1 cardiotoxicity  ENT1END  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05). Pretreatment with S. virgaurea extract for 5 weeks at a dose of 250 mg/kg followed by isoproterenol injection significantly prevented the observed alterations. ENT2 Captopril ENT2END (50 mg/kg/day, given orally), an inhibitor of angiotensin-converting enzyme used as a standard cardioprotective drug, was used as a positive control in this study
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENT1 cardiotoxicity  ENT1END  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, ENT2 alanine ENT2END transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENT1 cardiotoxicity  ENT1END  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total ENT2 cholesterol ENT2END , triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENT1 cardiotoxicity  ENT1END  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, ENT2 creatine ENT2END phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENT1 cardiotoxicity  ENT1END  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, ENT2 triglycerides ENT2END , free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
1	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on ENT1 isoproterenol  ENT1END -induced ENT2 cardiotoxicity ENT2END in rats
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENT1 cardiotoxicity  ENT1END  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum ENT2 fatty acid ENT2END , cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENT1 cardiotoxicity  ENT1END  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of ENT2 glutathione ENT2END and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENT1 cardiotoxicity  ENT1END  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and ENT2 superoxide ENT2END dismutase in cardiac tissue as compared to the normal control group (P < 0
0	We have described a patient with severe ENT1 rheumatoid arthritis ENT1END and a history of ENT2 mefenamic acid ENT2END nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function
0	Hyperkalemia induced by indomethacin and ENT1 naproxen  ENT1END  and reversed by fludrocortisone.We have described a patient with severe ENT2 rheumatoid arthritis ENT2END and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function
0	Hyperkalemia induced by ENT1 indomethacin  ENT1END  and naproxen and reversed by fludrocortisone.We have described a patient with severe ENT2 rheumatoid arthritis ENT2END and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function
0	Hyperkalemia induced by indomethacin and naproxen and reversed by ENT1 fludrocortisone  ENT1END .We have described a patient with severe ENT2 rheumatoid arthritis ENT2END and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function
0	We have described a patient with severe ENT1 rheumatoid arthritis ENT1END  and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function. It is likely that preexisting renal disease predisposed this patient to type IV renal tubular acidosis with ENT2 prostaglandin ENT2END synthetase inhibitors
0	We have described a patient with severe rheumatoid arthritis and a history of ENT1 mefenamic acid ENT1END  nephropathy in whom ENT2 hyperkalemia ENT2END and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function
1	ENT1 Hyperkalemia  ENT1END  induced by indomethacin and ENT2 naproxen ENT2END and reversed by fludrocortisone
1	ENT1 Hyperkalemia  ENT1END  induced by ENT2 indomethacin ENT2END and naproxen and reversed by fludrocortisone
0	Because he was unable to discontinue nonsteroidal anti-inflammatory drug therapy, ENT1 fludrocortisone ENT1END was added, correcting the ENT2 hyperkalemia ENT2END and allowing indomethacin therapy to be continued safely
0	It is likely that preexisting renal disease predisposed this patient to type IV renal tubular acidosis with ENT1 prostaglandin  ENT1END  synthetase inhibitors. Because he was unable to discontinue nonsteroidal anti-inflammatory drug therapy, fludrocortisone was added, correcting the ENT2 hyperkalemia ENT2END and allowing indomethacin therapy to be continued safely
1	We have described a patient with severe rheumatoid arthritis and a history of ENT1 mefenamic acid ENT1END  ENT2 nephropathy ENT2END in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function
0	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and ENT1 naproxen ENT1END  without major decline in renal function. It is likely that preexisting ENT2 renal disease ENT2END predisposed this patient to type IV renal tubular acidosis with prostaglandin synthetase inhibitors
0	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid ENT1 nephropathy ENT1END  in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both ENT2 indomethacin ENT2END and naproxen, without major decline in renal function
0	Hyperkalemia induced by indomethacin and naproxen and reversed by ENT1 fludrocortisone  ENT1END .We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid ENT2 nephropathy ENT2END in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function
0	It is likely that preexisting ENT1 renal disease  ENT1END  predisposed this patient to type IV renal tubular acidosis with ENT2 prostaglandin ENT2END synthetase inhibitors
0	We have described a patient with severe rheumatoid arthritis and a history of ENT1 mefenamic acid ENT1END  nephropathy in whom hyperkalemia and inappropriate ENT2 hypoaldosteronism ENT2END were caused by both indomethacin and naproxen, without major decline in renal function
1	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate ENT1 hypoaldosteronism  ENT1END  were caused by both indomethacin and ENT2 naproxen ENT2END , without major decline in renal function
1	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate ENT1 hypoaldosteronism  ENT1END  were caused by both ENT2 indomethacin ENT2END and naproxen, without major decline in renal function
0	It is likely that preexisting renal disease predisposed this patient to ENT1 type IV renal tubular acidosis  ENT1END with prostaglandin synthetase inhibitors. Because he was unable to discontinue nonsteroidal anti-inflammatory drug therapy, ENT2 fludrocortisone ENT2END was added, correcting the hyperkalemia and allowing indomethacin therapy to be continued safely
0	It is likely that preexisting renal disease predisposed this patient to ENT1 type IV renal tubular acidosis  ENT1END  with ENT2 prostaglandin ENT2END synthetase inhibitors
1	C57BL/6J, chosen as a "prototypic" mouse strain, was used to determine behavioral responses to a broad range (5-500 mg/kg) of ENT1 caffeine ENT1END doses. Five phenotypic characteristics--locomotor activity, righting ability, ENT2 clonic seizure ENT2END induction, stress-induced lethality, death without external stress--were scored at various caffeine doses in drug-naive animals under empirically optimized, rigidly constant experimental conditions
0	By any single behavioral criterion or a combination of these criteria, marked differences in response to toxic ENT1 caffeine ENT1END doses were observed between strains. These results indicate that behavioral ENT2 toxicity ENT2END testing of alkylxanthines in a single mouse strain may be misleading and suggest that toxic responses of the central nervous system to this class of compounds are genetically influenced in mammals
1	The incidence of ENT1 subependymal cysts ENT1END in infants exposed to ENT2 cocaine ENT2END prenatally was 44% (8 of 18) compared with 8% (8 of 99) in the unexposed group (p < 0
0	PURPOSE: Prenatal ENT1 cocaine ENT1END exposure has been linked with subependymal ENT2 hemorrhage ENT2END and the formation of cysts that are detectable on cranial sonography in neonates born at term
1	Prenatal cocaine exposure and cranial sonographic findings in ENT1 preterm infants  ENT1END .PURPOSE: Prenatal ENT2 cocaine ENT2END exposure has been linked with subependymal hemorrhage and the formation of cysts that are detectable on cranial sonography in neonates born at term
1	The incidence of ENT1 subependymal cysts  ENT1END in infants exposed to ENT2 cocaine ENT2END prenatally was 44% (8 of 18) compared with 8% (8 of 99) in the unexposed group (p < 0
0	Infants were assigned to the ENT1 cocaine ENT1END exposed group if there was a maternal history of ENT2 cocaine abuse ENT2END during pregnancy or if maternal or neonatal urine toxicology results were positive at the time of delivery
1	Acetaminophen (APAP) produces proximal ENT1 tubular necrosis ENT1END in Fischer 344 (F344) rats. Recently, ENT2 p-aminophenol ENT2END (PAP), a known potent nephrotoxicant, was identified as a metabolite of APAP in F344 rats
1	It is concluded that PAP formation, in vivo, accounts, at least in part, for ENT1 APAP ENT1END induced ENT2 renal tubular necrosis ENT2END
0	The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of ENT1 bis(p-nitrophenyl) phosphate  ENT1END  on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.Acetaminophen (APAP) produces proximal ENT2 tubular necrosis ENT2END in Fischer 344 (F344) rats
0	Therefore, the effect of bis(p-nitrophenyl) phosphate (BNPP), an acylamidase inhibitor, on APAP and ENT1 PAP ENT1END ENT2 nephrotoxicity ENT2END and metabolism was determined
0	The purpose of this study was to determine if PAP formation is a requisite step in ENT1 APAP ENT1END induced ENT2 nephrotoxicity ENT2END
0	The role of p-aminophenol in acetaminophen-induced ENT1 nephrotoxicity  ENT1END : effect of ENT2 bis(p-nitrophenyl) phosphate ENT2END on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats
1	Histamine antagonists and ENT1 d-tubocurarine  ENT1END -induced ENT2 hypotension ENT2END in cardiac surgical patients
0	Histamine antagonists and d-tubocurarine-induced ENT1 hypotension  ENT1END  in cardiac surgical patients.Hemodynamic effects and histamine release by bolus injection of 0.35 mg/kg of d-tubocurarine were studied in 24 patients. H1- and H2-histamine antagonists or placebo were given before dosing with d-tubocurarine in a randomized double-blind fashion to four groups: group 1--placebo; group 2--cimetidine, 4 mg/kg, plus placebo; group 3-- ENT2 chlorpheniramine ENT2END , 0
0	ENT1 Histamine  ENT1END  antagonists and d-tubocurarine-induced ENT2 hypotension ENT2END in cardiac surgical patients
0	Histamine antagonists and d-tubocurarine-induced ENT1 hypotension  ENT1END  in cardiac surgical patients.Hemodynamic effects and histamine release by bolus injection of 0.35 mg/kg of d-tubocurarine were studied in 24 patients. H1- and H2-histamine antagonists or placebo were given before dosing with d-tubocurarine in a randomized double-blind fashion to four groups: group 1--placebo; group 2-- ENT2 cimetidine ENT2END , 4 mg/kg, plus placebo; group 3--chlorpheniramine, 0
0	The left ventricular dysfunction was significantly lower in the groups treated with 25 and 50mg/kg of ENT1 metformin ENT1END  Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), ENT2 tumor ENT2END necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues
0	Metfromin markedly lowered ENT1 isoproterenol  ENT1END induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), ENT2 tumor ENT2END necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues
0	Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates ENT1 left ventricular dysfunction ENT1END  following myocardial infarction.Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of ENT2 AMP ENT2END -activated protein kinase (AMPK)
0	Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates ENT1 left ventricular dysfunction ENT1END  following myocardial infarction.Acute treatment with ENT2 metformin ENT2END has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK)
1	The ENT1 left ventricular dysfunction  ENT1END was significantly lower in the groups treated with 25 and 50mg/kg of metformin. Metfromin markedly lowered ENT2 isoproterenol ENT2END -induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues
0	Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of ENT1 AMP ENT1END -activated protein kinase (AMPK). In the present study, the effect of chronic pre-treatment with metformin on ENT2 cardiac dysfunction ENT2END and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed
0	In the present study, the effect of chronic pre-treatment with ENT1 metformin  ENT1END on ENT2 cardiac dysfunction ENT2END and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed
0	In the present study, the effect of chronic pre-treatment with metformin on ENT1 cardiac dysfunction ENT1END  and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed. Male Wistar rats were randomly assigned to one of 5 groups (n=6): normal control and groups were injected ENT2 isoproterenol ENT2END after chronic pre-treatment with 0, 25, 50, or 100mg/kg of metformin twice daily for 14 days
0	The left ventricular dysfunction was significantly lower in the groups treated with 25 and 50mg/kg of ENT1 metformin ENT1END . Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor ENT2 necrosis ENT2END factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues
0	Metfromin markedly lowered ENT1 isoproterenol  ENT1END -induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor ENT2 necrosis ENT2END factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues
0	Acute treatment with metformin has a protective effect in ENT1 myocardial infarction  ENT1END by suppression of inflammatory responses due to activation of ENT2 AMP ENT2END -activated protein kinase (AMPK)
0	Chronic pre-treatment with ENT1 metformin  ENT1END reduces post- ENT2 myocardial infarction ENT2END cardiac dysfunction and suppresses inflammatory responses, possibly through inhibition of TLR4 activities
1	Isoproterenol (100mg/kg) was injected subcutaneously on the 13th and 14th days to induce ENT1 acute myocardial infarction ENT1END  ENT2 Isoproterenol ENT2END alone decreased left ventricular systolic pressure and myocardial contractility indexed as LVdp/dtmax and LVdp/dtmin
1	Flumazenil induces ENT1 seizures  ENT1END  and death in mixed cocaine ENT2 diazepam ENT2END intoxications
1	STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask ENT1 seizures ENT1END in mixed ENT2 cocaine ENT2END -benzodiazepine intoxication
0	STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask ENT1 seizures  ENT1END  in mixed cocaine- ENT2 benzodiazepine ENT2END intoxication
1	ENT1 Flumazenil  ENT1END  induces ENT2 seizures ENT2END and death in mixed cocaine-diazepam intoxications
0	CONCLUSION: This report describes the case of a woman with LACNP that developed after a ENT1 steroid ENT1END injection for the treatment of ENT2 lateral epicondylitis ENT2END
0	MATERIAL AND METHOD: A 40-year-old woman presented with decreased sensation and paresthesia over her right lateral forearm; the paresthesia had occurred after a ENT1 steroid ENT1END injection in the right lateral epicondyle 3 months before. Her sensation of light touch and ENT2 pain ENT2END was diminished over the lateral side of the right forearm and wrist area
0	Lateral antebrachial cutaneous ENT1 neuropathy  ENT1END  after ENT2 steroid ENT2END injection at lateral epicondyle
1	MATERIAL AND METHOD: A 40-year-old woman presented with decreased sensation and paresthesia over her right lateral forearm; the ENT1 paresthesia  ENT1END had occurred after a ENT2 steroid ENT2END injection in the right lateral epicondyle 3 months before
1	Sprague-Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of ENT1 aminophylline ENT1END until onset of maximal ENT2 seizures ENT2END which occurred after 28 and 30 minutes respectively
0	Sprague-Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of aminophylline until onset of maximal ENT1 seizures ENT1END  which occurred after 28 and 30 minutes respectively. ENT2 Theophylline ENT2END concentrations at this endpoint in serum (total) and CSF were similar but serum (free) and brain concentrations were slightly different in pregnant rats
0	The purpose of this investigation was to determine whether the ENT1 neurotoxicity  ENT1END of theophylline is altered in advanced pregnancy. Sprague-Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of ENT2 aminophylline ENT2END until onset of maximal seizures which occurred after 28 and 30 minutes respectively
0	ENT1 Theophylline ENT1END ENT2 neurotoxicity ENT2END in pregnant rats
0	Flurothyl seizure thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in flurothyl ENT1 seizure  ENT1END  testing. ENT2 Monosodium glutamate ENT2END (MSG) administration to neonatal rodents produces convulsions and results in numerous biochemical and behavioral deficits
0	ENT1 Flurothyl ENT1END ENT2 seizure ENT2END thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in flurothyl seizure testing
0	A flurothyl ENT1 ether ENT1END ENT2 seizure ENT2END screening technique was used to evaluate seizure susceptibility in adult mice that received neonatal injections of MSG (4 mg/g and 1 mg/g)
0	MSG treatment resulted in significant reductions in whole brain weight but did not alter ENT1 seizure ENT1END threshold. A ENT2 naloxone ENT2END (5 mg/kg) challenge was also ineffective in altering the seizure thresholds of either control of MSG-treated mice
0	A naloxone (5 mg/kg) challenge was also ineffective in altering the seizure thresholds of either control of ENT1 MSG ENT1END treated mice. Flurothyl ether produced ENT2 hypothermia ENT2END which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear
1	ENT1 Flurothyl  ENT1END ether produced ENT2 hypothermia ENT2END which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear
0	Flurothyl ENT1 ether  ENT1END produced ENT2 hypothermia ENT2END which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear
0	A ENT1 naloxone  ENT1END  (5 mg/kg) challenge was also ineffective in altering the seizure thresholds of either control of MSG-treated mice. Flurothyl ether produced ENT2 hypothermia ENT2END which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear
0	selectively inhibited the ENT1 enlargement of pulse pressure ENT1END and the tachycardia following i.c. carbachol (1 mug). On the other hand, the pressor response to i.c. carbachol (1 mug) was almost completely blocked by i.c. atropine (3 mug) or hexamethonium (500 mug), and significantly reduced by i.c. ENT2 chlorpromazine ENT2END (50 mug) but significantly potentiated by i
0	) injection of ENT1 guanethidine  ENT1END (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the ENT2 enlargement of pulse pressure ENT2END and the tachycardia following i
1	selectively inhibited the ENT1 enlargement of pulse pressure ENT1END  and the tachycardia following i.c. ENT2 carbachol ENT2END (1 mug)
0	) injection of guanethidine (5 mg), hexamethonium (10 mg) or ENT1 phentolamine  ENT1END (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the ENT2 enlargement of pulse pressure ENT2END and the tachycardia following i
0	) injection of guanethidine (5 mg), ENT1 hexamethonium  ENT1END (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the ENT2 enlargement of pulse pressure ENT2END and the tachycardia following i
1	ENT1 desmethylimipramine  ENT1END (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the ENT2 enlargement of pulse pressure ENT2END and the tachycardia following i
0	selectively inhibited the ENT1 enlargement of pulse pressure ENT1END  and the tachycardia following i.c. carbachol (1 mug). On the other hand, the pressor response to i.c. carbachol (1 mug) was almost completely blocked by i.c. ENT2 atropine ENT2END (3 mug) or hexamethonium (500 mug), and significantly reduced by i
0	3 mg), while ENT1 propranolol  ENT1END (0.5 mg) i.v. selectively inhibited the ENT2 enlargement of pulse pressure ENT2END and the tachycardia following i
0	selectively inhibited the enlargement of pulse pressure and the ENT1 tachycardia  ENT1END following i.c. carbachol (1 mug). On the other hand, the pressor response to i.c. carbachol (1 mug) was almost completely blocked by i.c. atropine (3 mug) or hexamethonium (500 mug), and significantly reduced by i.c. ENT2 chlorpromazine ENT2END (50 mug) but significantly potentiated by i
0	) injection of ENT1 guanethidine  ENT1END  (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the ENT2 tachycardia ENT2END following i
1	selectively inhibited the enlargement of pulse pressure and the ENT1 tachycardia  ENT1END  following i.c. ENT2 carbachol ENT2END (1 mug)
0	) injection of guanethidine (5 mg), hexamethonium (10 mg) or ENT1 phentolamine  ENT1END  (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the ENT2 tachycardia ENT2END following i
0	selectively inhibited the enlargement of pulse pressure and the ENT1 tachycardia ENT1END  following i.c. carbachol (1 mug). On the other hand, the pressor response to i.c. carbachol (1 mug) was almost completely blocked by i.c. atropine (3 mug) or ENT2 hexamethonium ENT2END (500 mug), and significantly reduced by i
0	ENT1 desmethylimipramine  ENT1END  (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the ENT2 tachycardia ENT2END following i
0	selectively inhibited the enlargement of pulse pressure and the ENT1 tachycardia  ENT1END  following i.c. carbachol (1 mug). On the other hand, the pressor response to i.c. carbachol (1 mug) was almost completely blocked by i.c. ENT2 atropine ENT2END (3 mug) or hexamethonium (500 mug), and significantly reduced by i
0	3 mg), while ENT1 propranolol  ENT1END  (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the ENT2 tachycardia ENT2END following i
1	Normoammonemic encephalopathy: solely ENT1 valproate ENT1END  induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive confusion, aggression, auditory hallucinations and ENT2 delusions ENT2END
0	Normoammonemic encephalopathy: solely valproate induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive confusion, aggression, auditory hallucinations and ENT1 delusions ENT1END . In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed hemiplegic migraine. Valproate was withdrawn soon after admission and her cognitive abilities have gradually improved over 3 months of follow-up. Valproate levels taken prior to withdrawal were subtherapeutic and the patient was normoammonaemic. EEG undertaken during inpatient stay showed changes consistent with encephalopathy, and low titre ENT2 N-methyl-D-aspartate ENT2END (NMDA) receptor antibodies were present in this patient
0	Normoammonemic encephalopathy: solely ENT1 valproate ENT1END  induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive confusion, ENT2 aggression ENT2END , auditory hallucinations and delusions
0	Normoammonemic encephalopathy: solely valproate induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive confusion, ENT1 aggression  ENT1END , auditory hallucinations and delusions. In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed hemiplegic migraine. Valproate was withdrawn soon after admission and her cognitive abilities have gradually improved over 3 months of follow-up. Valproate levels taken prior to withdrawal were subtherapeutic and the patient was normoammonaemic. EEG undertaken during inpatient stay showed changes consistent with encephalopathy, and low titre ENT2 N-methyl-D-aspartate ENT2END (NMDA) receptor antibodies were present in this patient
0	In the preceding months, the patient had a number of admissions with transient unilateral ENT1 hemiparesis ENT1END with facial droop, and had been started on ENT2 valproate ENT2END for presumed hemiplegic migraine
0	In the preceding months, the patient had a number of admissions with transient unilateral ENT1 hemiparesis  ENT1END  with facial droop, and had been started on valproate for presumed hemiplegic migraine. Valproate was withdrawn soon after admission and her cognitive abilities have gradually improved over 3 months of follow-up. Valproate levels taken prior to withdrawal were subtherapeutic and the patient was normoammonaemic. EEG undertaken during inpatient stay showed changes consistent with encephalopathy, and low titre ENT2 N-methyl-D-aspartate ENT2END (NMDA) receptor antibodies were present in this patient
1	Normoammonemic encephalopathy: solely ENT1 valproate ENT1END  induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive ENT2 confusion ENT2END , aggression, auditory hallucinations and delusions
0	Normoammonemic encephalopathy: solely valproate induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive ENT1 confusion  ENT1END , aggression, auditory hallucinations and delusions. In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed hemiplegic migraine. Valproate was withdrawn soon after admission and her cognitive abilities have gradually improved over 3 months of follow-up. Valproate levels taken prior to withdrawal were subtherapeutic and the patient was normoammonaemic. EEG undertaken during inpatient stay showed changes consistent with encephalopathy, and low titre ENT2 N-methyl-D-aspartate ENT2END (NMDA) receptor antibodies were present in this patient
0	The possible aetiologies of ENT1 valproate ENT1END induced encephalopathy and NMDA receptor-associated ENT2 encephalitis ENT2END present a diagnostic dilemma
0	The possible aetiologies of valproate-induced encephalopathy and ENT1 NMDA  ENT1END receptor-associated ENT2 encephalitis ENT2END present a diagnostic dilemma
0	In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed ENT1 hemiplegic migraine ENT1END  ENT2 Valproate ENT2END was withdrawn soon after admission and her cognitive abilities have gradually improved over 3 months of follow-up
0	In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed ENT1 hemiplegic migraine  ENT1END . Valproate was withdrawn soon after admission and her cognitive abilities have gradually improved over 3 months of follow-up. Valproate levels taken prior to withdrawal were subtherapeutic and the patient was normoammonaemic. EEG undertaken during inpatient stay showed changes consistent with encephalopathy, and low titre ENT2 N-methyl-D-aspartate ENT2END (NMDA) receptor antibodies were present in this patient
0	Normoammonemic ENT1 encephalopathy  ENT1END : solely ENT2 valproate ENT2END induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive confusion, aggression, auditory hallucinations and delusions
0	The possible aetiologies of valproate-induced ENT1 encephalopathy  ENT1END and ENT2 NMDA ENT2END receptor-associated encephalitis present a diagnostic dilemma
1	Normoammonemic encephalopathy: solely ENT1 valproate ENT1END  induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive confusion, aggression, ENT2 auditory hallucinations ENT2END and delusions
0	Normoammonemic encephalopathy: solely valproate induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive confusion, aggression, ENT1 auditory hallucinations  ENT1END  and delusions. In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed hemiplegic migraine. Valproate was withdrawn soon after admission and her cognitive abilities have gradually improved over 3 months of follow-up. Valproate levels taken prior to withdrawal were subtherapeutic and the patient was normoammonaemic. EEG undertaken during inpatient stay showed changes consistent with encephalopathy, and low titre ENT2 N-methyl-D-aspartate ENT2END (NMDA) receptor antibodies were present in this patient
0	Four types of experimental ENT1 arrhythmia ENT1END are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine. The compound ENT2 P11 ENT2END is introduced in doses of 0
0	On the antiarrhythmic activity of one N-substituted ENT1 piperazine  ENT1END  derivative of trans-2-amino-3-hydroxy-1, 2, 3, 4-tetrahydroanaphthalene.The antiarrhythmic activity of the compound N-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)-piperazine hydrochloride, referred to as P11, is studied on anaesthesized cats and Wistar albino rats, as well as on non-anaesthesized rabbits. Four types of experimental ENT2 arrhythmia ENT2END are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine
1	Four types of experimental ENT1 arrhythmia ENT1END  are used--with BaCl2, with chloroform-adrenaline, with ENT2 strophantine G ENT2END and with aconitine
1	Four types of experimental ENT1 arrhythmia ENT1END  are used--with ENT2 BaCl2 ENT2END , with chloroform-adrenaline, with strophantine G and with aconitine
1	The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the ENT1 arrhythmia ENT1END induced by ENT2 chloroform ENT2END -adrenaline (in 90 per cent) and with BaCl2 (in 84 per cent)
1	The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the ENT1 arrhythmia  ENT1END  induced by chloroform- ENT2 adrenaline ENT2END (in 90 per cent) and with BaCl2 (in 84 per cent)
1	Four types of experimental ENT1 arrhythmia ENT1END  are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with ENT2 aconitine ENT2END
0	009), and higher baseline plasma ENT1 bilirubin ENT1END value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001). CONCLUSIONS: Patients with drug-induced hepatocellular jaundice have 11.7% chance of progressing to death or transplantation. Amoxicillin-clavulanate stands out as the most common drug related to ENT2 DILI ENT2END
1	ENT1 Amoxicillin-clavulanate  ENT1END stands out as the most common drug related to ENT2 DILI ENT2END
0	009), and higher baseline plasma ENT1 bilirubin ENT1END  value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001). CONCLUSIONS: Patients with drug-induced hepatocellular ENT2 jaundice ENT2END have 11
1	CONCLUSIONS: Patients with drug-induced hepatocellular ENT1 jaundice  ENT1END  have 11.7% chance of progressing to death or transplantation. ENT2 Amoxicillin-clavulanate ENT2END stands out as the most common drug related to DILI
0	Factors associated with the development of ENT1 fulminant hepatic failure  ENT1END were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), hepatocellular damage (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma ENT2 bilirubin ENT2END value (OR = 1
0	Factors associated with the development of ENT1 fulminant hepatic failure  ENT1END  were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), hepatocellular damage (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma bilirubin value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001). CONCLUSIONS: Patients with drug-induced hepatocellular jaundice have 11.7% chance of progressing to death or transplantation. ENT2 Amoxicillin-clavulanate ENT2END stands out as the most common drug related to DILI
0	The liver damage was characterized according to hepatocellular, ENT1 cholestatic ENT1END  and mixed laboratory criteria and to histologic criteria when available. Further evaluation of causality assessment was centrally performed. RESULTS: Since April 1994 to August 2004, 461 out of 570 submitted cases, involving 505 drugs, were deemed to be related to DILI. The antiinfective group of drugs was the more frequently incriminated, ENT2 amoxicillin-clavulanate ENT2END accounting for the 12
1	We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa, and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these ENT1 levodopa ENT1END induce ENT2 ocular dyskinesias ENT2END
0	Usually they occur simultaneously with limb peak-dose ENT1 choreatic dyskinesias ENT1END  We report on a patient with leftward and upward deviations of gaze during the peak effect of ENT2 levodopa ENT2END , and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa-induce ocular dyskinesias
0	Levodopa-induced ocular dyskinesias in ENT1 Parkinson's disease  ENT1END . ENT2 Levodopa ENT2END -induced ocular dyskinesias are very uncommon
1	Reports that satisfy defined criteria were classified as ENT1 acute kidney injury ENT1END  kidney tubular dysfunction and Fanconi syndrome. Of the 407 Yellow Card records analysed, 106 satisfied criteria for ENT2 TDF ENT2END -related kidney disease, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had Fanconi syndrome
0	The potential for ENT1 tenofovir  ENT1END to cause a range of kidney syndromes has been established from mechanistic and randomised clinical trials. However, the exact pattern of kidney involvement is still uncertain. We undertook a descriptive analysis of Yellow Card records of 407 HIV-positive persons taking tenofovir disoproxil fumarate (TDF) as part of their antiretroviral therapy regimen and submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA) with suspected kidney adverse effects. Reports that satisfy defined criteria were classified as ENT2 acute kidney injury ENT2END , kidney tubular dysfunction and Fanconi syndrome
1	Of the 407 Yellow Card records analysed, 106 satisfied criteria for TDF-related kidney disease, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had ENT1 Fanconi syndrome ENT1END  The median ENT2 TDF ENT2END exposure was 316 days (interquartile range 120-740)
0	The potential for ENT1 tenofovir ENT1END  to cause a range of kidney syndromes has been established from mechanistic and randomised clinical trials. However, the exact pattern of kidney involvement is still uncertain. We undertook a descriptive analysis of Yellow Card records of 407 HIV-positive persons taking tenofovir disoproxil fumarate (TDF) as part of their antiretroviral therapy regimen and submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA) with suspected kidney adverse effects. Reports that satisfy defined criteria were classified as acute kidney injury, kidney tubular dysfunction and ENT2 Fanconi syndrome ENT2END
0	Of the 407 Yellow Card records analysed, 106 satisfied criteria for ENT1 TDF ENT1END -related ENT2 kidney disease ENT2END , of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had Fanconi syndrome
0	An investigation of the pattern of ENT1 kidney injury  ENT1END  in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database).The potential for ENT2 tenofovir ENT2END to cause a range of kidney syndromes has been established from mechanistic and randomised clinical trials
1	ENT1 Neuroleptic  ENT1END -associated ENT2 hyperprolactinemia ENT2END
0	Neuroleptic-associated ENT1 hyperprolactinemia  ENT1END . Can it be treated with ENT2 bromocriptine ENT2END ?Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine
1	This suggests that bromocriptine should be further evaluated as potential therapy for ENT1 neuroleptic ENT1END associated hyperprolactinemia and ENT2 amenorrhea ENT2END /galactorrhea
0	Can it be treated with ENT1 bromocriptine ENT1END ?Six stable psychiatric outpatients with hyperprolactinemia and ENT2 amenorrhea ENT2END /oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine
1	Can it be treated with bromocriptine?Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/ ENT1 oligomenorrhea ENT1END associated with their ENT2 neuroleptic medications ENT2END were treated with bromocriptine
0	Can it be treated with bromocriptine?Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/ ENT1 oligomenorrhea ENT1END  associated with their neuroleptic medications were treated with ENT2 bromocriptine ENT2END
0	Can it be treated with bromocriptine?Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their ENT1 neuroleptic medications ENT1END  were treated with bromocriptine. Daily dosages of 5-10 mg corrected the hyperprolactinemia and restored menstruation in four of the six patients. One woman, however, developed worsened ENT2 psychiatric symptoms ENT2END while taking bromocriptine, and it was discontinued
1	One woman, however, developed worsened ENT1 psychiatric symptoms ENT1END  while taking ENT2 bromocriptine ENT2END , and it was discontinued
0	This suggests that bromocriptine should be further evaluated as potential therapy for ENT1 neuroleptic  ENT1END -associated hyperprolactinemia and amenorrhea/ ENT2 galactorrhea ENT2END
0	This suggests that ENT1 bromocriptine  ENT1END should be further evaluated as potential therapy for neuroleptic-associated hyperprolactinemia and amenorrhea ENT2 galactorrhea ENT2END
0	We propose that remoxipride and benzene may induce ENT1 aplastic anemia ENT1END via production of similar reactive metabolites and that the ability of NCQ436 and ENT2 NCQ344 ENT2END to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
0	The catechol and hydroquinone metabolites, NCQ436 and NCQ344, induced apoptosis in HL60 and HBMP cells in a time- and concentration dependent manner, while the phenols, NCR181, FLA873, and ENT1 FLA797  ENT1END  and the derivatives formed by oxidation of the pyrrolidine ring, FLA838, NCM001, and NCL118, had no effect. No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations. These data show that the catechol and hydroquinone metabolites of remoxipride have direct toxic effects in HL60 and HBMP cells, leading to apoptosis, while the phenol metabolites were inactive. Similarly, benzene-derived catechol and hydroquinone, but not phenol, induce apoptosis in HBMP cells [Moran et al., Mol. Pharmacol., 50 (1996) 610-615]. We propose that remoxipride and benzene may induce ENT2 aplastic anemia ENT2END via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
0	The catechol and hydroquinone metabolites, NCQ436 and NCQ344, induced apoptosis in HL60 and HBMP cells in a time- and concentration dependent manner, while the ENT1 phenols  ENT1END  NCR181, FLA873, and FLA797, and the derivatives formed by oxidation of the pyrrolidine ring, FLA838, NCM001, and NCL118, had no effect. No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations. These data show that the catechol and hydroquinone metabolites of remoxipride have direct toxic effects in HL60 and HBMP cells, leading to apoptosis, while the phenol metabolites were inactive. Similarly, benzene-derived catechol and hydroquinone, but not phenol, induce apoptosis in HBMP cells [Moran et al., Mol. Pharmacol., 50 (1996) 610-615]. We propose that remoxipride and benzene may induce ENT2 aplastic anemia ENT2END via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
1	We propose that remoxipride and ENT1 benzene  ENT1END may induce ENT2 aplastic anemia ENT2END via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
0	The antipsychotic agent, remoxipride [(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide] has been associated with acquired ENT1 aplastic anemia ENT1END  We have examined the ability of remoxipride, three pyrrolidine ring metabolites and five aromatic ring metabolites of the parent compound to induce apoptosis in HL60 cells and human bone marrow progenitor (HBMP) cells. Cells were treated for 0-24 h with each compound (0-200 microM). Apoptosis was assessed by fluorescence microscopy in ENT2 Hoechst 33342 ENT2END - and propidium iodide stained cell samples
0	Similarly, benzene-derived catechol and hydroquinone, but not ENT1 phenol  ENT1END  induce apoptosis in HBMP cells [Moran et al., Mol. Pharmacol., 50 (1996) 610-615]. We propose that remoxipride and benzene may induce ENT2 aplastic anemia ENT2END via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
0	The antipsychotic agent, remoxipride [(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide] has been associated with acquired ENT1 aplastic anemia ENT1END . We have examined the ability of remoxipride, three pyrrolidine ring metabolites and five aromatic ring metabolites of the parent compound to induce apoptosis in HL60 cells and human bone marrow progenitor (HBMP) cells. Cells were treated for 0-24 h with each compound (0-200 microM). Apoptosis was assessed by fluorescence microscopy in Hoechst 33342- and ENT2 propidium iodide ENT2END stained cell samples
1	Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19- human bone marrow progenitor cells: potential relevance to ENT1 remoxipride  ENT1END -induced ENT2 aplastic anemia ENT2END
0	Similarly, benzene-derived ENT1 catechol  ENT1END and hydroquinone, but not phenol, induce apoptosis in HBMP cells [Moran et al., Mol. Pharmacol., 50 (1996) 610-615]. We propose that remoxipride and benzene may induce ENT2 aplastic anemia ENT2END via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
0	We propose that remoxipride and benzene may induce ENT1 aplastic anemia ENT1END  via production of similar reactive metabolites and that the ability of ENT2 NCQ436 ENT2END and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
0	Similarly, benzene-derived catechol and ENT1 hydroquinone  ENT1END  but not phenol, induce apoptosis in HBMP cells [Moran et al., Mol. Pharmacol., 50 (1996) 610-615]. We propose that remoxipride and benzene may induce ENT2 aplastic anemia ENT2END via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
0	The antipsychotic agent, remoxipride [(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide] has been associated with acquired ENT1 aplastic anemia ENT1END . We have examined the ability of remoxipride, three ENT2 pyrrolidine ENT2END ring metabolites and five aromatic ring metabolites of the parent compound to induce apoptosis in HL60 cells and human bone marrow progenitor (HBMP) cells
0	No ENT1 necrosis ENT1END was observed in cells treated with NCQ436 but ENT2 NCQ344 ENT2END had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations
0	The catechol and hydroquinone metabolites, NCQ436 and NCQ344, induced apoptosis in HL60 and HBMP cells in a time- and concentration dependent manner, while the phenols, NCR181, FLA873, and ENT1 FLA797  ENT1END , and the derivatives formed by oxidation of the pyrrolidine ring, FLA838, NCM001, and NCL118, had no effect. No ENT2 necrosis ENT2END was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations
0	The catechol and hydroquinone metabolites, NCQ436 and NCQ344, induced apoptosis in HL60 and HBMP cells in a time- and concentration dependent manner, while the ENT1 phenols  ENT1END , NCR181, FLA873, and FLA797, and the derivatives formed by oxidation of the pyrrolidine ring, FLA838, NCM001, and NCL118, had no effect. No ENT2 necrosis ENT2END was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations
0	No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and ENT1 necrosis ENT1END at higher concentrations. These data show that the catechol and hydroquinone metabolites of remoxipride have direct toxic effects in HL60 and HBMP cells, leading to apoptosis, while the phenol metabolites were inactive. Similarly, ENT2 benzene ENT2END -derived catechol and hydroquinone, but not phenol, induce apoptosis in HBMP cells [Moran et al
0	Apoptosis was assessed by fluorescence microscopy in ENT1 Hoechst 33342  ENT1END - and propidium iodide stained cell samples. Results were confirmed by determination of internucleosomal DNA fragmentation using gel electrophoresis for HL60 cell samples and terminal deoxynucleotidyl transferase assay in HBMP cells. The catechol and hydroquinone metabolites, NCQ436 and NCQ344, induced apoptosis in HL60 and HBMP cells in a time- and concentration dependent manner, while the phenols, NCR181, FLA873, and FLA797, and the derivatives formed by oxidation of the pyrrolidine ring, FLA838, NCM001, and NCL118, had no effect. No ENT2 necrosis ENT2END was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations
0	No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and ENT1 necrosis ENT1END  at higher concentrations. These data show that the catechol and hydroquinone metabolites of remoxipride have direct toxic effects in HL60 and HBMP cells, leading to apoptosis, while the ENT2 phenol ENT2END metabolites were inactive
0	Apoptosis was assessed by fluorescence microscopy in Hoechst 33342- and ENT1 propidium iodide  ENT1END  stained cell samples. Results were confirmed by determination of internucleosomal DNA fragmentation using gel electrophoresis for HL60 cell samples and terminal deoxynucleotidyl transferase assay in HBMP cells. The catechol and hydroquinone metabolites, NCQ436 and NCQ344, induced apoptosis in HL60 and HBMP cells in a time- and concentration dependent manner, while the phenols, NCR181, FLA873, and FLA797, and the derivatives formed by oxidation of the pyrrolidine ring, FLA838, NCM001, and NCL118, had no effect. No ENT2 necrosis ENT2END was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations
0	No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and ENT1 necrosis ENT1END  at higher concentrations. These data show that the catechol and hydroquinone metabolites of ENT2 remoxipride ENT2END have direct toxic effects in HL60 and HBMP cells, leading to apoptosis, while the phenol metabolites were inactive
0	No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and ENT1 necrosis ENT1END  at higher concentrations. These data show that the ENT2 catechol ENT2END and hydroquinone metabolites of remoxipride have direct toxic effects in HL60 and HBMP cells, leading to apoptosis, while the phenol metabolites were inactive
0	No ENT1 necrosis ENT1END  was observed in cells treated with ENT2 NCQ436 ENT2END but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations
0	No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and ENT1 necrosis ENT1END  at higher concentrations. These data show that the catechol and ENT2 hydroquinone ENT2END metabolites of remoxipride have direct toxic effects in HL60 and HBMP cells, leading to apoptosis, while the phenol metabolites were inactive
0	The catechol and hydroquinone metabolites, NCQ436 and NCQ344, induced apoptosis in HL60 and HBMP cells in a time- and concentration dependent manner, while the phenols, NCR181, FLA873, and FLA797, and the derivatives formed by oxidation of the ENT1 pyrrolidine  ENT1END ring, FLA838, NCM001, and NCL118, had no effect. No ENT2 necrosis ENT2END was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations
0	Left ventricular function (assessed by echocardiography) showed that PPA increased the ENT1 stroke ENT1END volume 30% (from 62.5 +/- 20.9 to 80.8 +/- 22.4 ml), the ejection fraction 9% (from 64% +/- 10% to 70% +/- 7%), and cardiac output 14% (from 3.6 +/- 0.6 to 4.1 +/- 1.0 L/min). Intravenous propranolol reversed these effects. Systemic vascular resistance was increased by PPA 28% (from 1710 +/- 200 to 2190 +/- 700 dyne X sec/cm5) and was further increased by propranolol 22% (to 2660 +/- 1200 dyne X sec/cm5). We conclude that PPA increases blood pressure by increasing systemic vascular resistance and cardiac output, and that propranolol antagonizes this increase by reversing the effect of PPA on cardiac output. That propranolol antagonizes the pressor effect of PPA is in contrast to the interaction in which propranolol enhances the pressor effect of ENT2 norepinephrine ENT2END
0	Left ventricular function (assessed by echocardiography) showed that ENT1 PPA  ENT1END increased the ENT2 stroke ENT2END volume 30% (from 62
0	Intravenous ENT1 propranolol  ENT1END after PPA also decreased blood pressure. Left ventricular function (assessed by echocardiography) showed that PPA increased the ENT2 stroke ENT2END volume 30% (from 62
1	Propranolol antagonism of phenylpropanolamine-induced ENT1 hypertension  ENT1END . ENT2 Phenylpropanolamine ENT2END (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death
0	We studied the efficacy and safety of propranolol in the treatment of PPA-induced ENT1 hypertension ENT1END  Subjects received ENT2 propranolol ENT2END either by mouth for 48 hours before PPA or as a rapid intravenous infusion after PPA
0	Phenylpropanolamine ( ENT1 PPA ENT1END  ENT2 overdose ENT2END can cause severe hypertension, intracerebral hemorrhage, and death
0	ENT1 Propranolol  ENT1END  antagonism of phenylpropanolamine-induced hypertension.Phenylpropanolamine (PPA) ENT2 overdose ENT2END can cause severe hypertension, intracerebral hemorrhage, and death
0	Phenylpropanolamine ( ENT1 PPA ENT1END ) overdose can cause severe hypertension, ENT2 intracerebral hemorrhage ENT2END , and death
0	Phenylpropanolamine (PPA) overdose can cause severe hypertension, ENT1 intracerebral hemorrhage ENT1END , and death. We studied the efficacy and safety of ENT2 propranolol ENT2END in the treatment of PPA-induced hypertension
0	From the results obtained, haemodialysis can therefore be suggested as a useful therapy in rare cases of progressive ENT1 acute renal failure ENT1END caused by ENT2 desferrioxamine ENT2END
0	Given the progressive deterioration of the symptoms and of the laboratory values, despite adequate medical treatment, a decision was made to introduce haemodialytical therapy in order to remove the drug and therapy reduce the ENT1 nephrotoxicity  ENT1END  From the results obtained, haemodialysis can therefore be suggested as a useful therapy in rare cases of progressive acute renal failure caused by ENT2 desferrioxamine ENT2END
0	A patient with transfusion-dependent ENT1 thalassemia ENT1END was undergoing home intravenous ENT2 desferrioxamine ENT2END (DFX) treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy
1	A patient with transfusion-dependent thalassemia was undergoing home intravenous desferrioxamine ( ENT1 DFX ENT1END  treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy. Due to an accidental malfunctioning of the infusion pump, the patient was inadvertently administered a toxic dosage of the drug which caused ENT2 renal insufficiency ENT2END
0	B2 receptor-deficient mice were less sensitive to this drug than the WT mice, as shown by reduced ENT1 weight loss ENT1END  better preservation of kidney function, down regulation of inflammatory cytokines and less acute tubular necrosis. Moreover, treatment with the kinin B2 receptor antagonist effectively reduced the levels of serum ENT2 creatinine ENT2END and blood urea after cisplatin administration
0	B2 receptor-deficient mice were less sensitive to this drug than the WT mice, as shown by reduced ENT1 weight loss ENT1END , better preservation of kidney function, down regulation of inflammatory cytokines and less acute tubular necrosis. Moreover, treatment with the kinin B2 receptor antagonist effectively reduced the levels of serum creatinine and blood ENT2 urea ENT2END after cisplatin administration
1	Additionally, WT mice were treated with a B2 receptor antagonist after ENT1 cisplatin  ENT1END administration. B2 receptor-deficient mice were less sensitive to this drug than the WT mice, as shown by reduced ENT2 weight loss ENT2END , better preservation of kidney function, down regulation of inflammatory cytokines and less acute tubular necrosis
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of ENT1 creatinine ENT1END and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a). The kinin B2 receptor has been associated with the inflammation process, as well as the regulation of cytokine expression, and its deletion resulted in an improvement in the ENT2 diabetic nephropathy ENT2END status
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and ENT1 urea  ENT1END  increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a). The kinin B2 receptor has been associated with the inflammation process, as well as the regulation of cytokine expression, and its deletion resulted in an improvement in the ENT2 diabetic nephropathy ENT2END status
0	The kinin B2 receptor has been associated with the inflammation process, as well as the regulation of cytokine expression, and its deletion resulted in an improvement in the ENT1 diabetic nephropathy ENT1END  status. To examine the role of the kinin B2 receptor in ENT2 cisplatin ENT2END -induced acute kidney injury, kinin B2 receptor knockout mice were challenged with cisplatin
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of ENT1 creatinine ENT1END  and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a). The kinin B2 receptor has been associated with the ENT2 inflammation ENT2END process, as well as the regulation of cytokine expression, and its deletion resulted in an improvement in the diabetic nephropathy status
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and ENT1 urea  ENT1END , increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a). The kinin B2 receptor has been associated with the ENT2 inflammation ENT2END process, as well as the regulation of cytokine expression, and its deletion resulted in an improvement in the diabetic nephropathy status
0	The kinin B2 receptor has been associated with the ENT1 inflammation  ENT1END  process, as well as the regulation of cytokine expression, and its deletion resulted in an improvement in the diabetic nephropathy status. To examine the role of the kinin B2 receptor in ENT2 cisplatin ENT2END -induced acute kidney injury, kinin B2 receptor knockout mice were challenged with cisplatin
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of ENT1 creatinine ENT1END  and urea, increase the ENT2 acute tubular necrosis ENT2END score and up-regulate cytokines (e
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and ENT1 urea  ENT1END , increase the ENT2 acute tubular necrosis ENT2END score and up-regulate cytokines (e
1	B2 receptor-deficient mice were less sensitive to this drug than the WT mice, as shown by reduced weight loss, better preservation of kidney function, down regulation of inflammatory cytokines and less ENT1 acute tubular necrosis ENT1END  Moreover, treatment with the kinin B2 receptor antagonist effectively reduced the levels of serum creatinine and blood urea after ENT2 cisplatin ENT2END administration
0	Moreover, treatment with the kinin B2 receptor antagonist effectively reduced the levels of serum ENT1 creatinine ENT1END  and blood urea after cisplatin administration. Thus, our data suggest that the kinin B2 receptor is involved in cisplatin-induced acute kidney injury by mediating the ENT2 necrotic ENT2END process and the expression of inflammatory cytokines, thus resulting in declined renal function
0	Moreover, treatment with the kinin B2 receptor antagonist effectively reduced the levels of serum creatinine and blood ENT1 urea  ENT1END  after cisplatin administration. Thus, our data suggest that the kinin B2 receptor is involved in cisplatin-induced acute kidney injury by mediating the ENT2 necrotic ENT2END process and the expression of inflammatory cytokines, thus resulting in declined renal function
0	Thus, our data suggest that the kinin B2 receptor is involved in ENT1 cisplatin  ENT1END induced acute kidney injury by mediating the ENT2 necrotic ENT2END process and the expression of inflammatory cytokines, thus resulting in declined renal function
0	Moreover, treatment with the kinin B2 receptor antagonist effectively reduced the levels of serum ENT1 creatinine ENT1END  and blood urea after cisplatin administration. Thus, our data suggest that the kinin B2 receptor is involved in cisplatin-induced acute kidney injury by mediating the necrotic process and the expression of inflammatory cytokines, thus resulting in declined renal function. These results highlight the kinin B2 receptor antagonist treatment in amelioration of ENT2 nephrotoxicity ENT2END induced by cisplatin therapy
0	Moreover, treatment with the kinin B2 receptor antagonist effectively reduced the levels of serum creatinine and blood ENT1 urea  ENT1END  after cisplatin administration. Thus, our data suggest that the kinin B2 receptor is involved in cisplatin-induced acute kidney injury by mediating the necrotic process and the expression of inflammatory cytokines, thus resulting in declined renal function. These results highlight the kinin B2 receptor antagonist treatment in amelioration of ENT2 nephrotoxicity ENT2END induced by cisplatin therapy
0	These results highlight the kinin B2 receptor antagonist treatment in amelioration of ENT1 nephrotoxicity ENT1END  induced by ENT2 cisplatin ENT2END therapy
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce ENT1 acute kidney injury  ENT1END due its ability to negatively affect renal function, augment serum levels of ENT2 creatinine ENT2END and urea, increase the acute tubular necrosis score and up-regulate cytokines (e
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce ENT1 acute kidney injury  ENT1END  due its ability to negatively affect renal function, augment serum levels of creatinine and ENT2 urea ENT2END , increase the acute tubular necrosis score and up-regulate cytokines (e
1	Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced ENT1 acute renal injury  ENT1END . ENT2 Cisplatin ENT2END treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e
0	Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated ENT1 creatinine ENT1END clearance and, possibly, female gender all increase the risk for nephrotoxicity. Other causes of ENT2 acute renal failure ENT2END , such as shock, appear to have an additive effect
0	Clinical trials of ENT1 aminoglycosides ENT1END in seriously ill patients indicate that the relative risk for developing ENT2 acute renal failure ENT2END during therapy ranges from 8 to 10 and that the attributable risk is 70% to 80%
0	Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated ENT1 creatinine ENT1END  clearance and, possibly, female gender all increase the risk for nephrotoxicity. Other causes of acute renal failure, such as ENT2 shock ENT2END , appear to have an additive effect
0	Further analysis of these data suggests that the duration of therapy, plasma ENT1 aminoglycoside  ENT1END levels, liver disease, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity. Other causes of acute renal failure, such as ENT2 shock ENT2END , appear to have an additive effect
0	Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated ENT1 creatinine ENT1END  clearance and, possibly, female gender all increase the risk for ENT2 nephrotoxicity ENT2END
1	Studies of risk factors for ENT1 aminoglycoside ENT1END ENT2 nephrotoxicity ENT2END
0	Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, ENT1 liver disease  ENT1END  advanced age, high initial estimated ENT2 creatinine ENT2END clearance and, possibly, female gender all increase the risk for nephrotoxicity
0	Further analysis of these data suggests that the duration of therapy, plasma ENT1 aminoglycoside  ENT1END  levels, ENT2 liver disease ENT2END , advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity
0	Delayed ENT1 anemia  ENT1END  after treatment with injectable ENT2 artesunate ENT2END in the Democratic Republic of the Congo: a manageable issue
0	6%] > 5 years of age) were followed-up after treatment with injectable ENT1 artesunate ENT1END for severe ENT2 malaria ENT2END in hospitals and health centers of the Democratic Republic of the Congo
1	Cases of delayed ENT1 hemolytic anemia ENT1END have been described after treatment with injectable ENT2 artesunate ENT2END , the current World Health Organization (WHO)-recommended first-line drug for the treatment of severe malaria
0	A 1-year-old female presented with neuroleptic malignant syndrome probably caused by ENT1 methylphenidate  ENT1END  She had defects in the supratentorial brain including the basal ganglia and the striatum ( ENT2 multicystic encephalomalacia ENT2END ) due to severe perinatal hypoxic-ischemic encephalopathy, which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome
0	She had defects in the supratentorial brain including the basal ganglia and the striatum ( ENT1 multicystic encephalomalacia ENT1END ) due to severe perinatal hypoxic-ischemic encephalopathy, which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome. A dopaminergic blockade mechanism generally is accepted as the pathogenesis of this syndrome. However, methylphenidate is a ENT2 dopamine ENT2END agonist via the inhibition of uptake of dopamine, and therefore dopaminergic systems in the brainstem (mainly the midbrain) and the spinal cord were unlikely to participate in the onset of this syndrome
0	She had defects in the supratentorial brain including the basal ganglia and the striatum ( ENT1 multicystic encephalomalacia ENT1END ) due to severe perinatal hypoxic-ischemic encephalopathy, which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome. A dopaminergic blockade mechanism generally is accepted as the pathogenesis of this syndrome. However, methylphenidate is a dopamine agonist via the inhibition of uptake of dopamine, and therefore dopaminergic systems in the brainstem (mainly the midbrain) and the spinal cord were unlikely to participate in the onset of this syndrome. A relative gamma-aminobutyric acid-ergic deficiency might occur because ENT2 diazepam ENT2END , a gamma-aminobutyric acid-mimetic agent, was strikingly effective
0	She had defects in the supratentorial brain including the basal ganglia and the striatum ( ENT1 multicystic encephalomalacia ENT1END ) due to severe perinatal hypoxic-ischemic encephalopathy, which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome. A dopaminergic blockade mechanism generally is accepted as the pathogenesis of this syndrome. However, methylphenidate is a dopamine agonist via the inhibition of uptake of dopamine, and therefore dopaminergic systems in the brainstem (mainly the midbrain) and the spinal cord were unlikely to participate in the onset of this syndrome. A relative ENT2 gamma-aminobutyric acid ENT2END -ergic deficiency might occur because diazepam, a gamma-aminobutyric acid-mimetic agent, was strikingly effective
1	ENT1 Neuroleptic malignant syndrome  ENT1END  and ENT2 methylphenidate ENT2END
0	She had defects in the supratentorial brain including the basal ganglia and the striatum (multicystic encephalomalacia) due to severe perinatal hypoxic-ischemic encephalopathy, which was considered to be a possible predisposing factor causing ENT1 neuroleptic malignant syndrome  ENT1END  A dopaminergic blockade mechanism generally is accepted as the pathogenesis of this syndrome. However, methylphenidate is a ENT2 dopamine ENT2END agonist via the inhibition of uptake of dopamine, and therefore dopaminergic systems in the brainstem (mainly the midbrain) and the spinal cord were unlikely to participate in the onset of this syndrome
0	A relative gamma-aminobutyric acid-ergic deficiency might occur because ENT1 diazepam ENT1END , a gamma-aminobutyric acid-mimetic agent, was strikingly effective. This is the first reported patient with ENT2 neuroleptic malignant syndrome ENT2END probably caused by methylphenidate
0	A relative gamma-aminobutyric acid-ergic deficiency might occur because diazepam, a ENT1 gamma-aminobutyric acid  ENT1END mimetic agent, was strikingly effective. This is the first reported patient with ENT2 neuroleptic malignant syndrome ENT2END probably caused by methylphenidate
0	A 1-year-old female presented with neuroleptic malignant syndrome probably caused by ENT1 methylphenidate ENT1END . She had defects in the supratentorial brain including the basal ganglia and the striatum (multicystic encephalomalacia) due to severe perinatal ENT2 hypoxic-ischemic encephalopathy ENT2END , which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome
0	She had defects in the supratentorial brain including the basal ganglia and the striatum (multicystic encephalomalacia) due to severe perinatal ENT1 hypoxic-ischemic encephalopathy  ENT1END , which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome. A dopaminergic blockade mechanism generally is accepted as the pathogenesis of this syndrome. However, methylphenidate is a ENT2 dopamine ENT2END agonist via the inhibition of uptake of dopamine, and therefore dopaminergic systems in the brainstem (mainly the midbrain) and the spinal cord were unlikely to participate in the onset of this syndrome
0	She had defects in the supratentorial brain including the basal ganglia and the striatum (multicystic encephalomalacia) due to severe perinatal ENT1 hypoxic-ischemic encephalopathy  ENT1END , which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome. A dopaminergic blockade mechanism generally is accepted as the pathogenesis of this syndrome. However, methylphenidate is a dopamine agonist via the inhibition of uptake of dopamine, and therefore dopaminergic systems in the brainstem (mainly the midbrain) and the spinal cord were unlikely to participate in the onset of this syndrome. A relative gamma-aminobutyric acid-ergic deficiency might occur because ENT2 diazepam ENT2END , a gamma-aminobutyric acid-mimetic agent, was strikingly effective
0	She had defects in the supratentorial brain including the basal ganglia and the striatum (multicystic encephalomalacia) due to severe perinatal ENT1 hypoxic-ischemic encephalopathy  ENT1END , which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome. A dopaminergic blockade mechanism generally is accepted as the pathogenesis of this syndrome. However, methylphenidate is a dopamine agonist via the inhibition of uptake of dopamine, and therefore dopaminergic systems in the brainstem (mainly the midbrain) and the spinal cord were unlikely to participate in the onset of this syndrome. A relative ENT2 gamma-aminobutyric acid ENT2END -ergic deficiency might occur because diazepam, a gamma-aminobutyric acid-mimetic agent, was strikingly effective
0	Efficacy of ENT1 olanzapine  ENT1END  in acute ENT2 bipolar mania ENT2END : a double-blind, placebo-controlled study
1	However, ENT1 olanzapine ENT1END treated patients had a statistically significant greater mean (+/- SD) ENT2 weight gain ENT2END than placebo-treated patients (2
0	There were no statistically significant differences in ENT1 EPSs  ENT1END between groups. However, ENT2 olanzapine ENT2END -treated patients had a statistically significant greater mean (+/- SD) weight gain than placebo-treated patients (2
1	3 kg, respectively) and also experienced more treatment-emergent ENT1 somnolence ENT1END (21 patients [38.2%] vs 5 [8.3% ], respectively). CONCLUSION: ENT2 Olanzapine ENT2END demonstrated greater efficacy than placebo in the treatment of acute bipolar mania and was generally well tolerated
0	Grade 3/4 nonhematologic ENT1 toxicities ENT1END were uncommon. Among the 34 patients evaluable for response, there were three complete responses (9%) and 18 partial responses (53%) for an overall response rate of 62%. Of the 19 evaluable patients with prior ENT2 doxorubicin ENT2END exposure, 11 (58%) responded compared with nine of 15 (60%) without prior doxorubicin
0	ENT1 Paclitaxel ENT1END and 5-fluorouracil have additive ENT2 cytotoxicity ENT2END in MCF-7 cell lines
0	Paclitaxel and ENT1 5-fluorouracil  ENT1END have additive ENT2 cytotoxicity ENT2END in MCF-7 cell lines
0	Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 neutropenia requiring hospitalization; seven (4%) cycles in two patients required ENT1 granulocyte colony-stimulating factor  ENT1END due to neutropenia; no patient required platelet transfusions. Grade 3/4 nonhematologic ENT2 toxicities ENT2END were uncommon
0	Paclitaxel and 5-fluorouracil have additive ENT1 cytotoxicity ENT1END  in MCF-7 cell lines. We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by ENT2 folinic acid ENT2END 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer
0	Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 neutropenia requiring hospitalization; seven (4%) cycles in two patients required granulocyte colony-stimulating factor due to ENT1 neutropenia  ENT1END  no patient required platelet transfusions. Grade 3/4 nonhematologic toxicities were uncommon. Among the 34 patients evaluable for response, there were three complete responses (9%) and 18 partial responses (53%) for an overall response rate of 62%. Of the 19 evaluable patients with prior ENT2 doxorubicin ENT2END exposure, 11 (58%) responded compared with nine of 15 (60%) without prior doxorubicin
1	We performed a phase II trial of ENT1 paclitaxel ENT1END 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer. Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 ENT2 neutropenia ENT2END requiring hospitalization; seven (4%) cycles in two patients required granulocyte colony-stimulating factor due to neutropenia; no patient required platelet transfusions
1	We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before ENT1 5-fluorouracil  ENT1END 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer. Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 ENT2 neutropenia ENT2END requiring hospitalization; seven (4%) cycles in two patients required granulocyte colony-stimulating factor due to neutropenia; no patient required platelet transfusions
0	Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 neutropenia requiring hospitalization; seven (4%) cycles in two patients required ENT1 granulocyte colony-stimulating factor  ENT1END  due to ENT2 neutropenia ENT2END ; no patient required platelet transfusions
1	We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by ENT1 folinic acid  ENT1END  300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer. Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 ENT2 neutropenia ENT2END requiring hospitalization; seven (4%) cycles in two patients required granulocyte colony-stimulating factor due to neutropenia; no patient required platelet transfusions
0	Of the 19 evaluable patients with prior doxorubicin exposure, 11 (58%) responded compared with nine of 15 (60%) without prior ENT1 doxorubicin ENT1END  Plasma paclitaxel concentrations were measured at the completion of paclitaxel infusion and at 24 hours in 19 patients. TFL is an active, well-tolerated regimen in metastatic ENT2 breast cancer ENT2END
0	5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic ENT1 breast cancer  ENT1END patients. ENT2 Paclitaxel ENT2END and 5-fluorouracil have additive cytotoxicity in MCF-7 cell lines
0	5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic ENT1 breast cancer  ENT1END  patients. Paclitaxel and ENT2 5-fluorouracil ENT2END have additive cytotoxicity in MCF-7 cell lines
0	We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic ENT1 breast cancer  ENT1END  Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 neutropenia requiring hospitalization; seven (4%) cycles in two patients required ENT2 granulocyte colony-stimulating factor ENT2END due to neutropenia; no patient required platelet transfusions
0	Paclitaxel, 5-fluorouracil, and ENT1 folinic acid  ENT1END  in metastatic ENT2 breast cancer ENT2END : BRE-26, a phase II trial
0	The dose-dependent effect of ENT1 misoprostol  ENT1END  on indomethacin-induced ENT2 renal dysfunction ENT2END in well compensated cirrhosis
1	The dose-dependent effect of misoprostol on ENT1 indomethacin  ENT1END -induced ENT2 renal dysfunction ENT2END in well compensated cirrhosis
0	Misoprostol (200 micrograms) has been shown to acutely counteract the indomethacin-induced ENT1 renal dysfunction ENT1END in well compensated cirrhotic patients. The aim of this study was to determine if the prophylactic value of misoprostol was dose-dependent. Parameters of renal hemodynamics and tubular ENT2 sodium ENT2END and water handling were assessed by clearance techniques in 26 well compensated cirrhotic patients before and after an oral combination of 50 mg of indomethacin and various doses of misoprostol
0	The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated ENT1 cirrhosis  ENT1END . ENT2 Misoprostol ENT2END (200 micrograms) has been shown to acutely counteract the indomethacin-induced renal dysfunction in well compensated cirrhotic patients
0	The dose-dependent effect of misoprostol on ENT1 indomethacin  ENT1END -induced renal dysfunction in well compensated ENT2 cirrhosis ENT2END
0	Parameters of renal hemodynamics and tubular ENT1 sodium ENT1END  and water handling were assessed by clearance techniques in 26 well compensated ENT2 cirrhotic ENT2END patients before and after an oral combination of 50 mg of indomethacin and various doses of misoprostol
0	Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and trimethoprim-sulfamethoxazole but negative with ENT1 sulfamethoxazole ENT1END  The patient recovered after discontinuing the drug, with no recurrence in 2 years. Other causes of ENT2 anemia ENT2END should be considered in patients with worse-than-expected anemia after chemotherapy
0	Drug studies using the indirect antiglobulin test were strongly positive with ENT1 trimethoprim  ENT1END and trimethoprim-sulfamethoxazole but negative with sulfamethoxazole. The patient recovered after discontinuing the drug, with no recurrence in 2 years. Other causes of ENT2 anemia ENT2END should be considered in patients with worse-than-expected anemia after chemotherapy
0	Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and ENT1 trimethoprim-sulfamethoxazole  ENT1END but negative with sulfamethoxazole. The patient recovered after discontinuing the drug, with no recurrence in 2 years. Other causes of ENT2 anemia ENT2END should be considered in patients with worse-than-expected anemia after chemotherapy
0	During red cell transfusion, he developed ENT1 hemoglobinuria  ENT1END  Transfusion reaction workup was negative. Drug-induced immune hemolytic anemia was suspected because of positive direct antiglobulin test, negative eluate, and microspherocytes on smear pre- and post-transfusion. Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and trimethoprim-sulfamethoxazole but negative with ENT2 sulfamethoxazole ENT2END
0	ENT1 Trimethoprim  ENT1END -induced immune hemolytic anemia in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction.A 10-year-old male with acute leukemia presented with post-chemotherapy anemia. During red cell transfusion, he developed ENT2 hemoglobinuria ENT2END
0	During red cell transfusion, he developed ENT1 hemoglobinuria  ENT1END . Transfusion reaction workup was negative. Drug-induced immune hemolytic anemia was suspected because of positive direct antiglobulin test, negative eluate, and microspherocytes on smear pre- and post-transfusion. Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and ENT2 trimethoprim-sulfamethoxazole ENT2END but negative with sulfamethoxazole
0	Drug-induced immune ENT1 hemolytic anemia  ENT1END was suspected because of positive direct antiglobulin test, negative eluate, and microspherocytes on smear pre- and post-transfusion. Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and trimethoprim-sulfamethoxazole but negative with ENT2 sulfamethoxazole ENT2END
1	ENT1 Trimethoprim  ENT1END -induced immune ENT2 hemolytic anemia ENT2END in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction
0	Drug-induced immune ENT1 hemolytic anemia  ENT1END  was suspected because of positive direct antiglobulin test, negative eluate, and microspherocytes on smear pre- and post-transfusion. Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and ENT2 trimethoprim-sulfamethoxazole ENT2END but negative with sulfamethoxazole
0	A 10-year-old male with ENT1 acute leukemia  ENT1END presented with post-chemotherapy anemia. During red cell transfusion, he developed hemoglobinuria. Transfusion reaction workup was negative. Drug-induced immune hemolytic anemia was suspected because of positive direct antiglobulin test, negative eluate, and microspherocytes on smear pre- and post-transfusion. Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and trimethoprim-sulfamethoxazole but negative with ENT2 sulfamethoxazole ENT2END
0	ENT1 Trimethoprim  ENT1END -induced immune hemolytic anemia in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction.A 10-year-old male with ENT2 acute leukemia ENT2END presented with post-chemotherapy anemia
0	A 10-year-old male with ENT1 acute leukemia  ENT1END  presented with post-chemotherapy anemia. During red cell transfusion, he developed hemoglobinuria. Transfusion reaction workup was negative. Drug-induced immune hemolytic anemia was suspected because of positive direct antiglobulin test, negative eluate, and microspherocytes on smear pre- and post-transfusion. Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and ENT2 trimethoprim-sulfamethoxazole ENT2END but negative with sulfamethoxazole
0	Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and trimethoprim-sulfamethoxazole but negative with ENT1 sulfamethoxazole ENT1END . The patient recovered after discontinuing the drug, with no recurrence in 2 years. Other causes of anemia should be considered in patients with worse-than-expected anemia after chemotherapy. Furthermore, ENT2 hemolysis ENT2END during transfusion is not always a transfusion reaction
0	Drug studies using the indirect antiglobulin test were strongly positive with ENT1 trimethoprim  ENT1END  and trimethoprim-sulfamethoxazole but negative with sulfamethoxazole. The patient recovered after discontinuing the drug, with no recurrence in 2 years. Other causes of anemia should be considered in patients with worse-than-expected anemia after chemotherapy. Furthermore, ENT2 hemolysis ENT2END during transfusion is not always a transfusion reaction
0	Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and ENT1 trimethoprim-sulfamethoxazole  ENT1END  but negative with sulfamethoxazole. The patient recovered after discontinuing the drug, with no recurrence in 2 years. Other causes of anemia should be considered in patients with worse-than-expected anemia after chemotherapy. Furthermore, ENT2 hemolysis ENT2END during transfusion is not always a transfusion reaction
0	She was admitted to our center for severe ENT1 anemia ENT1END due to menorrhagia and deterioration of renal function. She was infused three units of packed cells during a session of hemodialysis. ENT2 Tranexamic acid ENT2END (TNA) 1 g 8-hourly was administered to her to control bleeding per vaginum
0	Thus, the precipitating cause of convulsions was believed to be an ENT1 overdose ENT1END of ENT2 TNA ENT2END
0	ENT1 Tranexamic acid ENT1END  overdosage-induced generalized seizure in renal failure.We report a 45-year-old lady with chronic kidney disease stage 4 due to chronic ENT2 tubulointerstial disease ENT2END
0	ENT1 Tranexamic acid ENT1END  overdosage-induced generalized seizure in renal failure.We report a 45-year-old lady with ENT2 chronic kidney disease ENT2END stage 4 due to chronic tubulointerstial disease
0	ENT1 Tranexamic acid  ENT1END  overdosage-induced generalized seizure in ENT2 renal failure ENT2END
0	Thus, the precipitating cause of ENT1 convulsions  ENT1END was believed to be an overdose of ENT2 TNA ENT2END
0	She was admitted to our center for severe anemia due to ENT1 menorrhagia  ENT1END and deterioration of renal function. She was infused three units of packed cells during a session of hemodialysis. ENT2 Tranexamic acid ENT2END (TNA) 1 g 8-hourly was administered to her to control bleeding per vaginum
0	ENT1 TNA ENT1END was discontinued. Investigations of the patient revealed no biochemical or structural central ENT2 nervous system abnormalities ENT2END that could have provoked the convulsions
0	Tranexamic acid (TNA) 1 g 8-hourly was administered to her to control ENT1 bleeding ENT1END per vaginum. Two hours after the sixth dose of ENT2 TNA ENT2END , she had an episode of generalized tonic clonic convulsions
1	Two hours after the sixth dose of TNA, she had an episode of generalized ENT1 tonic clonic convulsions ENT1END ENT2 TNA ENT2END was discontinued
0	Twenty carcinomas of the urinary bladder and one ENT1 carcinoma of the prostate ENT1END have been reported in association with its use. The present case is the first carcinoma of the renal pelvis reported in association with ENT2 cyclophosphamide ENT2END treatment
0	Invasive carcinoma of the renal pelvis following ENT1 cyclophosphamide ENT1END  therapy for nonmalignant disease.A 47-year-old woman with right ENT2 hydroureteronephrosis ENT2END due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih cyclophosphamide for cerebral vasculitis
1	Twenty ENT1 carcinomas of the urinary bladder  ENT1END and one carcinoma of the prostate have been reported in association with its use. The present case is the first carcinoma of the renal pelvis reported in association with ENT2 cyclophosphamide ENT2END treatment
0	Invasive ENT1 carcinoma of the renal pelvis  ENT1END  following ENT2 cyclophosphamide ENT2END therapy for nonmalignant disease
0	It is the third urinary tract cancer reported in association with ENT1 cyclophosphamide ENT1END treatment for nonmalignant disease. The association of the ENT2 tumor ENT2END with preexisting hydroureteronephrosis suggests that stasis prolonged and intensified exposure of upper urinary tract epithelium to cyclophosphamide
0	The present case is the first carcinoma of the renal pelvis reported in association with ENT1 cyclophosphamide ENT1END  treatment. It is the third ENT2 urinary tract cancer ENT2END reported in association with cyclophosphamide treatment for nonmalignant disease
1	A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross ENT1 hematuria ENT1END after being treated for five years wtih ENT2 cyclophosphamide ENT2END for cerebral vasculitis
0	Although the ability of ENT1 cyclophosphamide ENT1END to cause ENT2 hemorrhagic cystitis ENT2END and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract
0	A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih ENT1 cyclophosphamide ENT1END  for ENT2 cerebral vasculitis ENT2END
0	Although the ability of ENT1 cyclophosphamide ENT1END  to cause ENT2 hemorrhagic cystitis ENT2END and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract
1	Although the ability of ENT1 cyclophosphamide ENT1END  to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade ENT2 carcinoma ENT2END is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract
0	Intradermal injections of glutamate and ENT1 capsaicin ENT1END are attractive to use in human experimental ENT2 pain ENT2END models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders
0	Intradermal injections of ENT1 glutamate  ENT1END and capsaicin are attractive to use in human experimental ENT2 pain ENT2END models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders
0	Intradermal injections of glutamate and ENT1 capsaicin ENT1END  are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical ENT2 pain disorders ENT2END
0	Intradermal injections of ENT1 glutamate  ENT1END  and capsaicin are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical ENT2 pain disorders ENT2END
1	In conclusion, glutamate and ENT1 capsaicin ENT1END yield reproducible ENT2 hyperalgesic ENT2END and allodynic responses, and the present model is well suited for basic research, as well as for assessing the modulation of central phenomena
0	Intra-individual variability was generally lower for the VAS response to von Frey and brush compared with areas of secondary hyperalgesia and ENT1 allodynia ENT1END  In conclusion, ENT2 glutamate ENT2END and capsaicin yield reproducible hyperalgesic and allodynic responses, and the present model is well suited for basic research, as well as for assessing the modulation of central phenomena
1	Protective effect of Terminalia chebula against experimental ENT1 myocardial injury  ENT1END  induced by ENT2 isoproterenol ENT2END
0	Protective effect of ENT1 Terminalia chebula  ENT1END  against experimental ENT2 myocardial injury ENT2END induced by isoproterenol
0	Cardioprotective effect of ethanolic extract of Terminalia chebula fruits (500 mg/kg body wt) was examined in isoproterenol (200 mg/kg body wt) induced ENT1 myocardial damage ENT1END in rats. In isoproterenol administered rats, the level of lipid ENT2 peroxides ENT2END increased significantly in the serum and heart
1	Histopathological examination was carried out to confirm the myocardial ENT1 necrosis ENT1END  T. chebula extract pretreatment was found to ameliorate the effect of ENT2 isoproterenol ENT2END on lipid peroxide formation and retained the activities of the diagnostic marker enzymes
0	Histopathological examination was carried out to confirm the myocardial ENT1 necrosis ENT1END . ENT2 T. chebula extract ENT2END pretreatment was found to ameliorate the effect of isoproterenol on lipid peroxide formation and retained the activities of the diagnostic marker enzymes
0	Histopathological examination was carried out to confirm the myocardial ENT1 necrosis ENT1END . T. chebula extract pretreatment was found to ameliorate the effect of isoproterenol on lipid ENT2 peroxide ENT2END formation and retained the activities of the diagnostic marker enzymes
0	5 mg/dL (44 micromol/L) in the serum ENT1 creatinine ENT1END level that is greater than 50% of baseline immediately after conditioning. Urine sediment score was the sum of the individual types of sediment identified on urine microscopy. RESULTS: Of the 80 patients studied, ARI developed in 18.8% of the patients after high-dose melphalan. Univariate analysis identified age, ENT2 hypoalbuminemia ENT2END , heavy proteinuria, diuretic use, and urine sediment score (>3) as risk factors
0	8% of the patients after high-dose ENT1 melphalan  ENT1END  Univariate analysis identified age, ENT2 hypoalbuminemia ENT2END , heavy proteinuria, diuretic use, and urine sediment score (>3) as risk factors
0	Acute renal insufficiency ( ENT1 ARI  ENT1END  after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum ENT2 creatinine ENT2END level that is greater than 50% of baseline immediately after conditioning
1	Ongoing tubular injury may be a prerequisite for ENT1 renal injury ENT1END by ENT2 melphalan ENT2END as evidenced by the active urinary sediment
0	METHODS: Consecutive ENT1 AL  ENT1END patients who underwent PBSCT were studied retrospectively. Acute renal insufficiency (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum ENT2 creatinine ENT2END level that is greater than 50% of baseline immediately after conditioning
0	METHODS: Consecutive ENT1 AL ENT1END  patients who underwent PBSCT were studied retrospectively. Acute renal insufficiency (ARI) after high-dose ENT2 melphalan ENT2END was defined by a minimum increase of 0
0	Acute renal insufficiency after high-dose ENT1 melphalan  ENT1END  in patients with ENT2 primary systemic amyloidosis ENT2END during stem cell transplantation
0	5 mg/dL (44 micromol/L) in the serum ENT1 creatinine ENT1END  level that is greater than 50% of baseline immediately after conditioning. Urine sediment score was the sum of the individual types of sediment identified on urine microscopy. RESULTS: Of the 80 patients studied, ARI developed in 18.8% of the patients after high-dose melphalan. Univariate analysis identified age, hypoalbuminemia, heavy ENT2 proteinuria ENT2END , diuretic use, and urine sediment score (>3) as risk factors
0	8% of the patients after high-dose ENT1 melphalan  ENT1END . Univariate analysis identified age, hypoalbuminemia, heavy ENT2 proteinuria ENT2END , diuretic use, and urine sediment score (>3) as risk factors
0	It was possible to suppress the increased ENT1 ornithine ENT1END decarboxylase activity with both beta-blockers in ENT2 hypertrophied hearts ENT2END , but there was no effect on the heart mass
1	The studies were performed using an experimental model of ENT1 isoproterenol ENT1END induced ENT2 heart hypertrophy ENT2END in rats
0	Subacute effects of ENT1 propranolol  ENT1END  and B 24/76 on isoproterenol-induced rat ENT2 heart hypertrophy ENT2END in correlation with blood pressure
0	Both beta-blockers influenced the development of ENT1 hypertrophy  ENT1END to a different, but not reproducible extent. It was possible to suppress the increased ENT2 ornithine ENT2END decarboxylase activity with both beta-blockers in hypertrophied hearts, but there was no effect on the heart mass
0	Neither propranolol nor B 24/76 could stop the changes in the characteristic myosin isoenzyme pattern of the ENT1 hypertrophied ENT1END rat heart. Thus, the investigations did not provide any evidence that the beta-receptor blockers propranolol and B 24/76 have the potency to prevent ENT2 isoproterenol ENT2END from producing heart hypertrophy
0	Neither ENT1 propranolol  ENT1END nor B 24/76 could stop the changes in the characteristic myosin isoenzyme pattern of the ENT2 hypertrophied ENT2END rat heart
0	Quetiapine-induced neutropenia in a ENT1 bipolar ENT1END  patient with hepatocellular carcinoma.OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to ENT2 clozapine ENT2END , which has the highest risk of causing blood dyscrasias, especially neutropenia
0	ENT1 Quetiapine  ENT1END -induced neutropenia in a ENT2 bipolar ENT2END patient with hepatocellular carcinoma
1	Hepatic dysfunction may be one of the possible risk factors, and concomitant ENT1 fever ENT1END may be a diagnostic marker for adverse reaction to ENT2 quetiapine ENT2END
0	OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to ENT1 clozapine ENT1END , which has the highest risk of causing ENT2 blood dyscrasias ENT2END , especially neutropenia
0	OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing ENT1 blood dyscrasias ENT1END , especially neutropenia. There are some case reports about this side effect of ENT2 quetiapine ENT2END , but possible risk factors are seldom discussed and identified
0	CONCLUSIONS: Although neutropenia is not a common side effect of ENT1 quetiapine ENT1END  physicians should be cautious about its presentation and associated risk factors. ENT2 Hepatic dysfunction ENT2END may be one of the possible risk factors, and concomitant fever may be a diagnostic marker for adverse reaction to quetiapine
0	Quetiapine-induced neutropenia in a bipolar patient with ENT1 hepatocellular carcinoma  ENT1END .OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to ENT2 clozapine ENT2END , which has the highest risk of causing blood dyscrasias, especially neutropenia
0	Quetiapine-induced neutropenia in a bipolar patient with ENT1 hepatocellular carcinoma ENT1END .OBJECTIVE: ENT2 Quetiapine ENT2END is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia
0	OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to ENT1 clozapine ENT1END , which has the highest risk of causing blood dyscrasias, especially neutropenia. There are some case reports about this side effect of quetiapine, but possible risk factors are seldom discussed and identified. A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here. CASE REPORT: A 62-year-old Taiwanese widow with bipolar disorder was diagnosed with hepatocellular carcinoma at age 60. She developed ENT2 leucopenia ENT2END after being treated with quetiapine
1	She developed ENT1 leucopenia ENT1END  after being treated with ENT2 quetiapine ENT2END
0	OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to ENT1 clozapine ENT1END , which has the highest risk of causing blood dyscrasias, especially ENT2 neutropenia ENT2END
1	ENT1 Quetiapine  ENT1END -induced ENT2 neutropenia ENT2END in a bipolar patient with hepatocellular carcinoma
0	A 47-year-old man who had been taking ENT1 minocycline ENT1END for palmoplantar pustulosis developed fever, myalgias, ENT2 polyneuropathy ENT2END , and testicular pain, with elevated C-reactive protein (CRP)
0	A 47-year-old man who had been taking ENT1 minocycline ENT1END  for ENT2 palmoplantar pustulosis ENT2END developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP)
0	A 47-year-old man who had been taking ENT1 minocycline ENT1END  for palmoplantar pustulosis developed ENT2 fever ENT2END , myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP)
0	ENT1 Minocycline  ENT1END -induced ENT2 vasculitis ENT2END fulfilling the criteria of polyarteritis nodosa
1	These manifestations met the American College of Rheumatology 1990 criteria for the classification of ENT1 polyarteritis nodosa ENT1END  Stopping ENT2 minocycline ENT2END led to amelioration of symptoms and normalization of CRP level
0	A 47-year-old man who had been taking ENT1 minocycline ENT1END  for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and ENT2 testicular pain ENT2END , with elevated C-reactive protein (CRP)
0	A 47-year-old man who had been taking ENT1 minocycline ENT1END  for palmoplantar pustulosis developed fever, ENT2 myalgias ENT2END , polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP)
1	001) ENT1 Dex ENT1END induced hypertension. LF prevented body ENT2 weight loss ENT2END and significantly reduced the elevated plasma H2O2 and increased FRAP values
0	LF prevented body ENT1 weight loss ENT1END  and significantly reduced the elevated plasma ENT2 H2O2 ENT2END and increased FRAP values
0	Dexamethasone- (Dex-) induced ENT1 hypertension ENT1END is associated with enhanced oxidative stress. Lactoferrin (LF) is an ENT2 iron ENT2END -binding glycoprotein with antihypertensive properties
1	In this study, we investigated the effect of chronic administration of LF on oxidative stress and ENT1 hypertension ENT1END upon ENT2 Dex ENT2END administration
0	001) Dex-induced ENT1 hypertension  ENT1END  LF prevented body weight loss and significantly reduced the elevated plasma ENT2 H2O2 ENT2END and increased FRAP values
1	Early paracentral ENT1 visual field loss  ENT1END  in patients taking ENT2 hydroxychloroquine ENT2END
0	Two cases of downbeat nystagmus and oscillopsia associated with ENT1 carbamazepine  ENT1END . ENT2 Downbeat nystagmus ENT2END is often associated with structural lesions at the craniocervical junction, but has occasionally been reported as a manifestation of metabolic imbalance or drug intoxication
1	Two cases of downbeat nystagmus and ENT1 oscillopsia  ENT1END  associated with ENT2 carbamazepine ENT2END
0	Milk-alkali syndrome induced by ENT1 1,25(OH)2D  ENT1END  in a patient with ENT2 hypoparathyroidism ENT2END
0	This article presents a patient with ENT1 hypoparathyroidism ENT1END who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous ENT2 pamidronate ENT2END on his first admission and with hydrocortisone on the second
0	This article presents a patient with ENT1 hypoparathyroidism ENT1END  who was treated with ENT2 calcium carbonate ENT2END and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome
0	Milk-alkali syndrome induced by 1,25(OH)2D in a patient with ENT1 hypoparathyroidism ENT1END .Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of ENT2 calcium ENT2END and alkali
0	Milk-alkali syndrome induced by 1,25(OH)2D in a patient with ENT1 hypoparathyroidism ENT1END .Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and ENT2 sucralfate ENT2END ), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Milk-alkali syndrome induced by 1,25(OH)2D in a patient with ENT1 hypoparathyroidism ENT1END .Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali. Although with current ulcer therapy (H-2 blockers, ENT2 omeprazole ENT2END , and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	This article presents a patient with ENT1 hypoparathyroidism ENT1END  who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous pamidronate on his first admission and with ENT2 hydrocortisone ENT2END on the second
0	Milk-alkali syndrome induced by 1,25(OH)2D in a patient with ENT1 hypoparathyroidism ENT1END .Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and ENT2 alkali ENT2END
0	Milk-alkali syndrome induced by ENT1 1,25(OH)2D ENT1END  in a patient with hypoparathyroidism.Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENT2 peptic ulcer disease ENT2END with large amounts of calcium and alkali
0	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENT1 peptic ulcer disease  ENT1END  with large amounts of calcium and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous ENT2 pamidronate ENT2END on his first admission and with hydrocortisone on the second
0	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENT1 peptic ulcer disease  ENT1END  with large amounts of calcium and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with ENT2 calcium carbonate ENT2END and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome
0	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENT1 peptic ulcer disease  ENT1END  with large amounts of ENT2 calcium ENT2END and alkali
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENT1 peptic ulcer disease  ENT1END  with large amounts of calcium and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and ENT2 sucralfate ENT2END ), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENT1 peptic ulcer disease  ENT1END  with large amounts of calcium and alkali. Although with current ulcer therapy (H-2 blockers, ENT2 omeprazole ENT2END , and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENT1 peptic ulcer disease  ENT1END  with large amounts of calcium and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous pamidronate on his first admission and with ENT2 hydrocortisone ENT2END on the second
0	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENT1 peptic ulcer disease  ENT1END  with large amounts of calcium and ENT2 alkali ENT2END
1	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENT1 renal impairment ENT1END remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and ENT2 calcitriol ENT2END resulting in two admissions to the hospital for milk-alkali syndrome
0	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENT1 renal impairment  ENT1END  remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous ENT2 pamidronate ENT2END on his first admission and with hydrocortisone on the second
1	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENT1 renal impairment  ENT1END  remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with ENT2 calcium carbonate ENT2END and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of ENT1 calcium  ENT1END  and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENT2 renal impairment ENT2END remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, omeprazole, and ENT1 sucralfate  ENT1END ), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENT2 renal impairment ENT2END remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, ENT1 omeprazole  ENT1END , and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENT2 renal impairment ENT2END remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENT1 renal impairment  ENT1END  remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous pamidronate on his first admission and with ENT2 hydrocortisone ENT2END on the second
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and ENT1 alkali  ENT1END . Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENT2 renal impairment ENT2END remains the hallmark of the syndrome
1	ENT1 Milk-alkali syndrome  ENT1END  induced by ENT2 1,25(OH)2D ENT2END in a patient with hypoparathyroidism
0	This illustrates intravenous ENT1 pamidronate ENT1END as a valuable therapeutic tool when ENT2 milk-alkali syndrome ENT2END presents as hypercalcemic emergency
1	This article presents a patient with hypoparathyroidism who was treated with ENT1 calcium carbonate ENT1END  and calcitriol resulting in two admissions to the hospital for ENT2 milk-alkali syndrome ENT2END
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of ENT1 calcium ENT1END  and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of ENT2 milk-alkali syndrome ENT2END has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, omeprazole, and ENT1 sucralfate  ENT1END ), the frequency of ENT2 milk-alkali syndrome ENT2END has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, ENT1 omeprazole  ENT1END , and sucralfate), the frequency of ENT2 milk-alkali syndrome ENT2END has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	The patient was successfully treated with intravenous pamidronate on his first admission and with ENT1 hydrocortisone  ENT1END  on the second. This illustrates intravenous pamidronate as a valuable therapeutic tool when ENT2 milk-alkali syndrome ENT2END presents as hypercalcemic emergency
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and ENT1 alkali  ENT1END . Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of ENT2 milk-alkali syndrome ENT2END has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
1	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENT1 alkalosis  ENT1END  and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and ENT2 calcitriol ENT2END resulting in two admissions to the hospital for milk-alkali syndrome
0	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENT1 alkalosis  ENT1END , and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous ENT2 pamidronate ENT2END on his first admission and with hydrocortisone on the second
1	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENT1 alkalosis  ENT1END , and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with ENT2 calcium carbonate ENT2END and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of ENT1 calcium  ENT1END  and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENT2 alkalosis ENT2END , and renal impairment remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, omeprazole, and ENT1 sucralfate  ENT1END ), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENT2 alkalosis ENT2END , and renal impairment remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, ENT1 omeprazole  ENT1END , and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENT2 alkalosis ENT2END , and renal impairment remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENT1 alkalosis  ENT1END , and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous pamidronate on his first admission and with ENT2 hydrocortisone ENT2END on the second
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and ENT1 alkali  ENT1END . Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENT2 alkalosis ENT2END , and renal impairment remains the hallmark of the syndrome
0	Milk-alkali syndrome induced by ENT1 1,25(OH)2D ENT1END  in a patient with hypoparathyroidism.Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali. Although with current ENT2 ulcer ENT2END therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Although with current ENT1 ulcer  ENT1END  therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous ENT2 pamidronate ENT2END on his first admission and with hydrocortisone on the second
0	Although with current ENT1 ulcer  ENT1END  therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with ENT2 calcium carbonate ENT2END and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome
0	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of ENT1 calcium  ENT1END  and alkali. Although with current ENT2 ulcer ENT2END therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Although with current ENT1 ulcer  ENT1END  therapy (H-2 blockers, omeprazole, and ENT2 sucralfate ENT2END ), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Although with current ENT1 ulcer  ENT1END  therapy (H-2 blockers, ENT2 omeprazole ENT2END , and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Although with current ENT1 ulcer  ENT1END  therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous pamidronate on his first admission and with ENT2 hydrocortisone ENT2END on the second
0	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and ENT1 alkali  ENT1END . Although with current ENT2 ulcer ENT2END therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Recent studies show that the YMDD motif mutants (resistant hepatitis B virus) occur as natural genome variability in ENT1 lamivudine ENT1END untreated ENT2 chronic hepatitis B ENT2END patients
1	YMDD motif mutants were not detected in any of the patients despite the liver enzyme levels and the presence of ENT1 HBeAg ENT1END or anti-HBe. CONCLUSION: Although the natural occurrence of YMDD motif mutants in lamivudine-untreated patients with ENT2 chronic hepatitis B ENT2END has been reported, these mutants were not detected in Iranian lamivudine-untreated chronic hepatitis B patients
0	Recent studies show that the YMDD motif mutants (resistant ENT1 hepatitis B  ENT1END virus) occur as natural genome variability in ENT2 lamivudine ENT2END -untreated chronic hepatitis B patients
0	Recent studies show that the YMDD motif mutants (resistant ENT1 hepatitis B ENT1END  virus) occur as natural genome variability in lamivudine-untreated chronic hepatitis B patients. In this study we aimed to determine the rate of YMDD motif mutants in lamivudine-untreated chronic hepatitis B patients in Iran. PATIENTS AND METHODS: A total of 77 chronic hepatitis B patients who had not been treated with lamivudine were included in the study. Serum samples from patients were tested by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for detection of YMDD motif mutants. All patients were also tested for liver enzymes, anti-HCV, ENT2 HBeAg ENT2END , and anti-HBe
1	This study shows that 17alpha-ethinylestradiol ( ENT1 EE ENT1END -induced ENT2 intrahepatic cholestasis ENT2END in rats is associated with selective inhibition of the neutral pathway of bile salt (BS) synthesis
0	This study shows that 17alpha-ethinylestradiol (EE)-induced ENT1 intrahepatic cholestasis ENT1END  in rats is associated with selective inhibition of the neutral pathway of ENT2 bile salt ENT2END (BS) synthesis
0	In addition, mRNA levels of ENT1 sterol  ENT1END 12alpha-hydroxylase and lithocholate 6beta-hydroxylase were increased by bile diversion and suppressed by EE. This study shows that 17alpha-ethinylestradiol (EE)-induced ENT2 intrahepatic cholestasis ENT2END in rats is associated with selective inhibition of the neutral pathway of bile salt (BS) synthesis
0	BACKGROUND: Thrombocytopenia in patients with end-stage liver disease is a common disorder caused mainly by ENT1 portal hypertension ENT1END  low levels of thrombopoetin, and endotoxemia. The impact of immune-mediated ENT2 heparin ENT2END -induced thrombocytopenia type II (HIT type II) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results
0	CONCLUSIONS: The incidence of HIT in patients with ENT1 end-stage hepatic failure ENT1END is, with about 1.95%, rare. For further reduction of HIT type II, the use of intravenous ENT2 heparin ENT2END should be avoided and the prophylactic anticoagulation should be performed with low-molecular-weight heparin after normalization of platelet count
1	Incidence of ENT1 heparin  ENT1END -induced ENT2 thrombocytopenia type II ENT2END and postoperative recovery of platelet count in liver graft recipients: a retrospective cohort analysis
0	6%) of 205 patients had thrombocytopenia before transplantation, significantly influenced by Model of End-Stage Liver Disease score and ENT1 liver cirrhosis  ENT1END  The platelet count exceeded 100,000/uL in most of the patients (n = 193) at a medium of 7 d. Regarding HIT II, there were four (1.95%) patients with a background of HIT type II. CONCLUSIONS: The incidence of HIT in patients with end-stage hepatic failure is, with about 1.95%, rare. For further reduction of HIT type II, the use of intravenous ENT2 heparin ENT2END should be avoided and the prophylactic anticoagulation should be performed with low-molecular-weight heparin after normalization of platelet count
0	BACKGROUND: Thrombocytopenia in patients with end-stage liver disease is a common disorder caused mainly by portal hypertension, low levels of thrombopoetin, and ENT1 endotoxemia  ENT1END  The impact of immune-mediated ENT2 heparin ENT2END -induced thrombocytopenia type II (HIT type II) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results
0	The impact of immune-mediated ENT1 heparin ENT1END -induced thrombocytopenia type II (HIT type II) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results. The aim of our study was to demonstrate the perioperative course of thrombocytopenia after liver transplantation and determine the occurrence of clinical HIT type II. METHOD: We retrospectively evaluated the medical records of 205 consecutive adult patients who underwent full-size liver transplantation between January 2006 and December 2010 due to ENT2 end-stage or malignant liver disease ENT2END
0	Prominent white-matter hypertrophy may result from altered myelination and adaptive glial changes, including ENT1 gliosis ENT1END secondary to neuronal damage. These brain substrates may help account for the symptoms of ENT2 MA ENT2END abuse, providing therapeutic targets for drug-induced brain injury
0	On average, ENT1 MA ENT1END abusers had 7.8% smaller hippocampal volumes than control subjects (p < 0.01; left, p = 0.01; right, p < 0.05) and significant white-matter ENT2 hypertrophy ENT2END (7
0	Using magnetic resonance imaging (MRI) and new computational brain-mapping techniques, we determined the pattern of structural brain alterations associated with chronic ENT1 MA ENT1END abuse in human subjects and related these deficits to ENT2 cognitive impairment ENT2END
0	Prominent white-matter hypertrophy may result from altered myelination and adaptive glial changes, including gliosis secondary to ENT1 neuronal damage  ENT1END  These brain substrates may help account for the symptoms of ENT2 MA ENT2END abuse, providing therapeutic targets for drug-induced brain injury
1	MRI-based maps suggest that chronic methamphetamine abuse causes a selective pattern of cerebral deterioration that contributes to ENT1 impaired memory performance ENT1END  ENT2 MA ENT2END may selectively damage the medial temporal lobe and, consistent with metabolic studies, the cingulate-limbic cortex, inducing neuroadaptation, neuropil reduction, or cell death
1	We visualize, for the first time, the profile of ENT1 structural deficits in the human brain ENT1END associated with chronic ENT2 methamphetamine ENT2END (MA) abuse
0	Studies of human subjects who have used ENT1 MA ENT1END chronically have revealed deficits in dopaminergic and serotonergic systems and cerebral ENT2 metabolic abnormalities ENT2END
0	METHODS: Sixty normotensive American Society of Anesthesiologists I-II adult patients undergoing FESS under controlled hypotension anesthesia caused by ENT1 propofol ENT1END remifentanil-TIVA were randomly assigned into two groups: group I, FRLMA; group II, ETT. ENT2 Hemorrhage ENT2END was measured and the visibility of the operative field was evaluated according to a six-point scale
0	METHODS: Sixty normotensive American Society of Anesthesiologists I-II adult patients undergoing FESS under controlled hypotension anesthesia caused by propofol- ENT1 remifentanil  ENT1END TIVA were randomly assigned into two groups: group I, FRLMA; group II, ETT. ENT2 Hemorrhage ENT2END was measured and the visibility of the operative field was evaluated according to a six-point scale
1	METHODS: Sixty normotensive American Society of Anesthesiologists I-II adult patients undergoing FESS under controlled ENT1 hypotension  ENT1END anesthesia caused by ENT2 propofol ENT2END -remifentanil-TIVA were randomly assigned into two groups: group I, FRLMA; group II, ETT
1	CONCLUSION: In summary, our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced ENT1 hypotension ENT1END with low doses of ENT2 remifentanil ENT2END during TIVA in patients undergoing FESS
0	The participation of reactive oxygen species in aminoglycoside-induced ENT1 ototoxicity  ENT1END has been deduced from observations that aminoglycoside- ENT2 iron ENT2END complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo
0	The participation of reactive ENT1 oxygen  ENT1END species in aminoglycoside-induced ENT2 ototoxicity ENT2END has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo
0	The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ENT1 ototoxicity  ENT1END in vivo. We therefore hypothesized that overexpression of Cu/ ENT2 Zn ENT2END -superoxide dismutase (h-SOD1) should protect transgenic mice from ototoxicity
0	The participation of reactive oxygen species in ENT1 aminoglycoside  ENT1END induced ENT2 ototoxicity ENT2END has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo
0	Overexpression of copper/zinc-superoxide dismutase protects from ENT1 kanamycin  ENT1END -induced hearing loss.The participation of reactive oxygen species in aminoglycoside-induced ENT2 ototoxicity ENT2END has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo
0	The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ENT1 ototoxicity ENT1END  in vivo. We therefore hypothesized that overexpression of ENT2 Cu ENT2END /Zn-superoxide dismutase (h-SOD1) should protect transgenic mice from ototoxicity
0	The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of ENT1 superoxide  ENT1END radicals in vitro and that antioxidants attenuate ENT2 ototoxicity ENT2END in vivo
0	Overexpression of copper/zinc-superoxide dismutase protects from kanamycin-induced ENT1 hearing loss  ENT1END .The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside ENT2 iron ENT2END complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo
0	Overexpression of copper/zinc-superoxide dismutase protects from kanamycin-induced ENT1 hearing loss  ENT1END .The participation of reactive ENT2 oxygen ENT2END species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo
0	Overexpression of copper/ ENT1 zinc  ENT1END -superoxide dismutase protects from kanamycin-induced ENT2 hearing loss ENT2END
0	Overexpression of copper/zinc-superoxide dismutase protects from kanamycin-induced ENT1 hearing loss  ENT1END .The participation of reactive oxygen species in ENT2 aminoglycoside ENT2END -induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo
1	Overexpression of copper/zinc-superoxide dismutase protects from ENT1 kanamycin  ENT1END -induced ENT2 hearing loss ENT2END
0	Overexpression of ENT1 copper  ENT1END /zinc-superoxide dismutase protects from kanamycin-induced ENT2 hearing loss ENT2END
0	Overexpression of copper/zinc- ENT1 superoxide  ENT1END  dismutase protects from kanamycin-induced ENT2 hearing loss ENT2END
0	Bepridil, a novel active compound for prophylactic treatment of anginal attacks, induced persistent bradycardia and a non-specific anti- ENT1 tachycardial ENT1END effect, the mechanisms of which were investigated in vitro and in vivo. In vitro perfusion of ENT2 bepridil ENT2END in the life-support medium for isolated sino-atrial tissue from rabbit heart, caused a reduction in action potential (AP) spike frequency (recorded by KCl microelectrodes) starting at doses of 5 X 10(-6) M
0	Bepridil, a novel active compound for prophylactic treatment of anginal attacks, induced persistent bradycardia and a non-specific anti- ENT1 tachycardial ENT1END  effect, the mechanisms of which were investigated in vitro and in vivo. In vitro perfusion of bepridil in the life-support medium for isolated sino-atrial tissue from rabbit heart, caused a reduction in action potential (AP) spike frequency (recorded by ENT2 KCl ENT2END microelectrodes) starting at doses of 5 X 10(-6) M
0	ENT1 Bepridil ENT1END  a novel active compound for prophylactic treatment of ENT2 anginal attacks ENT2END , induced persistent bradycardia and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo
0	Bepridil, a novel active compound for prophylactic treatment of ENT1 anginal attacks  ENT1END , induced persistent bradycardia and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo. In vitro perfusion of bepridil in the life-support medium for isolated sino-atrial tissue from rabbit heart, caused a reduction in action potential (AP) spike frequency (recorded by ENT2 KCl ENT2END microelectrodes) starting at doses of 5 X 10(-6) M
1	Studies on the ENT1 bradycardia  ENT1END  induced by ENT2 bepridil ENT2END
0	Bepridil, a novel active compound for prophylactic treatment of anginal attacks, induced persistent ENT1 bradycardia  ENT1END and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo. In vitro perfusion of bepridil in the life-support medium for isolated sino-atrial tissue from rabbit heart, caused a reduction in action potential (AP) spike frequency (recorded by ENT2 KCl ENT2END microelectrodes) starting at doses of 5 X 10(-6) M
0	Chronic progesterone pretreatment (5 mg/kg/day for 21 days) caused a significant increase in bupivacaine arrhythmogenicity in intact ENT1 pentobarbital ENT1END anesthetized rats. There was a significant decrease in the time to onset of ENT2 arrhythmia ENT2END as compared with control nonprogesterone-treated rats (6
1	Potentiation of ENT1 bupivacaine ENT1END ENT2 arrhythmia ENT2END in myocyte cultures suggests that this effect is at least partly mediated at the myocyte level
1	After determining the bupivacaine AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become ENT1 arrhythmic ENT1END , we determined the effect of 1-hour progesterone HCl exposure on myocyte contractile rhythm. Each concentration of progesterone (6.25, 12.5, 25, and 50 micrograms/ml) caused a significant and concentration-dependent reduction in the AD50 for bupivacaine. ENT2 Estradiol ENT2END treatment also increased the arrhythmogenicity of bupivacaine in myocyte cultures, but was only one fourth as potent as progesterone
0	After determining the bupivacaine AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become ENT1 arrhythmic ENT1END ), we determined the effect of 1-hour progesterone ENT2 HCl ENT2END exposure on myocyte contractile rhythm
1	After determining the bupivacaine AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become ENT1 arrhythmic ENT1END ), we determined the effect of 1-hour ENT2 progesterone ENT2END HCl exposure on myocyte contractile rhythm
0	Neither progesterone nor estradiol effects on bupivacaine arrhythmogenicity were potentiated by ENT1 epinephrine  ENT1END  Chronic progesterone pretreatment (5 mg/kg/day for 21 days) caused a significant increase in bupivacaine arrhythmogenicity in intact pentobarbital-anesthetized rats. There was a significant decrease in the time to onset of ENT2 arrhythmia ENT2END as compared with control nonprogesterone-treated rats (6
1	ENT1 Vasovagal syncope  ENT1END  and severe bradycardia following intranasal ENT2 dexmedetomidine ENT2END for pediatric procedural sedation
0	Vasovagal syncope and severe bradycardia following intranasal ENT1 dexmedetomidine ENT1END  for pediatric procedural sedation.We report ENT2 syncope ENT2END and bradycardia in an 11-year-old girl following administration of intranasal dexmedetomidine for sedation for a voiding cystourethrogram
1	Vasovagal syncope and severe ENT1 bradycardia  ENT1END  following intranasal ENT2 dexmedetomidine ENT2END for pediatric procedural sedation
0	CONCLUSION: Verapamil responsiveness is not a reliable finding for the differential diagnosis of ENT1 hyperprolactinemia ENT1END  However, ENT2 verapamil ENT2END unresponsiveness discriminates stalk effect (i
1	8%), and ENT1 risperidone ENT1END induced ENT2 hyperprolactinemia ENT2END (N
0	Here, we aimed to re-investigate the diagnostic value of verapamil in a population who were all screened for ENT1 macroprolactinemia ENT1END  Prolactin responses to ENT2 verapamil ENT2END in 65 female patients (age: 29
0	19, PRL: 21%), ENT1 macroprolactinemia  ENT1END (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and ENT2 risperidone ENT2END -induced hyperprolactinemia (N
1	Rechallenge of patients who developed oral candidiasis or ENT1 hoarseness  ENT1END  with ENT2 beclomethasone dipropionate ENT2END
0	We conclude that patients may be restarted on inhaled beclomethasone when clinically indicated; however, because of the high recurrence rate, patients who develop ENT1 hoarseness ENT1END should not be re-challenged. Concomitant use of oral ENT2 prednisone ENT2END and topical beclomethasone may increase the risk of developing hoarseness or candidiasis
1	Rechallenge of patients who developed ENT1 oral candidiasis  ENT1END  or hoarseness with ENT2 beclomethasone dipropionate ENT2END
0	Oral ENT1 thrush  ENT1END did not recur, but 60% (3/5) of patients with hoarseness had recurrence. We conclude that patients may be restarted on inhaled beclomethasone when clinically indicated; however, because of the high recurrence rate, patients who develop hoarseness should not be re-challenged. Concomitant use of oral ENT2 prednisone ENT2END and topical beclomethasone may increase the risk of developing hoarseness or candidiasis
0	Concomitant use of oral prednisone and topical ENT1 beclomethasone ENT1END may increase the risk of developing hoarseness or ENT2 candidiasis ENT2END
0	Concomitant use of oral ENT1 prednisone  ENT1END  and topical beclomethasone may increase the risk of developing hoarseness or ENT2 candidiasis ENT2END
0	Rechallenge of patients who developed oral candidiasis or hoarseness with ENT1 beclomethasone dipropionate ENT1END .Of 158 ENT2 asthmatic ENT2END patients who were placed on inhaled beclomethasone, 15 (9
1	Stereological methods reveal the robust size and stability of ectopic hilar granule cells after ENT1 pilocarpine  ENT1END -induced ENT2 status epilepticus ENT2END in the adult rat
0	Interestingly, the size of the population appears to be correlated with the frequency of behavioral seizures, because animals with more ectopic granule cells in the hilus have more frequent behavioral ENT1 seizures ENT1END  The hilar ectopic granule cell population does not appear to vary systematically across the septotemporal axis, although it is associated with an increase in volume of the hilus. The results provide new insight into the potential role of ectopic hilar granule cells in the ENT2 pilocarpine ENT2END model of temporal lobe epilepsy
1	The results provide new insight into the potential role of ectopic hilar granule cells in the ENT1 pilocarpine ENT1END  model of ENT2 temporal lobe epilepsy ENT2END
0	ENT1 Phenytoin  ENT1END  induced fatal ENT2 hepatic injury ENT2END
1	The hematologic, biochemical and pathologic features indicate a mixed hepatocellular damage due to ENT1 drug hypersensitivity ENT1END  In a patient receiving ENT2 phenytoin ENT2END who presents a viral-like illness, early recognition and discontinuation of the drug are mandatory
1	A 61 year old female developed fatal ENT1 hepatic failure ENT1END after ENT2 phenytoin ENT2END administration
0	Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and ENT1 amitriptyline ENT1END are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of ENT2 depressive and psychotic symptoms ENT2END
0	Five cases of paranoid exacerbation with the serotonin reuptake inhibitors ENT1 fluoxetine  ENT1END and amitriptyline are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of ENT2 depressive and psychotic symptoms ENT2END
0	Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of ENT1 depressive and psychotic symptoms ENT1END . Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors. Although the pharmacology and neurobiology of paranoia remain cryptic, several mechanisms, including 5HT3 receptor-mediated ENT2 dopamine ENT2END release, beta-noradrenergic receptor downregulation, or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia (possibly in lateral orbitofrontal or anterior cingulate circuits), might apply to this phenomenon
0	Five cases of paranoid exacerbation with the ENT1 serotonin  ENT1END reuptake inhibitors fluoxetine and amitriptyline are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of ENT2 depressive and psychotic symptoms ENT2END
0	Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and ENT1 amitriptyline ENT1END  are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of ENT2 depressive and psychotic symptoms ENT2END
0	Five cases of paranoid exacerbation with the serotonin reuptake inhibitors ENT1 fluoxetine  ENT1END  and amitriptyline are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of ENT2 depressive and psychotic symptoms ENT2END
0	Complicated ENT1 depressive disorders  ENT1END (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors. Although the pharmacology and neurobiology of paranoia remain cryptic, several mechanisms, including 5HT3 receptor-mediated ENT2 dopamine ENT2END release, beta-noradrenergic receptor downregulation, or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia (possibly in lateral orbitofrontal or anterior cingulate circuits), might apply to this phenomenon
0	Five cases of paranoid exacerbation with the ENT1 serotonin  ENT1END  reuptake inhibitors fluoxetine and amitriptyline are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of ENT2 depressive and psychotic symptoms ENT2END
0	Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and ENT1 amitriptyline ENT1END  are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of depressive and psychotic symptoms. Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, ENT2 psychosis ENT2END , bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors
0	Five cases of paranoid exacerbation with the serotonin reuptake inhibitors ENT1 fluoxetine  ENT1END  and amitriptyline are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of depressive and psychotic symptoms. Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, ENT2 psychosis ENT2END , bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors
0	Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary ENT1 psychosis  ENT1END  may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors. Although the pharmacology and neurobiology of paranoia remain cryptic, several mechanisms, including 5HT3 receptor-mediated ENT2 dopamine ENT2END release, beta-noradrenergic receptor downregulation, or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia (possibly in lateral orbitofrontal or anterior cingulate circuits), might apply to this phenomenon
0	Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary ENT1 psychosis ENT1END ) may present particular vulnerability to paranoid exacerbations associated with ENT2 serotonin ENT2END reuptake inhibitors
1	Five cases of ENT1 paranoid  ENT1END exacerbation with the serotonin reuptake inhibitors fluoxetine and ENT2 amitriptyline ENT2END are reported here
1	Five cases of ENT1 paranoid  ENT1END  exacerbation with the serotonin reuptake inhibitors ENT2 fluoxetine ENT2END and amitriptyline are reported here
0	Although the pharmacology and neurobiology of ENT1 paranoia  ENT1END remain cryptic, several mechanisms, including 5HT3 receptor-mediated ENT2 dopamine ENT2END release, beta-noradrenergic receptor downregulation, or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia (possibly in lateral orbitofrontal or anterior cingulate circuits), might apply to this phenomenon
0	These cases call attention to possible ENT1 paranoid ENT1END exacerbations with ENT2 serotonin ENT2END reuptake blockers in select patients and raise neurobiological considerations regarding paranoia
0	Factors contributing to ENT1 ribavirin  ENT1END -induced ENT2 anemia ENT2END
0	Factors contributing to ribavirin-induced ENT1 anemia ENT1END .BACKGROUND AND AIM: ENT2 Interferon ENT2END and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia
0	BACKGROUND AND AIM: Interferon and ENT1 ribavirin ENT1END combination therapy for ENT2 chronic hepatitis C ENT2END produces hemolytic anemia
0	METHODS: Eighty-eight patients with ENT1 chronic hepatitis C ENT1END who received ENT2 interferon-alpha-2b ENT2END at a dose of 6 MU administered intramuscularly for 24 weeks in combination with ribavirin administered orally at a dose of 600 mg or 800 mg participated in the study
1	BACKGROUND AND AIM: Interferon and ENT1 ribavirin ENT1END  combination therapy for chronic hepatitis C produces ENT2 hemolytic anemia ENT2END
1	BACKGROUND AND AIM: ENT1 Interferon  ENT1END  and ribavirin combination therapy for chronic hepatitis C produces ENT2 hemolytic anemia ENT2END
1	The 225 mg/m2 level was expanded for the phase II study since the highest level achieved (250 mg/m2) required modification because of nonhematologic toxicities (arthralgia and ENT1 sensory neuropathy ENT1END . Therapeutic effects were noted at all dose levels, with objective responses in 17 (two complete and 15 partial regressions) of 41 previously untreated patients. Toxicities were compared with a cohort of patients in a phase I trial of ENT2 paclitaxel ENT2END alone at identical dose levels
0	The 225 mg/m2 level was expanded for the phase II study since the highest level achieved (250 mg/m2) required modification because of nonhematologic toxicities (arthralgia and ENT1 sensory neuropathy ENT1END ). Therapeutic effects were noted at all dose levels, with objective responses in 17 (two complete and 15 partial regressions) of 41 previously untreated patients. Toxicities were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels. ENT2 Carboplatin ENT2END did not appear to add to the hematologic toxicities observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks
0	ENT1 Toxicities  ENT1END were compared with a cohort of patients in a phase I trial of ENT2 paclitaxel ENT2END alone at identical dose levels
0	ENT1 Toxicities  ENT1END  were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels. ENT2 Carboplatin ENT2END did not appear to add to the hematologic toxicities observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks
1	0 by the Calvert formula, whereas ENT1 paclitaxel  ENT1END was escalated in patient cohorts from 150 mg/m2 (dose level I) to 175, 200, 225, and 250 mg/m2. The 225 mg/m2 level was expanded for the phase II study since the highest level achieved (250 mg/m2) required modification because of nonhematologic toxicities ( ENT2 arthralgia ENT2END and sensory neuropathy)
0	The 225 mg/m2 level was expanded for the phase II study since the highest level achieved (250 mg/m2) required modification because of nonhematologic toxicities ( ENT1 arthralgia  ENT1END  and sensory neuropathy). Therapeutic effects were noted at all dose levels, with objective responses in 17 (two complete and 15 partial regressions) of 41 previously untreated patients. Toxicities were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels. ENT2 Carboplatin ENT2END did not appear to add to the hematologic toxicities observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks
0	Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with carboplatin in a phase I/II study directed to patients with ENT1 non-small cell lung cancer  ENT1END  Carboplatin was given at a fixed target area under the concentration-time curve of 6.0 by the Calvert formula, whereas ENT2 paclitaxel ENT2END was escalated in patient cohorts from 150 mg/m2 (dose level I) to 175, 200, 225, and 250 mg/m2
0	Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with carboplatin in a phase I/II study directed to patients with ENT1 non-small cell lung cancer ENT1END . ENT2 Carboplatin ENT2END was given at a fixed target area under the concentration-time curve of 6
1	Carboplatin did not appear to add to the ENT1 hematologic toxicities ENT1END observed, and the ENT2 paclitaxel ENT2END /carboplatin combination could be dosed every 3 weeks
0	Carboplatin did not appear to add to the ENT1 hematologic toxicities  ENT1END  observed, and the paclitaxel/ ENT2 carboplatin ENT2END combination could be dosed every 3 weeks
0	ENT1 Sulfadiazine ENT1END acute nephrotoxicity is reviving specially because of its use in ENT2 toxoplasmosis ENT2END in HIV-positive patients
0	Under treatment with ENT1 sulfadiazine ENT1END they developed oliguria, ENT2 abdominal pain ENT2END , renal failure and showed multiple radiolucent renal calculi in echography
0	Under treatment with ENT1 sulfadiazine ENT1END  they developed oliguria, abdominal pain, ENT2 renal failure ENT2END and showed multiple radiolucent renal calculi in echography
0	Under treatment with ENT1 sulfadiazine ENT1END  they developed ENT2 oliguria ENT2END , abdominal pain, renal failure and showed multiple radiolucent renal calculi in echography
1	Under treatment with ENT1 sulfadiazine ENT1END  they developed oliguria, abdominal pain, renal failure and showed multiple radiolucent ENT2 renal calculi ENT2END in echography
1	Patterns of ENT1 sulfadiazine ENT1END ENT2 acute nephrotoxicity ENT2END
0	A nephrostomy tube had to be placed in one of the patients for ENT1 ureteral lithiasis ENT1END in a single functional kidney. None of them needed dialysis or a renal biopsy because of a typical benign course. Treatment with ENT2 sulfadiazine ENT2END requires exquisite control of renal function, an increase in water ingestion and possibly the alcalinization of the urine
0	Phase 2 trial of liposomal ENT1 doxorubicin  ENT1END  (40 mg/m(2)) in platinum/paclitaxel-refractory ENT2 ovarian and fallopian tube cancers ENT2END and primary carcinoma of the peritoneum
0	Definite, although limited, antineoplastic activity is observed in patients with well-defined platinum- and ENT1 paclitaxel ENT1END refractory ENT2 ovarian cancer ENT2END
0	BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in ENT1 platinum ENT1END resistant ENT2 ovarian cancer ENT2END , with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and stomatitis
1	CONCLUSION: This modified liposomal ENT1 doxorubicin ENT1END regimen results in less toxicity (stomatitis, ENT2 hand-foot syndrome ENT2END ) than the standard FDA-approved dose schedule
0	CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, ENT1 hand-foot syndrome  ENT1END ) than the standard FDA-approved dose schedule. Definite, although limited, antineoplastic activity is observed in patients with well-defined platinum- and ENT2 paclitaxel ENT2END -refractory ovarian cancer
0	BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in ENT1 platinum ENT1END -resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe ENT2 erythrodysesthesia ENT2END ("hand-foot syndrome") and stomatitis
1	CONCLUSION: This modified liposomal ENT1 doxorubicin  ENT1END  regimen results in less toxicity ( ENT2 stomatitis ENT2END , hand-foot syndrome) than the standard FDA-approved dose schedule
0	BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and ENT1 stomatitis  ENT1END  We wished to develop a more tolerable liposomal doxorubicin treatment regimen and document its level of activity in a well-defined patient population with platinum/ ENT2 paclitaxel ENT2END -refractory disease
0	BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and ENT1 stomatitis ENT1END . We wished to develop a more tolerable liposomal doxorubicin treatment regimen and document its level of activity in a well-defined patient population with ENT2 platinum ENT2END /paclitaxel-refractory disease
0	CONCLUSION: This modified liposomal ENT1 doxorubicin ENT1END  regimen results in less ENT2 toxicity ENT2END (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule
0	CONCLUSION: This modified liposomal doxorubicin regimen results in less ENT1 toxicity  ENT1END  (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule. Definite, although limited, antineoplastic activity is observed in patients with well-defined platinum- and ENT2 paclitaxel ENT2END -refractory ovarian cancer
0	BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in ENT1 platinum ENT1END -resistant ovarian cancer, with dose limiting ENT2 toxicity ENT2END of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and stomatitis
0	Phase 2 trial of liposomal ENT1 doxorubicin  ENT1END  (40 mg/m(2)) in platinum/paclitaxel-refractory ENT2 ovarian and fallopian tube cancers ENT2END and primary carcinoma of the peritoneum
0	Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/ ENT1 paclitaxel  ENT1END -refractory ENT2 ovarian and fallopian tube cancers ENT2END and primary carcinoma of the peritoneum
0	Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in ENT1 platinum  ENT1END /paclitaxel-refractory ENT2 ovarian and fallopian tube cancers ENT2END and primary carcinoma of the peritoneum
0	Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary ENT1 carcinoma of the peritoneum ENT1END .BACKGROUND: Several studies have demonstrated liposomal ENT2 doxorubicin ENT2END (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and stomatitis
0	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary ENT1 peritoneal carcinoma  ENT1END with platinum/ ENT2 paclitaxel ENT2END -refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks
0	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary ENT1 peritoneal carcinoma ENT1END  with ENT2 platinum ENT2END /paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks
1	One patient developed grade 3 ENT1 diarrhea ENT1END requiring hospitalization for hydration. Six (12%) individuals required dose reductions. The median number of courses of liposomal ENT2 doxorubicin ENT2END administered on this protocol was 2 (range: 1-12)
0	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/ ENT1 paclitaxel  ENT1END -refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks. RESULTS: A total of 49 patients (median age: 60; range 41-81) entered this phase 2 trial. The median number of prior regimens was 2 (range: 1-6). Six (12%) and 4 (8%) patients experienced grade 2 hand-foot syndrome and stomatitis, respectively (no episodes of grade 3). One patient developed grade 3 ENT2 diarrhea ENT2END requiring hospitalization for hydration
0	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with ENT1 platinum  ENT1END /paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks. RESULTS: A total of 49 patients (median age: 60; range 41-81) entered this phase 2 trial. The median number of prior regimens was 2 (range: 1-6). Six (12%) and 4 (8%) patients experienced grade 2 hand-foot syndrome and stomatitis, respectively (no episodes of grade 3). One patient developed grade 3 ENT2 diarrhea ENT2END requiring hospitalization for hydration
0	Immuno/histochemistry and electron microscopy were carried out on the offspring cerebellum, and levels of malondialdehyde and ENT1 superoxide ENT1END dismutase were determined. Histopathologically, typical findings were observed in the cerebella from the control groups, but the findings consistent with early embryonic development were noted in BCNU-exposed ENT2 cortical dysplasia ENT2END group
0	This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous ENT1 melatonin ENT1END upon cerebellar BCNU-induced ENT2 cortical dysplasia ENT2END , using histological and biochemical analyses
0	Immuno/histochemistry and electron microscopy were carried out on the offspring cerebellum, and levels of ENT1 malondialdehyde  ENT1END and superoxide dismutase were determined. Histopathologically, typical findings were observed in the cerebella from the control groups, but the findings consistent with early embryonic development were noted in BCNU-exposed ENT2 cortical dysplasia ENT2END group
1	Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of ENT1 BCNU  ENT1END -induced ENT2 cortical dysplasia ENT2END
0	However, the bupivacaine/placebo group reported significantly more ENT1 pain ENT1END at 24 h and ENT2 PGE2 ENT2END levels during the first 4 h were significantly higher than the other three treatment groups
0	After extraction, a microdialysis probe was placed at the surgical site for PGE2 and thromboxane B2 ( ENT1 TXB2 ENT1END  measurements. RESULTS: The bupivacaine/rofecoxib group reported significantly less ENT2 pain ENT2END , as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h
0	The differential effects of bupivacaine and ENT1 lidocaine  ENT1END  on prostaglandin E2 release, cyclooxygenase gene expression and ENT2 pain ENT2END in a clinical pain model
0	However, the ENT1 bupivacaine  ENT1END placebo group reported significantly more ENT2 pain ENT2END at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups
0	RESULTS: The bupivacaine/ ENT1 rofecoxib  ENT1END group reported significantly less ENT2 pain ENT2END , as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h
0	However, the bupivacaine/placebo group reported significantly more ENT1 pain ENT1END  at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups. Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the lidocaine/placebo group. ENT2 Thromboxane ENT2END levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1
0	CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after ENT1 tissue injury ENT1END  which is associated with higher ENT2 PGE2 ENT2END production and pain after the local anesthetic effect dissipates
0	After extraction, a microdialysis probe was placed at the surgical site for PGE2 and thromboxane B2 ( ENT1 TXB2  ENT1END ) measurements. RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups. Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the lidocaine/placebo group. Thromboxane levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1. CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after ENT2 tissue injury ENT2END , which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates
0	Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the ENT1 lidocaine  ENT1END placebo group. Thromboxane levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1. CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after ENT2 tissue injury ENT2END , which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates
0	CONCLUSIONS: These results suggest that ENT1 bupivacaine  ENT1END stimulates COX-2 gene expression after ENT2 tissue injury ENT2END , which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates
0	RESULTS: The bupivacaine/ ENT1 rofecoxib  ENT1END  group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups. Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the lidocaine/placebo group. Thromboxane levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1. CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after ENT2 tissue injury ENT2END , which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates
0	ENT1 Thromboxane  ENT1END  levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1. CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after ENT2 tissue injury ENT2END , which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates
0	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 ( ENT1 PGE2 ENT1END  production and cyclooxygenase (COX) gene expression that increases ENT2 postoperative pain ENT2END in human subjects
0	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases ENT1 postoperative pain ENT1END  in human subjects. METHODS: Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h. Oral mucosal biopsies were taken before surgery and 48 h after surgery. After extraction, a microdialysis probe was placed at the surgical site for PGE2 and ENT2 thromboxane B2 ENT2END (TXB2) measurements
0	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases ENT1 postoperative pain ENT1END  in human subjects. METHODS: Subjects (n = 114) undergoing extraction of impacted third molars received either 2% ENT2 lidocaine ENT2END or 0
1	In the present study, we describe the proinflammatory effects of ENT1 bupivacaine  ENT1END on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases ENT2 postoperative pain ENT2END in human subjects
0	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases ENT1 postoperative pain ENT1END  in human subjects. METHODS: Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either ENT2 rofecoxib ENT2END 50 mg or placebo orally 90 min before surgery and for the following 48 h
0	BACKGROUND: In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate ENT1 inflammation ENT1END  In the present study, we describe the proinflammatory effects of bupivacaine on local ENT2 prostaglandin E2 ENT2END (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects
0	BACKGROUND: In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate ENT1 inflammation  ENT1END . In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects. METHODS: Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h. Oral mucosal biopsies were taken before surgery and 48 h after surgery. After extraction, a microdialysis probe was placed at the surgical site for PGE2 and ENT2 thromboxane B2 ENT2END (TXB2) measurements
0	The differential effects of bupivacaine and ENT1 lidocaine  ENT1END  on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.BACKGROUND: In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate ENT2 inflammation ENT2END
1	BACKGROUND: In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate ENT1 inflammation  ENT1END . In the present study, we describe the proinflammatory effects of ENT2 bupivacaine ENT2END on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects
0	BACKGROUND: In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate ENT1 inflammation  ENT1END . In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects. METHODS: Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either ENT2 rofecoxib ENT2END 50 mg or placebo orally 90 min before surgery and for the following 48 h
0	We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing hemolytic anemia crisis induced by ENT1 trimethoprim-sulfomethoxazole ENT1END  resulting in ENT2 cerebral anoxia ENT2END leading to permanent damage
1	We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing ENT1 hemolytic anemia  ENT1END crisis induced by ENT2 trimethoprim-sulfomethoxazole ENT2END , resulting in cerebral anoxia leading to permanent damage
0	We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing hemolytic anemia crisis induced by ENT1 trimethoprim-sulfomethoxazole ENT1END , resulting in cerebral anoxia leading to permanent damage. Magnetic Resonance imaging revealed cortical laminar ENT2 necrosis ENT2END in arterial border zones in both cerebral hemispheres, ischemic changes in subcortical white matter of left cerebral hemisphere, and in the left putamen